<SEC-DOCUMENT>0001689548-23-000044.txt : 20230207
<SEC-HEADER>0001689548-23-000044.hdr.sgml : 20230207
<ACCEPTANCE-DATETIME>20230207081138
ACCESSION NUMBER:		0001689548-23-000044
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230207
DATE AS OF CHANGE:		20230207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Praxis Precision Medicines, Inc.
		CENTRAL INDEX KEY:			0001689548
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39620
		FILM NUMBER:		23592845

	BUSINESS ADDRESS:	
		STREET 1:		99 HIGH STREET, 30TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-300-8460

	MAIL ADDRESS:	
		STREET 1:		99 HIGH STREET, 30TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>prax-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:912e1565-2dff-44dd-bfb3-af6c8a11fb3c,g:26ec8c83-18eb-4378-8ac1-2975735259ca,d:3603669404fe4fc8b59d31b31e26e467--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:prax="http://praxismedicines.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>prax-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV8xLTEtMS0xLTU5NTg0_a37bbcec-fd4a-40f1-b0ba-59e56a81d6ab">false</ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV8yLTEtMS0xLTU5NTg0_ed8effe1-6f43-4e34-9278-828cd8e92cfd">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV8zLTEtMS0xLTU5NTg0_81019ee5-e9b6-482f-91ec-226f18d26c68">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV81LTEtMS0xLTU5NTg0_c1479157-4094-4a6a-b5c6-ef7da5eef031">0001689548</ix:nonNumeric><ix:nonNumeric contextRef="ica6b7381be214302904bad838ac442b9_I20221231" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_21159827-a52f-45e4-914d-16111d124035">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_4c186cd4-1d36-4e49-a94e-eb059faddb23">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" name="us-gaap:RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjg_fb095add-7293-4af1-90e2-816d4ff050b8">http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ibba3fdb81c274cda9b548a2f92b2852d_D20201008-20201008" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzMvZnJhZzoxMDEyMDI0ZmFjZjc0YWIzOWZjNDBmMWJjYzA0NDExZS90ZXh0cmVnaW9uOjEwMTIwMjRmYWNmNzRhYjM5ZmM0MGYxYmNjMDQ0MTFlXzIzOA_ce82ec93-1a90-4e6f-a7d3-4e0b8a78edce">.4673</ix:nonFraction><ix:nonNumeric contextRef="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTU5_f31a878b-51d8-49e1-8652-9a345f90aac3">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTYw_c651d9dc-e4c5-4069-8a23-904dc552dfc6">http://fasb.org/us-gaap/2022#GeneralAndAdministrativeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="prax-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a728182f04043d39d4792ebfafe466a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ice112e6c2ffe47f9a03da78fda972c84_I20230203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ica6b7381be214302904bad838ac442b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica5b4ea7f3da432faad4765b7291efb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2344b1ab9c3a4878a68866f2972e66c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad98315af3d41a282deab5221cf97e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be9750a865b4e6e91d05a084c54ac34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eba7ebb706b4dfa80a4a7810dd535c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09992728bef4f0bae174a9c6128fa25_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0b9cad54eb49588e17c54b674ca49b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida8c1ac19c834c578b8b2ece2ac3cb77_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74d74d369a54b27a1f0a0997271d1da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7789b54e2a114c39b31e80ed274bb4dd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2585ba6f7d1140968c2b676bef9b6a76_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b99720f46e48d785dd30506df4095a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e08f1293150426397b0487ecffc04ea_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af8704c56174ca1b37faec33a912463_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba601030eba426189040ccc2833c493_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65bc52cfad8d4c54b16d280f13ff2223_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a93c7b7231e485d9dcb693c55f01c36_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196d0f35a1c74e6e8d4415c7632ab49f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f912841859b41cabd50be81996afef1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc40af393984b69a6f339c706f7a8cc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b46df47ce94205bcab6f972efaee12_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93ce564963d491aba684e9adfb498e6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0a8e5710134eb08c67c0c06b7b24da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c148e140a84df0a85d7419acf357d6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea6fb2e7f9c4653980110ad0997c840_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37e0cde373b74b1fbcdea62d3b9b067d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0b11d79884461a83cccb8dc6bbcdd3_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3477c218f40b4c7c970a4c3f3626732d_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51354d96fa5d42aca6c0254acaecbeed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b3da6cf3fb4b80b31db69d5e75e733_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id33de74923df41ec83c75880cf5f279b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2656057b4b1f4ddab56bd4e68b9a8313_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d1517befc54004869962cb5db5d4db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5685a97c7eb649f18683911595830a0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c72dd27f4db45c5a09009b132c11e0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2015d475fd417da87c4d8147258dc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2ef18fc101489483b20f45d8d64499_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc21efa6afc42e49f591f790c790431_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9132bcbc9a0e463d891bcdf0f039bb90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186b0778379c4993937fb55c38327183_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9293a98a8dd4a93a09eb1a71841867b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e4c52a182b04c4ab5d1d08a712e89e9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28901937c12f479a8152673d4168671a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7be4e0e05564f3fafa58c61f9b1fd10_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab0b74c530d04342bf1f589de16e0e3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2685775b6e74db4912d26db6ca928e3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ce13338d7446b8bdc23590e058954d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ab2e142b2d4fd391309d3aeb7a644b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f78ffae117408b9d174f79b6dadfc4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61be35db0ffd454eb578dd8a53db2fdc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabb872f5f3514052982389e3861ab98b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2628ce7abeb41ba95f3481aac7564a5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2b8a2121cf494bb5534c112dd72a9e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3004733fd54cbaa6eaea0ca6842030_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifefc7fcacec24cc2a304b8269c3aab86_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78de702859e243238daafb422255ef7f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f734a83c044c69af0d89604a75b839_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3238b6279a242f289e5ffa4033bab55_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0eb91dd5deb4936a88808d25a6364c8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3418d0f46f24a79a25d7259e2c96794_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5663f6ee44464a959cce62a6559179_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f0624b7d6cc44bcb25109c266ffa6b8_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:A2022OfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f20c793f4244b09a0b12e6890ea02f5_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cebf03629447b68ee074d4fbbd0250_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632d279a2efe44aea3fdf28603091934_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>prax:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia2d950c598cd455e8bb7e9014cef8268_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia737e914cf5e40249acbf0bf1ee2f218_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fa9a695a6e4fb0ba67088018be15ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a71c9652034aa088cfbfe7454ba32b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55923be6a1c64b7eaac49c978815f27c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie24f78a034d8434ea805bba77e18db42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>prax:program</xbrli:measure></xbrli:unit><xbrli:context id="if74bbcf7115f440d8a7727a6bd51c63f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4155d454f999412a8921a320b1dac7b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863005b39586407793ad56aa5956d85b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602db591ac4e4681915e753d9c9f647b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b26d9edbae245159b56fa3a00570a2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f52406efb649548003a483847ad691_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e5a8fc79f44e908279f9f4451ffcbf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7963bf676f4ac8a945b019d828f54d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3294a9a7ece4c74870e2e39a7c3d8c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d0ac36134f4884ba2a77e339a74cf2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i067bfcb424b847af96504067bd13ea3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9179d2848e4437a83ec90af5318502_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f74f35a8bd4e0d88f85f5805b2b164_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ba78adb17f4a0397707c92359e2504_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if58d705233dd47d8aee4f5ab6cfb7200_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a0c3d7a4f446ce8e8a686a819a00e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e26ad8bb6f04d92a24db27f1e62aee2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc35a88c136a419baf53d23fb148a052_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3aa83e6bc8e4ae9b4d9cbb367c26259_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e590dbad5c94c6bb050a64eccee552f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a98be32db89466fb3fa4f64deb01f21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb01972b2a0f443d89fb162c0416b297_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd8cd471062406d938bc8f398785ba9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id43b84cc8f724c1790306900f9eab5c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244c9b8a8bc64d05805e6f9efdd28890_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28ab65adfac24345b56927930bd81e0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09d1356850af46b7a820dcbe285a8867_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47fa3e30c05c4125a934754580ac61d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62409ab1a9324ce686d28857f3d25ed8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1040caddcfac467f932bd93ddc355481_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b254a6d21743ceb007eeb41999093b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb6df78b28c4de8a6b362faa5295589_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3ad0541c6044f3af2172c901923f02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1964efc982e4dd5bfee80bfedb3be00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cbc72ab825d46fbb9a436e63f3c57ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e19833c70214691b2d072f303950003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5a509f1d7046e5a8180c53dbfa8c7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6bcfca8aec14570ad5ec15d6bc82cc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136b3f69ecaa46faa9ac4cd6b513328e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia93a96f76f6246f2aae4871e03bbf942_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003402f9a7274f688237578608beb52e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42340b78da843ad9d0bb3e0bc2a70c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933e341b21264671b5246e7e4b47974b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ec332f151445f7b78b848590737181_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8742d8224d8c45c5bdaf37d3f6ba1094_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fcf4921a72b4aab9503d8d482d73745_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i716e562883f3424aaef16a9b22f5c8e7_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if36d77c9c53144d09601968a0865fbce_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1738436c1e4a4aaabe1692876228c53a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:UCBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-18</xbrli:startDate><xbrli:endDate>2021-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8aa498682824f9bb5c5eed3af34a7de_I20210518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie851e6aa9211407fbf15412951580a0b_D20210518-20210518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-18</xbrli:startDate><xbrli:endDate>2021-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac3370fe8f2b42789eb23526e5ecb703_D20211103-20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921f704070724adca8d013ad9ca44f7a_D20211103-20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c285fb70c14984a035bed8222bb71a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:JefferiesOpenMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a93dc661184757b579f3d8def24296_D20211103-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:JefferiesOpenMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e73530e136b479c80208cb925bbade7_I20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia026dc966a754812a61ad0c096814457_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5afc5d945ba4bafadfb0d0c3dac741e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66f40fdf3e9849dc95aff9107e6a2abc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib353ee652a0c4a69b3370039987754bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc86f7ac19204f0e8a499e53f47bb1fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00847cec0267471db96ca9e81a3449ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfec095cffc9489f9b959bfbd8233e2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibab1d12675f44c9183ae81a1c19d02b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da243485d114cb4884c5da895b1ce3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba3fdb81c274cda9b548a2f92b2852d_D20201008-20201008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-08</xbrli:startDate><xbrli:endDate>2020-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ab45cd01a247ec83adf3c948df3f0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd4bd8649214980a4a5f8233252d50e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentySeventeenEmployeeStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2996ff42e2cd4a599e5553a465ddee81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentySeventeenEmployeeStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73413d9e77ac43d0ba5a6eb2639a610b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f0a02e5c3f43b595b8742c748bc727_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09eef053696d47e58b2abf3b796af5de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90c01ec3e3ba4a2980aae7d5fa413eb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f60c5a963444cba12bc6600fceeae2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75efa4697b4345348551061c24679c66_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a1b80e6fa1480abd9c373178bf12e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prax:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5c9571e9f8424ab4b2a1bb9d76588f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prax:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5ce00fe1944639b5669f121145e350_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b521b0c1334a6d99bffb35ef881760_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086cadcb8e4b43b0b1cf5d9e023a28e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d22bb870c64b27b65b8cba9ec3536b_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:RogconMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08d935b650f48b894cff86c998390d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:RogconMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">prax:LicensingAgreementsProfitSharePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e78b82d33fe4b7ea06ff1555beedb9f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:IonisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3928d36a17d4572b98fb4d36c5bc667_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:IonisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db4fda94de8472aa375ed40f41dd0c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:IonisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb80111739064117857d8ff63d282ee7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1e903808d0417082b7ca141017b6d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3beb3fccfcac48b1a1b2abcb40888aa0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce3a4228571459f975e7c892d40666b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a68deb4cf0f483abe816b51999d287c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0e4722ba7b4b88b3538c783c5b2e05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56cac62e36f40bcb5f9287718900ca1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ff1ec2beed4170862a47ce96834fcd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c24e65906d4987bf2662bc0bef89a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd10fe8bfcc4606aabb82073574d6fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3603669404fe4fc8b59d31b31e26e467_1"></div><div style="min-height:7.2pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.972%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.639%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYw_e721d28e-e719-4a46-a17b-ebcc1117ff3f">10-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.639%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.402%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6MTY1MDA0MmE4MmI2NGUwYzg1ZWE1MzUxYzYwZjAzMDkvdGFibGVyYW5nZToxNjUwMDQyYTgyYjY0ZTBjODVlYTUzNTFjNjBmMDMwOV8wLTAtMS0xLTU5NTg0_89453502-08c6-4590-8a16-f7dfadb3511a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xMjk_e1c01433-482c-4b3a-aeb6-507104ecf671"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xMjk_05fe4cca-a96d-4d43-9012-3b24fdab9f8e">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.402%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjE5ZTk5MjFhZTBmNDJkMThjYjg2ZmEwOTExNzQ4YjgvdGFibGVyYW5nZTo2MTllOTkyMWFlMGY0MmQxOGNiODZmYTA5MTE3NDhiOF8wLTAtMS0xLTU5NTg0_27ff7242-ca14-444f-8e7c-71ab7f7c3cd7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from________ to_________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYz_971e25ae-708d-4cf7-abb0-851ec4118932">001-39620</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.639%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjY3_3e9870b9-ef95-4126-9d1c-728c96fcb9fc">PRAXIS PRECISION MEDICINES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.639%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.306%"><tr><td style="width:1.0%"></td><td style="width:25.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.896%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8wLTAtMS0xLTU5NTg0_b0e04c9d-fb8e-4652-943a-47349bf1e37a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8wLTItMS0xLTU5NTg0_35e69191-f1dd-4f88-b7c7-25ce50909461">47-5195942</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8zLTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTgxYzk0MTY0YzlmNGRiZGIxZWI3ODMyM2IzZTc3ZTBfNA_9e666ced-e35b-4c2c-97cd-3b09936ec695">99 High Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8zLTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTgxYzk0MTY0YzlmNGRiZGIxZWI3ODMyM2IzZTc3ZTBfOA_b8eacab9-c20d-4088-86dd-46cb8f26de61">30th Floor</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl80LTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTc4YzFiYThjMTU3NGEwNWEzZWJhODJlZWEyYjAwNmZfNA_5d3f5a78-a7d0-4bdd-a1d0-890448287f9e">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl80LTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTc4YzFiYThjMTU3NGEwNWEzZWJhODJlZWEyYjAwNmZfOA_9bd2d96f-b92c-416b-ada6-be76ced7c4de">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl80LTItMS0xLTU5NTg0_bffacc3d-a736-44c8-8d80-5e86c4a1d7f8">02110</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjU2_423456b6-0f3b-48ee-b5e8-da0391bac60f">617</ix:nonNumeric>-<ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjU3_0912625d-af53-4d9c-945a-0ac4829ee514">300-8460</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.639%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.972%"><tr><td style="width:1.0%"></td><td style="width:33.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6ZTVmODlmMDc1OTU4NDBmMTgxMjE0Yjg3YjA2NmM5MmIvdGFibGVyYW5nZTplNWY4OWYwNzU5NTg0MGYxODEyMTRiODdiMDY2YzkyYl8xLTAtMS0xLTU5NTg0_ed4735bd-3821-4564-87b4-d00938410d99">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6ZTVmODlmMDc1OTU4NDBmMTgxMjE0Yjg3YjA2NmM5MmIvdGFibGVyYW5nZTplNWY4OWYwNzU5NTg0MGYxODEyMTRiODdiMDY2YzkyYl8xLTItMS0xLTU5NTg0_8a36999d-1fa9-4e9a-b73d-3bab591e738e">PRAX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6ZTVmODlmMDc1OTU4NDBmMTgxMjE0Yjg3YjA2NmM5MmIvdGFibGVyYW5nZTplNWY4OWYwNzU5NTg0MGYxODEyMTRiODdiMDY2YzkyYl8xLTQtMS0xLTU5NTg0_fc797df6-a7f8-46c4-8220-95f0dbb8ba0c">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes   &#9744;  <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY183MTQ2ODI1NTg0ODc3_d10aa3f4-43c0-4dbf-9e42-369fe1cdeb3f">No</ix:nonNumeric>   &#9746; </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  &#9744;    <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjU4_ca1205f2-d9a5-446d-a95c-cc5e96a06525">No</ix:nonNumeric>  &#9746;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYx_195a9de8-18fc-4290-8f6f-ef87b681f44f">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYy_24e04e91-fd7c-4ad9-ab05-467111406383">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="height:7.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:7.2pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.402%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6OGRiMDA0ZmMzZjEwNDExYmI0YWI1NDFiZjliMWU1MzAvdGFibGVyYW5nZTo4ZGIwMDRmYzNmMTA0MTFiYjRhYjU0MWJmOWIxZTUzMF8yLTAtMS0xLTcwNDk1_f0e9762e-17ad-4b60-b21f-59e3bf4de85e">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6OGRiMDA0ZmMzZjEwNDExYmI0YWI1NDFiZjliMWU1MzAvdGFibGVyYW5nZTo4ZGIwMDRmYzNmMTA0MTFiYjRhYjU0MWJmOWIxZTUzMF8yLTMtMS0xLTU5NTg0_226ca2ef-b1b2-4107-a3f1-31bd5b31710e">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6OGRiMDA0ZmMzZjEwNDExYmI0YWI1NDFiZjliMWU1MzAvdGFibGVyYW5nZTo4ZGIwMDRmYzNmMTA0MTFiYjRhYjU0MWJmOWIxZTUzMF80LTMtMS0xLTU5NTg0_84a4ca74-c75a-42e7-901d-f46d1fd3ff47">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;  </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xMTU0NDg3MjA5NTk5Nw_553674f8-2ec8-4fe0-8ee3-e5b52bb5cb4f">&#9744;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjY2_2d53b51a-5d34-4d9a-b593-b6275177c465">&#9744;</ix:nonNumeric>    No  &#9746;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant, based on the closing price of a share of common stock on June 30, 2022 as reported by the Nasdaq Global Select Market on such date was approximately $<ix:nonFraction unitRef="usd" contextRef="i0a728182f04043d39d4792ebfafe466a_I20220630" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xNjQ5MjY3NDQ2MDAw_65f4dd52-145e-4dd5-9b7f-551d67c6652d">103.8</ix:nonFraction> million. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;3, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ice112e6c2ffe47f9a03da78fda972c84_I20230203" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18yODky_426161a2-1415-4c70-bb0c-78fe94f2ba39">52,393,118</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.972%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:7.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_16">Part I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_19">Item 1. Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_19">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_22">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_22">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_25">Item 1B. Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_25">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_28">Item 2. Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_28">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_31">Item 3. Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_31">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_34">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_34">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_37">Part II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_40">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_40">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_43">Item 6. Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_43">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_46">Item 7. Management's Discussion and Analysis of Financial Condition and results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_46">84</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_73">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_73">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_76">Item 8. Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_76">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_157">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_157">126</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_160">Item 9A. Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_160">126</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_163">Item 9B. Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_163">126</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_166">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_166">126</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_169">Part III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_172">Item 10. Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_172">127</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_175">Item 11. Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_175">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_178">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_178">141</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_181">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_181">145</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_184">Item 14. Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_184">148</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_187">Part IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_190">Item 15. Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_190">149</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_193">Item 16. Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_193">152</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_196">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_10"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the U.S. Food and Drug Administration, or the FDA, and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical and clinical drug development involves a lengthy, complex and expensive process, with an uncertain outcome. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following regulatory approval, if obtained.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we encounter difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into, and may enter into, license or other collaboration agreements that impose certain obligations on us. If we fail to comply with our obligations under such agreements with third parties or otherwise experience disruptions to our business relationships with our current or future licensors, we could lose rights that may be important to our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on our executive officers, principal consultants and others, and the loss of their services would materially harm our business. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our stock has been and may in the future be volatile, and you could lose all or part of your investment.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_13"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our product candidate development activities and clinical trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements and collaboration agreements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize our product candidates, if approved, in light of the intellectual property rights of others;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and, if approved, commercialization of our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of our product candidates, if approved;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to research, develop and, if approved, commercialize our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved product;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our product candidates, if approved;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our product candidates, if approved;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report on Form 10-K and the documents that we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference in this Annual Report on Form 10-K and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Annual Report on Form 10-K, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_19"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPANY OVERVIEW</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs, with significant potential for additional program and indication expansion: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Cerebrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Solidus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, our antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cerebrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (small molecule platform)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a platform, Cerebrum&#8482;, which is enabled by innovative computational and experimental tools, to discover and develop first- and best-in-class CNS small molecule therapies. Our world-class ion channel discovery science team, along with external collaborators, accelerate our ability to create and execute novel screening cascades for our selected genetic targets. Fundamental to advancement of candidates are our multiscale disease models that link genetic cause to network function to elucidate novel drivers of disease phenotype. We employ translational biomarkers such as </span><span style="color:#202124;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quantitative electroencephalography</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or qEEG, to guide dose selection, with the goal of improving probability of success in the clinic. The precision application of our candidates is guided by genomics and informatics to identify, stratify and activate patients for trial recruitment and execution. To date, Cerebrum&#8482; has generated three clinical stage product candidates &#8211; ulixacaltamide (formerly known as PRAX-944), PRAX-562 and PRAX-628, and has the potential to continue delivering first- and best-in-class orally available therapies for genetic CNS targets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Solidus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (ASO platform)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a platform, Solidus&#8482;, to discover and develop first- and best-in-class ASOs with high probability of advancement into the clinic. Solidus&#8482; is enabled by our proprietary, computational workflow to discover ASOs with desired drug-like properties to optimize for up/down-regulation, avoidance of toxic motifs and optimization of binding affinity and specificity. Furthermore, we are collaborating with Cerebral Therapeutics on next-generation, intracerebroventricular, or ICV, CNS delivery technology for select disease targets that necessitate biodistribution to deeper brain areas such as the caudate, striatum and thalamic and subthalamic nucleii. We believe this will provide a gateway for the advancement of ASOs against targets where others have previously failed or not endeavored to advance. Led by our clinical-stage product candidate, PRAX-222, Solidus&#8482; has also generated novel ASOs with preclinical proof of mechanism, including PRAX-080, for which we expect to nominate a development candidate for the treatment of PCDH19 in the second half of 2023, PRAX-090 and PRAX-100, and the platform is uniquely positioned to continue discovering and advancing new ASOs for novel genetic CNS targets. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our portfolio:</span></div><div><span><br/></span></div><div style="text-align:center"><img src="prax-20221231_g1.jpg" alt="prax-20221231_g1.jpg" style="height:292px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*PRAX-020 (KCNT1) is a research collaboration with UCB Biopharma SRL</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+PRAX-080 (PCDH19), PRAX-090 (SYNGAP1) &amp; PRAX-100 (SCN2A-LoF) ASOs are a collaboration with The Florey Institute of Neuroscience and Mental Health</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy &amp; Approach to Drug Development</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage the genetics of epilepsy as a gateway for CNS drug discovery and development. Recent investigations have led to the identification of over 500 genes that are causal or risk factors for different forms of epilepsy, providing the field with an outsized understanding of epilepsy genetics relative to other diseases such as Alzheimer&#8217;s disease, </span><span style="background-color:#ffffff;color:#202124;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amyotrophic lateral sclerosis, or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALS, and many others. The genetic origin provides clarity around how to address the underlying disease biology and precisely meet the needs of patients not only suffering from epilepsy, but also other neurological disorders of neuronal imbalance with shared pathophysiological mechanisms informed by the same genetics, including movement disorders. It is through our two platforms, Cerebrum&#8482; and Solidus&#8482;, that we aim to translate these insights into the discovery, development and potential commercialization of clinically meaningful medicines for patients.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that fostering an ecosystem of collaborators to support our internal research, clinical and commercial efforts is critical to our strategy. Our collaborators include world-renowned research groups and drug developers, clinical research organizations, or CROs, innovative patient mapping database companies, experts in translational tools, next-generation drug delivery technology companies and others. In addition, we are deeply embedded within the communities that we serve and believe that the more we know about the impact on patients, caregivers and communities at large, the better positioned we will be to deliver on what patients actually need. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underlying each of our programs are four key principles that we believe will increase probability of success and allow us to sustainably and efficiently translate insights into high-impact therapies for patients and society:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.67pt">Focus on therapeutic targets identified through human genetics.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying insights derived from the genetics of epilepsies, we have identified biological targets that are implicated in determining neuronal excitability in epilepsies and also in other CNS disorders. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.67pt">Utilize translational tools to validate the potential of our targets and product candidates.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage translational tools to both confirm pharmacodynamic effects of our drug product candidates in the brain and establish on-mechanism effects. Our programs utilize target-specific electroencephalogram, or EEG, endpoints to serve as robust markers of pharmacological engagement of the drug target and novel transgenic animal models to assess the therapeutic activity of our molecules. We expect these tools, along with rigorous preclinical pharmacokinetics, or PK, and pharmacodynamic characterization of our molecules will position us to more efficiently translate preclinical findings into clinical utility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.67pt">Pursue efficient, rigorous clinical development paths to proof-of-concept in humans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our development strategies are focused on defining efficient paths to demonstrate the safety and therapeutic activity of our programs in humans. We select indications that we believe will enable early and robust demonstration of desired effect in a relatively small patient sample and we focus on clinical endpoints that minimize inter-patient variability. Our global network of CROs and scientists affords us the flexibility to conduct research and development activities in diverse geographic locations to help accelerate development timelines and limit geographic risks.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.67pt">Apply patient-guided development strategies.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue the development of candidates that address the treatment needs of patients, caregivers and the treating community, including targeting the underlying disease pathology versus just symptom management. We focus on clinical endpoints that offer a clear connection between pharmacodynamic effects and clinical measures that are meaningful to patients, physicians and regulatory agencies. We intend to develop therapies that provide patients long-term relief from their disorders and significantly reduce the overall burden to patients and caregivers. Our development strategies are tailored to demonstrate these benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL STAGE PROGRAMS </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have advanced four product candidates to clinical stage, including three small molecules through the Cerebrum&#8482; platform and one ASO through the Solidus&#8482; platform:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ulixacaltamide for Essential Tremor and Parkinson&#8217;s disease</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced program, ulixacaltamide, is a differentiated and highly selective small molecule inhibitor of T-type calcium channels currently being studied for the treatment of Essential Tremor, or ET, in a Phase 2b study, and for the treatment of Parkinson&#8217;s disease, or PD, in a proof of concept, Phase 2 study. In ET, ulixacaltamide demonstrated positive results in a Phase 2a study (NCT05021978) in 2022 and the Phase 2b Essential1 study (NCT05021991) is ongoing, with topline results expected in the first quarter of 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ulixacaltamide Phase 2b Essential1 study </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Essential1 study is a multi-center, randomized, double-blind, placebo-controlled, dose-range finding Phase 2b clinical trial evaluating the efficacy, safety and tolerability of once-daily treatment of ulixacaltamide compared to placebo after 56 days in participants with moderate-to-severe ET. Approximately 130 participants have been randomized to receive one of two titrated, fixed-dose regimens for 56 days (60 or 100 mg) or placebo, administered orally every morning. The primary endpoint for Essential1 is change from baseline to Day 56 in the modified Activities of Daily Living, or mADL, score, the suggested efficacy endpoint for ET by the U.S. Food and Drug Administration, or the FDA. The mADL endpoint is a composite measure of tremor-related activities over the previous week that assesses the direct impact of ET on the lives of patients. The mADL endpoint is functionally relevant for people living with ET, representing a modified measure of the Essential Tremor Rating Assessment Scale, or TETRAS, ADL subscale with the addition of two items from the TETRAS performance section, or PS . </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ulixacaltamide Phase 2 study for PD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        We plan to initiate a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the efficacy, safety and tolerability of once-daily treatment of up to 100 mg of ulixacaltamide as a non-dopaminergic treatment for the motor symptoms of PD in the first quarter of 2023. The primary endpoint will be change from baseline in the International Parkinson and Movement Disorder Society Unified Parkinson&#8217;s Disease Rating Scale, or UPDRS, Part III (motor examination) score in the OFF state. Topline results are expected in the fourth quarter of 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Essential Tremor</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ET is the most common movement disorder with a prevalence of approximately 7 million patients in the United States alone, including more than two million diagnosed patients, one million of whom are actively treated for their ET. ET is characterized by involuntary rhythmic movements in the upper limbs that significantly disrupt ability to function and are progressive in nature. There is only one approved pharmacotherapy for ET, a beta blocker (propranolol), approved by the FDA in 1967, that offers limited efficacy and poor tolerability and is contraindicated for comorbidities that affect a significant share of the ET population. Other CNS drugs are used off-label, though similarly are characterized by limited efficacy and poor tolerability. For these reasons, approximately 40% of patients who seek pharmacotherapy treatment discontinue within two years. As a last line therapy, a small subset of patients will opt for invasive procedures such as gamma knife and MRI guided focused ultrasound thalamotomy, where part </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the thalamus involved in the cerebello-thalamo-cortical, or CTC, circuit is ablated, or deep brain stimulation, or DBS, where an electrode is implanted to deliver therapeutic electrical stimulation to the thalamus. While these procedures are generally effective, they are associated with significant side effects and risk. Therefore, many patients who are eligible elect not to have these procedures. In totality, there is significant unmet need for an effective and tolerable pharmacotherapy targeted for ET.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Parkinson&#8217;s Disease</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PD is the second most common movement disorder behind ET, with approximately one million diagnosed patients in the United States and 10 million patients worldwide. Roughly 60,000 patients are diagnosed with PD each year in the United States alone. PD is characterized by slow movement (bradykinesia), in combination with either rest tremor and/or rigidity. Symptoms progress over time in severity and eventually affect both sides of the body, often impairing ADLs such as dressing and eating. Non-motor symptoms, such as impaired smell, sleep disorders, gastrointestinal symptoms and psychiatric disorders like depression also play a pivotal role in the daily life of PD patients.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of treatment for PD has been dopaminergic replacement therapy. L-dopa, or levodopa, a formulation of replacement dopamine, is considered the standard treatment of PD. Levodopa has been shown to be highly effective in improving symptoms of bradykinesia and rigidity, but has a variable impact on tremor. Other common PD medications mainly reduce dopamine metabolism or are dopamine receptor agonists. While chronic dopaminergic therapy is effective, it can result in distressing side effects of motor fluctuations (wearing off) and levodopa-induced dyskinesias, impulse control disorders and psychosis. These side effects are disabling and, at times, more severe and distressing than the PD symptoms themselves. Patients may also opt for a more invasive procedure to deliver continuous dopamine stimulation with levodopa-carbidopa enteral suspension to continuously control motor fluctuations and dyskinesias. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DBS is typically reserved for those patients who respond to dopaminergic therapy, like levodopa, but have residual symptoms. Further, DBS carries significant risks associated with brain surgery, including intracerebral hemorrhage, infection, hemiparesis and cognitive decline. The prospect of neurosurgery in later years is often overwhelming or contraindicated (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, due to presence of cognitive impairment), and many patients are not treated with DBS. Therefore, we believe there is significant unmet need for an effective and tolerable treatment for motor symptoms associated with PD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAX-562 for rare, monogenic DEEs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRAX-562 is a first-in-class preferential inhibitor of persistent sodium current, presently in development for the treatment of rare developmental and epileptic encephalopathies, or DEEs. In-vivo studies of PRAX-562 have demonstrated dose-dependent block of seizures up to complete inhibition of seizure activity in SCN2A, SCN8A and other DEE mouse models. PRAX-562 has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of voltage-gated sodium channel, or NaV channel, blocking effects. PRAX-562 has received Orphan Drug Designation, or ODD, and Rare Pediatric Disease Designation, or RPD, from the FDA, and ODD from the European Medicines Agency, or EMA, for the treatment of SCN2A-DEE and SCN8A-DEE, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRAX-562 Phase 2 EMBOLD study</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced plans to initiate the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with DEEs, following FDA authorization to proceed with the study as we proposed, up to the planned maximum dose of 1.0 mg/kg/day. The study is expected to initiate in the first quarter of 2023, with two cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients. The EMBOLD study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, efficacy (motor seizure frequency) and PK of PRAX-562 in pediatric participants aged 2 to 18 years with DEEs, followed by an open-label extension. Approximately 20 participants will be enrolled initially in two distinct cohorts (n&#8776;10 for SCN2A-DEE and n&#8776;10 for SCN8A-DEE). Topline results for both cohorts are expected in the second half of 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rare, monogenic DEEs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Epilepsies are common neurological disorders characterized by brain excitation-inhibition, or E/I, imbalance. Hyperexcitability can lead to abnormal synchronization of neurons and neuronal circuits, which is the electrical basis of a seizure. Fundamentals of brain electrophysiology and mechanisms dictating seizure genesis are conserved across species and, consequently, animal models of seizures and epilepsy enable a clinically predictive and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore efficient drug development path. A subset of epilepsies are rare, monogenic DEEs characterized by early onset (less than 2 years of age), frequent seizures, abnormal epileptiform EEG activity, developmental impairment and resistance to available antiepileptic drugs, or AEDs. Furthermore, these DEEs are associated with a high mortality rate and comorbidities such as developmental delay in addition to behavioral disorders, movement disorders, pain and sensory dysfunction and sleep disruptions. The understanding of the etiology of DEEs has been revolutionized by recent whole-exome sequencing initiatives that revealed over 60 genetic causes of epilepsy. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An underlying pathologic feature of many DEEs is dysregulated neuronal activity leading to hyperexcitability, seizures and associated comorbidities. This phenomenon is observed in many pediatric DEEs with an identified genetic cause, such as PCDH19, SCN8A, SCN2A, KCNT1, KCNQ2, KCNQ1, STXBP1 and SYNGAP1, as well as epilepsies in which a genetic cause remains unclear, such as Lennox Gastaut Syndrome, or Doose Syndrome. Up to 40% of DEEs are caused by single gene mutations, enabling precision medicine approaches. Given the overlapping biology, phenotypic presentation and clinical execution considerations, we believe that developing a portfolio of drugs to treat DEEs will create a distinct body of knowledge that can be leveraged within our operating ecosystem to develop meaningful therapies for this group of patients with devastating unmet clinical needs. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard-of-care sodium channel blockers modulate neuronal activity by targeting peak sodium current, which can reverse the pathological neuronal hyperexcitability that underlies many CNS conditions, but simultaneously affects the physiological cellular action potential firing required for a functioning nervous and cardiovascular system. While standard-of-care sodium channel blockers inhibit persistent sodium current, they also block peak sodium current at therapeutic concentrations, which can cause significant adverse events, or AEs, such as ataxia, drowsiness and dizziness, and therefore have a very narrow Therapeutic Index, or TI, resulting in subpar outcomes for patients and significant need for better therapeutic options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there is a significant medical unmet need in DEEs, coupled with an untapped and significant market opportunity for targeted drugs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SCN2A-DEE</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early onset SCN2A-DEE is a rare condition caused by a gain-of-function, or GoF, variant in the SCN2A gene. The SCN2A gene encodes the NaV1.2 subunit of brain sodium channels, which control neuronal excitability by regulating the flow of sodium ions into neurons. This movement of sodium ions is a major component of generating electrical signals called action potentials, the way in which the cells communicate. Early-onset SCN2A-DEE presents before three months of life and can lead to profound impact on patients, including drug-resistant seizures, significant cognitive impairment, movement disorders such as dystonia or ataxia, and problems in other body systems such as the gastrointestinal or ocular systems. Currently, there are no approved treatments for SCN2A-DEE, and the standard-of-care typically involves a regimen of many concurrent anti-seizure medications as well as medications for comorbidities. Despite these interventions, it is estimated that more than 80% of early-onset SCN2A-DEE patients live with uncontrolled seizures, and approximately 75% live with severe intellectual disability. It is estimated that there are at least 1,500 patients in the United States with GoF changes in SCN2A leading to epileptic encephalopathy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SCN8A-DEE</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCN8A-DEE is a rare DEE caused by a gain-of-function variant in the SCN8A gene. Similar to SCN2A-DEE, patients with SCN8A-DEE suffer from recurrent, typically drug-resistant seizures, which start as early as the first day of life. The seizures can be of multiple different types, up to dozens per day, with poor response to current treatment options. Patients with SCN8A-DEE have significant cognitive disabilities, ranging from moderate to severe, often have movement disorders, such as dystonia or ataxia, and have problems in other body systems such as the gastrointestinal or ocular systems. SCN8A-DEE patients also may experience autonomic features such as increases or decreases in heart rate, abnormal breathing and cyanosis. It is estimated that there are at least 1,000 patients in the United States with SCN8A-DEE.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAX-222 for SCN2A-DEE</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRAX-222 is a clinical-stage ASO designed to down-regulate Na</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">V</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 expression, an effect that has demonstrated disease-modifying activity in animal models of SCN2A epileptic encephalopathy. In transgenic mice carrying a human SCN2A GoF mutation, we observed a significant, dose-dependent reduction in seizures and increased survival of mice treated with a mouse ASO that is designed to down-regulate SCN2A. The survival benefit from the ASO was maintained with repeat dosing. We also observed survival benefits following administration of a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mouse ASO to a group of mice after onset of disease and around the time of onset of mortality. PRAX-222 has received ODD and RPD from the FDA, and ODD from the EMA for the treatment of SCN2A-DEE.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRAX-222 EMBRAVE study</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced plans to initiate the PRAX-222 EMBRAVE study for the treatment of pediatric patients with early-onset SCN2A-DEE, after the FDA allowed us to proceed under an Investigational New Drug, or IND, application for the initial dose cohort, or Part 1 of the study. Following collection of the safety and efficacy data from Part 1, the data will be evaluated and submitted to the FDA to support further dose escalation. Part 1 of the EMBRAVE study is a 21-week open label cohort, in which participants will receive PRAX-222 for up to 13 weeks, designed to determine the safety and tolerability of intrathecal delivery of PRAX-222. We expect topline results from the first dose cohort of the PRAX-222 EMBRAVE study in mid-2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAX-628 for Focal Epilepsy</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRAX-628 is a potential best-in-class sodium channel blocker designed with enhanced targeting of both the persistent sodium current and disease-state dependent peak sodium current hyperexcitability, being developed for the treatment of focal epilepsy. In vivo studies have demonstrated best-in-class potency across preclinical disease models that have shown strong historical translation to the clinic. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRAX-628 Phase 1 first-in-human study</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase 1 healthy volunteer study of PRAX-628 in the fourth quarter of 2022 to evaluate the tolerability, PK, pharmacodynamics and food effect of PRAX-628 across single and multiple ascending dose cohorts. We expect to report topline results from the Phase 1 study in mid-2023 and subsequently initiate a Phase 2 study in focal epilepsy in the fourth quarter of 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focal Epilepsy</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Focal epilepsy is the most common type of epilepsy, accounting for approximately 60% of all cases. In the United States alone, it is estimated that focal epilepsy affects approximately two million people. Focal epilepsy is characterized by seizures that originate in one side or area of the brain and affects one side of the body. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Focal epilepsy patients are treated with sodium channel targeting AEDs, such as Tegretol (carbamazepine), Lamictal (lamotrigine), Xcopri (cenobamate) and many others. However, despite the plethora of marketed treatments, up to 30% of patients remain refractory to treatment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two forms of therapeutically relevant sodium current: (1) persistent sodium current and (2) peak sodium current. Standard of care sodium channel targeting AEDs can produce severe toxicity at therapeutic doses from excessive inhibition of peak sodium current, as physiological levels of peak sodium current are required for normal neuronal function. Therefore, novel compounds that inhibit persistent and peak sodium channel hyperexcitability while sparing physiological levels of peak sodium current may improve clinical efficacy and tolerability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by rapidly advancing technologies, strong competition and an emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific personnel provide us with competitive advantages, we face substantial competition from many different sources, including large and small pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private institutions.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety, convenience, cost, effectiveness of promotional support and intellectual property protection of our products. Our competitors fall primarily into the following groups of treatment:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">T-type calcium channel inhibitor programs in development targeting ET, including that of Jazz Pharmaceuticals, as well as other programs in clinical development targeting other mechanisms of action and approved therapies, such as propranolol, and off-label therapies, such as primidone.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sodium channel blocker or similar programs in development for DEEs, including those of SK-Pharma, Xenon Pharmaceuticals, Neurocrine Biosciences and Stoke Therapeutics, as well as other programs in clinical development targeting other mechanisms of action and approved therapies including other existing ion channel blockers.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have substantially greater financial resources, expertise and capabilities in research and development, the regulatory approval process, manufacturing and marketing than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through merger and acquisition activity and sizeable collaborative arrangements with established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of neuroscience that may be important for the development of our business. We additionally may rely on regulatory and other protections afforded through data exclusivity, market exclusivity and patent term extensions, where available.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent expiration dates noted in the following paragraphs refer to statutory expiration dates and do not take into account any potential patent term adjustment or extension that may be available. Depending upon the timing, duration and specifics of FDA approval of our drug product candidates, some of our United States, or U.S., patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the drug product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a New Drug Application, or NDA, plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, or the USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T-type Calcium channel blockers</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own six patent families directed to T-type Calcium channel blockers. One patent family discloses and claims compositions of matter of certain T-type calcium channel modulators, including ulixacaltamide. This patent family has issued in many major pharmaceutical markets and is pending in others and expires in 2029. A second family is directed to methods of use of certain T-type calcium channel modulators, including ulixacaltamide, in treating disease such as epilepsy. This patent family is pending in the United States and expires in 2037. A third patent family is directed to certain pharmaceutical formulations of ulixacaltamide and methods of use in treating disorders such as essential tremor. This patent family is pending in multiple jurisdictions of potential commercial interest and expires in 2040. A fourth family is directed to titration methods of using ulixacaltamide and expires in 2041. A fifth patent family is directed to certain analog compounds of ulixacaltamide and expires in 2040. The sixth patent family is directed to the adjunctive use of a beta blocker and/or certain anticonvulsants with ulixacaltamide and expires in 2043.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Persistent sodium current blockers</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own fifteen patent families directed to persistent sodium current blockers, including a patent family that relates to PRAX-562 and PRAX-628, two additional patent families that relate to PRAX-562 program, and the remaining patent families related to other persistent sodium current blockers. One patent family discloses and claims certain persistent sodium current blockers, including PRAX-562 and PRAX-628, and methods of use in treating diseases such as epilepsy (including pediatric epilepsy), as well as migraine and pain. In this patent family, PRAX-562 is covered by a patent that has granted in the United States (U.S. 11,014,931), and patent applications pending in other potentially commercially relevant jurisdictions, which expire in 2039. A second family discloses other persistent sodium current blockers and generically claims PRAX-562, as well as methods of treating diseases such as pediatric epilepsy. This patent family is pending in multiple jurisdictions and expires in 2037. A third family is directed to pharmaceutical formulations of PRAX-562, methods of use in treating diseases such as pediatric </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epilepsy, cephalgia, short-lasting unilateral neuralgiform headache attacks with conjunctival injection, or SUNCT, and tearing and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms, or SUNA, and methods of making PRAX-562, and expires in 2040. The remaining patent families are directed to other persistent sodium current blockers of various core structures and methods of use in treating diseases such as pediatric epilepsy, expiring between 2037 and 2043.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCN2A downregulation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusively in-licensed three patent families directed to our SCN2A program. Two of these patent families are owned by RogCon, Inc., and disclose and claim certain ASOs targeting SCN2A and methods of use in treating diseases such as epilepsy, including epilepsy having certain SCN2A mutations. One patent family is pending in the United States and expires in 2038. A second patent family is directed to methods of treating SCN1A encephalopathy using ASOs targeting SCN2A and expires in 2039.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other in-licensed patent family is owned by Ionis Pharmaceuticals, Inc., and is directed to compositions of matter of PRAX-222. This family expires in 2041. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own two patent families directed to our PRAX-222 program. The first has claims directed to a method of treating SCN2A gain of function neurological diseases using certain ASOs. This patent family is pending in the United States and expires in 2041. The second is directed to methods of treating SCN2A-related disorders using SCN2A inhibitors and expires in 2043.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KCNT1 blockers</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own eleven patent families directed to KCNT1 blockers including ten families related to our KCNT1 program and one family related to ASOs. Ten patent families disclose and claim small molecule KCNT1 blockers and methods of use in treating diseases such as epilepsy, including epilepsy having certain KCNT1 mutations, and expire between 2040 and 2043. One patent family is directed to certain ASOs and methods of use in treating diseases such as epilepsy, including epilepsy having certain KCNT1 mutations, and expires in 2039.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GABA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> receptor positive allosteric modulators</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own five patent families directed to GABA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receptor positive allosteric modulators. One patent family discloses and claims salts and polymorphs of PRAX-114. Two patents are granted in the United States (U.S. 10,562,930 and U.S. 10,927,141), which expire in 2039. A second patent family is directed to alternative salt forms of PRAX-114, which expires in 2042. Other patent applications cover methods of use and processes for making related to PRAX-114, which expire from 2041 to 2043.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LICENSE AGREEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with RogCon</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we and RogCon, Inc., or RogCon, entered into a Cooperation and License Agreement, or the RogCon Agreement, to collaborate to develop ASOs for the treatment of epilepsy caused by mutations of the SCN2A gene. RogCon had an existing collaboration arrangement with Ionis Pharmaceuticals, Inc., or Ionis, and as a result, we and Ionis negotiated a Research Collaboration, Option and License Agreement, or the Ionis Agreement, (described below) in order to complete the license agreement with RogCon. Under the RogCon Agreement, RogCon granted us, subject to a concurrent license grant of certain rights to Ionis, an exclusive, worldwide license under RogCon&#8217;s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Under the RogCon Agreement, we will conduct, at our own cost and expense, the research and development activities assigned to us under the research plan set out in the Research Collaboration, Option and License Agreement with Ionis. Under the terms of the RogCon Agreement, RogCon is eligible to receive a one-time milestone payment of $3.0 million as well as profit share payments as a percentage of net profits in the mid-teens. Profit share payments will be calculated and due quarterly on any net profits generated from a product commercialized under the RogCon Agreement. The $3.0&#160;million milestone payment will become due when (i) the first profit share payment has become due and payable and (ii)&#160;the Additional Milestone, the Initial Interest Amount and the Second Interest Amount (each as defined within the Ionis Agreement as described below) have all become due and payable to Ionis under our collaboration agreement with Ionis. As part of the RogCon Agreement, we agreed to provide up-front consideration of $2.1&#160;million, consisting of a $1.0&#160;million deposit, $0.7&#160;million in cash reimbursements for certain historical costs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously incurred by RogCon and $0.4&#160;million for the retirement of existing loan balances as of September&#160;11, 2019.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September&#160;11, 2019, we will reimburse RogCon for its out-of-pocket costs incurred for activities performed under the RogCon Agreement. We expense these costs as incurred as research and development. Expenses incurred for all periods presented were not material.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, RogCon has agreed to certain defined exclusivity obligations. The RogCon Agreement, unless earlier terminated, will continue until the latest of: (i)&#160;the expiration of all patent rights within RogCon patents, (ii)&#160;we certify we have abandoned the research, development and commercialization of product with no intention to re-establish such activities and (iii)&#160;no third party is obligated to pay any amounts that comprise net sublicense revenue. Either party may terminate the RogCon Agreement for material breach or insolvency of the other party. Additionally, we may terminate for convenience with prior written notice to RogCon. Upon termination by either party, all rights and licenses granted by RogCon to us will revert back to RogCon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ionis Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we and Ionis entered into the Ionis Agreement to discover and develop ASOs to treat forms of epilepsy caused by mutations of the SCN2A gene. Pursuant to the Ionis Agreement, we and Ionis each conducted certain research activities and Ionis was responsible for identifying a development candidate and conducting an IND-enabling toxicology study. The design of the IND-enabling toxicology study was prepared and mutually agreed to by us and Ionis.&#160;We are obligated to reimburse any out-of-pocket costs incurred by Ionis related to research activities, identification of a development candidate and conducting IND-enabling studies. Ionis granted us an exclusive option to obtain the rights and license to further develop and commercialize a development candidate in the field of epilepsy and neurodevelopmental disorders, other than Dravet Syndrome, following the results of the IND-enabling toxicology study. We exercised this exclusive option in January 2022 and paid a $2.0 million license fee. Ionis is eligible to receive certain contingent payments from us relating to development and other milestones, interest payments, royalties as a percentage of net product sales worldwide in the low-20s and any potential sublicense fees calculated as a percentage of sublicense revenue using a rate in the low-to-mid double digits.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development milestones of $5.0&#160;million for each product developed under the agreement are due upon the completion of the first clinical trial for each product, or the Development Milestone. Ionis will be entitled to receive an additional one-time milestone payment of $5.0&#160;million, or the Additional Milestone, upon the earliest to occur of the following (each, a Payment Trigger): (i)&#160;the first acceptance of an NDA filing for a product by the regulatory authority in a major market, (ii)&#160;we have both (a)&#160;received, in the aggregate, $300.0&#160;million in cash since September&#160;11, 2019 and (b)&#160;initiated the first clinical study with respect to a product or (iii)&#160;the closing of a change of control event affecting Praxis. In addition, upon the occurrence of a Payment Trigger, Ionis is also entitled to certain interest payments equal to (i)&#160;10% simple interest per annum calculated from the effective date of the agreement on the Additional Milestone, or the Initial Interest Amount, plus (ii)&#160;10% simple interest per annum calculated from the date the Additional Milestone is paid on the initial Interest Amount, or the Second Interest Amount, until the earliest to occur of the following: (i) aggregate net sales of $100.0&#160;million has been received, (ii)&#160;a change in control event affecting Praxis occurs or (iii)&#160;the Ionis Agreement has been terminated. Upon the occurrence of one of these three payment triggers, both the Initial Interest Amount and Second Interest Amount are due and payable to Ionis.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ionis Agreement will continue in full force and effect until the expiration of all payment obligations to Ionis, unless terminated earlier by either party. Either party may terminate the agreement upon material breach or insolvency of the other party. Praxis is able to terminate the Ionis Agreement for convenience with prior written notice. Ionis may terminate if we fail to achieve certain performance milestones. Upon termination by us for convenience, we will stop selling all products, subject to certain wind-down provisions and all products will revert back to Ionis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently source all of our non-clinical and clinical compound supply through third-party contract development and manufacturing organizations, or CDMOs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For clinical supply, we rely on CDMOs to manufacture drug substance and drug product in accordance with the FDA&#8217;s current Good Manufacturing Practices, or cGMP. We expect to rely on third parties for our manufacturing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processes and the production of all clinical supply drug substance and drug product and currently expect to continue to do so for commercial supplies of our product candidates, if approved. We use additional contract manufacturers to fill, label, package, store and distribute our investigational drug products and currently expect to continue to do so for commercial supplies of our product candidates, if approved. It is our intent to identify and qualify additional manufacturers to provide active pharmaceutical ingredient and fill-and-finish services prior to submission of a new drug application, or NDA, to the FDA for any product candidates that complete clinical development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of prescription drugs, such as those we are developing. These agencies regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of drug products. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. regulation of drug products</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each intended use;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of an NDA;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of potential FDA audits of clinical trial sites to assess compliance with GCPs and the integrity of the clinical data; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical studies</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any product candidate in humans, the product candidate must undergo preclinical testing. Preclinical studies generally include laboratory evaluation of product chemistry, formulation and stability, as well as animal studies to assess potential toxicity, which support subsequent clinical testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature and a proposed clinical protocol, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. Additionally, the FDA will review any data from clinical trials conducted outside the United States when determining whether to allow an IND to proceed in the United States. Specifically, the FDA&#8217;s acceptance of data from trials conducted outside of the United States and not under an IND is subject to certain conditions, including that the clinical trial must be well designed and conducted in accordance with GCPs, and the FDA must be able to validate the data from the study through an on-site inspection, if necessary. Clinical holds also may be imposed by the FDA at any time before or during studies due to safety concerns or non-compliance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study, and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. Specifically, information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. Information related to the product candidate, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three phases, which may overlap or be combined. In Phase 1, the product candidate is introduced into healthy human subjects or patients with the target disease or condition to test for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early evaluation of effectiveness. In Phase 2, the product candidate is administered to a limited patient population with a specified disease or condition to evaluate possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for the specified disease or condition, and to determine dosage tolerance and optimal dosage. In Phase 3, the product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product candidate for approval, to establish the overall risk-benefit profile of the product candidate, and to provide adequate information for the labeling of the product candidate.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or sponsors may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies, may be conducted after initial marketing approval, and may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition or requirement of approval of an NDA.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports summarizing the results of clinical trials and nonclinical studies, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and investigators if serious and unexpected suspected adverse events occur, findings from other studies of the same or similar drug or from animal or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing suggest a significant risk, or there is an increased incidence of a serious suspected adverse reaction compared to that in the protocol or investigator brochure.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution for a variety of reasons, including if the clinical trial is not being conducted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing application submission and FDA review and approval</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The submission of an NDA is subject to a substantial application user fee, unless a waiver or exemption applies. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be withdrawn and resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once an application is accepted for filing, the FDA has a goal of ten months from the date of &#8220;filing&#8221; to complete a standard review of an NDA for a drug that is a new molecular entity, and six months from the filing date to complete a priority review. The FDA does not always meet its goal dates, and the review process can be extended by FDA requests for additional information or clarification and a sponsor&#8217;s process to respond to such inquiries. This FDA review process typically takes 10 months from the date the NDA is accepted for filing by the FDA (for a standard review) or six months from the filing date (for a priority review). Once the submission is accepted for filing, the FDA begins an in-depth substantive review. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facilities in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Before approving an NDA, the FDA typically will inspect the facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites and/or the study sponsor to assure compliance with GCP requirements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA may refer any application to an advisory committee, including applications for novel drug candidates that present difficult questions of safety or efficacy. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. The FDA must send a non-compliance letter </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities, sponsor,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and clinical trial sites, the FDA may issue either an approval letter or a complete response letter, or CRL. An approval letter authorizes commercial marketing of the drug with specific prescribing information and for specific indications. A CRL will describe all of the deficiencies in the NDA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA in condition for approval, including requests for additional information or clarification. If a CRL is issued, the applicant may choose to either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. If those deficiencies have been addressed to the FDA&#8217;s satisfaction, the FDA will issue an approval letter. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess safety, require testing and surveillance programs to monitor the product, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation and exclusivity</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan drug designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same disease or condition for seven years. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or to provide a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee. Orphan product designation, however, does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rare pediatric disease designation and priority review vouchers</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the United States within one year following the date of approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. Congress has only authorized the Rare Pediatric Disease Priority Review Voucher program until September 30, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, sponsors of marketing applications approved after that date will not receive the voucher unless Congress reauthorizes the program.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the program is not reauthorized, if a drug candidate receives Rare Pediatric Disease Designation before October 1, 2024, the sponsor of the marketing application for such drug will only be eligible to receive a voucher if the application for the designated drug is approved by the FDA before October 1, 2026.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast track, breakthrough therapy and priority review designations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible for a fast track designation, the FDA must determine that a product candidate is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address unmet medical needs for the condition. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product candidate. The FDA may also agree to review sections of the NDA for a fast track product candidate on a rolling basis before the complete application is submitted. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the FDA may designate an NDA for priority review if the product candidate treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the product candidate represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by, among other things, evidence of increased effectiveness, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months from the filing date for an NDA for a new molecular entity. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review and breakthrough therapy designation do not change the standards for approval and may not ultimately expedite the development or approval process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated approval pathway</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A drug product may also be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and provides a meaningful therapeutic benefit over existing treatments. Such product candidates can be approved upon a determination that the product candidate has an effect on either a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint. The FDA may withdraw approval of a drug or indication approved under accelerated approval on an expedited basis if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product or the sponsor fails to conduct such confirmatory trials in a timely manner or in accordance with applicable regulations. Drugs granted accelerated approval must meet the same </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statutory standards for safety and effectiveness as those granted traditional approval. In addition, all promotional materials for products approved under the accelerated approval program are subject to prior review by the FDA. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. drug product marketing exclusivity</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for a generic or follow-on version of the protected drug product, respectively, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA also provides three years of marketing exclusivity when an NDA, or a supplement to an existing NDA, includes new clinical investigations, other than bioavailability studies, conducted or sponsored by the applicant that are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs or follow-on 505(b)(2) NDAs if the protected clinical data are not referenced. Five-year and three-year exclusivity will not delay the submission or approval of a stand-alone NDA submitted under section 505(b)(1) of the FDCA. However, an applicant submitting a stand-alone NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness, if applicable.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-approval requirements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new prescription drug product, the manufacturer and the approved drug are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to monitoring and recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. After approval, most changes to the approved product, such as adding new indications or other labeling claims or changes to the manufacturing processes or facilities, are subject to prior FDA review and approval. There are continuing, annual program fee requirements for any marketed products.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of post-marketing studies or clinical trials to assess new safety risks, or restrictions under a REMS program;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the marketing, manufacturing or distribution of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs must be promoted by a manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. The FDA does not regulate the behavior of physicians in their choice of treatments, but it does restrict the manufacturer&#8217;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare laws and regulations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states in which they conduct their business, which may constrain the financial arrangements and relationships through which these companies and their partners research, sell, market and distribute any products for which marketing approval is obtained. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims and transparency laws regarding drug pricing and payments and other transfer of value to physicians and other healthcare providers. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future healthcare reform legislation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and likely will continue to be, a number of legislative and regulatory changes regarding the healthcare system directed at broadening the availability of health care, improving the quality of health care and containing or lowering the cost of health care. For example, in March 2010 the Affordable Care Act, or ACA, was enacted, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars; expanded the types of entities eligible for the 340B drug discount program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; established annual fees and taxes on manufacturers of certain branded prescription drugs; and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of January 2019) point-of-sale discounts off </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, administrative, executive and legislative challenges to certain aspects of the ACA. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2021 the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order to, among other things, instruct certain governmental agencies to review and reconsider their existing policies and rules that limit access to health care, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers. These reductions went into effect on April 1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payment methodologies may also be subject to changes in healthcare legislation and regulatory initiatives. For example, Centers for Medicare and Medicaid Services may develop new payment and delivery models, such as bundled payment models. There also has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. By way of example, in August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, pricing and reimbursement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. Sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such drug products. In the United States, third-party payors include federal and state healthcare programs, government authorities, private manage care providers, private health insurers and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates, if approved, in addition to the costs required to obtain the FDA approvals. Nonetheless, our product candidates may not be considered medically necessary or cost-effective. Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and could increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations outside of the United States</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we may be subject to a variety of regulations in foreign jurisdictions that govern, among other things, preclinical and clinical studies, commercial sales and distribution of our future products. Most countries outside of the United States, including the European Union, or the EU, require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In addition, whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approval from comparable regulatory authorities outside the United States before we can commence clinical studies or marketing of the product candidate in those countries. The requirements and process governing the conduct of clinical trials, approval, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-clinical studies and clinical trials in the European Union</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Non-clinical studies are performed to demonstrate the health or environmental safety of new biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on good clinical practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      Medicines used in clinical trials must be manufactured in accordance with good manufacturing practice. Other national and EU-wide regulatory requirements may also apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        The aforementioned EU rules are generally applicable in the European Economic Area, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of drug products and healthcare laws and regulations outside of the United States</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may be subject in the future to laws and regulations related to drug products and health care imposed by jurisdictions outside of the United States, including the European Union, or EU, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. Outside of the United States, the provision of health care, including the pricing of pharmaceutical products, is subject to governmental control in many countries, and efforts to control prices and costs, including legislative action, will likely continue as countries attempt to manage healthcare expenditures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data privacy and security laws</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including the Health Insurance Portability and Accountability Act, or HIPAA, and federal and state consumer protection laws and regulations that govern the collection, use, disclosure, and protection of health-related and other personal information could apply now or in the future to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act of 2018, the California Privacy Rights Act of 2020, and the General Data Protection Regulation, or GDPR, and the U.K. GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing international operations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered by U.S. authorities that enforce the FCPA, including the Department of Justice, to be foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Praxis, we are fiercely dedicated to our mission to translate genetic insights into the development of therapies for CNS disorders characterized by neuronal imbalance. We strive each day to innovate and adapt to deliver treatments that could potentially change the course of CNS disorders and to do so based on a culture built to attract, develop and retain a talent-dense workforce. We are committed to developing our culture and our employees through our company core values &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trust</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ownership</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Curiosity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the strength of our culture and our work environment that allow us to attract top talent to Praxis. As of February 3, 2023, we have 109 employees and plan to grow as we continue to realize the potential of our pipeline.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trust</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each other&#8217;s judgement, which is why we do not implement excessive policies. We value transparency among team members that leads to direct, clear, and timely feedback so we can all improve together.  We commit to be one another&#8217;s checks and balances. We respect all opinions and encourage diversity.  Discrimination is never tolerated. Because we trust employees to have good judgment, there is a lot of freedom built into the way we operate. As an example, we do not have prescriptive policies on vacation, sick or personal time &#8211; we encourage employees to take that time as they need it and align with their manager about their plans. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adapted to new working methodologies that embrace a virtual and cooperative work environment while emphasizing personal </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ownership</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for actions and outcomes. We want employees to own projects and stay engaged through communication, but we also make sure employees know that Praxis is not a nine-to-five culture. We are a culture where employees have real accountability as we all work towards a greater goal. Our headquarters is designated as a collaborative workspace where we gather in teams or as a company when practical and safe. Being able to own projects, while expressing when you need a break, is something we value. Allowing employees to best structure their days to their needs is one of the most important foundations we believe is necessary for having a sturdy organization.  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Curiosity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is at the center of innovation, and we are always asking how we can better help our patients. We love to learn. One day a month, we commit to what we call &#8220;Curiosity Day.&#8221; We ask our employees to step away from the computer, meetings and calls for a single day to focus solely on being curious &#8211; whether that means </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">catching up on professional articles or journals, diving deeper into a rare disease we do not currently support, challenging ourselves by exploring an area outside our comfort zone, perfecting a new skill, or even taking some time to safely enjoy the outdoors. These opportunities have a positive impact on our employees, and enable them to bring the new knowledge and learnings to the work they do and increase the ability to deliver on our mission.  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we pursue objectives to achieve the ultimate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we challenge ourselves daily. Through trust, ownership and curiosity, our employees are positioned to leave lasting results that reach the communities we serve. At the end of the day, the magic we witness when employees put their minds together is what we are most proud of as a company.   </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In identifying our employer value proposition, we have highlighted the following aspects of working at Praxis:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Building.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our approach to building a robust clinical pipeline provides a platform and forum for exploration and innovation. At Praxis, we are all involved in building the company together, and as a flat and agile organization, each employee has an impact. With our company values of Trust, Ownership, Curiosity and Results as the foundation of our efforts, we are challenged to question each other and our own assumptions to deliver treatments for patients and caregivers.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caring.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our people, the patient communities we serve and their caregivers and families are at the forefront of our efforts. Our ways of working are team-based and focused on co-creation, with respect for all opinions and points of view. We show we care by giving and receiving candid feedback, and we support curiosity and ownership for all aspects of our business. This environment fuels our growth and propels us forward. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Grit. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delivering life-altering treatments for CNS disorders is incredibly demanding, but our focus on patients with unmet needs highlights the urgency to deliver effective treatments faster and more effectively than ever before. Our employees are passionate and persistent about transforming neuroscience because of the incredible need to positively change the lives of patients with CNS disorders.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Dare For More</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We Dare For More</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in every aspect of our journey, from the patients we are working for, to the portfolio we build and advance every day, and quite importantly ourselves and our fellow team members. People stay at Praxis to surround themselves with exceedingly motivated and passionate peers who highly value consistent excellence in their colleagues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet address is http://praxismedicines.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available through the &#8220;Investors + Media&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_22"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission, or SEC, before deciding to invest in our common stock. The risks described below are not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating results and financial condition to suffer materially. In such event, the trading price of our common stock could decline, and you might lose all or part of your investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Past Financial Condition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue to date, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials. Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Our net losses were $214.0&#160;million and $167.1&#160;million for the years ended December 31, 2022 and 2021, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $530.6 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of and seek regulatory approvals for our product candidates in our initial and potential additional indications as well as for other product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop and conduct clinical trials, including in expanded geographies such as Europe, for our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate and continue research and development, including preclinical, clinical and discovery efforts for any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates that may successfully complete clinical development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our product candidate development and help us comply with our obligations as a public company;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to commercialize various products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or the FDA, or other regulatory authorities to perform clinical trials in addition to those that we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Future Financial Condition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. If we are able to gain marketing approval for our product candidates, we will require significant additional amounts of cash in order to launch and commercialize such product candidates to the extent that such launch and commercialization are not the responsibility of a future collaborator that we may contract with in the future. In addition, other unanticipated costs may arise in the course of our development efforts. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidates we develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our current product candidates and other product candidates we may develop and pursue, including drug product manufacturing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and uncertainty of, and the costs involved in, obtaining marketing approvals for our current product candidates, and other product candidates we may develop and pursue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of future product candidates that we may pursue and their development requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of jurisdictions in which we plan to seek regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if approved, the costs of commercialization activities for our product candidates for any approved indications, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of our product candidates for any approved indications or any other product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing costs of operating as a public company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Any of our current or future license agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December&#160;31, 2022 may not be sufficient to fund operations for at least the next twelve months from the date of issuance of our consolidated financial statements which raises substantial doubt about the our ability to continue as a going concern, and we will need to obtain additional funding. Our estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. In the event that we are unable to obtain sufficient additional funding, there can be no assurance that we will be able to continue as a going concern, and we will be forced to delay, reduce or discontinue our product candidate programs. If potential investors decline to participate in any future financings or potential collaborators decline to do business with us, our ability to increase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our cash position may be limited. Furthermore, the price per share of our common stock could be materially adversely affected and our stockholders could lose part or all of their investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our planned operations. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, our existing stockholders' ownership interests may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our stockholders. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations or marketing, distribution, licensing and royalty arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage biopharmaceutical company with a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company, focused on translating genetic insights into the development of therapies for CNS disorders characterized by neuronal imbalance. We commenced operations in 2016, have no products approved for commercial sale and have not generated any revenue from product sales. Our operations have been focused on developing and conducting preclinical and clinical studies of our product candidates. To date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing our product candidates. Our ability to generate revenue and achieve profitability depends on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiating and successfully completing research and preclinical and clinical development of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials, if any;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, assessing, acquiring and/or developing new product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, if any, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining an adequate price for our product candidates in the countries where our products are commercialized, if any;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining adequate reimbursement for our product candidates from payors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of our product candidates as viable treatment options;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving milestone and other payments under any future collaboration arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#8217; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. We are currently evaluating (i) ulixacaltamide for the treatment of essential tremor, or ET, and Parkinson's disease, (ii) PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy, or SCN2A-DEE, and SCN8A development and epileptic encephalopathy, or SCN8A-DEE; (iii) PRAX-222 for the treatment of SCN2A-DEE; and (iv) PRAX-628 for the treatment of focal epilepsy. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe we will be able to efficiently generate proof-of-concept data. If any of our product candidates is approved, we then intend to expand to clinical testing and potentially seek regulatory approvals in other neurological disease indications based on genetic and mechanistic overlap with the primary indication. However, even if our product candidates are able to gain regulatory approval in one indication, there is no guarantee that we will be able to gain regulatory approval in another indication or expand to other indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may focus resources on pursuing indications outside of neurology based on the same strategic approach (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, human genetics, mechanistic rationale, the availability of translational tools, clinical development path, commercial opportunity) we utilize in determining on which of our discovery programs to focus. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. For example, in June 2022, we announced that we are undergoing a strategic realignment to focus resources on our ulixacaltamide, PRAX-562, PRAX-222 and PRAX-628 programs, as well as our preclinical programs across our Cerebrum&#8482; and Solidus&#8482; platforms. Additionally, we may reprioritize product candidate development plans and activities at any time and delay or terminate development of any product candidates we identify. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurological diseases, our business, financial condition, and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and disease pathways that may later prove to have greater commercial potential than those we choose to pursue or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Research and Development and the Biopharmaceutical Industry</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Preclinical and Clinical Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially harmed. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to our product candidates are subject to extensive regulation. In the United States, obtaining marketing approval for a new drug requires the submission of a New Drug Application, or NDA, to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the NDA for that product candidate. An NDA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing, and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted an NDA to the FDA or similar marketing authorization application to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. Obtaining approval of an NDA can be a lengthy, expensive, and uncertain process, and as a company we have no experience with the preparation of an NDA submission or any other marketing authorization application. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, or regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the submission; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or those of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of and opinions on our preclinical and clinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial designs, or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any comparable foreign regulatory authority. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical drug development involves a lengthy, complex and expensive process, with an uncertain outcome. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, pivotal clinical trials typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing, even after observing promising signs of activity in earlier preclinical studies or clinical trials. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. For example, in June 2022, we announced that the Phase 2/3 Aria Study evaluating the efficacy and safety of PRAX-114 for monotherapy treatment of major depressive disorder did not achieve statistical significance on the primary endpoint of change from baseline in the 17-item Hamilton Depression Rating Scale total score at Day 15, or on any secondary endpoints. There can be no assurance that any of our future clinical trials will ultimately be successful or support further clinical development of our product candidates. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely completion of preclinical laboratory tests, animal studies and formulation studies in accordance with the Good Laboratory Practice requirements and other applicable regulations of the U.S. Food and Drug Administration, or the FDA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching a consensus with regulatory agencies on study design and obtaining regulatory authorization to commence clinical trials; delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in identifying, recruiting and training suitable clinical investigators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting suitable patients to participate in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a temporary or permanent clinical hold by regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments on trials conducted by competitors for related technology that raises FDA or foreign regulatory authority concerns about risk to patients of the technology broadly, or if the FDA or a foreign </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting, screening and enrolling patients and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays caused by operational issues at clinical sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty collaborating with patient groups and investigators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s Good Clinical Practice requirements, or applicable regulatory guidelines in other countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trials of the same class of agents conducted by other companies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to the clinical trial protocols;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates being greater than we anticipated;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfer of manufacturing processes to larger-scale facilities operated by a contract development and manufacturing organization, or CDMO, and delays or failure by our CDMOs or us to make any necessary changes to such manufacturing process; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties being unwilling or unable to satisfy their contractual obligations to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where the clinical trials are conducted. Before commencing a clinical trial, the FDA or comparable foreign regulatory authorities could raise questions about or concerns with our proposed clinical protocol. For example, the FDA has previously issued clinical holds on certain of our product candidates, and we could not commence the respective clinical trial until such questions or concerns were resolved. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, we may need to amend clinical trial protocols that could require us to resubmit our clinical trial protocols to IRBs or ethics committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our trials are, have been, and may in the future be open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment.  In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may interpret the information of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials. Additionally, the trial design differences and placebo effects that may be possible in clinical research for the indications we are studying may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials or to interpret the clinical data in any of our trials. In addition, we plan to conduct clinical trials of certain of our product candidates, including ulixacaltamide, utilizing novel primary endpoints for which the FDA and other regulatory authorities may have limited experience in interpreting and reviewing. Although we plan to seek consensus with FDA and other regulatory authorities in connection with the design and implementation of our clinical studies, utilizing novel trial endpoints may increase the risk that the FDA and other regulatory authorities will consider the results from such trials, even if successful, insufficient to establish the safety or efficacy of our product candidates, which could require us to conduct additional studies beyond those we currently contemplate for our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials in foreign countries, such as the European Union, for our product candidates presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the completion of any preclinical studies or clinical trials of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our preclinical studies or clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following regulatory approval, if obtained.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In addition, many compounds that have initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Additionally, the composition of our product candidates or learnings in preclinical studies or clinical trials may result in contraindications for any product candidates for which we may obtain regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If unacceptable side effects arise in the development of our product candidates, we, foreign regulatory authorities, or the FDA, the IRBs or DSMBs at the institutions in which our trials are conducted could suspend or terminate our preclinical studies or clinical trials or foreign regulatory authorities or the FDA could order us to cease preclinical studies or clinical trials or deny approval of our product candidates for any or all targeted indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment-emergent side effects that are deemed to be drug-related could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Undesirable side effects in one of our clinical trials for our product candidates in one indication could adversely affect enrollment in clinical trials, regulatory approval and commercialization of our product candidates in other indications. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to side effects caused by our product candidates, the administration process or related procedures of our product candidates could cause adverse side effects, such as the intrathecal or intravitreal administration process or related procedures for ASOs. If any such adverse events occur, our clinical trials could be suspended or terminated. Even if we can demonstrate that adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the clinical trial. Additionally, other ASOs in clinical development utilizing intrathecal delivery could also generate data that could adversely affect the clinical, regulatory or commercial perception of our product candidates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar products) after such approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw or limit their approval of such product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a Boxed Warning or contraindications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way such product candidates are distributed or administered, or change the labeling of the product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may require a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools, and regulatory authorities in other jurisdictions may require comparable risk mitigation plans;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety and efficacy of the product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may in the future, experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria defined in the protocol;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case clinical trials focused on rare disease, the small size of the patient population and the potential of a patient being undiagnosed or misdiagnosed;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of patients to trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Delays in patient enrollment may result in increased costs, affect the timing or outcome of the planned clinical trials, product candidate development and approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to advance the development of our product candidates, cause the value of our company to decline and limit our ability to obtain additional financing if needed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, such as</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously reported. As a result, topline and preliminary data should be viewed with caution until the final data are available. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. Others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, preliminary or topline data that we report differ from later, final or actual results, or if others, including the FDA and comparable foreign regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The markets for our product candidates may be smaller than we expect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the potential market opportunities in each of our platforms include several key assumptions based on our industry knowledge, industry publications and third-party research reports and other data sources and estimates. There can be no assurance that any of these assumptions are, or will remain, accurate.  If the actual markets identified for our product candidates, or for any other product candidate we may develop in the future, is smaller than we expect, our revenues, if any, may be limited and it may be more difficult for us to achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for a number of reasons, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to design such product candidates with the pharmacological or pharmacokinetic properties that we desire; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We conduct clinical trials for our product candidates in the United States, Europe and other jurisdictions, and the FDA, the European Medicines Agency, or EMA, and applicable foreign regulatory authorities may not accept data from trials conducted outside those respective jurisdictions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acceptance of study data from preclinical studies and clinical trials conducted outside the United States may be subject to certain conditions for acceptance. For example, in cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and the trials were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCP and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. For such trials not subject to an IND, the FDA generally does not review the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the trial design or protocol for a non-United States clinical trial was inadequate, which could require us to conduct additional clinical trials. Many foreign regulatory bodies, such as the EMA, have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We obtained orphan drug designation for PRAX-562 and PRAX-222 and may plan to seek orphan drug designation for additional product candidates, but we may be unable to obtain or maintain such a designation or the benefits associated with orphan drug status, including marketing exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recovered from sales in the United States for that drug. Orphan drug designation must be requested and granted by the FDA before a new NDA is submitted. After the FDA grants orphan drug designation, it will disclose publicly the generic identity of the drug and its potential orphan use. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The FDA granted orphan drug designation to PRAX-562 for the treatment of SCN2A-DEE and SCN8A-DEE, respectively, and to PRAX-222 for the treatment of SCN2A-DEE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable that market exclusivity is no longer justified. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is clinically superior because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or comparable foreign regulatory authority later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar disease or condition containing a different active ingredient. In addition, if a subsequent drug is approved for marketing for the same or a similar disease or condition as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We received rare pediatric disease designation for PRAX-562 and PRAX-222. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, U.S. Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor.  The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the United States within one year following the date of approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received rare pediatric disease designation for PRAX-562 for the treatment of SCN2A-DEE and SCN8A-DEE, and for PRAX-222 for the treatment of SCN2A-DEE. Designation of a drug product as a product for a rare pediatric disease does not guarantee that a NDA for such drug product will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, we will need to request a rare pediatric disease priority review voucher in our original NDA for our product candidates for which we have received rare pediatric disease designation. The FDA may determine that a NDA for any such product candidates, if approved, do not meet the eligibility criteria for a priority review voucher.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authority for the FDA to award rare pediatric disease priority review vouchers for drug products after September 30, 2024 is currently limited to product candidates that receive rare pediatric disease designation on or prior to September 30, 2024, and the FDA may only award rare pediatric disease priority review vouchers through September 30, 2026. However, it is possible the authority for the FDA to award rare pediatric disease priority review vouchers will be further extended by Congress.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ulatory Approval</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants approval of a product candidate, comparable regulatory authorities in other jurisdictions, including Australia and Europe, must also approve the manufacturing, marketing and sale of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must also be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to governmental approval. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration, or DEA, and other regulatory agencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may be classified as controlled substances, which are subject to state, federal, and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation, and distribution. Among other things, controlled substances are regulated under the federal Controlled Substances Act of 1970, and regulations of the DEA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Prior to commercialization, centrally acting drugs, such as those we are developing, are generally subject to review and potential scheduling by the DEA. It is possible that our product candidates may be regulated by the DEA as controlled substances, which would subject such product candidates to additional restrictions regarding their manufacture, shipment, storage, sale and use, depending on the scheduling of the active ingredients, and may limit the commercial potential of any of our product candidates, if approved. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various states also independently regulate controlled substances. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rule making or a legislative action. State scheduling may delay commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. We or our collaborators must also obtain separate state registrations in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any of our product candidates classified as controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates, and, in the future, the ability to produce and distribute our products in the volume needed to meet commercial demand. Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing our product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our product candidates that are classified as controlled substances.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following our products&#8217; marketing approval and commercialization. Product liability lawsuits brought against us or any of our future collaborators could divert our resources and attention, require us to cease clinical testing, cause us to incur substantial liabilities or limit commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biopharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the use of our product candidates by us and any collaborators in clinical trials may expose us to liability claims. We will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our partners if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable for human use during product testing, manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. Such claims could be made by participants enrolled in our clinical trials, patients, health care providers, biopharmaceutical companies, our collaborators or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the merits or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any of our future approved products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant litigation costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to, or costly settlements with, patients or other claimants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or a change in the indications for which any approved drug products may be used;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity associated with illness or other adverse effects resulting from physicians&#8217; or patients&#8217; use or misuse of our products or any similar products distributed by other companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage including clinical trial liability, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if we commercialize any product that receives regulatory approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from biopharmaceutical companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we face competition with T-type calcium channel inhibitor programs in development targeting ET, including that of Jazz Pharmaceuticals, as well as other programs in clinical development targeting other mechanisms of action, and approved therapies, such as propranolol, and off-label therapies, such as primidone; and sodium channel blocker or similar programs in development for DEEs, including those of SK-Pharma, Xenon Pharmaceuticals, Neurocrine Biosciences and Stoke Therapeutics, as well as other programs in clinical development targeting other mechanisms of action, and approved therapies including other existing ion channel blockers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these competitors or competitors for our other product candidates receive FDA approval before we do, our product candidates would not be the first treatment on the market, and our market share may be limited. In addition to competition from other companies targeting our target indications, any products we may develop may also face competition from other types of therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their strategic partners, have:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">products that have been approved or are in late stages of development; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborative arrangements in our target markets with leading companies and research institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease indications or similar indications, which could give such products significant regulatory and market timing advantages over our product candidates. Our competitors also may obtain FDA or other comparable foreign regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that we are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of our Product Candidates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Post-Marketin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Regulatory Requirements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to ongoing regulatory requirements in the applicable jurisdictions for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information. In addition, we will be subject to continued compliance with cGMP or similar regulatory requirements outside the United States and GCP requirements for any clinical trials that we conduct post-approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and their facilities are required to comply with extensive regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP or other similar regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP or similar regulatory requirements and adherence to commitments made in any marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. In the United States, the FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Similar requirements may apply in foreign jurisdictions. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and elsewhere, the FDA and foreign regulatory authorities may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information or other restrictions; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS or similar program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the manufacturing of our products, the approved manufacturers or the manufacturing process;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of the product from the market or voluntary product recalls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters from the FDA or comparable notice of violations from foreign regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions of any of our ongoing clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the FDCA relating to the promotion of prescription drugs may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. Accordingly, to the extent we receive marketing approval for one or more of our product candidates, we and our third-party partners will continue to expend time, money and effort in all areas of regulatory compliance, including promotional and labeling compliance, manufacturing, production, product surveillance and quality control. Any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow to, or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about drug products. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. For example, any regulatory approval that the FDA grants is limited to those indications and patient populations for which a drug is deemed to be safe and effective by the FDA.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While physicians in the United States may choose, and are generally permitted, to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any of our products candidates, if approved, will be narrowly limited to those indications and populations that are specifically approved by the FDA or such other regulatory agencies, and if we are found to have promoted such off-label uses, we may become subject to significant liability. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Sales, Marketing and Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends upon attaining significant market acceptance of our drug product candidates, if approved, among physicians, patients, third-party payors and other members of the medical community.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of the product candidates we develop receives marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, such as Medicare and Medicaid programs and managed care organizations in the United States, and others in the medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efficacy and potential advantages compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products, if approved, for sale at competitive prices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions by the medical community, physicians, and patients, regarding the safety and effectiveness of our products and the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market for such product candidate, based on the size of the patient subsets that we are targeting, in the territories for which we gain regulatory approval;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recommendations with respect to our product candidates in guidelines published by various scientific organizations applicable to us and our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of sales, marketing and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of any such marketing approval in relation to other product approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on concomitant use of other medications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support from patient advocacy groups;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain sufficient third-party coverage and adequate reimbursement; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates in the United States will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and biopharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, determines whether and to what extent new products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for our products and related treatments will be available from third-party payors. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy for coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for our products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decision by a third-party payor not to cover or not to separately reimburse for our medical products or therapies using our products could reduce physician utilization of our products once approved. Assuming there is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage for our product candidates, or therapies using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, in the European Union, member states can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and they can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Approaches between member states are diverging. For example, in France, effective market access will be supported by agreements with hospitals and products may be reimbursed by the Social Security Fund. The price of reimbursed medicines is negotiated with the Economic Committee for Health Products, or CEPS. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain approval of any of our product candidates in the United States or Europe, we may never obtain approval or commercialize such products in other countries, which would limit our ability to realize their full market potential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products in the United States or Europe, we must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals outside of where our clinical trials currently have been conducted could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we expect to establish a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ongoing Regulatory and Legal Compliance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Healthcare and Related Laws</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, upon commercialization of our product candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments in the United States as well as foreign governments in the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors, customers and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable federal, state and foreign healthcare laws and regulations laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The term remuneration has been interpreted broadly to include anything of value. Further, courts have found that if &#8220;one purpose&#8221; of remuneration is to induce referrals, the federal Anti-Kickback statute is violated. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs; knowingly making, using or causing to be made or used, a false record or statement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material to a false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. In addition, a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring qui tam actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery or settlement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician providers including physician providers including physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous U.S. state, local and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and other relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state and local laws that require the registration of biopharmaceutical sales representatives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that governmental and enforcement authorities will conclude that our business practices, including our arrangements with physicians and other healthcare providers, some of whom may receive stock options as compensation for services provided, may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to significant sanctions, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, exclusion from participation in federal and state funded healthcare programs, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to similar penalties. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. All of these could harm our ability to operate our business and our financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to, or may in the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the United States and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the General Data Protection Regulation, or GDPR, took effect in May 2018. The GDPR imposes stringent requirements on entities that process personal data of individuals in the European Economic Area, or EEA. These requirements include, for example, establishing a legal basis for processing, providing notice to data subjects about how personal data is collected and processed, developing procedures to vindicate expanded data subject rights, implementing appropriate technical and organizational measures to safeguard personal data, introducing the obligation to notify data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, imposing limitations on retention of personal data, maintaining a record of data processing and complying with the principal of accountability and the obligation to demonstrate compliance through policies, procedures, training and audit. In addition, the GDPR establishes obligations for entities that process &#8220;special categories&#8221; of personal data, such as health data. Nearly all clinical trials involve the processing of these &#8220;special categories&#8221; of personal data, and processing of personal data collected during the course of clinical trials is therefore subject to heightened protections under the GDPR. Violations of the GDPR can lead to potential fines of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant undertaking, whichever is greater. In addition to the foregoing, a breach of the GDPR could result in regulatory investigations, reputational damage, orders to cease / change our processing of our data, enforcement notices, and/ or assessment notices (for a compulsory audit). We may also face civil claims including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the European Union and the United States remains uncertain. For example, in 2016, the European Union and United States agreed to a transfer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">framework for data transferred from the European Union to the United States called the Privacy Shield, but in July 2020 the Court of Justice of the EU, or the CJEU, limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses, or SCCs. While the CJEU upheld the adequacy of the SCCs, it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the SCCs must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the SCCs cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. The revised SCCs apply only to the transfer of personal data outside of the EEA and not the United Kingdom, or the U.K.; the U.K.&#8217;s Information Commissioner&#8217;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, since January 2021, we may also be subject to the U.K. GDPR, which, together with the UK Data Protection Act 2018, retains the GDPR in U.K. national law. The U.K. GDPR mirrors the fines under the GDPR, meaning the potential of parallel fines of up to the greater of &#163;17.5 million or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the U.K. adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/ extends that decision and remains under review by the Commission during this period. In September 2021, the U.K. government launched a consultation on its proposals for wide-ranging reform of U.K. data protection laws following Brexit. There is a risk that any material changes which are made to the U.K. data protection regime could result in the European Commission reviewing the U.K. adequacy decision, and the United Kingdom losing its adequacy decision if the European Commission deems the United Kingdom to no longer provide adequate protection for personal data. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains uncertain, and it is unclear how U.K. data protection laws and regulations will develop in the medium to longer term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, including protected health information, or PHI, by health plans, certain health care clearinghouses and health care providers that submit certain covered transactions electronically, or covered entities, and their &#8220;business associates,&#8221; which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI, as well as their covered subcontractors. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA, we may receive individually identifiable health information from these entities. Failure to receive this information properly could subject us to HIPAA&#8217;s criminal penalties. Further, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Various states, such as California and Massachusetts, have also implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, or the CMIA, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to imposing fines and penalties, some of these state laws afford private rights of action to individuals who </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for significant penalties and permit injured parties to sue for damages. In addition to the CMIA, California also enacted the California Consumer Privacy Act of 2018, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the California Privacy Rights Act, or CPRA, which generally went into effect on January 1, 2023, significantly amends the CCPA and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have been passed in Virginia, Colorado, Connecticut and Utah, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Federal Trade Commission, or the FTC, and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. The legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing focus on privacy and data security issues which may affect our business. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with current and future laws and regulations could result in government enforcement actions (including the imposition of significant penalties), criminal and/or civil liability for us and our officers and directors, private litigation and/or adverse publicity that negatively affects our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and in some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative initiatives and regulatory changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the ACA was enacted, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, expands the types of entities eligible for the 340B drug discount program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; established annual fees and taxes on manufacturers of certain branded prescription drugs; and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of January 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been numerous judicial, administrative, executive and legislative challenges to certain aspects of the ACA.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 17, 2021 the U.S. Supreme Court dismissed the recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s AMP, for single source and innovator multiple source drugs, beginning January 1, 2024. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payment methodologies may also be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. Recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their products. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship b</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">etween pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. By way of example, in August 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level in the United States, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or in any other jurisdictions. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the United States, inadequate funding for the FDA, the SEC, and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherently fluid and unpredictable. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and or modifications to approved drugs or to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to International Re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ulations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ultimately intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national laws of EU member states, and in respect of the United Kingdom (which is longer a member of the European Union), the U.K. Bribery Act of 2010. Infringement of these laws could result in substantial fines and imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians must often be subject to a prior notification and/or approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. This regulation which entered into force in January 2022 and will become applicable from January 12, 2025 onwards, intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal, political and economic uncertainty surrounding the exit of the United Kingdom from the European Union may be a source of instability in international markets, create significant currency fluctuations, adversely affect our operations in the United Kingdom and pose additional risks to our business, revenue, financial condition and results of operations.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the United Kingdom held a referendum in which a majority of the eligible members of the electorate voted to leave the European Union, commonly referred to as Brexit. Pursuant to Article 50 of the Treaty on EU, the United Kingdom ceased being an EU member state on January 31, 2020. On December 30, 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement, or TCA, which includes an agreement on free trade between the two parties and has been provisionally applicable since January 1, 2021. Since January 1, 2021, the United Kingdom has operated under a separate regulatory regime to the European Union. EU laws regarding medicinal products only apply in respect of the United Kingdom to Northern Ireland (as set out in the Protocol on Ireland/Northern Ireland). The EU laws that have been transposed into U.K. law through secondary legislation remain applicable as &#8220;retained EU law.&#8221; However, under the Retained EU Law (Revocation and Reform) Bill 2022, which is currently before the U.K. parliament, any retained EU law not expressly preserved and &#8220;assimilated&#8221; into domestic law or extended by ministerial regulations (to no later than 23 June 2026) will automatically expire and be revoked by December 31, 2023. In addition, new EU legislation will not be applicable in Great Britain. The TCA includes specific provisions concerning medicinal products, which include the mutual recognition of Good Manufacturing Practice, or GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued (such mutual recognition can be rejected by either party in certain circumstances), but does not foresee wholesale mutual recognition of U.K. and EU pharmaceutical regulations. Therefore, there remains political and economic uncertainty regarding to what extent the regulation of medicinal products will differ between the United Kingdom and the EU in the future. The U.K. government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicines and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps. There is a possibility that over time, national laws will be amended and that consequently the regulatory framework in Great Britain will diverge from that of the EU. Any divergences will increase the cost and complexity of running our business, including with respect to the conduct of clinical trials. Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our drug candidates is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derived from EU directives and regulations, Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our drug candidates in the United Kingdom or the European Union. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Great Britain (England, Scotland and Wales) is no longer covered by the European Union&#8217;s procedures for the grant of marketing authorizations (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). A separate marketing authorization will be required to market medicinal products in Great Britain. As of January 1, 2021, the Medicines and Healthcare Products regulatory Agency, or MHRA, is the United Kingdom's standalone medicines and medical devices regulator. It is currently unclear whether the MHRA is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, could prevent us and our collaborators or delay us and our collaborators from commercializing our drug candidates in the United Kingdom and/or the EEA and restrict our ability to generate revenue and achieve and sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The uncertainty concerning the United Kingdom&#8217;s legal, political and economic relationship with the European Union after Brexit may be a source of instability in the international markets, create significant currency fluctuations and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise) beyond the date of Brexit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These developments, or the perception that any of them could occur, may have a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the U.K. financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates and credit ratings may also be subject to increased market volatility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such a withdrawal from the European Union is unprecedented, and it is unclear how the United Kingdom&#8217;s access to the European single market for goods, capital, services and labor within the European Union, or single market, and the wider commercial, legal and regulatory environment, will impact our current and future operations (including business activities conducted by third parties and contract manufacturers on our behalf) and clinical activities in the United Kingdom. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional laws and regulations governing international operations could negatively impact or restrict our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business entity from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals and healthcare providers in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information products classified for national security purposes, as well as certain products, technology and technical data relating to those products. If we continue and expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products, if approved, in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees and our business, prospects, operating results and financial condition. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Licensed Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies and methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities and whether a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications, or obtain, maintain and/or enforce patents or trademarks that may issue or be registered based on our applications, at a reasonable cost or in a timely manner. In addition, our pending and future patent applications may not result in issued patents that protect our technology or products, in whole or in part, or may not effectively prevent others from commercializing competitive technologies and products.Changes in either patent laws or interpretation of patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Further, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and biopharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications that we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop new or improved products and threaten our ability to commercialize our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Similarly, for United States applications in which at least one claim is not entitled to a priority date before March 16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#8217;s disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, would adequately protect our product candidates, or would be found by a court to be infringed by a competitor&#8217;s technology or product. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that may issue that cover our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-to-file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">others may be able to make or use compounds that are similar to the compositions of our product candidates but that are not covered by the claims of our patents or those of our licensors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">it is possible that our pending patent applications will not result in issued patents;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">it is possible that others may circumvent our owned or in-licensed patents;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or may be held invalid or unenforceable as a result of legal challenges by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents or become hostile to us or the patents or patent applications on which they are named as inventors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we have engaged in scientific collaborations in the past, and are likely to continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">it is possible that product candidates or diagnostic tests that we develop may be covered by third parties&#8217; patents or other exclusive rights; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to License and Collaboration A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">reements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into, and may enter into, license or other collaboration agreements that impose certain obligations on us. If we fail to comply with our obligations under such agreements with third parties or otherwise experience disruptions to our business relationships with our current or future licensors, we could lose rights that may be important to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our efforts to expand our pipeline of product candidates, we have entered into and may further enter into certain licenses or other collaboration agreements in the future pertaining to the in-license of rights to additional candidates. Such agreements may impose various reporting, diligence, milestone payment, royalty, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed intellectual property, or to pursue other remedies.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to obtain licenses at a reasonable cost or on reasonable terms, if at all. Furthermore, if we lose intellectual property rights licensed under existing agreements or fail to obtain future licenses, we may be required to expend considerable time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected proprietary technologies and product candidates, which could harm our business significantly. Third-party patents may exist which might be enforced against our current or future proprietary technologies and product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the priority of invention of patented technology.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or could increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. If any of our current or future licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business and our competitors could market competing products using the intellectual property. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners, including loss of our right to prosecute the licensed patent applications or early termination of the license by our licensor. We also may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technology licensed from third parties may be subject to retained rights.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any license we may enter into could provide for the retention by the licensor of certain rights under their agreements with us, including for example, the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether any future licensors will limit their use of the technology to these uses, and we may incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The U.S. government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. The Bayh-Dole Act also imposes other obligations, including the requirement that products covered by the government funded patents be manufactured in the United States.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with academic institutions to accelerate our preclinical research or development. In the future, we may own or license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act. If the federal government exercises its rights under the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on trade secrets and proprietary know-how, which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets and proprietary know-how, our business and competitive position would be harmed.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Additionally, because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Potential Third-Party Claims</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be subject to, or threatened with, other third party claims relating to alleged infringement of intellectual property or other proprietary rights, including breach of nondisclosure, nonuse, noncompetition and non-solicitation provisions, intellectual property assignment and ownership, and misuse or misappropriation of intellectual property, trade secrets and other confidential information, among others. If a court of competent jurisdiction finds us liable for any such claims, we may be prohibited from using certain intellectual property, trade secrets and confidential information, effectively blocking our ability to seek patent protection for our inventions and slowing or halting the progress of our clinical development and commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third-party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross- licenses to intellectual property rights for our products and any license that is available may be non-exclusive, which could result in our competitors gaining access to the same intellectual property; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">redesigning our product candidates or processes so that they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing technologies, product candidates or products. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing technologies, product candidates or products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. A finding of infringement could prevent us from commercializing our technologies, product candidates or products or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop non-infringing technology, which may not be possible on a cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop or otherwise arising from the collaboration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collaborate with several institutions, universities, medical centers, physicians and researchers in scientific matters and expect to continue to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators, or the written agreements we have do not cover intellectual property rights. Also, we rely on numerous third parties to provide us with materials that we use to conduct our research activities and develop our product candidates. If we cannot successfully negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party collaborator&#8217;s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator&#8217;s samples, or data developed in a collaborator&#8217;s study, in cases where written agreements either do or do not exist, we may be limited in our ability to capitalize on the market potential of these inventions or developments.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that employees, former employees or third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors or not named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, or portion of such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be third-party patents of which we are currently unaware with claims to compounds, compositions of matter, materials, formulations, methods of manufacture or methods of use that encompass the composition, use or manufacture of our product candidates. There may be currently pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or their use or manufacture may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidates. If any third-party patent were held by a court of competent jurisdiction to cover our product candidates, intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible, or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A court could also prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing our compounds and pre-existing biopharmaceutical compounds. We may be unable to acquire or in-license any compounds, compositions, formulations, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compounds, compositions formulations, methods of use or processes covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have different or greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, or the patents or intellectual property of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors or other third parties may infringe our patents, trademarks, copyrights or other intellectual property, or the intellectual property of our current or future licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In addition, in any infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex-parte </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re-examination, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing or, in some cases, not at all, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on inventions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we may not have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Patent Laws and Protection</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on any issued patent and/or patent application are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during patent prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive position, business, financial conditions, and prospects. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, our current licensed or owned patents are expected to expire between 2029 and 2041, without taking into account any possible patent term adjustments or extensions. Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. Our current licensed or owned pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2029 through 2043, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent applications not already granted or that a court will uphold any patents already issued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March 16, 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter-parties review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biopharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive technologies and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. We may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and tradenames.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Third Parties Generally</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to assist in conducting our preclinical studies and clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely on third parties, such as laboratories, CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our preclinical studies and clinical trials and expect to rely on these third parties to conduct preclinical studies and clinical trials of any other product candidate that we develop. Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. Moreover, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our reliance on these third parties for preclinical and clinical development activities limits our control over these activities, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. Moreover, human clinical research must comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and IRBs. If we or our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the regulatory authorities may require us to perform additional clinical trials before approving our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates, which would delay the regulatory approval process. We cannot be certain that, upon inspection, a regulatory authority will determine that any of our clinical trials comply with GCPs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. These outside contractors may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationships with any third parties conducting our studies are terminated, we may be unable to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. Switching or adding third parties to conduct our studies involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired preclinical and clinical development timelines. Although we carefully manage our relationships with third parties conducting our studies, we cannot assure that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material and adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Third-Party Manufacturers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with third parties for the manufacture of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the breach by the third-party contractors of our agreements with them;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of third-party contractors to comply with applicable regulatory requirements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of the third party to manufacture our product candidates according to our specifications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical supplies not being delivered to clinical sites on time and at expected cost due to inflationary impacts, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP or similar regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP or similar regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the quality of the product, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Third-Party Suppliers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party suppliers for key raw materials used in our manufacturing processes, some of which are our sole source of supply, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our CDMOs to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. We do not have, nor do we expect to enter into, any agreements for the commercial production of these raw materials, and we do not expect to have any control over the process or timing of our CDMOs&#8217; acquisition of raw materials needed to produce our product candidates. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial due to a manufacturer&#8217;s need to replace a third-party supplier of raw materials could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. Additionally, if our future manufacturers or we are unable to purchase these raw materials to commercially produce any of our product candidates that gains regulatory approvals, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, for those third-party suppliers who may be our sole source of supply of certain materials, we may not have arrangements in place for a redundant or second-source supply of any such materials in the event any of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our current suppliers cease their operations for any reason. Establishing additional or replacement suppliers for the raw materials used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may seek in the future, third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop. For example, we have a collaboration with Ionis Pharmaceuticals, Inc. to further our development of product candidates and to enhance our research efforts directed to developing a product candidate for the treatment of epilepsy. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies and academic institutions, such as The Florey Institute of Neuroscience. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our research programs, or any product candidates we may develop, pose the following risks to us:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or research programs, or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our product candidates or research programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may control certain interactions with regulatory authorities, which may impact our ability to obtain and maintain regulatory approval of our products candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may restrict us from researching, developing or commercializing certain products or technologies without their involvement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how or intellectual property of the collaborator relating to our products, product candidates or research programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders or disrupt our management and business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our collaborations with them, we may not be able to develop or commercialize product candidates as planned;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully control and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. The failure to develop and commercialize a product candidate pursuant to our agreements with our current or future collaborators could prevent us from receiving future payments under such agreements, which could negatively impact our revenues. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this &#8220;Risk Factors&#8221; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions or alliances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Our Business and Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Business Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing and changing regulatory requirements in non-U.S. countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States, including our ability to prosecute or maintain patents in Russia due to the sanctions imposed by the United States and other countries on Russia as a result of Russia&#8217;s invasion of Ukraine and our ability to enforce patents due to Russia's March 2022 decree that allows the use of inventions, utility models and industrial designs that are held by intellectual property owners from "unfriendly countries," including the United States, without the consent of or payment of any compensation to such owners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in non-U.S. currency exchange rates and currency controls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative consequences from changes in tax laws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the Foreign Corrupt Practices Act, U.K. Bribery Act of 2010 or comparable foreign laws, including expanded sanctions imposed by the United States and other countries on Russia due to Russia's invasion of Ukraine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, such as Russia's invasion of Ukraine, natural disasters including earthquakes, typhoons, floods and fires, or health epidemics such as COVID-19; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cyberattacks, which are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect, including an increased likelihood that Russia's invasion of Ukraine could result in more cyberattacks or cybersecurity incidents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend may be adversely affected by natural disasters, health epidemics or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters or health epidemics could severely disrupt our operations, and have a material adverse impact on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, health epidemic or other event occurred that prevented us from conducting our clinical trials, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">releasing clinical trial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results or delaying our ability to obtain regulatory approval for our product candidates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, since December 2019, several novel strains of coronavirus have been identified and continue to spread globally, including in the United States, and the disease they cause, COVID-19, has been declared a pandemic by the World Health Organization. The COVID-19 pandemic and government measures taken in response thereto have impacted the global economy and may impact our operations, including the potential interruption of our clinical trial activities, regulatory reviews and our supply chain. As a result of stringent COVID-19 lockdown restrictions, we had previously observed delays in trial enrollment for our Phase 2a trial for ulixacaltamide in Australia. While these lockdowns did not lead to a material impact on our business, we cannot predict the scope and severity of potential shutdowns or disruptions of businesses due to COVID-19 or another pandemic, epidemic or outbreak of an infectious disease in the future. At present, we are not experiencing significant impact or delays from the COVID-19 pandemic on our business, operations and, if our product candidates are approved, commercialization plans.We continue to closely monitor the COVID-19 pandemic as we evolve our clinical development plans. The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the novel coronavirus strains, and of any future-identified novel coronavirus strains, the effectiveness of actions taken in the United States and other countries to contain the coronavirus strains or treat their impact, including the adoption and effectiveness of vaccines and vaccine distribution efforts and the extent and duration of the pandemic's impact on economic conditions and social activity, including with respect to inflationary pressures and supply chain shortages and disruptions, among others. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Employees</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on our executive officers, principal consultants and others, and the loss of their services would materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, and will likely continue to depend, upon our ability to retain the services of our current executive officers, principal consultants and others, including Marcio Souza, our President and Chief Executive Officer, and Timothy Kelly, our Chief Financial Officer. We have entered into employment agreements with Mr. Souza and Mr. Kelly, but they may terminate their employment with us at any time. The loss of their services might impede the achievement of our research, development and commercialization objectives. In August 2022, Bernard Ravina stepped down as our Chief Medical Officer and transitioned to a part-time role as strategic advisor. This change in our senior management may be disruptive to our business, and if we are unable to manage an orderly transition of Dr. Ravina's duties to our clinical team or to a new Chief Medical Officer, our business may be adversely affected. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our industry has experienced significant demand for, and a high rate of turnover of, management personnel in recent years. Replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have a limited number of employees to manage and operate our business. We cannot ensure that we will be able to maintain adequate staff to develop our product candidates, to run our operations or accomplish our objectives. If we are unable to maintain adequate staffing levels, our business and operations could be materially adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, collaborators and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing standards;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws that require the accurate reporting of financial information or data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product materials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this kind of activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, integrity oversight and reporting obligations, possible exclusion from participation in the United States in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of regulatory affairs and sales, marketing and distribution, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational, quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Data Privacy and Cybersecurity</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyberattacks or other failures in our telecommunications or information technology systems, or those of our collaborators, contract research organizations, third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our collaborators, our CROs, third-party logistics providers, distributors and other contractors and consultants utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including third parties gaining access to employee accounts using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks or other means, and deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. Attacks upon information technology systems are also increasing in their levels of persistence and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not believe that we have experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. These threats pose a risk to the security of our, our collaborators&#8217;, our CROs&#8217;, third-party logistics providers&#8217;, distributors&#8217; and other contractors&#8217; and consultants&#8217; systems and networks, and the confidentiality, availability and integrity of our data. There can be no assurance that we will be successful in preventing cyberattacks or successfully mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting our clinical and other data that is stored on their systems. Any cyberattack, data breach or destruction or loss of data could result in a violation of applicable U.S. and international privacy, data protection and other laws, and subject us to litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the United States and by international regulatory entities, resulting in exposure to material civil and/or criminal liability. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed; and could have a material adverse effect on our business and prospects. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials for any of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyberattacks or other data security breaches and may incur significant additional expense to implement further data protection measures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a set of cloud-based software services and access these services via the Internet for the vast majority of our computing, storage, bandwidth and other services. Any disruption of or interference with our use of our cloud-based services would negatively affect our operations and could seriously harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use several distributed computing infrastructure platforms for business operations, or what is commonly referred to as &#8220;cloud&#8221; computing services and we access these services via the Internet. Any transition of the cloud services currently provided by an existing vendor to another cloud provider would be difficult to implement and will cause us to incur significant time and expense. Given this, any significant disruption of or interference with our use of these cloud computing services would negatively impact our operations and our business would be seriously harmed. If our employees or partners are not able to access our cloud computing services or encounter difficulties in doing so, we may experience business disruption. The level of service provided by our cloud computing vendors, including the ability to secure our confidential information and the confidential information of third parties that is shared with us, may also impact the perception of our company and could seriously harm our business and reputation and create liability for us. If a cloud computing service that we use experiences interruptions in service regularly or for a prolonged basis, or other similar issues, our business could be seriously harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a cloud computing service may take actions beyond our control that could seriously harm our business, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discontinuing or limiting our access to its platform;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing pricing terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminating or seeking to terminate our contractual relationship altogether; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modifying or interpreting its terms of service or other policies in a manner that impacts our ability to run our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cloud computing services have broad discretion to change and interpret its terms of service and other policies with respect to us, and those actions may be unfavorable to us. Our cloud computing services may also alter how we are able to process data on the platform. If a cloud computing services makes changes or interpretations that are unfavorable to us, our business could be seriously harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to protect the information shared with us may be unsuccessful due to the actions of third parties, software bugs or other technical malfunctions, employee error or malfeasance or other factors. In addition, third parties may attempt to fraudulently induce employees or users to disclose information to gain access to our data or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party data entrusted to us. If any of these events occur, our or third-party information could be accessed or disclosed improperly. Some partners or collaborators may store information that we share with them on their own computing system. If these third parties fail to implement adequate data-security practices or fail to comply with our policies, our data may be improperly accessed or disclosed. And even if these third parties take all of these steps, their networks may still suffer a breach, which could compromise our data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any incidents where our information is accessed without authorization, or is improperly used, or incidents that violate our policies, could damage our reputation and our brand and diminish our competitive position. In addition, affected parties or government authorities could initiate legal or regulatory action against us over those incidents, which could cause us to incur significant expense and liability or result in orders or consent decrees forcing us to modify our business practices. Concerns over our privacy practices, whether actual or unfounded, could damage our reputation and brand and deter users, advertisers and partners from using our products and services. Any of these occurrences could seriously harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Tax Laws</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation or other changes in U.S. tax law could adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislation, regulations and rules regarding U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department and by state and local tax agencies. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. In particular, the U.S. federal government may enact significant changes to the taxation of business entities including, among others, an increase in the corporate income tax rate and the imposition of minimum taxes or surtaxes on certain types of income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It cannot be predicted whether, when, in what form or with what effective dates any changes in tax laws, regulations or rules, promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. If any such changes are enacted or implemented, we care currently unable to predict the ultimate impact on our business or holders of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our U.S. federal and state net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to use our U.S. federal and state net operating losses and tax credits is dependent upon our generation of future taxable income and income tax liabilities, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income or income tax liabilities to use any or all of our net operating losses or tax credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unused U.S. federal net operating losses generated in tax years beginning before January 1, 2018, and unused state net operating losses subject to expiration, will carry forward to offset future taxable income, if any, until such unused net operating losses expire. Our unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017 will not expire and may be carried forward indefinitely, although, for taxable years beginning after December 31, 2020, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in such taxable year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, both our current and future net operating losses and tax credits may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if we undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders or groups of stockholders over a rolling three-year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Investment in Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock has been and may in the future be volatile, and you could lose all or part of your investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been and is likely to continue to be highly volatile and has been subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. For example, the trading price of our common stock experienced a significant decline after our June </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 announcement of the Phase 2/3 Aria Study results. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, factors that may affect the trading price of our common stock include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, enrollment, completion or results of our current clinical trials of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in identifying and advancing a clinical candidate for our other programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval of any of our product candidates or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to establish collaborations, if needed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to commercialize our product candidates, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of the healthcare payment systems;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as a result of the COVID-19 pandemic and general economic conditions. Broad market and industry factors have negatively affected and may continue to negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and their affiliates and our principal stockholders own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on shares outstanding as of December 31, 2022, our executive officers, directors and their affiliates and our principal stockholders beneficially hold, in the aggregate, approximately 49.2% of our outstanding voting stock. These stockholders, acting together, would be able to exert significant influence over all matters requiring stockholder approval. The concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. This concentration of ownership control may adversely affect the market price of our common stock by:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delaying, deferring or preventing a change in control;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entrenching our management and the board of directors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impeding a merger, consolidation, takeover or other business combination involving us that other stockholders may desire; and/or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Controls and Reporting Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd- Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations applicable to public companies substantially increase our legal and financial compliance costs and make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined under SEC rules. As a smaller reporting company, we are able to take advantage of certain exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and providing only two years of audited financial statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion over the use of our cash and cash equivalents and may not use them effectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending our use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Charter and Bylaws</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our bylaws (in each case, as they may be amended from time to time) or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided, however, that this exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated bylaws also specify that unless we consent in writing to the selection of an alternate forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clause in our bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The enforceability of similar choice of forum provisions in other companies&#8217; governing documents has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sublease a facility containing 25,445 square feet of office space, which is located at 99 High Street, Boston, Massachusetts 02110. Our sublease expires on January&#160;31, 2026. We believe that our current facility is sufficient to meet our current and&#160;near-term&#160;needs and that, should it be needed, suitable additional space will be available. </span></div><div id="i3603669404fe4fc8b59d31b31e26e467_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Information Regarding the Trading of Our Common Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol &#8220;PRAX&#8221; on the Nasdaq Global Select Market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of Our Common Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 3, 2023, there were approximately three holders of record of shares of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to fund the development and expansion of our business, and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not make any sales of unregistered securities during the three months ended December 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from Initial Public Offering</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we completed the initial public offering of our common stock, or IPO, pursuant to which we issued and sold 11,500,000 shares of our common stock at a price to the public of $19.00 per share. All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No. 333-249074), which was declared effective by the Securities and Exchange Commission on October 15, 2020. As of December 31, 2022, we had used all of the net proceeds from the IPO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no repurchases of shares of common stock made during the three months ended December 31, 2022.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Selected Financial Data </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and financing needs, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted in our Company Overview in Part I of this report, we are a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs, with significant potential for additional program and indication expansion: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Cerebrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Solidus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, our antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For our most advanced product candidate under the Cerebrum&#8482; platform, ulixacaltamide (formerly known as PRAX-944), we expect to announce topline results from the Phase 2b Essential1 clinical trial in essential tremor, or ET, in the first quarter of 2023. We also plan to initiate an ulixacaltamide Phase 2 clinical trial in Parkinson's disease, or PD, in the first quarter of 2023 and expect topline results in the fourth quarter of 2023. We plan to initiate</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our PRAX-562 Phase 2 EMBOLD study in the first quarter of 2023, with initial cohorts in SCN2A-DEE and SCN8A-DEE, and expect to announce topline results for both cohorts in the second half of 2023. We also initiated a Phase 1 healthy volunteer study of PRAX-628 in the fourth quarter of 2022 and expect to report topline results in mid-2023. For our most advanced product candidate under the Solidus&#8482; platform, PRAX-222, we expect to announce topline results from the first dose cohort of our EMBRAVE study in mid-2023. For further details on our business, refer to the Business section of Part I of this report.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 2015 and commenced operations in 2016. Since inception, we have devoted substantially all of our resources to developing our preclinical and clinical product candidates, building our intellectual property, or IP, portfolio, business planning, raising capital and providing general and administrative support for these operations. We employ a &#8220;virtual&#8221; research and development model, relying heavily upon external consultants, collaborators, contract development and manufacturing organizations and contract research organizations, or CROs, to conduct our preclinical and clinical activities. Since inception, we have financed our operations primarily with proceeds from the sale and issuance of equity securities.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage company and we have not generated any revenue from product sales, and do not expect to do so for several years, if at all. All of our product candidates are still in preclinical and clinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates, if approved. We have incurred recurring operating losses since inception, including net losses of $214.0&#160;million and $167.1&#160;million for the years ended December 31, 2022 and 2021, respectively. As of December&#160;31, 2022, we had an accumulated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deficit of $530.6 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our lead product candidate, ulixacaltamide, to a late stage clinical trial for the treatment of ET;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance ulixacaltamide in our Phase 2 clinical trial for the treatment of PD;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our PRAX-562 product candidate in the EMBOLD clinical trial;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our PRAX-222 product candidate in the EMBRAVE clinical trial;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our PRAX-628 product candidate in the Phase 1 clinical trial;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our preclinical candidates to clinical trials;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further invest in our pipeline;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further invest in our manufacturing capabilities;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approval for our product candidates;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand, protect and defend our IP portfolio;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license technology;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when needed, increase our headcount to support our development efforts and any future commercialization efforts.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities of $100.5 million, which will enable us to fund our operating expenses and capital expenditures into the first quarter of 2024. Since our cash, cash equivalents and marketable securities as of December&#160;31, 2022 are not sufficient to fund our operations for at least the next twelve months from the date of issuance of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, there is substantial doubt about our ability to continue as a going concern. Our future viability is dependent on our ability to raise additional capital to finance our operations. We expect to finance our operations through potential public or private equity financings, debt financings, collaboration agreements or other capital sources. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. We have based our assessment on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, we began a strategic realignment to focus resources on our ulixacaltamide, PRAX-562, PRAX-222 and PRAX-628 product candidates, as well as our preclinical programs across our Cerebrum&#8482; and Solidus&#8482; platforms, which resulted in a reduction of our workforce. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in research and development expenses and $0.4 million has been recognized in general and administrative expenses in the consolidated statement of operations during the year ended December&#160;31, 2022. These costs relate to employee severance, benefits and related costs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, all costs related to the strategic realignment were paid.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue since inception and do not expect to generate any revenue from the sale of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval or collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 9 to our audited consolidated financial statements, we have entered into a collaboration agreement that will result in the recognition of $5.0&#160;million of revenue upon the satisfaction of the performance obligation identified within the agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities generate a significant amount of research and development costs. Research and development expenses represent costs incurred by us for the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to develop our portfolio;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discovery efforts leading to development candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical development costs for our product candidates; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to develop our manufacturing technology and infrastructure.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs above comprise the following categories:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, such as consultants, investigative sites and CROs, that conduct our preclinical and clinical studies and in-licensing arrangements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred to maintain compliance with regulatory requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred with third-party contract development and manufacturing organizations to acquire, develop and manufacture materials for preclinical and clinical studies; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depreciation, amortization and other direct and allocated expenses, including rent and other operating costs, such as information technology, incurred as a result of our research and development activities.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated balance sheets as prepaid expenses or accrued expenses. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company operating in a virtual environment, a significant portion of our research and development costs have been external costs. We track direct external research and development expenses to specific platforms and product candidates upon commencement. Due to the number of ongoing studies and our ability to use resources across platforms, indirect or shared operating costs incurred for our research and development platforms, such as personnel, facility costs and certain consulting costs, are not recorded or maintained on a platform-specific basis.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our research and development expenses, including direct expenses summarized by platform and indirect or shared operating costs recognized as research and development expenses during each period presented (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cerebrum&#8482;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solidus&#8482;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel-related (including stock-based compensation)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other indirect research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will be maintained or increase in the foreseeable future as we advance our product candidates through the development phase, and as we continue to discover and develop additional product candidates, build manufacturing capabilities and expand into additional therapeutic areas.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to add and retain key research and development personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and progress of preclinical and clinical development activities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully complete clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration, or the FDA, or any comparable foreign regulatory authority;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our successful enrollment in and completion of clinical trials;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patent, trade secret and other IP protection and regulatory exclusivity for our product candidates, if approved;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize products, if approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued acceptable safety profiles of our product candidates.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete our clinical development activities. We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and require significant development costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, legal, commercial and administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; commercial-related costs to support market assessments and scenario planning; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for office rent and other operating costs, such as information technology. Costs to secure and defend our IP are expensed as incurred and are classified as general and administrative expenses. These costs relate to the operation of the business and are unrelated to the research and development function or any individual platform or product candidate. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses may increase in the future as we increase our headcount, when needed, to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur additional IP-related expenses as we file patent applications to protect innovations arising from our research and development activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. As of December 31, 2022 and 2021, we had U.S. federal and state net operating loss carryforwards which may be available to offset future taxable income and which begin to expire in 2035. As of December 31, 2022 and 2021, we also had federal and state research and development tax credit carryforwards which may be available to offset future income tax liabilities and which begin to expire in 2031.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the years ended December 31, 2022 and 2021.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2022 and 2021</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated statements of operations for each period presented (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214,029)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,061)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,968)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cerebrum&#8482;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solidus&#8482;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel-related (including stock-based compensation)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other indirect research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $34.8 million increase in research and development expenses was primarily attributable to the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$20.0&#160;million increase in expense related to our Cerebrum&#8482; platform, driven primarily by:</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an increase in clinical, manufacturing and toxicology-related spend for our ulixacaltamide program, including our Phase 2b Essential1 clinical trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an increase in clinical-related spend for our PRAX-114 Phase 2 clinical trials, all of which were wound down during the second and third quarters of 2022 due to our strategic realignment;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an increase in clinical-related spend for our PRAX-628 Phase 1 clinical trial; and</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">an increase in costs associated with our Phase 1 PRAX-562 clinical trial in healthy volunteers and startup costs related to the EMBOLD Phase 2 clinical trial, partially offset by a decrease related to prior year toxicology-related spend for PRAX-562.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$9.9&#160;million increase in expense related to our Solidus&#8482; platform, driven primarily by an increase in clinical-related spend to support the initiation of the PRAX-222 EMBRAVE clinical trial, an increase in preclinical activities for our earlier stage assets and the payment of a $2.0 million license fee to Ionis Pharmaceuticals, Inc. in January of 2022 upon exercise of our exclusive option to obtain the rights and license to further develop and commercialize PRAX-222; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$6.3&#160;million&#160;increase in personnel-related costs due to changes in headcount.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $12.9 million increase in general and administrative expenses was primarily attributable to an $11.8 million increase in personnel-related costs due to changes in headcount, including an increase of $5.3 million in stock-based compensation expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the years ended December 31, 2022 and 2021 was comprised of interest income on our cash, cash equivalents and marketable securities and investment premium and discount amortization.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses in each period. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, a follow-on public offering and at-the-market offerings under our shelf registration statement. From inception through December&#160;31, 2022, we have raised $526.0&#160;million in aggregate cash proceeds from such transactions, net of issuance costs. As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities of $100.5 million. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2021, we entered into an Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of $125.0 million of common stock from time to time in at-the-market offerings for which Jefferies acts as sales agent. During the year ended December&#160;31, 2022, we issued and sold 3,595,273 shares under the Sales Agreement for aggregate net proceeds of $9.6 million after deducting commissions and offering expenses payable by us. As of December&#160;31, 2022, we have issued and sold a total of 3,987,270 shares under the Sales Agreement for aggregate net proceeds of $16.6 million after deducting commissions and offering expenses payable by us. Subsequent to December&#160;31, 2022, we issued and sold a total of 2,942,083 shares under the Sales Agreement for aggregate net proceeds of $11.2 million after deducting commissions and offering expenses payable by us. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for each period presented (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(185,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,689)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157,488)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support the business. We have historically experienced negative cash flows from operating activities as we have invested in developing our portfolio, drug discovery efforts and related infrastructure. The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in operating assets and liabilities, which are primarily the result of increased expenses and timing of vendor payments.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash used in operating activities of $185.0&#160;million was primarily due to our $214.0 million net loss and $1.8 million in changes in operating assets and liabilities primarily related to a decrease in accrued expenses, partially offset by $30.8 million of non-cash charges primarily related to stock-based compensation.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash used in operating activities of $124.6 million was primarily due to our $167.1 million net loss, partially offset by $26.4 million of non-cash charges primarily related to stock-based compensation and $16.1 million in changes in operating assets and liabilities primarily related to increases in accounts payable and accrued expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash provided by investing activities of $96.9&#160;million primarily related to the maturities of marketable securities, partially offset by purchases of marketable securities.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash used in investing activities of $140.5 million primarily related to the purchase of marketable securities, partially offset by the maturities of marketable securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, net cash provided by financing activities of $10.5&#160;million consisted of net proceeds from at-the-market offerings of $9.6 million and proceeds from purchases of common stock under our employee stock purchase plan and from the exercise of stock options of $1.4 million, partially offset by the payment of issuance costs for our at-the-market offerings and the payment of taxes related to the vesting of restricted stock units.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash provided by financing activities of $107.6 million consisted of net proceeds from our follow-on public offering of $98.4&#160;million and at-the-market offerings of $7.3 million and net proceeds from the exercise of stock options of $2.4 million, partially offset by the payment of issuance costs for our initial public offering.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operation and Future Funding Requirements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the clinical development of our clinical-stage product candidates within our Cerebrum&#8482; and Solidus&#8482; platforms;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance the development of any additional product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and continue preclinical development of potential product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make strategic investments in manufacturing capabilities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain our IP portfolio and opportunistically acquire complementary IP;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to obtain regulatory approvals for our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when needed, add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 we had cash, cash equivalents and marketable securities of $100.5 million. Subsequent to December&#160;31, 2022, we issued and sold a total of 2,942,083 shares under the Sales Agreement for aggregate net proceeds of $11.2 million after deducting commissions and offering expenses payable by us. We are unable to estimate the exact amount of our working capital requirements, but based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December&#160;31, 2022, together with net proceeds raised under the Sales Agreement subsequent to December&#160;31, 2022, will enable us to fund our operating expenses and capital expenditures into the first quarter of 2024. We have incurred recurring losses since our inception, including a net loss of $214.0&#160;million for the year ended December&#160;31, 2022. In addition, as of December&#160;31, 2022, we had an accumulated deficit of $530.6 million. We expect to continue to generate operating losses for the foreseeable future. We have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year of the issuance of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. Since we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect that our cash, cash equivalents and marketable securities as of December&#160;31, 2022 will not be sufficient to fund operations for at least the next twelve months from the date of issuance of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, there is substantial doubt about our ability to continue as a going concern. Our future viability is dependent on our ability to raise additional capital to finance our operations. We expect to finance our operations through potential public or private equity financings, debt financings, collaboration agreements or other capital sources. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. We have based our assessment on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development and potential collaborations with third parties for the development of our product candidates, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of preclinical studies and clinical trials for our platforms and product candidates;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of product candidates and technologies that we develop or may in-license;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs necessary to obtain regulatory approvals, if any, for products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our IP rights and defending any IP-related claims;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs we incur in maintaining business operations;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such acquisitions or investments in businesses.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. Market volatility could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially result in dilution to the holders of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_61"></div><div style="margin-top:12pt"><span id="icd224b2aff5f48c9839b9aca4b4a8b4e_6552"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into certain agreements under which we have incurred or may in the future incur obligations and commitments that could have a material impact on our capital resources.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sublease building space in Boston, Massachusetts. Our sublease will expire on January&#160;31, 2026. As of December&#160;31, 2022, our operating lease commitments for the remainder of the lease term were $4.0 million. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into collaboration and license agreements with RogCon Inc., or RogCon, and Ionis Pharmaceuticals, Inc., or Ionis, under which we could be obligated to pay certain fees, milestone payments and cost reimbursements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreement with RogCon, Inc., or RogCon, we are obligated to reimburse RogCon for its out-of-pocket costs incurred for activities performed under the license agreement. Additionally, we may be obligated to pay RogCon a milestone payment of $3.0 million and profit share payments. The $3.0 million milestone payment is due when the first profit share payment has become due and payable and certain contingent payments have become due and payable to Ionis under our collaboration agreement with Ionis. The profit share payments are based on a low-double-digit percentage of net profits, depending on sales volume. Either party may terminate the license agreement for material breach or insolvency of the other party. Additionally, we may terminate for convenience with prior notice to RogCon. See &#8220;Business&#8212;License Agreements&#8212;License Agreement with RogCon.&#8221;</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement with Ionis Pharmaceuticals, Inc., or Ionis,, we reimbursed Ionis for identifying a development candidate and conducting an investigational new drug application, or IND, enabling toxicology study, as well as out of pocket costs incurred by Ionis related to research activities. Ionis granted us an exclusive option to obtain the rights and license to further develop and commercialize the development candidate in the field of epilepsy and neurodevelopmental disorders, other than Dravet Syndrome, following the results of the IND-enabling toxicology study. We exercised this exclusive option in January 2022 and paid a $2.0 million license fee. We may be required to make additional payments to Ionis including development milestone payments, additional milestone payments and sales royalties or sublicense fees. Either party may terminate the collaboration agreement upon material breach or insolvency of the other party. Ionis may terminate if we fail to achieve a performance milestone. See &#8220;Business&#8212;License Agreements&#8212;Ionis Collaboration Agreement.&#8221;</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into multiple agreements with third parties under which we may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified product candidates. Payments under these agreements generally become due and payable upon achievement of such milestones and sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in our financial statements.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with certain vendors for various services, including services related to clinical operations and support, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Under such agreements, we are contractually obligated to make certain payments to vendors to reimburse them for their unrecoverable outlays incurred prior to cancellation. The exact amounts of such obligations are dependent on the timing of termination and the exact terms of the relevant agreement and cannot be reasonably estimated. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we enter into indemnification agreements and agreements containing indemnification provisions in the ordinary course of business. Pursuant to these agreements, we agree to indemnify, hold harmless and reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally our business collaborators, in connection with any U.S. patent or any copyright or other IP infringement claim by any third party with respect to our product candidates. The term of these indemnification agreements is generally perpetual upon execution of the agreement. The maximum potential amount of future payments we could be required to make under these indemnification agreements cannot be reasonably estimated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses and Related Accruals and Prepaids</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs directly attributable to the conduct of research and development activities, including personnel-related expenses such as salaries, benefits and stock-based compensation expense; materials; supplies; manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical trials; and the allocable portions of facility costs, such as rent, utilities, depreciation and general support services. All costs associated with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued and prepaid research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates in determining our accrued and prepaid research and development expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. When evaluating the adequacy of the accrued liabilities and prepaid expenses, we analyze progress of the studies or trials related to these services, including the phase or completion of events, invoices received and contracted costs. Examples of estimated accrued and prepaid research and development expenses include fees paid to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs in connection with performing research services and preclinical and clinical studies;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigative sites or other providers in connection with preclinical and clinical studies;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with preclinical and clinical development activities; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors related to product manufacturing, development and distribution of preclinical and clinical supplies.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial terms of our agreements with CROs are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of milestones. In expensing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the expense accordingly. Significant judgments and estimates are made in determining the accrued and prepaid research and development expenses at the end of any reporting period. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our current operations.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Fluctuation Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our cash, cash equivalents and marketable securities are or may be in the form of money market funds or marketable debt securities and are or may be invested in U.S. Treasury and U.S. government agency obligations. However, because of the short-term nature and low risk profile of the instruments in our portfolio, an immediate change in market interest rates of 100 basis points would not have a material impact on the fair market value of our investment portfolio or on our financial position or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Fluctuation Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may continue to contract with foreign vendors. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item 15, Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_82">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N183OS9mcmFnOjJlMjNiZTZjNWVjOTRmZmNiYzBkODQzMjk1ZGRjMjQwL3RhYmxlOjc5NmNlZWUyMTMxYzRiNTFiYWRmM2Q3NDUwNzdjOWYxL3RhYmxlcmFuZ2U6Nzk2Y2VlZTIxMzFjNGI1MWJhZGYzZDc0NTA3N2M5ZjFfMi0wLTEtMS01OTU4NC90ZXh0cmVnaW9uOmM1MTc0ZDE0MmVlYjRlODM5YjQ1ZGVlYzNjNDgyZGUyXzcx_78dbd9cc-e07d-45d3-a2af-307a524d2650">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_82">97</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_85">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_85">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_88">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_88">100</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_91">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_91">101</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_94">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_94">Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_94">102</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_97">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_97">104</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_100">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_100">105</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Praxis Precision Medicines, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Praxis Precision Medicines, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, has limited financial resources, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ulixacaltamide Essential1 Accrued and Prepaid Research and Development Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:150%">Description of the Matter</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accrued costs for research and development expenses totaled $10.7 million at December 31, 2022, including accruals related to the Company&#8217;s ulixacaltamide Essential1 clinical trial. In addition, the Company&#8217;s prepaid expenses and other current assets were $10.4 million, which included amounts that were paid in advance of services incurred pursuant to the ulixacaltamide Essential1 clinical trial. As discussed in Note 2 to the consolidated financial statements, the Company analyzes the progress of the clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued and prepaid balances at the end of any reporting period for the Company&#8217;s ulixacaltamide Essential1 clinical trial. The Company is required to estimate such accruals and prepaids using judgment based on certain information, including actual costs incurred or level of effort expended, as provided by its vendors. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheet within accrued or prepaid expenses and other current assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accrued and prepaid research and development costs for the ulixacaltamide Essential1 clinical trial was complex, as accounting for the costs associated with this clinical trial required subjective estimates of the level of services performed and the associated costs incurred by service providers. Furthermore, due to the duration of the Company&#8217;s ulixacaltamide Essential1 clinical trial, and the timing of information received from third parties, the actual amounts incurred are not typically known at the time the consolidated financial statements are issued.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:150%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate the accrued and prepaid research and development costs for the ulixacaltamide Essential1 clinical trial, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the significant judgments and estimates made by management to determine the recorded accruals and prepayments. To test the significant judgments and estimates, we corroborated the progress of research and development activities through discussion with the Company&#8217;s research and development personnel that oversee the research and development projects and inspected the Company&#8217;s contracts with third parties and any pending change orders to assess the impact on amounts recorded. In addition, we reviewed estimates of costs incurred to date provided to the Company from third parties. We also analyzed fluctuations in accruals by vendor and by trial throughout the period subject to audit, evaluated the costs incurred per trial, site and/or patient for reasonableness and tested subsequent invoices received from third parties.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">/s/ <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184Mi9mcmFnOjZiNjc3YWE0NjY3ZTQ2NTc5YmU3ZDZkNTM5YmI0NTI1L3RleHRyZWdpb246NmI2NzdhYTQ2NjdlNDY1NzliZTdkNmQ1MzliYjQ1MjVfMzY3Nw_5b8f63ca-b419-401c-994d-bef862a3ade1">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2019.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184Mi9mcmFnOjZiNjc3YWE0NjY3ZTQ2NTc5YmU3ZDZkNTM5YmI0NTI1L3RleHRyZWdpb246NmI2NzdhYTQ2NjdlNDY1NzliZTdkNmQ1MzliYjQ1MjVfMzY3OA_6311d1d7-d308-4771-969a-2af13e11e114">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 7, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNC0xLTEtMS01OTU4NA_567f17de-1086-457e-b7de-c804e56b4eb7">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNC0zLTEtMS01OTU4NA_dc8db2b0-0181-4169-903c-d9d0f83109a5">138,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNS0xLTEtMS01OTU4NA_f92250ac-f5de-4819-96f8-011b7bf0da52">38,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNS0zLTEtMS01OTU4NA_ce0b1d2f-d45c-4358-9c14-6ac159278f54">137,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNi0xLTEtMS01OTU4NA_55d9d57d-b4f9-42e6-aa72-2cb82114c666">10,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNi0zLTEtMS01OTU4NA_27ca927f-635a-42c1-9fe5-b905cdbb5b7f">11,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNy0xLTEtMS01OTU4NA_6f3480a9-bb99-47f1-9c13-3c493f9c0b6f">110,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNy0zLTEtMS01OTU4NA_0cb8165a-fd6a-4594-9a23-bf4dcbe3490b">287,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOC0xLTEtMS01OTU4NA_e1d78539-c7d6-48e0-99bf-a428023fde50">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOC0zLTEtMS01OTU4NA_c2d9dd19-63e7-440b-b139-a4fc1cfb764e">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOS0xLTEtMS01OTU4NA_defd8a5b-ef04-41de-9287-e13271eef036">2,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOS0zLTEtMS01OTU4NA_dda760f2-6f7d-4dfa-b388-c269b6a67397">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTAtMS0xLTEtNTk1ODQ_65bc9841-ebc8-4687-a30a-06f0d8b89608">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTAtMy0xLTEtNTk1ODQ_1809616c-70fc-4c66-b3df-adaf995ced3d">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTEtMS0xLTEtNTk1ODQ_a8596a69-ad23-47e2-97bb-e497c029091a">115,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTEtMy0xLTEtNTk1ODQ_d0829b9e-eb2c-4dfa-8b9e-3d83cdff4b38">292,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTQtMS0xLTEtNTk1ODQ_09fae10c-76e7-49ff-a966-19015a4a7536">14,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTQtMy0xLTEtNTk1ODQ_6d656a7d-9c27-4641-8373-faf7d3c03545">10,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTUtMS0xLTEtNTk1ODQ_82229d10-90ad-4cfb-8cf9-2bc9c49991b1">15,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTUtMy0xLTEtNTk1ODQ_8f9e542a-20e9-46d8-bb9f-fedb679fb40d">26,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTYtMS0xLTEtNTk1ODQ_796353d4-5015-45c8-9911-68940bb59155">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTYtMy0xLTEtNTk1ODQ_345eea4f-7014-4395-9a70-3eb394cff1dc">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMS0xLTEtNjkyNzI_45a0e60e-d4e2-4f29-8aa3-655f2573ddb5">2,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMy0xLTEtNjkyNzI_b38ad462-507e-46b7-9170-3a94739a9fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMS0xLTEtNTk1ODQ_c1c0cef5-b67c-43c6-b26c-d02f9b959002">34,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMy0xLTEtNTk1ODQ_f6d6f9ae-186b-422b-a529-1f82c378d39e">38,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTktMS0xLTEtNTk1ODQ_379eb16c-8a8f-48a7-9d6c-84a5fd61d9cb">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTktMy0xLTEtNTk1ODQ_c247e592-e2ed-473f-a222-752b7a62a493">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMS0xLTEtNjY5MzY_54dc78ad-70c7-44a1-a391-bf6bc1edb4f3">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMy0xLTEtNjY5MzY_97124898-4c5c-4d2f-bfe8-df64508dca7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMS0xLTEtNTk1ODQ_a39f7675-9039-4b17-a566-1b6becb3963f">39,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMy0xLTEtNTk1ODQ_35ec9193-6c6c-43db-8f8d-08f055fb293a">41,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjEtMS0xLTEtNTk1ODQ_4a47c460-777a-4a00-9ae6-7b1d444729e9"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjEtMy0xLTEtNTk1ODQ_d688a27b-9f05-419d-a060-6a7e687c32b7"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8yMQ_a6b4fe0d-23d5-4e3f-8a43-3e85ac90f356"><ix:nonFraction unitRef="usdPerShare" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8yMQ_c98eeccd-d6a5-4011-9317-ad8b0d052173">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8zNQ_37322fd1-4e5b-4c1e-9ff6-068968186c0a"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8zNQ_d3845336-e962-405b-849f-54610cef59de">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_2fb64e20-d5c0-44dc-8671-70bc695d0a59"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_375baf63-85ed-4abc-aafb-dca7d50968ad"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_5acfa803-7fc5-4554-9d6d-0b1dc9138544"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_9b75cc53-1ebd-4422-9646-fae92ded8291">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of December&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMS0xLTEtNTk1ODQ_883ec23c-f41d-43f9-aa7d-f2075110432d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMy0xLTEtNTk1ODQ_fd848b2e-7275-47b2-b161-d534664ec58a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjIz_14130309-9e71-4b2d-91c9-e40c3d1f702a"><ix:nonFraction unitRef="usdPerShare" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjIz_f080d998-ff71-4f17-96e3-070e4e5f3212">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjU1_3e23f15b-4601-46d4-a75a-406109ceb789"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjU1_dff220f5-7c60-4f7c-bf4c-99521c968180">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzUz_1fe67ca3-3c18-43f3-8117-e67fed18256e"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzUz_8a917dce-bcbb-4015-a7ea-117f64ec3736">49,382,453</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022, and <ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzIy_8b595ef3-3857-4921-a476-6cb6e6f1d99d"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzIy_d3dabcf3-cec1-4747-b3b0-aea92e27a832">45,300,514</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMS0xLTEtNTk1ODQ_54da305e-1632-4a55-8f4e-12e71c560dbb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMy0xLTEtNTk1ODQ_efa9752e-cfc5-47a7-b309-add42215d90c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjUtMS0xLTEtNTk1ODQ_f5661d40-8ef8-4671-99ba-95d9977275cf">606,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjUtMy0xLTEtNTk1ODQ_6a6b4817-e7db-4e39-9fec-2c88a5f1b339">567,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjYtMS0xLTEtNTk1ODQ_95421f9b-96cb-4f7e-b050-35c80185474e">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjYtMy0xLTEtNTk1ODQ_df76f7a3-f8de-49a1-bd3f-607c01f014eb">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjctMS0xLTEtNTk1ODQ_163eaac8-5675-488e-a7e3-42ea1d9c8df6">530,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjctMy0xLTEtNTk1ODQ_5c634938-cd0e-4f6d-9d3a-3de637cd314d">316,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjgtMS0xLTEtNTk1ODQ_2a24d079-2435-43c1-90af-795bbe39680d">76,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjgtMy0xLTEtNTk1ODQ_915f256f-7bcb-44f6-9eea-1bd30296ab50">250,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjktMS0xLTEtNTk1ODQ_9b709b77-42a9-4c8a-b56f-b6cd916b1eb1">115,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjktMy0xLTEtNTk1ODQ_2445311b-e189-4552-92fb-4d9e9d565d93">292,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMy0xLTEtMS01OTU4NA_46b5e9b3-a914-4312-971a-d71729f88be0">155,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMy0zLTEtMS01OTU4NA_73f9604b-5cfb-4fdf-aa54-2160d12eba46">120,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNC0xLTEtMS01OTU4NA_efd6411c-1c4e-407c-9d8a-19f8c9a1e076">59,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNC0zLTEtMS01OTU4NA_8325fd6c-a11c-4482-9966-852197005a27">47,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNS0xLTEtMS01OTU4NA_f84ee78e-e624-4a03-8dac-c41d227996df">214,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNS0zLTEtMS01OTU4NA_53a9fcf5-e270-4eda-bcbb-e5c0bb6556f7">167,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNi0xLTEtMS01OTU4NA_d7f771cc-0f23-4911-a93b-67395f6b96b5">214,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNi0zLTEtMS01OTU4NA_f4a20f6a-e01e-4659-85f3-0321cb963379">167,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfOC0xLTEtMS01OTU4NA_e3424f58-4929-4c1c-87db-46de44d11b77">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfOC0zLTEtMS01OTU4NA_62223d1e-4d98-4549-8798-7090d556d872">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTEtMS0xLTEtNTk1ODQ_e19d6d77-7a4d-472a-a074-1445ae854911">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTEtMy0xLTEtNTk1ODQ_6943e0fc-b8e5-4ded-829d-103b43b2a085">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTQtMS0xLTEtNTk1ODQ_4e4ab308-1182-4a04-9330-2edf917f2c25">214,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTQtMy0xLTEtNTk1ODQ_10ca4967-5de2-470c-8cea-44dc0b3a6442">167,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMS0xLTEtNTk1ODQ_138411af-4657-42b4-b674-78eb96250fee"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMS0xLTEtNTk1ODQ_284fd66b-c421-4de8-9d5f-8d65c491bfa9">4.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMy0xLTEtNTk1ODQ_25741e6e-c942-4849-8a51-8e6a79cdfcb6"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMy0xLTEtNTk1ODQ_5844f63c-61db-46b9-a88b-3de903962925">3.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMS0xLTEtNTk1ODQ_2ba6be67-02f3-44ac-abbc-67694fa0006f"><ix:nonFraction unitRef="shares" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMS0xLTEtNTk1ODQ_f738c9cb-bf35-44e9-9616-7cabc71b7c60">46,096,737</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMy0xLTEtNTk1ODQ_023ea646-7783-4ccf-b099-3a173050c943"><ix:nonFraction unitRef="shares" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMy0xLTEtNTk1ODQ_d5875df9-2864-49ad-8a0a-9128e2f2728f">42,454,055</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMi0xLTEtMS01OTU4NA_2da21731-6697-4ba6-bcb2-8d9ecb526c3d">214,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMi0zLTEtMS01OTU4NA_9fcfed17-cc5e-4490-97b6-b390cdae4099">167,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMy0xLTEtMS01OTU4NA_d961a613-6456-4f2c-8b9b-3502e8d2b1ac">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMy0zLTEtMS01OTU4NA_5d4918f9-d901-4c24-a0a9-c72d57a279ea">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfNC0xLTEtMS01OTU4NA_5f5e5f19-06cc-4925-9c1a-27646947d5eb">214,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfNC0zLTEtMS01OTU4NA_d230f373-6ecf-496b-8abc-7d6011f7c7d9">167,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi0xLTEtMS01OTU4NA_35569e8c-bd9d-4a9b-9d04-2a9c0ed1c4c8">45,300,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi0zLTEtMS01OTU4NA_49970f06-3a12-4431-9f9b-8a1d9a4b5d8c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2344b1ab9c3a4878a68866f2972e66c2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi01LTEtMS01OTU4NA_2cc769f2-029c-41b1-957b-995e0a774218">567,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ad98315af3d41a282deab5221cf97e4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi03LTEtMS01OTU4NA_f2c55fea-ee15-4ef0-a3d8-ba6ecc6c887d">316,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3be9750a865b4e6e91d05a084c54ac34_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi05LTEtMS01OTU4NA_b9a4afc9-44f4-4964-90bf-1183471eece6">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi0xMS0xLTEtNTk1ODQ_961d8c2a-6583-4ab8-aae6-69e83f507941">250,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMy01LTEtMS01OTU4NA_c77cb19a-edae-49a3-b02e-78d37819dc63">7,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMy0xMS0xLTEtNTk1ODQ_fadaa639-4c43-490a-9d06-1fc99760f62a">7,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market public offerings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNC0xLTEtMS01OTU4NA_76b7e50b-1bd3-4c24-909d-a0250fa48a54">70,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNC01LTEtMS01OTU4NA_25d518a7-7f09-4ce0-8e09-9fc88d42587c">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNC0xMS0xLTEtNTk1ODQ_08712020-1d18-426b-8b4a-e70465bda743">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNS0xLTEtMS01OTU4NA_b890486d-5211-4e41-ae4e-f5232edea311">81,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares withheld for taxes for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNi0xLTEtMS01OTU4NA_5cbb9372-0180-48ed-ad5c-f41dd6e76d3a">17,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNi01LTEtMS01OTU4NA_092d508b-f5cd-4ba2-8688-8fd20597ca08">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNi0xMS0xLTEtNTk1ODQ_21b5a4aa-2608-4afe-b6e4-3ff6a3566453">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNy0xLTEtMS01OTU4NA_d320c35a-ed1c-430e-8670-84f4d530fa80">72,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNy01LTEtMS01OTU4NA_fb2c101a-2825-4205-bd46-9e9e9deb5e0c">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNy0xMS0xLTEtNTk1ODQ_b47c05e1-523c-4aa1-92a7-30aec824bdf3">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6eba7ebb706b4dfa80a4a7810dd535c9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOC05LTEtMS01OTU4NA_bb98ba68-0483-46ca-9dff-7fd3a450c025">430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOC0xMS0xLTEtNTk1ODQ_a8962d9f-b98a-4fe2-bbb8-405ca6876b66">430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic09992728bef4f0bae174a9c6128fa25_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOS03LTEtMS01OTU4NA_143b89a2-c1a4-4cc8-b234-0dcd64dd52a3">68,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOS0xMS0xLTEtNTk1ODQ_f4a2ced3-14e7-4670-9566-3ca668cc11c4">68,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b0b9cad54eb49588e17c54b674ca49b_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtMS0xLTEtNTk1ODQ_c0385960-913b-4a28-a513-1cdcdd0ba771">45,506,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0b9cad54eb49588e17c54b674ca49b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtMy0xLTEtNTk1ODQ_af4537a8-be31-41cb-a258-e224c364d0f3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida8c1ac19c834c578b8b2ece2ac3cb77_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtNS0xLTEtNTk1ODQ_b76f5976-3a39-4154-9b49-2306ad26fcad">576,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic74d74d369a54b27a1f0a0997271d1da_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtNy0xLTEtNTk1ODQ_577756e2-ab3e-4ab4-82d9-c942a8a335f3">385,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7789b54e2a114c39b31e80ed274bb4dd_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtOS0xLTEtNTk1ODQ_0a5be613-4243-4c5b-af43-835d38b7a404">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2585ba6f7d1140968c2b676bef9b6a76_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtMTEtMS0xLTU5NTg0_9cf34c71-14a3-4683-8d07-3e307f98711b">191,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTEtNS0xLTEtNTk1ODQ_890e476b-3154-4c6c-a009-a616d151597f">7,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTEtMTEtMS0xLTU5NTg0_57c25a89-4ae7-444c-8b53-79fcbfa34425">7,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTItMS0xLTEtNTk1ODQ_80f770e1-51b1-4996-91f8-6cf841d2e439">51,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTItNS0xLTEtNTk1ODQ_ed542de1-4b8c-4036-a95c-76901a0a6d50">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTItMTEtMS0xLTU5NTg0_c0d60df7-6313-4f00-a9bf-9b7494571e9e">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTMtMS0xLTEtNTk1ODQ_065f7ea3-697f-4673-a3ea-addfe4a128df">6,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares withheld for taxes for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTQtMS0xLTEtNTk1ODQ_cde957af-9481-40f7-b6dc-b360cb2b6f4a">2,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTQtNS0xLTEtNTk1ODQ_5b46a6d6-9b1c-49bb-9c74-a901ed0b22cb">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTQtMTEtMS0xLTU5NTg0_952ce428-0d66-44f0-ada5-4a51fd670e62">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTUtMS0xLTEtNTk1ODQ_390e9d27-8c7b-497a-902a-ecf46f7fd0e0">13,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTUtNS0xLTEtNTk1ODQ_1060cd98-9911-4924-a31b-03b6b67f325d">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTUtMTEtMS0xLTU5NTg0_6260da18-e642-4f7d-bb4a-6822705cfeb4">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e08f1293150426397b0487ecffc04ea_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTYtOS0xLTEtNTk1ODQ_7cf80ca0-1bf8-448e-b6e3-2c9299645077">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTYtMTEtMS0xLTU5NTg0_7a0b7e9b-781c-4cb9-aa12-b247e49c2c57">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8af8704c56174ca1b37faec33a912463_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTctNy0xLTEtNTk1ODQ_83bd9148-8aea-44f1-b580-920dd4087620">60,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTctMTEtMS0xLTU5NTg0_d71e0ba0-2ab4-49d8-8745-ddfae791def6">60,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ba601030eba426189040ccc2833c493_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtMS0xLTEtNTk1ODQ_057b8f82-ead7-4e6c-9c0e-4c47481f2033">45,575,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba601030eba426189040ccc2833c493_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtMy0xLTEtNTk1ODQ_eee60861-7d80-45e6-b426-566cb9f5936f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bc52cfad8d4c54b16d280f13ff2223_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtNS0xLTEtNTk1ODQ_0260972e-389e-4102-9137-5537cb3e26a9">585,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a93c7b7231e485d9dcb693c55f01c36_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtNy0xLTEtNTk1ODQ_7bca62ad-65a3-4656-b7de-1157ce0953af">445,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i196d0f35a1c74e6e8d4415c7632ab49f_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtOS0xLTEtNTk1ODQ_5e25d635-c2e5-4808-85e3-1cab8db56d5a">680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a728182f04043d39d4792ebfafe466a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtMTEtMS0xLTU5NTg0_3493974d-401f-45fa-96e1-662305830088">138,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTktNS0xLTEtNTk1ODQ_0aed566d-ad47-46e2-b5ab-7eaccd3bc11f">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTktMTEtMS0xLTU5NTg0_2a90e06e-0e25-4ad8-a6bb-d364992c6e70">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market public offerings, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjplZGM5YjY2YTk4ODk0YzFhODE2OWFlNzEzOGNjODlkNl8xNjQ5MjY3NDQxNzYy_f820b64d-abf1-4ca5-a208-69fdb15e2775">109</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtMS0xLTEtNTk1ODQ_cd8c3bc7-13e9-4dc3-a459-c461bd0c2f3b">1,105,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtNS0xLTEtNTk1ODQ_af1c278c-f460-4c02-b874-2e6597957e5b">2,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtMTEtMS0xLTU5NTg0_6aa4881a-2394-4fac-acea-8dba1850729e">2,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtMS0xLTEtNjQyNjI_b77368fe-48fa-47d2-aec5-82aff5066746">5,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares withheld for taxes for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItMS0xLTEtNjQyNjI_eebadb6f-a8a2-4b2d-8ea3-b2efb24ec601">1,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItNS0xLTEtNjQyNjI_05e4a8b1-d672-44ca-a945-57280d822cd0">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItMTEtMS0xLTY0MjYy_3cf981bc-69d6-4bb4-83fe-60bba323f165">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtMS0xLTEtNTk1ODQ_d5f562de-391a-4752-a8b2-39e244aaceb9">180,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtNS0xLTEtNTk1ODQ_4d8c547c-d4cb-461f-9d1e-93073f35416a">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtMTEtMS0xLTU5NTg0_008ef4a7-fafe-46de-9f42-0df4d1ebde94">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc40af393984b69a6f339c706f7a8cc_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItOS0xLTEtNTk1ODQ_354c02c8-c0c0-431e-8e7f-739546c81e48">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItMTEtMS0xLTU5NTg0_d01d59bc-228e-4657-b830-d3c62962f325">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85b46df47ce94205bcab6f972efaee12_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjMtNy0xLTEtNTk1ODQ_c29a15c7-8b71-4979-b521-c84735aa509e">43,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjMtMTEtMS0xLTU5NTg0_c9d28aca-445a-4f62-9a27-c61466931ac6">43,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie93ce564963d491aba684e9adfb498e6_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtMS0xLTEtNTk1ODQ_2be79eaa-6455-4d0a-8d7b-3bc8699abd58">46,864,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93ce564963d491aba684e9adfb498e6_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtMy0xLTEtNTk1ODQ_0238b9c9-88a3-4fd4-8e3e-d2e34136491b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0a8e5710134eb08c67c0c06b7b24da_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtNS0xLTEtNTk1ODQ_d452c787-a652-493a-b63d-1fdb72fb5f12">595,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70c148e140a84df0a85d7419acf357d6_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtNy0xLTEtNTk1ODQ_2869e6dd-a5eb-4bc1-8576-7e730ce20781">489,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibea6fb2e7f9c4653980110ad0997c840_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtOS0xLTEtNTk1ODQ_93569786-e435-4541-8a9a-b8472182274d">536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e0cde373b74b1fbcdea62d3b9b067d_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtMTEtMS0xLTU5NTg0_07266d70-eee2-4904-acde-76c4dda6fc42">105,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjctNS0xLTEtNjQyNjI_71126ef9-6a43-4501-bd01-d090fb4af393">6,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjctMTEtMS0xLTY0MjYy_07c0729e-5dc7-4d83-9312-7ce6f55dbf8a">6,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMS0xLTEtNjY5ODU_a3cda1a2-c63b-4611-b6af-377ecabbfdb1">89,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtNS0xLTEtNjY5ODU_935b3c28-f831-42d1-84cb-4a833d8c510e">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMTEtMS0xLTY2OTg1_48d825b4-b857-4833-a7f6-553a7869eece">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market public offerings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMS0xLTEtNjQyNjI_5b5a7b01-5e07-4abe-8933-45591ac000f8">2,419,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtNS0xLTEtNjQyNjI_e5af9066-95c8-4058-80a3-02f919a59464">5,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMTEtMS0xLTY0MjYy_e9930182-1ee5-40c9-bb28-263a67509db8">5,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjktMS0xLTEtNjQyNjI_28942f6e-7eca-4b66-828a-55fffc84f2bb">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares withheld for taxes for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzAtMS0xLTEtNjQyNjI_bb5254f5-0c3a-473f-b370-19d9e0c2a6a7">3,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzAtNS0xLTEtNjQyNjI_90c00d38-4c87-438a-bc4e-d465edbba766">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzAtMTEtMS0xLTY0MjYy_2d769e4f-37af-4d40-81da-2d28d2a3f19b">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0b11d79884461a83cccb8dc6bbcdd3_D20221001-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzItOS0xLTEtNjQyNjI_af19a7c5-a8cb-4d75-9cba-c86e62fa0a11">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzItMTEtMS0xLTY0MjYy_5c6a0ebe-176b-4c45-abb3-b72204d781f3">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3477c218f40b4c7c970a4c3f3626732d_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzMtNy0xLTEtNjQyNjI_06c585af-b077-447b-b916-d7a028aea24f">41,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzMtMTEtMS0xLTY0MjYy_086f2355-6d15-4f1c-9e42-72c1f1bb1d39">41,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51354d96fa5d42aca6c0254acaecbeed_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtMS0xLTEtNjQyNjI_f81dbc51-d9f3-42e4-a327-c56299809bff">49,382,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51354d96fa5d42aca6c0254acaecbeed_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtMy0xLTEtNjQyNjI_6bc75bcc-ae80-4af1-aba3-876b1a6728ea">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b3da6cf3fb4b80b31db69d5e75e733_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtNS0xLTEtNjQyNjI_785e886c-b924-4f16-ae95-6bf2e5eb5bb1">606,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id33de74923df41ec83c75880cf5f279b_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtNy0xLTEtNjQyNjI_713d4301-62b2-4afb-b285-33b80b15908f">530,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2656057b4b1f4ddab56bd4e68b9a8313_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtOS0xLTEtNjQyNjI_2febdbd4-5968-40bf-8ebc-394ce5fe59f1">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtMTEtMS0xLTY0MjYy_33e023de-5e7a-4c10-8e29-80d3e08f937c">76,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (continued)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:44.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.626%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi0xLTEtMS02NDMyOA_7e4d9430-c04a-427c-9621-5b59f728abc6">38,268,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi0zLTEtMS02NDMyOA_44271227-3fa6-4243-ac10-d255680e8031">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d1517befc54004869962cb5db5d4db_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi01LTEtMS02NDMyOA_a69cdea1-fe4a-4518-8689-97633480c261">437,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5685a97c7eb649f18683911595830a0d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi03LTEtMS02NDMyOA_a26dcf25-8ef2-4555-8d86-44a2643e4af0">149,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c72dd27f4db45c5a09009b132c11e0f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi05LTEtMS02NDMyOA_9cfd3765-75d2-4425-abfd-6d301a6e2002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2015d475fd417da87c4d8147258dc6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi0xMS0xLTEtNjQzMjg_ae046cdd-6d2f-4540-a740-e65981431a92">287,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2ef18fc101489483b20f45d8d64499_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMy01LTEtMS02NDMyOA_03c9eeff-03eb-4a1c-af52-2de164a003fc">4,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMy0xMS0xLTEtNjQzMjg_33ae1221-d212-43c1-ae2d-6fdd7f9f3c22">4,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc21efa6afc42e49f591f790c790431_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNC0xLTEtMS02NDMyOA_eab62558-57ca-41f4-9dfe-a01341aa8166">352,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2ef18fc101489483b20f45d8d64499_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNC01LTEtMS02NDMyOA_9aab9c70-6538-4b42-8224-42e57a6babd0">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNC0xMS0xLTEtNjQzMjg_8e991790-61e8-4e5a-9d9b-16955871e624">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9132bcbc9a0e463d891bcdf0f039bb90_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNS05LTEtMS02NDMyOA_7a5384ce-c1bb-42c0-83e8-ed89e96b5d1c">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNS0xMS0xLTEtNjQzMjg_32688e92-ccef-4e54-9674-a0d129a44072">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186b0778379c4993937fb55c38327183_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNi03LTEtMS02NDMyOA_fe849bb3-85af-4c13-8164-135bea6cd02d">27,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNi0xMS0xLTEtNjQzMjg_e50141c5-f5f7-41b5-8407-be70f7124b0e">27,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9293a98a8dd4a93a09eb1a71841867b_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy0xLTEtMS02NDMyOA_56092ad9-2b2e-41c3-8fe0-a9ff886a8304">38,621,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9293a98a8dd4a93a09eb1a71841867b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy0zLTEtMS02NDMyOA_75873ad4-032c-48d7-844e-ed84363a03e8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e4c52a182b04c4ab5d1d08a712e89e9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy01LTEtMS02NDMyOA_5ef19886-972d-440b-b177-34bb047a73ab">442,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28901937c12f479a8152673d4168671a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy03LTEtMS02NDMyOA_c4025092-bcdc-400b-bbd6-405a2673f1cb">176,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7be4e0e05564f3fafa58c61f9b1fd10_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy05LTEtMS02NDMyOA_f5d85d36-6a45-45e1-8a65-97abfedeaad1">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0b74c530d04342bf1f589de16e0e3a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy0xMS0xLTEtNjQzMjg_6e356336-294f-49e9-9885-43de4606f593">265,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOC01LTEtMS02NDMyOA_6254f499-c8d0-498a-a45a-2c2c4ed30825">5,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOC0xMS0xLTEtNjQzMjg_071b2973-22a1-468a-a32e-be75ce462e78">5,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from follow-on public offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0wLTEtMS02NDMyOC90ZXh0cmVnaW9uOmQxZDEyZDM5OGY5NjQwODc4OTkzYmU1NmEyNGY5NmU2XzE2NDkyNjc0NDE3NTc_584224e5-11aa-4b14-ae0b-376afd919b9d">229</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0xLTEtMS02NDMyOA_a0aa4134-f68c-405b-95e0-1f851cd87a28">5,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0zLTEtMS02NDMyOA_bfeeced4-efaf-4083-bb38-1091eb8f0394">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS01LTEtMS02NDMyOA_3dc64de2-ffba-4a1a-9edf-939862c1e726">98,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0xMS0xLTEtNjQzMjg_8540bb6c-f369-422a-b5d5-da8919af4afd">98,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTAtMS0xLTEtNjQzMjg_b12556f5-0af2-4c0c-94eb-5b7988e5120c">322,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTAtNS0xLTEtNjQzMjg_032a9f4b-7cbe-4337-a3ec-6ef701f37fb1">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTAtMTEtMS0xLTY0MzI4_761312e0-3a7e-41fd-b6bd-569644f23935">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2685775b6e74db4912d26db6ca928e3_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTEtOS0xLTEtNjQzMjg_ab5569ff-9b6d-4141-90cb-c9f6660df8f8">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTEtMTEtMS0xLTY0MzI4_c19eda55-3970-4cdd-a528-1eea3f86fa8e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70ce13338d7446b8bdc23590e058954d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTItNy0xLTEtNjQzMjg_32e5b613-d660-42d5-9132-248464580585">36,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTItMTEtMS0xLTY0MzI4_ee2b6027-ad54-4c42-b2fa-ae978f1ae400">36,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17ab2e142b2d4fd391309d3aeb7a644b_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtMS0xLTEtNjQzMjg_7f414f06-8693-48ae-a3f5-1eea2fcc5757">44,693,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ab2e142b2d4fd391309d3aeb7a644b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtMy0xLTEtNjQzMjg_28e4325e-2251-43dc-aa45-711b61d9d3e0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f78ffae117408b9d174f79b6dadfc4_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtNS0xLTEtNjQzMjg_ff579083-46d8-4003-87fb-25a58d44eca5">547,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61be35db0ffd454eb578dd8a53db2fdc_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtNy0xLTEtNjQzMjg_d5ccf04d-fb7d-4739-80f5-7bab5b0573dc">213,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabb872f5f3514052982389e3861ab98b_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtOS0xLTEtNjQzMjg_5797cf39-ded7-428f-baba-155953f306b1">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2628ce7abeb41ba95f3481aac7564a5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtMTEtMS0xLTY0MzI4_533f6616-d7c8-4606-8152-1b16da30c067">333,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2b8a2121cf494bb5534c112dd72a9e_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTQtNS0xLTEtNjQzMjg_94c5aeb7-4a33-48c1-ae47-c49561c764a5">6,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTQtMTEtMS0xLTY0MzI4_ee855cca-4806-4e29-80fb-55d7e462f527">6,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba3004733fd54cbaa6eaea0ca6842030_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTUtMS0xLTEtNjQzMjg_31da0663-db8c-4d2e-bc84-ef161e9ba5bd">90,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2b8a2121cf494bb5534c112dd72a9e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTUtNS0xLTEtNjQzMjg_1af62f5d-7e8f-4ee8-81dc-cf58c2ff1623">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTUtMTEtMS0xLTY0MzI4_b62e30ea-ab4d-4e2f-8224-885dab018088">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefc7fcacec24cc2a304b8269c3aab86_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTYtOS0xLTEtNjQzMjg_52d413a0-7abb-42f9-94dc-a9e4d2fa1bd9">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTYtMTEtMS0xLTY0MzI4_b3e5b62b-f52e-4ce5-9a40-df9ae89ca677">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78de702859e243238daafb422255ef7f_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTctNy0xLTEtNjQzMjg_b578923b-9bd3-4b64-9dea-25e9a73d87df">44,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTctMTEtMS0xLTY0MzI4_9b485d78-6ff3-490e-88ef-d0a783aa3b58">44,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83f734a83c044c69af0d89604a75b839_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtMS0xLTEtNjQzMjg_090970b5-7cc5-4e73-a121-fddf0205a1f4">44,784,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f734a83c044c69af0d89604a75b839_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtMy0xLTEtNjQzMjg_ed3cee22-e044-4465-ad8f-fea1581a22a6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3238b6279a242f289e5ffa4033bab55_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtNS0xLTEtNjQzMjg_acb573ad-882b-4f78-919b-1cd71ae013c3">553,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0eb91dd5deb4936a88808d25a6364c8_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtNy0xLTEtNjQzMjg_38c5afaa-a628-4c4d-8594-6fd8db926f47">258,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3418d0f46f24a79a25d7259e2c96794_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtOS0xLTEtNjQzMjg_c9adb31c-4ef9-4fc4-b535-e297b9af137e">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5663f6ee44464a959cce62a6559179_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtMTEtMS0xLTY0MzI4_b9b5bdbe-abd2-4ae3-82b2-e53181374267">295,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTktNS0xLTEtNjQzMjg_bf9f190d-c5a6-41de-a0d8-635bc376c551">6,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTktMTEtMS0xLTY0MzI4_945fb8ba-b03a-4816-b4a4-8b82eb3bb43d">6,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market public offerings, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i0f0624b7d6cc44bcb25109c266ffa6b8_D20211001-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtMC0xLTEtNjQzMjgvdGV4dHJlZ2lvbjozMjBiZTJlYWUwZWQ0YWE3YWVmOWY2M2NlMTg0YTE3OF8xNjQ5MjY3NDQxNzYy_f66f67a5-f8c3-43ca-98b2-2cf695e215f2">598</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f20c793f4244b09a0b12e6890ea02f5_D20211001-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtMS0xLTEtNjQzMjg_7fb7c95f-20bf-40b3-bb04-6c651a307ddf">391,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtNS0xLTEtNjQzMjg_96dc1aa7-6400-4c80-a67e-c59295de2bd2">7,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtMTEtMS0xLTY0MzI4_c6809a4a-4674-4267-874f-415b04247baf">7,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f20c793f4244b09a0b12e6890ea02f5_D20211001-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjEtMS0xLTEtNjQzMjg_dfe887b0-3977-4754-8495-0b038d5b11c9">124,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjEtNS0xLTEtNjQzMjg_65fc4113-a21f-4a0e-bfa6-51a2a42a7bb9">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjEtMTEtMS0xLTY0MzI4_4e517e0b-8ba1-475b-9b48-39b1d8897a49">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05cebf03629447b68ee074d4fbbd0250_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjItOS0xLTEtNjQzMjg_31e67b1f-4676-4dbd-9365-e4a829144fbc">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjItMTEtMS0xLTY0MzI4_41f1cfc6-f8ec-423f-918f-9c817b524b6d">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632d279a2efe44aea3fdf28603091934_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjMtNy0xLTEtNjQzMjg_d8ef7b56-a83b-44f2-a114-ea4d487eb746">58,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjMtMTEtMS0xLTY0MzI4_56796554-301b-4d4f-aca1-63a9a4b1db2b">58,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtMS0xLTEtNjQzMjg_36d675a8-e0ab-4beb-bee7-5a32b6fd68d5">45,300,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtMy0xLTEtNjQzMjg_290e07f6-112b-49de-a048-372e913f6c13">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2344b1ab9c3a4878a68866f2972e66c2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtNS0xLTEtNjQzMjg_b6b514e0-3921-4997-97fe-2598e7515aaa">567,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ad98315af3d41a282deab5221cf97e4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtNy0xLTEtNjQzMjg_aff6a9ae-ce8d-4fde-80d4-339568299a7a">316,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3be9750a865b4e6e91d05a084c54ac34_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtOS0xLTEtNjQzMjg_4dc7387e-2817-46a0-af6c-90b4d2808d25">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtMTEtMS0xLTY0MzI4_51f4f7f1-d513-4e41-a047-698f8b185c33">250,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMy0xLTEtMS01OTU4NA_d5223313-dac7-4675-b615-bbbfdcdcdf6c">214,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMy0zLTEtMS01OTU4NA_e2906acf-baf7-4d1f-882b-6f8a7ed65bc3">167,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNS0xLTEtMS01OTU4NA_429a1ed3-7472-44fb-84aa-addf35ef9122">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNS0zLTEtMS01OTU4NA_f9e32521-f7f2-4505-b428-9dcf291755d8">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNi0xLTEtMS01OTU4NA_263dbd65-8c96-4071-8510-cc5c9768a341">28,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNi0zLTEtMS01OTU4NA_7e811cd3-f4d7-4948-a179-a99bbcb4d8ee">22,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNy0xLTEtMS01OTU4NA_5610a555-e346-4cb0-b357-ba6a2f122a4a">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNy0zLTEtMS01OTU4NA_7db28104-a3de-49cc-8e6b-2b6565f4da11">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfOC0xLTEtMS01OTU4NA_aca85c4d-59f3-476d-99f9-81c5fdbee658">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfOC0zLTEtMS01OTU4NA_88d11ce4-6b65-44d5-85c2-fd885eddf27c">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTAtMS0xLTEtNTk1ODQ_9eda9850-b53c-46fa-b761-fe0e157d17d5">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTAtMy0xLTEtNTk1ODQ_389d895f-9089-4e7c-96dd-519ea4b84ece">5,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTEtMS0xLTEtNTk1ODQ_aa28707b-acb4-4453-936a-f5a94f6be633">3,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTEtMy0xLTEtNTk1ODQ_34f8db06-014d-4449-b380-4ea4ad82490d">7,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTItMS0xLTEtNTk1ODQ_cbc3b88d-32f9-4e17-bf8d-51aa7cfa564f">10,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTItMy0xLTEtNTk1ODQ_be2874de-1adc-4694-bded-b6c30caefb04">15,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="prax:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTMtMS0xLTEtNTk1ODQ_be4f741e-8568-47dc-a048-d2690c5e1e6b">811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="prax:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTMtMy0xLTEtNTk1ODQ_1dcf89f4-4371-4852-a4c6-3e0afd116ec1">763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMS0xLTEtNjcwMTc_dacb31f8-f40b-4adc-b0bf-6b5dbb9ae93b">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMy0xLTEtNjcwMTc_26ad4fd5-7fdd-462f-81cd-096fdd96b6e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMS0xLTEtNTk1ODQ_2e53b816-190f-458f-b25e-32ccae4ecf5a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMy0xLTEtNTk1ODQ_892aa124-600c-41e3-81f2-059e873fc98b">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTUtMS0xLTEtNTk1ODQ_c4ee247a-1c93-48f4-bfbf-5ccaae3fccd5">185,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTUtMy0xLTEtNTk1ODQ_adbb5b7e-ee71-486d-8fb3-51607b017ca6">124,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTctMS0xLTEtNTk1ODQ_861e7501-683f-4ae1-8ac2-80dda48b19d7">444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTctMy0xLTEtNTk1ODQ_1b9daab2-af6c-40bc-8d8e-5a47564f09ff">1,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTgtMS0xLTEtNTk1ODQ_dec503a8-e1c3-42c1-b014-b1d085bc2385">83,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTgtMy0xLTEtNTk1ODQ_b8a15fb9-d14e-4268-92d4-3ea27e2f5eb9">164,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTktMS0xLTEtNTk1ODQ_6a3e1793-e305-41ce-b7d4-831328144db9">180,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTktMy0xLTEtNTk1ODQ_5d13b2f8-8da5-4d67-9102-9f4afd9c2678">24,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjAtMS0xLTEtNTk1ODQ_7ce25c7c-33d7-4e51-9872-0ed96dce2e8f">96,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjAtMy0xLTEtNTk1ODQ_cf524a0b-d422-4579-858c-4b98d08fcaf3">140,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from at-the-market offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="prax:ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjItMS0xLTEtNTk1ODQ_b3a7d059-9ffa-4ac0-ac8a-8ebb0bc9258b">9,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="prax:ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjItMy0xLTEtNTk1ODQ_546b8df8-15d7-4b8c-972f-5ecc88c5544c">7,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from follow-on public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjMtMS0xLTEtNTk1ODQ_42d8690c-afba-4640-ae20-635f3469cfe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjMtMy0xLTEtNTk1ODQ_f0af9171-6c9e-4e9c-99f3-5fc59fd0c83b">98,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of issuance costs for at-the-market offerings and initial public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjUtMS0xLTEtNjcwNjA_8ebafee8-596b-4667-ba3e-e8e061af0627">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjUtMy0xLTEtNjcwNjA_8617accc-cac5-4c47-9ef6-d83594fd4d0e">575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of tax withholdings related to vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMS0xLTEtNjcxMTc_24150d4d-a3f0-40e9-affc-f89584314b5f">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMy0xLTEtNjcxMTc_0f48794c-c10b-4cdf-be77-65ee2c3d70a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options and employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMS0xLTEtNTk1ODQ_e15a16f3-95c1-4526-8d50-beb54ae9c955">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMy0xLTEtNTk1ODQ_07f4ebaf-6ac6-4339-b9f4-dc76a73c1549">2,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjktMS0xLTEtNTk1ODQ_56dbb2fd-75bd-4a0f-8406-b509091c5920">10,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjktMy0xLTEtNTk1ODQ_244b2b8d-1bf8-4050-a424-0ea9611db66a">107,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzAtMS0xLTEtNTk1ODQ_8094d76c-2910-4164-9b69-ed3477d355c0">77,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzAtMy0xLTEtNTk1ODQ_428266e7-d42c-4708-9900-eef041ab85ae">157,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzEtMS0xLTEtNTk1ODQ_f2ca308a-872a-4e44-b71d-28bffaa0a02f">139,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2015d475fd417da87c4d8147258dc6_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzEtMy0xLTEtNTk1ODQ_0b5fcadc-1b57-4070-8a28-b76e99195fd7">297,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzItMS0xLTEtNTk1ODQ_8dd7b7ee-512c-4453-a4bc-bff240efab53">62,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzItMy0xLTEtNTk1ODQ_750aec58-d4e3-4091-894a-d301a2720d17">139,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzQtMS0xLTEtNTk1ODQ_0b2eff26-a897-49db-acda-0fbe1d7ed619">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzQtMy0xLTEtNTk1ODQ_9bdfc509-c4a0-475c-bb56-da2a42eade48">138,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzUtMS0xLTEtNTk1ODQ_15e9e2a0-fbd7-41be-a129-d349e57cb6e9">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzUtMy0xLTEtNTk1ODQ_85c42962-7dbe-4f08-b770-f856d75f3077">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzYtMS0xLTEtNTk1ODQ_eafe9adc-81b3-4b68-b0e8-68bb631b0763">62,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzYtMy0xLTEtNTk1ODQ_6c64700c-e001-4821-9ff7-dbbee731adf0">139,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzgtMS0xLTEtNTk1ODQ_6237b0d2-af57-492e-8978-2e73c0144ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzgtMy0xLTEtNTk1ODQ_b9ebad16-f11a-4c2d-9153-4b5e1932789a">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offering costs included in accrued expenses</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="prax:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzktMS0xLTEtNTk1ODQ_7d1ce427-aeec-4f20-b2c3-5f84f1f969a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="prax:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzktMy0xLTEtNTk1ODQ_c26b4df6-b8e3-4eac-abfc-5213b48457b7">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNDAtMS0xLTEtNTk1ODQ_83b64f2e-b4d6-4a51-81ce-6661a35dd055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNDAtMy0xLTEtNTk1ODQ_027165a1-50f4-4728-adf1-ee804cf2d917">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_100"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzc0Njg_12e086bf-e73a-4c52-bcd1-41d9ef121133" continuedAt="i6fdf3dd303dc4a4dad1176f83e14d5a8" escape="true">Nature of the Business</ix:nonNumeric></span></div><ix:continuation id="i6fdf3dd303dc4a4dad1176f83e14d5a8" continuedAt="i5eafd0ebe3a841cab5a43ec460f2c3cc"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis Precision Medicines, Inc. (&#8220;Praxis&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Each platform has multiple programs currently, with significant potential for additional program and indication expansion: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Cerebrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, the Company's small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Solidus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, the Company's antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum&#8482; platform, ulixacaltamide (formerly known as PRAX-944), it expects to announce topline results from the Phase 2b Essential1 clinical trial in essential tremor in the first quarter of 2023. The Company also plans to initiate an ulixacaltamide Phase 2 clinical trial in Parkinson's disease in the first quarter of 2023 and expects topline results in the fourth quarter of 2023. The Company plans to initiate</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its PRAX-562 Phase 2 EMBOLD study in the first quarter of 2023, with initial cohorts in SCN2A-DEE and SCN8A-DEE, and expects to announce topline results for both cohorts in the second half of 2023. The Company also initiated a Phase 1 healthy volunteer study of PRAX-628 in the fourth quarter of 2022 and expects to report topline results in mid-2023. For the Company's most advanced product candidate under the Solidus&#8482; platform, PRAX-222, it expects to announce topline results from the first dose cohort of its EMBRAVE study in mid-2023. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, and from the sale of common stock through an initial public offering ("IPO"), a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through December&#160;31, 2022, the Company raised $<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzQ4MjM_fadc8cfb-0ecf-4b45-aa6c-4a3f2dd940f7">526.0</ix:nonFraction>&#160;million in aggregate cash proceeds from these transactions, net of issuance costs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2014-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5eafd0ebe3a841cab5a43ec460f2c3cc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses since its inception, including a net loss of $<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzY0OTc_54929b40-8ca9-4c49-8de1-d7d5d4ecec0a">214.0</ix:nonFraction> million for the year ended December&#160;31, 2022. In addition, as of December&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzY1ODg_9e54ce92-eed8-45b1-8961-a6fd98b8a9e0">530.6</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash, cash equivalents and marketable securities as of December&#160;31, 2022, together with net proceeds raised under the Open Market Sale Agreement ("the Sales Agreement") subsequent to December&#160;31, 2022, may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial statements which raises substantial doubt about the Company's ability to continue as a going concern, and the Company will need to obtain additional funding. The Company expects to finance its operations through potential public or private equity financings, debt financings, collaboration agreements or other capital sources. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</span></div></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIy_e35b3393-85a0-4a19-b834-edb502232df8" continuedAt="i9bfdf995d44e4bf091f91516325e51b6" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i9bfdf995d44e4bf091f91516325e51b6" continuedAt="iddc81d6f4fb3425d82d82deff36abdba"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM2_e3aebaf7-e88e-42b8-bb69-b4aadb343860" escape="true">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and ASUs of the FASB.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMy_e3096931-db1c-4b66-b4d3-c128d7462b55" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Praxis Security Corporation and Praxis Precision Medicines Australia Pty Ltd. All intercompany transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM3_a5beeafe-e2c4-4122-b6a2-af2dd2154fb9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, stock-based compensation expense and the recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM4_cd244612-3296-4282-8493-c940e120fb0e" continuedAt="i4bcfe74b3ca54d7aa86064114836f3bf" escape="true">Segments</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="iddc81d6f4fb3425d82d82deff36abdba" continuedAt="i2068fda9d142458790511a73c3626060"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4bcfe74b3ca54d7aa86064114836f3bf">The Company has <ix:nonFraction unitRef="segment" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzE2NTI_1eb7677b-1d41-4195-946f-e347d5cde866">one</ix:nonFraction> operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. The majority of the Company&#8217;s long-lived assets are held in the United States.</ix:continuation></span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMz_84ebad87-358e-40a6-90a7-d2e56d69c1db" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in interest-bearing money market funds. Cash equivalents are carried at cost, which approximates their fair market value.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash comprises letters of credit for the benefit of the landlord in connection with the Company&#8217;s lease facilities. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIw_6a5be7ee-4a73-4638-b830-8f1a6ff5d8f6" escape="true"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIw_f3245853-719f-44be-844a-9e105628b45e" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzItMS0xLTEtNTk1ODQ_3d46a881-9b3f-4eb2-8773-19915d628563">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzItMy0xLTEtNTk1ODQ_f4c91977-67f8-4e47-9569-0a7749ca3282">138,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzMtMS0xLTEtNTk1ODQ_a1868495-68fd-44ad-af59-4173389de61e">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzMtMy0xLTEtNTk1ODQ_e12d6bf2-8cf4-4e42-a05d-6a1cae942462">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzQtMS0xLTEtNTk1ODQ_030a507c-5d12-4728-b5eb-37b29e450632">62,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzQtMy0xLTEtNTk1ODQ_19c5c96f-9ffb-4aa2-9307-89cb18baacfd">139,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM0_a04ab904-bb0e-4fe2-8b4d-e08fa60faa0f" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its marketable securities. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders&#8217; equity. Realized gains and losses are included in the Company's consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. As a result, the Company has categorized all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company's intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in other comprehensive loss, net of applicable taxes unless deemed other than temporary.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIx_74a7c947-e783-4c13-97aa-e54dbc971939" continuedAt="ia3fa1a1aae55465c9a4e171e379ae4c1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers and License Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company's investment portfolio comprises money market funds, marketable debt securities, including debt securities issued by U.S. government agencies and corporations, and commercial paper. The Company investments are limited to investment-grade securities with strong credit ratings with the objective of maintaining safety and liquidity. The Company also maintains deposits in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i2068fda9d142458790511a73c3626060" continuedAt="i0c46502b11cd466d8bc6e813053c822e"><ix:continuation id="ia3fa1a1aae55465c9a4e171e379ae4c1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) up to $250,000. As of December&#160;31, 2022 and 2021, the Company&#8217;s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.</span></div></ix:continuation><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIz_00af3087-39cc-48e9-be3c-afc7b62cba34" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts or other hedging arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMw_2f70f18b-336d-46af-b96c-18bd8ef52127" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under GAAP. The fair values of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items measured at fair value on a recurring basis include cash equivalents and marketable securities (Note 4 and Note 5). The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i0c46502b11cd466d8bc6e813053c822e" continuedAt="i4eff4d5c6bce4cd6b3210cc2ca3dc7f6"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzcxNDY4MjU2MjU2MTE_5ad667ae-3a2b-47a3-a5e4-a9432a05598e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzQw_979141f7-97ff-46a2-8c1f-1387db50fc85" continuedAt="i9c41b5777f6b4c0c834b2bbace95cb9c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia2d950c598cd455e8bb7e9014cef8268_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphMzA5NDk1ZmRhNWM0Y2EzYmIzZWI0NWZlNDU3NzJlZi90YWJsZXJhbmdlOmEzMDk0OTVmZGE1YzRjYTNiYjNlYjQ1ZmU0NTc3MmVmXzEtMS0xLTEtNTk1ODQ_12b3ab90-f84b-4833-920d-1acc7d858993">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia737e914cf5e40249acbf0bf1ee2f218_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphMzA5NDk1ZmRhNWM0Y2EzYmIzZWI0NWZlNDU3NzJlZi90YWJsZXJhbmdlOmEzMDk0OTVmZGE1YzRjYTNiYjNlYjQ1ZmU0NTc3MmVmXzItMS0xLTEtNTk1ODQ_5729152f-f016-4a37-9be4-c678912c4d68">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5fa9a695a6e4fb0ba67088018be15ca_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphMzA5NDk1ZmRhNWM0Y2EzYmIzZWI0NWZlNDU3NzJlZi90YWJsZXJhbmdlOmEzMDk0OTVmZGE1YzRjYTNiYjNlYjQ1ZmU0NTc3MmVmXzMtMS0xLTEtNTk1ODQ_6609bbf8-b17c-4b6d-b9f4-87ae902fad09">3</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal, retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance that do not improve or extend the lives of the respective assets are charged to expense as incurred.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzQx_299384ca-6cd0-4d18-b8fe-1dcb12a03c88" continuedAt="i600f1c428f0443a09f8718e43fcf3f89" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i600f1c428f0443a09f8718e43fcf3f89">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows.</ix:continuation> The Company did <ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzExNzA5_11fa59f3-a1b6-4b78-be17-eaa1d19874fd"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzExNzA5_d1cf0547-837b-44dc-9af3-d62a28b82c72">no</ix:nonFraction></ix:nonFraction>t record any impairment losses on long-lived assets during the years ended December 31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI0_a0f8d94c-2408-49a2-ae61-48841091c59e" continuedAt="i371624413205484d9ee834fe89838f58" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842. The Company determines if an arrangement is a lease at contract inception. Operating lease right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable, based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine operating lease right-of-use assets may include lease incentives and stated rent increases. The Company&#8217;s lease agreements may include both lease and non-lease components, which the Company accounts for as a single lease component when the payments are fixed, for all classes of underlying assets. Variable payments included in the lease agreement are expensed as incurred.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i371624413205484d9ee834fe89838f58">The Company&#8217;s operating leases are reflected in operating lease right-of-use assets and in current operating lease liabilities and long-term operating lease liabilities in its consolidated balance sheets. The Company&#8217;s operating lease right-of-use asset as of December&#160;31, 2022 and 2021 did not include any lease incentives. Lease expense for future lease payments is recognized on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzcxNDY4MjU2MjU2MDk_79f0e566-2dff-4b73-bfa9-f72ae8ae5576" continuedAt="iffc3c2ffc9b54b6e8a9b399a32fb7b7d" escape="true">Collaboration Agreements</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i4eff4d5c6bce4cd6b3210cc2ca3dc7f6" continuedAt="i6bb47a974bcf46a58996554801ea3d49"><ix:continuation id="iffc3c2ffc9b54b6e8a9b399a32fb7b7d" continuedAt="ifbc65ed83f914ceeb7d26fef7998e86d"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808"), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of ASC 606 under which the Company may license or provide options to license certain development or product candidates and, in certain cases, may perform research and development services. The terms of these agreements may include payment of non-refundable, upfront fees, option exercise fees, development and commercial milestone payments and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for agreements determined to be within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as an option to obtain a license, it evaluates whether such options are material rights that should be treated as separate performance obligations. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received to estimate the amount expected to be received. The amount of variable consideration included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal of the cumulative revenue recognized will not occur in a future period.</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount of the transaction price that it allocated to the respective performance obligation when or as each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an output or input method. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For example, f</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or research and development services that are recognized over time, the Company measures its progress using an input method. The input methods used are based on the effort the Company expends or costs it incurs toward the satisfaction of its performance obligation. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i6bb47a974bcf46a58996554801ea3d49" continuedAt="i7e64673471b84f3eafe13331340ce058"><ix:continuation id="ifbc65ed83f914ceeb7d26fef7998e86d"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the amount of effort it expends, including the time it estimates it will take to complete the activities, or costs it incurs in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that is multiplied by the transaction price to determine the amount of revenue recognized each period. If the estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that is recognized in the current and future periods.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company performs its obligations under these agreements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had one collaboration, option and license agreement with UCB Biopharma SRL ("UCB"), which it entered into in December 2022. The accounting accounting related to the collaboration agreement is outlined in Note 9, UCB Option and License Agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI2_c7a7a128-ac8b-460f-8926-115c6e3e213e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. Costs incurred to obtain licenses are recognized as research and development expense as incurred if the technology licensed has no alternative future uses.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development related contracts with parties both inside and outside of the United States. These agreements are cancellable, and related fees are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent-Related Costs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM1_b4af67c0-f545-4bf5-87cd-b813b75420d2" continuedAt="i623034f964734bc9851286857167f10b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718"). For stock-based awards issued to employees, non-employees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of the grant. The Company recognizes compensation expense for those awards granted to employees and members of the Board over the requisite service period, which is generally the vesting period of the respective award. For non-employee awards, compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards on a straight-line basis over the vesting period. To date, the Company has not issued any stock-based awards with performance or market-based vesting conditions. The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary or service payments are classified.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i7e64673471b84f3eafe13331340ce058" continuedAt="i227e61af78274dc0a8293542ba676a7f"><ix:continuation id="i623034f964734bc9851286857167f10b"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs of subjective assumptions, including: (i)&#160;the expected volatility of the Company&#8217;s stock; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; (iv)&#160;expected dividends; and (v)&#160;the fair value of common stock. Due to the lack of Company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline publicly-traded companies that issued options with substantially similar terms. For this analysis, the Company selects companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company determines expected volatility using a weighted average of the historical volatilities of the guideline group of companies. The Company expects to continue to apply this process until such time as it has adequate historical data regarding the volatility of its own traded stock price. As permitted under ASC 718, the Company has elected to use the contractual term as the expected term for certain non-employee awards, on an award-by-award basis. For all other awards, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. The Company utilizes this method as it has insufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for instruments with a term commensurate with the expected term assumption. The expected dividend yield is assumed to be <ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:DividendsStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzIxOTkwMjMzMDgxNjg_a4c1c446-0401-4974-83e6-b4dab7069304">zero</ix:nonFraction> as the Company has never paid dividends, and does not have current plans to pay any dividends on its common stock. Subsequent to the IPO, the fair value of the common stock underlying the Company's stock-based awards is the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is estimated based on the fair value of the Company's underlying common stock on the date of grant.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMx_75a2fbb4-6f0e-4469-a359-c06f099aff9a" continuedAt="i218b75f4ed8d4bc98da77b039222a6d8" escape="true">Foreign Currency</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i218b75f4ed8d4bc98da77b039222a6d8">The functional currency of the Company&#8217;s wholly owned foreign subsidiary in Australia is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzIxOTQ5_25170d95-de8d-4969-b590-7d0e2fdf21cb"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="INF" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzIxOTQ5_5bf87f9c-dcfe-4f95-9334-2dfd3e1b2a38">no</ix:nonFraction></ix:nonFraction> material foreign currency gains or losses for the years ended December 31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI5_cc54917e-87c0-4c2c-aa9d-5ee0599589a0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent that it believes based upon the weight of available evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI1_47047026-5292-4436-b642-8aa693968871" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss. For the years ended December 31, 2022 and 2021,comprehensive loss consists of net loss and changes in unrealized losses on marketable securities.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI3_59ba0adc-de58-4f5d-9e5a-b7a4ded53604" continuedAt="id344f09a658e4963bbc34c112613d698" escape="true">Net Loss per Share</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i227e61af78274dc0a8293542ba676a7f" continuedAt="if0a2c8c0695042979f5582afdbecb74f"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id344f09a658e4963bbc34c112613d698">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested restricted common stock and potential shares issuable under the employee stock purchase plan are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</ix:continuation></span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM5_3f1cf0bc-acb4-4eb8-acea-e772fccb7285" continuedAt="i676c3ac9a709480bb740891b3394cf54" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2019-12"). The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders&#8217; equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. On January 1, 2021, the Company early adopted ASU 2019-12 on a prospective basis, with no material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Financial Instruments&#8212;Credit Losses (Topic&#160;326)&#8212;Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which has been subsequently amended by ASU&#160;No.&#160;2018-19, ASU&#160;No.&#160;2019-04, ASU&#160;No.&#160;2019-05, ASU&#160;No.&#160;2019-10, ASU&#160;No.&#160;2019-11 and ASU&#160;No.&#160;2020-03 (&#8220;ASU&#160;2016-13&#8221;). The provisions of ASU&#160;2016-13&#160;modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. On October 1, 2021, the Company early adopted ASU 2016-13 and its related amendments using a modified retrospective approach. Given the composition of the Company's investment portfolio, there was no material impact on the Company's consolidated financial statements and related disclosures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i676c3ac9a709480bb740891b3394cf54"><ix:continuation id="if0a2c8c0695042979f5582afdbecb74f">N</ix:continuation>one.</ix:continuation></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzU4Mw_ff8a8110-25e3-49bf-8102-8b372e21cc67" continuedAt="ib3927f22a1ab46c5bf9dfd3ad11cc803" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="ib3927f22a1ab46c5bf9dfd3ad11cc803"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company had restricted cash of $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1Xzc1_92bf3e5c-35af-41c6-a94a-e0e2fa060780">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NDg3NzkwNzAwOTQ_621c7924-a5fa-4dbd-9d38-2dd419491a08">1.0</ix:nonFraction> million, respectively, held as letters of credit for the benefit of its current and former landlords. The Company's Boston, Massachusetts sublease expires on January&#160;31, 2026, and the related letter of credit of $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="prax:LettersOfCreditReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NQ_2f24d64c-25e7-4a3f-b8c7-ff4854298929"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-5" name="prax:LettersOfCreditReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NQ_83aed366-f6fb-43d1-992d-570fdd8edb30">0.4</ix:nonFraction></ix:nonFraction> million was classified within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_21159827-a52f-45e4-914d-16111d124035"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_4c186cd4-1d36-4e49-a94e-eb059faddb23">other non-current assets</span></span> on the consolidated balance sheet as of December&#160;31, 2022 and 2021. The Company's Cambridge, Massachusetts sublease expired on December&#160;31, 2021, and the related letter of credit of $<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-5" name="prax:LettersOfCreditReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NDg3NzkwNzAxMjM_5b7f8e18-efa5-4f8b-8911-b7bf1d59d120">0.6</ix:nonFraction> million was classified within prepaid expenses and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjg_fb095add-7293-4af1-90e2-816d4ff050b8">other current assets</span> on the consolidated balance sheet as of December&#160;31, 2021.</span></ix:continuation></div><div id="i3603669404fe4fc8b59d31b31e26e467_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzk0Mg_e8ca6ded-7b05-444d-8d80-e2511ff0d174" continuedAt="i111a6e033c80459abe662373ec138c38" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i111a6e033c80459abe662373ec138c38" continuedAt="i8e93dd43a4314eea9d2385895cd85431"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzk0Mw_05ae463e-4a16-40bc-8bf6-06c3b89ae45a" continuedAt="i7f3e3ffd06e7404fb0717ad42978d876" escape="true">The following is a summary of the Company's investment portfolio as of December&#160;31, 2022 and 2021 (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i8e93dd43a4314eea9d2385895cd85431"><ix:continuation id="i7f3e3ffd06e7404fb0717ad42978d876"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtMi0xLTEtNTk1ODQ_b7099060-804a-4bdc-9dda-6489ff962bd3">35,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtNC0xLTEtNTk1ODQ_7f478d11-f6e2-4a20-911d-36860a87fb7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtNi0xLTEtNTk1ODQ_e2771983-877c-43b5-8c73-96560829a10d">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtOC0xLTEtNTk1ODQ_0f03c5f1-c9a7-48db-916a-0596f155eb3c">34,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtMi0xLTEtNTk1ODQ_3042495a-7f68-4ce9-89d8-ffa2a3d4c527">4,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtNC0xLTEtNTk1ODQ_3ef61a75-a038-498e-b7b3-5d3bac5f7f3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtNi0xLTEtNTk1ODQ_2f3d50a1-bc4c-4431-99ca-f747a75b1ed7">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtOC0xLTEtNTk1ODQ_55ae0c6e-07e4-403b-a4d6-cfe767564f3e">3,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctMi0xLTEtNTk1ODQ_d598f868-dbf2-41f5-b3b6-9bca9b51ddfe">39,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctNC0xLTEtNTk1ODQ_7c92482a-3211-458d-9f9d-4a4f26dfdb8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctNi0xLTEtNTk1ODQ_527b22bd-d1d7-4835-8bb5-612fc7447138">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctOC0xLTEtNTk1ODQ_50e26bb7-5ac4-4f74-b447-a335c20f40fa">38,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTItMS0xLTU5NTg0_1dc329f0-b607-463f-83bd-593e76aecb61">39,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTQtMS0xLTU5NTg0_cd5beeb7-b205-4bff-b5a7-c8858498d708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTYtMS0xLTU5NTg0_856c308a-99c0-4897-b4ca-c28025d28b1c">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTgtMS0xLTU5NTg0_f4743a1d-d11a-4151-bce9-5593b94a3193">38,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtMi0xLTEtNjcyOTI_7738b28b-3be3-4268-ab09-bdd39679fb50">52,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtNC0xLTEtNjcyOTI_2a0091e6-1bd5-48bb-9f94-9dc342365c28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtNi0xLTEtNjcyOTI_f6be2e58-d5de-4532-bf13-db7673a4d05b">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtOC0xLTEtNjcyOTI_0cf9f2c6-357e-4567-b02c-a647737376fb">52,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtMi0xLTEtNjcyOTI_24a98403-4ea9-4ccd-bc51-1d02859a3602">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtNC0xLTEtNjcyOTI_9b31dd07-52df-4963-80bb-574b1160449a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtNi0xLTEtNjcyOTI_98c017a0-57a5-4173-ba4e-c805695ebd2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtOC0xLTEtNjcyOTI_787b882f-3456-4af0-9b85-4c3df1284fee">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtMi0xLTEtNjcyOTI_9efe5e7a-c7d9-4855-87db-7b99ecc83258">12,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtNC0xLTEtNjcyOTI_a680649d-6434-4708-b1f3-7d0c86ff315f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtNi0xLTEtNjcyOTI_3dcf0102-9e01-465e-ab25-d8845910c9f8">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtOC0xLTEtNjcyOTI_1898363f-7812-4dc0-94a0-a69356232f93">12,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctMi0xLTEtNjcyOTI_02b2f36c-b92d-4856-89a1-4846416c371b">6,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctNC0xLTEtNjcyOTI_11bae626-c4ae-4ad4-995a-cf85546e2459">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctNi0xLTEtNjcyOTI_4efa7866-eefa-4fa8-b828-5b201e3651e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctOC0xLTEtNjcyOTI_2c4cf168-842d-44f4-8c0a-8dbc9ee2fd36">6,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtMi0xLTEtNjcyOTI_05eff959-8ff9-4215-a42c-9224e0e682db">105,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtNC0xLTEtNjcyOTI_d29f239c-16b1-45ba-836c-e667927872fe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtNi0xLTEtNjcyOTI_d041bde5-165d-40fc-a37e-a9e3811d984b">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtOC0xLTEtNjcyOTI_89351ab1-b39b-4e26-9817-c0eb628ed3f9">105,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTItMS0xLTY3Mjky_ba7ab358-12b8-4e36-aace-fe0995175cb9">31,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTQtMS0xLTY3Mjky_873b375b-92ec-4c53-96ce-3762db159140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTYtMS0xLTY3Mjky_1fb068d5-7f7f-4846-bded-f947c8d4b0b4">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTgtMS0xLTY3Mjky_1d430f83-b8d4-46e3-993b-d18d498458e7">31,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTItMS0xLTY3Mjky_96bcbfee-ed32-443c-aa8b-8c7fe837fcee">31,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTQtMS0xLTY3Mjky_2ea35a09-2e4a-4f04-8403-d0a7220d3162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTYtMS0xLTY3Mjky_df464411-cc0d-4bb2-9c73-a173b2d7014e">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTgtMS0xLTY3Mjky_b12584d5-473c-4b9e-a42d-ad84a4048f55">31,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTItMS0xLTY3Mjky_703c0a58-a4dc-4a1d-b6af-ab5d2a81903f">137,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTQtMS0xLTY3Mjky_e59454b4-40cc-429c-b4ed-31b8311d0704">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTYtMS0xLTY3Mjky_31fceb50-ded4-486e-ad4e-35a905cc9231">177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTgtMS0xLTY3Mjky_940472d7-2921-427d-ab71-ea973ff5df36">137,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="program" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzIwNw_697887c3-35ac-4a51-8a8e-bf2a4f5cf480">7</ix:nonFraction> securities with a total fair market value of $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzI1NQ_170f307d-3da2-439b-b1a5-621e979f05d8">38.9</ix:nonFraction> million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and is primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance for credit losses was not recognized.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the years ended December 31, 2022 and 2021.</span></div></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90ZXh0cmVnaW9uOmYxNDhlZDgzOWQ0ZTRhMDdiMjM5YjlmNGJjMmIwMmI2XzEwNDg_db1c60a1-7f28-4e3b-b009-420c3b7f852e" continuedAt="ibb5221b639294a08abf5a0e531fc858b" escape="true">Fair Value of Financial Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibb5221b639294a08abf5a0e531fc858b" continuedAt="ic5798e9ff60542c29cdec37eaba1a24c"> <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90ZXh0cmVnaW9uOmYxNDhlZDgzOWQ0ZTRhMDdiMjM5YjlmNGJjMmIwMmI2XzEwNDk_50dbd477-5133-451a-ae68-57f928db0736" continuedAt="ic9fb3c96cd7a46fc8488d75253b23988" escape="true">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2022 and 2021 (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ic5798e9ff60542c29cdec37eaba1a24c"><ix:continuation id="ic9fb3c96cd7a46fc8488d75253b23988"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74bbcf7115f440d8a7727a6bd51c63f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtMS0xLTEtNTk1ODQ_a0489a22-deb1-4f9c-beda-9a906576c3b6">34,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4155d454f999412a8921a320b1dac7b8_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtMy0xLTEtNTk1ODQ_e64993f8-76e3-4dcf-a6d6-e4c033b217f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863005b39586407793ad56aa5956d85b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtNS0xLTEtNTk1ODQ_f0bccc4b-a74b-4c77-9434-f975089f460f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602db591ac4e4681915e753d9c9f647b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtNy0xLTEtNTk1ODQ_cf805a5b-93ef-4c6e-b221-d88d409761de">34,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b26d9edbae245159b56fa3a00570a2d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtMS0xLTEtNTk1ODQ_9ab6b8ed-6116-434a-b8b9-aa7ba7d0d10b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f52406efb649548003a483847ad691_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtMy0xLTEtNTk1ODQ_39669230-6c76-411d-99af-b326f2182448">34,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e5a8fc79f44e908279f9f4451ffcbf_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtNS0xLTEtNTk1ODQ_a6f6fd57-220f-4152-9db9-f56a5aed2b79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7963bf676f4ac8a945b019d828f54d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtNy0xLTEtNTk1ODQ_a1b6c73a-6cb1-4e37-9586-4ab1dfa48f26">34,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3294a9a7ece4c74870e2e39a7c3d8c2_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtMS0xLTEtNTk1ODQ_3c189bfc-df2b-444d-9cce-bdb03133e102">3,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d0ac36134f4884ba2a77e339a74cf2_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtMy0xLTEtNTk1ODQ_e5b1d10e-0ef5-47a0-a9d4-d29cf1b61646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067bfcb424b847af96504067bd13ea3b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtNS0xLTEtNTk1ODQ_0b45b00f-d327-4afd-85fc-ba932c42dd04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9179d2848e4437a83ec90af5318502_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtNy0xLTEtNTk1ODQ_6dbc4a42-1f46-467d-b035-f5fb55d7260b">3,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f74f35a8bd4e0d88f85f5805b2b164_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTEtMS0xLTU5NTg0_3d512c6b-464b-4720-be4d-e101f0237e9b">38,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ba78adb17f4a0397707c92359e2504_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTMtMS0xLTU5NTg0_b7af03de-c083-43b4-9b2e-b49ceca8a775">34,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58d705233dd47d8aee4f5ab6cfb7200_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTUtMS0xLTU5NTg0_6f99a1df-8b0a-4e21-9039-49fa00a97254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a0c3d7a4f446ce8e8a686a819a00e1_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTctMS0xLTU5NTg0_4fb629a6-ae04-4fd0-a50a-e6625b3a8642">73,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e26ad8bb6f04d92a24db27f1e62aee2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMS0xLTEtNjQxMTM_c9df0be8-08c1-484f-a977-fe228164f4cb">131,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc35a88c136a419baf53d23fb148a052_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMy0xLTEtNjQxMTM_795142f3-30b6-4847-98e3-1dedebe711f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3aa83e6bc8e4ae9b4d9cbb367c26259_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNS0xLTEtNjQxMTM_514f7287-349b-4188-8113-0b36ac22197e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e590dbad5c94c6bb050a64eccee552f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNy0xLTEtNjQxMTM_9bf23198-d555-4d32-8881-5c6133b51991">131,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a98be32db89466fb3fa4f64deb01f21_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtMS0xLTEtNjQxMTM_80fef839-c587-4f84-8c69-bc1754ba1d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb01972b2a0f443d89fb162c0416b297_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtMy0xLTEtNjQxMTM_23cd1e69-fc9c-4764-b2f9-1f4711cab70d">83,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd8cd471062406d938bc8f398785ba9_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtNS0xLTEtNjQxMTM_0d899161-2b18-4623-b4e4-2547ca67b1ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43b84cc8f724c1790306900f9eab5c1_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtNy0xLTEtNjQxMTM_68a1b914-ebb6-4327-809d-5bf5ac2ee9d5">83,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244c9b8a8bc64d05805e6f9efdd28890_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctMS0xLTEtNjQxMTM_6ccadbd8-7515-41eb-ba44-e0b859608292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ab65adfac24345b56927930bd81e0d_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctMy0xLTEtNjQxMTM_29a8d1fc-4834-46a4-a752-8e9034a4f403">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09d1356850af46b7a820dcbe285a8867_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctNS0xLTEtNjQxMTM_f7213f4f-6b3f-4757-961c-91a62509b72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47fa3e30c05c4125a934754580ac61d8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctNy0xLTEtNjQxMTM_1d05bae7-70b6-4447-aba0-49e456c599da">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62409ab1a9324ce686d28857f3d25ed8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtMS0xLTEtNjQxMTM_6da5a58a-94ea-445c-848a-d0f5fa9db718">12,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1040caddcfac467f932bd93ddc355481_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtMy0xLTEtNjQxMTM_f3ec90ef-c7cb-44fc-a37b-d23def8b6a34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b254a6d21743ceb007eeb41999093b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtNS0xLTEtNjQxMTM_06e6104f-35ec-43f0-80f2-27c90c90ac37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb6df78b28c4de8a6b362faa5295589_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtNy0xLTEtNjQxMTM_54373f93-6e76-4836-8ca9-99d916a7ea03">12,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3ad0541c6044f3af2172c901923f02_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMS0xLTEtNTk1ODQ_a3febcac-ee46-462e-b6e5-deff5c20128c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1964efc982e4dd5bfee80bfedb3be00_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMy0xLTEtNTk1ODQ_7bbe5bc5-0d99-44da-a241-1569148662ce">6,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cbc72ab825d46fbb9a436e63f3c57ce_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNS0xLTEtNTk1ODQ_4a3dba52-8d5a-4244-bb20-bb8cd57884c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e19833c70214691b2d072f303950003_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNy0xLTEtNTk1ODQ_fc522c1c-fed8-4b82-ac48-9019b0e3a2a9">6,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5a509f1d7046e5a8180c53dbfa8c7b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtMS0xLTEtNTk1ODQ_59a30b36-60f9-4433-af9e-e6ae0c1ca7a4">143,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6bcfca8aec14570ad5ec15d6bc82cc3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtMy0xLTEtNTk1ODQ_9ef219a7-a383-4fb6-8877-09e87e1d5abe">125,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136b3f69ecaa46faa9ac4cd6b513328e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtNS0xLTEtNTk1ODQ_c318d09c-a83f-4b89-a6bb-97459ee5376e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93a96f76f6246f2aae4871e03bbf942_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtNy0xLTEtNTk1ODQ_151568ec-2547-4623-9908-c154e642a20e">268,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its marketable securities classified as Level 2 by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</span></div></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90ZXh0cmVnaW9uOjJjOWY4ZjQ4OTdmZDRlNGZhMWZiMTU1ZmM1NmIwMjViXzE3MA_bedc69ac-e329-4ce0-a719-b17102e4cf25" continuedAt="ifa2aa59b25ea482889e11a226b726fc0" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="ifa2aa59b25ea482889e11a226b726fc0"><ix:continuation id="i9c41b5777f6b4c0c834b2bbace95cb9c"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003402f9a7274f688237578608beb52e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzItMS0xLTEtNTk1ODQ_5dbc7d52-bc21-412a-979b-377d2fcff020">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42340b78da843ad9d0bb3e0bc2a70c6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzItMy0xLTEtNTk1ODQ_c6b081e1-7e4b-419e-839c-b4dd6c5a7a41">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933e341b21264671b5246e7e4b47974b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzMtMS0xLTEtNTk1ODQ_005f6a51-a39f-469a-8f01-403eefc82c29">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ec332f151445f7b78b848590737181_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzMtMy0xLTEtNTk1ODQ_850b9b5c-7523-413c-bfd5-f8d5368ba7ba">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8742d8224d8c45c5bdaf37d3f6ba1094_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzQtMS0xLTEtNTk1ODQ_f981adcc-b843-4fbc-8e28-e7aecebadd2e">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fcf4921a72b4aab9503d8d482d73745_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzQtMy0xLTEtNTk1ODQ_3bd599ac-fc5f-4ce3-970e-63808260229e">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzUtMS0xLTEtNTk1ODQ_b02d0c1d-0e1e-42a4-9bc9-b0bede7bd0a5">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzUtMy0xLTEtNTk1ODQ_8105f8ac-ddae-4e01-ad64-6cc353a2ccf7">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzYtMS0xLTEtNTk1ODQ_df182ced-d736-42fa-8d0e-1f16e5be7721">572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzYtMy0xLTEtNTk1ODQ_1a8054cf-c2c3-4ff8-84a6-00da565503ff">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzctMS0xLTEtNTk1ODQ_718150b2-cd7f-4b9b-b3ea-f965c6ca937d">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzctMy0xLTEtNTk1ODQ_8bd60ed5-e408-4a2d-a04e-079335d413ae">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90ZXh0cmVnaW9uOjJjOWY4ZjQ4OTdmZDRlNGZhMWZiMTU1ZmM1NmIwMjViXzEwOTk1MTE2MjgwOTA_8b9883e4-be2a-426a-9385-a01584a2bf0d">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90ZXh0cmVnaW9uOjJjOWY4ZjQ4OTdmZDRlNGZhMWZiMTU1ZmM1NmIwMjViXzE2NDkyNjc0NDE5MjY_19cff90c-eb7d-441a-beb9-75fa2f3803cb">0.2</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_121"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90ZXh0cmVnaW9uOmNjZDJkYWQzNzg4MzQ2Zjg5MGRhMjZiNGQ2MDhlOTNjXzg1_c5f761de-05e3-4be0-8837-7b0570324e3b" continuedAt="i6b09574b27384715922c3792c5c6f0d8" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i6b09574b27384715922c3792c5c6f0d8"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90ZXh0cmVnaW9uOmNjZDJkYWQzNzg4MzQ2Zjg5MGRhMjZiNGQ2MDhlOTNjXzg2_78c534c6-f167-463e-9b35-9a8b6630f1cb" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:AccruedExternalResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzItMS0xLTEtNTk1ODQ_8b656dd7-5d85-41f5-b302-6a7173b11f0b">10,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:AccruedExternalResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzItMy0xLTEtNTk1ODQ_972c1261-3390-45a3-a055-684ee43b6d8a">17,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:AccruedPersonnelRelatedExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzMtMS0xLTEtNTk1ODQ_bf097ed8-25ff-41c2-9757-8cf846fecad0">2,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:AccruedPersonnelRelatedExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzMtMy0xLTEtNTk1ODQ_fb0bd35b-8141-4471-ad20-b429e120aace">7,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzUtMS0xLTEtNTk1ODQ_f5573289-38ee-4ab1-82a8-689258dc0399">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzUtMy0xLTEtNTk1ODQ_7de009d3-a825-4493-88bf-591acfc18006">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzYtMS0xLTEtNTk1ODQ_0fd00ed0-1eef-4edb-8740-db3cb66b01c5">15,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzYtMy0xLTEtNTk1ODQ_d99c59c4-dd49-4c5d-b5fa-94233f730b55">26,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDY_1f5ff631-d3a7-4174-bb3f-8f2d1fa22c84" continuedAt="i5ef73f68d6a14b4e88db2b401b7918f9" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i5ef73f68d6a14b4e88db2b401b7918f9" continuedAt="i5c31a340e05c4ed39384be84086ac826"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts. The sublease expires on January&#160;31, 2026, with no option to renew or terminate early. The base rent increases by approximately <ix:nonFraction unitRef="number" contextRef="i716e562883f3424aaef16a9b22f5c8e7_I20211001" decimals="2" name="prax:PercentageIncreaseInAnnualBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzM0OA_be445bdb-c3eb-4b02-b956-a843865b2903">2</ix:nonFraction>% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash (Note 3). This lease qualifies as an operating lease. At inception, the Company recorded an operating lease right-of-use asset and operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i716e562883f3424aaef16a9b22f5c8e7_I20211001" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzYzNQ_559b3142-1ac9-4477-9218-f382ab5e5212"><ix:nonFraction unitRef="usd" contextRef="i716e562883f3424aaef16a9b22f5c8e7_I20211001" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzYzNQ_87db63cf-b542-4619-af6c-fcdfa5f4fe81">4.1</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a sublease agreement for office space located in Cambridge, Massachusetts which expired on December&#160;31, 2021. The base rent increased by approximately <ix:nonFraction unitRef="number" contextRef="if36d77c9c53144d09601968a0865fbce_I20181031" decimals="2" name="prax:PercentageIncreaseInAnnualBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzE2NDkyNjc0NDcwMjM_e43b9341-3307-43f7-8b29-0e787e7d4acb">1</ix:nonFraction>% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash (Note 3). This lease qualified as an operating lease. </span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="prax:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDc_16063b85-3789-482b-9f54-a64fdb61541a" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the operating leases in the Company&#8217;s consolidated balance sheets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzMtMS0xLTEtNTk1ODQ_e7f3cbfb-512f-4a12-a5b2-9ffd9f65b61e">2,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzMtMy0xLTEtNTk1ODQ_d9cbf5e9-67ad-40c7-b6ab-30093f216912">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzUtMS0xLTEtNTk1ODQ_a6f75a18-7ff0-4d02-b8db-4b9c841c3622">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzUtMy0xLTEtNTk1ODQ_b9fbd556-54e2-4696-a982-82ff8bbd52d2">810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzYtMS0xLTEtNTk1ODQ_fb603303-a588-4cea-b0f7-26f80acaec5d">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzYtMy0xLTEtNTk1ODQ_250f7284-0f9a-42a5-b22b-a9b1bff4c928">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzctMS0xLTEtNTk1ODQ_bca8e18f-8daa-4bd2-be44-cbdf00c54c2c">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzctMy0xLTEtNTk1ODQ_0f4e44f2-3959-4f01-a58e-f74f3b4c70ce">4,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDQ_6e8beb39-154c-4003-9844-097020e96dda" continuedAt="if84275ae941249808193c32b41102b2f" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total lease costs recognized in the Company&#8217;s consolidated statements of operations (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzItMS0xLTEtNTk1ODQ_78165e01-52dc-4913-b422-f6e67746c076">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzItMy0xLTEtNTk1ODQ_45e24a3d-390f-43e8-a79f-ab04a33ca88d">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzMtMS0xLTEtNTk1ODQ_02c544ef-6ccc-4dab-a2e8-d377d55ce75e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzMtMy0xLTEtNTk1ODQ_b7ec3932-822f-441f-af9c-3fb8fb1879aa">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzQtMS0xLTEtNTk1ODQ_47dc4a27-4dbe-4d18-92fd-f325e42d5306">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzQtMy0xLTEtNTk1ODQ_748e83d6-8527-4e58-8ecb-0238c863fec6">1,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs were primarily related to operating expenses, taxes and insurance associated with the operating leases, which were assessed based on the Company&#8217;s proportionate share of such costs for the leased premises. As these costs are generally variable in nature, they were not included in the measurement of the operating lease right-of-use asset and related lease liability. Total lease costs are included as operating expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5c31a340e05c4ed39384be84086ac826"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDk_3bc6b72c-38fa-4c17-aac6-f9c61f5293f6" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable lease agreements as of&#160;December&#160;31, 2022 were as follows (in&#160;thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future&#160;Lease<br/>Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzEtMS0xLTEtNTk1ODQ_411b16b8-eefc-4242-ab9e-0740cec58adf">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzItMS0xLTEtNTk1ODQ_20ba85e8-70f2-4d43-bb1c-2db350821ff2">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzMtMS0xLTEtNTk1ODQ_34c650ae-74fd-4f35-8694-441401311cec">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzQtMS0xLTEtNTk1ODQ_fe0e39e6-5176-4b1b-bc87-85e17b15539c">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzYtMS0xLTEtNTk1ODQ_78d97b9b-c54c-4c1b-80d1-aef73c52d9d7">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzctMS0xLTEtNTk1ODQ_ec8e5102-41b4-4f91-9f95-7d3d37840974">497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzgtMS0xLTEtNTk1ODQ_df1fb59d-a77c-4144-b08c-fbac39d0038b">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="if84275ae941249808193c32b41102b2f"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average incremental borrowing rate of the Company&#8217;s operating lease were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica6b7381be214302904bad838ac442b9_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzItMS0xLTEtNTk1ODQ_89f80d52-56fa-494b-b63e-92d1221dad5e">3.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzItMy0xLTEtNTk1ODQ_e1a7b7f5-02d9-4bba-aa12-3413d57217ad">4.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average incremental borrowing rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzMtMS0xLTEtNTk1ODQ_21d1b27f-ba03-48ea-a8b3-442213cb888d">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzMtMy0xLTEtNTk1ODQ_31db6850-ebd2-447d-8eb8-09efa9aa4d53">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and no material legal proceedings are currently pending or threatened.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Orders</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with third parties for various services, including services related to research, preclinical and clinical operations and support, for which the Company is not contractually able to terminate for convenience to avoid future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, the Company is contractually obligated to make certain payments to vendors, primarily to reimburse them for their unrecoverable outlays incurred prior to cancellation. The actual amounts the Company could pay in the future to the vendors under such agreements may differ from the purchase order amounts due to cancellation provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into indemnification agreements and agreements containing indemnification provisions in the ordinary course of business. Pursuant to these agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual upon execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into multiple agreements with third parties under which it may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified product candidates. Payments under these agreements generally become due and payable upon achievement of such milestones and sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company's financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_1099511629421"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV83Njk2NTgxNDExOTk2_c8900ffd-f8a5-4b60-893b-1a2bc4958526" continuedAt="iab8db083e4134dbb9fc1c00eb78e8abd" escape="true">UCB Option and License Agreement</ix:nonNumeric></span></div><ix:continuation id="iab8db083e4134dbb9fc1c00eb78e8abd" continuedAt="ie425b079c6374a6bb93ff6eecd4ebd58"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into an Option and License Agreement (&#8220;the Collaboration Agreement&#8221;) with UCB for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a $<ix:nonFraction unitRef="usd" contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjUzODIw_0486b902-9852-4738-8f64-0c2fafa1bbb1">5.0</ix:nonFraction> million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to $<ix:nonFraction unitRef="usd" contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231" decimals="-5" name="prax:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjU2MDM4_f457e6f9-a5f0-441d-aacd-b45968ef14c4">98.5</ix:nonFraction>&#160;million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be $<ix:nonFraction unitRef="usd" contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjU2MTU1_dafe8376-1b50-4e9b-a999-58a2ed4dd845">5.0</ix:nonFraction>&#160;million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie425b079c6374a6bb93ff6eecd4ebd58">The Company will recognize revenue for its research services performance obligation over time using an input method over the duration of the research services. During the year ended December&#160;31, 2022, the Company did not recognize any collaboration revenue related to the Collaboration Agreement as no services had been provided. As of December&#160;31, 2022, the $<ix:nonFraction unitRef="usd" contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjU2MTYz_aa0c434e-6e6e-44d6-a643-b7d1751eb78f">5.0</ix:nonFraction>&#160;million upfront payment is included in deferred revenue in the consolidated balance sheet.</ix:continuation></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i3603669404fe4fc8b59d31b31e26e467_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzQzMTk_23c82157-bf27-4e1b-9a55-f2c58147e077" continuedAt="i49628d1a1a6c4718989e689c9aa4c6f5" escape="true">Common Stock and Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="i49628d1a1a6c4718989e689c9aa4c6f5" continuedAt="ia572a8cf357f46ba9568a9f8f056a1f4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;18, 2021, the Company completed a follow-on public offering in which the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE0MjY_8cec359a-3608-4aa6-969a-bd9119a83091">5,750,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8aa498682824f9bb5c5eed3af34a7de_I20210518" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE0ODY_47489544-d0f1-4052-bb46-de10c9f27503">18.25</ix:nonFraction> per share, including <ix:nonFraction unitRef="shares" contextRef="ie851e6aa9211407fbf15412951580a0b_D20210518-20210518" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE1MTA_68786673-5934-451a-8e5c-18aa800d4718">750,000</ix:nonFraction> shares of common stock issued and sold pursuant to the underwriters' exercise, in full, of their option to purchase additional shares of common stock, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518" decimals="-5" name="prax:SaleOfStockConsiderationReceivedGrossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2OTY_956b1453-691e-4b6a-89c9-81e6290bc70e">104.9</ix:nonFraction> million. The Company received approximately $<ix:nonFraction unitRef="usd" contextRef="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE3MzU_b28627e4-b189-4e06-93b8-c25d193ea5ac">98.4</ix:nonFraction> million in net proceeds after deducting discounts, commissions and offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2021, the Company filed an automatic shelf registration with the Securities and Exchange Commission, which was automatically declared effective on November&#160;3, 2021 in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. The Company also simultaneously entered into the Sales Agreement with Jefferies LLC ("Jefferies"), to provide for the offering, issuance and sale of up to an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="iac3370fe8f2b42789eb23526e5ecb703_D20211103-20211103" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTE0MDk_a859fdfe-5d18-45c0-a7a0-af591f586352">125.0</ix:nonFraction> million of common stock from time to time in at-the-market offerings under the shelf registration and subject to the limitations thereof. Jefferies is entitled to compensation at a commission rate of <ix:nonFraction unitRef="number" contextRef="i921f704070724adca8d013ad9ca44f7a_D20211103-20211103" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTE0MTk_92209d52-44a2-441c-9213-7bb4fe38387c">3</ix:nonFraction>% of the gross sales price of common stock sold under the Sales Agreement. During the year ended December&#160;31, 2022, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="ic6c285fb70c14984a035bed8222bb71a_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMxNzk_1af28109-5599-4784-b347-bc08315b5440">3,595,273</ix:nonFraction> shares under the Sales Agreement for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic6c285fb70c14984a035bed8222bb71a_D20220101-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMzMzg_f3d2ac28-f3de-4545-af88-72f35ffd3468">9.6</ix:nonFraction> million after deducting commissions and offering expenses payable by the Company. As of December&#160;31, 2022, the Company issued and sold a total of <ix:nonFraction unitRef="shares" contextRef="i82a93dc661184757b579f3d8def24296_D20211103-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMzNjE_50b993ee-c34e-4eca-9ccf-e838ca47e2d7">3,987,270</ix:nonFraction> shares under the Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i82a93dc661184757b579f3d8def24296_D20211103-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMzNjg_69f69c92-48ab-4413-8583-a96665d077a9">16.6</ix:nonFraction> million after deducting commissions and offering expenses payable by the Company. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the authorized capital stock of the Company included <ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzI5MjE_b0cafa75-bbd9-41b4-9d64-1f0642afc6e4"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzI5MjE_c9f500cb-ded6-4acf-afca-c58ba8563663">150,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e73530e136b479c80208cb925bbade7_I20201020" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzI5NDg_b1730168-7205-4c13-86e7-a1dd9d831bcb">0.0001</ix:nonFraction> par value, pursuant to the Amended and Restated Certificate of Incorporation effective upon the completion of the IPO. Holders of such shares of common stock have the exclusive right to vote for the election of the Company's directors and are entitled to one vote per share. In the event of the voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to a pro </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ia572a8cf357f46ba9568a9f8f056a1f4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rata distribution of the Company's net assets. Dividends may be declared and paid to such holders only when, as, and if declared by the Board or an authorized committee thereof.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of December&#160;31, 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="ia026dc966a754812a61ad0c096814457_I20221231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM1ODA_b531c926-7993-49ae-bb04-2234165673b8">no</ix:nonFraction>t hold any treasury shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzQzMjE_c82b3a12-bbcc-4296-90e4-3ba149fff40e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5afc5d945ba4bafadfb0d0c3dac741e_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzItMS0xLTEtNTk1ODQ_43a3b76a-12c9-490d-8a69-fca8572e8382">8,838,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66f40fdf3e9849dc95aff9107e6a2abc_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzItMy0xLTEtNTk1ODQ_e2f5a211-c421-48e1-a5c0-874f2ea3aeff">6,468,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib353ee652a0c4a69b3370039987754bd_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzMtMS0xLTEtNTk1ODQ_4430d965-24cf-4500-9323-c4daa874c969">1,650,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc86f7ac19204f0e8a499e53f47bb1fd_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzMtMy0xLTEtNTk1ODQ_0d29adaa-1584-4234-88fd-67f94e887f4c">2,667,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00847cec0267471db96ca9e81a3449ce_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzQtMS0xLTEtNTk1ODQ_f7ee6f57-fc91-433f-9334-0ee869be0dd7">839,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfec095cffc9489f9b959bfbd8233e2c_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzQtMy0xLTEtNTk1ODQ_377172ac-b833-42a9-89cd-ec19f4dbdc08">654,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibab1d12675f44c9183ae81a1c19d02b4_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzUtMS0xLTEtNTk1ODQ_736b2dca-9de0-4dab-8bc7-6244dffd8ee8">743,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7da243485d114cb4884c5da895b1ce3b_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzUtMy0xLTEtNTk1ODQ_04ff93ac-5a3c-4804-9b11-d52c7049c799">440,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzYtMS0xLTEtNTk1ODQ_dd989c35-574e-4ded-9768-af40b019544c">12,072,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzYtMy0xLTEtNTk1ODQ_e93f6458-89d7-4316-8999-ff73af4c87f8">10,230,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company was authorized to issue <ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM4MDA_71487a5f-77df-44fb-84b7-ccf9cb1dc59c"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM4MDA_af4680b9-3302-466a-96ac-4c7c6a45b63d">10,000,000</ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM4NDM_48ef9648-ac20-415d-a480-eec34bbaf952">0.0001</ix:nonFraction> par value, in one or more series, and is authorized to fix the powers, designations, preferences and relative participating option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company's shareholders. As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_371491e4-c2b2-4269-b34c-50d1e8233c53"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_37695702-e616-4dac-8097-c7571d0e5125"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_9a433e05-909a-402a-9e69-dea9161449e2"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_d4b1d425-2f2b-440c-894f-1caf377c7b5e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock issued or outstanding.</span></div></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNTY_4190116c-3bad-423c-b352-8b549015f929" continuedAt="i1c0d920e2e484cdd8b3185b8cd9d712d" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i1c0d920e2e484cdd8b3185b8cd9d712d" continuedAt="i49b66c2e94b749c68d44517bb38d94a5"><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan") as of December&#160;31, 2022 and December&#160;31, 2021 was <ix:nonFraction unitRef="shares" contextRef="ia026dc966a754812a61ad0c096814457_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNzk_f096130b-e642-49fe-955a-3c4d68142d5f">7,449,480</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ia2ab45cd01a247ec83adf3c948df3f0f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNzI_158aa10b-2452-4eef-95a5-6e1497248adb">5,184,455</ix:nonFraction> shares, respectively. The total number of shares of common stock authorized for issuance under the 2017 Stock Inventive Plan (the "2017 Plan") as of December&#160;31, 2022 and 2021 was <ix:nonFraction unitRef="shares" contextRef="i8bd4bd8649214980a4a5f8233252d50e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNjU_10ca8551-b111-4e82-8d0e-c024411902eb"><ix:nonFraction unitRef="shares" contextRef="i2996ff42e2cd4a599e5553a465ddee81_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNjU_a0b669de-eb12-4a81-8822-5e49d100874b">5,937,763</ix:nonFraction></ix:nonFraction> shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under the 2020 Plan and 2017 Plan expire <ix:nonNumeric contextRef="i73413d9e77ac43d0ba5a6eb2639a610b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzg4OA_439fbd54-fac9-4987-962a-3d11bf81b580">ten years</ix:nonNumeric> from the date of grant. Shares that expire, are terminated, surrendered or canceled under the 2020 Plan and 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future awards. Upon stock option exercise, the Company issues new shares and delivers them to the participant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e total shares authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP") as of December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 was <ix:nonFraction unitRef="shares" contextRef="id1f0a02e5c3f43b595b8742c748bc727_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTA5NTU_3f96eb3f-4b0d-4d6a-917d-de8155ae1434">981,306</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i09eef053696d47e58b2abf3b796af5de_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE4MTQ_7e76d058-d74d-4105-ad07-c237dd2533e8">654,204</ix:nonFraction> shares, respectively. During the year ended December&#160;31, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i90c01ec3e3ba4a2980aae7d5fa413eb1_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTEyMzA_01e1877c-e0a5-42a6-8a5c-5a151287a9c0">141,384</ix:nonFraction> shares under the 2020 ESPP. The Company did <ix:nonFraction unitRef="shares" contextRef="i99f60c5a963444cba12bc6600fceeae2_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzIxOTkwMjMyNjU5ODc_02b4d96d-c384-424d-87af-03ceaa017f25">no</ix:nonFraction>t issue any shares under the 2020 ESPP during the year ended December&#160;31, 2021. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i49b66c2e94b749c68d44517bb38d94a5" continuedAt="ia0273c80d9c14b08a37b46fe4667c789"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNjE_c805f162-feda-4363-aceb-201f3dc8d31e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7da243485d114cb4884c5da895b1ce3b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzEtMS0xLTEtNTk1ODQ_aab3cdf5-5c70-4f43-90fd-a7a8e355922f">440,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7da243485d114cb4884c5da895b1ce3b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzEtMy0xLTEtNTk1ODQ_c135d00a-4352-4121-b5e3-c9f976c3ce6e">41.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231" decimals="INF" name="prax:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzItMS0xLTEtNTk1ODQ_68db6424-8d8d-46d2-b560-717e9e7741d7">676,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231" decimals="2" name="prax:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzItMy0xLTEtNTk1ODQ_011a03ac-fd22-4b83-b165-dfa63b94c7fa">14.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzMtMS0xLTEtNTk1ODQ_1d4a445e-69e2-4f2c-bc93-b773864c18dc">104,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzMtMy0xLTEtNTk1ODQ_4d73b9a4-f0b3-418a-9f5e-3f193eaf644c">44.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzQtMS0xLTEtNTk1ODQ_75936d57-5597-440c-8ea8-f96a1bcd1bee">268,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzQtMy0xLTEtNTk1ODQ_da6ce4f6-3799-424d-8f26-505cd560d188">22.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibab1d12675f44c9183ae81a1c19d02b4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzUtMS0xLTEtNTk1ODQ_48bc0b40-1d76-4243-a787-5f1cc91730da">743,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibab1d12675f44c9183ae81a1c19d02b4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzUtMy0xLTEtNTk1ODQ_9c3c771d-aed9-4bef-b31b-2b31978f2627">23.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i92a1b80e6fa1480abd9c373178bf12e6_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzI1MDc_ad780c51-594b-4f47-99a7-fe338f386de3">12.4</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i8b5c9571e9f8424ab4b2a1bb9d76588f_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzI1ODA_988a31d9-1a89-4d2a-9e3b-668714939f63">2.65</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNTk_b246673d-b322-4d31-a6ec-f1ba6eade15b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzItMS0xLTEtNTk1ODQ_743242ce-07db-4f82-babd-5054e23b1af1">6,468,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzItMy0xLTEtNTk1ODQ_9e3ea303-065d-4978-9dd9-4a2ed4bbaea2">16.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzMtMS0xLTEtNTk1ODQ_bacfb6af-cb77-48ba-8abf-0421e78f9161">3,969,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzMtMy0xLTEtNTk1ODQ_bf8bb945-1cd5-47a0-96d7-1a15512a39cc">9.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzQtMS0xLTEtNTk1ODQ_7ac38916-44ad-4544-b218-325af32cfd31">265,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzQtMy0xLTEtNTk1ODQ_a202e2d1-d6d6-40dd-99b6-e92701128b6e">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzQtNy0xLTEtNTk1ODQ_89142563-d7ee-44e6-9e90-fdc1a17068d2">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzUtMS0xLTEtNTk1ODQ_0005b852-819d-46da-a4ae-73bb55629a61">1,334,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzUtMy0xLTEtNTk1ODQ_4df35692-2bcb-4307-8943-84014506a721">16.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtMS0xLTEtNTk1ODQ_741a9e14-ee92-4c51-8496-bef4d7cbeac8">8,838,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtMy0xLTEtNTk1ODQ_f7b87120-6216-45c8-b7ba-cde7395164c0">13.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtNS0xLTEtNTk1ODQ_7ec75c02-7fdc-416c-9fdc-3dcadfd33dbe">8.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtNy0xLTEtNTk1ODQ_77b4b404-46a2-4930-bae1-ba4fd5a37471">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctMS0xLTEtNTk1ODQ_8a118269-a0ef-4b6a-92ab-7b8e9f5e8ff9">3,315,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctMy0xLTEtNTk1ODQ_5b8e32cd-dd38-45bd-a32e-a839ed67f9dd">14.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctNS0xLTEtNTk1ODQ_bf758d89-1734-442c-a261-0a3f9eb4d027">7.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctNy0xLTEtNTk1ODQ_c582239a-2866-4d92-8e63-e0f9271522e6">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtMS0xLTEtNTk1ODQ_e005a0b2-eb42-4100-a063-2acf6541cc06">8,635,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtMy0xLTEtNTk1ODQ_57e92a56-283a-46ad-b956-a64fbb1fe08f">13.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtNS0xLTEtNTk1ODQ_50a54f98-611a-4211-8236-bf29454692f0">8.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtNy0xLTEtNTk1ODQ_0f43233e-c3a6-4b89-a9f5-b86a4d609b77">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised for the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzEwOTk1MTE2MzgxODg_b53e561a-8a3a-4286-975a-fe6ed5ac907f">19.7</ix:nonFraction>&#160;million. The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#8217;s common stock at December&#160;31, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#8217;s common stock on the date of exercise for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock on the exercise date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="ia0273c80d9c14b08a37b46fe4667c789"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees, members of the Board, and non-employees on the date of grant were as follows for the for the years ended December 31, 2022 and 2021:</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNjA_9b1bffeb-5356-4e3a-9c1c-90e9b18c5d3a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzMtMS0xLTEtNTk1ODQ_4d645ea8-6bb5-4f7f-bca5-9ffd4b473ccc">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzMtMy0xLTEtNTk1ODQ_3b7b6e10-b839-4980-b284-57cd6ff7f1d6">0.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzQtMS0xLTEtNTk1ODQ_4032e384-cb70-495d-a450-bf048da7100d">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzQtMy0xLTEtNTk1ODQ_7a67e7f6-80e3-4e0f-9d68-297091022133">6.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzUtMS0xLTEtNTk1ODQ_e8d8441c-e6d5-416b-91ee-a3c3bd8ea454">89.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzUtMy0xLTEtNTk1ODQ_418f7bda-f03f-42f4-b63d-e7ec6950c16d">85.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzYtMS0xLTEtNTk1ODQ_448703a8-f06c-4f9b-ac14-7db5c6d54db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzYtMy0xLTEtNTk1ODQ_631cf43b-95c1-4890-a2d0-b7d6c8c33a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzctMS0xLTEtNTk1ODQ_633bbd40-82c3-4c29-8763-3da6a5fbffa3">6.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzctMy0xLTEtNTk1ODQ_9285bcbd-0141-438e-9360-566f96ee8db4">27.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock options was $<ix:nonFraction unitRef="usd" contextRef="ib5afc5d945ba4bafadfb0d0c3dac741e_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzM4OTk_ecd3b3c3-c15b-4dd1-a34b-515e531cddf2">45.9</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzM5NzI_6650130b-437c-4bb9-bc25-358131cef182">2.17</ix:nonNumeric> years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNTc_3ef4f58f-c6a0-47dc-ac87-db8507bf3c47" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzItMS0xLTEtNTk1ODQ_43ddf134-658b-4237-ba26-9fe8a9d663e5">9,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b521b0c1334a6d99bffb35ef881760_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzItMy0xLTEtNTk1ODQ_eef1d59f-7ebd-45de-b584-158bca315844">9,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzMtMS0xLTEtNTk1ODQ_adf69449-959f-421f-93b4-44a92f60c3fd">18,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086cadcb8e4b43b0b1cf5d9e023a28e9_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzMtMy0xLTEtNTk1ODQ_1fe1da6b-1edc-414c-964d-8bae8ea71cd0">13,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzQtMS0xLTEtNTk1ODQ_6ef5458a-9961-443c-a6e9-b54a629e834d">28,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzQtMy0xLTEtNTk1ODQ_3561f812-d5b0-4661-8c80-808750b89812">22,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="prax:SignificantAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzgyMzQ_ecbcfbc0-6be9-40a1-90d0-dcb2c3346db2" continuedAt="i0751bf2cea7447b08706134af9b38e07" escape="true">Significant Agreements</ix:nonNumeric></span></div><ix:continuation id="i0751bf2cea7447b08706134af9b38e07" continuedAt="i5c40760164ac477cb922ae6cd73c7ff5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RogCon and Ionis Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2019, the Company entered into both a Cooperation and License Agreement (the &#8220;License Agreement&#8221;) with RogCon, Inc. ("RogCon"), and a Research, Collaboration, Option and License Agreement (the &#8220;Ionis Collaboration Agreement&#8221;) with Ionis Pharmaceuticals, Inc. ("Ionis"). The agreements were entered into contemporaneously to enable the parties to advance their collective efforts related to SCN2A. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RogCon Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon&#8217;s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Under the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. As part of the agreement, the Company agreed to provide up-front consideration of $<ix:nonFraction unitRef="usd" contextRef="i59d22bb870c64b27b65b8cba9ec3536b_I20190910" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc2OTg_082b6c7c-8e20-4a62-a60b-aabeac8d0332">2.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September&#160;11, 2019, the Company will reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. The Company expenses these costs as incurred as research and development. Expenses incurred for all periods presented were <ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="INF" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzExNTQ0ODcyMTAxNDQ4_59f01f6c-34b3-4597-b196-e7648398f682">no</ix:nonFraction>t material. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company may pay RogCon a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="id08d935b650f48b894cff86c998390d7_I20221231" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc3NDY_d30013a9-5869-4aa6-8d36-ae2a0b582e6a">3.0</ix:nonFraction> million and profit share payments. The $<ix:nonFraction unitRef="usd" contextRef="id08d935b650f48b894cff86c998390d7_I20221231" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc3NTE_d30013a9-5869-4aa6-8d36-ae2a0b582e6a">3.0</ix:nonFraction> million milestone payment will become due when the first profit share payment has become due and certain contingent payments have become payable to Ionis under the Ionis Collaboration Agreement, which are subject to the Company exercising its option to obtain license rights to a development candidate, as well as other contingent events. The profit share payments will be based on a low-double-digit percentage of net profits, depending on sales volume. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5c40760164ac477cb922ae6cd73c7ff5"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement, unless earlier terminated, will continue until the latest of: (i)&#160;expiration of all patent rights within RogCon patents, (ii)&#160;the Company and its affiliates certify they have abandoned the research, development and commercialization of product with no intention to re-establish such activities, and (iii)&#160;no third party is obligated to pay the Company or its affiliates any amounts that comprise net sublicense revenue. Either party may terminate the License Agreement for material breach or insolvency of the other party. Additionally, the Company may terminate for convenience with prior written notice to RogCon. Upon termination by either party, all rights and licenses granted by RogCon to the Company will revert back to RogCon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ionis Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ionis Collaboration Agreement, both parties participated in research activities related to the downregulation of SCN2A gene products associated with the treatment of any and all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene, other than one severe type of epilepsy. Ionis was also responsible for identifying a development candidate and conducting an IND-enabling toxicology study. The Company reimbursed Ionis for out-of-pocket costs incurred related to the research activities, identification of a development candidate and conducting an IND-enabling toxicology study. The reimbursement of out-of-pocket costs was recognized as research and development expense as incurred. The Company expensed a total of $<ix:nonFraction unitRef="usd" contextRef="i8e78b82d33fe4b7ea06ff1555beedb9f_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzY2NDE_bf8a82aa-5872-41c3-b0c0-0320039077fa">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3928d36a17d4572b98fb4d36c5bc667_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzY2NDg_30a0d4a4-9bba-4fa1-8c4c-dfb2e3fb71a7">1.9</ix:nonFraction> million, as research and development expense under the Ionis Collaboration Agreement for the years ended December 31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ionis granted the Company an exclusive option to obtain the rights and license to further develop and commercialize a development candidate in the field of epilepsy and neurodevelopmental disorders, other than Dravet Syndrome, following the results of the investigational new drug application-enabling toxicology study. The Company exercised this exclusive option in January 2022, paid a $<ix:nonFraction unitRef="usd" contextRef="i6db4fda94de8472aa375ed40f41dd0c4_I20221231" decimals="-5" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc3NTk_ea85230e-f8e9-4215-aef4-6703f58a6757">2.0</ix:nonFraction> million license fee and recognized the license fee in research and development expenses in the consolidated statement of operations during the year ended December&#160;31, 2022. After option exercise, the Company is responsible for clinical development and commercialization of the development candidate. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ionis may be entitled to additional development milestone payments, additional milestone payments, and sales royalties or sublicense fees.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ionis Collaboration Agreement will continue until the expiration of all payment obligations to Ionis, unless earlier terminated. Either party may terminate the Ionis Collaboration Agreement upon material breach or insolvency of the other party. Ionis may terminate if the Company fails to achieve a performance milestone. The Company may terminate for convenience with prior written notice to Ionis. Upon termination by the Company for convenience, the Company will stop selling all products, subject to certain wind-down provisions, and all products will revert back to Ionis.</span></div></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_142"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90ZXh0cmVnaW9uOjAxNDcwMDZkMTdkODQwMmU4NDgxM2IxNTU3YTZjMDU5XzQ1OA_9021748a-5104-4eac-a558-470ab3a9d13d" continuedAt="ic33c55eb470a443a9a87b6ddd6b9e2ec" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="ic33c55eb470a443a9a87b6ddd6b9e2ec"><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90ZXh0cmVnaW9uOjAxNDcwMDZkMTdkODQwMmU4NDgxM2IxNTU3YTZjMDU5XzQ2MA_0fb3dde8-1990-4f33-a66c-73c9ede0d3ff" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb80111739064117857d8ff63d282ee7_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzItMS0xLTEtNTk1ODQ_9cef6e02-5658-485a-9e3e-d27342288602">8,838,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1e903808d0417082b7ca141017b6d2_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzItMy0xLTEtNTk1ODQ_1586fff3-7d66-4b01-98b6-2768f3521ff4">6,468,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3beb3fccfcac48b1a1b2abcb40888aa0_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzMtMS0xLTEtNTk1ODQ_0ca4043e-485d-4895-b38d-9ad12e73b08e">743,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ce3a4228571459f975e7c892d40666b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzMtMy0xLTEtNTk1ODQ_bcc448a4-3e86-4db7-86e2-6525cc86a06e">440,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a68deb4cf0f483abe816b51999d287c_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzQtMS0xLTEtNTk1ODQ_34930828-ff2b-4ed6-a861-4eb26b098d2c">283,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb0e4722ba7b4b88b3538c783c5b2e05_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzQtMy0xLTEtNTk1ODQ_8440e4d1-66c6-44ad-99ac-b60d59653b0b">33,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzUtMS0xLTEtNTk1ODQ_00401d13-ed91-4d44-b695-03864e06719c">9,865,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzUtMy0xLTEtNTk1ODQ_e9346874-edfb-4def-ac3e-a0964c5bb9fe">6,942,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3603669404fe4fc8b59d31b31e26e467_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzYxNzE_b1d933a0-acb4-460c-b481-f58894bdec05" continuedAt="id3226e704fc34973b6d354a95ede5a1c" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id3226e704fc34973b6d354a95ede5a1c" continuedAt="i0ec5a5f4595e43cea2716beba20c14c4">The Company maintains a full valuation allowance on its U.S. net deferred tax assets due to the uncertainty of future taxable income. The Company did not recognize an income tax benefit in the years ended December&#160;31, </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i0ec5a5f4595e43cea2716beba20c14c4" continuedAt="i5b62454d873d494381f44673d525028b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 or 2021 related to its U.S. operations due to the uncertainty regarding future taxable income. In the years ended December 31, 2022 and 2021, the difference between the statutory tax rate in the U.S. and the Company&#8217;s effective tax rate was due primarily to the valuation allowance recorded to offset any potential tax benefit. The income tax benefit (provision) recognized for the years ended December 31, 2022 and 2021 was not material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzYxNzI_08272650-3a2e-4ee5-b9c3-594a37953f10" escape="true"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzItMS0xLTEtNTk1ODQ_639366da-97af-4f40-9dc6-ca63bd9e92bf">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzItMy0xLTEtNTk1ODQ_f43a71d6-ee88-4a99-aa9c-b317f295b128">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal and state research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzMtMS0xLTEtNTk1ODQ_131a7853-ae01-48e0-94f2-0482c897a2c9">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzMtMy0xLTEtNTk1ODQ_ac8c8771-b7fa-4ef8-baa6-d205f9b7b0af">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzQtMS0xLTEtNTk1ODQ_09b32766-5a3f-423b-b0a6-5a8c1116686b">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzQtMy0xLTEtNTk1ODQ_1ef8746a-d1fc-4c97-b4cf-c3a102e545fd">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzUtMS0xLTEtNTk1ODQ_98ced08a-287b-4761-8d99-013d2efda0e2">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzUtMy0xLTEtNTk1ODQ_ed328b66-cccc-4966-8f93-f4ec29522203">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMS0xLTEtNzU5MjY_ce4d8bf8-2f95-4518-a929-9bce0fed137b">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMy0xLTEtNzU5MjY_19322df9-0680-4c9c-be40-d00aaa5f6e4f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMS0xLTEtNTk1ODQ_6f876d97-5ad3-4e52-9c0c-2f9797cb76fe">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMy0xLTEtNTk1ODQ_c103c735-35bf-4d83-8927-0ba6b9e469ca">29.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzctMS0xLTEtNTk1ODQ_bc64b75c-b159-4719-a966-30d582365b2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzctMy0xLTEtNTk1ODQ_9eca14c7-b598-4a81-89d4-b35acce8888b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzgtMS0xLTEtNTk1ODQ_1124e8de-dc82-41d6-b508-01111663b677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzgtMy0xLTEtNTk1ODQ_7ea4559d-683c-424d-a452-82ec86d9dbeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzYxNzM_a00f0660-2afa-4285-9d61-a2ce93283bcc" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzMtMS0xLTEtNTk1ODQ_06e9a8ca-5e30-4d9e-8221-e252d7e268fa">60,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzMtMy0xLTEtNTk1ODQ_122f2d88-cdd5-4d17-9504-7ddba09d043a">56,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMS0xLTEtNzUxNzY_47bdc7c7-7b34-4280-b563-37be88ff37c0">34,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMy0xLTEtNzUxNzY_0cc20a0b-9497-4a6c-9bf8-ffb4fb521a3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:DeferredTaxAssetsTaxDeferredExpenseAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMS0xLTEtNTk1ODQ_c275a293-453f-42a8-8906-7bbaac0107cd">24,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DeferredTaxAssetsTaxDeferredExpenseAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMy0xLTEtNTk1ODQ_e7d43251-a0c5-4db6-97d6-e1583788c700">14,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzUtMS0xLTEtNTk1ODQ_6c67c6f6-88b9-4d3a-89ad-aea28255552f">17,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzUtMy0xLTEtNTk1ODQ_bcb4a25f-00e5-4bcb-9c14-2799b069e287">9,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzYtMS0xLTEtNTk1ODQ_8f51b605-a6ca-4a2c-832b-97aeb00ebb9f">6,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzYtMy0xLTEtNTk1ODQ_80d9fd5f-d04b-4ad3-b21c-9ad64b02a1a4">3,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzctMS0xLTEtNTk1ODQ_d6b47a44-f527-445e-8376-51be1a82139f">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzctMy0xLTEtNTk1ODQ_72197af2-8919-4520-ba3a-a70132fb3df2">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzgtMS0xLTEtNTk1ODQ_060de93d-3561-4d93-b171-9b3452bb6071">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzgtMy0xLTEtNTk1ODQ_540f6b4c-cb1f-4610-874f-4fa33d8e146a">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzktMS0xLTEtNTk1ODQ_ac28fe33-6de6-4d45-a6ee-70012af7c106">144,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzktMy0xLTEtNTk1ODQ_01bc02f1-89f8-4c13-9dba-885919d211cc">86,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEwLTEtMS0xLTU5NTg0_3876f0a1-1120-49a2-bba4-29822a24f2f9">143,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEwLTMtMS0xLTU5NTg0_64371613-23a5-4fcd-a69a-f93e87411b08">85,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzExLTEtMS0xLTU5NTg0_2632199f-ab4c-4262-bd4c-d50181407ef1">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzExLTMtMS0xLTU5NTg0_da0a16c8-b1e4-4c3c-aeea-1b2c4477f29b">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="prax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEzLTEtMS0xLTU5NTg0_17db5b71-694e-4890-94f4-832287f2d89d">744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="prax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEzLTMtMS0xLTU5NTg0_19015eda-bf58-4793-aa59-0e70fc1f2db7">959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE0LTEtMS0xLTU5NTg0_8095bf4e-da33-4760-a3da-4e94ab9d57dc">744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE0LTMtMS0xLTU5NTg0_b7da6732-db7e-4329-af42-c423cc9f2583">959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE1LTEtMS0xLTU5NTg0_b8fc7533-b326-4fb0-9b07-1c2646533451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE1LTMtMS0xLTU5NTg0_fab37030-0513-4f29-ae6f-3649effc650a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had U.S. federal net operating loss carryforwards which may be able to offset future income tax liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzkyMA_18c4f83b-fa67-4698-94fe-73b787dbc6b4">226.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzkyNw_2ff9994b-110f-4cf4-944e-493434db77ed">212.3</ix:nonFraction> million, respectively. Federal net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzk4OQ_fe58c35f-4e4d-4073-bd12-2c953c6e111c">7.7</ix:nonFraction> million will expire at various dates from 2035 through 2037 and approximately $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzEwNTg_7bda9a73-3fe0-4d62-a900-4f606c4d25a0">218.6</ix:nonFraction> million may be carried forward indefinitely.&#160;As of December 31, 2022 and 2021, the Company also had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzExODU_8727425f-fed8-436f-91cd-2e6e3d954b12">197.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzExOTI_8ac76156-f763-4ab8-8a77-bbb132a31784">187.6</ix:nonFraction> million, respectively, which may be available to offset future income tax liabilities and expire at various dates from 2036 through 2042.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ic56cac62e36f40bcb5f9287718900ca1_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE0MjI_644bd8b5-b4d6-43e4-8e2f-b0fed45a8262">14.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6ff1ec2beed4170862a47ce96834fcd_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE0Mjk_d77b0b11-3883-4e8b-8306-627a76ea9037">7.3</ix:nonFraction> million, respectively, available to reduce future tax liabilities which expire at various dates from 2039 through 2042.&#160;As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i27c24e65906d4987bf2662bc0bef89a2_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE2Mzk_22e7f9cc-9de6-4899-91a6-23dd5518a5d7">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1cd10fe8bfcc4606aabb82073574d6fb_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE2NDY_bf0de2a4-a225-49fa-a885-9c245590a447">2.5</ix:nonFraction> million, respectively, available to reduce future tax liabilities which expire at various dates from 2031 through 2037.&#160;The Company has </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="i5b62454d873d494381f44673d525028b" continuedAt="i3dafb9f392cf4171b48cce82b5381e41"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generated research credits but has not conducted a study to document the qualified activity.&#160;This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.&#160;A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.&#160;Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change.&#160;Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study.&#160;If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all of the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2022 and 2021 because management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception. As a result, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="ica6b7381be214302904bad838ac442b9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUwOTg_491ef594-3cd7-48c5-bdd8-62427a8c3cdb">143.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUxMDU_962c5297-ca74-404d-bf73-c2aa7183ca55">86.0</ix:nonFraction> million has been established at December 31, 2022 and 2021, respectively.&#160;Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUyODU_290e109c-8716-4c7a-a546-0ea8c46c87a1">58.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUyOTI_88c09bc8-31ae-416a-9060-e06be23cfc49">49.1</ix:nonFraction> million during the years ended December 31, 2022 and 2021, respectively, due primarily to the generation of net operating losses.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3dafb9f392cf4171b48cce82b5381e41">The Company has not recorded any amounts for unrecognized tax benefits as of December 31, 2022 and 2021.&#160;The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision.&#160;As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s consolidated statement of operations for either year ended December&#160;31, 2022 or 2021.&#160;The statute of limitations for federal and state tax authorities is open for tax years ended December&#160;31, 2019 through December&#160;31, 2022. Since the Company is in a net loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</ix:continuation> </span></div><div id="i3603669404fe4fc8b59d31b31e26e467_148"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDgvZnJhZzpjMjhjYTIxM2Y3MGQ0NWY3YjBiNWVjMjdmNTMyZWUwYS90ZXh0cmVnaW9uOmMyOGNhMjEzZjcwZDQ1ZjdiMGI1ZWMyN2Y1MzJlZTBhXzYyMg_f5cc2ca5-9b07-42f4-8d20-10caea857190" continuedAt="if0985aea3d7e4e34aed5b8e1c9a83d44" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if0985aea3d7e4e34aed5b8e1c9a83d44">One of the founders of RogCon is the Company's General Counsel. During the years ended December 31, 2022 and 2021, the Company reimbursed RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement (Note 12).</ix:continuation> </span></div><div id="i3603669404fe4fc8b59d31b31e26e467_151"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTEvZnJhZzo0YWY5YTc5OWI3ZmE0YmZmOTE1OGViOWRlNGZhZWZiMC90ZXh0cmVnaW9uOjRhZjlhNzk5YjdmYTRiZmY5MTU4ZWI5ZGU0ZmFlZmIwXzUwMw_a5438428-efb7-4808-849f-46faac5c6e51" continuedAt="ib7f092278cf9411f8a4f52cedb73582b" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Continued)</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="ib7f092278cf9411f8a4f52cedb73582b"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code for eligible employees. The plan covers substantially all employees who meet a minimum age requirement and allows participants to defer a portion of their annual compensation on a pre-tax basis. Under the plan, the Company is not obligated to match any participant contributions. The Company made contributions of $<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTEvZnJhZzo0YWY5YTc5OWI3ZmE0YmZmOTE1OGViOWRlNGZhZWZiMC90ZXh0cmVnaW9uOjRhZjlhNzk5YjdmYTRiZmY5MTU4ZWI5ZGU0ZmFlZmIwXzQ0Nw_be4ee9e5-d077-4cbb-b66a-340cf79676da">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTEvZnJhZzo0YWY5YTc5OWI3ZmE0YmZmOTE1OGViOWRlNGZhZWZiMC90ZXh0cmVnaW9uOjRhZjlhNzk5YjdmYTRiZmY5MTU4ZWI5ZGU0ZmFlZmIwXzQ1NA_31799571-1bbd-459e-80a6-497bd1a1f7ea">1.0</ix:nonFraction> million during the years ended December&#160;31, 2022 and 2021, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div id="i3603669404fe4fc8b59d31b31e26e467_1649267443270"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83Njk2NTgxMzk1ODQ2_a78069ee-a0bf-4f19-aeaa-c00fc93c0b89" continuedAt="i60ab7479385f4a08976f18a874076980" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i60ab7479385f4a08976f18a874076980" continuedAt="idaa56f3cbefe47c29cbd20e90c132ec9"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Company began a strategic realignment to focus resources on its ulixacaltamide, PRAX-562, PRAX-222 and PRAX-628 product candidates, as well as its preclinical programs across our Cerebrum&#8482; and Solidus&#8482; platforms, which resulted in a reduction of the Company&#8217;s workforce. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl8xNjQ5MjY3NDQyOTQ0_d8c52f33-0158-4439-8abb-bfab03e7e8e0">1.0</ix:nonFraction> million of costs related to the realignment, of which $<ix:nonFraction unitRef="usd" contextRef="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl8xNjQ5MjY3NDQyOTUx_79dc2343-ec58-4c91-9e0c-aa9bb53d3518">0.6</ix:nonFraction> million has been recognized in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTU5_f31a878b-51d8-49e1-8652-9a345f90aac3">research and development expenses</span> and $<ix:nonFraction unitRef="usd" contextRef="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl8xNjQ5MjY3NDQyOTU5_1dc171e9-d042-4282-963d-0a2225024834">0.4</ix:nonFraction> million has been recognized in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTYw_c651d9dc-e4c5-4069-8a23-904dc552dfc6">general and administrative expenses</span> in the consolidated statement of operations during the year ended December&#160;31, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idaa56f3cbefe47c29cbd20e90c132ec9">As of December&#160;31, 2022, all costs related to the strategic realignment have been paid.</ix:continuation> </span></div><div id="i3603669404fe4fc8b59d31b31e26e467_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTQvZnJhZzozODAwNjYyNmM5ZDU0NTNiOTc5ZWUxNDliZDFmMTU2MS90ZXh0cmVnaW9uOjM4MDA2NjI2YzlkNTQ1M2I5NzllZTE0OWJkMWYxNTYxXzI5NQ_4cc8e5c1-b366-482a-8436-80b0f2cb92fb" continuedAt="i5d0909eaea52400d898c100fef1a807d" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d0909eaea52400d898c100fef1a807d">Subsequent to December&#160;31, 2022, the Company issued and sold a total of <ix:nonFraction unitRef="shares" contextRef="i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTQvZnJhZzozODAwNjYyNmM5ZDU0NTNiOTc5ZWUxNDliZDFmMTU2MS90ZXh0cmVnaW9uOjM4MDA2NjI2YzlkNTQ1M2I5NzllZTE0OWJkMWYxNTYxXzEwOTk1MTE2MjgyNDI_3fafc06b-e851-4129-98b1-fcf73b605cc2">2,942,083</ix:nonFraction> shares under the Sales Agreement for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTQvZnJhZzozODAwNjYyNmM5ZDU0NTNiOTc5ZWUxNDliZDFmMTU2MS90ZXh0cmVnaW9uOjM4MDA2NjI2YzlkNTQ1M2I5NzllZTE0OWJkMWYxNTYxXzEwOTk1MTE2MjgzMDk_fca9e9e2-44bf-4fdc-a560-ff023cb144d9">11.2</ix:nonFraction> million after deducting commissions and offering expenses payable by the Company.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the three months ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management's Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f), to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of December&#160;31, 2022. Management based its assessment on criteria established in "Internal Control - Integrated Framework (2013)" issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that assessment, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_163"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the name, age, and position of each of our current executive officers and directors as of February 3, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.348%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Officers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marcio Souza</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President,&#160;Chief&#160;Executive&#160;Officer,&#160;Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Kelly</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Nemiroff, J.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel, Corporate Secretary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole Sweeny</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Employee Directors:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dean Mitchell(2)(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Chodakewitz, M.D.(3)(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merit Cudkowicz, M.D.(2)(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jill DeSimone(1)(2)(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory Norden(1)(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Young(1)(2)(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Member of the Audit Committee.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Member of the Compensation Committee.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Member of the Nominating and Corporate Governance Committee.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Member of the Science and Technology Committee</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marcio Souza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board of Directors and our President and Chief Executive Officer since April 2020. Prior to joining us, Mr. Souza was at PTC Therapeutics, Inc., or PTC, where he served as its Chief Operating Officer from May 2017 to April 2020 and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Prior to joining PTC, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. Mr. Souza has served on the board of directors of Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) since June 2021. From May 2019 to May 2020, Mr. Souza also served on the board of directors of Clearpoint Neuro, Inc. (NASDAQ: CLPT) (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of S&#227;o Paulo and an M.B.A. from Funda&#231;&#227;o Dom Cabral. We believe Mr. Souza is qualified to serve on our Board of Directors because of his business and leadership experience in the life sciences industry and his scientific background.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Timothy Kelly</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Financial Officer since May 2021. Prior to his role as Chief Financial Officer, Mr. Kelly served as Chief Financial Officer of Foundation Medicine, Inc. from 2019 to April 2021. In this position, he led the finance and corporate management teams, providing strategic leadership and oversight for the corporate functions, which included accounting and tax, billing and reimbursement, procurement, corporate development, project management and financial planning and analysis. Prior to his time at Foundation Medicine, Mr. Kelly served in several finance roles of increasing responsibility at the F. Hoffman-La Roche AG, or Roche, and Genentech (before being acquired by Roche in 2009) from 2003 to 2019, including finance and corporate services director for Roche Pharma in the United Kingdom from 2017 to 2019 and head of group strategic planning for the Roche Group in Switzerland from 2013 to 2017. Mr. Kelly holds a B.A. in economics from the College of William and Mary and an M.B.A. from the Columbia Business School.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alex Nemiroff, J.D.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our General Counsel since June 2020. Prior to his role as General Counsel, Mr. Nemiroff served as our Vice President of Legal from January 2020 to June 2020. Mr. Nemiroff was also a co-founder of RogCon, Inc. and RogCon U.R., Inc., and he has served as both entities&#8217; Chief Executive Officer since inception in November 2015. Mr. Nemiroff has experience working in commercial and securities litigation while at Greenberg Traurig LLP, and served as law clerk to the Honorable Paul C. Huck of the United States District Court for the Southern District of Florida. Mr. Nemiroff received a B.B.A from the University of Michigan&#8217;s Ross School of Business, and a J.D. from Northwestern University School of Law.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nicole Sweeny</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Commercial Officer since August 2020. Prior to joining us, Ms. Sweeny was at Takeda Pharmaceutical Co. Ltd., or Takeda, where she served as Vice President, Franchise Head, Rare Diseases from February 2019 to July 2020. Prior to Takeda, Ms. Sweeny served in several roles at Shire plc, a biopharmaceutical company acquired by Takeda, from August 2010 to January 2019, including Vice President, Head of US Marketing from September 2017 to January 2019 and Vice President, Global Product Strategy Lead from December 2016 to August 2017. Prior to joining Shire, Ms. Sweeny served in commercial positions of increasing responsibility at AMAG Pharmaceuticals, Inc. and Sanofi Genzyme Corporation. Ms. Sweeny received her B.S. from Boston College.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dean Mitchell</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as chairman of our Board of Directors since September 2020. He served as executive chairman of the board of directors of Covis Pharma Holdings S.&#224;.r.l., a specialty pharmaceutical company, from August 2013 until its sale in March 2020 and was chairman of PaxVax Corporation, a biotechnology company from January 2016 until its sale in October 2018. Mr. Mitchell served as President and Chief Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from July 2010 to August 2013. Prior to Lux Biosciences, he served as President and Chief Executive Officer of both Alpharma, Inc., a publicly traded specialty pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008, and Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused in oncology and acute care, from 2004 until its acquisition by MGI Pharma Inc. in 2005. From 2001 to 2004, he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company. Prior to Bristol-Myers Squibb Company, he spent 14 years at GlaxoSmithKline plc, in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell currently serves on the boards of directors of Theravance Biopharma, Inc. (NASDAQ: TBPH), ImmunoGen Inc. (NASDAQ: IMGN), Precigen Inc. (formerly Intrexon Inc.) (NASDAQ: PGEN) and Kinnate Biopharma Inc. (NASDAQ: KNTE). Mr. Mitchell holds an M.B.A. from City University London and a B.Sc. in Biology from Coventry University. We believe Mr. Mitchell is qualified to serve on our Board of Directors because of his management experience in the pharmaceutical and biotherapeutics industries and his experience as a president, chief executive officer and board member of multiple biotechnology companies.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeffrey Chodakewitz, M.D.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board of Directors since April 2021. Dr. Chodakewitz has served as an external senior advisor for Ascenta Capital, a life sciences investment firm, since December 2022. He previously served as a senior advisor to Blackstone Life Sciences, a life sciences private equity firm from March 2019 to January 2022. From April 2018 through March 2019, he served as Executive Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals, Inc., or Vertex. Prior to that role, Dr. Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs at Vertex from January 2014 to April 2018 and was a member of the Vertex Executive Committee. Prior to Vertex, Dr. Chodakewitz spent over 20 years at Merck &amp; Co. serving in several positions, including leadership roles as Head of Infectious Diseases and Vaccines Global Development, Senior Vice President of Global Scientific Strategy (infectious disease, respiratory &amp; immunology), Vice President of Early-Stage Development and Senior Vice President of Late-Stage Development. Dr. Chodakewitz currently serves on the boards of directors of Adicet Bio, Inc. (NASDAQ: ACET), Freeline Therapeutics Holdings plc (NASDAQ: FRLN) and Schr&#246;dinger, Inc. (NASDAQ:SDGR). Dr. Chodakewitz received a B.S. in Biochemistry cum laude from Yale University and an M.D. from the Yale University School of Medicine. We believe Dr. Chodakewitz is qualified to serve on our Board of Directors because of his extensive business and leadership experience working in the biotechnology industry.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merit Cudkowicz, M.D.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board of Directors since April 2021. Dr. Cudkowicz has served as the Chief of Neurology at Massachusetts General Hospital since 2012 and is the Director of the Sean M. Healey &amp; AMG Center for ALS and Director and the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, she has led innovations to accelerate the development of treatments for people with neurological disorders such as ALS, including the first platform trial in ALS, and serving in a senior role in the research and development of the first antisense oligonucleotide treatment for a neurological </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disorder. Dr. Cudkowicz is also the principal investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke&#8217;s Neurology Network of Excellence in Clinical Trials, or NeuroNEX. Dr. Cudkowicz received a B.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a MSc. in Clinical Epidemiology from Harvard School of Public Health. We believe Dr. Cudkowicz is qualified to serve on our Board of Directors because of her extensive medical background and experience.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jill DeSimone</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board of Directors since May 2022. Ms. DeSimone served as President of U.S. Oncology at Merck &amp; Co., Inc., or Merck, from 2014 to May 2022. During her time at Merck, Ms. DeSimone also temporarily served as Interim President of U.S. Pharma to help navigate the business through the COVID-19 pandemic. Prior to joining Merck, she served as Senior Vice President of Global Women&#8217;s Health at Teva Pharmaceutical Industries Ltd, or Teva, from 2012 to 2014. Prior to her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including Senior Vice President of Oncology and Senior Vice President of Commercial Operations. Ms. DeSimone serves on the board of directors of Oncternal Therapeutics (NASDAQ: ONCT), Kinnate Biopharma Inc. (NASDAQ: KNTE), effective March 1, 2023, and Affini-T Therapeutics, Inc., a private company. She also serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that helps individuals with their essential living expenses while they undergo treatment for cancer. Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania. We believe Ms. DeSimone is qualified to serve on the Board because of her leadership and extensive business experience in the pharmaceutical industry.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gregory Norden</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board of Directors since March 2019. Mr. Norden is the former Chief Financial Officer of Wyeth Pharmaceuticals Inc. and has served as the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate advisory services, since 2010. Mr. Norden currently serves on the boards of directors of Zoetis Inc. (NYSE: ZTS), NanoString Technologies, Inc. (NASDAQ: NSTG) and Royalty Pharma plc (NASDAQ: RPRX). Mr. Norden is a former director of Human Genome Sciences, Univision and Welch Allyn. Mr. Norden received a B.S. in Management and Economics from the State University of New York at Plattsburgh and an M.S. in Accounting from LIU Post. We believe Mr. Norden is qualified to serve on our Board of Directors because of his background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, as well as his public company board experience.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">William Young</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board of Directors since December 2016. Mr. Young is a Senior Advisor with Blackstone Life Sciences, which he joined in November 2018. Prior to its acquisition by Blackstone, Mr. Young joined Clarus Ventures LLC in March 2010 and held various roles, including Venture Partner, Senior Advisor and portfolio company board member. Prior to joining Clarus, Mr. Young was chairman of the board of directors and Chief Executive Officer of Monogram Biosciences Inc. from 2000 until its acquisition by Laboratory Corporation of America Holdings in 2009. Previously, Mr. Young spent 20 years at Genentech, Inc. in roles of increasing responsibility, culminating as Chief Operating Officer from 1997 to 1999. Mr. Young currently serves as the chairman of the board of directors of NanoString Technologies, Inc. (NASDAQ: NSTG), and as a member of the board of directors of Theravance BioPharma, Inc. (NASDAQ: TBPH) and Autolus Therapeutics plc (NASDAQ: AUTL). Mr. Young also served as the chairman of the board of directors of Annexon, Inc. (NASDAQ: ANNX) from March 2017 to February 2021, and as a member of the boards of directors of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) from May 2015 to June 2020 and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from September 2010 to November 2015. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology. Mr. Young received a B.S. in Chemical Engineering from Purdue University and an M.B.A. from Indiana University in Marketing and Finance and holds an honorary doctorate in Engineering from Purdue University. We believe Mr. Young is qualified to serve on our Board of Directors because of his scientific background, business experience and his service on the board of directors of other life sciences companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among any of our executive officers or directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the corporate governance section of our website, which is located at https://investors.praxismedicines.com/corporate-governance/governance-overview. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a Form&#160;8-K. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recommendation of Director Nominees by Stockholders</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the procedures by which our stockholders may recommend nominees to the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gregory Norden, Jill DeSimone and William Young serve on the Audit Committee, which is chaired by Gregory Norden. Our Board of Directors has determined that Gregory Norden, Jill DeSimone and William Young are &#8220;independent&#8221; for audit committee purposes as that term is defined in the rules of the SEC and the applicable Nasdaq rules, and each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our Board of Directors has designated Gregory Norden as an &#8220;audit committee financial expert,&#8221; as defined under the applicable rules of the SEC. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to:</span></div><div style="margin-top:4pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide a fair, flexible and market-based total compensation package;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract, motivate, incentivize and retain key management personnel who contribute to our short and long-term success; </span></div><div style="margin-top:4pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">emphasize performance-based total compensation that is aligned with the external market and rewards the achievement of our business objectives and key results; and </span></div><div style="margin-top:4pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively align the interests of our executives with those of our stockholders by focusing on long-term equity incentives that correlate to the growth of sustainable long-term value for our stockholders. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of our Board of Directors, which is comprised entirely of independent directors, is responsible for discharging our Board of Directors&#8217; responsibilities relating to compensation of our executive officers, overall compensation structure, policies and programs, and our processes and procedures for the consideration and determination of executive compensation. The Chief People Officer and Chief Executive Officer develop preliminary recommendations regarding compensation matters with respect to all executive officers, other than the Chief Executive Officer, and provide these recommendations to the Compensation Committee. The Compensation Committee reviews management&#8217;s preliminary recommendations and makes final compensation decisions. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee is authorized to retain the services of one or more executive compensation advisors, as it sees fit, in connection with the establishment of our executive compensation programs and related policies. The Compensation Committee engaged Frederic W. Cook&#160;&amp; Co., Inc., or FW Cook, as its independent compensation consultant to provide objective analysis, advice and recommendations on executive officer pay in connection with the Compensation Committee&#8217;s decision-making process for 2022. During 2022, FW Cook did not provide services to us other than the services to our Compensation Committee described herein. Our Compensation Committee performs an annual assessment of its compensation consultants&#8217; independence to determine whether the consultants are independent. Based on its evaluation, the Compensation Committee has determined that FW Cook is independent and that its work has not raised any conflicts of interest. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation provided to our named executive officers for the fiscal year ended December 31, 2022 is detailed in the 2022 Summary Compensation Table and accompanying footnotes and narrative that follow. Our named executive officers for the fiscal year ended December 31, 2022 were:  </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Marcio Souza, our President and Chief Executive Officer; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Timothy Kelly, our Chief Financial Officer;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nicole Sweeny, our Chief Commercial Officer; and</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bernard Ravina, M.D., our former Chief Medical Officer</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221; as that term is used under the rules promulgated under the Securities Act of 1933, as amended, and as such have used the reduced compensation disclosure requirements applicable to smaller reporting companies consistent with SEC rules.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Summary Compensation Table</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers for services rendered to us in all capacities during the fiscal years indicated.  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:17.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name and Principal Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Salary ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bonus<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock<br/>Awards<br/>($)(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Option<br/>Awards<br/>($)(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Equity<br/>Incentive Plan<br/>Compensation<br/>($)(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">All Other<br/>Compensation<br/>($)(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marcio Souza</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">625,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,340,140</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,649,420</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">375,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,518</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,028,078</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">570,834</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,773,584</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,883,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">646,875</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,727</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,905,820</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Timothy Kelly</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">465,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">434,640</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,235,085</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,688</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,303,213</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nicole Sweeny</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Chief Commercial Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">434,640</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,235,085</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,283,756</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882,504</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,193,280</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,738</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,727,856</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bernard Ravina, M.D.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Former Chief Medical Officer(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,249</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416,667(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226,158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,314</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,763,754</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,287,616</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,451,050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,838</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,509,171</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The amounts reported represent the aggregate grant date fair value of the stock options and restricted stock units awarded to the named executive officers during the year indicated, calculated in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, ASC, Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 11 to our consolidated financial statements in this Annual Report. The amounts reported in this column reflect the accounting cost for these awards and do not correspond to the actual economic value that may be received by the named executive officers upon the exercise of the stock options, vesting or settlement of restricted stock units or any sale of the underlying shares of common stock. For Dr. Ravina, the 2022 amount reported also includes $32,946 in the Stock Awards column and $85,433 in the Option Awards column, representing the incremental fair value attributable to modifications made to his equity awards in 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The amounts reported represent actual bonuses earned for performance during the applicable year by our named executive officers based upon the achievement of our corporate objectives for such year, as described under &#8220;Narrative to Summary Compensation Table &#8212; Annual Bonus.&#8221; For 2022, the Board of Directors elected to offer the named executive officers the ability to receive up to 100% of their 2022 annual bonuses in the form of fully vested options to purchase shares of our common stock issued under our 2020 Stock Option and Incentive Plan. Mr. Souza elected to receive 100% of his 2022 annual bonus in the form of options and was issued an option to purchase 213,975 shares on January 12, 2023. Mr. Kelly elected to receive 50% of his 2022 annual bonus in the form of options and was issued an option to purchase 42,455 shares on January 12, 2023. Ms. Sweeny elected to receive 50% of her 2022 annual bonus in the form of options and was issued an option to purchase 41,085 shares on January 12, 2023. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Amounts reported for 2022 include cell phone reimbursement, tax gross ups on taxable long-term disability and tax gross up for wellness benefit, as well as discretionary matching company contributions under our 401(k) plan. For Mr. Souza, the amounts reported also include reimbursement for premiums and a tax gross up on a supplemental long-term disability and life insurance policy owned by him. For Dr. Ravina, the 2022 amount reported also includes the Company paid portion of his premiums for continued participation in the Company's group health plans following his resignation and a cash payment equal to nine months of base salary in accordance with his transition agreement with the Company, as described under "Narrative to Summary Compensation Table - Employment Arrangements with our Named Executive Officers."</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Dr. Ravina resigned as our Chief Medical Officer effective August 1, 2022. The amount reported in the salary column for 2022 is comprised of $287,249 in base salary earned by Dr. Ravina prior to his resignation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Dr. Ravina received a retention bonus pursuant to a retention incentive award letter agreement, as described under "Narrative to the 2022 Summary Compensation Table." </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Narrative to the 2022 Summary Compensation Table</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salaries</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each named executive officer&#8217;s base salary is a fixed component of annual compensation for performing specific duties and functions, and has been established by our Board of Directors or Compensation Committee taking into account each individual&#8217;s role, responsibilities, skills and expertise. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved by our Compensation Committee or our Board of Directors and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. Effective January 1, 2022, the annual base salaries for Mr. Souza, Mr. Kelly, Ms. Sweeny and Dr. Ravina were $625,000 (increased from $575,000), $465,000 (increased from $425,000), $450,000 (increased from $400,000), and $489,250 (increased from $475,000), respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Bonus</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended December 31, 2022, each of our named executive officers was eligible to earn an annual bonus based on the achievement of certain pre-determined corporate performance objectives and individual performance. For the 2022 annual bonus program, corporate performance objectives generally related to delivering on financial and compliance performance milestones, establishing a leading central nervous system portfolio, generating a neurology pipeline anchored on human genetics and continuing our transformation as a best-in-class biotechnology company, as well as incorporating individual objectives associated with an executive&#8217;s area of primary responsibility within our organization. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the target annual bonuses for Mr. Souza, Mr. Kelly, Ms. Sweeny and Dr. Ravina were 75%, 40%, 40% and 40% of their base salary, respectively. The annual bonus earned by each named executive officer with respect to the fiscal year ended December 31, 2022 is reported under the &#8220;Non-Equity Incentive Plan Compensation&#8221; column in the &#8220;2022 Summary Compensation Table&#8221; above and was determined based upon achievement of the corporate performance objectives at 80% of target and achievement of individual performance objectives.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that equity grants provide our executives with a strong link to our long-term performance, bolster an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our Compensation Committee or Board of Directors periodically reviews the equity incentive compensation of our named executive officers and considers equity awards to be a key component of the annual compensation program, representing long-term alignment with stockholders. Our named executive officers have been granted certain options to purchase shares of our common stock and restricted stock units relating to our common stock, as described in more detail in the &#8220;Outstanding Equity Awards at 2022 Fiscal Year-End&#8221; table below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Arrangements with our Named Executive Officers </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment agreements with Mr. Souza, Mr. Kelly and Ms. Sweeny, which we refer to as the Employment Agreements. The Employment Agreements provide for specified payments and benefits in connection with a termination of employment in certain circumstances. The material terms of the Employment Agreements with Mr. Souza, Mr. Kelly and Ms. Sweeny are summarized below. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marcio Souza.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Employment Agreement with Mr. Souza, Mr. Souza has continued to serve as our President and Chief Executive Officer on an at-will basis. Mr. Souza&#8217;s current annual base salary is $625,000, which is subject to annual review, and he is eligible to earn an annual bonus with a target amount equal to 75% of his base salary. Mr. Souza is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tim Kelly</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the Employment Agreement with Mr. Kelly, Mr. Kelly has continued to serve as our Chief Financial Officer on an at-will basis. Mr. Kelly&#8217;s current annual base salary is $465,000, which is subject to annual review, and he is eligible to earn an annual bonus with a target amount equal to 40% of his base salary. Mr. Kelly is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nicole Sweeny.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Employment Agreement with Ms. Sweeny, Ms. Sweeny has continued to serve as our Chief Commercial Officer on an at-will basis. Ms. Sweeny&#8217;s current annual base salary is $450,000, which is subject to annual review, and she is eligible to earn an annual bonus with a target amount equal to 40% of her base salary. Ms. Sweeny is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Employment Agreements, in the event that Mr. Souza&#8217;s, Mr. Kelly's or Ms. Sweeny&#8217;s employment is terminated by us without &#8220;cause&#8221; or Mr. Souza, Mr. Kelly or Ms. Sweeny resigns for &#8220;good reason&#8221; (as defined in the Employment Agreements), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, Mr. Souza, Mr. Kelly or Ms. Sweeny, as applicable, (i) will be entitled to receive base salary continuation for nine months (12 months for Mr. Souza) following termination, and (ii) subject to the executive&#8217;s co-payment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to the executive had such executive remained employed with us until the earliest of (A) nine months (12 months for Mr. Souza) following termination, (B) the executive&#8217;s eligibility for group medical plan benefits under any other employer&#8217;s group medical plan or (C) the end of the executive&#8217;s COBRA health continuation period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In lieu of the payments and benefits described in the preceding sentence, in the event Mr. Souza&#8217;s, Mr. Kelly's or Ms. Sweeny&#8217;s employment is terminated by us without cause or Mr. Souza, Mr. Kelly or Ms. Sweeny resigns for good reason, in either case on or within 12 months following a &#8220;change of control&#8221; (as defined in the Employment Agreements), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) the executive will be entitled to receive a lump sum in cash equal to one times (1.5 times for Mr. Souza) the sum of (A) the executive&#8217;s then-current annual base salary (or the executive&#8217;s annual base salary in effect immediately prior to the change of control, if higher) plus (B) the executive&#8217;s target annual cash incentive compensation for the year of termination (or the executive&#8217;s target annual cash incentive compensation in effect immediately prior to the change of control, if higher), (ii) subject to the executive&#8217;s co-payment of premium amounts at the applicable active employees&#8217; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to the executive had such executive remained employed with us until the earliest of (A) 12 months (18 months for Mr. Souza) following termination, (B) the executive&#8217;s eligibility for group medical plan benefits under any other employer&#8217;s group medical plan or (C) the end of the executive&#8217;s COBRA health continuation period, and (iii) the vesting of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by the executive shall be accelerated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments and benefits provided to each of the executives in connection with a change of control may not be eligible for a federal income tax deduction for the company pursuant to Section 280G of the Code and may subject the executive to an excise tax under Section 4999 of the Code. If the payments or benefits payable to the executive in connection with a change of control would be subject to the excise tax on golden parachutes imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the executive. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bernard Ravina, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Employment Agreement with Dr. Ravina, Dr. Ravina was entitled to the same severance and change of control benefits as Mr. Kelly and Ms. Sweeny described above. Dr. Ravina resigned as our Chief Medical Officer effective August 1, 2022 and transitioned to a role as strategic advisor to the Company. In connection with his resignation, and subject to the Company&#8217;s receipt of a general release of claims and pursuant to the terms of a transition agreement, Dr. Ravina is entitled to receive (i) a cash payment equal to nine months of his base salary, to be paid in equal installments over the nine-month period ending May 1, 2023; (ii) continued time-based vesting of the unvested portions of Dr. Ravina&#8217;s outstanding equity awards during the period in which Dr. Ravina provides advisory services to the Company; and (iii) continued health insurance coverage (to the extent permitted under applicable law and the terms of the Company&#8217;s health insurance plan) during the period in which Dr. Ravina provides advisory services to the Company at the same cost as immediately before his resignation.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we entered into a retention incentive award letter agreement with Dr. Ravina pursuant to which Dr. Ravina was entitled to receive a retention bonus, subject to Dr. Ravina&#8217;s continued employment with the Company, among other specified conditions. Pursuant to the agreement, Dr. Ravina received a lump sum payment of $333,333 in April 2022 and $27,778 per month for each of the three months thereafter that he was employed by us. Dr. Ravina forfeited his rights to any unearned portion of the retention bonus when he resigned in August 2022. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at 2022 Fiscal Year-End</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2022. Each of the awards set forth in the table below was granted under our 2017 Stock Incentive Plan or our 2020 Stock Option and Incentive Plan. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:16.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vesting<br/>Commencement<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable<br/>(1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable<br/>(1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Option<br/>Exercise<br/>Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Option<br/>Expiration<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares or units of stock that have not vested (#)(2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Market Value of shares of units of stock that have not vested ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marcio Souza</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">04/20/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">636,897</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318,452</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/04/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">09/08/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">578,264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449,773</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">09/13/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">02/12/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,700</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">02/12/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94,248</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">259,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176,120</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tim Kelly</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">05/25/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,166</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,834</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">05/25/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,120</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nicole Sweeny</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">08/10/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133,618</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95,447</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">08/18/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">02/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,894</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">02/12/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,600</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,988</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57,120</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bernard Ravina, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">08/21/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,644</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10/16/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">05/28/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,517</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/03/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">09/08/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,569</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">09/12/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">02/12/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">02/12/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,558</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">01/07/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,360</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">06/22/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The stock options vest over four years, with 25% of the total shares vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 approximately equal monthly installments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Represents restricted stock units that vest in equal annual installments on each of the first four anniversaries of the vesting commencement date. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pay Versus Performance</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the SEC&#8217;s disclosure requirements regarding pay versus performance, or PVP, this section presents the SEC-defined &#8220;Compensation Actually Paid,&#8221; or CAP. Also required by the SEC, this section compares CAP to various measures used to gauge performance at Praxis.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation decisions at Praxis are made independently of disclosure requirements. CAP is a supplemental measure to be viewed alongside performance measures as an addition to the philosophy and strategy of compensation-setting discussed elsewhere in the overview of the executive compensation program, not in replacement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pay versus Performance Table - Compensation Definitions</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salary, Bonus, Non-Equity Incentive Plan Compensation, and All Other Compensation are each calculated in the same manner for purposes of both CAP and SCT, or Summary Compensation Table, values. The primary difference between the calculation of CAP and SCT total compensation is &#8220;Stock Awards&#8221; and &#8220;Option Awards.&#8221;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">SCT Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">CAP</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Stock and Option Awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Grant date fair value of stock and option awards granted during the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Year over year change in the fair value of stock and option awards that are unvested as of the end of the year, or vested or were forfeited during the year</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pay Versus Performance Table</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the SEC&#8217;s new PVP rules, the following table sets forth information concerning the compensation of our NEOs for each of the fiscal years ended December 31, 2021 and 2022, and our financial performance for each such fiscal year:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"><br/><br/><br/><br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Year (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"><br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Summary Compensation Table Total for PEO ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"><br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Compensation Actually Paid to PEO ($)(2)(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Average Summary Compensation Table Total for Non-PEO NEOs ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Average Compensation Actually Paid to Non-PEO NEOs ($)(2)(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Value of Initial Fixed $100 Investment Based on: Total Shareholder Return ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"><br/><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">GAAP<br/>Net Income ($)(4)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">6,028,078</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-17,643,206</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2,450,241</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-1,595,040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-214</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10,905,820</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-62,152,872</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4,118,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-6,315,773</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">35.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-167</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The PEO (CEO) in both reporting years is Marcio Souza. The non-PEO NEOs in the 2022 reporting year are Tim Kelly, Nicole Sweeny, and Bernard Ravina. The non-PEO NEOs in the 2021 reporting year are Nicole Sweeny and Bernard Ravina.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The CAP was calculated beginning with the PEO&#8217;s SCT total. Thee following amounts were deducted from and added to the applicable SCT total compensation:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">SCT Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Stock Awards Deducted from SCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Stock Awards Added to CAP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Stock Option Awards Deducted from SCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Stock Option Awards Added to CAP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Total CAP</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">E</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">A - (B + D) + (C + E)</span></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">PEO</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">6,028,078</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1,340,140</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-600,172</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3,649,420</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-18,081,552</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-17,643,206</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10,905,820</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2,773,584</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1,040,160</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">6,883,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-64,441,468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-62,152,872</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Average Non-PEO NEO</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2,450,241</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">433,549</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-131,979</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1,232,109</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-2,247,645</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-1,595,040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4,118,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1,085,060</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">406,923</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2,322,165</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-7,433,985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-6,315,773</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The fair value of stock options reported for CAP purposes in columns (C) and (E) is estimated using a Black-Scholes option pricing model for the purposes of this PVP calculation in accordance with the SEC rules. This model uses both historical data and current market data to estimate the fair value of options and requires several assumptions. The assumptions used in estimating fair value for awards granted during 2021-2022 are as follows: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">            </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">86.34 &#8211; 90.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">86.71 &#8211; 92.49%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Expected life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.16 &#8211; 9.02 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.80 &#8211; 9.12 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0.00%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Risk-free rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1.21 &#8211; 4.22%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0.29 &#8211; 1.50%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Values shown are in millions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Narrative Disclosure to Pay Versus Performance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relationship between Pay and TSR</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graphs below reflect the relationship between the PEO and Average Non-PEO NEO CAP and the Company&#8217;s cumulative indexed Total Shareholder Return, or TSR, (assuming an initial fixed investment of $100) for the fiscal years ended December 31, 2021 and 2022:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CEO Pay vs Performance: Total Shareholder Return (12/31/20 to 12/31/22)</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><img src="prax-20221231_g2.jpg" alt="prax-20221231_g2.jpg" style="height:379px;margin-bottom:5pt;vertical-align:text-bottom;width:549px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Average Other NEO Pay vs Performance: Total Shareholder Return (12/31/20 to 12/31/22)</span></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><img src="prax-20221231_g3.jpg" alt="prax-20221231_g3.jpg" style="height:379px;margin-bottom:5pt;vertical-align:text-bottom;width:549px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Relationship between Pay and Net Income (GAAP)</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below reflects the relationship between the PEO and Average Non-PEO NEO CAP and the Company&#8217;s GAAP Net Income for the applicable reporting year.</span></div><div style="margin-top:6pt;text-align:center"><img src="prax-20221231_g4.jpg" alt="prax-20221231_g4.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:549px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Director Compensation Policy</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-employee director compensation policy enables us to attract and retain, on a long-term basis, highly qualified non-employee directors. Under the policy, each director who is not an employee is paid cash compensation as set forth below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Annual Retainer</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Board of Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$40,000</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional retainer for non-executive chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$30,000</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Audit Committee:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members (other than chair)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,000</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retainer for chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$16,000</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Compensation Committee:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members (other than chair)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,000</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retainer for chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$12,000</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members (other than chair)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,000</span></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retainer for chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,000</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Science &amp; Technology Committee:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members (other than chair)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,000</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retainer for chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,000</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the non-employee director compensation policy provides that, upon initial election to our Board of Directors, each non-employee director will be granted an option to purchase a number of shares equal to 0.1% of the total number of shares of our common stock issued and outstanding on the grant date, or the Initial Grant. The Initial Grant vests in equal monthly installments over three years from the grant date, subject to continued service as a director through the applicable vesting date. Furthermore, each non-employee director who continues as a non-employee director following the Annual Meeting will be granted an annual option to purchase a number of shares equal to 0.05% of the total number of shares of our common stock issued and outstanding on the grant date, or the Annual Grant. The Annual Grant vests in 12 equal monthly installments, subject to continued service as a director through the applicable vesting date. Such awards are subject to full accelerated vesting upon the sale of the company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board of Directors and committees.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Director Compensation Table</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total compensation for each person who served as a non-employee member of our Board of Directors during the year ended December 31, 2022. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or non-equity awards to or pay any other compensation to any of the non-employee members of our Board of Directors in 2022 for their services as members of the Board of Directors. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fees Earned or Paid in Cash ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option<br/>Awards<br/>($)(1)(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All Other<br/>Compensation<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey Chodakewitz, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,543</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,364</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merit Cudkowicz, M.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,821</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,821</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jill DeSimone(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,991</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,325</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367,316</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dean Mitchell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,821</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,821</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stefan Vitorovic(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,543</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,364</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory Norden</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,821</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,821</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">William Young</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,821</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,821</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The amount reported represents the aggregate grant date fair value of stock options awarded during fiscal year 2022, calculated in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 11 of our consolidated financial statements included in this Annual Report. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying shares of common stock.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">As of December 31, 2022, Dr. Chodakewitz held options to purchase 61,332 shares of our common stock, Dr. Cudkowicz held options to purchase 61,332 shares of our common stock, Ms. DeSimone held options to purchase 45,511 shares of our common stock, Mr. Mitchell held options to purchase 110,516 shares of our common stock, Mr. Norden held options to purchase 144,620 shares of our common stock and Mr. Young held options to purchase 147,250 shares of our common stock. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Ms. DeSimone was appointed as a member of our Board of Directors in May 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Mr. Vitorovic resigned as a director in August 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of December 31, 2022 regarding shares of common stock that may be issued under our equity compensation plans, consisting of our 2017 Stock Incentive Plan, our 2020 Stock Option and Incentive Plan and our 2020 Employee Stock Purchase Plan.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:29.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number of securities to be issued upon exercise of outstanding options, restricted stock units and rights</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted Average exercise price of outstanding options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number of securities remaining available for future issuance under equity compensation plan (excluding securities referenced in column (a))</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Equity compensation plans approved by security holders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,581,978(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.93(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,490,877(3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Equity compensation plans not approved by security holders:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,581,978</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,490,877</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Includes 8,838,028 shares of common stock issuable upon the exercise of outstanding options and 743,950 shares subject to restricted stock units that will entitle the holder to one share of common stock for each unit that vests.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">The calculation does not take into account the 743,950 shares of common stock subject to outstanding restricted stock units. Such shares will be issued at the time the restricted stock unit vests, without any cash consideration payable for those shares.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">As of December 31, 2022, there were no shares available for grant under the 2017 Stock Incentive Plan, 1,650,955 shares available for grants under the 2020 Stock Option and Incentive Plan and 839,922 shares available for grants under the 2020 Employee Stock Purchase Plan (of which 283,861 shares were subject to outstanding purchase rights). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock outstanding as of February 3, 2023 for:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person, or group of affiliated persons, who is known by us to be the beneficial owner of five percent or more of our outstanding common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our named executive officers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our current directors and executive officers as a group.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities as well as any shares of common stock that the person has the right to acquire within 60 days of February 3, 2023 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. Each individual or entity shown on the table has furnished information with respect to beneficial ownership. Except as otherwise indicated below, the address of each officer, director and five percent stockholder listed below is c/o Praxis Precision Medicines, Inc., 99 High Street, 30th Floor, Boston, MA 02110.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of beneficial ownership in the table below is based on 52,393,118 shares of common stock deemed to be outstanding as of February 3, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMMON STOCK BENEFICIALLY OWNED</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PERCENTAGE</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5% or Greater Stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clarus Lifesciences III, L.P. (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894,109</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Avidity (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Eventide (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810,599</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janus Henderson Group plc (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342,569</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Vanguard Group (5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blackrock, Inc. (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971,762</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vida Ventures, LLC (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939,329</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6%</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Kingdon (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855,989</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors, Named Executive Officers and Other Executive Officers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dean Mitchell (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,555</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Chodakewitz (10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,616</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merit Cudkowicz (11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,616</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jill DeSimone (12)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory Norden (13)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,328</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Young (14)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,838</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marcio Souza (15)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834,286</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Kelly (16)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole Sweeny (17)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,860</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernard Ravina (18)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,829</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All executive officers and directors as a group (10 persons) (19)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,917,581</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Represents beneficial ownership of less than one percent.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G/A filed jointly by Clarus Lifesciences III, L.P., or Clarus Lifesciences, BSOF Parallel Master Fund L.P., or BSOF, Clarus Ventures III GP, L.P., or Clarus Ventures, Blackstone Clarus III L.L.C., or Blackstone Clarus, Blackstone Strategic Opportunity Associates L.L.C., or Blackstone Strategic, Blackstone Alternative Solutions L.L.C., or Blackstone Alternative, Blackstone Holdings I L.P., or Holdings I, Blackstone Holdings II L.P., or Holdings II, Blackstone Holdings I/II GP L.L.C., or Holdings I/II, Blackstone Inc., or Blackstone, Blackstone Group Management L.L.C., or Blackstone Group, and Stephen A. Schwarzman with the SEC on February 11, 2022. Clarus Lifesciences directly holds 4,894,109 shares of common stock and BSOF holds zero shares of common stock. Clarus Ventures is the general partner of Clarus Lifesciences. Blackstone Clarus is the general partner of Clarus. The sole member of Blackstone Clarus is Holdings. Blackstone Strategic is the general partner of BSOF. Holdings is the sole member of Blackstone Strategic. Blackstone Alternative is the investment manager of BSOF. Holdings I is the sole member of Blackstone Alternative. The general partner of Holdings I and Holdings II is Holdings I/II. The sole member of Holdings I/II is Blackstone. The sole holder of the Series II preferred stock of Blackstone is Blackstone Group. Blackstone Group is wholly-owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such entities and Mr. Schwarzman may be deemed to beneficially own the shares of common stock beneficially owned by Clarus Lifesciences directly or indirectly controlled by it or him, but each (other than Clarus to the extent of its direct ownership) disclaims beneficial ownership of such shares. The address for each of Clarus Lifesciences and Clarus Ventures is c/o Clarus Ventures LLC, 101 Main Street, Suite 1210, Cambridge, MA 02142. The address for each of the other entities and Mr. Schwarzman is c/o The Blackstone Group Inc., 345 Park Avenue, New York, NY 10154.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G filed by Avidity Partners Management LP, or APM LP, with the SEC on February 2, 2023. According to this Schedule 13G, APM LP, Avidity Partners Management (GP) LLC, or APM GP, Avidity Capital Partners Fund (GP) LP, or ACPF, Avidity Capital Partners (GP) LLC, or ACP, share voting and dispositive power with respect to 4,100,000 shares, of which 3,600,234 shares are further subject to shared voting and dispositive power with Avidity Master Fund LP, or AMF and together with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APM LP, APM GP, ACPF and ACP, the Avidity Funds. APM GP is the general partner of APM LP. ACP is the general partner of ACPF. ACPF is the general partner of AMF. David Witzke and Michael Gregory are Managing Members of APM GP and ACP and directly or indirectly control the Avidity Funds and as a result may be deemed to have voting and dispositive power over the securities held directly by the Avidity Funds. The address for each of the Avidity Funds, Mr. Witzke and Mr. Gregory is 2828 North Harwood Street, Suite 1220, Dallas, Texas 75201.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G/A filed by Eventide Asset Management, LLC with the SEC on February 14, 2022. Eventide Asset Management, LLC, a Delaware limited liability company, is the beneficial owner of 3,810,599 shares of common stock by virtue of being the investment adviser to the Eventide Gilead Fund and the Eventide Healthcare &amp; Life Sciences Fund which are registered investment companies (the &#8220;Funds&#8221;). The Eventide Gilead Fund directly holds 1,574,013 shares of common stock and the Eventide Healthcare &amp; Life Sciences Fund directly holds 2,236,586 shares of common stock. The address for Eventide Asset Management, LLC is One International Place, Suite 4210, Boston, Massachusetts 02110.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G filed by Janus Henderson Group plc with the SEC on February 11, 2022. Janus Henderson Group plc has an indirect 97% ownership stake in Intech Investment Management LLC, or Intech, and a 100% ownership stake in Janus Henderson Investors U.S. LLC, or JHIUS, Henderson Global Investors Limited, or HGIL, and Janus Henderson Investors Australia Institutional Funds Management Limited, or JHIAIFML (each an &#8220;Asset Manager&#8221; and collectively, the &#8220;Asset Managers&#8221;). Due to the above ownership structure, holdings for the Asset Managers are aggregated. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as &#8220;Managed Portfolios&#8221;). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 3,338,282 shares or 7.4% of the shares of common stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. The address of Janus Henderson Group plc is 201 Bishopsgate, EC2M 3AE, United Kingdom.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G filed by The Vanguard Group with the SEC on February 10, 2022. According to this Schedule 13G, The Vanguard Group has shared voting power over 29,376 shares of common stock, sole dispositive power over 3,241,881 shares of common stock, and shared dispositive power over 50,562 shares of common stock. The address of The Vanguard Group is 100 Vanguard Boulevard, Malvern, PA 19355.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G/A filed by BlackRock, Inc. with the SEC on February 1, 2023. According to this Schedule 13G/A, BlackRock, Inc. has sole voting power over 2,895,474 shares of common stock and sole dispositive power over 2,971,762 shares of common stock. The address for BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G filed by Vida Ventures, LLC, or Vida, with the SEC on February 16, 2021. Vida, a United States limited liability company, is the record owner of 2,939,329 shares of common stock. VV Manager, LLC, or VV Manager, is the managing member of Vida. Stefan Vitorovic, Arjun Goyal, Fred Cohen, Arie Belldegrun and Leonard Potter are managers of VV Manager, and may be deemed to share voting and dispositive power over the shares of common stock held by Vida. The address of Vida is 40 Broad Street, Suite 201, Boston, Massachusetts 02109.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.78pt">Based solely on information contained in a Schedule 13G filed by Kingdon Capital Management, L.L.C., or Kingdon with the SEC on January 25, 2023. According to this Schedule 13G, all shares are held directly by advisory clients of Kingdon and Kingdon shares voting and dispositive power with respect to all 2,855,989 shares, of which 2,427,591 shares are further subject to shared voting and dispositive power with M. Kingdon Offshore Master Fund L.P., or KOMF, and Kingdon GP, LLC, or K GP and, together with Kingdon and KOMF, the Kingdon Funds. KOMF and K GP are advisory clients of Kingdon. K GP is the general partner of KOMF. None of Kingdon&#8217;s advisory clients, other than KOMF, may be deemed to beneficially own more than 5% of the common stock. Kingdon is controlled by Mark Kingdon. The address of each of the Kingdon Funds and Mr. Kingdon is 152 West 57th Street, 50th Floor, New York, New York 10019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Consists of (i) 25,000 shares of common stock and (ii) 83,555 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of 43,616 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of 43,616 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of 12,641 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 2,826 shares of common stock and (ii) 114,502 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 28,473 shares of common stock and (ii) 116,365 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 96,199 shares of common stock, (ii) 1,724,887 shares of common stock underlying options exercisable within 60 days of February 3, 2023 and (iii) 13,200 shares of common stock underlying restricted stock units vesting within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 20,416 shares of common stock and (ii) 158,621 shares of common stock underlying options exercisable within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 9,475 shares of common stock, (ii) 244,185 shares of common stock underlying options exercisable within 60 days of February 3, 2023 and (iii) 4,200 shares of common stock underlying restricted stock units vesting within 60 days of February 3, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 66,970 shares of common stock, (ii) 172,159 shares of common stock underlying options exercisable within 60 days of February 3, 2023 and (iii) 4,700 shares of common stock underlying restricted stock units vesting within 60 days of February 3, 2023. Dr. Ravina resigned as our Chief Medical Officer effective August 1, 2022 and transitioned to a role as strategic advisor to the Company.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.22pt">Consists of (i) 198,283 shares of common stock, (ii) 2,698,798 shares of common stock underlying options exercisable within 60 days of February 3, 2023 and (iii) 20,500 shares of common stock underlying restricted stock units vesting within 60 days of February 3, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_181"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the compensation agreements and other arrangements described under &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in this Annual Report on Form 10-K and the transactions described below, since January 1, 2021, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, the lesser of $120,000 or one percent of our average total assets at fiscal year-end for the last two completed fiscal years and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration Rights</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our Fourth Amended and Restated Investors&#8217; Rights Agreement, dated as of July 24, 2020, as amended, or the Investors&#8217; Rights Agreement, certain of our stockholders are entitled to rights with respect to the registration of their shares, which we refer to herein as registrable securities, under the Securities Act, including demand registration rights and piggyback registration rights.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Form S-1 Registration Rights</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Investors&#8217; Rights Agreement, we are required, upon the request of holders holding at least a majority of the registrable securities then outstanding, to file a registration statement on Form S-1 registering the resale of such holders&#8217; registrable securities and the registrable securities of such other holders who elect to have their shares registered; provided that the anticipated aggregate offering price, net of related fees and expenses, of the registrable securities registered on such registration statement would equal at least $10 million. We are required to effect only two registrations pursuant to this provision of the Investors&#8217; Rights Agreement. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Form S-3 Registration Rights</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Investors&#8217; Rights Agreement, if we are eligible to file a registration statement on Form S-3, we are required, upon the request of holders holding at least a majority of the registrable securities then outstanding, to file a registration restatement on Form S-3 registering the resale of such holders&#8217; registrable securities and the registrable securities of such other holders who elect to have their shares registered; provided that the anticipated aggregate offering price, net of related fees and expenses, of the registrable securities registered on such registration statement would equal at least $3 million. We are required to effect only two registrations in any twelve-month period pursuant to this provision of the Investors&#8217; Rights Agreement. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Piggyback Registration Rights</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, if we register any of our securities either for our own account or for the account of security holders other than the holders party to the Investors&#8217; Rights Agreements, the holders of shares of registrable securities are entitled to include their shares in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investors&#8217; Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expiration of Registration Rights</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The demand registration rights and short-form registration rights granted under the Investors&#8217; Rights Agreement will terminate on the earliest to occur of: (i) the fifth anniversary of the completion of our initial public offering and (ii) as to each holder of registrable securities, such time as either Rule 144 as promulgated under the Securities Act or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">another similar exemption under the Securities Act is available for the sale of all of such holder&#8217;s shares without limitation during a three-month period without registration or such holder no longer holds any registrable securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Agreements with Related Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RogCon</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into an agreement with RogCon Inc., or RogCon, pursuant to which we agreed to advance RogCon a deposit of up to $1.0&#160;million related to the cooperation and license agreement described below. The amounts funded to RogCon under this agreement were applied towards the purchase price of the license agreement with RogCon described below.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we entered into a cooperation and license agreement with RogCon, further described in this Annual Report under &#8220;Business&#8212;License Agreements.&#8221;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alex Nemiroff, our General Counsel and Corporate Secretary, is a co-founder and Chief Executive Officer of RogCon.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and in the future plan to enter into, agreements to indemnify our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#8217;s status as a member of our Board of Directors to the maximum extent allowed under Delaware law. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policies for Approval of Related Party Transactions</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. We have a formal written policy that our executive officers, directors, holders of more than five percent of any class of our voting securities, and any member of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a related party transaction with us without the prior consent of our Audit Committee, or other independent members of our Board of Directors in the event it is inappropriate for our Audit Committee to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an executive officer, director, holders of more than 5% of any class of our voting securities, or any of their immediate family members or affiliates, in which the amount involved exceeds $120,000 must first be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee considers the relevant facts and circumstances available and deemed relevant to our Audit Committee, including, but not limited to, whether the transaction will be on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) rules require a majority of a listed company&#8217;s board of directors to be comprised of independent directors. In addition, the Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and that compensation committee members satisfy additional independence criteria set forth in the Nasdaq rules. Under applicable Nasdaq rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Nasdaq independence definition also includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In addition, in affirmatively determining the independence of any director who will serve on a company&#8217;s compensation committee, the Nasdaq rules require that a company&#8217;s board of directors must consider all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including: the source of compensation to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">director, including any consulting, advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has determined that all members of our Board of Directors, except Marcio Souza, are independent directors, including for purposes of the rules of Nasdaq and the SEC. In making such independence determination, our Board of Directors considered the relationships that each non-employee director has with us and all other facts and circumstances that our Board of Directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. In considering the independence of the directors listed above, our Board of Directors considered the association of our directors with the holders of more than 5% of our common stock. There are no family relationships among any of our directors or executive officers. Mr. Souza is not an independent director under these rules because he is an executive officer of the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-indent:18pt"><span><br/></span></div><div id="i3603669404fe4fc8b59d31b31e26e467_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP has served as our independent auditor since 2019. Praxis incurred the following fees from Ernst &amp; Young LLP for the audit of the consolidated financial statements and for other services provided during the years ended December&#160;31, 2022 and 2021. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit fees(1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$796,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,143,241</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit-related fees(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax fees(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,730</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other fees(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,180</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">899,849</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,236,151</span></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consist of fees for professional services rendered in connection with the audit of our annual consolidated financial statements, the review of the interim consolidated financial statements included in quarterly reports, services rendered in connection with the secondary public offering, and services that are normally provided by Ernst &amp; Young LLP, such as comfort letters, in connection with statutory and regulatory filings or engagements.</span></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) There were no </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">audit-related fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> billed in 2022 or 2021.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consist of fees for professional services rendered for tax return preparation and tax advisory services.</span></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All other fees </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are related to licensing fees paid to Ernst &amp; Young LLP for access to its proprietary accounting research database. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee Pre-Approval Policy and Procedures</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has adopted a policy requiring pre-approval of all audit and non-audit related services to be performed by our independent auditor regardless of amount. These services may include audit services, audit-related services, tax services and other related services. Ernst &amp; Young LLP and management are required to periodically report to the Audit Committee regarding the extent of services provided by Ernst &amp; Young LLP in accordance with this pre-approval and the fees for the services performed to date. The Audit Committee may also pre-approve particular services on a case-by-case basis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i3603669404fe4fc8b59d31b31e26e467_190"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)(1)  Financial Statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_79">96</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)(2)  Financial Statement Schedules.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)(3)  List of Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520272877/d94620dex31.htm">Amended and Restated Certificate of Incorporation of Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on October 20, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000110465922002260/tm222120d1_ex3-1.htm">Amended and Restated Bylaws of Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on January 7, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex41.htm">Specimen Stock Certificate Evidencing the Shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000110465921133741/tm2131445d2_ex4-2.htm">Fourth Amended and Restated Investors&#8217; Rights Agreement among Praxis Precision Medicines, Inc. and certain of its stockholders, effective as of July 24, 2020, as amended (incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-3 (File No. 333-260726) filed on November 3, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit43-descriptionofsec.htm">Description of Securities of Praxis Precision Medicines, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit43-descriptionofsec.htm"> (incorporated by reference to Exhibit 4.3 to the Registrant's Annual Report on Form 10-K (File No. 001-39620) filed on February 28, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex101.htm">Form of Director Indemnification Agreement, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex102.htm">Form of Officer Indemnification Agreement (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-249074) filed on September 25, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954821000016/exhibit1032017plan.htm">Praxis Precision Medicines, Inc. 2017 Stock Incentive Plan, as amended, and form of award agreements thereunder (incorporated by reference to Exhibit 10.3 to the Registrant's Annual Report on Form 10-K (File No. 001-39620) filed on March 17, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex104.htm">Praxis Precision Medicines, Inc. 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex105.htm">Form of Incentive Stock Option Agreement under the 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex106.htm">Form of Non-Qualified Stock Option Agreement for Company Employees under the 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex107.htm">Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under the 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex108.htm">Form of Restricted Stock Award Agreement under the 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex109.htm">Form of Restricted Stock Award Agreement for Company Employees under the 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex1010.htm">Form of Restricted Stock Award Agreement for Non-Employee Directors under the 2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex1011.htm">Praxis Precision Medicines, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrant's Registration Statement on Form S-1/A (File No. 333-249074) filed on October 9, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1012.htm">Amended and Restated Employment Agreement, dated October 20, 2020, by and between Praxis Precision Medicines, Inc. and Marcio Souza</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1012.htm"> (incorporated by reference to Exhibit 10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1012.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1012.htm">12 to the Registrant's Annual Report on Form 10-K (File No. 001-39620) filed on February 28, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013-cfoemploymenta.htm">Amended and Restated Employment Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013-cfoemploymenta.htm">May 13, 2021,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013-cfoemploymenta.htm"> by and between Praxis Precision Medicines, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013-cfoemploymenta.htm">Timothy Kelly </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1014.htm">Amended and Restated Employment Agreement, dated October 20, 2020, by and between Praxis Precision Medicines, Inc. and Nicole Sweeny</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1014.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1014.htm">(incorporated by reference to Exhibit 10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1014.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1014.htm"> to the Registrant's Annual Report on Form 10-K (File No. 001-39620) filed on February 28, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm">Amended and Restated Employment Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm">October 20, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm">, by and between Praxis Precision Medicines, Inc. and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm"> Bernard Ravina</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm">incorporated by reference to Exhibit 10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1013.htm"> to the Registrant's Annual Report on Form 10-K (File No. 001-39620) filed on February 28, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954821000081/exhibit10120210830.htm">Retention Incentive Award Letter Agreement, dated August 30, 2021, by and between Praxis Precision Medicines, Inc. and Bernard Ravina (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on August 30, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/exhibit101.htm">Transition Agreement, dated July 26, 2022, by and between Praxis Precision Medicines, Inc. and Bernard Ravina (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/exhibit101.htm">July 26, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000099/exhibit101.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1016.htm">Non-Employee Director Compensation Policy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1016.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1016.htm">(incorporated by reference to Exhibit 10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1016.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954822000014/exhibit1016.htm"> to the Registrant's Annual Report on Form 10-K (File No. 001-39620) filed on February 28, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1015.htm">Cooperation and License Agreement, dated September 11, 2019, by and between RogCon Inc. and Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 10.15 to the Registrant's Registration Statement on Form S-1 (File No. 333-249074) filed on September 25, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1016.htm">Research Collaboration, Option and License Agreement, dated September 11, 2019, by and between Ionis Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 10.16 to the Registrant's Registration Statement on Form S-1 (File No. 333-249074) filed on September 25, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000168954821000054/exhibit10120210527.htm">Sublease, dated May 27, 2021, by and between CBRE, Inc. and Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on June 2, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex211.htm">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-249074) filed on September 25, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231-eyconsent2022.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included on signature page hereto)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-peo302certifica.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-pfo302certifica.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-peoandpfo906cer.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**<br/></span><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/><br/><br/></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10&#8211;K Summary</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><div id="i3603669404fe4fc8b59d31b31e26e467_196"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3603669404fe4fc8b59d31b31e26e467_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRAXIS PRECISION MEDICINES, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;7, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marcio Souza</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marcio Souza<br/>Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Marcio Souza and Alex Nemiroff, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marcio Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marcio Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lauren Mastrocola</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lauren Mastrocola</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dean Mitchell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dean Mitchell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Chodakewitz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Chodakewitz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Merit Cudkowicz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merit Cudkowicz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jill DeSimone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jill DeSimone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gregory Norden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory Norden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>exhibit1013-cfoemploymenta.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i32e898c8b6b1411f8831d66480f5ab66_1"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.2pt;padding-left:135.05pt;padding-right:135.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Praxis Precision Medicines, Inc.</font></div><div style="margin-top:11.65pt;padding-left:134.82pt;padding-right:134.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.15pt;padding-left:134.82pt;padding-right:134.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">for</font></div><div style="margin-top:0.1pt;padding-left:134.82pt;padding-right:134.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Executive Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made between Praxis Precision Medicines, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Timothy E. Kelly (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and is effective upon the Executive&#8217;s first date of employment with the Company, on May 25, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">, the Company desires Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services&#59; and</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows&#58;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Employment by the Company.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Position and Duties. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall serve as the Company&#8217;s Chief Financial Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). During the term of Executive&#8217;s employment with the Company, Executive shall devote one hundred percent of Executive&#8217;s business time on behalf of the Company and, on a full-time basis, use Executive&#8217;s skills and render services to the best of Executive&#8217;s abilities on behalf of the Company, and shall comply fully with the policies and procedures of the Company. Executive shall report directly to the Company&#8217;s Chief Executive Officer (the &#8220;CEO&#8221;). Executive shall perform those duties typically associated with the Position and such other duties consistent with the Position as may be assigned by the CEO, including but not limited to executive responsibility for business operations, finance, corporate development, systems, and strategic planning and management. Notwithstanding the foregoing, nothing herein shall preclude Executive from</font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) serving, with the prior written consent of the CEO, as a member of the boards of directors or advisory boards of non-competitive businesses and charitable organizations, (ii) engaging in charitable activities and community affairs, and (iii) managing Executive&#8217;s personal investments and affairs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the activities set out in clauses (i), (ii), and</font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">(iii) shall be limited by Executive so as not to materially interfere, individually or in the aggregate, with the performance of Executive&#8217;s duties and responsibilities hereunder and shall not, in the judgment of the CEO pose a conflict of interest with Executive&#8217;s duties to the Company or its affiliates.</font></div><div style="margin-top:11.35pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:15.4pt">Location of Work. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Executive shall work </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">remotely </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">in the USA. The Company reserves the right to reasonably require Executive to perform Executive&#8217;s duties</font></div><div style="height:69.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font></div></td></tr></table></div></div></div><div id="i32e898c8b6b1411f8831d66480f5ab66_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">at places other than Executive&#8217;s primary office location from time to time, and to require reasonable business travel.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Policies and Procedures. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Compensation.</font></div><div style="margin-top:11.65pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Salary. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For services to be rendered hereunder, Executive shall receive an initial base salary at the rate of $425,000 per year, subject to standard payroll deductions and withholdings and payable in accordance with the Company&#8217;s regular payroll schedule (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Executive&#8217;s Base Salary will be reviewed annually by the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Annual Cash Bonus. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive will be eligible for an annual cash bonus with a target amount of forty percent (40%) of Executive&#8217;s Base Salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Whether Executive receives an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the Board or the Compensation Committee based upon the Company&#8217;s and Executive&#8217;s achievement of objectives and milestones to be determined by the Board or the Compensation Committee on an annual basis. Except as otherwise provided herein or in applicable incentive compensation plan that may be in effect from time to time, Executive will not be eligible for, and will not earn, any Annual Bonus if Executive is not employed by the Company on the payment date (regardless of the reason for the separation from employment).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Equity. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to approval of the Board or its delegate, Executive will receive a stock option grant of 200,000 shares of Company equity. The options&#8217; vesting will be in accordance with the Company&#8217;s stock plan. The options will vest as follows&#58; one quarter of the shares will vest on the first anniversary of the Effective Date and following that 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the shares will vest on a monthly basis, in arrears. The stock options and any other stock-based awards granted to Executive shall be governed by the terms and conditions of the Company&#8217;s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such stock options and other stock-based awards (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and notwithstanding anything to the contrary in the Equity Documents, Section 5.3(ii)(b) of this Agreement shall apply in the event of a termination of Executive&#8217;s employment by the Company without Cause or by Executive for Good Reason, in either case within the Change of Control Period (as such terms are defined below).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.4pt">Standard Company Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall be entitled to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees. The Company reserves the right to cancel or change the benefit plans or programs it offers to its employees at any time.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.4pt">Expenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in furtherance or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Termination of Employment&#59; Severance.</font></div><div style="margin-top:11.65pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:15.4pt">At-Will Employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Executive&#8217;s employment relationship is at- will. Either Executive or the Company may terminate the employment relationship at any time, with or without cause subject to the terms of this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:15.4pt">Severance Pay and Benefits Upon a Termination Without Cause or Resignation for Good Reason Outside the Change of Control Period.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;padding-left:19.09pt">The Company may terminate Executive&#8217;s employment with the Company at any time without Cause. Executive may terminate Executive&#8217;s employment with the Company at any time for any reason, including for Good Reason.</font></div><div style="margin-top:11.45pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.76pt">In the event that Executive&#8217;s employment with the Company is terminated by the Company without Cause or by Executive for Good Reason, in either case outside of the Change of Control Period, then, provided that Executive remains in compliance with the terms of this Agreement, the Company shall provide Executive with the following severance benefits&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:185.6pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.07pt">The Company shall pay Executive, as severance, nine</font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9) months of Executive&#8217;s Base Salary in effect as of the date of Executive&#8217;s employment termination, subject to standard payroll deductions and withholdings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Subject to Section 5.2(iii) below, the Severance will be paid in equal installments on the Company&#8217;s regular payroll schedule over the nine (9) month period following Executive&#8217;s termination of employment.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.75pt">Provided Executive timely elects continued coverage under COBRA, the Company shall pay the Company&#8217;s portion of Executive&#8217;s COBRA premiums, equal to the percentage of health premiums paid by the Company prior to Executive&#8217;s termination, to continue Executive&#8217;s coverage (including coverage for eligible dependents, if applicable) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) through the period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA Premium Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) starting on Executive&#8217;s date of termination and ending on the earliest to occur of&#58; (i) the nine (9) month anniversary of Executive&#8217;s date of termination&#59; (ii) the date Executive becomes eligible for group health insurance coverage through a new employer&#59; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer&#8217;s group health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equal to the applicable COBRA premiums for that month (including premiums for Executive and Executive&#8217;s eligible dependents who have elected and remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Special Cash Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the remainder of the COBRA Premium Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.43pt">The amounts payable under this Section 5.2, to the extent taxable, shall be paid or commence to be paid within 60 days after the date of termination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:5.6pt;padding-right:5.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%;padding-left:15.4pt">Severance Pay and Benefits Upon Termination Without Cause or Resignation for Good Reason Within the Change of Control Period.</font></div><div style="margin-top:11.2pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.09pt">The provisions of this Section 5.3 shall apply in lieu of, and expressly supersede, the provisions of Section 5.2 regarding severance pay and benefits upon a termination of employment by the Company without Cause or by Executive for Good Reason if such termination of employment occurs on or within 12 months after the occurrence of the first event constituting a Change of Control (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). These provisions shall terminate and be of no further force or effect after the Change of Control Period</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.76pt">In the event that Executive&#8217;s employment with the Company is terminated by the Company without Cause or by Executive for Good Reason, in either case during the Change of Control Period, then, provided Executive remains in compliance with the terms of this Agreement, the Company shall provide Executive with the following severance benefits&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%;padding-left:16.42pt">The Company shall pay Executive, as severance, a lump sum in cash in an amount equal to one (1) times the sum of (A) Executive&#8217;s then current Base Salary (or Executive&#8217;s Base Salary in effect immediately prior to the Change of Control, if higher) plus (B) Executive&#8217;s Annual Bonus for the then-current year (or Executive&#8217;s Annual Bonus in effect immediately prior to the Change of Control, if higher) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Change of Control Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#8221;).</font></div><div style="margin-top:11.15pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.75pt">Notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all time-based stock options and other stock-based awards subject to time-based vesting held by Executive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Time-Based Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the date of termination or (ii) the effective date of the Separation Agreement (as defined below) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accelerated Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the date of termination in the absence of this Agreement will</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be delayed until the effective date of the Separation Agreement and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between Executive&#8217;s date of termination and the Accelerated Vesting Date.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.1pt">Provided Executive timely elects continued coverage under COBRA, the Company shall pay the Company&#8217;s portion of Executive&#8217;s COBRA premiums, equal to the percentage of health premiums paid by the Company prior to Executive&#8217;s termination, to continue Executive&#8217;s coverage (including coverage for eligible dependents, if applicable) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COC COBRA Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) through the period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COC COBRA Premium Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) starting on Executive&#8217;s date of termination and ending on the earliest to occur of&#58; (i) the twelve (12) month anniversary of Executive&#8217;s date of termination&#59;</font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) the date Executive becomes eligible for group health insurance coverage through a new employer&#59; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer&#8217;s group health plan or otherwise ceases to be eligible for COBRA during the COC COBRA Premium Period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COC COBRA Premiums without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including premiums for Executive and Executive&#8217;s eligible dependents who have elected and remain enrolled in such COBRA coverage), subject to applicable tax withholdings (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COC Special Cash Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the remainder of the COC COBRA Premium Period. Executive may, but is not obligated to, use such COC Special Cash Payments toward the cost of COBRA premiums.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.43pt">The amounts payable under this Section 5.3, to the extent taxable, shall be paid or commence to be paid within 60 days after the date of termination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.74pt">Additional Limitation.</font></div><div style="margin-top:11.6pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.42pt">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Aggregate Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which Executive</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">becomes subject to the excise tax imposed by Section 4999 of the Code&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such reduction shall only occur if it would result in Executive receiving a higher After Tax Amount (as defined below) than Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code&#58; (1) cash payments not subject to Section 409A of the Code&#59; (2) cash payments subject to Section 409A of the Code&#59; (3) equity-based payments and acceleration&#59; and (4) non-cash forms of benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that in the case of all the foregoing Aggregate Payments, all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&#38;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&#38;A-24(b) or (c).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.75pt">For purposes of this Section 5.3(iv), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">After Tax Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on Executive as a result of Executive&#8217;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.1pt">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 5.3(iv)(a) shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall provide detailed supporting calculations both to the Company and Executive within 15 business days of the date of termination, if applicable, or at such earlier time as is reasonably requested by the Company or Executive. Any determination by the Accounting Firm shall be binding upon the Company and Executive.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:113.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.05pt">Termination for Cause&#59; Resignation without Good Reason&#59; Death</font></div><div style="margin-top:0.1pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">or Disability.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:149.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.74pt">The Company may terminate Executive&#8217;s employment with</font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">the Company at any time for Cause. Further, Executive may resign at any time for any reason other than Good Reason. Executive&#8217;s employment with the Company may also be terminated due to Executive&#8217;s death or Disability (as defined below).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15.76pt">If Executive resigns without Good Reason, or the Company terminates Executive&#8217;s employment for Cause, or upon Executive&#8217;s death or Disability, then</font></div><div style="margin-top:0.15pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (ii) Executive will not be entitled to any severance benefits, including (without limitation) the Severance, COBRA Premiums, the Change of Control Severance or the COC COBRA Premiums.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.4pt">Conditions to Receipt of Severance, COBRA Premiums, Special Cash Payments and Vesting Acceleration. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The receipt of the payments and benefits described in Section 5.2 and Section 5.3 will be subject to subject to (i) Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities and, in the Company&#8217;s sole discretion, a one-year post-employment noncompetition agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Separation Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the date of termination (or such shorter period as set forth in the Separation Agreement), which shall include a seven business day revocation period. No amounts will be paid or provided under Section 5.2 or Section</font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3 until the Separation Agreement becomes effective. Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of Executive&#8217;s employment for any reason. Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Section 409A.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.4pt">Anything in this Agreement to the contrary notwithstanding, if at the time of Executive&#8217;s separation from service within the meaning of Section 409A of the Code, the Company determines that Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Executive becomes entitled to under this Agreement or otherwise on account of Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after Executive&#8217;s separation from service, or (B) Executive&#8217;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six- month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.4pt">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.4pt">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Executive&#8217;s termination of</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment, then such payments or benefits shall be payable only upon Executive&#8217;s &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.4pt">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.4pt">The Company makes no representation or warranty and shall have no liability to Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Definitions.</font></div><div style="margin-top:11.65pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for termination will mean&#58; (a) conviction of or please of guilty or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any felony or any crime involving dishonesty&#59; (b) participation in any fraud against the Company&#59; (c) material breach of any Company&#8217;s policy or procedure after written notice from the Company and a reasonable period of not less than twenty-one (21) calendar days in which to cure such breach (if curable)&#59; (d) persistent failure or refusal to perform Executive&#8217;s job duties after written notice from the Company and a reasonable period of not less than twenty-one (21) calendar days in which to cure such performance issues (if curable)&#59; (e) intentional damage to any property of the Company&#59; (f) willful misconduct that causes harm&#59; (g) breach of any written agreement by and between Executive and the Company after written notice from the Company and a reasonable period of not less than twenty-one (21) calendar days in which to cure such breach (if curable)&#59; and (h) conduct by Executive which in the good faith and reasonable determination of the Company demonstrates gross unfitness (i.e., equivalent to gross negligence) to serve.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:15.4pt">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#8221; shall mean&#58; a &#8220;Sale Event,&#8221; as defined in the Company&#8217;s 2020 Stock Option and Incentive Plan.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Executive&#8217;s physical or mental condition that renders Executive unable to substantially perform for a period of ninety (90) aggregate days (regardless of whether or not continuous) during any three hundred sixty (360) day period, Executive&#8217;s regular responsibilities hereunder, with or without a reasonable accommodation.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean&#58; (a) a material reduction in Executive&#8217;s Base Salary (unless pursuant to a salary reduction applicable generally to the Company&#8217;s similarly situated employees)&#59; (b) the relocation of Executive&#8217;s place of work for the Company that is more than 40 miles from Executive&#8217;s primary place of work, unless mutually agreed upon&#59; or (c) a material diminution in Executive&#8217;s responsibilities, authority, or duties. Notwithstanding the foregoing, no act or omission described in subclauses (a), (b) or (c) above shall constitute &#8220;Good Reason&#8221; unless&#58; (1) Executive first gives the Company written notice of such act or omission within forty-five (45) days of the later of the occurrence of such act or omission or Executive&#8217;s first becoming aware thereof, (2) the Company fails to cure such act or omission within twenty-one (21) days after receiving such written notice from Executive, and (3) Executive resigns from employment (and all other positions, including as a member of the Board) within ten (10) days after the end of the cure period.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.05pt">Other Obligations.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Restrictive Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with Executive&#8217;s employment with the Company, Executive will continue to receive access to Company confidential information and trade secrets and develop valuable goodwill with the Company&#8217;s customers, partners and vendors. To protect the Company&#8217;s legitimate business interests, Executive will execute the Praxis Confidentiality, Assignment, Noncompetition and Nonsolicitation Agreement in conjunction with this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidentiality and Noncompetition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Executive acknowledges and agrees that (i) the Confidentiality and Noncompetition Agreement shall continue in full force and effect in accordance with its terms, and (ii) Executive will abide by the terms of the Confidentiality and Noncompetition Agreement at all times.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Third-Party Agreements and Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive represents and warrants that Executive&#8217;s employment by the Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Executive will perform Executive&#8217;s duties to the Company without violating any such agreement. Executive represents and warrants that Executive will not use or disclose confidential information arising out of prior employment, consulting, or other third party relationships, in connection with Executive&#8217;s employment by the Company, except as expressly authorized by that third party. During Executive&#8217;s employment by the Company, Executive will use in the performance of Executive&#8217;s duties only information which is generally known and used by persons with training and experience comparable to Executive&#8217;s own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executive&#8217;s work for the Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.05pt">Outside Activities During Employment.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.4pt">Non-Company Business. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except with the prior written consent of the Board, Executive will not during the term of Executive&#8217;s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. In any event, Executive may engage in civic</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font></div></td></tr></table></div></div></div><div id="i32e898c8b6b1411f8831d66480f5ab66_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">and not-for-profit activities so long as such activities do not materially interfere with the performance of Executive&#8217;s duties hereunder.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.4pt">No Adverse Interests. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees that during his employment he shall not acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:77.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.05pt">General Provisions.</font></div><div style="margin-top:11.65pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:9.4pt">Notices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.</font></div><div style="margin-top:11.45pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.4pt">Severability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.4pt">Waiver. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.4pt">Complete Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive embodiment of the Parties&#8217; agreement. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:9.4pt">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.</font></div><div style="margin-top:11.5pt;padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:9.4pt">Headings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.4pt">Successors and Assigns. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be binding upon and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive</font></div><div style="height:69.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:4.340%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font></div></td></tr></table></div></div></div><div id="i32e898c8b6b1411f8831d66480f5ab66_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">may not assign any of his duties hereunder and he may not assign any of his rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.4pt">Tax Withholding and Indemnification. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:15.4pt">Choice of Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the Commonwealth of Massachusetts.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:134.82pt;padding-right:134.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font></div><div style="text-align:center"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4pt;padding-left:5.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">, the Parties have executed this Agreement on the day and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:221.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Praxis Precision Medicines, Inc.</font></div><div><font><br></font></div><div style="margin-top:8.9pt;padding-left:221.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Marcio Souza&#160;&#160;&#160;&#160;</font></div><div style="padding-left:244.1pt;padding-right:72.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Name&#58; Marcio Souza Title&#58; CEO</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i32e898c8b6b1411f8831d66480f5ab66_13"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.777%"><div style="margin-top:4.8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date&#58;</font></div><div style="margin-top:5.15pt;padding-left:11.85pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.445%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.778%"><div style="padding-left:11.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 13, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> ______________________________________</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:0.95pt"><font><br></font></div></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Timothy Kelly&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Name&#58; Timothy Kelly</font></div><div style="margin-top:4.5pt;padding-left:221.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> May 13, 2021</font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.777%"><div style="margin-top:0.3pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.445%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.778%"></div></div><div style="height:69.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit231-eyconsent2022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i40ad048d4aaf46c9aa17bb8915c517b1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in the following Registration Statements&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">     </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">      </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Registration Statement and related prospectus (Form S-3 No. 333-260726) of Praxis Precision Medicines, Inc., and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Registration Statement (Form S-8 Nos. 333-263081, 333-254410, and 333-249522) pertaining to the 2020 Stock Option and Incentive Plan, 2020 Employee Stock Purchase Plan and 2017 Stock Incentive Plan, of Praxis Precision Medicines, Inc.&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">       </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">of our report dated February 7, 2023, with respect to the consolidated financial statements of Praxis Precision Medicines, Inc. included in this Annual Report (Form 10-K) of Praxis Precision Medicines, Inc. for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Boston, Massachusetts </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">February 7, 2023</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311-peo302certifica.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i31a0a6fba7fd43228ee25b446d301ebf_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Marcio Souza, certify that&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Annual Report on Form 10-K of Praxis Precision Medicines, Inc.&#59;</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.402%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#47;s&#47;&#160;&#160;MARCIO SOUZA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marcio Souza</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312-pfo302certifica.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id16e70edd6f0428f802eb9eeffdcc8da_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Timothy Kelly, certify that&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">I have reviewed this Annual Report on Form 10-K of Praxis Precision Medicines, Inc.&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:43.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.329%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; February&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; TIMOTHY KELLY&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Timothy Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321-peoandpfo906cer.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia30347836feb4222833fe8f391f84b38_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Praxis Precision Medicines, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:43.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.259%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; February&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#47;s&#47;&#160;&#160;MARCIO SOUZA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Marcio Souza</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; February&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; TIMOTHY KELLY&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Timothy Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>prax-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:912e1565-2dff-44dd-bfb3-af6c8a11fb3c,g:26ec8c83-18eb-4378-8ac1-2975735259ca-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prax="http://praxismedicines.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://praxismedicines.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prax-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prax-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prax-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prax-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://praxismedicines.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://praxismedicines.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://praxismedicines.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusiness" roleURI="http://praxismedicines.com/role/NatureoftheBusiness">
        <link:definition>0000010 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCash" roleURI="http://praxismedicines.com/role/RestrictedCash">
        <link:definition>0000012 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://praxismedicines.com/role/MarketableSecurities">
        <link:definition>0000013 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssets" roleURI="http://praxismedicines.com/role/FairValueofFinancialAssets">
        <link:definition>0000014 - Disclosure - Fair Value of Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://praxismedicines.com/role/PropertyandEquipmentNet">
        <link:definition>0000015 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://praxismedicines.com/role/AccruedExpenses">
        <link:definition>0000016 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://praxismedicines.com/role/CommitmentsandContingencies">
        <link:definition>0000017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UCBOptionandLicenseAgreement" roleURI="http://praxismedicines.com/role/UCBOptionandLicenseAgreement">
        <link:definition>0000018 - Disclosure - UCB Option and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStock" roleURI="http://praxismedicines.com/role/CommonStockandPreferredStock">
        <link:definition>0000019 - Disclosure - Common Stock and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://praxismedicines.com/role/StockBasedCompensation">
        <link:definition>0000020 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreements" roleURI="http://praxismedicines.com/role/SignificantAgreements">
        <link:definition>0000021 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://praxismedicines.com/role/NetLossperShare">
        <link:definition>0000022 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://praxismedicines.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://praxismedicines.com/role/RelatedPartyTransactions">
        <link:definition>0000024 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://praxismedicines.com/role/EmployeeBenefitPlan">
        <link:definition>0000025 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://praxismedicines.com/role/Restructuring">
        <link:definition>0000026 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://praxismedicines.com/role/SubsequentEvents">
        <link:definition>0000027 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://praxismedicines.com/role/MarketableSecuritiesTables">
        <link:definition>0000030 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsTables" roleURI="http://praxismedicines.com/role/FairValueofFinancialAssetsTables">
        <link:definition>0000031 - Disclosure - Fair Value of Financial Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://praxismedicines.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000032 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://praxismedicines.com/role/AccruedExpensesTables">
        <link:definition>0000033 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://praxismedicines.com/role/CommitmentandContingenciesTables">
        <link:definition>0000034 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockTables" roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockTables">
        <link:definition>0000035 - Disclosure - Common Stock and Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://praxismedicines.com/role/StockBasedCompensationTables">
        <link:definition>0000036 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://praxismedicines.com/role/NetLossperShareTables">
        <link:definition>0000037 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://praxismedicines.com/role/IncomeTaxesTables">
        <link:definition>0000038 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails" roleURI="http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails">
        <link:definition>0000039 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails" roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCashDetails" roleURI="http://praxismedicines.com/role/RestrictedCashDetails">
        <link:definition>0000043 - Disclosure - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesInvestmentProfileDetails" roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails">
        <link:definition>0000044 - Disclosure - Marketable Securities - Investment Profile (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesInvestmentProfileDetails_1" roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1">
        <link:definition>0000044 - Disclosure - Marketable Securities - Investment Profile (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>0000045 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000046 - Disclosure - Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://praxismedicines.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000047 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryofAccruedExpensesDetails" roleURI="http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails">
        <link:definition>0000048 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000049 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails" roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails">
        <link:definition>0000050 - Disclosure - Commitments and Contingencies - Operating Lease, Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTotalLeaseCostsDetails" roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails">
        <link:definition>0000051 - Disclosure - Commitments and Contingencies - Total Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureLeasePaymentsDetails" roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails">
        <link:definition>0000052 - Disclosure - Commitments and Contingencies - Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureLeasePaymentsDetails_1" roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1">
        <link:definition>0000052 - Disclosure - Commitments and Contingencies - Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails" roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails">
        <link:definition>0000053 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Incremental Borrowing Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UCBOptionandLicenseAgreementDetails" roleURI="http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails">
        <link:definition>0000054 - Disclosure - UCB Option and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockAdditionalInformationDetails" roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails">
        <link:definition>0000055 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails">
        <link:definition>0000056 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>0000057 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>0000058 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>0000059 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" roleURI="http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails">
        <link:definition>0000060 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>0000061 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsDetails" roleURI="http://praxismedicines.com/role/SignificantAgreementsDetails">
        <link:definition>0000062 - Disclosure - Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" roleURI="http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails">
        <link:definition>0000063 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>0000064 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>0000065 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000066 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://praxismedicines.com/role/EmployeeBenefitPlanDetails">
        <link:definition>0000067 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringDetails" roleURI="http://praxismedicines.com/role/RestructuringDetails">
        <link:definition>0000068 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://praxismedicines.com/role/SubsequentEventsDetails">
        <link:definition>0000069 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_TwentyTwentyEmployeeStockIncentivePlanMember" abstract="true" name="TwentyTwentyEmployeeStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_AccruedPersonnelRelatedExpensesCurrent" abstract="false" name="AccruedPersonnelRelatedExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_UCBMember" abstract="true" name="UCBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_OfficeFurnitureAndEquipmentMember" abstract="true" name="OfficeFurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_IonisMember" abstract="true" name="IonisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_SaleOfStockConsiderationReceivedGrossAmount" abstract="false" name="SaleOfStockConsiderationReceivedGrossAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_A2022OfferingsMember" abstract="true" name="A2022OfferingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" abstract="true" name="ScheduleOfCommonStockReservedForFutureIssuanceTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" abstract="false" name="ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" abstract="true" name="TwoThousandTwentyEmployeeStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_RogconMember" abstract="true" name="RogconMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_UnvestedRestrictedStockUnitsMember" abstract="true" name="UnvestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_SignificantAgreementsTextBlock" abstract="false" name="SignificantAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_TwentySeventeenEmployeeStockIncentivePlanMember" abstract="true" name="TwentySeventeenEmployeeStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_PercentageIncreaseInAnnualBaseRent" abstract="false" name="PercentageIncreaseInAnnualBaseRent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="prax_LicensingAgreementsProfitSharePaymentsMember" abstract="true" name="LicensingAgreementsProfitSharePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_LettersOfCreditReceivableNoncurrent" abstract="false" name="LettersOfCreditReceivableNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_LettersOfCreditReceivableCurrent" abstract="false" name="LettersOfCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_FollowOnPublicOfferingMember" abstract="true" name="FollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_JefferiesOpenMarketAgreementMember" abstract="true" name="JefferiesOpenMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_TwentyTwentyEmployeeStockPurchasePlanMember" abstract="true" name="TwentyTwentyEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" abstract="true" name="ScheduleOfCommonStockReservedForFutureIssuanceLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedExternalResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxAssetsOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>prax-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:912e1565-2dff-44dd-bfb3-af6c8a11fb3c,g:26ec8c83-18eb-4378-8ac1-2975735259ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f471d781-4a8b-4f5b-8d99-b48d5160539a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_375647a7-78fb-41b9-a4cf-7fc6cbaf3f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f471d781-4a8b-4f5b-8d99-b48d5160539a" xlink:to="loc_us-gaap_AssetsCurrent_375647a7-78fb-41b9-a4cf-7fc6cbaf3f3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe5476c4-db1c-40b7-8d64-58dbdfb6fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f471d781-4a8b-4f5b-8d99-b48d5160539a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fe5476c4-db1c-40b7-8d64-58dbdfb6fc04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcd024c1-fcb5-4507-ab78-22b1b915b6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f471d781-4a8b-4f5b-8d99-b48d5160539a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcd024c1-fcb5-4507-ab78-22b1b915b6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_44576a1b-e433-4269-9dd6-8496753aa5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f471d781-4a8b-4f5b-8d99-b48d5160539a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_44576a1b-e433-4269-9dd6-8496753aa5e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_faab5816-492e-490d-9c3f-59a524061430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42ebfa2b-140f-41dd-b975-0de281ed4dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_faab5816-492e-490d-9c3f-59a524061430" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42ebfa2b-140f-41dd-b975-0de281ed4dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3d2b8f4-875f-4fc2-ab29-ae81739c8e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_faab5816-492e-490d-9c3f-59a524061430" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3d2b8f4-875f-4fc2-ab29-ae81739c8e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6bb442b-4170-4321-83a9-2112ae7112ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_faab5816-492e-490d-9c3f-59a524061430" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6bb442b-4170-4321-83a9-2112ae7112ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e339b6c4-cd73-4ad7-8e16-542d2d5ea08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6ac0af52-498f-4c9d-8fff-07e38b273436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e339b6c4-cd73-4ad7-8e16-542d2d5ea08a" xlink:to="loc_us-gaap_Liabilities_6ac0af52-498f-4c9d-8fff-07e38b273436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03e3e52f-d1ab-437d-88f3-a806f9adb193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e339b6c4-cd73-4ad7-8e16-542d2d5ea08a" xlink:to="loc_us-gaap_StockholdersEquity_03e3e52f-d1ab-437d-88f3-a806f9adb193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f974a7b-d803-410a-8fbc-f8d99c73895f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6f12f45b-f47e-4144-9dfc-8b7b982b9cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f974a7b-d803-410a-8fbc-f8d99c73895f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6f12f45b-f47e-4144-9dfc-8b7b982b9cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d1ae70d-4d28-4368-8d06-4bb2914ed46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f974a7b-d803-410a-8fbc-f8d99c73895f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d1ae70d-4d28-4368-8d06-4bb2914ed46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1b0a9581-a0d5-4294-9257-875b77fbec53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f974a7b-d803-410a-8fbc-f8d99c73895f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1b0a9581-a0d5-4294-9257-875b77fbec53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ceacf201-f60e-4525-b495-a117dc9383da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f974a7b-d803-410a-8fbc-f8d99c73895f" xlink:to="loc_us-gaap_AccountsPayableCurrent_ceacf201-f60e-4525-b495-a117dc9383da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc7838d4-b060-4e5a-a53b-4c9bcd005b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_29ca8c42-9820-45b5-9a25-146c89587d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc7838d4-b060-4e5a-a53b-4c9bcd005b4b" xlink:to="loc_us-gaap_CommonStockValue_29ca8c42-9820-45b5-9a25-146c89587d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a78d33b1-3c46-49a5-a871-063e4cb43e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc7838d4-b060-4e5a-a53b-4c9bcd005b4b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a78d33b1-3c46-49a5-a871-063e4cb43e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3653aa8a-b211-4e38-b48f-50abf8b889ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc7838d4-b060-4e5a-a53b-4c9bcd005b4b" xlink:to="loc_us-gaap_PreferredStockValue_3653aa8a-b211-4e38-b48f-50abf8b889ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_30758dab-c5d2-459f-a2e0-3e2c7c452e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc7838d4-b060-4e5a-a53b-4c9bcd005b4b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_30758dab-c5d2-459f-a2e0-3e2c7c452e0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_319604e8-39ba-48ce-954d-50bf8d6c41ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dc7838d4-b060-4e5a-a53b-4c9bcd005b4b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_319604e8-39ba-48ce-954d-50bf8d6c41ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f3664612-29a7-4473-ad4f-f22a7df64b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9eecd247-2750-4a66-8839-9f05bee61f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3664612-29a7-4473-ad4f-f22a7df64b8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9eecd247-2750-4a66-8839-9f05bee61f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_deee1ec0-ef4b-44b3-84b1-d52bbfadb337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3664612-29a7-4473-ad4f-f22a7df64b8b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_deee1ec0-ef4b-44b3-84b1-d52bbfadb337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_93e75e35-216d-4b68-b42b-216916473a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f3664612-29a7-4473-ad4f-f22a7df64b8b" xlink:to="loc_us-gaap_LiabilitiesCurrent_93e75e35-216d-4b68-b42b-216916473a28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d50aeb7f-ee45-4212-a472-f6259e5ba555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_17849c85-79ed-42e8-91d5-88cd8b71f0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d50aeb7f-ee45-4212-a472-f6259e5ba555" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_17849c85-79ed-42e8-91d5-88cd8b71f0a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5a6fe6ba-9189-4b67-b9ea-7f8addd498fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d50aeb7f-ee45-4212-a472-f6259e5ba555" xlink:to="loc_us-gaap_OperatingIncomeLoss_5a6fe6ba-9189-4b67-b9ea-7f8addd498fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_57b625bd-66d6-49b8-97e5-e1c7476ba7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a4ef2c58-8970-41a7-b36e-ce010b5780dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_57b625bd-66d6-49b8-97e5-e1c7476ba7e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a4ef2c58-8970-41a7-b36e-ce010b5780dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8ed20126-147b-492c-9c92-d46237dad62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_57b625bd-66d6-49b8-97e5-e1c7476ba7e9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8ed20126-147b-492c-9c92-d46237dad62b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0060a65b-df44-4814-8038-9b53a6e8f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c846b19a-79eb-4cb8-a7e3-67761d2b805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0060a65b-df44-4814-8038-9b53a6e8f3eb" xlink:to="loc_us-gaap_OperatingExpenses_c846b19a-79eb-4cb8-a7e3-67761d2b805a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4e089a33-4790-46ba-b77a-e20c8e8ba277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_63a4e3af-c62f-4201-8277-58337c5b58d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4e089a33-4790-46ba-b77a-e20c8e8ba277" xlink:to="loc_us-gaap_InterestIncomeOther_63a4e3af-c62f-4201-8277-58337c5b58d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccc394b7-2d46-412e-9fc9-1c9a14e5a146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_31d323bc-1692-42dc-b7bf-b2bae721c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccc394b7-2d46-412e-9fc9-1c9a14e5a146" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_31d323bc-1692-42dc-b7bf-b2bae721c0c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0651a74d-8e7b-4609-9ec2-c556b3bd15a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccc394b7-2d46-412e-9fc9-1c9a14e5a146" xlink:to="loc_us-gaap_NetIncomeLoss_0651a74d-8e7b-4609-9ec2-c556b3bd15a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107109ca-0dcb-4e46-8781-01dd1a022e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107109ca-0dcb-4e46-8781-01dd1a022e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_46e2627e-4c94-4bf8-a00d-8ad9ce7e6239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_46e2627e-4c94-4bf8-a00d-8ad9ce7e6239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ebd54080-2984-4341-b487-34f857bc3aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ebd54080-2984-4341-b487-34f857bc3aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ba8e3b88-3595-4000-b39d-d6823a018fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_Depreciation_ba8e3b88-3595-4000-b39d-d6823a018fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d84ba768-1321-410f-a32c-ba383d8064f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d84ba768-1321-410f-a32c-ba383d8064f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bd43c43f-53ef-45b6-807b-5bffb5fe2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bd43c43f-53ef-45b6-807b-5bffb5fe2d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_IncreaseDecreaseInOperatingLeaseLiabilities_502c9f04-af01-4963-b424-9bb3b0e319f1" xlink:href="prax-20221231.xsd#prax_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_prax_IncreaseDecreaseInOperatingLeaseLiabilities_502c9f04-af01-4963-b424-9bb3b0e319f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_c965c5f5-a894-4822-ac84-163bcb353624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_c965c5f5-a894-4822-ac84-163bcb353624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fb9d0429-841c-45e1-9a64-f52243590bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fb9d0429-841c-45e1-9a64-f52243590bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_53af2972-643c-4d8c-9389-7c7c7865bf45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_ShareBasedCompensation_53af2972-643c-4d8c-9389-7c7c7865bf45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_910700f7-3007-4153-99a7-1f65b890b511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a5994d-63d6-462c-ae28-fd9698814a7f" xlink:to="loc_us-gaap_NetIncomeLoss_910700f7-3007-4153-99a7-1f65b890b511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b01a8267-2e5c-418a-a9d5-42a69c44ec10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d568153-a699-4968-a5ed-3d43b8d5ca80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b01a8267-2e5c-418a-a9d5-42a69c44ec10" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d568153-a699-4968-a5ed-3d43b8d5ca80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2a034140-44b3-452b-95e3-960e40ff2cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b01a8267-2e5c-418a-a9d5-42a69c44ec10" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2a034140-44b3-452b-95e3-960e40ff2cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_06f99c60-eb5f-4bf5-b6c6-a0392c79df28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b01a8267-2e5c-418a-a9d5-42a69c44ec10" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_06f99c60-eb5f-4bf5-b6c6-a0392c79df28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbb5946-eb3c-48bb-ab57-f37b1aee7176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a878ad86-dad5-4899-9df8-0e64da305ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbb5946-eb3c-48bb-ab57-f37b1aee7176" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a878ad86-dad5-4899-9df8-0e64da305ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9ed7503d-6944-4cdf-9c36-5a9c60691ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbb5946-eb3c-48bb-ab57-f37b1aee7176" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9ed7503d-6944-4cdf-9c36-5a9c60691ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_4620fa26-9ecb-4d63-ab74-71c22c5c50e0" xlink:href="prax-20221231.xsd#prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbb5946-eb3c-48bb-ab57-f37b1aee7176" xlink:to="loc_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_4620fa26-9ecb-4d63-ab74-71c22c5c50e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f8e5278d-d76c-4d31-af15-f1b76789b4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbb5946-eb3c-48bb-ab57-f37b1aee7176" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f8e5278d-d76c-4d31-af15-f1b76789b4e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ef3d5087-7456-4076-a3f7-e40d3a3d58ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbb5946-eb3c-48bb-ab57-f37b1aee7176" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ef3d5087-7456-4076-a3f7-e40d3a3d58ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2dd4d3d0-2f5a-4542-aadd-93bccaf682b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_771a00a7-0887-45e3-98ab-db7dde8feeca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2dd4d3d0-2f5a-4542-aadd-93bccaf682b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_771a00a7-0887-45e3-98ab-db7dde8feeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3a410a0-11d7-41d8-93e8-0d5a425d2c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2dd4d3d0-2f5a-4542-aadd-93bccaf682b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3a410a0-11d7-41d8-93e8-0d5a425d2c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d6bb2120-d996-4251-a1b2-e0a71850e35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2dd4d3d0-2f5a-4542-aadd-93bccaf682b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d6bb2120-d996-4251-a1b2-e0a71850e35a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8405f879-b720-44c3-9c8d-5bbea774dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_82a72159-1cf0-48e9-b578-de49333f4332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8405f879-b720-44c3-9c8d-5bbea774dfda" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_82a72159-1cf0-48e9-b578-de49333f4332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92eb81fd-ab1d-4a0c-98b5-35913dfae2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8405f879-b720-44c3-9c8d-5bbea774dfda" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92eb81fd-ab1d-4a0c-98b5-35913dfae2a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesInvestmentProfileDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a39941d1-e520-45ed-967d-bc9ca68f4647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_2f9ed34b-bd4d-4d5e-a4bb-82c970276fe8" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a39941d1-e520-45ed-967d-bc9ca68f4647" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_2f9ed34b-bd4d-4d5e-a4bb-82c970276fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_63a5230b-61b1-45fa-82b2-7c409ce29aea" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a39941d1-e520-45ed-967d-bc9ca68f4647" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_63a5230b-61b1-45fa-82b2-7c409ce29aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_efd42ad9-e824-4d03-8be2-505b183f67c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_8d0fb2c7-7ddf-4f4c-8e6e-6002ec148e59" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_efd42ad9-e824-4d03-8be2-505b183f67c5" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_8d0fb2c7-7ddf-4f4c-8e6e-6002ec148e59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7a091108-a584-4b2c-a6d3-4c414b7c94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_efd42ad9-e824-4d03-8be2-505b183f67c5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7a091108-a584-4b2c-a6d3-4c414b7c94ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_aa9a52b2-67de-44b7-9a79-23cde2c3c3d2" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_efd42ad9-e824-4d03-8be2-505b183f67c5" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_aa9a52b2-67de-44b7-9a79-23cde2c3c3d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2896b99-d223-4fb8-aaa4-66e06ea4dd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35870fa5-eebf-4e21-8928-3880257aca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2896b99-d223-4fb8-aaa4-66e06ea4dd08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35870fa5-eebf-4e21-8928-3880257aca8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5e0fa009-7e3f-4ff6-b89c-5e608a1b24e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2896b99-d223-4fb8-aaa4-66e06ea4dd08" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5e0fa009-7e3f-4ff6-b89c-5e608a1b24e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e987f8d-6805-44ef-98ca-052e5f05b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2896b99-d223-4fb8-aaa4-66e06ea4dd08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e987f8d-6805-44ef-98ca-052e5f05b88c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc3d8a2b-6832-4cf0-9eea-4a5d7f7cb239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b549c39f-5bc4-4cff-a7c9-e2f1bcfc739e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc3d8a2b-6832-4cf0-9eea-4a5d7f7cb239" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b549c39f-5bc4-4cff-a7c9-e2f1bcfc739e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fbdde41e-9657-4955-96a2-ac3e6633ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc3d8a2b-6832-4cf0-9eea-4a5d7f7cb239" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fbdde41e-9657-4955-96a2-ac3e6633ce7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_dd70906b-fc40-4862-99e3-ea78f09baf21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7ad8fdb8-c3bf-4766-8bc3-483cc61d13bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_dd70906b-fc40-4862-99e3-ea78f09baf21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7ad8fdb8-c3bf-4766-8bc3-483cc61d13bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_369855f0-468e-48ad-a53a-35206b56d1df" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_dd70906b-fc40-4862-99e3-ea78f09baf21" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_369855f0-468e-48ad-a53a-35206b56d1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_b3fd3fc1-5957-48cd-8b01-b118f1835f35" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_dd70906b-fc40-4862-99e3-ea78f09baf21" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_b3fd3fc1-5957-48cd-8b01-b118f1835f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_433151a6-bbad-430e-a7b3-42d80ede88f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_b0992905-5db7-46cf-9d00-595986dc696b" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_433151a6-bbad-430e-a7b3-42d80ede88f2" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_b0992905-5db7-46cf-9d00-595986dc696b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_fd770fff-e3a6-40d3-9707-b9db3685500e" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_433151a6-bbad-430e-a7b3-42d80ede88f2" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_fd770fff-e3a6-40d3-9707-b9db3685500e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesInvestmentProfileDetails_1"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1c05f159-0f16-42e6-8015-6941bace82b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d302812a-e864-4a42-a28b-6fadc6bdbb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1c05f159-0f16-42e6-8015-6941bace82b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d302812a-e864-4a42-a28b-6fadc6bdbb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_93be6ca5-d4a2-4a6d-9235-ae418c727a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1c05f159-0f16-42e6-8015-6941bace82b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_93be6ca5-d4a2-4a6d-9235-ae418c727a2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7a508efb-3385-4078-8aa0-c4518fae698a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_80f58a59-4810-4bc3-ab32-4822e35c67b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7a508efb-3385-4078-8aa0-c4518fae698a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_80f58a59-4810-4bc3-ab32-4822e35c67b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_94b04ff2-d1af-425b-94c8-efbd4ae044f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7a508efb-3385-4078-8aa0-c4518fae698a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_94b04ff2-d1af-425b-94c8-efbd4ae044f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1121972f-705f-4ca6-a810-4990000a6136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6e6ff9db-5e8f-4afe-8f50-004242edf4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1121972f-705f-4ca6-a810-4990000a6136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6e6ff9db-5e8f-4afe-8f50-004242edf4e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9e0bea85-1ef5-4d58-aeec-d28b35655db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1121972f-705f-4ca6-a810-4990000a6136" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9e0bea85-1ef5-4d58-aeec-d28b35655db3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e01f412f-c287-43f7-91c1-7a2823fed973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_b29ba51a-b85e-4262-b70b-8a8506a49ab6" xlink:href="prax-20221231.xsd#prax_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e01f412f-c287-43f7-91c1-7a2823fed973" xlink:to="loc_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_b29ba51a-b85e-4262-b70b-8a8506a49ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AccruedPersonnelRelatedExpensesCurrent_16ce6c28-a226-45a4-a12b-024e6e267b5d" xlink:href="prax-20221231.xsd#prax_AccruedPersonnelRelatedExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e01f412f-c287-43f7-91c1-7a2823fed973" xlink:to="loc_prax_AccruedPersonnelRelatedExpensesCurrent_16ce6c28-a226-45a4-a12b-024e6e267b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_98d636ae-579b-40ad-82cc-eeba106dc332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e01f412f-c287-43f7-91c1-7a2823fed973" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_98d636ae-579b-40ad-82cc-eeba106dc332" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_83eb90cc-9a69-470b-9ccd-063df73d2a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01ce49df-89fb-487d-864f-08c0062d50b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_83eb90cc-9a69-470b-9ccd-063df73d2a50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01ce49df-89fb-487d-864f-08c0062d50b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83912b1d-3a50-4f53-9e3d-fc0e1a378446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_83eb90cc-9a69-470b-9ccd-063df73d2a50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83912b1d-3a50-4f53-9e3d-fc0e1a378446" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesTotalLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_593e7713-0a62-4f99-947f-5bc6b8ea9a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ded56417-f0ee-4f2a-93e9-05fd9bf389f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_593e7713-0a62-4f99-947f-5bc6b8ea9a94" xlink:to="loc_us-gaap_VariableLeaseCost_ded56417-f0ee-4f2a-93e9-05fd9bf389f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_428af18e-6564-4e3e-b94f-7062f3e17856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_593e7713-0a62-4f99-947f-5bc6b8ea9a94" xlink:to="loc_us-gaap_OperatingLeaseCost_428af18e-6564-4e3e-b94f-7062f3e17856" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesFutureLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61c78fb3-edc1-4872-acec-32424dfc4834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c12f7bbe-7255-4ea4-a64f-9a67c6637ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61c78fb3-edc1-4872-acec-32424dfc4834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c12f7bbe-7255-4ea4-a64f-9a67c6637ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1291c2b7-056e-4b8c-b423-4b3f4a54c519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61c78fb3-edc1-4872-acec-32424dfc4834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1291c2b7-056e-4b8c-b423-4b3f4a54c519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7562e399-be38-4384-ab41-94982d121dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61c78fb3-edc1-4872-acec-32424dfc4834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7562e399-be38-4384-ab41-94982d121dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_165aa4b7-2c51-4108-9450-53beb5947cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61c78fb3-edc1-4872-acec-32424dfc4834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_165aa4b7-2c51-4108-9450-53beb5947cfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesFutureLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10a1d0e5-3f58-457b-b7d6-c614738a6dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1656975f-0638-4a9c-93c7-716c6a1a037f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10a1d0e5-3f58-457b-b7d6-c614738a6dc0" xlink:to="loc_us-gaap_OperatingLeaseLiability_1656975f-0638-4a9c-93c7-716c6a1a037f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bacc5ee1-df43-4d9c-9820-476146d0fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10a1d0e5-3f58-457b-b7d6-c614738a6dc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bacc5ee1-df43-4d9c-9820-476146d0fda6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7704b2c0-04a5-43cd-a823-97e6d414e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7704b2c0-04a5-43cd-a823-97e6d414e8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_be24a32a-5075-49dd-a26f-2cc1b1d46460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_be24a32a-5075-49dd-a26f-2cc1b1d46460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fe25fa0b-0f6e-493f-8638-4c971abef3de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fe25fa0b-0f6e-493f-8638-4c971abef3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_5ebd81ce-4ca2-4e42-9962-5a68b3e6e981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_5ebd81ce-4ca2-4e42-9962-5a68b3e6e981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_80aaaf2d-eb42-4d0e-b697-2049c0d6e84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_80aaaf2d-eb42-4d0e-b697-2049c0d6e84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_38f50357-2ba6-4bfb-8cd9-fe49af3fa91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_38f50357-2ba6-4bfb-8cd9-fe49af3fa91c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_4f7edd3a-196f-4c04-8652-3f6b1f7bf675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_533e05a6-f667-41dd-835e-ce402a55fa0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_4f7edd3a-196f-4c04-8652-3f6b1f7bf675" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesNetDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_40c6e341-61e9-40a9-9a57-bda5a53c87fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fe971436-ac4a-4c48-bc47-83ebc46a1f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_40c6e341-61e9-40a9-9a57-bda5a53c87fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fe971436-ac4a-4c48-bc47-83ebc46a1f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2898c953-0dae-4658-a5a4-e14440301c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_40c6e341-61e9-40a9-9a57-bda5a53c87fb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2898c953-0dae-4658-a5a4-e14440301c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5efbd5f4-f7be-4bac-ab2c-152ea3c46591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_fd1ddb6b-952b-44b5-90e9-4ea954499922" xlink:href="prax-20221231.xsd#prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5efbd5f4-f7be-4bac-ab2c-152ea3c46591" xlink:to="loc_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_fd1ddb6b-952b-44b5-90e9-4ea954499922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6692c657-0e65-41e7-861a-ff0c35a54ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a5d57803-5130-43f3-afd2-0dc3b12bb58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6692c657-0e65-41e7-861a-ff0c35a54ff8" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a5d57803-5130-43f3-afd2-0dc3b12bb58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_88ab7d3c-19f6-463d-93e6-720cf4900951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6692c657-0e65-41e7-861a-ff0c35a54ff8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_88ab7d3c-19f6-463d-93e6-720cf4900951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_174b6ccd-e740-46b1-a863-4a04eaa36858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_174b6ccd-e740-46b1-a863-4a04eaa36858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_942b15ef-f259-4564-af6a-7052770cfe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_942b15ef-f259-4564-af6a-7052770cfe8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_b2ffe470-c9aa-4b95-bc47-919accc5bc0d" xlink:href="prax-20221231.xsd#prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_b2ffe470-c9aa-4b95-bc47-919accc5bc0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2ad2b009-05e6-4f82-8753-d8dd9e9bff3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2ad2b009-05e6-4f82-8753-d8dd9e9bff3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_15460590-6b60-4c5a-944e-9add90ce8e8e" xlink:href="prax-20221231.xsd#prax_DeferredTaxAssetsTaxDeferredExpenseAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_15460590-6b60-4c5a-944e-9add90ce8e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_96572fbe-e114-4c80-a733-04f339e7da24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_96572fbe-e114-4c80-a733-04f339e7da24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_5f3dfa0a-bf3e-47ef-8fc7-5fc3a442b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a30d89bb-32e9-4264-afa7-74b192b28731" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_5f3dfa0a-bf3e-47ef-8fc7-5fc3a442b55b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>prax-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:912e1565-2dff-44dd-bfb3-af6c8a11fb3c,g:26ec8c83-18eb-4378-8ac1-2975735259ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2011fa3855b94af6b1d913f2e7101022_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e4200c40-aec6-4e45-9ae7-bb7946411a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e4200c40-aec6-4e45-9ae7-bb7946411a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0452eaae-54da-487a-80dc-c2bc1ca236ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0452eaae-54da-487a-80dc-c2bc1ca236ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b95160c5-54dc-4a7a-a7d0-5eb0d7de053d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockholdersEquity_b95160c5-54dc-4a7a-a7d0-5eb0d7de053d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afa470b8-0aaa-4844-a26c-6520343583df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afa470b8-0aaa-4844-a26c-6520343583df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f9c93bfa-239f-4618-a50b-6564bcd81870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f9c93bfa-239f-4618-a50b-6564bcd81870" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f80c2b4b-5c6d-46bc-98df-4e442305ee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f80c2b4b-5c6d-46bc-98df-4e442305ee7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3ceb022-274c-4806-88c1-7f5a01eedc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3ceb022-274c-4806-88c1-7f5a01eedc6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f074d392-7429-49d4-bf36-8e70c609f300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f074d392-7429-49d4-bf36-8e70c609f300" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c27e972d-0247-4e30-97ee-3fd491c2e082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c27e972d-0247-4e30-97ee-3fd491c2e082" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4f3c3281-1da8-4020-9c3c-cf3ca976c28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4f3c3281-1da8-4020-9c3c-cf3ca976c28c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d74bfca0-3a96-4fbf-a0d5-6edde074114a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d74bfca0-3a96-4fbf-a0d5-6edde074114a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec452523-b84c-4740-b134-3e64074aae30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec452523-b84c-4740-b134-3e64074aae30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8c225f90-2646-4042-bfcd-df348a4585c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8c225f90-2646-4042-bfcd-df348a4585c0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4ec3ed57-b82e-4ef4-b0c2-fe81d8ae9672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4ec3ed57-b82e-4ef4-b0c2-fe81d8ae9672" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2c131c8-abd7-4bdf-a8cd-2d45f3cd1d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_NetIncomeLoss_b2c131c8-abd7-4bdf-a8cd-2d45f3cd1d0d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_be32c033-dcb5-4e5f-b319-8e24048770dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b7641c2-da50-4212-b661-b067bd7943f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e4200c40-aec6-4e45-9ae7-bb7946411a5b" xlink:to="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_776bd731-39d4-4066-a575-7f17dfaf42d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:to="loc_us-gaap_EquityComponentDomain_776bd731-39d4-4066-a575-7f17dfaf42d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:to="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_390afb3e-687a-4f50-aae3-17710ba36f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_CommonStockMember_390afb3e-687a-4f50-aae3-17710ba36f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_efff00ed-0581-4b3a-942d-eccda3c6a1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_efff00ed-0581-4b3a-942d-eccda3c6a1cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0f00cf46-43ab-4fbc-baca-eabd573127e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_RetainedEarningsMember_0f00cf46-43ab-4fbc-baca-eabd573127e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1865bc06-db96-4c29-805d-338ff959693b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1865bc06-db96-4c29-805d-338ff959693b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i4044d749ee5b42fe97ac058e03345836_ConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9071f9d1-f6a2-4689-a092-acc13836d729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_270236d9-77fb-40b9-ae13-3d123d8ee030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9071f9d1-f6a2-4689-a092-acc13836d729" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_270236d9-77fb-40b9-ae13-3d123d8ee030" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9071f9d1-f6a2-4689-a092-acc13836d729" xlink:to="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c193e87-dbc0-48a8-8691-688f5e84abc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2c193e87-dbc0-48a8-8691-688f5e84abc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_787c685d-47f2-459c-9f7b-3e11e00fa8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_787c685d-47f2-459c-9f7b-3e11e00fa8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_A2022OfferingsMember_7bb2d3af-ed8f-4926-b804-4751e661adcb" xlink:href="prax-20221231.xsd#prax_A2022OfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_787c685d-47f2-459c-9f7b-3e11e00fa8bf" xlink:to="loc_prax_A2022OfferingsMember_7bb2d3af-ed8f-4926-b804-4751e661adcb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i91e601a575a84d84a482d16e4e5dc63b_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ce630b5c-f951-4962-9c61-b52e5a28ef31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ce630b5c-f951-4962-9c61-b52e5a28ef31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsStock_368e0c1a-4a18-4e61-a4d2-5e9ea5f11647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_DividendsStock_368e0c1a-4a18-4e61-a4d2-5e9ea5f11647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_6f90c534-d77a-4471-99d9-68a453bedbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_6f90c534-d77a-4471-99d9-68a453bedbed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c32ae88-4e81-4bbf-af41-9b4580842f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c32ae88-4e81-4bbf-af41-9b4580842f48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_06bf870f-0b6d-49ed-a640-761d382d9f8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:to="loc_us-gaap_EquityComponentDomain_06bf870f-0b6d-49ed-a640-761d382d9f8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5abc097a-e7a9-4534-b368-4fa189550624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:to="loc_us-gaap_EquityComponentDomain_5abc097a-e7a9-4534-b368-4fa189550624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07cd7eae-2f18-4f21-a624-685b395f3d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5abc097a-e7a9-4534-b368-4fa189550624" xlink:to="loc_us-gaap_CommonStockMember_07cd7eae-2f18-4f21-a624-685b395f3d5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails" xlink:type="extended" id="i9933ab59ebee4a048d603b48ff46ccce_SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b217e23-0817-4e41-8f4b-ba6fd4519c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9e8e8b1b-276a-4f19-a902-141f2357f40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b217e23-0817-4e41-8f4b-ba6fd4519c57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9e8e8b1b-276a-4f19-a902-141f2357f40a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b217e23-0817-4e41-8f4b-ba6fd4519c57" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1510a09-dabe-4f38-9619-d3831292d758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1510a09-dabe-4f38-9619-d3831292d758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_OfficeFurnitureAndEquipmentMember_6f93a469-5d6c-4ea4-b0d9-bd99d80017d6" xlink:href="prax-20221231.xsd#prax_OfficeFurnitureAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:to="loc_prax_OfficeFurnitureAndEquipmentMember_6f93a469-5d6c-4ea4-b0d9-bd99d80017d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LaboratoryEquipmentMember_09c26a91-26fb-495e-96c6-233254bf5025" xlink:href="prax-20221231.xsd#prax_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:to="loc_prax_LaboratoryEquipmentMember_09c26a91-26fb-495e-96c6-233254bf5025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_09bf409a-9b34-48bd-8345-c6cbccd859be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:to="loc_us-gaap_ComputerEquipmentMember_09bf409a-9b34-48bd-8345-c6cbccd859be" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesInvestmentProfileDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" xlink:type="extended" id="i2eb95741580d44bd8162f24971679a9d_MarketableSecuritiesInvestmentProfileDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_63fdced1-e40d-443a-bfb5-27f163bd7242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_63fdced1-e40d-443a-bfb5-27f163bd7242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_2358e491-17f7-4954-ab82-5f0799c2b8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_2358e491-17f7-4954-ab82-5f0799c2b8c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_99455da6-9ead-437d-90fa-a76b97d44211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_99455da6-9ead-437d-90fa-a76b97d44211" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_571e367e-5302-40ae-adb4-29ec06552142" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_571e367e-5302-40ae-adb4-29ec06552142" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_ab2e501b-3100-48a9-a5ff-b061d8d5444a" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_ab2e501b-3100-48a9-a5ff-b061d8d5444a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec56d603-e602-4f4f-8de5-bff1816c8693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec56d603-e602-4f4f-8de5-bff1816c8693" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_26cd2916-5ca8-4689-bc4b-d72ab87de98b" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_26cd2916-5ca8-4689-bc4b-d72ab87de98b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_84a92996-1b79-4d86-880a-9da6ffe9d72b" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_84a92996-1b79-4d86-880a-9da6ffe9d72b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac969817-7d40-4cdf-a0e9-28a3e1877f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac969817-7d40-4cdf-a0e9-28a3e1877f42" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1eb55552-66a3-46da-9cd3-e9dcaee8d0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1eb55552-66a3-46da-9cd3-e9dcaee8d0bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8c1e6231-2cf4-41c8-b156-7fc9160b1835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8c1e6231-2cf4-41c8-b156-7fc9160b1835" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7699179b-a079-44cd-8f7e-69c1ba98c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7699179b-a079-44cd-8f7e-69c1ba98c5c9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b913f10-ebb3-4ec4-9776-338050184412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b913f10-ebb3-4ec4-9776-338050184412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cd40fff2-807c-4ec4-ad68-6b6eb06346ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cd40fff2-807c-4ec4-ad68-6b6eb06346ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_eaae23d6-91a6-4552-a6c0-dadbc393d58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_CommercialPaperMember_eaae23d6-91a6-4552-a6c0-dadbc393d58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_72ff152a-e098-483a-9f10-ededb8f06af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_72ff152a-e098-483a-9f10-ededb8f06af8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_86bc6a71-ba6c-421d-8186-3f67a5ccb3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_86bc6a71-ba6c-421d-8186-3f67a5ccb3d4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i4ecd575bc47941e0b7fed7ee6a47c2c5_FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4c3091f1-1f7e-4f95-bab7-67b7d34fbc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4c3091f1-1f7e-4f95-bab7-67b7d34fbc01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6d3de7f1-6988-4f6e-9f13-9711b19eaf51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6d3de7f1-6988-4f6e-9f13-9711b19eaf51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_667878a6-44ad-4669-9b2e-6113e3f98d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_667878a6-44ad-4669-9b2e-6113e3f98d22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fb9f6930-9cb6-4987-a8c8-80dd30c5f659_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fb9f6930-9cb6-4987-a8c8-80dd30c5f659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_731282d3-1d70-4810-a399-3d391154734f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_MoneyMarketFundsMember_731282d3-1d70-4810-a399-3d391154734f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_04771a60-ee15-43ea-9972-7f02db47b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_04771a60-ee15-43ea-9972-7f02db47b46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f58e570c-1b5c-4fc4-8473-ce81a3161297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_CommercialPaperMember_f58e570c-1b5c-4fc4-8473-ce81a3161297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9ec0a567-738f-462d-ad39-c40e9146ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9ec0a567-738f-462d-ad39-c40e9146ee5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_b1ab13c1-86aa-4478-857c-084ec5426c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_b1ab13c1-86aa-4478-857c-084ec5426c3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c59811b9-7e72-4453-a0e9-e1584c31db7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c59811b9-7e72-4453-a0e9-e1584c31db7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2643e0c4-74df-44b4-aa83-234a9596bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2643e0c4-74df-44b4-aa83-234a9596bcb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7ae22c64-fa37-43bf-b220-b2050a89e787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7ae22c64-fa37-43bf-b220-b2050a89e787" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c56f6f3-b3bc-4c07-ab25-38934184efe7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c56f6f3-b3bc-4c07-ab25-38934184efe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_86f30183-b174-43cc-b480-6a0f13efd580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_86f30183-b174-43cc-b480-6a0f13efd580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bc6a4b7f-5164-4a09-af36-951740791839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_86f30183-b174-43cc-b480-6a0f13efd580" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bc6a4b7f-5164-4a09-af36-951740791839" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i0c470e66e2bd48eb9cd1c64eeca0e8fb_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4916fc99-0929-445d-b1cc-a6ed535732a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4916fc99-0929-445d-b1cc-a6ed535732a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_278907df-b13f-43dd-988c-5059cbc6d975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_278907df-b13f-43dd-988c-5059cbc6d975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bec8d77c-54a4-4d20-b439-38dfcb4eb7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bec8d77c-54a4-4d20-b439-38dfcb4eb7a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_856f67f8-0002-4c3c-bf0a-1a973881f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_Depreciation_856f67f8-0002-4c3c-bf0a-1a973881f95e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddb86899-0c6b-46a6-b10b-67887cbc1a73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ddb86899-0c6b-46a6-b10b-67887cbc1a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0dddfa57-3e02-44df-ac7c-6a5102ba627a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:to="loc_us-gaap_ComputerEquipmentMember_0dddfa57-3e02-44df-ac7c-6a5102ba627a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_OfficeFurnitureAndEquipmentMember_28fa87cb-186e-4539-97db-850c65457ec9" xlink:href="prax-20221231.xsd#prax_OfficeFurnitureAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:to="loc_prax_OfficeFurnitureAndEquipmentMember_28fa87cb-186e-4539-97db-850c65457ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LaboratoryEquipmentMember_3d1aa0c9-84fb-4713-87b9-431bc38b7f04" xlink:href="prax-20221231.xsd#prax_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:to="loc_prax_LaboratoryEquipmentMember_3d1aa0c9-84fb-4713-87b9-431bc38b7f04" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#UCBOptionandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails" xlink:type="extended" id="i1e71361837864a4e8f5caf1200220195_UCBOptionandLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8f92ac63-92c4-4426-8a3b-71973e7e5f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8f92ac63-92c4-4426-8a3b-71973e7e5f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_5f4b9ee2-eae1-4d94-98ce-ef594dd93cc5" xlink:href="prax-20221231.xsd#prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_5f4b9ee2-eae1-4d94-98ce-ef594dd93cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_df87aafc-35dc-4384-9258-2e85b1f69878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_df87aafc-35dc-4384-9258-2e85b1f69878" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5788463a-2f51-4bde-a3cb-4d43903491c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5788463a-2f51-4bde-a3cb-4d43903491c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c7a87f7-b894-4f32-9f8e-4ac1b31830d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c7a87f7-b894-4f32-9f8e-4ac1b31830d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_UCBMember_b2278e3c-6da8-48f2-9296-9c6522bbee36" xlink:href="prax-20221231.xsd#prax_UCBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c7a87f7-b894-4f32-9f8e-4ac1b31830d7" xlink:to="loc_prax_UCBMember_b2278e3c-6da8-48f2-9296-9c6522bbee36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:to="loc_srt_ProductsAndServicesDomain_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_861dd514-d2e3-43d9-837a-e55185db37a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:to="loc_srt_ProductsAndServicesDomain_861dd514-d2e3-43d9-837a-e55185db37a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6c55c827-5973-4fea-b828-9c02d2443ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_861dd514-d2e3-43d9-837a-e55185db37a6" xlink:to="loc_us-gaap_LicenseMember_6c55c827-5973-4fea-b828-9c02d2443ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_828986fd-d1a1-4eb6-9849-993d32cf6047_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:to="loc_us-gaap_PlanNameDomain_828986fd-d1a1-4eb6-9849-993d32cf6047_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1395511-91d5-4938-ad2f-94701ab28fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:to="loc_us-gaap_PlanNameDomain_c1395511-91d5-4938-ad2f-94701ab28fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_cb8f0fac-7ab1-462f-8ce4-252411a2ac7d" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c1395511-91d5-4938-ad2f-94701ab28fde" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_cb8f0fac-7ab1-462f-8ce4-252411a2ac7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommonStockandPreferredStockAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" xlink:type="extended" id="ib4b491b8bd784cdab090b0d3f5c7d55c_CommonStockandPreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_640b50cd-79c7-4233-b3ff-6fa5ae5615f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_640b50cd-79c7-4233-b3ff-6fa5ae5615f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_15e439be-9228-4989-9ee6-06175458870d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_15e439be-9228-4989-9ee6-06175458870d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_SaleOfStockConsiderationReceivedGrossAmount_d57b4a74-bb36-47a1-9c00-4d229967a461" xlink:href="prax-20221231.xsd#prax_SaleOfStockConsiderationReceivedGrossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_prax_SaleOfStockConsiderationReceivedGrossAmount_d57b4a74-bb36-47a1-9c00-4d229967a461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e2a34d10-5cb2-4277-8e73-4f11eb5ee218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e2a34d10-5cb2-4277-8e73-4f11eb5ee218" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd81d686-e2d4-49df-b90c-5f78de78f748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd81d686-e2d4-49df-b90c-5f78de78f748" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7ba97c43-dbec-490e-88a3-16aa60da018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7ba97c43-dbec-490e-88a3-16aa60da018a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a76274-229d-417a-8bc8-5b0f9d310f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a76274-229d-417a-8bc8-5b0f9d310f8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_73f67b8d-5283-4f91-87e0-fa988cf1723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_TreasuryStockShares_73f67b8d-5283-4f91-87e0-fa988cf1723f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7047d573-824d-4839-a046-b8eefccc02a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7047d573-824d-4839-a046-b8eefccc02a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f988d037-291e-4856-9590-aacf6dd510bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f988d037-291e-4856-9590-aacf6dd510bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7aeb33e1-3225-4987-a48b-09206b3736ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7aeb33e1-3225-4987-a48b-09206b3736ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c25cee1a-63e2-4460-b45e-9300b10bf5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c25cee1a-63e2-4460-b45e-9300b10bf5ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ad02d059-b68f-4cda-9449-4ec437c3a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ad02d059-b68f-4cda-9449-4ec437c3a65c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ee529a6d-afd0-4493-8449-0dd96c2d52f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:to="loc_us-gaap_EquityComponentDomain_ee529a6d-afd0-4493-8449-0dd96c2d52f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0996ab74-cc41-4147-8f5a-95f64fe09334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:to="loc_us-gaap_EquityComponentDomain_0996ab74-cc41-4147-8f5a-95f64fe09334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_845a2981-3f3b-4fb6-b5c2-c84ecd5e7970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0996ab74-cc41-4147-8f5a-95f64fe09334" xlink:to="loc_us-gaap_CommonStockMember_845a2981-3f3b-4fb6-b5c2-c84ecd5e7970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11b9fa45-46d8-4387-a933-f1637d796025_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11b9fa45-46d8-4387-a933-f1637d796025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e454cae2-0ec9-46d5-bb6d-9416a82902fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e454cae2-0ec9-46d5-bb6d-9416a82902fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_FollowOnPublicOfferingMember_522090ef-dfc1-400e-bda4-87e718056955" xlink:href="prax-20221231.xsd#prax_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:to="loc_prax_FollowOnPublicOfferingMember_522090ef-dfc1-400e-bda4-87e718056955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_JefferiesOpenMarketAgreementMember_252855fb-fb7b-4b08-8bc9-323494febe97" xlink:href="prax-20221231.xsd#prax_JefferiesOpenMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:to="loc_prax_JefferiesOpenMarketAgreementMember_252855fb-fb7b-4b08-8bc9-323494febe97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7c78d918-cf54-4c6f-be63-c592ea7b3310_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:to="loc_us-gaap_PlanNameDomain_7c78d918-cf54-4c6f-be63-c592ea7b3310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f0d295f1-7eea-4ae5-ba62-255b9ef8e3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:to="loc_us-gaap_PlanNameDomain_f0d295f1-7eea-4ae5-ba62-255b9ef8e3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_157c8cf5-ca5b-498a-bf9b-28edfcee845e" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f0d295f1-7eea-4ae5-ba62-255b9ef8e3d2" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_157c8cf5-ca5b-498a-bf9b-28edfcee845e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" id="i9b6727db98b14659a2cb9eb0193d1500_CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_7ee50a59-bbad-4fb5-92d2-36c53764880f" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bf8a93c2-77d1-4dbc-bff8-08d21dbe8870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_7ee50a59-bbad-4fb5-92d2-36c53764880f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bf8a93c2-77d1-4dbc-bff8-08d21dbe8870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_7ee50a59-bbad-4fb5-92d2-36c53764880f" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:to="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d500a111-2266-4add-80df-13846fa9dac2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d500a111-2266-4add-80df-13846fa9dac2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80a9f28d-69da-4a1a-a93e-2671585bbae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80a9f28d-69da-4a1a-a93e-2671585bbae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_61b2f38e-3037-4d1e-bebe-bacae78242ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:to="loc_us-gaap_StockCompensationPlanMember_61b2f38e-3037-4d1e-bebe-bacae78242ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c08916f5-ff6a-41fd-bd64-a1e8cb68ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:to="loc_us-gaap_RestrictedStockMember_c08916f5-ff6a-41fd-bd64-a1e8cb68ab50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:to="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4eb7c18-bdbb-4378-a665-d501306c06d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:to="loc_us-gaap_PlanNameDomain_d4eb7c18-bdbb-4378-a665-d501306c06d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:to="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentyTwentyEmployeeStockIncentivePlanMember_f1787f97-7ef1-47be-bbfd-681692507536" xlink:href="prax-20221231.xsd#prax_TwentyTwentyEmployeeStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:to="loc_prax_TwentyTwentyEmployeeStockIncentivePlanMember_f1787f97-7ef1-47be-bbfd-681692507536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentyTwentyEmployeeStockPurchasePlanMember_855fc013-ae21-41c5-a3ff-25dc295db6f8" xlink:href="prax-20221231.xsd#prax_TwentyTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:to="loc_prax_TwentyTwentyEmployeeStockPurchasePlanMember_855fc013-ae21-41c5-a3ff-25dc295db6f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i6fd112df435540a893894850b0568947_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da72acef-8db8-4e31-85ad-3b642c2b71ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da72acef-8db8-4e31-85ad-3b642c2b71ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4cfc6431-e3de-4772-9673-732bd9249c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4cfc6431-e3de-4772-9673-732bd9249c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ec38fc65-4dea-4698-ad4b-a07fc874c460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ec38fc65-4dea-4698-ad4b-a07fc874c460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10b5aa0e-e9de-4cec-90ee-66e159f9532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10b5aa0e-e9de-4cec-90ee-66e159f9532e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdb3fb9-25ba-475f-ae4f-ade680987d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdb3fb9-25ba-475f-ae4f-ade680987d00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_80d7e7fb-c30a-4921-8ec2-f9897f9e9e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_80d7e7fb-c30a-4921-8ec2-f9897f9e9e4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d68e9e02-3d90-4ae0-908f-6238edecef67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d68e9e02-3d90-4ae0-908f-6238edecef67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:to="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e8b4ce65-a1c6-491b-9170-f006e50b0fae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:to="loc_us-gaap_PlanNameDomain_e8b4ce65-a1c6-491b-9170-f006e50b0fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:to="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_a56a6e4d-b247-4680-8916-61ff5472cca9" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_a56a6e4d-b247-4680-8916-61ff5472cca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentySeventeenEmployeeStockIncentivePlanMember_d7ea5cb1-04b3-4c4c-bf3e-47b864ce37a4" xlink:href="prax-20221231.xsd#prax_TwentySeventeenEmployeeStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:to="loc_prax_TwentySeventeenEmployeeStockIncentivePlanMember_d7ea5cb1-04b3-4c4c-bf3e-47b864ce37a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_2c018da4-5afc-45d0-9389-bf5d1344e3d0" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_2c018da4-5afc-45d0-9389-bf5d1344e3d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:to="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ef5ce16-185f-491b-addd-acbd7cbddab5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ef5ce16-185f-491b-addd-acbd7cbddab5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24a64dc5-cf3c-4282-8d4c-d350d7f5cc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24a64dc5-cf3c-4282-8d4c-d350d7f5cc14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_UnvestedRestrictedStockUnitsMember_5e74d587-781c-4258-926a-cd701a5a27bb" xlink:href="prax-20221231.xsd#prax_UnvestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24a64dc5-cf3c-4282-8d4c-d350d7f5cc14" xlink:to="loc_prax_UnvestedRestrictedStockUnitsMember_5e74d587-781c-4258-926a-cd701a5a27bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="ie755ae52cfc6417391ff7fb2deada7cc_StockBasedCompensationSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77a285e5-c6f6-4b3c-8611-fb097d8ca9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77a285e5-c6f6-4b3c-8611-fb097d8ca9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_b25c7ea2-7355-4d4c-ab53-94d48e1b447a" xlink:href="prax-20221231.xsd#prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_b25c7ea2-7355-4d4c-ab53-94d48e1b447a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84acafd4-1cf7-4f7b-8dfe-38fa2364efe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84acafd4-1cf7-4f7b-8dfe-38fa2364efe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_93f4ff6e-b5d9-4a2f-9562-92071f6b567d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_93f4ff6e-b5d9-4a2f-9562-92071f6b567d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_79b5fb03-b3a0-4276-ac92-946bd14ee771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5228f35e-408a-474a-9baf-97cedaebb82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5228f35e-408a-474a-9baf-97cedaebb82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_244bedeb-47a8-4f46-a830-1bd5ab7fe426" xlink:href="prax-20221231.xsd#prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_244bedeb-47a8-4f46-a830-1bd5ab7fe426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9cef2048-e411-419e-8b29-efceb52e3158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9cef2048-e411-419e-8b29-efceb52e3158" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_58e6af5b-350b-43da-87eb-82ff6e3d4edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_58e6af5b-350b-43da-87eb-82ff6e3d4edb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57db5eb2-3290-4760-8cee-b9630febdb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:to="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108e8571-ae98-4965-b275-178fe0bfaf36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_108e8571-ae98-4965-b275-178fe0bfaf36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91015d04-a5b3-4f41-8965-f14f7effa753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91015d04-a5b3-4f41-8965-f14f7effa753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_acd93fc4-bd63-406e-b214-67a759686343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91015d04-a5b3-4f41-8965-f14f7effa753" xlink:to="loc_us-gaap_RestrictedStockMember_acd93fc4-bd63-406e-b214-67a759686343" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" xlink:type="extended" id="ibc0f09c0bc974d7fb9dc518bc5b6d8ef_StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dca2c4be-cc4a-483c-9100-3ae485952b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dca2c4be-cc4a-483c-9100-3ae485952b2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ad0b278-bba8-45a2-b865-39adfbaa0ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ad0b278-bba8-45a2-b865-39adfbaa0ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d0ee71b4-6222-491f-a3aa-75fbcc8912e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d0ee71b4-6222-491f-a3aa-75fbcc8912e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a8fd665b-9cee-4166-a2ae-e706cab65395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a8fd665b-9cee-4166-a2ae-e706cab65395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f57c5040-7a56-4f1a-b566-ae75487f0e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f57c5040-7a56-4f1a-b566-ae75487f0e6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1d3d7495-1f09-43f6-880b-84b7ebefdd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1d3d7495-1f09-43f6-880b-84b7ebefdd0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3b3b72e-41ac-4cf2-8ca5-f6f56e862b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3b3b72e-41ac-4cf2-8ca5-f6f56e862b9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:to="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f64c4246-5ea0-4a65-b686-c5cf9c24d51d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f64c4246-5ea0-4a65-b686-c5cf9c24d51d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3eddb8b8-69b8-48aa-b304-a098446e6490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3eddb8b8-69b8-48aa-b304-a098446e6490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_195a198c-4393-4dcb-9dc7-6039f33dddac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3eddb8b8-69b8-48aa-b304-a098446e6490" xlink:to="loc_us-gaap_EmployeeStockOptionMember_195a198c-4393-4dcb-9dc7-6039f33dddac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i6ab8402bc38443fc9d7529de1860cbb3_StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19f86e24-4a7a-4698-af7d-c8d07ca7e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2003bf9-3861-4a6e-825e-8f9ed39ac615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19f86e24-4a7a-4698-af7d-c8d07ca7e84c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2003bf9-3861-4a6e-825e-8f9ed39ac615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19f86e24-4a7a-4698-af7d-c8d07ca7e84c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_feb84998-ca22-41cc-ac87-ad6b47fe1d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_feb84998-ca22-41cc-ac87-ad6b47fe1d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a47b1ff3-7b3d-4ba7-998a-2d98e58f6896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a47b1ff3-7b3d-4ba7-998a-2d98e58f6896" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SignificantAgreementsDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/SignificantAgreementsDetails" xlink:type="extended" id="i89d490b80ac14029bde057f88262f0b2_SignificantAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_e17258c6-0646-477e-80fa-1e5264c827fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_OtherCommitment_e17258c6-0646-477e-80fa-1e5264c827fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9e3d328c-2b03-4823-8f8c-7e7367186818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9e3d328c-2b03-4823-8f8c-7e7367186818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fc39f5b0-ec0a-42de-8ec6-e013f230c667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fc39f5b0-ec0a-42de-8ec6-e013f230c667" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:to="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9a918231-fea9-4313-a360-62e6e8391541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9a918231-fea9-4313-a360-62e6e8391541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_10531da1-0605-44cc-9400-68bab48179fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:to="loc_us-gaap_OtherCommitmentsDomain_10531da1-0605-44cc-9400-68bab48179fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_54f19417-45f5-4d12-89ac-725ddad31e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_10531da1-0605-44cc-9400-68bab48179fb" xlink:to="loc_us-gaap_LicensingAgreementsMember_54f19417-45f5-4d12-89ac-725ddad31e56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LicensingAgreementsProfitSharePaymentsMember_a33af50e-722b-4e38-83ed-a78a56bb1cc6" xlink:href="prax-20221231.xsd#prax_LicensingAgreementsProfitSharePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LicensingAgreementsMember_54f19417-45f5-4d12-89ac-725ddad31e56" xlink:to="loc_prax_LicensingAgreementsProfitSharePaymentsMember_a33af50e-722b-4e38-83ed-a78a56bb1cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:to="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29b0b0c3-bd08-46b6-856a-c1cc6c390f29_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29b0b0c3-bd08-46b6-856a-c1cc6c390f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_RogconMember_1506c6fe-65a2-4895-8f83-30c7bef7f967" xlink:href="prax-20221231.xsd#prax_RogconMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:to="loc_prax_RogconMember_1506c6fe-65a2-4895-8f83-30c7bef7f967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_IonisMember_09d1abbe-9cdb-4130-bc0f-5d0e6e73fa16" xlink:href="prax-20221231.xsd#prax_IonisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:to="loc_prax_IonisMember_09d1abbe-9cdb-4130-bc0f-5d0e6e73fa16" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" xlink:type="extended" id="i977c29525ce9468693fb4ce755e2c6d7_NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6b6b914-12be-4070-b4a9-a98a0f83bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_536e6b1b-9da9-4961-85a7-99b9f5fec1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6b6b914-12be-4070-b4a9-a98a0f83bfcc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_536e6b1b-9da9-4961-85a7-99b9f5fec1df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6b6b914-12be-4070-b4a9-a98a0f83bfcc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_09f94c83-4d2c-4fcf-b837-a6f007dfc175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_09f94c83-4d2c-4fcf-b837-a6f007dfc175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24a64705-8fbc-4582-b9eb-e8607cbf1384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24a64705-8fbc-4582-b9eb-e8607cbf1384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2f1a26ad-c951-4bb9-ad6e-540972e90391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:to="loc_us-gaap_RestrictedStockMember_2f1a26ad-c951-4bb9-ad6e-540972e90391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ecf09f2a-eb58-469e-84aa-0626ff16dbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:to="loc_us-gaap_EmployeeStockMember_ecf09f2a-eb58-469e-84aa-0626ff16dbf0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="ibf297b9aee084367957c4d6bf72a9980_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_2f747f2b-8bf1-40f9-9245-d3eee00f0109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_2f747f2b-8bf1-40f9-9245-d3eee00f0109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b70e3004-01fb-4818-a66f-73e2bd264f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b70e3004-01fb-4818-a66f-73e2bd264f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a3284109-c1d5-4a93-8ff4-40e837841caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a3284109-c1d5-4a93-8ff4-40e837841caf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_893c16b5-9baf-4675-b121-a45f5875d6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_893c16b5-9baf-4675-b121-a45f5875d6c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74d9cd7d-b8a6-4968-81d6-d61ab4e69ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74d9cd7d-b8a6-4968-81d6-d61ab4e69ddb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_358024b4-4859-4359-a2fc-e489f52dd53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_358024b4-4859-4359-a2fc-e489f52dd53c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_84bab2d9-8747-4370-83f3-d6fcf7d9b2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_84bab2d9-8747-4370-83f3-d6fcf7d9b2c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2353677f-2c12-458a-ba7a-1c237d0ac30d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2353677f-2c12-458a-ba7a-1c237d0ac30d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9d08f375-1b6d-480e-b405-dc9df18717d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:to="loc_us-gaap_DomesticCountryMember_9d08f375-1b6d-480e-b405-dc9df18717d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_363c9a08-e7e8-423c-ab77-00add460dcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_363c9a08-e7e8-423c-ab77-00add460dcde" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/RestructuringDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#RestructuringDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/RestructuringDetails" xlink:type="extended" id="ie9112ee8299d4cb5993840e0e14da9f0_RestructuringDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0d907566-4d0d-4813-905e-4de7f6eccbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0d907566-4d0d-4813-905e-4de7f6eccbac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7073d283-ea30-4389-bebd-777f8c3ac935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7073d283-ea30-4389-bebd-777f8c3ac935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_503b21f2-a4ee-4722-b0c1-09904c2d2c30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_503b21f2-a4ee-4722-b0c1-09904c2d2c30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148fa7d-97bd-427a-a312-b55b79ee62b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148fa7d-97bd-427a-a312-b55b79ee62b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_94faee3b-2704-4a25-8bbd-12a9fa67482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_94faee3b-2704-4a25-8bbd-12a9fa67482a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://praxismedicines.com/role/SubsequentEventsDetails" xlink:type="extended" id="i9c9e967034e54e058162e53cefc24513_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4765c7e8-0a7d-4c50-814b-23e7782dff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4765c7e8-0a7d-4c50-814b-23e7782dff73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702dd282-89ad-4247-81ea-529203cc9258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702dd282-89ad-4247-81ea-529203cc9258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:to="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69c6e4b8-33a9-417a-868f-da6d2449b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69c6e4b8-33a9-417a-868f-da6d2449b3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_efcb820e-ef25-4f2a-931f-379c4d234e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69c6e4b8-33a9-417a-868f-da6d2449b3ab" xlink:to="loc_us-gaap_SubsequentEventMember_efcb820e-ef25-4f2a-931f-379c4d234e64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>prax-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:912e1565-2dff-44dd-bfb3-af6c8a11fb3c,g:26ec8c83-18eb-4378-8ac1-2975735259ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_bfd9dcfb-55a1-4576-b1cc-01b0b65764c1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc6a45ca-fbdc-47be-9fab-acdad41a2bae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86aa031a-f443-4a99-91d4-1271dada8c87_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5cc35674-9df0-4295-af37-8f387627736a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_ca69545d-4c34-4f82-8be7-99f06ddda23b_terseLabel_en-US" xlink:label="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="lab_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f0e8a10a-75e0-4e86-9bf7-41eb0cc2ff00_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_297e7a62-4c6a-43fc-8d44-f2d356b4dd37_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_fbd0895a-bcdd-4906-aa06-3dc422c55c39_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_22402688-e552-44c3-8c7a-b6d483dd1e06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_78087788-90f3-44ea-9bda-9bded57894a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_475f6285-c60d-4f38-8140-5626a45b383f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1980ac42-a3ae-4d97-954b-182b470e019f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_SaleOfStockConsiderationReceivedGrossAmount_0c3d0c3c-ed25-48d2-b7c4-22342c5b4e8c_terseLabel_en-US" xlink:label="lab_prax_SaleOfStockConsiderationReceivedGrossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received, gross amount</link:label>
    <link:label id="lab_prax_SaleOfStockConsiderationReceivedGrossAmount_label_en-US" xlink:label="lab_prax_SaleOfStockConsiderationReceivedGrossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received, Gross Amount</link:label>
    <link:label id="lab_prax_SaleOfStockConsiderationReceivedGrossAmount_documentation_en-US" xlink:label="lab_prax_SaleOfStockConsiderationReceivedGrossAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received, Gross Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_SaleOfStockConsiderationReceivedGrossAmount" xlink:href="prax-20221231.xsd#prax_SaleOfStockConsiderationReceivedGrossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_SaleOfStockConsiderationReceivedGrossAmount" xlink:to="lab_prax_SaleOfStockConsiderationReceivedGrossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81637afb-f3f6-4172-a1f6-941acf8c2ffd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities:</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_65801333-5f73-4a1c-bc64-b1dc13d3f562_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_1a03f4b1-f6cb-4ad9-94d8-eb675b60f424_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1619753d-f4f9-4ec1-84b9-4ab2da894237_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e7f0f73-ec2d-4d1a-985c-76044f73a14f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7209c576-59e8-446a-8403-2850286acb75_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_4fd4e01c-a18e-4ced-89fe-4f8410f41524_terseLabel_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common stock reserved for future issuance</link:label>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_82ef7c97-7deb-4791-8bda-e30251d68d94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ce5a87b7-fc6e-47c5-88f2-bc1056b50364_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_b539266e-3919-4014-890b-3a85da67a295_negatedLabel_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, accumulated gross unrealized loss, current, before tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_label_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_documentation_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" xlink:to="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_3382c781-741c-4caa-ae6a-3df67f437d3e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6ff99bfe-1cbb-4f79-b546-921fbeb4ff7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4ea15a4c-1af9-4677-a3d7-4e7849621749_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a909a985-fa73-453a-ab65-379adfbca220_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_18575a28-a49b-4f7c-9fa6-2dade2e075a9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58833255-68c1-4e48-8fad-d1e414a61340_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_60e672a7-2729-4df1-a10e-65ce257f76e9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_ba6c6789-0ca4-45a2-b156-c6a9750b57b2_terseLabel_en-US" xlink:label="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_label_en-US" xlink:label="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Amortization</link:label>
    <link:label id="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_documentation_en-US" xlink:label="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" xlink:href="prax-20221231.xsd#prax_DeferredTaxAssetsTaxDeferredExpenseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" xlink:to="lab_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5bdefe34-bf01-4494-9f76-93f9fa434443_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_40eff161-0e37-4722-a792-3155f470b0bf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_686aa694-bf6a-4549-8ca8-8196139f9dc1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c60f2728-3e4e-4bb0-b6a6-be6f40daaa86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6074cc72-40c8-4db7-b955-7585f4fdc257_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e717b73e-f9b4-494d-9555-753677c10f58_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_affc9640-d529-4047-9a7e-ade996274a7e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_afd6f192-c61e-4b2d-bfcc-755c9e214680_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b53ef6ae-ce8e-4ff5-a14c-ba06118d8949_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_302509c7-81d8-4665-b4dc-85498fbc9a62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price cancelled or forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_6303cf56-a831-40e6-934b-4bbaf1e7a605_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9c9fbf99-4604-4363-bc15-fb7b520ac549_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_f2134edb-cca0-49fb-88d7-df292acde740_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, state and local</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_94db4858-43a6-4de9-851e-97e3efb296bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bbc200da-1557-4f80-9555-8f1ebc414bbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_2f6bc312-650a-4737-94f1-321d110b089e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares issuable under the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a7dbf1ed-c8d7-408a-8c00-d54971dbae9c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_96176e8d-00e1-4b8d-970a-8567a04db7ea_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_3a53a6a5-d914-4b42-a3a9-d6fe672d1a73_terseLabel_en-US" xlink:label="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the-market offerings, net of issuance costs</link:label>
    <link:label id="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_label_en-US" xlink:label="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at the market offerings, net of issuance costs</link:label>
    <link:label id="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at the market offerings, net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" xlink:href="prax-20221231.xsd#prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" xlink:to="lab_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3e49afe2-56cb-4aa4-8531-e405acd695de_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ffa9710-08bf-4b22-988b-7e7ce980e9ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_315281ec-1116-458f-a61e-795deb085171_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_RogconMember_d94d85e4-6d12-4067-a587-646bf0a897ec_terseLabel_en-US" xlink:label="lab_prax_RogconMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RogCon</link:label>
    <link:label id="lab_prax_RogconMember_label_en-US" xlink:label="lab_prax_RogconMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RogCon [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_RogconMember" xlink:href="prax-20221231.xsd#prax_RogconMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_RogconMember" xlink:to="lab_prax_RogconMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a1941395-ca55-4463-9a6f-4d31cbe5ac7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_11f9ae7d-9d70-472c-8006-cafd34ca9a52_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_e4a67590-0d2f-4b17-a6ec-219d4eee9de6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6292b220-78d1-455d-ac66-3d7a73ef8d39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_34981870-cf9a-4353-a699-fdaa54617c9e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares canceled or forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_783c734e-fb3f-4a83-a7c3-38e1ca453edf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8eb6962f-3d62-451b-a592-7a25b104199d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3054e25f-1cfc-42ef-b4c4-1eddeb6cb043_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a045eb24-e1f6-43ec-b21c-8242ffb028d1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd996aaa-67a2-49c7-bf8b-02f6de72cae8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d63411c4-eba3-4fe4-a4e1-df33dcd2dd4c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_420c9de7-b3cb-4299-9c39-38d761f2bf46_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from at-the-market public offerings</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e123ca88-cf5a-440f-91ea-749a8a7000d0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae76c95a-b6d0-4b3a-8c26-6b3ac9b642ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_d5080010-79a7-4a05-8a39-4b15664c549a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6cbe97b1-aed3-4a45-bf35-1e9d535ca072_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a31d44a4-6120-4d19-acb0-2159447acb39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value, Available-for-sale, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0c2a96eb-4439-4fa8-8c48-a99adf2ec92e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0496d9d1-d640-4ada-8706-dd47269344db_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcc96cdc-64fd-41d3-836d-02266aad17f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_eeea41ec-a303-40f1-9961-6cc135d90447_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_72ef08d2-b1c7-4fb6-8315-5fd32e7d29a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_253b2901-312b-4ecb-b6cf-a6621a7a638f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b8ebc44e-7d14-4db9-96d0-27ffb52d68f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_A2022OfferingsMember_0292d72d-d1d5-4fd9-a54e-c8bf239d3ff7_terseLabel_en-US" xlink:label="lab_prax_A2022OfferingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Offerings</link:label>
    <link:label id="lab_prax_A2022OfferingsMember_label_en-US" xlink:label="lab_prax_A2022OfferingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Offerings [Member]</link:label>
    <link:label id="lab_prax_A2022OfferingsMember_documentation_en-US" xlink:label="lab_prax_A2022OfferingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_A2022OfferingsMember" xlink:href="prax-20221231.xsd#prax_A2022OfferingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_A2022OfferingsMember" xlink:to="lab_prax_A2022OfferingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e2ce1c90-2f90-4cd9-84d8-d01058cf4a6d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_98bcec61-365b-4348-8739-12a0942708df_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ecc2223d-e957-4a88-8a69-631391f5780b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4c6f41b4-c709-4c3c-b5ce-22272cc9a362_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_2dcc92a6-8978-42cc-a0f7-6c3f753fc4a8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0ee22524-7fd7-4e66-b4ae-e14965ef285e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9d287524-8354-4845-9561-bc8fa6db744f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_UnvestedRestrictedStockUnitsMember_00c663c3-f445-45da-b151-cf55707a56d9_terseLabel_en-US" xlink:label="lab_prax_UnvestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock Units</link:label>
    <link:label id="lab_prax_UnvestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_prax_UnvestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_prax_UnvestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_prax_UnvestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_UnvestedRestrictedStockUnitsMember" xlink:href="prax-20221231.xsd#prax_UnvestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_UnvestedRestrictedStockUnitsMember" xlink:to="lab_prax_UnvestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_ca26de1d-5ed5-4860-a6a6-d98f9fd09496_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_167143cb-c666-402b-b843-1d876569940c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9d491951-c181-461f-b27b-10cd54712386_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_877688ff-b04c-499a-8108-652b852a26e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, gross proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_735a6c2c-0906-4c75-9718-7d70a05dbbf3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_AccruedPersonnelRelatedExpensesCurrent_ea7cebd2-cadc-42ce-ba4b-213f633f3c6f_terseLabel_en-US" xlink:label="lab_prax_AccruedPersonnelRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued personnel-related expenses</link:label>
    <link:label id="lab_prax_AccruedPersonnelRelatedExpensesCurrent_label_en-US" xlink:label="lab_prax_AccruedPersonnelRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Personnel Related Expenses Current</link:label>
    <link:label id="lab_prax_AccruedPersonnelRelatedExpensesCurrent_documentation_en-US" xlink:label="lab_prax_AccruedPersonnelRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Personnel Related Expenses, Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AccruedPersonnelRelatedExpensesCurrent" xlink:href="prax-20221231.xsd#prax_AccruedPersonnelRelatedExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_AccruedPersonnelRelatedExpensesCurrent" xlink:to="lab_prax_AccruedPersonnelRelatedExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e61f82f6-a4be-4d03-9456-b621ee3206ef_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_e740af16-f228-4ea3-aabe-99c35aca68c0_terseLabel_en-US" xlink:label="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs included in accrued expenses</link:label>
    <link:label id="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="prax-20221231.xsd#prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ca4a2a05-0674-40e5-9081-bc8ee93ef9a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_23e6f3de-597d-49f3-a731-c1c053a01786_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e0ddb3e6-bf02-4083-8c82-b1a87ecb5d7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_66699f56-a0aa-42bf-9073-b22f5c77687d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d756247c-2d7c-4933-8d06-aaa0f554869f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d838005e-abae-4144-ba89-4b388f791953_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_f7c3e50f-0f2f-4a4f-837a-34366efeb214_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_79a86bb8-169f-4639-8845-f5880985a999_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1376c122-4b4b-4a2e-815b-154da9e3046c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87d8410f-5f43-4ac8-aa8c-5279b45b6f08_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of stock option awards on the grant date using the Black-Scholes option valuation model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_6616161c-580d-4c0e-ab9a-90cba8ad924e_terseLabel_en-US" xlink:label="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses</link:label>
    <link:label id="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development Expenses Current</link:label>
    <link:label id="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued External Research And Development Expenses, Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:href="prax-20221231.xsd#prax_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:to="lab_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7be8638-5c91-4cdc-af2e-924c510afb12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_92b248ca-534b-4733-8766-4c18e953310f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_098a2acf-fde4-445a-932c-2a1211e83902_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense expected to be recognised (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a31cf7d4-fd97-4e56-93bb-d0c2176dc42b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_dba03028-29dc-4fb6-ae95-90c611dac2b3_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b5812c5c-b1cb-43d0-967b-4b71864862d0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54e13d6e-2244-43bd-a48e-1bdd72d7035a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from at-the-market public offerings (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6d6379ee-98c8-4063-a704-58d3c1730742_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bdd0340d-7548-4e50-9919-f277ae137d38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e97c85c7-5ea6-416d-9493-a0e08ecc0b8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d5ac0518-6753-4415-9679-91dc76d34e43_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_50e04543-1e0b-44bd-8f52-a322c1dd4240_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cd44235e-76e1-40a0-9107-c2f14d4f6321_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ca68b03f-d062-4964-9380-e80e4323cdce_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_08a1a50f-c8a2-45fb-afb8-52dd55a9c045_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e5ab0207-e08e-4878-b33a-35c4c39e5a64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2ab7739b-e0fa-48f8-b4dc-cb4a35aa0ed8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c1fefea2-620d-4d6e-907e-1895bd4f1d4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b16901d4-1168-4c72-9b80-bf7061e18008_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_LettersOfCreditReceivableNoncurrent_ab52bd11-1ecb-4451-a736-8602a1296275_terseLabel_en-US" xlink:label="lab_prax_LettersOfCreditReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Receivable, Noncurrent</link:label>
    <link:label id="lab_prax_LettersOfCreditReceivableNoncurrent_label_en-US" xlink:label="lab_prax_LettersOfCreditReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Receivable, Noncurrent</link:label>
    <link:label id="lab_prax_LettersOfCreditReceivableNoncurrent_documentation_en-US" xlink:label="lab_prax_LettersOfCreditReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LettersOfCreditReceivableNoncurrent" xlink:href="prax-20221231.xsd#prax_LettersOfCreditReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_LettersOfCreditReceivableNoncurrent" xlink:to="lab_prax_LettersOfCreditReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_59c42c55-ef68-44d9-8396-0412e8fc1816_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_553fb2bc-3101-4eb9-9b67-fc621ce54616_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_94b02250-a91e-4ed8-bc91-27ef3f9201eb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4656e63f-e0e9-4b6f-acdc-63a3f02f0756_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f38504ef-1448-454c-91a5-d2fb109eeefc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4514a721-aabe-4b4f-8d1e-24fae44411bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_871a51ff-e33e-40d4-8eb4-d0cf2e98f107_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_33b901d8-fac6-4a5f-80ff-83212a059f3d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_153ed2e9-8a9f-4ab3-9789-b125d30ede89_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d690c1ed-7c30-4498-aa63-d1f9d3724405_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_00179b32-3ee1-47a8-a7a5-0cd24ab81f9f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ba5d0e17-7480-4881-892b-009a3f28fe68_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities_d058c8c0-6c38-49f1-aac5-c026400e768d_verboseLabel_en-US" xlink:label="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="prax-20221231.xsd#prax_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_prax_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a016dcff-74ee-4f62-b8d0-82620fce929c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax_5c1b2213-a548-484e-863e-835ae460f92e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_84b0249e-e93a-4e01-9e69-eed70ee5acc8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_65a1e825-a3b7-4ae8-ac3f-a4e37ca9ff84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b66edb13-188e-4cc0-b2ce-a0bf0eb4cd5d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_b3f86480-97b8-411e-9fb1-618376aff461_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Other than Long-Term Debt, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7eeedf30-8b71-43dd-8fef-669be29a879e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_17c06f5f-9530-4339-bc7e-5bf35655186b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2561afdd-ef3e-49fd-b3fe-4646cdc4859b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cd00b6dd-78ad-44f3-9672-a18cc34102a3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b050ac2b-35b2-4b2a-b063-b32c8b75e251_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9a6ac04d-6919-4b1c-ac15-2bf4c4f94bdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cadd878d-95ac-4939-af63-ff3cbca21ab5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock_deed9d1e-ba86-4211-aa46-d9e1fbc5c26b_terseLabel_en-US" xlink:label="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Consolidated Balance Sheets</link:label>
    <link:label id="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="prax-20221231.xsd#prax_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_prax_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a016f428-a582-4f1e-babe-c0b493b3e7db_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_50ec2885-9db6-4662-a6a0-69541e78d81b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in follow-on public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_820a5298-54d5-49c6-adb6-7136c5584842_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_UCBMember_8447a03c-9dac-4646-a58e-d62f929b18d7_terseLabel_en-US" xlink:label="lab_prax_UCBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:label id="lab_prax_UCBMember_label_en-US" xlink:label="lab_prax_UCBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB [Member]</link:label>
    <link:label id="lab_prax_UCBMember_documentation_en-US" xlink:label="lab_prax_UCBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_UCBMember" xlink:href="prax-20221231.xsd#prax_UCBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_UCBMember" xlink:to="lab_prax_UCBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3d7cbadd-feeb-4e73-800c-1bf123bed1f3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7fd4ad5e-1bf3-4235-a613-4b9a95cfbbb5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b0f65cfb-fff1-4316-b5d2-74192bebc4a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ae81d114-9c72-4e90-be45-f1122cceb49f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested stock based awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_333806a4-22a1-40e1-982b-c0085cda7b90_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_56f5d299-e2f2-4dc1-9b55-deda8fe49b28_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2fe52909-a3d3-46b8-ade6-b749d4b0ff21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8b407924-1830-4287-aa5e-d93aaac3af88_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6d70d916-bc6f-4dd0-8aa3-f6999e5f69d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember_1868c140-1359-464e-95d4-91693d9869cd_terseLabel_en-US" xlink:label="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Stock Incentive Plan</link:label>
    <link:label id="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember_label_en-US" xlink:label="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Seventeen Employee Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember_documentation_en-US" xlink:label="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Seventeen Employee Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentySeventeenEmployeeStockIncentivePlanMember" xlink:href="prax-20221231.xsd#prax_TwentySeventeenEmployeeStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_TwentySeventeenEmployeeStockIncentivePlanMember" xlink:to="lab_prax_TwentySeventeenEmployeeStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_fa93b8e1-f270-4200-8f2d-c20b4c55c49f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6396124d-bf41-4175-8027-9146aebcbb2b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0ea74b30-4e9b-4280-b959-4efa1459e4cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_582906a5-8c49-442c-a439-20bf8c48a313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0eceba11-f38f-4c1e-be0e-9d7309a15471_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_25a16127-ed9a-45c6-b9d7-64db59be96d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f182d7e2-6f8b-4a13-8021-8fdfe887299d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_LicensingAgreementsProfitSharePaymentsMember_863684a6-8089-4bcc-9a07-8e99a5851671_terseLabel_en-US" xlink:label="lab_prax_LicensingAgreementsProfitSharePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, profit share payments</link:label>
    <link:label id="lab_prax_LicensingAgreementsProfitSharePaymentsMember_label_en-US" xlink:label="lab_prax_LicensingAgreementsProfitSharePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Profit Share Payments [Member]</link:label>
    <link:label id="lab_prax_LicensingAgreementsProfitSharePaymentsMember_documentation_en-US" xlink:label="lab_prax_LicensingAgreementsProfitSharePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Profit Share Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LicensingAgreementsProfitSharePaymentsMember" xlink:href="prax-20221231.xsd#prax_LicensingAgreementsProfitSharePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_LicensingAgreementsProfitSharePaymentsMember" xlink:to="lab_prax_LicensingAgreementsProfitSharePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_21cdea6f-a566-41ee-be82-07a899937bd4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7319b5b2-73de-4196-8ef9-43515e02c347_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_8d49e2e4-7113-4c2b-a78e-66a3cdbf144e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_12916632-ef5a-4e2f-85d3-b02154afc836_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5bed253c-bd3b-4cec-857b-de77171944ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_703be0c6-1207-403d-a72a-d4287b62e80a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6a05b7f3-592e-4b2d-b84e-313e975df9cc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e83b1a33-2e51-469e-bf41-f9d380b66103_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e57016f9-63ea-4b6d-a241-e9eecc911ece_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7517a9d4-29f7-4198-8951-b17eb2fc345f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_JefferiesOpenMarketAgreementMember_1ee1d029-a661-4337-947a-c8d3b800bb0f_terseLabel_en-US" xlink:label="lab_prax_JefferiesOpenMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies Open Market Agreement</link:label>
    <link:label id="lab_prax_JefferiesOpenMarketAgreementMember_label_en-US" xlink:label="lab_prax_JefferiesOpenMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies Open Market Agreement [Member]</link:label>
    <link:label id="lab_prax_JefferiesOpenMarketAgreementMember_documentation_en-US" xlink:label="lab_prax_JefferiesOpenMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies Open Market Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_JefferiesOpenMarketAgreementMember" xlink:href="prax-20221231.xsd#prax_JefferiesOpenMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_JefferiesOpenMarketAgreementMember" xlink:to="lab_prax_JefferiesOpenMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a4f9d09-9fd0-43c8-9fa4-f8619f992084_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_17039aae-2fe0-4c7a-a56d-b7d6e8c73e73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_5de3dd54-e919-486f-9cd0-0b9e079bbcb6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0832357f-811a-426d-8222-11451b259e60_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505a7336-d4ad-42f7-9c0e-7659ed4efef4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b640441d-f823-4e14-96bf-32fd6f1da806_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_245f0abc-5b65-408c-a145-8b6b063ceeb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_IonisMember_ae4c8cdd-cee6-4d90-bd77-459b8ec6d528_terseLabel_en-US" xlink:label="lab_prax_IonisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis</link:label>
    <link:label id="lab_prax_IonisMember_label_en-US" xlink:label="lab_prax_IonisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis [Member]</link:label>
    <link:label id="lab_prax_IonisMember_documentation_en-US" xlink:label="lab_prax_IonisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_IonisMember" xlink:href="prax-20221231.xsd#prax_IonisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_IonisMember" xlink:to="lab_prax_IonisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bf11db53-3392-49aa-b8e3-70d89f430354_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9ce484fb-82f4-47dc-bc3f-014bcc60325c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_64e39eb1-9e40-49d6-b638-dbe556840cfb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_903f7dc3-a6d0-4bb6-b865-ad6a5cb8b762_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_96f2e711-f773-4d77-af9f-2fab74f69644_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_95fc7580-0cc9-4eea-8269-4596f22a7fb7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_464e61d8-a2e4-4bd5-a6ea-2cbefac0712b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1c9d9f1e-d1d5-427d-a35d-9377c2925cef_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e04ee860-dac2-416f-ad7f-10b5873e930d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ee66c83c-0613-4bbd-a92a-0f11b6ed479b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_84810931-4c92-4b08-8c3c-47c9de749440_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0f0cf12b-8f3e-442c-b224-072310ceaa78_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_2c7dc6db-aa18-4262-a0c9-0ffd34af688c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, domestic</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c3c287d4-960f-45d0-acd2-972b3878276d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1c6e261d-3e9a-4318-bf6a-09da45841ae1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_94f7ed45-a45c-4ebc-a029-bf9b83ad3a59_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_06fc2e2f-f605-4777-a2c3-c6269cf3add3_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_df6113a9-f40b-49e1-8034-b31bb8a40816_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3cd7020e-d7cf-4e67-aa74-744d2d502d4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7928fae8-b6a8-494c-8b14-2ee06385ee66_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_07c54b29-6cbd-4793-856f-a4be8d3e961b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_62512f95-ede6-4cfc-aaa4-66600e140825_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4198a11-7674-4e0d-8fc4-aed15cbe6a72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cfffa57b-b7a4-40d8-b981-478dc0a4d7dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3fa12104-1001-4beb-9d73-af66061fd5f0_terseLabel_en-US" xlink:label="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Shares</link:label>
    <link:label id="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_label_en-US" xlink:label="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period</link:label>
    <link:label id="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_documentation_en-US" xlink:label="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:href="prax-20221231.xsd#prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_19c4b706-045b-4186-bfe7-3748ca8997f3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_919e802d-1d06-4190-b5b7-353d5d3c52f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_680eb391-604f-4b4d-878e-b7cd8a8441e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5d0fff0c-42c6-41c8-87ea-ed9c5d34ea17_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0cfaf58c-4209-4e96-a617-96a51b347e8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_a82327ac-92e4-4141-a0dc-da6dd41982b1_terseLabel_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, accumulated gross unrealized gain, noncurrent, before tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_label_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_documentation_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" xlink:to="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba3bc430-7768-46f8-9232-dceed37294aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ca1e55eb-5ef8-41f9-acf5-4afb43a0c222_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_81e15551-9e53-4f34-95ea-d3469e990bdb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d7c15001-137a-4673-ba5f-8f57ca94a47d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_017ba4f6-e5cd-44aa-8c46-8d927af7a24f_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ef7cac29-d251-49ef-b264-bc5e15072a59_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4ec07efc-db44-48cb-a408-65d1cd72723b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_13d59612-9fa1-4042-811e-a13ada65cbdc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c808e079-61ae-4f5d-82ee-6ce122e6ae00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1911e0cd-7769-4184-8261-d151cb0ee0d8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_FollowOnPublicOfferingMember_f1f664eb-ad33-43d6-a46e-9621d9973453_terseLabel_en-US" xlink:label="lab_prax_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow on public offering</link:label>
    <link:label id="lab_prax_FollowOnPublicOfferingMember_label_en-US" xlink:label="lab_prax_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow on public offering [Member]</link:label>
    <link:label id="lab_prax_FollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_prax_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow on public offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_FollowOnPublicOfferingMember" xlink:href="prax-20221231.xsd#prax_FollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_FollowOnPublicOfferingMember" xlink:to="lab_prax_FollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_377f292d-8a6c-4f54-937a-fe182ce362ed_terseLabel_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance-Sheet Risk</link:label>
    <link:label id="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="lab_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_99b58b7e-2ea6-4d94-9ec7-f71d5513ccab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3e0cf4a5-3386-4093-99c9-6a91d5a07545_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_OfficeFurnitureAndEquipmentMember_8d0e9ce3-b8a0-4a04-ac32-390b51c793b2_terseLabel_en-US" xlink:label="lab_prax_OfficeFurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_prax_OfficeFurnitureAndEquipmentMember_label_en-US" xlink:label="lab_prax_OfficeFurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
    <link:label id="lab_prax_OfficeFurnitureAndEquipmentMember_documentation_en-US" xlink:label="lab_prax_OfficeFurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Furniture and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_OfficeFurnitureAndEquipmentMember" xlink:href="prax-20221231.xsd#prax_OfficeFurnitureAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_OfficeFurnitureAndEquipmentMember" xlink:to="lab_prax_OfficeFurnitureAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_370632d5-66a3-4515-a677-837f3e0a9595_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_67bb0500-7f11-403c-b498-5da470e73df0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 150,000,000 shares authorized; 49,382,453 shares issued and outstanding as of December&#160;31, 2022, and 45,300,514 shares issued and outstanding as of December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_014b746d-d05f-49c3-85be-6c22c55978ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_20d983b7-ac54-42e2-a395-41372bbb0652_terseLabel_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_label_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Line Items]</link:label>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_documentation_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Line items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:to="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2c6926f8-49ee-4e44-8504-84b0ef952282_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_030eb49b-93d9-437a-86aa-3962a28e1b62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_86641275-6413-49ac-b145-5fe1475e9d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cc7269b3-ba38-427d-9bda-f81231fbc5cf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e26ae00c-fda6-432b-a1f4-7238de16bc28_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c3204a9a-fe35-481b-b5b2-376ebd23f030_terseLabel_en-US" xlink:label="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in usd per share)</link:label>
    <link:label id="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, issued in period, weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:href="prax-20221231.xsd#prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91d639ae-d080-48bb-b5ac-b53b0d0cdb41_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6133147f-fcd2-4467-87a0-6dae9993fde9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d869e82b-70ec-4dfd-8344-2d006ff45967_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11c2cc6d-972c-4b46-ad79-a119e0cc283b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList_9a802129-96d6-40de-a2c2-0b6f1e28d78c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b76a3f66-7e79-4316-80d7-6f4c39646975_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8884dff8-5944-4a23-a4ec-efc1b1f75c6c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ed9dcada-281d-4010-9b51-a97e7cdfb116_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options and employee stock purchase plan contributions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_26122e84-56c7-4991-ac4f-3a48dcdbd00a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_49233b94-8048-403b-9ae6-5b5d2fad0b84_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_980a2847-8221-4cd4-a26f-7c2c3a8f3ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8a501748-82f7-491b-b998-f745736322e0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_965199d9-a0e2-4940-be67-0555146192c7_terseLabel_en-US" xlink:label="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="prax-20221231.xsd#prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8a8cf40a-2bbd-41bd-86f7-2164970d1b76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1393edd5-e8e3-4e31-8175-1b63cd3c2c13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_4db4f2af-d3b2-4ad6-9a5e-5e839218237c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c3edafef-09fa-446a-ab89-7fb977141056_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd55e02d-37bf-4d72-ac92-558cc52dc2b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities, unrealized loss position, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_db3eda0d-eb03-4d1d-9d82-33f11e187272_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_659774c7-cab2-41ed-99d3-979c9856c5ba_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_340b14c4-8ed7-492d-b7d2-59ce2b5df826_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_df02c1c8-3a2a-4607-b1ec-f43b83e3fb04_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7a59a3e7-2697-4986-b454-446366160c9f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_PercentageIncreaseInAnnualBaseRent_d425ee4e-44cc-4fbe-8b8d-23bca57a4f00_terseLabel_en-US" xlink:label="lab_prax_PercentageIncreaseInAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in annual base rent</link:label>
    <link:label id="lab_prax_PercentageIncreaseInAnnualBaseRent_label_en-US" xlink:label="lab_prax_PercentageIncreaseInAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase In Annual Base Rent</link:label>
    <link:label id="lab_prax_PercentageIncreaseInAnnualBaseRent_documentation_en-US" xlink:label="lab_prax_PercentageIncreaseInAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase In Annual Base Rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_PercentageIncreaseInAnnualBaseRent" xlink:href="prax-20221231.xsd#prax_PercentageIncreaseInAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_PercentageIncreaseInAnnualBaseRent" xlink:to="lab_prax_PercentageIncreaseInAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6e47aa70-3989-47ef-806c-fe6a8cec535e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_eab3ea79-7ebe-44b6-970a-8b6225e0a8cc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_23a4a4c9-5cea-40a8-bce1-198fa4e69273_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_08523d9f-930f-4ad8-9dd9-787d02269865_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9d235af-0ec5-4803-9cd1-21458ab21f72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_35ac602d-e1d0-4b30-8bbf-cc9ee4d04d98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7f0e3bb7-9a06-4dc7-a723-b28f303b0078_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5bb056d9-7063-4d85-a5e1-aa3b8ceb137b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2ce5c93b-bb15-4287-83bb-eec89a5e8f55_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5c41731d-f593-4856-a5f9-210a2f93b211_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9130dea4-6013-4d90-a226-4d37feb4fdb1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c25baa86-9fc4-4d7e-bc66-902f8fbae3fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2696d7e1-cd72-4854-9150-4a3ac9805769_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_AuditInformationAbstract_label_en-US" xlink:label="lab_prax_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_prax_AuditInformationAbstract_documentation_en-US" xlink:label="lab_prax_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AuditInformationAbstract" xlink:href="prax-20221231.xsd#prax_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_AuditInformationAbstract" xlink:to="lab_prax_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5c40e9fb-614c-49e1-ae03-4967481a5c78_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a6024cc7-ddee-4d01-8383-57abe7bc520b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c5c9f609-3742-4835-93a1-8d13771c9367_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f37956b7-100f-480f-a920-ef01b54e268a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f56f329a-ac61-49f5-b708-7c3ec2ab45ba_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5afccf84-af6c-4162-88f3-75dc3a523f6a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_SignificantAgreementsTextBlock_f3beb3c9-38c6-4d6f-9924-ef1534c51267_terseLabel_en-US" xlink:label="lab_prax_SignificantAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements</link:label>
    <link:label id="lab_prax_SignificantAgreementsTextBlock_label_en-US" xlink:label="lab_prax_SignificantAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements [Text Block]</link:label>
    <link:label id="lab_prax_SignificantAgreementsTextBlock_documentation_en-US" xlink:label="lab_prax_SignificantAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_SignificantAgreementsTextBlock" xlink:href="prax-20221231.xsd#prax_SignificantAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_SignificantAgreementsTextBlock" xlink:to="lab_prax_SignificantAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1bd44f22-877b-4863-b33c-f61fbc290b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b1e11d5-fa6f-4e1b-a663-2c67a24d0fb0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e5070d1b-fdec-4f64-b47b-eb0599961af1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b34dcbd-5cb1-4f6a-a84c-9c7c60e0df6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized losses on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f62a61f1-2c9e-4369-abc1-41476daee382_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2404613c-cb65-42c4-bb07-8db0a74429ac_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4f64afb4-706b-49e9-b45e-669c7af906c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3b9dd73e-7404-4b2a-aa08-67b0ce772d32_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88d0da55-b3bf-471f-9166-60b8b9cac310_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8278466e-eb56-4252-8865-9ab200733dd6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_d9bb0f60-ec39-453e-beaa-98e79a0dc79e_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Share-based Awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_1ef2e230-7a8b-43c8-b163-ae95aad1d34f_negatedLabel_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, accumulated gross unrealized loss, noncurrent, before tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_label_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_documentation_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" xlink:to="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_df217eeb-0ee5-4016-ad6a-d8774cce75b5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e9ade4c-7c14-454f-bd1b-e227cf31de98_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_eed5a88e-eec1-4690-849e-92d56c2b192d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c27928e7-e085-4d41-9466-3241525a141e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8d48b488-be01-4211-beb8-ad5b2f5f7807_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_14978e40-7c41-485e-93a5-abb2aa1fa3ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ceb12907-d9d7-4e4d-820b-fa4364fac5d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_debdb156-72f9-44e3-860c-f924f1f5086a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e0a415a1-e5bc-4ef8-86e8-71b65ccae7bd_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_e883c06b-b2a2-4dfa-909c-bfcf0bc06157_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d138bf18-b006-4b03-b1e0-0f584e0d28bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_5058c2f4-fca2-4244-94e1-f91aededa641_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b6293feb-c2d8-49e8-8adf-36849f5165d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fba692b5-fd80-49a8-9172-4d1b7832ba87_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ce3e050f-2cc2-4f5f-a642-14e2b033d568_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5b976003-4eb6-4f4a-8deb-4c134471de7f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_11a051e3-0110-4681-82b6-40936f6d80e3_terseLabel_en-US" xlink:label="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:href="prax-20221231.xsd#prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:to="lab_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5c78da16-2cc5-4d60-b4a3-80080befd009_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a8538c2-72fb-4fe6-9306-63e43e4c343f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember_6f161a49-c182-4db8-95a7-1774da9138a9_terseLabel_en-US" xlink:label="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Incentive Plan</link:label>
    <link:label id="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember_label_en-US" xlink:label="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Employee Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember_documentation_en-US" xlink:label="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Employee Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentyTwentyEmployeeStockIncentivePlanMember" xlink:href="prax-20221231.xsd#prax_TwentyTwentyEmployeeStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_TwentyTwentyEmployeeStockIncentivePlanMember" xlink:to="lab_prax_TwentyTwentyEmployeeStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bf1a3eb9-2ead-4e79-9e97-1f00cbb7ee21_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_8b941588-2f42-44d6-85fc-8e0f0c035fc5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a5959da3-768c-4c02-9eeb-d66ed9812ee3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_b4bc3b24-8468-493a-af38-4b4e586ea074_terseLabel_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, accumulated gross unrealized gain, current, before tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_label_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax</link:label>
    <link:label id="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_documentation_en-US" xlink:label="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" xlink:to="lab_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_39dd4d82-b97c-4c43-84b5-0d725744363d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7442c46e-13eb-4491-9296-470e7fccec5d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_70063d09-c1a7-43b8-8f8f-fa549d98abfc_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities issued by U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_01458428-ac94-44ac-b31f-6230996d6568_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_66679185-0a53-4f21-979b-d5e870392f14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_932393b4-6f56-4563-9e0d-56bdad5aab35_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9c3712a0-b624-4d2e-ade4-f027c40b2173_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1b0c836-5be9-410b-be37-95fb70b9a71c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9d52d161-a7e3-4503-b6ae-65b8a9de3006_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_948fcc63-6629-4f07-90b2-e8316839c6cb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, net of discounts, commissions and offering expenses</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_bd004a0b-dfc9-40ea-b8b1-d759591b4605_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3644721e-7470-418f-9dc9-af71adbbffb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2faf98c-8ee6-4845-9a0c-6e5d348af6d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ec81964e-9050-4b28-af2b-2694598762dc_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_7dee653e-a73d-44d3-a55e-c51674886367_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_07cd2e39-48ae-4df4-9585-401ea66bac87_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_eb5fd476-c4ad-44ef-9d1a-66a211039294_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from follow-on public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e6aef67-de5f-4512-b04c-3cdcb2efbf36_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7e929f57-f638-47d9-8792-beb95fc46887_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d9b97350-6bd8-4833-a391-23560c383415_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1c1ed138-fe46-4ffd-abf1-90f6b87183d2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5a0d7870-48d3-4974-b892-9d5ff2268cda_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f7f34a7-11ab-4fa2-9802-631f42baded2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_6589b2f6-fb44-4b8e-b30c-27309326abf3_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_b7b484df-9723-4f7d-8fcc-04b1593397db_terseLabel_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_label_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table]</link:label>
    <link:label id="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_documentation_en-US" xlink:label="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:to="lab_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f5c3c415-b849-4b29-90bb-1f0520cf1358_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_676d6da2-b1f8-458f-bd55-2faa31dc817e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3f4bf9be-93a0-4848-9694-c1718b379763_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_447f4fca-4cbf-4a8a-bbba-3f0328bfeee4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_bceedbd0-bc07-4db8-bf90-dbf7246dc59e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5d3002ca-397b-43c4-9ddd-48efc87bb96c_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ff98333e-d2e4-4c74-ad3d-2019d3b646ce_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f05d0200-6ccc-453a-b453-5a4e4cbc8cce_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_3e07c0c0-3e8b-4676-82f9-145de9d10c8d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a6408d14-13eb-44a4-a7ff-0522215aa061_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_7a9c9e0f-e7da-4f40-8107-cb3f298a0fd6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4768b6b5-a2a0-4174-9269-11f122b516eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_15d22c8d-0316-408b-9e9e-107c5479a523_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f84f320b-5b22-4760-acc6-2d8b6a93e6a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value, Available-for-sale, noncurrent</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bf7756c0-823f-439e-a090-32c0516566ff_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_cd467e71-71b9-4752-be46-02ae5531b029_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5e4440fa-f6e2-4a32-af56-1d600ec0ccf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsStock_cd6e1196-8a13-4053-89eb-bace802bcf70_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_DividendsStock_label_en-US" xlink:label="lab_us-gaap_DividendsStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsStock" xlink:to="lab_us-gaap_DividendsStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8a8410b8-9342-40c2-8135-4131843847fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of tax withholdings related to vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_462a36b2-b01b-439e-984b-491044534843_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_d9bbdbb0-d77b-41fc-9e55-dfc78f114880_terseLabel_en-US" xlink:label="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Incentive Plan</link:label>
    <link:label id="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_label_en-US" xlink:label="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Employee Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_documentation_en-US" xlink:label="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Employee Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" xlink:to="lab_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_19b9e820-36d2-4f64-b14d-36268374b582_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_926be681-1c21-4225-b1a5-52443aeb3c9d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2c788798-7c07-4461-9ee6-753497063a56_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b1aca32d-e0a0-4bc4-b05f-17ef1134b4f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_59183fea-985c-457b-8533-010e0c167a88_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_c8b6175e-747f-4505-b70d-387af06a2969_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b182cfd-3a72-4647-aee9-77c9868fc9ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b088cda2-0a79-41f7-808b-98666fac0459_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_fca5f420-6dd9-4225-8aaa-b381fb6ebe27_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d4108fd9-26ec-4d3d-ab3b-5385f579a917_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_f7b701b0-c241-464d-ba74-d089cb71e3e8_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0dd1b79f-7a96-4944-9b1e-00bf83b6ebfb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs for at-the-market offerings and initial public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4d30aa88-26ac-484c-b071-ff2864cfdebf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs for at-the-market offerings and initial public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4a2ab738-f4fa-4052-b754-c07fdadfcaae_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_LaboratoryEquipmentMember_1ca88285-94f4-4a3e-bfdc-a4b1f42d325e_terseLabel_en-US" xlink:label="lab_prax_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_prax_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_prax_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_prax_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_prax_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LaboratoryEquipmentMember" xlink:href="prax-20221231.xsd#prax_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_LaboratoryEquipmentMember" xlink:to="lab_prax_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_60ad246a-233f-4fd6-9ceb-95245eaa4ed5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b3e875e-a232-4fd1-b0bc-d41630295fb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d25fccc9-5f9f-4ec6-a7ba-3e955d71c4d2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_cd21ffe6-6771-4680-a116-ef17f01406e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_025e688b-542f-4c26-97d6-d3da3141178e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_37fa696f-5e0c-47fe-b84a-8f4b98a1de44_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c1f598dc-2bfc-46a6-89c9-d113dba02eba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c7c71699-2637-4d2e-aae5-05cd60930fbf_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_34861f14-71c9-4028-ad18-426f36b472d4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9915e21b-a4ae-4919-8081-4fcfe6967af8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_13addf57-e0a3-4e81-8635-ec02a04f4e08_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a6d97c21-4b73-4791-8d78-13033a2e0974_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_4ae7eea5-5206-40f6-8084-92780453d1d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e66ea879-48b7-4bd7-93db-8fe67c424f26_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember_17f2443b-5030-4841-98e1-4c977eaa40ff_terseLabel_en-US" xlink:label="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentyTwentyEmployeeStockPurchasePlanMember" xlink:href="prax-20221231.xsd#prax_TwentyTwentyEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_TwentyTwentyEmployeeStockPurchasePlanMember" xlink:to="lab_prax_TwentyTwentyEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_283a7993-f885-4f03-9689-83eccd0f03d3_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_41a409a2-ead8-453a-8ac0-fc33a8592ad8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_de90f4bc-2097-4fd1-a97d-babb95e5c408_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, increase (decrease), amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1b3eea23-0322-493f-b0cd-d2440beaccaa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f0039bc1-4c29-49c3-bfe1-c98c2769c5de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_214df22a-891f-4482-b790-88778330d502_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8f9b2414-98b0-48ae-9d70-eb460d8461be_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_ee4590a1-7980-4013-b323-f7f4ff619dc5_negatedTerseLabel_en-US" xlink:label="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="prax-20221231.xsd#prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2d632cb5-c686-4206-bc25-1233f71064ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_07d99f8b-9672-4c43-9206-b44e4db51eb2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_eb68c07c-d9c5-45fa-916c-d625696135f0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ae61cdad-9ad1-4ec3-b411-d8acc8335276_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e47348f0-ddd3-4321-afd0-3c45917a4ed9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6c74db08-b28b-4642-85d3-66d7c142808a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_bc1d4571-642b-49be-b59a-a5c0276f4d6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares witheld for taxes for vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_prax_LettersOfCreditReceivableCurrent_8b2f4ddd-69ce-4b8c-a93e-6a6feb494431_terseLabel_en-US" xlink:label="lab_prax_LettersOfCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters Of Credit Receivable, Current</link:label>
    <link:label id="lab_prax_LettersOfCreditReceivableCurrent_label_en-US" xlink:label="lab_prax_LettersOfCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters Of Credit Receivable, Current</link:label>
    <link:label id="lab_prax_LettersOfCreditReceivableCurrent_documentation_en-US" xlink:label="lab_prax_LettersOfCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters Of Credit Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LettersOfCreditReceivableCurrent" xlink:href="prax-20221231.xsd#prax_LettersOfCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prax_LettersOfCreditReceivableCurrent" xlink:to="lab_prax_LettersOfCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c957127b-5104-417c-80a4-d8a4f4e8014b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d9aba85d-c096-4a8d-97d0-12ad2ba9349b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_d3e86e89-a807-49cf-93ce-58c32f8ec613_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_c52a1d60-0492-4854-8f54-fcfbe6163baf_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d3f0c1f2-f4cd-431a-a00c-6e28b5541bda_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9a68a0f2-3f16-421c-bada-f2bc23885a5d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d20e9327-d0ce-471e-8608-a99ec67578f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_fb7f97dd-7dfd-4bbb-8989-76ccfb0e3e89_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c8470cfb-b74c-4c87-a7a0-5caffcb338b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b92c54f5-7d86-4a9a-b718-5701d972ebb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld for taxes for vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0e0d1eb-9dc2-4a25-aafc-475f128c48c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ffc17e9f-8b14-4eec-99b0-fb3d635b2095_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Option and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_8e8baba6-4b84-4afd-aedd-f92b89c9f13b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Significant Suppliers and License Agreements</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_24139c34-fb58-4ce4-8732-8b46e37053d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f257aa4b-df54-46e8-85f9-22bdafb1357b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3ef02de4-dbd9-421d-9a9e-06aaa070e4d0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3ef3bb81-7ef8-463b-b656-820819220955_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_f313a1fd-024b-4c5a-b4e0-03c8bad998bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other debt securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_9ddda875-f061-4d86-b34d-4c1c19966287_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c21bd96a-00d6-4baf-a233-978cc7935f42_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8ad9c0c8-4d4d-4b79-8edc-bebb0028a671_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e015b1ed-6148-4af5-b799-04d077524b16_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_012381c4-08cb-4085-a441-f5fc7982a5ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_364b626e-39d9-48af-8164-f76cad3f7895_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b4c2cea3-6c97-49f7-85ac-84dd202863f3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c9aa298-6137-49b2-b774-388c4131d0d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ec74cadc-0421-453e-a745-515bbe81edf7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c8c0bb15-e89b-4df1-b419-016271c561d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1d5a4807-5fda-4157-b2a7-189760d26a63_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5d1c5d82-8485-4569-ba0f-4043072d862d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_afaa49b0-234d-4e2c-9597-322cb0cd22ea_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>prax-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:912e1565-2dff-44dd-bfb3-af6c8a11fb3c,g:26ec8c83-18eb-4378-8ac1-2975735259ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://praxismedicines.com/role/CoverPage" xlink:type="simple" xlink:href="prax-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_570940a4-8e25-448a-8749-4e79aa911df0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_DocumentType_570940a4-8e25-448a-8749-4e79aa911df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_328d5b17-f491-4a60-a677-ff4413d7bd63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_DocumentAnnualReport_328d5b17-f491-4a60-a677-ff4413d7bd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e0fbe12a-c992-4599-8bf8-51a2e1a66e2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_DocumentPeriodEndDate_e0fbe12a-c992-4599-8bf8-51a2e1a66e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9ac7e1ba-c29d-4352-9867-d48df782b078" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_CurrentFiscalYearEndDate_9ac7e1ba-c29d-4352-9867-d48df782b078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ba3cf26b-0100-4d18-9faa-dbebab76ee82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_DocumentTransitionReport_ba3cf26b-0100-4d18-9faa-dbebab76ee82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bce7c4b2-1aa8-420a-9079-d2fa5d0021d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityFileNumber_bce7c4b2-1aa8-420a-9079-d2fa5d0021d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6a6c2829-c533-4f34-a451-c1ce7dc86962" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityRegistrantName_6a6c2829-c533-4f34-a451-c1ce7dc86962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b4ee3c09-5012-4c57-a9c3-592d590debda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b4ee3c09-5012-4c57-a9c3-592d590debda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a12381db-f00b-40c9-a80f-247da4ac51cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityTaxIdentificationNumber_a12381db-f00b-40c9-a80f-247da4ac51cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_22ace3a1-0d77-4820-a623-bb87993dddf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityAddressAddressLine1_22ace3a1-0d77-4820-a623-bb87993dddf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_7944a7be-176b-4f5e-8606-9eac568d0a58" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityAddressAddressLine2_7944a7be-176b-4f5e-8606-9eac568d0a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7fbeb3b5-7607-423f-afc3-81de642c0ae5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityAddressCityOrTown_7fbeb3b5-7607-423f-afc3-81de642c0ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6b3ba926-307a-42d8-8e75-2155bbbfa23f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityAddressStateOrProvince_6b3ba926-307a-42d8-8e75-2155bbbfa23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2e6f08b5-efa8-4fd9-87ef-19fac28aa733" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityAddressPostalZipCode_2e6f08b5-efa8-4fd9-87ef-19fac28aa733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e95f5add-23b7-4461-a820-19061540af7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_CityAreaCode_e95f5add-23b7-4461-a820-19061540af7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5fb79fe3-909c-4048-93fb-bd4137ffb7ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_LocalPhoneNumber_5fb79fe3-909c-4048-93fb-bd4137ffb7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f8dd023a-3ccf-48e6-a73d-4ac9f265977c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_Security12bTitle_f8dd023a-3ccf-48e6-a73d-4ac9f265977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e270c73a-3763-4834-aa8c-d2af81c79a34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_TradingSymbol_e270c73a-3763-4834-aa8c-d2af81c79a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_56ad36ee-db8b-4d52-83a6-3b8f9ef8de72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_SecurityExchangeName_56ad36ee-db8b-4d52-83a6-3b8f9ef8de72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f9175ba5-3ee1-4f42-9db8-3db17aae5394" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f9175ba5-3ee1-4f42-9db8-3db17aae5394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_efe3efc5-045e-4216-b958-044efe6826d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityVoluntaryFilers_efe3efc5-045e-4216-b958-044efe6826d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9ad349c3-57e2-43c7-8fa7-fa8f0d6ba6c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityCurrentReportingStatus_9ad349c3-57e2-43c7-8fa7-fa8f0d6ba6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ad0a8709-7a67-4902-890a-0c0dde0af803" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityInteractiveDataCurrent_ad0a8709-7a67-4902-890a-0c0dde0af803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_79ef7946-5d68-4aa8-8bcd-4acc381f4bb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityFilerCategory_79ef7946-5d68-4aa8-8bcd-4acc381f4bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0d61d187-95c6-4a7d-964a-3d09bbb193f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntitySmallBusiness_0d61d187-95c6-4a7d-964a-3d09bbb193f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_61cc2c22-19e2-4c00-ad7d-14ad63bbd527" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityEmergingGrowthCompany_61cc2c22-19e2-4c00-ad7d-14ad63bbd527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_482b8ede-5662-4b40-9841-57ad3f220aea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_482b8ede-5662-4b40-9841-57ad3f220aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_987b4114-75ed-4900-a717-85dba0a7719d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityShellCompany_987b4114-75ed-4900-a717-85dba0a7719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_156fec44-6203-4751-976b-5436e932c9d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityPublicFloat_156fec44-6203-4751-976b-5436e932c9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cfc8c529-dfae-4cf8-b9bd-689ae7a25a52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cfc8c529-dfae-4cf8-b9bd-689ae7a25a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_52c792b4-4d61-4909-98c1-5728debc5ee6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_AmendmentFlag_52c792b4-4d61-4909-98c1-5728debc5ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_49be614c-2e99-48f6-8e4d-c083162e0b83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_DocumentFiscalYearFocus_49be614c-2e99-48f6-8e4d-c083162e0b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6e5b8b10-4ec0-4674-85ac-e84eaa2221ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6e5b8b10-4ec0-4674-85ac-e84eaa2221ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cbc3d237-27a4-41ee-a858-f200f85e5907" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0991161b-169e-4cf3-b0c2-1310d14ce1a4" xlink:to="loc_dei_EntityCentralIndexKey_cbc3d237-27a4-41ee-a858-f200f85e5907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/AuditInformation" xlink:type="simple" xlink:href="prax-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prax_AuditInformationAbstract_ed5185f8-8324-4356-8eaf-cb47ba27c0ef" xlink:href="prax-20221231.xsd#prax_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c64558ad-012d-4016-a517-31ca0ce026d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_AuditInformationAbstract_ed5185f8-8324-4356-8eaf-cb47ba27c0ef" xlink:to="loc_dei_AuditorFirmId_c64558ad-012d-4016-a517-31ca0ce026d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_8f797e32-129f-42c0-beed-85959ec1f399" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_AuditInformationAbstract_ed5185f8-8324-4356-8eaf-cb47ba27c0ef" xlink:to="loc_dei_AuditorName_8f797e32-129f-42c0-beed-85959ec1f399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_23ae185b-f8af-46f2-bf80-b042a8831747" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_AuditInformationAbstract_ed5185f8-8324-4356-8eaf-cb47ba27c0ef" xlink:to="loc_dei_AuditorLocation_23ae185b-f8af-46f2-bf80-b042a8831747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2b21f82c-9f37-47b0-a6a3-b3d977bfe71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c16ceff1-c013-4dbf-8157-e1dbfa4263f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b21f82c-9f37-47b0-a6a3-b3d977bfe71d" xlink:to="loc_us-gaap_AssetsAbstract_c16ceff1-c013-4dbf-8157-e1dbfa4263f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c16ceff1-c013-4dbf-8157-e1dbfa4263f5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6f1b546-1d21-4272-ba19-f8c6c8afeec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6f1b546-1d21-4272-ba19-f8c6c8afeec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e202b2f3-5c49-4380-8705-6f498abdd38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e202b2f3-5c49-4380-8705-6f498abdd38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55093810-a0af-4841-af70-c48da4bb783c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55093810-a0af-4841-af70-c48da4bb783c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_17f3af47-a708-4f29-b521-759d8534764f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_AssetsCurrent_17f3af47-a708-4f29-b521-759d8534764f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0cf43db7-5de0-40b6-9e87-cd8102b8b6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0cf43db7-5de0-40b6-9e87-cd8102b8b6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8764e7b-d3ac-4772-9697-0d7c0fb34525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8764e7b-d3ac-4772-9697-0d7c0fb34525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_70a7aaa9-d038-4a60-bcba-dd137aeea20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_70a7aaa9-d038-4a60-bcba-dd137aeea20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edd8cae3-b79d-43d9-ab0f-45891ec5561c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c616c26-db11-4afc-90d0-da283810f353" xlink:to="loc_us-gaap_Assets_edd8cae3-b79d-43d9-ab0f-45891ec5561c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b21f82c-9f37-47b0-a6a3-b3d977bfe71d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_19306b27-fa62-457b-b7c6-32e033387cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:to="loc_us-gaap_AccountsPayableCurrent_19306b27-fa62-457b-b7c6-32e033387cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c0129b21-449a-461f-aa8b-a7ce88e4cb10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c0129b21-449a-461f-aa8b-a7ce88e4cb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_876824c8-01c6-4ead-972d-27f5660d740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_876824c8-01c6-4ead-972d-27f5660d740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_daa0ea08-2f46-4b4b-8090-7e1aa39dd9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_daa0ea08-2f46-4b4b-8090-7e1aa39dd9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e2c9552a-9774-4769-8bc3-f0ae1cb0637e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0f5e84c4-d73a-4d65-9ae4-2ad704e221f0" xlink:to="loc_us-gaap_LiabilitiesCurrent_e2c9552a-9774-4769-8bc3-f0ae1cb0637e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_95ee904e-6fff-4942-8b1c-a7fdc877a13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_95ee904e-6fff-4942-8b1c-a7fdc877a13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b072ace2-c5cf-43fd-b37c-492820004027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_95ee904e-6fff-4942-8b1c-a7fdc877a13c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b072ace2-c5cf-43fd-b37c-492820004027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_21598b39-4df6-417c-b573-9492db4ff57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_95ee904e-6fff-4942-8b1c-a7fdc877a13c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_21598b39-4df6-417c-b573-9492db4ff57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d9678b96-db2c-4d8e-abb5-605b6994c725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:to="loc_us-gaap_Liabilities_d9678b96-db2c-4d8e-abb5-605b6994c725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_656b9e8c-42e8-408e-af27-a872815c75fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:to="loc_us-gaap_CommitmentsAndContingencies_656b9e8c-42e8-408e-af27-a872815c75fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:to="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e9080ede-b0b8-43e4-9494-992e4974f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:to="loc_us-gaap_PreferredStockValue_e9080ede-b0b8-43e4-9494-992e4974f5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_088d5f1e-25f9-4e6f-bb35-c7c68fa63333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:to="loc_us-gaap_CommonStockValue_088d5f1e-25f9-4e6f-bb35-c7c68fa63333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cc0949c7-8952-47ba-9f9f-e5c24726f00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cc0949c7-8952-47ba-9f9f-e5c24726f00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8f43a69-23d0-4231-b99f-5918debfc466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8f43a69-23d0-4231-b99f-5918debfc466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0faf3f52-8d3d-4992-979a-de3d3fb4bc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0faf3f52-8d3d-4992-979a-de3d3fb4bc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f6da764c-6496-4516-8124-9dd1cadffb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3e5e9bd7-b257-49f4-834f-6a4321e26995" xlink:to="loc_us-gaap_StockholdersEquity_f6da764c-6496-4516-8124-9dd1cadffb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6780192a-2325-4a42-98a8-b9612615c838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6b45dc97-e973-4909-b56e-fa7f5cb63d00" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6780192a-2325-4a42-98a8-b9612615c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e0131274-a0be-4a45-a203-765445ed49e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e0131274-a0be-4a45-a203-765445ed49e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c4c95e37-4665-4d7b-83fd-adec211a2b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c4c95e37-4665-4d7b-83fd-adec211a2b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_500e0aeb-b5fc-4989-8a00-5a7cedeb0a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_500e0aeb-b5fc-4989-8a00-5a7cedeb0a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_610ace77-813a-48f1-82cd-6d525fddd5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_610ace77-813a-48f1-82cd-6d525fddd5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3c49e4f9-8406-41b5-a78a-d90bd4bc6882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3c49e4f9-8406-41b5-a78a-d90bd4bc6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_834059ca-4f06-4a59-9ba8-2a6505c377fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_834059ca-4f06-4a59-9ba8-2a6505c377fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1547637-430c-4125-a831-0fd2f30f6b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1547637-430c-4125-a831-0fd2f30f6b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f7c31ffa-c19c-4bec-8b0f-2a62eab4fe57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_CommonStockSharesIssued_f7c31ffa-c19c-4bec-8b0f-2a62eab4fe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3d409cb6-7af2-4f6b-87f1-8f1d33303629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3d409cb6-7af2-4f6b-87f1-8f1d33303629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_555a7025-d3c3-46a3-9f43-6558803210a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_acd77954-2788-4b4d-bf6a-0b4fcba3f64e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_555a7025-d3c3-46a3-9f43-6558803210a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b3fa2948-f4fe-43bc-996c-d26120afc267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b3fa2948-f4fe-43bc-996c-d26120afc267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_183155f8-68f1-46a1-8c92-317ccf6ca3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b3fa2948-f4fe-43bc-996c-d26120afc267" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_183155f8-68f1-46a1-8c92-317ccf6ca3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_23a70a91-b3d7-43d3-b06f-9f3300b83306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b3fa2948-f4fe-43bc-996c-d26120afc267" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_23a70a91-b3d7-43d3-b06f-9f3300b83306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_add49e94-e6f7-495c-b2c1-3aee5f8f9587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b3fa2948-f4fe-43bc-996c-d26120afc267" xlink:to="loc_us-gaap_OperatingExpenses_add49e94-e6f7-495c-b2c1-3aee5f8f9587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_88fd95fc-dd84-4f14-a026-04fe212309a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_OperatingIncomeLoss_88fd95fc-dd84-4f14-a026-04fe212309a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ff1a2b00-2517-40a5-b675-2deb97c9eb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ff1a2b00-2517-40a5-b675-2deb97c9eb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_90d373fa-4c20-4fd4-a7bd-6e87d0fe6987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ff1a2b00-2517-40a5-b675-2deb97c9eb89" xlink:to="loc_us-gaap_InterestIncomeOther_90d373fa-4c20-4fd4-a7bd-6e87d0fe6987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_370d4a3a-11c9-4d2d-9076-5585c5229fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ff1a2b00-2517-40a5-b675-2deb97c9eb89" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_370d4a3a-11c9-4d2d-9076-5585c5229fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ae528fd-4ebc-4be4-80c8-ee76d174de88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_NetIncomeLoss_1ae528fd-4ebc-4be4-80c8-ee76d174de88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b195fb35-1376-48d7-adcd-9f906b722ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_EarningsPerShareBasic_b195fb35-1376-48d7-adcd-9f906b722ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_af1be602-145b-49fa-bddb-4f797d962e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_af1be602-145b-49fa-bddb-4f797d962e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12955703-1776-4885-af23-8c5f638c3ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12955703-1776-4885-af23-8c5f638c3ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6bfa05d2-a71f-43c9-bc1a-1b758fa7d467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e50988e-0743-4018-b233-bc323e35a7d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6bfa05d2-a71f-43c9-bc1a-1b758fa7d467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a38ce0c-a5ed-41eb-835d-363e0b61e8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44e05455-abeb-42c7-9815-7088cff1fb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a38ce0c-a5ed-41eb-835d-363e0b61e8a4" xlink:to="loc_us-gaap_NetIncomeLoss_44e05455-abeb-42c7-9815-7088cff1fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_28400a28-d688-4cf4-84ef-7f47a5a50b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a38ce0c-a5ed-41eb-835d-363e0b61e8a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_28400a28-d688-4cf4-84ef-7f47a5a50b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_15713c8a-2e85-4a46-96e9-5d7bc589447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a38ce0c-a5ed-41eb-835d-363e0b61e8a4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_15713c8a-2e85-4a46-96e9-5d7bc589447d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_12fc83a5-56de-4fac-ae47-12c7f5fe43ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_12fc83a5-56de-4fac-ae47-12c7f5fe43ee" xlink:to="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_776bd731-39d4-4066-a575-7f17dfaf42d4" xlink:to="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_390afb3e-687a-4f50-aae3-17710ba36f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_CommonStockMember_390afb3e-687a-4f50-aae3-17710ba36f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_efff00ed-0581-4b3a-942d-eccda3c6a1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_efff00ed-0581-4b3a-942d-eccda3c6a1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0f00cf46-43ab-4fbc-baca-eabd573127e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_RetainedEarningsMember_0f00cf46-43ab-4fbc-baca-eabd573127e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1865bc06-db96-4c29-805d-338ff959693b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d113ee3a-9562-4736-b2df-0e4f8890f63b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1865bc06-db96-4c29-805d-338ff959693b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e4200c40-aec6-4e45-9ae7-bb7946411a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_14da9cee-05bd-4390-9294-138dadd6f838" xlink:to="loc_us-gaap_StatementLineItems_e4200c40-aec6-4e45-9ae7-bb7946411a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e4200c40-aec6-4e45-9ae7-bb7946411a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0452eaae-54da-487a-80dc-c2bc1ca236ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0452eaae-54da-487a-80dc-c2bc1ca236ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b95160c5-54dc-4a7a-a7d0-5eb0d7de053d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockholdersEquity_b95160c5-54dc-4a7a-a7d0-5eb0d7de053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afa470b8-0aaa-4844-a26c-6520343583df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_afa470b8-0aaa-4844-a26c-6520343583df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f9c93bfa-239f-4618-a50b-6564bcd81870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f9c93bfa-239f-4618-a50b-6564bcd81870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f80c2b4b-5c6d-46bc-98df-4e442305ee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f80c2b4b-5c6d-46bc-98df-4e442305ee7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3ceb022-274c-4806-88c1-7f5a01eedc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a3ceb022-274c-4806-88c1-7f5a01eedc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f074d392-7429-49d4-bf36-8e70c609f300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f074d392-7429-49d4-bf36-8e70c609f300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c27e972d-0247-4e30-97ee-3fd491c2e082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c27e972d-0247-4e30-97ee-3fd491c2e082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4f3c3281-1da8-4020-9c3c-cf3ca976c28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4f3c3281-1da8-4020-9c3c-cf3ca976c28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d74bfca0-3a96-4fbf-a0d5-6edde074114a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d74bfca0-3a96-4fbf-a0d5-6edde074114a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec452523-b84c-4740-b134-3e64074aae30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec452523-b84c-4740-b134-3e64074aae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8c225f90-2646-4042-bfcd-df348a4585c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8c225f90-2646-4042-bfcd-df348a4585c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4ec3ed57-b82e-4ef4-b0c2-fe81d8ae9672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4ec3ed57-b82e-4ef4-b0c2-fe81d8ae9672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2c131c8-abd7-4bdf-a8cd-2d45f3cd1d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_NetIncomeLoss_b2c131c8-abd7-4bdf-a8cd-2d45f3cd1d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_be32c033-dcb5-4e5f-b319-8e24048770dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_be32c033-dcb5-4e5f-b319-8e24048770dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b7641c2-da50-4212-b661-b067bd7943f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97f0628a-9586-41f2-905b-d80b9c4a03ca" xlink:to="loc_us-gaap_StockholdersEquity_6b7641c2-da50-4212-b661-b067bd7943f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0249a144-ecf6-40d8-af36-d5b95cf4d4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0249a144-ecf6-40d8-af36-d5b95cf4d4f6" xlink:to="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_787c685d-47f2-459c-9f7b-3e11e00fa8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2c193e87-dbc0-48a8-8691-688f5e84abc2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_787c685d-47f2-459c-9f7b-3e11e00fa8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_A2022OfferingsMember_7bb2d3af-ed8f-4926-b804-4751e661adcb" xlink:href="prax-20221231.xsd#prax_A2022OfferingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_787c685d-47f2-459c-9f7b-3e11e00fa8bf" xlink:to="loc_prax_A2022OfferingsMember_7bb2d3af-ed8f-4926-b804-4751e661adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9071f9d1-f6a2-4689-a092-acc13836d729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1a52773f-aa8f-4a8d-a93f-bdff0288f78e" xlink:to="loc_us-gaap_StatementLineItems_9071f9d1-f6a2-4689-a092-acc13836d729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_270236d9-77fb-40b9-ae13-3d123d8ee030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9071f9d1-f6a2-4689-a092-acc13836d729" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_270236d9-77fb-40b9-ae13-3d123d8ee030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="prax-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cc2dda7-13ff-4572-9143-4fed05be318d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cc2dda7-13ff-4572-9143-4fed05be318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72a363b3-0b33-4249-bd7b-ee3e5695b6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cc2dda7-13ff-4572-9143-4fed05be318d" xlink:to="loc_us-gaap_NetIncomeLoss_72a363b3-0b33-4249-bd7b-ee3e5695b6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8cc2dda7-13ff-4572-9143-4fed05be318d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e3549708-8aad-41cc-82ac-f57cf6751057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:to="loc_us-gaap_Depreciation_e3549708-8aad-41cc-82ac-f57cf6751057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_06df7ca7-6f08-4456-b7b6-163d607933d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:to="loc_us-gaap_ShareBasedCompensation_06df7ca7-6f08-4456-b7b6-163d607933d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_120287d7-c363-4f02-91bf-a4a7d0c2da58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_120287d7-c363-4f02-91bf-a4a7d0c2da58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_513c8125-7cfd-4a5f-af19-d46a6034f57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_513c8125-7cfd-4a5f-af19-d46a6034f57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce10e5de-fa8a-4ebe-8b9a-82f4be202d82" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_23264e3a-25c1-41fa-b9f9-64a650619324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_23264e3a-25c1-41fa-b9f9-64a650619324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4bb743d3-b8b0-4cf2-859d-b583f413b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4bb743d3-b8b0-4cf2-859d-b583f413b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fdf295e5-a765-47b8-b499-30ea83ecaa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fdf295e5-a765-47b8-b499-30ea83ecaa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_IncreaseDecreaseInOperatingLeaseLiabilities_f4063920-412c-4538-a79c-96715c34622b" xlink:href="prax-20221231.xsd#prax_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_prax_IncreaseDecreaseInOperatingLeaseLiabilities_f4063920-412c-4538-a79c-96715c34622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1bce26b4-be88-4f64-9ad7-7794d97e1ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1bce26b4-be88-4f64-9ad7-7794d97e1ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cf94ae-5d7e-4cc3-ab37-0110789382ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cf94ae-5d7e-4cc3-ab37-0110789382ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04104123-8cd6-44e8-aa1c-baa35da2be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61e960d-2088-4f71-8e67-006e10b5d4a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04104123-8cd6-44e8-aa1c-baa35da2be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de7be866-cbd6-4507-b3b6-e15b4bfd4578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de7be866-cbd6-4507-b3b6-e15b4bfd4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d4a01305-ccfe-49ea-89df-9dd274ef6a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de7be866-cbd6-4507-b3b6-e15b4bfd4578" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d4a01305-ccfe-49ea-89df-9dd274ef6a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_443a0416-213d-4dad-9572-579c4e7aae10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de7be866-cbd6-4507-b3b6-e15b4bfd4578" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_443a0416-213d-4dad-9572-579c4e7aae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f0c37810-96bf-45f8-b532-888f05e50dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de7be866-cbd6-4507-b3b6-e15b4bfd4578" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f0c37810-96bf-45f8-b532-888f05e50dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48b32c2d-3149-4b72-a563-7a7d04fc21c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de7be866-cbd6-4507-b3b6-e15b4bfd4578" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48b32c2d-3149-4b72-a563-7a7d04fc21c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_85d6a13d-6468-4adc-a16b-fd3b11556853" xlink:href="prax-20221231.xsd#prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:to="loc_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts_85d6a13d-6468-4adc-a16b-fd3b11556853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57b36b49-136e-4831-84af-ece7d8a51e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57b36b49-136e-4831-84af-ece7d8a51e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_aecea61b-fef6-4400-91ec-39c88524624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_aecea61b-fef6-4400-91ec-39c88524624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1f8ab026-28b3-4339-bdf4-f52388ea3bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1f8ab026-28b3-4339-bdf4-f52388ea3bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ff541a19-874a-483d-b2f7-57dd4f8a2063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ff541a19-874a-483d-b2f7-57dd4f8a2063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08f1247a-21e4-43f7-a106-6d69d244fd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b9c76b2-4f5d-4779-b494-bf5aa6e746da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08f1247a-21e4-43f7-a106-6d69d244fd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8d2425cc-b2cf-4a66-862a-1a531fae082e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8d2425cc-b2cf-4a66-862a-1a531fae082e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7153a0a2-23d8-47a5-87df-4c0cf74e63b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7153a0a2-23d8-47a5-87df-4c0cf74e63b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86ce841e-df68-4a0f-be4f-dc64e00b54d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86ce841e-df68-4a0f-be4f-dc64e00b54d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8595137e-52e7-4a38-b3eb-b6454d17c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8595137e-52e7-4a38-b3eb-b6454d17c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d05dad0e-0a04-427f-9ffe-aab459d02471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8595137e-52e7-4a38-b3eb-b6454d17c5ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d05dad0e-0a04-427f-9ffe-aab459d02471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c7bc3e11-9223-4678-998d-cbef3bffb36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8595137e-52e7-4a38-b3eb-b6454d17c5ce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c7bc3e11-9223-4678-998d-cbef3bffb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19325b67-fabe-41a5-a360-e302433f23d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8595137e-52e7-4a38-b3eb-b6454d17c5ce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19325b67-fabe-41a5-a360-e302433f23d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_369eb679-990f-4e28-b1a0-2e10597d5b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_38afb5a9-660a-423b-a95c-365655b9cc45" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_369eb679-990f-4e28-b1a0-2e10597d5b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c4e1ce8c-b68c-4b64-af19-5d069dc03453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_369eb679-990f-4e28-b1a0-2e10597d5b6c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c4e1ce8c-b68c-4b64-af19-5d069dc03453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_f28028f6-ed5e-4668-bad0-9116944e1665" xlink:href="prax-20221231.xsd#prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_369eb679-990f-4e28-b1a0-2e10597d5b6c" xlink:to="loc_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_f28028f6-ed5e-4668-bad0-9116944e1665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_60325935-d69e-4f9c-be11-4a32819d8488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_369eb679-990f-4e28-b1a0-2e10597d5b6c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_60325935-d69e-4f9c-be11-4a32819d8488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="prax-20221231.xsd#NatureoftheBusiness"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/NatureoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d228352c-b638-4af8-ad83-daf60df229ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_892168f6-43bf-4d17-b970-733e5dd5d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d228352c-b638-4af8-ad83-daf60df229ab" xlink:to="loc_us-gaap_NatureOfOperations_892168f6-43bf-4d17-b970-733e5dd5d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b8f119dd-72d1-4489-beca-d4b6c562ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cf6b2a77-3b2b-475c-8dec-52dc3fe9762a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b8f119dd-72d1-4489-beca-d4b6c562ef34" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cf6b2a77-3b2b-475c-8dec-52dc3fe9762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/RestrictedCash" xlink:type="simple" xlink:href="prax-20221231.xsd#RestrictedCash"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/RestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_16e1c84b-d811-4fbc-8c4d-3adc431e48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_ca5d627e-b8db-4a87-952e-64527de73c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_16e1c84b-d811-4fbc-8c4d-3adc431e48ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_ca5d627e-b8db-4a87-952e-64527de73c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecurities" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be524654-1d29-419b-a314-efcd69bfe705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2213a7d7-c7bb-4060-be0f-e4ab26b5c3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be524654-1d29-419b-a314-efcd69bfe705" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2213a7d7-c7bb-4060-be0f-e4ab26b5c3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/FairValueofFinancialAssets" xlink:type="simple" xlink:href="prax-20221231.xsd#FairValueofFinancialAssets"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/FairValueofFinancialAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_32805c4e-2207-4470-97e8-e5c5c8f58cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b656edd9-cfb9-4335-a9cf-f02cdfba6b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_32805c4e-2207-4470-97e8-e5c5c8f58cd3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b656edd9-cfb9-4335-a9cf-f02cdfba6b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="prax-20221231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a93c4dd7-0cad-447f-9cee-6bfc164d7166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d61e4897-a3f5-4dc4-97cd-079ee1840662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a93c4dd7-0cad-447f-9cee-6bfc164d7166" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d61e4897-a3f5-4dc4-97cd-079ee1840662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/AccruedExpenses" xlink:type="simple" xlink:href="prax-20221231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fedfb2a4-ee51-4bce-8bfb-92b45f49816a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3dc71d5b-2d7f-47db-9361-a112c9b93777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fedfb2a4-ee51-4bce-8bfb-92b45f49816a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3dc71d5b-2d7f-47db-9361-a112c9b93777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a300af1a-dca6-4aa2-9848-9bea291fb29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_af6ff9d0-d39a-45a8-881a-dffc1b04d730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a300af1a-dca6-4aa2-9848-9bea291fb29e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_af6ff9d0-d39a-45a8-881a-dffc1b04d730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/UCBOptionandLicenseAgreement" xlink:type="simple" xlink:href="prax-20221231.xsd#UCBOptionandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/UCBOptionandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d48306cb-3449-4a2d-8b05-f74f15903be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f704d6bf-1ead-4b3c-b4d2-7a4c10e7fe56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d48306cb-3449-4a2d-8b05-f74f15903be6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f704d6bf-1ead-4b3c-b4d2-7a4c10e7fe56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommonStockandPreferredStock" xlink:type="simple" xlink:href="prax-20221231.xsd#CommonStockandPreferredStock"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommonStockandPreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b0c982df-b402-4379-9928-64e2ecd7dd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4925f375-bc7c-4f29-822f-36afbbfdd159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b0c982df-b402-4379-9928-64e2ecd7dd81" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4925f375-bc7c-4f29-822f-36afbbfdd159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a437020-2c6a-4427-958b-0e2fa488d404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5315efe7-233f-4297-8074-43b1b356679e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a437020-2c6a-4427-958b-0e2fa488d404" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5315efe7-233f-4297-8074-43b1b356679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SignificantAgreements" xlink:type="simple" xlink:href="prax-20221231.xsd#SignificantAgreements"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SignificantAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a0dd0a4e-939f-4b77-987a-d6dabe4b1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_SignificantAgreementsTextBlock_d9dbb776-18ec-442f-96d3-39c2337e52b8" xlink:href="prax-20221231.xsd#prax_SignificantAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a0dd0a4e-939f-4b77-987a-d6dabe4b1d48" xlink:to="loc_prax_SignificantAgreementsTextBlock_d9dbb776-18ec-442f-96d3-39c2337e52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/NetLossperShare" xlink:type="simple" xlink:href="prax-20221231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5d4e110b-bd15-4a5d-9bae-53e69c500efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5b4f9a24-5ae8-475b-a155-704b5e92c721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5d4e110b-bd15-4a5d-9bae-53e69c500efd" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5b4f9a24-5ae8-475b-a155-704b5e92c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxes" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cda95557-ca24-4e21-9c3e-545ca9a15735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e5c9c045-c991-4860-84f5-5a6a9e601768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cda95557-ca24-4e21-9c3e-545ca9a15735" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e5c9c045-c991-4860-84f5-5a6a9e601768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="prax-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8393c179-6f3d-41a6-9336-109183674721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7c05d682-7c6b-4d16-af59-5bc0eaa727eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8393c179-6f3d-41a6-9336-109183674721" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7c05d682-7c6b-4d16-af59-5bc0eaa727eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="prax-20221231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8783585e-d187-4ece-857b-c78d25b79650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_99c68597-d51d-473f-acbf-ed430b6534c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8783585e-d187-4ece-857b-c78d25b79650" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_99c68597-d51d-473f-acbf-ed430b6534c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/Restructuring" xlink:type="simple" xlink:href="prax-20221231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7cb759f6-c162-46db-8345-4be445a04565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_09538e5a-2b9f-4d59-a29a-21708599d382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7cb759f6-c162-46db-8345-4be445a04565" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_09538e5a-2b9f-4d59-a29a-21708599d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SubsequentEvents" xlink:type="simple" xlink:href="prax-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bafafff7-9886-46ab-8278-2256fd2790f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_f38da0d9-e144-43e0-b5fa-6b88ab4ec548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bafafff7-9886-46ab-8278-2256fd2790f8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_f38da0d9-e144-43e0-b5fa-6b88ab4ec548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e993f28c-3ddf-42d2-a42e-08ec72e2464e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e993f28c-3ddf-42d2-a42e-08ec72e2464e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7bbb1331-285b-4a86-9cc0-bae338c9865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7bbb1331-285b-4a86-9cc0-bae338c9865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_904ec3de-9559-44ac-acb8-d6bda0759cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_UseOfEstimates_904ec3de-9559-44ac-acb8-d6bda0759cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_67cda58d-2d47-41b9-92ef-5f15e959d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_67cda58d-2d47-41b9-92ef-5f15e959d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c11ce324-f8c4-4ab8-a7e5-bda6bcc770d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c11ce324-f8c4-4ab8-a7e5-bda6bcc770d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_64707c5a-a697-4ee3-a734-5023c609ed3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_64707c5a-a697-4ee3-a734-5023c609ed3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e8d31334-a5ee-4015-ab4b-a8bff82e3a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e8d31334-a5ee-4015-ab4b-a8bff82e3a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_721e2ddd-5f86-48fc-b929-c20cf9dc5869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_721e2ddd-5f86-48fc-b929-c20cf9dc5869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b70f1cbc-b029-4bc7-b252-ef1ea127e98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b70f1cbc-b029-4bc7-b252-ef1ea127e98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3da631c5-a600-4cf7-aeef-7e1af582eddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3da631c5-a600-4cf7-aeef-7e1af582eddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3a810dea-3d0e-4639-8a39-ce9ebf1d1709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3a810dea-3d0e-4639-8a39-ce9ebf1d1709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_7c9b6bd3-cdd1-4335-9bae-dfe1964ab749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_7c9b6bd3-cdd1-4335-9bae-dfe1964ab749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_b4a2764d-d7cd-4952-a627-d161e9a86ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_b4a2764d-d7cd-4952-a627-d161e9a86ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a96f5c04-46fe-40fd-9374-31b76392a628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a96f5c04-46fe-40fd-9374-31b76392a628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c77fc9a0-835a-44c4-91f8-6295fbf7d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c77fc9a0-835a-44c4-91f8-6295fbf7d85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e056e8e9-e9b2-4568-a28d-acfd1c67ea24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e056e8e9-e9b2-4568-a28d-acfd1c67ea24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c33b8634-dbf7-4de4-8871-9e06b5bfbf61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c33b8634-dbf7-4de4-8871-9e06b5bfbf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5447988b-9f76-48df-8cfa-2f8abc2fc933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5447988b-9f76-48df-8cfa-2f8abc2fc933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_854d5d49-66aa-4f9d-8c13-734fd211b8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_854d5d49-66aa-4f9d-8c13-734fd211b8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_afd0bcd7-a548-42ac-b851-868b21711f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc659037-c385-456f-9729-e5010b25fd41" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_afd0bcd7-a548-42ac-b851-868b21711f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5d323cb3-1ced-4241-b068-fac671876c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_587c9430-d825-49d0-8ea8-cd48bbd90060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d323cb3-1ced-4241-b068-fac671876c72" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_587c9430-d825-49d0-8ea8-cd48bbd90060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1b5245b6-d6ae-4107-9dc8-ff4461b7f062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d323cb3-1ced-4241-b068-fac671876c72" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1b5245b6-d6ae-4107-9dc8-ff4461b7f062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8a37b4d4-5fda-481f-8dd2-a10156f01ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d323cb3-1ced-4241-b068-fac671876c72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8a37b4d4-5fda-481f-8dd2-a10156f01ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9f44a490-0508-4f30-acf2-c5a9df480b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1fa24454-a740-4f3d-a80e-e994a6e8c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9f44a490-0508-4f30-acf2-c5a9df480b55" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1fa24454-a740-4f3d-a80e-e994a6e8c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/FairValueofFinancialAssetsTables" xlink:type="simple" xlink:href="prax-20221231.xsd#FairValueofFinancialAssetsTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/FairValueofFinancialAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22001a9e-134d-410d-9dfe-c44d3d026feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6e354b83-9421-4dce-b332-c0f620695d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22001a9e-134d-410d-9dfe-c44d3d026feb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6e354b83-9421-4dce-b332-c0f620695d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="prax-20221231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7a6022aa-bdfc-4d88-bb60-df6580064118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7254a359-755f-45d0-b74a-643008e4ea9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7a6022aa-bdfc-4d88-bb60-df6580064118" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7254a359-755f-45d0-b74a-643008e4ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="prax-20221231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0dff6ca6-a728-41eb-a6cb-2fe0097db531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_203e6750-5cda-43e4-b075-4dbbbebfe07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0dff6ca6-a728-41eb-a6cb-2fe0097db531" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_203e6750-5cda-43e4-b075-4dbbbebfe07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09a9e46e-d076-4d8d-b281-a76b438cc2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AssetsAndLiabilitiesLesseeTableTextBlock_e9e9458d-51b1-48a6-80d0-94c8b4e0586e" xlink:href="prax-20221231.xsd#prax_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09a9e46e-d076-4d8d-b281-a76b438cc2a8" xlink:to="loc_prax_AssetsAndLiabilitiesLesseeTableTextBlock_e9e9458d-51b1-48a6-80d0-94c8b4e0586e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_60c815c2-12bf-4e47-a21b-27b583dae65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09a9e46e-d076-4d8d-b281-a76b438cc2a8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_60c815c2-12bf-4e47-a21b-27b583dae65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_db4a193d-c920-4839-b176-239430ae9b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09a9e46e-d076-4d8d-b281-a76b438cc2a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_db4a193d-c920-4839-b176-239430ae9b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockTables" xlink:type="simple" xlink:href="prax-20221231.xsd#CommonStockandPreferredStockTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommonStockandPreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e78b9e2c-7b0d-49c0-837b-c62ec580615f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_026c05c3-5902-4a13-83ae-5ee27996b45b" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e78b9e2c-7b0d-49c0-837b-c62ec580615f" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_026c05c3-5902-4a13-83ae-5ee27996b45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5dc0c2bf-efad-483c-885c-7fdc55feecbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_139c1e8e-b66f-4081-b215-de13a36843e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5dc0c2bf-efad-483c-885c-7fdc55feecbe" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_139c1e8e-b66f-4081-b215-de13a36843e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ee97fff4-c630-42ff-8ae9-10298a2b1233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5dc0c2bf-efad-483c-885c-7fdc55feecbe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ee97fff4-c630-42ff-8ae9-10298a2b1233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_10b0fbe9-185c-4b39-8f47-527320e30dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5dc0c2bf-efad-483c-885c-7fdc55feecbe" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_10b0fbe9-185c-4b39-8f47-527320e30dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f01e626-99f6-4bf8-b553-f718a4ac8bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5dc0c2bf-efad-483c-885c-7fdc55feecbe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f01e626-99f6-4bf8-b553-f718a4ac8bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="prax-20221231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ca21d46d-3971-4d65-9b6c-babd32b3fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_20ad4b52-2bf7-44da-b73c-9c8b76da1dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ca21d46d-3971-4d65-9b6c-babd32b3fd18" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_20ad4b52-2bf7-44da-b73c-9c8b76da1dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c9e067d3-2adb-48ba-ac75-edbc525f55d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_471e92f1-5e3a-4cbb-92ee-9d6873dc441e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9e067d3-2adb-48ba-ac75-edbc525f55d7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_471e92f1-5e3a-4cbb-92ee-9d6873dc441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_480b9726-c5e3-4bf3-8697-3e5eb2a4e09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9e067d3-2adb-48ba-ac75-edbc525f55d7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_480b9726-c5e3-4bf3-8697-3e5eb2a4e09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_900f6158-2456-4cf9-941a-39d8e23f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7344ac11-58b6-4d7a-bf58-ba123d17f6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_900f6158-2456-4cf9-941a-39d8e23f1a60" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7344ac11-58b6-4d7a-bf58-ba123d17f6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8732a31b-dde2-468b-b718-6b6f2ce92bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_900f6158-2456-4cf9-941a-39d8e23f1a60" xlink:to="loc_us-gaap_NetIncomeLoss_8732a31b-dde2-468b-b718-6b6f2ce92bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0686c894-6f9d-4a25-94ff-70cfa283d14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_900f6158-2456-4cf9-941a-39d8e23f1a60" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0686c894-6f9d-4a25-94ff-70cfa283d14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d5c6c315-58dd-4921-9be1-820dd1d4f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d5c6c315-58dd-4921-9be1-820dd1d4f7d6" xlink:to="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5abc097a-e7a9-4534-b368-4fa189550624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_06bf870f-0b6d-49ed-a640-761d382d9f8f" xlink:to="loc_us-gaap_EquityComponentDomain_5abc097a-e7a9-4534-b368-4fa189550624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07cd7eae-2f18-4f21-a624-685b395f3d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5abc097a-e7a9-4534-b368-4fa189550624" xlink:to="loc_us-gaap_CommonStockMember_07cd7eae-2f18-4f21-a624-685b395f3d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_717cd003-764e-4cf0-8dbc-ad4fea6ac24a" xlink:to="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ce630b5c-f951-4962-9c61-b52e5a28ef31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ce630b5c-f951-4962-9c61-b52e5a28ef31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsStock_368e0c1a-4a18-4e61-a4d2-5e9ea5f11647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_DividendsStock_368e0c1a-4a18-4e61-a4d2-5e9ea5f11647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_6f90c534-d77a-4471-99d9-68a453bedbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_ForeignCurrencyTransactionLossBeforeTax_6f90c534-d77a-4471-99d9-68a453bedbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c32ae88-4e81-4bbf-af41-9b4580842f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10898de5-6b1a-4a54-aa1f-bae9cb9e7057" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9c32ae88-4e81-4bbf-af41-9b4580842f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ddb4eb30-8722-40a5-9684-f1a65a31863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92794f5d-18bd-43c1-a3f9-a7501ca842ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddb4eb30-8722-40a5-9684-f1a65a31863c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92794f5d-18bd-43c1-a3f9-a7501ca842ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9f39c1c2-3176-40b8-adef-3f82c2941575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddb4eb30-8722-40a5-9684-f1a65a31863c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9f39c1c2-3176-40b8-adef-3f82c2941575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714ba5bd-b708-4450-8f60-4db9948211d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ddb4eb30-8722-40a5-9684-f1a65a31863c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714ba5bd-b708-4450-8f60-4db9948211d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0fdc6269-2825-4a58-a08e-89a360be9ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fdc6269-2825-4a58-a08e-89a360be9ee3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1510a09-dabe-4f38-9619-d3831292d758" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_OfficeFurnitureAndEquipmentMember_6f93a469-5d6c-4ea4-b0d9-bd99d80017d6" xlink:href="prax-20221231.xsd#prax_OfficeFurnitureAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:to="loc_prax_OfficeFurnitureAndEquipmentMember_6f93a469-5d6c-4ea4-b0d9-bd99d80017d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LaboratoryEquipmentMember_09c26a91-26fb-495e-96c6-233254bf5025" xlink:href="prax-20221231.xsd#prax_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:to="loc_prax_LaboratoryEquipmentMember_09c26a91-26fb-495e-96c6-233254bf5025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_09bf409a-9b34-48bd-8345-c6cbccd859be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca34869b-fb1f-4725-86c8-90b656c4d8be" xlink:to="loc_us-gaap_ComputerEquipmentMember_09bf409a-9b34-48bd-8345-c6cbccd859be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b217e23-0817-4e41-8f4b-ba6fd4519c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa8f337c-05e5-4448-a65f-04feef009287" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b217e23-0817-4e41-8f4b-ba6fd4519c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9e8e8b1b-276a-4f19-a902-141f2357f40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b217e23-0817-4e41-8f4b-ba6fd4519c57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9e8e8b1b-276a-4f19-a902-141f2357f40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/RestrictedCashDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#RestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/RestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_ac2541da-47fb-408f-b7ca-c656f2db3313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_0e2d4a66-0869-4377-aed8-1480188a9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ac2541da-47fb-408f-b7ca-c656f2db3313" xlink:to="loc_us-gaap_RestrictedCash_0e2d4a66-0869-4377-aed8-1480188a9bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_9e3e70bc-0d2a-45fb-8509-75fcfa5dd73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ac2541da-47fb-408f-b7ca-c656f2db3313" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList_9e3e70bc-0d2a-45fb-8509-75fcfa5dd73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList_8232a006-cf6a-46d3-b017-8395bc55daab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ac2541da-47fb-408f-b7ca-c656f2db3313" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList_8232a006-cf6a-46d3-b017-8395bc55daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LettersOfCreditReceivableCurrent_4dc27058-ca6b-4233-90d9-7d321ad3fe6d" xlink:href="prax-20221231.xsd#prax_LettersOfCreditReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ac2541da-47fb-408f-b7ca-c656f2db3313" xlink:to="loc_prax_LettersOfCreditReceivableCurrent_4dc27058-ca6b-4233-90d9-7d321ad3fe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LettersOfCreditReceivableNoncurrent_23c968c1-5450-4cd2-af08-ab02570f3e33" xlink:href="prax-20221231.xsd#prax_LettersOfCreditReceivableNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ac2541da-47fb-408f-b7ca-c656f2db3313" xlink:to="loc_prax_LettersOfCreditReceivableNoncurrent_23c968c1-5450-4cd2-af08-ab02570f3e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesInvestmentProfileDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2ab85061-0447-43b2-951f-6d58fa8ee79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2ab85061-0447-43b2-951f-6d58fa8ee79d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9b913f10-ebb3-4ec4-9776-338050184412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cd40fff2-807c-4ec4-ad68-6b6eb06346ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cd40fff2-807c-4ec4-ad68-6b6eb06346ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_eaae23d6-91a6-4552-a6c0-dadbc393d58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_CommercialPaperMember_eaae23d6-91a6-4552-a6c0-dadbc393d58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_72ff152a-e098-483a-9f10-ededb8f06af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_72ff152a-e098-483a-9f10-ededb8f06af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_86bc6a71-ba6c-421d-8186-3f67a5ccb3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b05caf52-c541-42a0-91be-0deec628536e" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_86bc6a71-ba6c-421d-8186-3f67a5ccb3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_245dc28e-1b55-468a-9e9b-e225b0eae51d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_63fdced1-e40d-443a-bfb5-27f163bd7242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_63fdced1-e40d-443a-bfb5-27f163bd7242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_2358e491-17f7-4954-ab82-5f0799c2b8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_2358e491-17f7-4954-ab82-5f0799c2b8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_99455da6-9ead-437d-90fa-a76b97d44211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_99455da6-9ead-437d-90fa-a76b97d44211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_571e367e-5302-40ae-adb4-29ec06552142" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax_571e367e-5302-40ae-adb4-29ec06552142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_ab2e501b-3100-48a9-a5ff-b061d8d5444a" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax_ab2e501b-3100-48a9-a5ff-b061d8d5444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec56d603-e602-4f4f-8de5-bff1816c8693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec56d603-e602-4f4f-8de5-bff1816c8693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_26cd2916-5ca8-4689-bc4b-d72ab87de98b" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax_26cd2916-5ca8-4689-bc4b-d72ab87de98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_84a92996-1b79-4d86-880a-9da6ffe9d72b" xlink:href="prax-20221231.xsd#prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax_84a92996-1b79-4d86-880a-9da6ffe9d72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac969817-7d40-4cdf-a0e9-28a3e1877f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac969817-7d40-4cdf-a0e9-28a3e1877f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1eb55552-66a3-46da-9cd3-e9dcaee8d0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1eb55552-66a3-46da-9cd3-e9dcaee8d0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8c1e6231-2cf4-41c8-b156-7fc9160b1835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8c1e6231-2cf4-41c8-b156-7fc9160b1835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7699179b-a079-44cd-8f7e-69c1ba98c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b3fe449d-a4b7-4e0f-b4a9-9c9001e5e04b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7699179b-a079-44cd-8f7e-69c1ba98c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesInvestmentProfileDetails_1"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9d5ee1c-0acb-413c-961f-9ca4eba9f1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_cfb26d65-f6ba-4606-ad48-1c56caa0c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9d5ee1c-0acb-413c-961f-9ca4eba9f1c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_cfb26d65-f6ba-4606-ad48-1c56caa0c41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6e964418-cbbd-4edf-94a3-d44228531fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9d5ee1c-0acb-413c-961f-9ca4eba9f1c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6e964418-cbbd-4edf-94a3-d44228531fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ece181d0-59ac-4e04-8d2f-2b73ed24f461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ece181d0-59ac-4e04-8d2f-2b73ed24f461" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_fb9f6930-9cb6-4987-a8c8-80dd30c5f659" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_731282d3-1d70-4810-a399-3d391154734f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_MoneyMarketFundsMember_731282d3-1d70-4810-a399-3d391154734f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_04771a60-ee15-43ea-9972-7f02db47b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_04771a60-ee15-43ea-9972-7f02db47b46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f58e570c-1b5c-4fc4-8473-ce81a3161297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_CommercialPaperMember_f58e570c-1b5c-4fc4-8473-ce81a3161297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9ec0a567-738f-462d-ad39-c40e9146ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9ec0a567-738f-462d-ad39-c40e9146ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_b1ab13c1-86aa-4478-857c-084ec5426c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_210f67dc-5e49-4760-b6d8-8154d448ca22" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_b1ab13c1-86aa-4478-857c-084ec5426c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd79937c-0cf3-42c7-a9ba-e4d1ce9d97fd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c59811b9-7e72-4453-a0e9-e1584c31db7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c59811b9-7e72-4453-a0e9-e1584c31db7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2643e0c4-74df-44b4-aa83-234a9596bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2643e0c4-74df-44b4-aa83-234a9596bcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7ae22c64-fa37-43bf-b220-b2050a89e787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5940cab4-3aca-4b08-ac7b-d63602e61797" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7ae22c64-fa37-43bf-b220-b2050a89e787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_86f30183-b174-43cc-b480-6a0f13efd580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5c56f6f3-b3bc-4c07-ab25-38934184efe7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_86f30183-b174-43cc-b480-6a0f13efd580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bc6a4b7f-5164-4a09-af36-951740791839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_86f30183-b174-43cc-b480-6a0f13efd580" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bc6a4b7f-5164-4a09-af36-951740791839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ec5aa76-092a-4de8-9e48-534c2f41098b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4c3091f1-1f7e-4f95-bab7-67b7d34fbc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4c3091f1-1f7e-4f95-bab7-67b7d34fbc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6d3de7f1-6988-4f6e-9f13-9711b19eaf51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6d3de7f1-6988-4f6e-9f13-9711b19eaf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_667878a6-44ad-4669-9b2e-6113e3f98d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf918bf-5bb2-4427-b3f3-d5af7177414e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_667878a6-44ad-4669-9b2e-6113e3f98d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ecc4a0e9-bc95-44f8-aff3-339bbe69e158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ecc4a0e9-bc95-44f8-aff3-339bbe69e158" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ddb86899-0c6b-46a6-b10b-67887cbc1a73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0dddfa57-3e02-44df-ac7c-6a5102ba627a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:to="loc_us-gaap_ComputerEquipmentMember_0dddfa57-3e02-44df-ac7c-6a5102ba627a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_OfficeFurnitureAndEquipmentMember_28fa87cb-186e-4539-97db-850c65457ec9" xlink:href="prax-20221231.xsd#prax_OfficeFurnitureAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:to="loc_prax_OfficeFurnitureAndEquipmentMember_28fa87cb-186e-4539-97db-850c65457ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LaboratoryEquipmentMember_3d1aa0c9-84fb-4713-87b9-431bc38b7f04" xlink:href="prax-20221231.xsd#prax_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_903c14e3-2eda-4edd-bd79-faa471de4c72" xlink:to="loc_prax_LaboratoryEquipmentMember_3d1aa0c9-84fb-4713-87b9-431bc38b7f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f31cdf19-5062-49b1-9982-ea5a3a690f7e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4916fc99-0929-445d-b1cc-a6ed535732a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4916fc99-0929-445d-b1cc-a6ed535732a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_278907df-b13f-43dd-988c-5059cbc6d975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_278907df-b13f-43dd-988c-5059cbc6d975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bec8d77c-54a4-4d20-b439-38dfcb4eb7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bec8d77c-54a4-4d20-b439-38dfcb4eb7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_856f67f8-0002-4c3c-bf0a-1a973881f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f283d789-335d-44e8-b64d-578fb40a38d4" xlink:to="loc_us-gaap_Depreciation_856f67f8-0002-4c3c-bf0a-1a973881f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e3304ac9-1f02-461f-b68b-f4eb2ca6aa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_b36f8144-932f-4817-adae-43a626d25461" xlink:href="prax-20221231.xsd#prax_AccruedExternalResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3304ac9-1f02-461f-b68b-f4eb2ca6aa8f" xlink:to="loc_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent_b36f8144-932f-4817-adae-43a626d25461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_AccruedPersonnelRelatedExpensesCurrent_ae17dd6c-ef0f-448a-993d-076c237978d5" xlink:href="prax-20221231.xsd#prax_AccruedPersonnelRelatedExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3304ac9-1f02-461f-b68b-f4eb2ca6aa8f" xlink:to="loc_prax_AccruedPersonnelRelatedExpensesCurrent_ae17dd6c-ef0f-448a-993d-076c237978d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_683ca2be-6bbe-443f-aa15-ae4c9d43f83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3304ac9-1f02-461f-b68b-f4eb2ca6aa8f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_683ca2be-6bbe-443f-aa15-ae4c9d43f83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_48a4d746-1159-47a9-9fc1-d090c35063c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e3304ac9-1f02-461f-b68b-f4eb2ca6aa8f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_48a4d746-1159-47a9-9fc1-d090c35063c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c6fc26a-eb71-4b52-b8b8-2c61befe7428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_PercentageIncreaseInAnnualBaseRent_763816c6-ddbb-4c72-aa3e-c6427b14b587" xlink:href="prax-20221231.xsd#prax_PercentageIncreaseInAnnualBaseRent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c6fc26a-eb71-4b52-b8b8-2c61befe7428" xlink:to="loc_prax_PercentageIncreaseInAnnualBaseRent_763816c6-ddbb-4c72-aa3e-c6427b14b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82b831d7-c83c-40ab-8a89-6be92b90a987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c6fc26a-eb71-4b52-b8b8-2c61befe7428" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82b831d7-c83c-40ab-8a89-6be92b90a987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c4773845-930e-4389-a38f-aa2fb0cc9e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c6fc26a-eb71-4b52-b8b8-2c61befe7428" xlink:to="loc_us-gaap_OperatingLeaseLiability_c4773845-930e-4389-a38f-aa2fb0cc9e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4bd5f27-fd65-4324-9d62-a823334e683a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e77c8831-b365-45fe-b4aa-ef7ed6cde3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4bd5f27-fd65-4324-9d62-a823334e683a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e77c8831-b365-45fe-b4aa-ef7ed6cde3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_044832c1-a57b-463a-af93-9cabb835ec39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4bd5f27-fd65-4324-9d62-a823334e683a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_044832c1-a57b-463a-af93-9cabb835ec39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aebcb700-5e95-452f-843e-7553b0563221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4bd5f27-fd65-4324-9d62-a823334e683a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aebcb700-5e95-452f-843e-7553b0563221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f17bded6-affd-4994-a042-6c5d433af10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4bd5f27-fd65-4324-9d62-a823334e683a" xlink:to="loc_us-gaap_OperatingLeaseLiability_f17bded6-affd-4994-a042-6c5d433af10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesTotalLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4ed60a0-e06b-42f5-86de-ea7de32f5edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c5ca117f-af73-4621-b993-9e5a61bfdf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4ed60a0-e06b-42f5-86de-ea7de32f5edc" xlink:to="loc_us-gaap_OperatingLeaseCost_c5ca117f-af73-4621-b993-9e5a61bfdf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a4244dd2-9410-4744-b2e2-b671d23615ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4ed60a0-e06b-42f5-86de-ea7de32f5edc" xlink:to="loc_us-gaap_VariableLeaseCost_a4244dd2-9410-4744-b2e2-b671d23615ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7abc4849-78ef-4d1b-9902-77105cb584f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4ed60a0-e06b-42f5-86de-ea7de32f5edc" xlink:to="loc_us-gaap_LeaseCost_7abc4849-78ef-4d1b-9902-77105cb584f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesFutureLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9a783724-7955-4a4e-bf56-26fcbd8c7dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9a783724-7955-4a4e-bf56-26fcbd8c7dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c0b1d0c-21e0-497d-a713-b45eab7bbe02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6c0b1d0c-21e0-497d-a713-b45eab7bbe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3064e0eb-3b84-4bbd-8cbe-3d47c8bb46bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3064e0eb-3b84-4bbd-8cbe-3d47c8bb46bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_27882608-9209-4dd4-a330-c0fbb29a6048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_27882608-9209-4dd4-a330-c0fbb29a6048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3703ded1-91cc-41b6-9578-22645a55c6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3703ded1-91cc-41b6-9578-22645a55c6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27836a87-7735-44d5-a7e4-abf519de72e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27836a87-7735-44d5-a7e4-abf519de72e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_50989a3b-25a0-403b-a3f9-2fcbc81f4564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c995af50-3a31-43ba-8f5a-943672894bbd" xlink:to="loc_us-gaap_OperatingLeaseLiability_50989a3b-25a0-403b-a3f9-2fcbc81f4564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesFutureLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2e797bab-5daf-4ca9-9707-11a498f196da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b2d001d9-2fc1-422d-974e-d045bc58181d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2e797bab-5daf-4ca9-9707-11a498f196da" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b2d001d9-2fc1-422d-974e-d045bc58181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4c1f849f-cb6a-429f-9228-9afd8dd12fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2e797bab-5daf-4ca9-9707-11a498f196da" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4c1f849f-cb6a-429f-9228-9afd8dd12fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#UCBOptionandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e31ac50-8e1e-4164-8ff6-a17568c7a283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e31ac50-8e1e-4164-8ff6-a17568c7a283" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c7a87f7-b894-4f32-9f8e-4ac1b31830d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5788463a-2f51-4bde-a3cb-4d43903491c3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c7a87f7-b894-4f32-9f8e-4ac1b31830d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_UCBMember_b2278e3c-6da8-48f2-9296-9c6522bbee36" xlink:href="prax-20221231.xsd#prax_UCBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c7a87f7-b894-4f32-9f8e-4ac1b31830d7" xlink:to="loc_prax_UCBMember_b2278e3c-6da8-48f2-9296-9c6522bbee36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_861dd514-d2e3-43d9-837a-e55185db37a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_be0d77c8-2ee4-4cb8-8fcd-4ecd88923fdd" xlink:to="loc_srt_ProductsAndServicesDomain_861dd514-d2e3-43d9-837a-e55185db37a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6c55c827-5973-4fea-b828-9c02d2443ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_861dd514-d2e3-43d9-837a-e55185db37a6" xlink:to="loc_us-gaap_LicenseMember_6c55c827-5973-4fea-b828-9c02d2443ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1395511-91d5-4938-ad2f-94701ab28fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_828986fd-d1a1-4eb6-9849-993d32cf6047" xlink:to="loc_us-gaap_PlanNameDomain_c1395511-91d5-4938-ad2f-94701ab28fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_cb8f0fac-7ab1-462f-8ce4-252411a2ac7d" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c1395511-91d5-4938-ad2f-94701ab28fde" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_cb8f0fac-7ab1-462f-8ce4-252411a2ac7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4e2cea8a-95c5-49e9-a4f4-1a56587a4c0c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8f92ac63-92c4-4426-8a3b-71973e7e5f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8f92ac63-92c4-4426-8a3b-71973e7e5f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_5f4b9ee2-eae1-4d94-98ce-ef594dd93cc5" xlink:href="prax-20221231.xsd#prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_5f4b9ee2-eae1-4d94-98ce-ef594dd93cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_df87aafc-35dc-4384-9258-2e85b1f69878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7183738a-c3c1-4b3a-a9be-645dfd92f19d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_df87aafc-35dc-4384-9258-2e85b1f69878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommonStockandPreferredStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_82d3ae29-8f80-4431-b629-506177f6930a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_82d3ae29-8f80-4431-b629-506177f6930a" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0996ab74-cc41-4147-8f5a-95f64fe09334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ee529a6d-afd0-4493-8449-0dd96c2d52f9" xlink:to="loc_us-gaap_EquityComponentDomain_0996ab74-cc41-4147-8f5a-95f64fe09334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_845a2981-3f3b-4fb6-b5c2-c84ecd5e7970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0996ab74-cc41-4147-8f5a-95f64fe09334" xlink:to="loc_us-gaap_CommonStockMember_845a2981-3f3b-4fb6-b5c2-c84ecd5e7970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11b9fa45-46d8-4387-a933-f1637d796025" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e454cae2-0ec9-46d5-bb6d-9416a82902fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e454cae2-0ec9-46d5-bb6d-9416a82902fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_FollowOnPublicOfferingMember_522090ef-dfc1-400e-bda4-87e718056955" xlink:href="prax-20221231.xsd#prax_FollowOnPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:to="loc_prax_FollowOnPublicOfferingMember_522090ef-dfc1-400e-bda4-87e718056955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_JefferiesOpenMarketAgreementMember_252855fb-fb7b-4b08-8bc9-323494febe97" xlink:href="prax-20221231.xsd#prax_JefferiesOpenMarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ef01020e-70cf-4951-af9e-9b5c6c2708ee" xlink:to="loc_prax_JefferiesOpenMarketAgreementMember_252855fb-fb7b-4b08-8bc9-323494febe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f0d295f1-7eea-4ae5-ba62-255b9ef8e3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7c78d918-cf54-4c6f-be63-c592ea7b3310" xlink:to="loc_us-gaap_PlanNameDomain_f0d295f1-7eea-4ae5-ba62-255b9ef8e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_157c8cf5-ca5b-498a-bf9b-28edfcee845e" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f0d295f1-7eea-4ae5-ba62-255b9ef8e3d2" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_157c8cf5-ca5b-498a-bf9b-28edfcee845e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_8849cb08-7bdb-4521-9c09-e867d14c584a" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_640b50cd-79c7-4233-b3ff-6fa5ae5615f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_640b50cd-79c7-4233-b3ff-6fa5ae5615f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_15e439be-9228-4989-9ee6-06175458870d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_15e439be-9228-4989-9ee6-06175458870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_SaleOfStockConsiderationReceivedGrossAmount_d57b4a74-bb36-47a1-9c00-4d229967a461" xlink:href="prax-20221231.xsd#prax_SaleOfStockConsiderationReceivedGrossAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_prax_SaleOfStockConsiderationReceivedGrossAmount_d57b4a74-bb36-47a1-9c00-4d229967a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e2a34d10-5cb2-4277-8e73-4f11eb5ee218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e2a34d10-5cb2-4277-8e73-4f11eb5ee218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd81d686-e2d4-49df-b90c-5f78de78f748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd81d686-e2d4-49df-b90c-5f78de78f748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7ba97c43-dbec-490e-88a3-16aa60da018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7ba97c43-dbec-490e-88a3-16aa60da018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a76274-229d-417a-8bc8-5b0f9d310f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_94a76274-229d-417a-8bc8-5b0f9d310f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_73f67b8d-5283-4f91-87e0-fa988cf1723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_TreasuryStockShares_73f67b8d-5283-4f91-87e0-fa988cf1723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7047d573-824d-4839-a046-b8eefccc02a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7047d573-824d-4839-a046-b8eefccc02a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f988d037-291e-4856-9590-aacf6dd510bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f988d037-291e-4856-9590-aacf6dd510bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7aeb33e1-3225-4987-a48b-09206b3736ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7aeb33e1-3225-4987-a48b-09206b3736ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c25cee1a-63e2-4460-b45e-9300b10bf5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c25cee1a-63e2-4460-b45e-9300b10bf5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ad02d059-b68f-4cda-9449-4ec437c3a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_909690b7-80c3-4a25-9795-ed316a7d2bc0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_ad02d059-b68f-4cda-9449-4ec437c3a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4d5a96c1-9358-4f13-b16b-dc780bd67508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4d5a96c1-9358-4f13-b16b-dc780bd67508" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:to="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d500a111-2266-4add-80df-13846fa9dac2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80a9f28d-69da-4a1a-a93e-2671585bbae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80a9f28d-69da-4a1a-a93e-2671585bbae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_61b2f38e-3037-4d1e-bebe-bacae78242ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:to="loc_us-gaap_StockCompensationPlanMember_61b2f38e-3037-4d1e-bebe-bacae78242ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c08916f5-ff6a-41fd-bd64-a1e8cb68ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_496dcba5-d5fd-4f53-a319-e2a69bc09f4e" xlink:to="loc_us-gaap_RestrictedStockMember_c08916f5-ff6a-41fd-bd64-a1e8cb68ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:to="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d4eb7c18-bdbb-4378-a665-d501306c06d2" xlink:to="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentyTwentyEmployeeStockIncentivePlanMember_f1787f97-7ef1-47be-bbfd-681692507536" xlink:href="prax-20221231.xsd#prax_TwentyTwentyEmployeeStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:to="loc_prax_TwentyTwentyEmployeeStockIncentivePlanMember_f1787f97-7ef1-47be-bbfd-681692507536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentyTwentyEmployeeStockPurchasePlanMember_855fc013-ae21-41c5-a3ff-25dc295db6f8" xlink:href="prax-20221231.xsd#prax_TwentyTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b2098764-a508-4bcd-b04b-fd1b4dbd0ba3" xlink:to="loc_prax_TwentyTwentyEmployeeStockPurchasePlanMember_855fc013-ae21-41c5-a3ff-25dc295db6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_7ee50a59-bbad-4fb5-92d2-36c53764880f" xlink:href="prax-20221231.xsd#prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceTable_24bd9ef9-bbdf-4a79-9f2b-16333c4b1b73" xlink:to="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_7ee50a59-bbad-4fb5-92d2-36c53764880f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bf8a93c2-77d1-4dbc-bff8-08d21dbe8870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems_7ee50a59-bbad-4fb5-92d2-36c53764880f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bf8a93c2-77d1-4dbc-bff8-08d21dbe8870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f299c063-84bb-4400-8998-07ceeed3736a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f299c063-84bb-4400-8998-07ceeed3736a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:to="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e8b4ce65-a1c6-491b-9170-f006e50b0fae" xlink:to="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_a56a6e4d-b247-4680-8916-61ff5472cca9" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockIncentivePlanMember_a56a6e4d-b247-4680-8916-61ff5472cca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwentySeventeenEmployeeStockIncentivePlanMember_d7ea5cb1-04b3-4c4c-bf3e-47b864ce37a4" xlink:href="prax-20221231.xsd#prax_TwentySeventeenEmployeeStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:to="loc_prax_TwentySeventeenEmployeeStockIncentivePlanMember_d7ea5cb1-04b3-4c4c-bf3e-47b864ce37a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_2c018da4-5afc-45d0-9389-bf5d1344e3d0" xlink:href="prax-20221231.xsd#prax_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2bcdf79-3eb2-4b00-9edc-c65da8f9f5d2" xlink:to="loc_prax_TwoThousandTwentyEmployeeStockPurchasePlanMember_2c018da4-5afc-45d0-9389-bf5d1344e3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:to="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24a64dc5-cf3c-4282-8d4c-d350d7f5cc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5ef5ce16-185f-491b-addd-acbd7cbddab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24a64dc5-cf3c-4282-8d4c-d350d7f5cc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_UnvestedRestrictedStockUnitsMember_5e74d587-781c-4258-926a-cd701a5a27bb" xlink:href="prax-20221231.xsd#prax_UnvestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24a64dc5-cf3c-4282-8d4c-d350d7f5cc14" xlink:to="loc_prax_UnvestedRestrictedStockUnitsMember_5e74d587-781c-4258-926a-cd701a5a27bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2764b8dd-0ffc-4247-a52a-7909af0cc29c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da72acef-8db8-4e31-85ad-3b642c2b71ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_da72acef-8db8-4e31-85ad-3b642c2b71ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4cfc6431-e3de-4772-9673-732bd9249c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4cfc6431-e3de-4772-9673-732bd9249c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ec38fc65-4dea-4698-ad4b-a07fc874c460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ec38fc65-4dea-4698-ad4b-a07fc874c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10b5aa0e-e9de-4cec-90ee-66e159f9532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10b5aa0e-e9de-4cec-90ee-66e159f9532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdb3fb9-25ba-475f-ae4f-ade680987d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbdb3fb9-25ba-475f-ae4f-ade680987d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_80d7e7fb-c30a-4921-8ec2-f9897f9e9e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_80d7e7fb-c30a-4921-8ec2-f9897f9e9e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d68e9e02-3d90-4ae0-908f-6238edecef67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac20df6-35ce-464c-b90d-60730728a588" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d68e9e02-3d90-4ae0-908f-6238edecef67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3773c5a-028c-4b98-910d-91b7e06fd65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b3773c5a-028c-4b98-910d-91b7e06fd65a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:to="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91015d04-a5b3-4f41-8965-f14f7effa753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_108e8571-ae98-4965-b275-178fe0bfaf36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91015d04-a5b3-4f41-8965-f14f7effa753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_acd93fc4-bd63-406e-b214-67a759686343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91015d04-a5b3-4f41-8965-f14f7effa753" xlink:to="loc_us-gaap_RestrictedStockMember_acd93fc4-bd63-406e-b214-67a759686343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_788a46f0-76ce-4821-815f-cdf1522db5f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77a285e5-c6f6-4b3c-8611-fb097d8ca9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77a285e5-c6f6-4b3c-8611-fb097d8ca9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_b25c7ea2-7355-4d4c-ab53-94d48e1b447a" xlink:href="prax-20221231.xsd#prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_b25c7ea2-7355-4d4c-ab53-94d48e1b447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84acafd4-1cf7-4f7b-8dfe-38fa2364efe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84acafd4-1cf7-4f7b-8dfe-38fa2364efe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_93f4ff6e-b5d9-4a2f-9562-92071f6b567d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_93f4ff6e-b5d9-4a2f-9562-92071f6b567d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_79b5fb03-b3a0-4276-ac92-946bd14ee771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_800ef89a-7ced-4d9e-80c0-25288ab06e3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_79b5fb03-b3a0-4276-ac92-946bd14ee771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_430f04a4-ea91-4186-a428-559528c353f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5228f35e-408a-474a-9baf-97cedaebb82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5228f35e-408a-474a-9baf-97cedaebb82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_244bedeb-47a8-4f46-a830-1bd5ab7fe426" xlink:href="prax-20221231.xsd#prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_244bedeb-47a8-4f46-a830-1bd5ab7fe426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9cef2048-e411-419e-8b29-efceb52e3158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9cef2048-e411-419e-8b29-efceb52e3158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_58e6af5b-350b-43da-87eb-82ff6e3d4edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_58e6af5b-350b-43da-87eb-82ff6e3d4edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57db5eb2-3290-4760-8cee-b9630febdb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea0b72d8-6deb-4fea-8da3-5881dcff0ba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_57db5eb2-3290-4760-8cee-b9630febdb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acdaf08-d609-4439-93a8-ad208317b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acdaf08-d609-4439-93a8-ad208317b0a3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1074f21-1291-4b23-b76e-3d0d50dd5660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1074f21-1291-4b23-b76e-3d0d50dd5660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7481cf7d-fbce-429f-b3f5-69fc7723b0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7481cf7d-fbce-429f-b3f5-69fc7723b0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bef32b59-9d1c-4026-b189-b9b2a17494cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bef32b59-9d1c-4026-b189-b9b2a17494cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e0201d5e-5748-43c0-b104-c42a42948b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e0201d5e-5748-43c0-b104-c42a42948b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_42d8240b-0cd1-471d-9b9d-313a1dd287a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_42d8240b-0cd1-471d-9b9d-313a1dd287a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2938d064-f0ab-447a-ab95-60b50f77d7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2938d064-f0ab-447a-ab95-60b50f77d7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_200c4f3a-a75c-4e52-9e67-f6132e75085c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_2479d88c-bfd5-4646-b9c1-eaf0fa174dc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_200c4f3a-a75c-4e52-9e67-f6132e75085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acdaf08-d609-4439-93a8-ad208317b0a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9b76ecb-f5a0-4597-a5ab-d08da5dbf5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9b76ecb-f5a0-4597-a5ab-d08da5dbf5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd2c617-6f83-4d5c-b6d4-f27cfc3132c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd2c617-6f83-4d5c-b6d4-f27cfc3132c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_858349a8-3e73-4793-a770-9c92c78ce7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_858349a8-3e73-4793-a770-9c92c78ce7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dba51ffe-5852-4812-aa09-5d73fe8b98fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dba51ffe-5852-4812-aa09-5d73fe8b98fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5a0acc-c811-46e3-a979-4a341cabe65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_90313e15-fe25-401b-a504-f05f1909fa10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5a0acc-c811-46e3-a979-4a341cabe65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f185bd8f-c01b-4ae1-8814-3fa63bd6dfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acdaf08-d609-4439-93a8-ad208317b0a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f185bd8f-c01b-4ae1-8814-3fa63bd6dfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_01c63016-4727-48fc-ad58-c8b235b6305f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acdaf08-d609-4439-93a8-ad208317b0a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_01c63016-4727-48fc-ad58-c8b235b6305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acdaf08-d609-4439-93a8-ad208317b0a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3a44d344-98a3-45b7-9857-90dbb8fc0275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3a44d344-98a3-45b7-9857-90dbb8fc0275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_94e18778-df2d-4ab6-abef-e54df24c3070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_94e18778-df2d-4ab6-abef-e54df24c3070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_eb3a6666-78f1-4272-908c-8feac58b1e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_eb3a6666-78f1-4272-908c-8feac58b1e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d94ff449-0718-4834-9c5d-f8169381694b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d94ff449-0718-4834-9c5d-f8169381694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_96743146-a289-46f4-b188-45e093eea0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_96743146-a289-46f4-b188-45e093eea0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c940e7d2-7924-4593-88e5-38fe963194bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c940e7d2-7924-4593-88e5-38fe963194bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8911071f-15cc-42dc-bf5c-cb2209bb42e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e6417ca4-830d-40ba-80ab-04a4c25c3a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1c309d2c-97b2-4ac9-997c-64141c38f2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e6417ca4-830d-40ba-80ab-04a4c25c3a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d6ea6cd-756e-460d-add7-47152087273d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d6ea6cd-756e-460d-add7-47152087273d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:to="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3eddb8b8-69b8-48aa-b304-a098446e6490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f64c4246-5ea0-4a65-b686-c5cf9c24d51d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3eddb8b8-69b8-48aa-b304-a098446e6490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_195a198c-4393-4dcb-9dc7-6039f33dddac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3eddb8b8-69b8-48aa-b304-a098446e6490" xlink:to="loc_us-gaap_EmployeeStockOptionMember_195a198c-4393-4dcb-9dc7-6039f33dddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bba22db-6059-4782-9e69-c365c8686999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dca2c4be-cc4a-483c-9100-3ae485952b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dca2c4be-cc4a-483c-9100-3ae485952b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ad0b278-bba8-45a2-b865-39adfbaa0ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ad0b278-bba8-45a2-b865-39adfbaa0ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d0ee71b4-6222-491f-a3aa-75fbcc8912e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d0ee71b4-6222-491f-a3aa-75fbcc8912e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a8fd665b-9cee-4166-a2ae-e706cab65395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a8fd665b-9cee-4166-a2ae-e706cab65395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f57c5040-7a56-4f1a-b566-ae75487f0e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f57c5040-7a56-4f1a-b566-ae75487f0e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1d3d7495-1f09-43f6-880b-84b7ebefdd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1d3d7495-1f09-43f6-880b-84b7ebefdd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3b3b72e-41ac-4cf2-8ca5-f6f56e862b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd7c3903-1af8-4fb2-8ce7-583cbcb0dcae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3b3b72e-41ac-4cf2-8ca5-f6f56e862b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb36e32-8640-4cd3-bbb3-db76126bee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb36e32-8640-4cd3-bbb3-db76126bee98" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_188b9c44-a4b3-4bfc-afb6-e6d2a2c0669a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_feb84998-ca22-41cc-ac87-ad6b47fe1d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_feb84998-ca22-41cc-ac87-ad6b47fe1d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a47b1ff3-7b3d-4ba7-998a-2d98e58f6896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6d3faf8-a7b0-493d-834e-3794b8cb65f5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a47b1ff3-7b3d-4ba7-998a-2d98e58f6896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19f86e24-4a7a-4698-af7d-c8d07ca7e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aba36c79-6ff0-4657-b180-afc9292618f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19f86e24-4a7a-4698-af7d-c8d07ca7e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2003bf9-3861-4a6e-825e-8f9ed39ac615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19f86e24-4a7a-4698-af7d-c8d07ca7e84c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2003bf9-3861-4a6e-825e-8f9ed39ac615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SignificantAgreementsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SignificantAgreementsDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18a2b63a-fa33-4171-9e11-3fed11f09f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18a2b63a-fa33-4171-9e11-3fed11f09f28" xlink:to="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:to="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_10531da1-0605-44cc-9400-68bab48179fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_9a918231-fea9-4313-a360-62e6e8391541" xlink:to="loc_us-gaap_OtherCommitmentsDomain_10531da1-0605-44cc-9400-68bab48179fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_54f19417-45f5-4d12-89ac-725ddad31e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_10531da1-0605-44cc-9400-68bab48179fb" xlink:to="loc_us-gaap_LicensingAgreementsMember_54f19417-45f5-4d12-89ac-725ddad31e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_LicensingAgreementsProfitSharePaymentsMember_a33af50e-722b-4e38-83ed-a78a56bb1cc6" xlink:href="prax-20221231.xsd#prax_LicensingAgreementsProfitSharePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LicensingAgreementsMember_54f19417-45f5-4d12-89ac-725ddad31e56" xlink:to="loc_prax_LicensingAgreementsProfitSharePaymentsMember_a33af50e-722b-4e38-83ed-a78a56bb1cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:to="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_29b0b0c3-bd08-46b6-856a-c1cc6c390f29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_RogconMember_1506c6fe-65a2-4895-8f83-30c7bef7f967" xlink:href="prax-20221231.xsd#prax_RogconMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:to="loc_prax_RogconMember_1506c6fe-65a2-4895-8f83-30c7bef7f967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_IonisMember_09d1abbe-9cdb-4130-bc0f-5d0e6e73fa16" xlink:href="prax-20221231.xsd#prax_IonisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9447802-3b27-4cdb-a57b-d51155dd9728" xlink:to="loc_prax_IonisMember_09d1abbe-9cdb-4130-bc0f-5d0e6e73fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ef53ab81-9179-442c-9eb7-4dfd3e1ce727" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_e17258c6-0646-477e-80fa-1e5264c827fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_OtherCommitment_e17258c6-0646-477e-80fa-1e5264c827fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9e3d328c-2b03-4823-8f8c-7e7367186818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9e3d328c-2b03-4823-8f8c-7e7367186818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fc39f5b0-ec0a-42de-8ec6-e013f230c667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a4333b56-00c7-4b80-b57e-eb087a4fe979" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fc39f5b0-ec0a-42de-8ec6-e013f230c667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8a32cfaf-4a94-4f36-90af-2bfb2cd4d2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8a32cfaf-4a94-4f36-90af-2bfb2cd4d2de" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_09f94c83-4d2c-4fcf-b837-a6f007dfc175" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24a64705-8fbc-4582-b9eb-e8607cbf1384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24a64705-8fbc-4582-b9eb-e8607cbf1384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2f1a26ad-c951-4bb9-ad6e-540972e90391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:to="loc_us-gaap_RestrictedStockMember_2f1a26ad-c951-4bb9-ad6e-540972e90391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ecf09f2a-eb58-469e-84aa-0626ff16dbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1bfb7b27-7828-4b96-9b8f-49ff2e368185" xlink:to="loc_us-gaap_EmployeeStockMember_ecf09f2a-eb58-469e-84aa-0626ff16dbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6b6b914-12be-4070-b4a9-a98a0f83bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c7a9eb-0acd-4618-a3e6-1e64a745d161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6b6b914-12be-4070-b4a9-a98a0f83bfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_536e6b1b-9da9-4961-85a7-99b9f5fec1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6b6b914-12be-4070-b4a9-a98a0f83bfcc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_536e6b1b-9da9-4961-85a7-99b9f5fec1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9b82b383-60eb-4d0c-9020-0c7eb9a3a069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9b82b383-60eb-4d0c-9020-0c7eb9a3a069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c73c2241-ba3f-4075-aa43-bfd537550aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c73c2241-ba3f-4075-aa43-bfd537550aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_edaaaf5c-c3a4-4d36-98f1-75d4b2b6662d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_edaaaf5c-c3a4-4d36-98f1-75d4b2b6662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_53d52d6f-6950-4840-a945-4f255a18b8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_53d52d6f-6950-4840-a945-4f255a18b8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_29cef4ab-d1c5-4f2a-a025-a774b3adc1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_29cef4ab-d1c5-4f2a-a025-a774b3adc1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0f228a3c-383b-48ac-b76d-3103457ff038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0f228a3c-383b-48ac-b76d-3103457ff038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_a8458345-fff7-44ec-af87-fc900a74cfce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_a8458345-fff7-44ec-af87-fc900a74cfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce763f04-1b70-4c7e-bec6-59d0c3f0adab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87c16e10-1614-41a1-b34d-8f6e1918e70c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce763f04-1b70-4c7e-bec6-59d0c3f0adab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesNetDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_31df65c6-9872-430a-b943-d6b3c2944180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31df65c6-9872-430a-b943-d6b3c2944180" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_14865fad-defd-4348-af3c-fa899f9f0bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_14865fad-defd-4348-af3c-fa899f9f0bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6bda089a-0177-461f-8546-317738e57562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6bda089a-0177-461f-8546-317738e57562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_d35bf704-542d-4066-a766-a02a4ed024da" xlink:href="prax-20221231.xsd#prax_DeferredTaxAssetsTaxDeferredExpenseAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization_d35bf704-542d-4066-a766-a02a4ed024da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_79a2f9d5-df20-4cf7-9c0d-658b213a4020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_79a2f9d5-df20-4cf7-9c0d-658b213a4020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_52e90269-b246-4a57-91ca-b3089a4507f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_52e90269-b246-4a57-91ca-b3089a4507f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_8abc989a-994e-44e8-8894-f5780c0ff1cd" xlink:href="prax-20221231.xsd#prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_8abc989a-994e-44e8-8894-f5780c0ff1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e9e3f2b7-2063-465b-ac43-62c42f4ca5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e9e3f2b7-2063-465b-ac43-62c42f4ca5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_dd79da30-0da3-4105-bf36-035f88808f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_fe2d2fcb-2655-4f37-833a-b5ba6667d434" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_dd79da30-0da3-4105-bf36-035f88808f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fb81cb58-3057-4707-bca2-a66dd319cbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31df65c6-9872-430a-b943-d6b3c2944180" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fb81cb58-3057-4707-bca2-a66dd319cbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ab7134a3-0352-4ce1-bb40-56e38cd937ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31df65c6-9872-430a-b943-d6b3c2944180" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ab7134a3-0352-4ce1-bb40-56e38cd937ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9c93fd94-4fb7-484f-a4da-ae375080b549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31df65c6-9872-430a-b943-d6b3c2944180" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9c93fd94-4fb7-484f-a4da-ae375080b549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_b823489f-7329-4001-b3c7-1faa3de79dbf" xlink:href="prax-20221231.xsd#prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9c93fd94-4fb7-484f-a4da-ae375080b549" xlink:to="loc_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_b823489f-7329-4001-b3c7-1faa3de79dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_085ed7fa-519b-4a63-a5ec-1d3d001630cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9c93fd94-4fb7-484f-a4da-ae375080b549" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_085ed7fa-519b-4a63-a5ec-1d3d001630cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_93a69f1e-da95-40fb-af9b-b4ef09fd663a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31df65c6-9872-430a-b943-d6b3c2944180" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_93a69f1e-da95-40fb-af9b-b4ef09fd663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_620e3fd3-fd77-4687-8d95-303724715e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_620e3fd3-fd77-4687-8d95-303724715e14" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2353677f-2c12-458a-ba7a-1c237d0ac30d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9d08f375-1b6d-480e-b405-dc9df18717d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:to="loc_us-gaap_DomesticCountryMember_9d08f375-1b6d-480e-b405-dc9df18717d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_363c9a08-e7e8-423c-ab77-00add460dcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9553384e-6e60-4062-86fa-37c2dfb884b5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_363c9a08-e7e8-423c-ab77-00add460dcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ff385380-0458-464a-838b-bc449f16d9d6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_2f747f2b-8bf1-40f9-9245-d3eee00f0109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_2f747f2b-8bf1-40f9-9245-d3eee00f0109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b70e3004-01fb-4818-a66f-73e2bd264f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_b70e3004-01fb-4818-a66f-73e2bd264f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a3284109-c1d5-4a93-8ff4-40e837841caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_a3284109-c1d5-4a93-8ff4-40e837841caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_893c16b5-9baf-4675-b121-a45f5875d6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_893c16b5-9baf-4675-b121-a45f5875d6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74d9cd7d-b8a6-4968-81d6-d61ab4e69ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_74d9cd7d-b8a6-4968-81d6-d61ab4e69ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_358024b4-4859-4359-a2fc-e489f52dd53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_358024b4-4859-4359-a2fc-e489f52dd53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_84bab2d9-8747-4370-83f3-d6fcf7d9b2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_fb75706a-b914-4b42-b611-7648c671beea" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_84bab2d9-8747-4370-83f3-d6fcf7d9b2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e6461572-dfda-4f77-bc44-53c12b8e77ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_0de1b43e-e9e0-49a8-a84f-e5b3b215bb47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e6461572-dfda-4f77-bc44-53c12b8e77ee" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_0de1b43e-e9e0-49a8-a84f-e5b3b215bb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/RestructuringDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#RestructuringDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/RestructuringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6e501be7-f891-4b99-90bd-2fcc6dac04e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6e501be7-f891-4b99-90bd-2fcc6dac04e8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_503b21f2-a4ee-4722-b0c1-09904c2d2c30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148fa7d-97bd-427a-a312-b55b79ee62b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1148fa7d-97bd-427a-a312-b55b79ee62b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_94faee3b-2704-4a25-8bbd-12a9fa67482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f4697789-cec5-4b8f-b259-60bd0960f245" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_94faee3b-2704-4a25-8bbd-12a9fa67482a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a50caac3-1760-400c-a5db-afdfa969c61c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0d907566-4d0d-4813-905e-4de7f6eccbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0d907566-4d0d-4813-905e-4de7f6eccbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7073d283-ea30-4389-bebd-777f8c3ac935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_13992be3-b5d6-4237-b832-42e885f8dd64" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7073d283-ea30-4389-bebd-777f8c3ac935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://praxismedicines.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="prax-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_07e0b173-8753-4e43-83a1-4fc05e03fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_07e0b173-8753-4e43-83a1-4fc05e03fbd8" xlink:to="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_69c6e4b8-33a9-417a-868f-da6d2449b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6db2c34b-cfa1-4ac5-b618-ceb2a219fee5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_69c6e4b8-33a9-417a-868f-da6d2449b3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_efcb820e-ef25-4f2a-931f-379c4d234e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_69c6e4b8-33a9-417a-868f-da6d2449b3ab" xlink:to="loc_us-gaap_SubsequentEventMember_efcb820e-ef25-4f2a-931f-379c4d234e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b1e2288a-c289-4d57-b0ec-74c59dcac7f2" xlink:to="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4765c7e8-0a7d-4c50-814b-23e7782dff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4765c7e8-0a7d-4c50-814b-23e7782dff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702dd282-89ad-4247-81ea-529203cc9258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f384f311-680b-4f48-834c-7a1b8eebe3d1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_702dd282-89ad-4247-81ea-529203cc9258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>prax-20221231_g1.jpg
<TEXT>
begin 644 prax-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ([!38# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ?RH 2BEVM_=/Y4;6_NG\J $HI=K?W3^5&UO[I_*@!**7:W]T_E1M;^Z?RH
M2BEVM_=/Y4;6_NG\J $HI=K?W3^5&UO[I_*@!**7:W]T_E1M;^Z?RH 2BEVM
M_=/Y4;6_NG\J $HI=K?W3^5&UO[I_*@!**7:W]T_E1M;^Z?RH 2BEVM_=/Y4
M;6_NG\J $HI=C?W3^5'EM_=/Y4 )12^6W]T_E1Y;?W3^5 "44OEM_=/Y4>6W
M]T_E0 E%+Y;?W3^5'EM_=/Y4 )12^6W]T_E1Y;?W3^5 "44OEM_=/Y4>6W]T
M_E0 E%+Y;?W3^5+Y;_W6_*@!M%.\M_[K?E1Y;_W6_*@!M%.\M_[K?E1Y;_W6
M_*@!M%.\M_[K?E1Y;_W6_*@!M%.\M_[K?E1Y;_W6_*@!M%.\M_[K?E1Y;_W6
M_*@!M%.\M_[K?E1Y3_W&_*@!M%.\I_[C?E1Y3_W&_*@!M%.\I_[C?E1Y3_W&
M_*@!M%.\I_[C?E1Y3_W&_*@!M%.\I_[C?E1Y3_W&_*@!M%.\I_[C?E1Y3_W&
M_*@!M%.\I_[C?E1Y,G]QORH ;13O)D_N-^5'DR?W&_*@!M%.\F3^XWY4>3)_
M<;\J &T4[R9/[C?E1Y,G]QORH ;13O)D_N-^5'DR?W&_*@!M%.\F3^XWY4>3
M)_<;\J &T4[R9/[C?E1Y,G]QORH ;13O)D_N-^5'DR?W&_*@!M%.\F3^XWY4
M>3)_<;\J &T4[R9/[C?E1Y,G]QORH ;13O)D_N-^5'DR?W&_*@!M%.\F3^XW
MY4>3)_<;\J &T4[R9/[C?D:7R9/^>;?D: &44_R9/^>;?D:/)D_YYM^1H 91
M3_)D_P">;?D:/)D_YYM^1H 913_)D_YYM^1H\F3_ )YM^1H 913_ "9/^>;?
MD:/)D_YYM^1H 913_)D_YYM^1I#"XY*,!]* &T444 >A?M%?\G!?$[_L:-4_
M]*Y:\]KT+]HK_DX+XG?]C1JG_I7+7GM  O6G4U>M.H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '+2TBTM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*O6DI5ZT .HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *5>M)2K0 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Y:6D6
MEH **** "BBB@ HHHH **** "BBB@ I],I] !1110 4444 %%%% !1110 44
M44 %.IM.H **** "BBB@ HHHH **** "BBB@!:=3:=0 4444 %%%% !1110
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M? 6E?$"W^%]U\0YKKQ$6C\*V^F3VJ:6FA7;K+?)IBM;%X[E8WC(4R *2!D4
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M]CMVNH+>0L7ABNFC,\:'<WRI(!\Q&.:^I-,^ NE_"_1O"S>*O!^CWGB;P?\
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MP7H5S-XDU-Y--U"TUMI[<_:Y?E<PZ=)&3_N.P]ZXW_A3?A'_ *+M\/\ _P
M?$/_ ,JJ /*EZTZO4Q\&_".?^2[?#_\ \ ?$/_RJIW_"F_"/_1=?A_\ ^ /B
M'_Y54 >545ZK_P *;\(_]%U^'_\ X ^(?_E51_PIOPC_ -%U^'__ ( ^(?\
MY54 >545Z[;_  +\,W49>+XX^ '4'&?L?B <_P#@JJ7_ (4%X>_Z+?X _P#
M/Q!_\JJ /':*]B_X4%X>_P"BW^ /_ /Q!_\ *JC_ (4%X>_Z+?X _P# /Q!_
M\JJ /':*]B_X4%X>_P"BW^ /_ /Q!_\ *JC_ (4%X>_Z+?X _P# /Q!_\JJ
M/':*]B_X4%X>_P"BW^ /_ /Q!_\ *JC_ (4%X>_Z+?X _P# /Q!_\JJ /':*
M]B_X4%X>_P"BW^ /_ /Q!_\ *JC_ (4%X>_Z+?X _P# /Q!_\JJ /':*]B_X
M4%X>_P"BW^ /_ /Q!_\ *JC_ (4%X>_Z+?X _P# /Q!_\JJ /(;>XEM9XYX)
M'AFC8.DD;%65@<@@CH0>]>X_$+]K_P 5?$/PMX@TJ;P[X5T74/$PA'B+Q#HV
MG/!J.M>6ZR#SW,C(-TBK(_E)'N91GCBLS_A07A[_ *+?X _\ _$'_P JJ/\
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M^ /_  #\0?\ RJH \=HKV+_A07A[_HM_@#_P#\0?_*JC_A07A[_HM_@#_P
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MQ%_\J:/^%'^&O^BV>!?_  7>(O\ Y4T >245ZW_PH_PU_P!%L\"_^"[Q%_\
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M./,^.'@-,]-UAXA&?_*50GP9\*2,%3XY> G8] MAXA)_]-5 'E5%>M?\*/\
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M(665%#;2S,/WCY!S@8/_  H_PW_T6SP+_P""[Q%_\JJ=_P *0\-?]%L\"_\
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M7X(^&64$?&WP*0>01I_B'_Y54O\ PI#PU_T6SP+_ ."[Q%_\JJ /)J=7J_\
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MFVP3%=SQ[6&)  RACD .XP<UN_\ "D?#?_1:_ W_ (+O$/\ \JJ/^%(^&_\
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M^BU^!O\ P7>(?_E51_PI'PW_ -%K\#?^"[Q#_P#*J@#3U3]J2]\6Z(FG>,_
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M_P %WB'_ .55'_"D?#?_ $6OP-_X+O$/_P JJ /)J*]9_P"%(^&_^BU^!O\
MP7>(?_E51_PI'PW_ -%K\#?^"[Q#_P#*J@#R:BO6?^%(^&_^BU^!O_!=XA_^
M55'_  I'PW_T6OP-_P""[Q#_ /*J@#R=:=7JZ_!'PW_T6OP-_P""[Q#_ /*J
MAO@GX:523\:_ P Y).G^(?\ Y54 >445ZE_PI_PG_P!%R\ _^ /B#_Y54?\
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MU !1110!T7AW_CR?_KH?Y"M2LOP[_P >3_\ 70_R%:E !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WB+_EW_X%_2J6B_\
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M\N__  +^E4M%_P"0E#_P+_T$U=\1?\N__ OZ52T7_D)0_P# O_030!U%%%%
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MDM$Y;=HV\SJJ<)TJF&I3H3M*<:#O*6BE5YM+*#=KI):Z=;]/GFBO8?B-\/\
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MM6CI/P?\-P?$C7=)NK:2\TZ&P2[@1I75HBS8(RI&<8.,UT2S"E%RBT[Q]/\
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MIY\-UY$C1F:W),;D'&5) )'X5]?^)UU9OA_J2VQMSXP_LJ,7/D??QAL[>_\
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MBBB@ KC:[*N-H ZRR_X\X/\ KFO\JFJ&R_X\X/\ KFO\JFH *?3*?0 4444
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MY&Y#O7Z<CZU'2JQ5@0<&I-R2</\ *W]X=/Q% ;D5%.>,Q]>AZ'L:;0(****
M"C-%% !1110 Y6/J?SI=Q]3^=-6EH&%%%% @HHHH *Q?$G_+O_P+^E;58OB3
M_EW_ .!?TH B\-N8[]F4X(C/\Q73%!<#*#;)W3U]Q_A7+^'?^/U_^N9_F*Z(
M$KR."*!W$HJRJF\Z+^]]APW_ ->F_977[Y6/_>8#]*!\KZ$%.:-HSAE*GW&*
MF6&/./,9SZ1H35F,&%<$/M])G 'Y4#4>Y56Y;@./,7WZCZ&I@[R#$4GF#_GE
M* 3^'K4H-KYG[R%"<9VH2/YXI!<67E@B$*^>X)_'J*1I;NRL9(FX>(HW^P<?
MH:>M@9QF)C_VT4K^O2KB7\.[YG3&,;O+(8?B*9*(I(@SLI3/WU9L_CD&@.5=
MRO'8W$?[P%5"_P 6X'^5/>SCD7S5E51_$J@G'T]J1EA,FY+UE9NI93_.IPWD
MXD9C< ?Q+&"/SS0"BB"-8H&?$[<=1M!#>W7FG&.TF*[93"S?PD<?SXI<6<BM
M((Y !U4,/E]_I3?D/^I$!]FSN_\ 'J0"-8H)&03C<HS\R$9^F.M!TNX^7 5@
MW3Y@/T-.:ZN8E*S*XC/'RC;CZ$57DA('FJQD3^]W'U]#3U%[O8F6/[(Q$DRK
MGAH]I;/U%.\NUD#-"LDC#_EF6P<>WK4 NY<89A*OI(,TY?(D8$,UL^>O)7_$
M4"370?:ZC]CN8IH;>$/$X==X+<@Y[FMWQS\1=5\?:M%J%\EO;31P"W"V:LJE
M0S-D[F)SECWK%DM7F7<P ?M*OW'_ ![&O9O^&._&_P#PO+7OA@U]H<>H:#8+
MJFK:W)<R)I=C:FVCN/-DE,8<*%E1?N?>/<#=4<D924VM4="Q5>G1GAHS:A)I
MM=VMONN>;^!_B7JW@&6^DL8[>Y-Y&(W^V*[8 S]W##GFG>'_ (G:IX?\*ZCX
M>2"TO=-OMQ=;M79DW  ["'&.@/U&:ZSX6_LW:W\4](US7HO$/AOPSX1TBY6R
ME\3>)+U[.PEN&Y2*,^69&<K\VW9D C=C(%:VG_L?^-]2^._A_P"%45YH?]K^
M(;(ZGI.KK>M)IE[:>1+.L\<R(S%&6&0 [/O#D <U$J%.3;<=[?AL=-+-L=0A
M"G3JM*"DDNRG\2]'U//O%7Q0U;Q7IVDV$L5K8VFF)L@BLD901M"C=N8YP!^I
MK<M/C5J[:?H5K]@TRY?1BK6WVB.0LQ52HY$@!P"./514'@_X$^)O&&L_$#25
M^R:5J7@?1[[6=7MM0D96"6DB1S1)L5@9=S@ '"\'YAW],\+_ +$M]XN\&WWB
MBQ^+WPN72=-@MI]2EEUFZ!T\3L%B6?%J0C%SLQG[P(J?J])Q4>71?J;QSS,8
MUI5U6?-))-]U&UONLK>AYG8_&W7+/QE=^(GC@-[<1?9Y(=K^2$&,#9NSP1Q\
MW<^IKC=6D;6-2N[^**!//D:5H;4,%0DY("L20/Q->P_#[]DWQK\8OB!K?A7P
M=<Z)XH31I88;OQ-87X&EKYH8Q'S'57<,591M0ME3P17D7BKPY>>"_%6KZ%>O
M&U]I=Y-92R6Y)1GC<HQ0D E25."0..U7"C"F[P5NASXG,L7C(>SQ%1SC=RU_
MFEN_GU-/P'\0M:\!W-R^E^7/%<)B>UN(S)$X'<@$'C)[]S6CJOQBUW7/$FE:
MO=1V;'2VWVMDL1%NA]=N[)/ []ABN4M-4,,C,XP[*5,J@$X]QWI)K,2)YL.W
MW"<J?IZ?0U+H4I3<W%7[F]+-L?2PT<+2KR5.+NHWTNG=?CK;:^IZ;<?M(>(+
MI]\VC:#,^,!I+61CC\9*YWP3\7-:\#V%S96JVMW9R.)%M;V(O&C9Y*X8$=O;
MBN(H-0L)047%05F;U.(\VJ5HXB6(ESQO9^MK^M[+<V_&'BS5/&6M-J>K.'N'
M0*@1=J(@SA5'IR?S-8M$;&-MP"GV89%&U?+')WYZ8XQ73&*@E&*LD>'6K5,3
M4E6K2<I2=VWJVPHI75HW*.-K#@BDJC 2E7*MD$@^HHHH 7<OEG*_/G.[/;TQ
M1(OE.5)4X[J<BDI5<Q[@ ,,,'(S0,0$KR#@]*>JB5HT1=KG@DMP3_2D$8<H(
M]SNPY7;W]O6F>N: %]?6BEW_ +O9M7KG=CGZ?2B11'(5#*X[,O0T )1110(*
M*** "BBB@ HHHH **** "BBB@ HHHH QO$7_ "[_ / OZ52T7_D)0_\  O\
MT$U=\1?\N_\ P+^E4M%_Y"4/_ O_ $$T =11110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7&UV5<;0!UEE_QYP?]<U_E4U0V7_'G!_US7^5
M34 %/IE/H **** "I8;6>Y#F&&24(-S;%)VCU..E15];_ M=)'PYT\Z>8C(0
MWVO&-WFY^8-^&,9[8K@QF*^J4U/EN?8<+\/KB/&2PKJJG:+E>UV]E9*Z[GSW
MX;\.V.CZ6GB3Q&A:Q)/V'3LX>^<>OI&.[=^@ZUSWB#Q!>>)M4DOKZ0/*V JJ
M,)&HX"*.R@< 5U7QOU2WU3XC:BUK<FY@A"0KAMR(54 JOH <\>N:X.M:"<TJ
MTMVON7;_ #.#-I1PM2>6X=_NZ<FF_P">2TYG_P"VK:*[MMLHHHKJ/G@HHHH
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ML.,GQ+XG^,_^%D?$KQ;XM^Q_V=_;VKW>J_8_-\WR//F>7R]^U=VW?C=@9QG
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MM)FY\M@/]KC^= U<=Y:7'^KPDG_///!^G^%1(SPR?*61AZ<&I/LNW[TL2?\
M LG]*L+Y,P"2.\C=!)&ASCW]:"[-D<=T P9T!;^^O!_P-.DMDFR]M\XZM'CE
M?P]*D>R$+$&%R/[SR!0:(Y$MV#J88V'3:6<_X4BN5[2*D<SP_==D]@:EBOC&
MV6CC<]^,9^N.M:=LZ:E/'%! 9[B1U0(J*&)) &,YSDU[:O[-=R-%WIJ\*:IL
MW"-K?,6['W<YSUP,X_"N6MBJ6'M[5VN?097D&8YPIO 0YU#?9?FUKY'@2PV]
MT&,3-"_7R\;A^'>F_P!GS,NZ,"5?5?\  U+>7%]9WDUO.3!<0NT;H% *L#@C
MZY%*-0FND"-(/,' W %6_P #75Z'@M13:DM2..WN[?)"&,'JKD '\#7ZG_ME
MVFD>*?"?QC\._#O4FM/'UM'I&M^-[41A9[_3$LHT2*)^IBA402N!Q^\//)4_
MEBNI2QY1XXV'0JRXKVV/]K_Q9_PT++\8DM-.LO$UQ'';W-G!'*=/N85MDMC%
M+$9"S(R1J2"WWAD8(& GW>C.E\865Q'_ ,$^_ 4<'D"W'CG4#>;'4'SOLJ>7
MN/KY>[KVQ[5VG[&6N_$75OVE_@=#XPAU!-#TS2-6M_#<]U8+ IM/[.NC^ZE"
M*9D#=&+-CH"*\C^&O[2&I^ --\1:)#X?\+^)/!VM7O\ :+>%=>L)+K3[6<$[
M&A7S1(A53LR6)*@ EL5;F_:N\=VOQMT'XEI9:&+WP[ISZ7H^AVMBT>F6%JUO
M+!Y*0QR!E4+-(P.\_,1R0 M%P=/2Z/ICP6J?%KP3\4OCG90K%=:[\*=:T/Q5
M#&,"#6K?[)^]P3P+B )* !@%'R2:^=O@3_R9_P#M/_\ 7#PU_P"G2O/_ (6_
MM#>+_@]X2\<^&=)^RW.C>,M,;3-1M=1C>0*I5E$L6'7;(%=P"<K\W*G QF>$
M_B[J'A/X;^//!-K9V:Z9XR2Q34+B1':6(6L_GQ^5AP%RW#9#9'3!YIF=CMOV
M(KB5?VJOAA;B5Q!)KL#O$&.UF4.%8CH2 S8/;<?6N)^-4RO\9O'T4V=G_"0:
MAM<#E/\ 29/S'M5+X7^.M5^$?Q!T'QIH<-G?ZAHMTMW;QW2N\+,O02*K*V.>
MQ'UK$\4>(+GQAXHU?7+N.)+W5+R:]FCMU(19)7+L%!)(&6.,DG'<T!JC-FA:
M!]K<]PPZ$>HIUM<R6LF^-L'N#T/UJQ%#(JO#<1NL8YY4Y4^W^%030"!D!8L3
MSD#@CU!I%<K6J+$EN+Q7N+=0I!_>0CJ/<>U4ZL6LT<,[D^8(R,<8S4TT*S-M
M+J+KV& _H?J?UH';F5UN4J*&4HQ5@58'!!'2DIF0JMM5@ I##'(S^5.51(T:
MQEB[<$' Y]J;2R1/"VV1&1NN&&#0,;R"01R.M+1N/EE,+@G.2.?SI_E^8V(=
MS<9^; /O0 RBDI:!!R""#@BEW+Y9!7YRV=^3^6*2DH =(GER%=RMCNIR#0LC
M(KJIP'&",4J2-'N"X^88/ -*(_,\M8MSR'JN._M0/T#RPVT1[G./F7'0]\>U
M,I59D8%258=QP:=\K*J@$2;NI/!']* &44YXVC=D8893@BFT""BBB@ HHHH
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M9 Q;&9 5P .,D$\$&K$'P5URZ\37^BP76GS2Z?&LEW=+,P@@W D*S%0<X!/
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MJ.[;]&?17A'XA6,7PR\5ZQ>ZM8IX@U22ZN5M'N4\T'8$C0)G=@;1CCI7S?\
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M_P#2N6O/: !>M.IJ]:=0 4M)2T =%X=8_8GZ_P"L/\A6KYK_ -YOSK)\/?\
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M>>(?%T:V<NZW1Y([=/FV8E+6AE^X6(^4'D8KLKC]J7X>Z-XX\;6/A+4O[#\
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MU8J<-F?.X[ U<!B)X?$1M.+LUN/CL9+R-CM2>55P&C?.X>_N*JMI=Q&H,J+
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M%-IZL$WAD#9&!G@J?6AH]JH<JVX9^4YQ['WH$,HHHH$%%%% !1110!C>(O\
MEW_X%_2J6B_\A*'_ (%_Z":N^(O^7?\ X%_2J6B_\A*'_@7_ *": .HHHHH
M**** "BBB@ HHHH **** "BBB@ KZP^&/BC3?A7^Q.WC.'P+X+\4>(+CXA2Z
M0;KQ3H,&HLEM_9L4H16<;@ X) SCYFXYKY/KZP^&/[0NJ?!C]B=K;PAXETO3
MO%UQ\0I9)M/G@M+RY-DVFQ#S?(G1\(9$"^8%'((SU% %[XV?LZCXJ^._A9=>
M M$T?PI?^-O!D/B;5]-C8VNFZ9MW&:ZY)\F J 0H&!CC<37E?BC]E/Q+X;\6
M?#K1[?Q!X8\16/CV]&G:+K^AW[W&GR3_ &A()%=C&'7RWECW?(>&XR0176?
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MVI^WS!?M\P!MXL<0)T#8[<<*/Q]*NQZS+9PK*EQ*;"',<$3L3]I?NS _P_\
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MRUY[0 +UIU-7K3J "BBB@#HO#O\ QY/_ -=#_(5J5E^'?^/)_P#KH?Y"M2@
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MQ[(BBNNY#N978Y.",=*\5N;R]MVCQ<Y1ERGDG"X^E?6W[6]IXIN/V<?V<?\
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M@XQQCDBM+XD6\/C#QEX=\.6\L<VK^1(;VXCEVB!, EL#JW#8'4;NV<U/X\\
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M?V2PV:Z8.6GOMW3VYJ>\KI[V7+TE8Y;2_AWJ>H0M?ZA+#I&DKRVI7SXC8?\
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MF8M;S2#8Y/7<,$GZ9XI*[V";ITU>;_$V=2U"YL\II=JEUTV%"L@0#IWR?H,
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M_P#2N6O/: !>M.IJ]:=0 4444 =%X=_X\G_ZZ'^0K4K+\._\>3_]=#_(5J4
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M&\(*!E4$EE(QG) Y'&#6SXN\&Z)XAC\#:_;:=;Z>^JW<$,]K"!Y;;B#P ,=
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MC<""J8_%O85#<^)+?5(F@N;3['$[ES]@;:"2<Y=3]\_B*J?V&USDV%S%??\
M3-3LE_[X;D_AFLZ:&2WD,<L;Q2+U5UP1^%"2WZDRJ3CHMC1_L077.GW<-Y_T
MR)\N7_OD]?P)K.N+>6UE,<T3Q2#JDBD'\C3*T(->NXXQ#*4O+<?\L;I?,4?0
MGD?@15:HQ]Q^1%9ZO?6(VP74L:=T#$J?P/%6O[:2;_CZT^TN#W94,3?FA _2
M@?V5?=/-TR7\98?_ (H?K3)M!NXXS-$JWEN.LUJWF*/J!R/Q I:=2_?6SNA^
M=&N.J7MDQ_NLLR_KM-2V]O' VZPUY(3Z/YD!_0$?K6.JLRLRJ2J_>(' ^M6
ML5K,A?9>*4R55F4!B.A/J/:G82EW7Z'0K#K5RJEO[/U2,G;OD:*3GZY#47&D
MO%)*DWAN24#Y1/9-(JGW (:N8:61H5B+L8U)8)G@$]3CUHCFDCQLD9/]UB*7
M*R_:QZK^ON-VXT^"XV+*FL6_EKM19;<2A1Z#[O'X5!_PC\4G^KOP/::VE0_H
MIJBNKW\?W;ZY7Z3-_C4G]O:G_P!!&[_[_M_C1:7<.>F]T7D\&W\W^H>"8_[+
MD?S J8_#W7AM)LU"L<!C,@'\ZQWU>^D^_>W+#_:F8_UJL\CR'+NSG_:)-%I=
MQ<U'^5_>;NI>!]5TN^EM94@9XR,E;A #D9[D']*J_P#",WP^\;5/]Z[B'_LU
M9DDC32%Y&:1SU9CDG\:9CVII/N0W3OHOQ-=?#KK_ *R_TZ+ZW2M_Z#FI;?1=
M':58]1UV".V;(E:WCD)"X_O%<#Z\UBK45[_QYW'_ %S;^5%GW!2BG\)S5]'!
M#?7"6TIFMED98I",%E!.#^(J"BBJ,V[NX4444""BBB@ HHHH *9-_J9/]T_R
MI],F_P!3)_NG^5 &51110!Z%^T5_R<%\3O\ L:-4_P#2N6O/:]"_:*_Y."^)
MW_8T:I_Z5RUY[0 +UIU-7K3J "BBB@#HO#O_ !Y/_P!=#_(5J5E^'?\ CR?_
M *Z'^0K4H **** "BBB@ HHHH **** "BBB@ HHHH ***55+' !)]A0 E*.U
M2>3M_P!8P3V)YHW1+PJESZM_A0.P^0BXFW1Q87'*]J39'&I\P@M_L\G\Z5EF
MD7YSY:>_RC\J9^Z3N9#^0H*'K.58"*-1^&2:3RSM/F,JYY/&6I1YSK^[C9$/
M]Q?ZTGV68_\ +)ORH 4W7ED&,88# =NM0N[2<L=Q]S4ZV$V06B;;WY J3[/&
MOWD(^LH_PI#M)E-:6KBQVHZC\I/_ *U.,=ICAQ]#DT7#D*-2K,%M_+\M2=V[
M<?Y5.D=NW\4(_P![=4BVZ?PQK(/5%+?^S47!1?0H[A\WRCGIUXHW#Y?E'R_7
MGZUHBWB12T@2)1_>7_Z]1_:;:/[L6]NS%0/THN/E[LKQK)RPVQJ?XCQ^59/B
M2]$8ML 3L-V'D'3IT[_G6_\ ;HY&_P"/7S&/3)S_ $K)\27T,/V?S+>+=\WR
M+R>W4TM2E;HS/T&Y%UJ#[O,1]AQY9R.H[5TWDALB5DE..B_ZS_/UKG?#^K-]
MNDV0Q1_NS]T<]170IJK+C]S&?S%&H7CU8W;MXMP%?T?[_P"&?Z5&+B>-L.&8
MCLX)Q_45:_M@[LE"/I@_TJ0:IYCC8[J?[K(&'Z<T#T[E<-%<_P"LC:-O[RC-
M,FTR9%WH/-3U4<_E5^:*ZV%UNMO^R6Q_G\:K.MU'AGNF ZY4LP_08H!Q75%6
M.&XC)(MV;/\ >CS4OEW/'^B#_OU4YOHIDVW$K,>SQ@J:C6Q$REHKDRC^Z%)8
M?AFF*RZ#?+NQT@5/^V:BD9+QAAF8#TW@?UJ)H(\D&< _[2L*3[*#]V:)O^!8
M_G02.^PR'JT8^LB_XTJV+=Y81_VT%,^Q3=0F\?[!#?RJ-E:-L,I4_P"T,4$Z
M=BW':F,Y%W#&?4.?\*M1R)M"7%Q;3I[@Y_,"LJB@:G;9&HT<.X+;WJ[3_P L
MYLE?U%1RVL"MMED2!_5=V/R(_K5#9A58_=)]<G\JF2[:+<@Q)$3PLHS_ /J_
M"@KF3W1<M[&7.Q9HI8B-VTG.1ZX-2+:SO&5@<1-G.WS 1] <_I5-8[>X_P!7
M(;:7^ZYROX'M1<>=#A;J'S!V?O\ @PZTBKJVP^3[='_K(F/NT8/ZXJ!KIAP8
MX<_[48%6+:XDC/\ HMP>>L,AP?P]:^[]4\">%F_X*J#P=_PCNC#PJ-1A0Z ^
MFP_82ITU7($.W9C>=V,=<F@E^I\$?:O^F4/_ '[%.6YDVLZQ1;5ZL(AQ7T?H
MW[*M]\1K3Q!XP36_!?@GPS;^*;O0%G\0ZD]BBSILD1458G4J4E& .?D;( &3
MA:;^Q[XMU'XA>.O"M]J.C^%G\%@2:YJ^O7GDZ=:J[ 1-YJJQ(DW H N2#R >
M*8M>YX>MY(K+F50A&3Y2 $>W2FKJ,Z@XFEWYX;?P!]*^^M?_ &?'TGQ'^RWH
M'@_0_ASX@\1ZAI>I-<WNH6PN=%UAD#,LMP\2;YUV9*$C(.W..:^;/A/^R?XG
M^,7AB+Q+'KWA7PAIE_JATC3O^$EU![0ZA>8#&&W58WR1N49.!DXSP:!<TCQ^
M35$NMHN;5)0!C<I*O]<TR.WCD!-K)^]SD!VV,/8=C7L?@O\ 9%\7>))/%4FN
M:OX=\ :;X9U/^QM0U+Q5J!M[<7V6!MXV1'WN A;@8Q@YP17JWP^^ J_#7P'^
MTUH7B[P_I>H>)_#>B6$UC>20QW?E^9+N2>VD*_*LD;*0RX..#@C%!7,W\1\J
MPW5QNVW4<@B48:21]K ^Q[_3FK$=Q%<,P@N%NY"-HBNN,CV..:]T\+?L;>/?
M$VBZ--/KOA&WU[7M..KZ5X)U#5 FLWUL5=T:&'9M&]48J"XX'.,'&1\*_P!E
M/7_BQX1BU^SU[PWX'L;S5#HMC_PE%^UK)J%Z "8( (V)(W <X&3CL<38V4_,
M\@N(!M6.:$(Q&4MU)4?]]#BJ4U^58(ZW%MM'"))P/P(YKUSP/^R_XZU[4/&%
MMJ.J:)X)TWPG=_V?J^K>*+\P6,-T9&C%N'57+N2K<*", $D;EST6G_L@>-)O
M'FM^$=1E\.Z=9:/I<>N7/B:ZU KHXL9%4QW"S;"Q1]V!A<DJW'!H%S*7D>#0
MZLA#+-,9HVX(GA!/YBK*V=EJ2[;98R4&3M9D/TY[_G7TE^TS\(/#WPS^!7P)
MAM/^$?U'4[J'6WN=?T#9/#J8%ZIA9IU56EVHX5=_*\K@8(KYEGL6_="XN9(D
M8_+$(L'\ O% TY-7>H_^PXXX_.'GC!^["5=OSXYJTJW$<T2+/Y.X?*C1EI#[
M$G.*2W:56DC\V(JB\A7S)CU9CP/Q_*K8=/E2U&_LVV;;GZ>WMQ479K&,>@D;
M>6SQKY,$K@;F63YF]@,Y'UJ;^U)8Y-DEL\:8RTK<X^O'.?8U3C-Q(TA\QHSO
M )DM\<>@]?J:ECFN#'*S/#)'T")*5 ]]V>OTI&BDRUBSU./:A5XB<%02O\OY
M4R:W@BG\M2%DPNT9)+#W!(S35NMT8$3-(Z@;D252K#N,GK^-3?;MHB18C'D9
M*O&P  ZC/;]:6I5XLKSV][9S--:P6D84[2S+M9O?_P#55RWO'=L./WA&/D)=
M/S[&J\:V\$JB.^DAW<B%VRASUP2/ZTMQ;ZA"S-%=1NK<".6(%L?AUH]1WMJB
MMJ&I6LDPCN;/RKB,\"9RGXJPJ6UU"*-26CNSN&-S-YZ?H:C6XU/<J2V=M<QY
MY380<>VZK:6,,C/)'9+"&!$BL3&WTX.*>A"NW=?D/MY+>:)=ZVS[FR@)()P>
M<!NGX5(TURLC[;9I%/)C=]H_#((_6L<R:G,Y_P!&@>W!QL+*Y ^I)Y]ZDM;C
M4^(I(5,/W5:!PK*>W0\_2E8I5.EC5BGMYU6.2*6(GYOWR[@O_ CD?K3+BS#1
MC+)=QL,AI%3*_3 YS40DOI/,BGBVP8*DDB16^@ W54L?L<+I'&+I'4X4,C +
M].,X/<$TBG*^Y9.K%)8;5-.GV+U,B@+CN>AJ2WU33K,G*Q6.X]"H#GZ@9_7%
M-U*UU'RX8K*\CC/)*!]I/KC/4#WJB9&L&\G4I(2[#*M%$ 3_ ,#QC]#3LF0Y
M2BS0N=2DC0-!<V]PDGRB967>I] .A_$U5L[C689&AF1KF)S\LS)E1['I@?RJ
MM!K$<B1FUD6*4$*T<XRS>XP,#\16C9K?"9H98S,&^]-+)N4]PNS'TZ4;!S<[
M339;CT])'\Y]L3[?WD*MNA?C@\CCZCTJ&[T^UEC6XCG%LK,%::U 8G/8MU'/
M>K7^AV,:&]FBC8\E=Q*Y_P!G/055U:ZO+.)%T:TC:&0 F2%02#]!Q^-2KW-9
M<J6HRTTDV-P\D5J( OWKNZEW%A[ ?UJ6^UJV@4!#;P,PQ'+)\XSW&%Z8^M/7
M4!>69CN9F@N]JM)' X8@9X(SQSZ52N+R=E= GEQ,P"7D:[]C<??4CY?? %/=
MZD\RBO="29%MC%JDDDD+MGS2 B^HV8.35JST^*-I([2+$<PW-YAR#V&$'&T^
M]161EM6>*6W75+IG&6C4*BG_ &CV(]Q]*W[6\1AL$?EN&P54$C<>>M*3ML5"
M*EO_ %\S U&SG:.T94BL&3<&CB 8D<8'H/>I-%CAAOT/EI"[;G;WX.23W^M6
M/$*&X2,+*"Z[L#)VYXQNQU%8<$BZ*8KB^G>>7<=K*@PA*D?(.WU.:RO=G3=0
M5SK=0U:ST]HQ<7)C9CA8T&2?TJQ'<0WJ#!*\Y&[@_D:S[6UCUJU2=6FA#_-F
M1 ) W W*?X<^U78[!+5%CBA!VD,9&YR<]>3]['<T.P*4F[]!T5M%(PDDC5I5
M;Y9)(QGZ_P#UZDB>W\Z9(6A,VX&5589S[CUJ@MP9C*$O55E?+.L988S]W)XS
M]*<UO9-Y3S0Q+++_ !S8#,0> 0<$_P#UJ!\W8L_87DE9VFF5G(.S>&5,'(QQ
MT/<4V;1([BZ^TERLH&%"L=G'W25[X/-27:SSJH67RBAW,D8#%QV7GIGZ5%;W
M,D4=Q+<1^6_!V1L7R/3&,Y_#O2NP?+LT(D8TNU9&-QJ,XW2;B S9[[>P^@J1
M[P6=NSW3B)2!LEF;!)/]X <8)Q35U%519VN(Q'D#<V51\] ,G@YIJWC7$J_:
M[14M_+)=VVLJ'H5)_P#U\4!S):)A<7UI9VZ3WB9C49,@C. <\8SS]*LV>JK=
M7CQ;4$156AD60,9 >^!R!52YL8=4N;8P336WEQLD9B ,;*1_GK4%IX9#6I6:
M6(D$[)K==A4$_,,9P,X[8[T_=MJ3S3YM%H:\EX5F2.1OLC-)MCWE2)N,X'I5
MG<6_=N_ER,2%*\'\,]ZSELS>1F&\7[;&S?.Q4(L3 <XSSC/\ZO#9;H2Y1;90
M"K,XPO&.#_\ 7[U#-XR9/Y9\LJ</N&#GC/KG%9UYX?M[NU2S,2K9]3&0=P[\
M-GBKRR1WD9P%EA8?*X8%6]N*CCO9%D$;6S(JI\S%P=I]#SZ#K238WRO='-:Q
MX--Q?%[9YX(-JJRP8. .@P2/TJ"'1==T^QF:V+2NP58XVDW%2.KC<,CV'O\
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M=V1 XW$COQGH":FG[:K1YJD;,Z,<LNR_-52P-7GIJ4;2^Z^NV_4^F;V_UO\
MX2RWLXM.671&3,URY'!P> /KCK6)X3M1IFO^-ET[+JIB,$0V$!MCD@ '/WB1
M\Q[=J\R^*6MZOXE\62?V%KUY;:7]F0&&.6:(,W);]WQ[<G&:M?".\T?P#H^M
MB^U"6UN]0C01QR*0YV"0 J$R0,MUS7D?591P[EU:6B7FM_,_37Q+A:V>0HN7
MN0G4E[24HV2]G**C!_RMVM=[V.V\1?;M;^'>I/K\0T;4F;R[67Y5ESQC&UCU
M.X8!Z?G4?PA\.Z?X'\-K<R[DN=5N%B:6Y*AW.2JCJ>IW8'O6+JWB[1]>\"M9
M:UJJPZI:Y*2RI(-W'0D=3M.",YR 35/Q+\>M&T&WTNP\.10ZQ:V\(!:>W= C
M+@+C=M.<#/3O5>QK2INA&+U;\E9=GYF:S3+*.-AFU6O%^SI146VI5'*3=^:*
ML[Q5T]-FG<CCN(?A?XVFAM8O)L[>3,D<(3+QOS@[GSW7_OFO0O%4UMX(TW5?
M$EI;R7-]=(L4"PQ[B"QR...,G<?IBO/M6U[P)\0/'7A_59;LR2QP9NH/(GX9
M2&12 F",LV3G&%]ZZ?5OB7H%TVK:?X@NX[?3K@@6C(KN_'&0J@MG(# ]C15C
M4J.$G!WM[VF^NWGW]"<OQ&"P,<50ABJ=G.3H/F34&X/WF[^ZK-1U^TMCS71?
M"&LZHD>H1:5J$OFR$E42*,D]27.-V23TSGGFO0?AS>3:?X3UYX+_ $]=:^T[
M"+RZS%$X"@*[>@ST4>W6O+)/'6H:/"UC!='1]+C<F)8[J<3R#/WMH8-SU^;%
M:GA?Q5X$U2QGA\26$]M([$PZG<*\P?ID8&<'/UZ]:]'$4ZE2#4EI=;*[^:N?
M#9%C<'@\7"="5JG+)-U)J,;M6]V2B[/>SEIYHV=?LO%_B+XB>&-%\2MIZV]P
M9)(KG3H\K)&%WR!6;D'"CTZCK71?%'P[XFU30=2T_3[2PB\.P(#]DM27O9-F
M&#8^[@D=,DX]3Q7/ZY\=M T_6M!BTBWN+O3=*&SSD'EEE*["JJV"0%]<<UJ:
M?X\\&Z??>(=7TC6Y[S5-73Y;&Z5D2-L' &Y1QD]B?:N%QKQ]G)0V6BMI>_X:
M'V4*^45%C*,L7=SE[TW47-R>R6D6U^\2G>-H[JS=RGX#\27&CV/A+P[X>T&:
MWNKIQ)J4][ H5XQCS6!#$C&>"P' 48YQ7F_QLCTN'XC:FFE)&D2E1,L7">=C
MY\8]^OOFO8? YT70? T>G+K=Q!JUQ !-=+!(\L6XGY8P5X YQQ[^E>3>,/"O
MASPYK!MO[:>ZM2BS,S0L;EW.<KG "KC!]>:[<-RK$RDDUOT>NN_^1\QGLYRR
M*A0E5IS=XNRE#]VE&R@HIWN]YO:^FNYQMCI-Q+>2Q%)8)XDWCY<;3P1N)(VC
MGJ32ZQXQ71[RV5C_ &K=QQ@&Y1C&%Y;C=UD/^\,<=#5^^U?3)8_)5;MK8'(@
MB*PH3ZM]XL?<FN:UVXL8;VT,FCQ103(")KB623Y=Q!.%(S7L-<VZ/S",O9_
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M_&N+_M2\_P"?N?\ [^'_ !IO]H7)ZW,Q_P"VAH'H=QY87H@^LCC^5(S\8:8
M?W8Q7#_;KG_GXE_[[-+]NN?^?B7_ +[-(+G9[HEZ(S_[QP*/M##A0$'^R,5Q
MGVZY_P"?B7_OLTGVZY_Y^)?^^S3%<[ MN.3R:2N0^W7/_/Q+_P!]FC[=<_\
M/Q+_ -]F@1V&\^IQ1N/J?SKC_MUS_P _$O\ WV:/MUS_ ,_$O_?9H ['S&'1
MB/QIRSR@?ZQA^-<:MY<LP GF)_WS4WG7"<S74J_["N2W\^*!ZG7K<R'J0_\
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M?C7DGCKP'\:/C9\>/ OPY^+$N[7+I)[NPNM4B5H["T*2/*X2'EV86CX!QED
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M6L4>^:,<*W^D;L8&.IST)]J='(8K5# &8[<!93F3ZG)S4+31Q*)I988\\ W
MV"1QT.?[OIUR#56\W7%UA-/5F[7$Z^9"P ]5.5J-]S1RML0-;ZA*[S17 FLF
M8^9:WL6PQ^N&QVZ\U=;28EACMI;&*ZME=7C\OY #GD]?J<=/K20ZA?7&H-:O
M9PK:CAIA)TX_NGUI\NN/;[L6$@B4X4;MA/N<X 7ZG)]*;;(7+NPO%,+F%+.&
M/3W_ -=="X$0&3S[YJM,^CPJMO<M#'N<2)LD;!;J&W =2*OVMU;7T<L4%DSA
MER4DC*Q'U&[&"?>K%M%$]N85"PR1CF*,AC'[#%+FMN5OL4&@TZQG5_L69%!1
M;AAA!SPI9CZ]/TK1Q]GA63!@C/R^7&H55/N<?YS35@@M@ NV251DLT@\SDYP
M-W^-5TAF\R2,0I)%QEKB;S=WS9 Y/X>QQUJ;\Q2]WH+)=?;MK[(TC4X5B-\F
M<<@#H#QZ_E6&\<UDSWMJ;C49$(7#2&64$C."/NH!C!QD_2I=>'B..^C^RW,?
MD-@%7*)R#P#GU%/F\'WFL-;W,EX]A=1G$JQRF08]0?7_ ":UC:*U>AC)N3T3
MNAOVJ'Q19&SU=8X6^^%AE#21$<9 &20<]^1W]:U])T=]#%SY<WVC3>&AM54N
MR'U5L_7BJUQI>FV=Y&)KMHKM_F+6Z[9)54?QD#IQSC%:$-S':68%C:?Z&!N*
ML!&J@Y))W'(YSUJ)2NO=V-(JSO/<[7Q+8_VIX'T.^A+ Z>[PM'&V 0<#!Y _
MA7K_ 'JXZ+48F9[9U6*XC&UEA5CY8/;=@#/KBM_P'X\T:YFN=*N;H2Z?>#8S
M8&R&3H"3V!X^8\9 YJ/Q/X??0[@VUZ"H&?)F7(W+GJK=CZCM^5<%/]W)TI^J
M^9]AFD?K^&I9I0U7+&%3^[**Y4WY2BE9[7NC=^'_ (T.@Q3Z?JD(M]-C)>WO
M/.WC!Y((QD+U.<GJ:TO$7QN\.V.E^;IM\NH2R@B*6)284/3<[' P#7F4BM=V
M<]H]OA6&1#<$DN.IY'!_#\NU>4WMQ?6=P6F"WFCL/)O(9ESY)[,R ?*0,89>
M#C/%*6!I5JG.]SLPO&V:8# K!4VFDK*37O)>6MM.ET['H5SXNDTZSBECA66&
M5%!U(#="I(^4$J<GW/;-;/PIU*^\0?$&U@N1/;_8T:YD6&4&W:,+PW(R06*X
MYK@=-MI_*LY]&6XU+S46/R4??YB[0%4+M.[!['GV[U[%=0V'P^\(/I<LD>E:
M]K,#*YB&X6R$<C/0=3P.,DXZ9KJQ'+&'LXKWI:?YOY'BY#1E/%?VA7=J-"TY
M/NUK&*?5R=EZ79Q.M>,]/\3>)+WS CE9Y62&YM 6(W':%Y.3C''?''I4T.H:
M7JTPB2Z6SN&42G$6PNH'&X,N"HQWKF+CP4EC#/\ :;DO>-("DD@P[JIR=BDC
MGISN/X51UJ^GUB:XA2T;2+J5LF$C;]J&.A)_BXX'0_7KU1IPLE#9'S=;$U:E
M256LM9-M_,[VXL@R _:IFAVG:$1FV?+R$*X(S[\D=,5R_A'3]#T'7=!O=0UF
M.%(-2ANC<+!(1Y:NI9?J,<CJ,5R6D>)=1T*;$$[;!\K6\I)0^Q&>*[/1=6TO
MQG"=/N;-8;^3)?:I(D(_B#=F]S^M7RRI:WT.;VD:VEM?,^RO%'Q7^"?A?]H;
MQ=\>?#7C]/&7BB:"9]%\.6UC<6H2Z>V%NLDLTP11&HW,0 6.>.F#P/A'4_!'
MCS]DSPOX&\5_%2S^'^N:?XBNM599-+GO4EMVCV*J"%2F,DGJ<8Y%?-\WP[M]
M/E=X+F.Y=6 5;P<1\9R57EC[' [\UE76GW5S=);O8W^LS@DH9CLA&>N-N>/^
M! 5?M%+8R]FX[GU7\'-4^%_A/3_C=\/M3^(NE6OA_P 2:98V>E^)K;2[D?:W
M!\R4M J%U*$E?F502"1P:Y'P5\+_ (??"GXP>%+^Q^*E[XDT687 N-4\/6EQ
MI=[I$NS$$P649F4.<E4P<*>O /@\TEOHK-]LO([5NVG:, &'L\O;\R:S=0\1
M7TT<<%@D=E!<#B*U;?*_.,.WWB?:G[STCL)\B=Y;GUE^U=XR\ >/?#/A739_
M%\/COXBV4T[:MXCTG2&TZ6]M>#%;RHP7S74\AF!( ."2Q)^;%^(&DZ:L<-A8
M7,<,0"A 4C+@=G;EC^8KDH]6\W;#J4;3A>%F4XGBQZ-WQZ']*VW\-S:['',6
M4&0;DU-E*12CTES]U_?O[]:)17_+P<9M+]T12>-+81SI;Z8ULLIRS17)1O\
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M%%R<YWG&3^9JG&3W=A*I%/W4V=HB^&Y6G\JXM]'O(Y ))C;%PH/'"R8VG/\
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MP[_QY/\ ]=#_ "%:E !1110 4444 %%%% !1110 4444 %%%% !4OEQ]Y?\
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M'<?NM)M(_ C^M(:MZCI)(8[<10  =-K0,X ^@X)]Z5K=[A55'F"8Y$)\I?\
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M?*W?KF@9"NGR2@OYJ2<\E"7-.6RC5F&R:?C@JFT9^IJRRA57==,JGU;R_P!
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M$T21C;^Z # +CJ2/FS^M:EE>3:G$&>U(4-@B=>,>@]_>IF6TTY8IC"D.P?\
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MM>VH"2Y]67H_Z'WK/V2CLB_:.6[)+G7M0M9G@O;*T:5#AH[BQC5A]<*#4?\
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MQWJY::UJ&G_\>NH75N!_SRF9?Y&M#_A,-07[L6GK]-/@_P#B*!XRU+NE@?\
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M;Z$"L"?POJD49=+5KF!>?,M6$RCW^0G%367C+5;&U-E+*+ZQSAK.^3S8_P
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M)$$DZD%OF+(5)4 J0 ,DC&.E?-&I:K;WUY,5@E6VWD0J9?G5,_*&P-I.,9(
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MOC)W(, _CUK90,G,NS:M*RF:(K#N;:3O+3-W.6/./IBL^63S)'95V*QSM!)
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MQD!09Y/_ !W\N]/?.1YS;SVB3_/%(K,X81 0Q_Q-_B:;YRQ B+.>\AZGZ>E
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M]/TFS2?[DC0J^!G&6W%B/Q%7[C2=-UZX#6FM6D%_.Q\V&0RB*1NN59EX)/\
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M$=JUX_$]U)&L5_'#JD*C 6[7+@>T@PP_.G[R\PT?D8]%;/EZ'??<EN=*D/\
M#*OGQ?\ ?0PP'X&I[/P1J&K744&FR6FI-(VT&WN%X]RK88#\*7.EOH'*^AS]
M36=Y-I]U%<VTC0SQ,'21>JD<@TEW:RV-U-;S+LFA=HW7T8'!%156C1.J9:O]
M0N-6OI[R[E::YF;?)(W5B:HWO_'G/_US;^52K45[_P ><_\ US;^5/;1".3]
M#W%;WAWQUKGA>[2XL-1F!0%1%*Q>/D8^Z3BL&BIE&,E:2N-2<=4;S:QI^N,?
M[7M_LUTQ_P"0A8H 2?62+A6^JX/UJO?>&;JUMVNX&CU&P'_+W9DNJ_[X^\A_
MW@*R:GL=0NM+N%N+.XDM9EZ/$Q4_3W'M4\KC\)7,G\17I:WO[:T[5N-6T\1S
M'_E]TX")S[M']QOPVGWH_P"$5-]\VCWUOJ@[0Y\JX_[]MU/^Z31SV^+0.6_P
MZF#14MW9W%A,8;J"2VF'6.9"C?D:BK2]]B IDW^ID_W3_*GTR;_4R?[I_E0!
ME4444 >A?M%?\G!?$[_L:-4_]*Y:\]KT+]HK_DX+XG?]C1JG_I7+7GM  O6G
M4U>M.H 6DHHH Z+P[_QY/_UT/\A6I67X=_X\G_ZZ'^0K4H **** "BBB@ HH
MHH MZ/I<^N:M8Z=;;?M-Y.EO%N.!N=@HR?3)KZS\0?"'X*_!"UTFQ\;B_P!9
MU2^4GS@\R@8(#.%B90J@GH23]:^9/ /A#Q#XT\206/ABU:ZUB,?:8E69(BNP
M@[@SL!D''>OJS0_BQ8_$+Q);?#3XM>"X7\1K(+99XMDJB1D!W94YC)&#N1B.
M>PK\]XFK8GVM.-"I+V<$Y5(TYJ-2W27?E7]>7U63TZ/)-U(+FDTH.<6X7ZKM
M<\S^/?[-<?A'QAX;M_!_F75GXAE-O;VLLF\PRC;_ !]2A5LY.<;6R>E=GJWP
MI^"?P2AT[2_'<UUK>NW40ED>-YU"+G&\)$PVID$#.2<'K4G@'X2Z7\*_VMK/
M2K:8SV4FFS:AIZS$%X]RNA0GN0%DP>N,?6O+_P!I+3=5\5_M':OI<$$MQ>3R
MVUK:0A3R##'MQ[9).?J:\?"U\1F5>AE\L9+V4:7M'->Y*5W97=W;E6^NMG<[
MZU*EA*=3%+#QYW/D47[T5IK;;?IVZ%[]I#X 67PWO]&U+PP\MQHFL/Y,4,C[
MS%,0"JJQZJP.1GI@\]*V?VK/A1X-^%7AWPQ#H6EBSU:]DD,TWVF:0R)&BAN'
M<J,LZG@#V[U[)\;K6WO_ !-\(?!9E$EW_:L-Y(JC/[F!,,3Z;OFQ]#Z5XW^W
M-K?VSXCZ-IB\I9:<)#S_ !R2-D?DB_G7/DF98[,,1EU*K5EHJDI:M<T4W&+E
MWU74US'!X;"TL7.$%JX)?W7N[=MSSG]G3P'8?$;XL:7I&K6XN]*\N::ZA\QT
M+*L;;0"I!'SE.A%>N:+\%_!6O?M1:UX3@T3'AG2=.\V6U%U/AI=L>3OW[_O2
MXQG'RU4_83T1;GQKXCU5E)-G8);J>P,LF?SQ$?UKT+]F=V\0?$_XL>+)BHAD
MO_LT4G^P'D.,^RK'6W$&9XFCC,=*E4E&-*E&*2;2YYR5G9=;/?<C*\'2J4,,
MIP3<YMW:3]V*>GI=;&:GPD^!OC;Q9K/@?1[.]T?Q+8^8IFCGG8;D(#%?,=E;
M!/((!ZX]:\O^"OP)M-0^.VM>#_%=I_:5GH]O-),L<CQ+)AD$;94AAD2!L9KH
M?V4=/N?&7QTU_P 6QP2BRB^TW$EPYX\R=SM3ZD%C_P !KV'X,WEIXH^.'Q8\
M06LL<T236NGQN@Z^6A1SGTS$.>A[5YV-QV,R>.,PL<1.:C2BVY2;<:DI*.CW
M6CO:YUX?#8?'NA7=*,6YR5DK)Q2;U6SU5CYKO/AKH>K?M.?\(IIED+7PXFJI
M;-:B61\QQJ#,H8MOYVR<YXSQTKL_B1\#/#E]\>M!\!>%;-M"M9K(7-],LTDQ
M R[,?WCD_=0  =VK-_9;M9?&O[1FH^()H)6%N+S4&>12/+>5B@#=LXD;CV/I
M5_Q-9^//&?[2WB?Q'X M8]0NO#]U%;,S3Q)&@$1B*$.Z[@Q24$#ISTXKW,1B
ML52Q_P!76(Y/8X?5RE:/M'[J<KNS>J=W?4\VE1HSPOM?9<WM*NB2UY5JTNOW
M':2?#/X%:+XVM_AY<6E]<>(YML9N#<3#:[('5696"[B"#C:1R*\;\5?!^P^'
M/Q^TKPM/#_;^E7]Q +>VN)'1GCF8QC>T94@JV3D$9VCL<5[?X1\7>"/VI;Z\
MT+Q'X3?3/%-K;,S7D0&]0K!3LE'S @D?*X(ZCFOE7Q=X>O/A?\0M3TVWU&5+
MW2KQD@NK.0I+P<JX8?=;&#QT.:C(?K<\15PM>O4554_>A-\R;>TX23T7DE\R
MLR]A&E"M2IQ<'+2459V7V91:U?F_N/=#\(O!WCS2?&*Z/I,&@R:?K1TNPNA>
M3NJ0V\BM=3L'D()\I\XQ_", $FO)?CEX:T+PK\4-6T?P_8M::?8K#'Y+S,_S
M^4K.S,Q)SN8C ...W2N97QGKMG;M NMZC#"S22&WAO) &:3_ %C-SU;'/KWK
M(U35[W6KR:[OKJ:[N9FWR33R%W=O5F)))]S7UN7Y;C,)B'4K8ASA9V3;>KY=
M=7KI'Y-NVYX>*Q>'K4E&%)1E=:V7GV]?N2["27 7&T^8XZ,1\J_0579BS$L<
MD]S35I:^G/&W"BBE +' &3VH$)13VC=-VY6&WALCI1Y?S*&8*",YZXH 96+X
MD^;[-CD_-_2MZ./S<JJLS]L=,5E>)'CMVMCP\N& "$A1T[]Z!V*OAFU>2X>4
ME4CV$%F/N*ZI6BM5WJ#@CAF^^WT]![US>@%EOF:4>9-Y1VQ <+R.H_I6\UO/
M(VZ3Y2>\AQ^E24133-,V6X X"CH*8 6P ,GT%7%L4C&9&)'_ 'P/S//Y"E-U
M%""(^?\ KG\H_$GD_I3OV%;N-M]-::0*[K$<9VGEOR[?C5DFSLFVB0L>_DX)
M^FX]/PJA)<R2*5'R)UVH,#\?7\:8(_N;OE5NAZG\J5F]QW2V-!]6C"A(H/+0
M<_>'Z\5+I&GW7B35(+"RT^6]O9SB*&,/([GT %9\<&YY(1&SS$X3';GG-?3L
M?V;]EOX>VDWEQW'Q+UZVR)IUW?V=">@"^H]/XF!SPN*\;,L>\$H4J,.>K4=H
MQ_-M](QW;^74]#!X;ZPY3J2Y81U;_1>;Z&/9_L]^&_ NEV]]\4O$MKH<KJ'C
MT?36\VZ.>QX;/IPK#_:J*^US]GBQD$<OA[Q-J+]#<>;M8_[6/.7'TP/I7B6J
MZIJ6M:C<:A=RW%U>W#%Y;V\?,CD]\GI5-+6.U)-Q+'YW9.6Q[G'7Z5P1RC$5
MO?QF+FY=H/DBO1+5^K;.IXZE3]W#T(I?WES-^M]/N1] 1_#WX,?$;RH_#WBV
M^\)Z@XS%I^MA5B;T&3CDGC[Y/H#7F_Q-^$^O?#/5A::Q9F*)L_9[P*7MIE']
MQAW_ -D@-R,CFN%589F9LRSR$XQD*6)].M>__!/XL0>(EA^&OC"!]8T#4"(;
M:Y9C))82XPFUCD[0>A_AS_=S6%:GC\GBZ]*I*M26LHRLY)=7&6E[?RRO?H[F
ME.>&QS]E."IS>S6S?9K6U^ZV['A7V=XV785N+A>/+5Q@>^./RK2\/^$=4\0:
MA%'!83ZE?S'$5I$N68^I]!7J^O\ P=TKX3ZQ=KXP\0JT2,SVEEIZAKFZAR=K
ME?NQ XP2QX.<9KD=:^,MRMK)H_A&Q3P[I<APZVI+3W'O+,?F?H..%]J]&&8R
MQL4\OCS)_:=U'_-^B]&T<LL+'#NV*?*UT6K_ .!\_DF:MEX7T3X<ZM;:MXKU
M@ZGK]G(L\&AZ$X;R'4AE\Z?[J8.#M&3Q7N=S^VUH-OX?+R:)?1ZXT65M59'A
MWGOOSG;]5S[5\>2:B(]HF5+F=>Z\*GY<$U4;R+ABWFR(['GS1N'YC_"N#&<-
MX3-'&>8MU)1ZWLO1)=/6[\SIH9O6P:<<(E%/YOU;?7[EY&AKGB2;Q%JEY?W8
MDN;F[F>>3<VU2[,6.%7W/K59KS["-L<<4=QW9%^Y[9/>C['+:*2@$TYXS&<^
M6/IUS_*J_P!E$/\ Q\OY3?\ /-1E_P NWXU]7&,8I1CLCQ'*3=WNS6\+V>J>
M,/%&CZ%:W?EW.IWD-E"TC817D<(I.!TRPKZE\9_ OX0Z/K7COX?Z=XW\5Z3\
M0_"=C/+_ &KXFDL[71=4NH I>VA5@LB-(21'EVSC/S#&?E_P=HTWB+Q1HVF6
M5Q9Z,]]>PVL>J:I,8X;=GD"B1W .U5)W$JI( )YK[RG\+^+_ (NQ_$CP3^T!
MX(MYM5\(Z!>WEG\4H]-DLY!):@F+?<@*EU"X8%00I*@G[QRM?(G7N>%W7[,,
MGC;2/@AJ?@'6-4N;3QY)_8^I"^=)FTW5(GQ< >6J_NO+S*JM\VR-B6/;O_ '
M['OA'XO>)/CUI7@;Q-KUR/!Z6\/AF6]N(76^G8RHZRD1JKB22$K&4V8$B$[J
M@_8I^(VJ>$?V>?CQ>01VZGP[81:UHCM$'>POIHYK.2YB+9PYBDV\\';CH3GC
M_P!G'Q?JWAW]F/\ :,UW2KR2QU/2V\+7=E<*=S0RIJP9&&<@D$ \C!^E*UPO
M8XZ;X5:;'^RW<?$62ZU&#78?&B>&FM)FA$!@-DUP6=2N[S-ZX^_@#C;GFO6-
M8_9[^ G@'X@VOPJ\<^+O$6F>/3!#'J'B!/L<.A:?=RPB55=742-&N] 7W+US
M\O..F_:BET#Q)^P[9>/O#@BMK/QS\0K?7;O3HLXL-0.F7$-Y",X)'GPR.#@9
M608XQ72^,/".L:I^WI/J47PJTWXE_#WXA7^CW$.O:CI$VH6L.G2I")KBWEB<
M1QLJF3+/D#RP<8ZOE#F/E_X!_ KPS\3_ (U7'A;Q!K4=IX9T>&]O=;UO1[Q#
M%#9VJ,7GCE964H6" -@@AP<4V\_9WTO1/VL;3X3:KJ5Y!9OXLM]$>12@N'M9
M;E$216VE0S1.K@E2,L,KVKW3P7H7@'X7^#?VB?%/B!M4TSPOXE\57'@71Y?"
M5K;RW,5HLTEQ.L)F=8Q"\:0QDYZ#CG!&C\0M/\.>,/VD/V8/BYX=N=0N](\5
MZGH^GO/J%ND5U/?6%]#;223[&9 S((>%.#MR.#PK6ZA>_0Y"^_9:^#7C?7/B
M+X/^'^I^-K3QKX1M[^Z4:_<64]E?_8Y"LT2F*.-D9L?*S' SR*YKP7^S+X)\
M5? 7QQXZ_P"$UDUCQ5X?TB/4(_#>EVI2WL=\I1$GF<$2L0-VV/&,<DYKJ/C-
M^TYX7^''C_XN6/@;X8MH7C;5[K5?#]SXEN=?EO!Y4ERRW$L5MY2+&[E3M.X[
M,\9&0>9_95MC:_LZ_M.&<[,^';$E%(WC_2&[=OQHUZL-.B/E^XMKR68>;#,9
M#P 4(_ 59AL[>WC$DYWNI^;G* ]@/[S>W3UJ:*]N+>$/ODM[=?F$2N2[^[$]
M!_D"D;5IY$,]TL,B-GRH6C!!]^F0/YTM65HB*YO&;9-(,'&8(3T4?WS_ $_P
MJ&SFEC=KN2:147C<&Y<_W1_CVJ>.YBN]\]W:1B,'#2(S*S'L!SU_E2M>:9<[
M/-MKF(*-JB*0$ ?0BCY!\RO)K5Y("/.906R-I/'M]*=_;%P9-Q=PN,;%<CG'
M7-6EAT23[MQ.A])1C^0-2+I]BW^JGLW_ .NL[C],"E>/8+/N9,E]+-'M>25W
MS]YI#C'IBKEHLUN[2K$L%NPP5N&.QN.N/XORJY]@N(_]1-90^\ R?SP34)T*
M2;?)+/)(P&3A,D_3)%%TPLT('TV0", >;U&05B+>F?O >W2O7?V=_A58?%S7
M]8L?$,]Y:P6]LLT:Z?(L98[P,EBK;A@^M>1I:BS97AMF#@8\RXN%4?7 /]:^
MC/V)))F\9>(%DN870:>NV&$_*O[Q>< 8KYKB3$5<+E->O0ERRBE9_-'L932A
M6QU.G55TWM\C.F^"/@+X@^$]?U3X>^(-6O;O18O,FTV\V!&7:S!5(1<%MC8/
M/(Y]:M6/P>^'&D?"GPUXI\2ZQKVD)JT2[QI\D10.03CF(MC"GN:Y^\_:9TC3
M_#>KZ-X.\$V?@\:I'Y5Q=QOYS,N"OW0J\@$@9)QD\5[!)X@\,:%\"_AD?%VD
M6>NZ5=200-)<MM2WRC_O@NT[L#/R\<$\U\5C*N<82-.%5U%&52T5S0=3EY&V
MKKW=U==3Z"A# 5W*4%&ZCJ[2Y+\RMH]=MSP+XY?"&R^#]YH=QI&H/J>EZU"T
MUK>72@R1A=A/  !XD4@X'7&.*[7Q9^S/8^%?@J/%:SWUWXEAMH+^]LYGC,:J
MQY&W;N&W.3\QSL:NS^+'@?4?'/[1?@[1]1 N?#(A%Q8PV\2I#'!& TP8Y.22
MJC@8PR5Z%:>*/ _BCXH^)-%_X2C^T=2U6T.CW&AM XC40B0N%<KM)^>7//<^
ME<M;B#'4\)@YPFYRC'VE1Q5[QYK*,K*R]WFYF[*Z-Z>5X:5>NI144WR1N[6=
MKMJ[UUM9:Z,^7O@W\(=!^,7A#Q.4O=0B\;:?&T]O;B:/[/< @["5,>[[P*G#
M<94^U/\ B!\'=$^%OPET+5]2N]23QMK"@IIXEC6*%#\S%DV;N%*J?F^\WM7;
M?LX_#>Z\"_$7QAXCU>9],T?PK]HM96#829@,D'GE0F'^K)4/[5VCMX\T3PK\
M2=&GEN]&O;9+5X7;BV8DLO'09)96]&4>M>U_:E:>>QPM.N_J\G%W_O.+:IW[
M2TE;Y'G?4X1RUUI4OWJ37RYDG.W=;?B?,=?3>C_LR^#-/A\,Z/XJ\1:G;>+O
M$4!EM8+.-?(B8*&VME#DC./O#)S7FWCCXH>$/$7A6?2M+^&UAH&I,8PNJ07G
MF,NU@6POE#[P!'7O7T]KWA[4?'7Q*^$?BS1;;[=H-O:M)/>1R+MB!0$9YSGM
MTZ@BM\^S3&4X4N;FPZ?M&]87;C"\%=<RLWTW=C++,%AY2G:U5KDZ2V<K2TT>
MBZ[(\'\!_LWV]]XB\<P^+-5GL](\) FZET]09IU"LX900V!L3/W2>0!WJ+XD
M_L_Z98VO@O5/!.IW.H:5XGN([.W340!*DC_=8X4?+US\O&/>O;O MQ!J7Q(^
M,_B+P_(NL:U#MMK72_.Q#<%(=N6&0&!D0J#VY]:J_$S4'T^+X-^)_%2KH.L0
M:K##=:5#)MMX8V!WR!"2%V83G.0&P2<"O CGN8O,(?O'M'W--W1YK<MN;XOM
M7LMK'IO+<(L++W>K][7;VG+?FVV^S\SB;K]EOP7>ZEJ_A'1O%&HS^/-,LENY
M8KB-1:MD*0,!<@'>G\9QO'6O//#'[,?BWQ1X#N_$,%I,EUNB-CIQ1,WD;'#/
MO,@V;?0C)KZ:T3PGJ?A[]I3QQXXU"!;;PO-HJ!-0>1=AVI;;N_;R7)^@]:^*
M;CQSJBZ;KVD6ET8=%U>Z%S<6K1(2Y5RR$M@L,>QKU<DQF:9A&4,-B5*RHR;D
ME*SDKU(JUNVVZVO%NZXLQP^"PK4JM%K6HDD[:+2,M;_?\[/8YVBBBOU(^+"B
MBB@ HHHH QO$7_+O_P "_I5+1?\ D)0_\"_]!-7?$7_+O_P+^E4M%_Y"4/\
MP+_T$T =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%6=/TZ[
MU:\BM+&VFO+J4[8X+>,N[GT ')I.2BKO8:3;LBM7&U]&Z'^RM\2=<@\[^PA8
M1GI]NN$B8_\  <[A^(%<_KO[&WQ4T2%I5T&+4HU&6-C>1.P]@I(8GZ UX?\
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MS+6:2)I,M&Q4F.0,O!QPP)!'N#BNC\$_#/Q3\29IH_#NDSZGY./,D#*D:9Z
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MX@L5\0:A"CI' LWV=8]R,@"G:V% 9N,=\]>:]/O_ -M#1=5N6N+WX6V%Y<,
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M2:ZS]CV\BM?CCIL<C8:XM;B*/W;RRV/R4UYEX@TN;1_$6K6LVQ+VWNY8I-S
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MAWN)^%:V@^(]:\*S&ZTG5=0T=IQY;S6%P\+.H()&5(R/KQ6:-L+J?DFRO<'
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ME!WB['$:3K>H^'[P7FEW]UIMVHP)[29HI /3<I!IVM>(=5\270N=6U*\U2X
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M.U>3D#IVKT'QQ^QO\6_AOX=U37/$7ANST_3=,7==N->TZ62/#!2/+CN&<G)
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M=0L2@G9<LI'8MR_/?>,?*:\,6U^SD&=E&X<)]Y^?;L?K7LOP?^-&F>&='N/
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M?.EY7^%3_&?\*BDD:5BS')_SQ18+G0>&_B!K_@^\>ZT74I],G?AVM9&C#^S
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M$[_L:-4_]*Y:\]H %ZTZFKUIU !1110!T7AW_CR?_KH?Y"M2LOP[_P >3_\
M70_R%:R[>=Q(^@H ;UH4%C@#)]JDW1KT3/\ O&D,S],[1Z*,4#%\DK]]@GUZ
M_E1N1/NKN/JW^%1T4 /:1I/O'CTIAHHH$%%%% !1110 4444 %%%% !1110
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M*YKX2_LXZW\5O"^I^*&\0>&O!GA>PNTT]M:\5Z@UI;2W3(7$$95'9G"?,1C
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M#,)@W QP!ZY]::S,[,S'<Q.231UR3UHH **** "BBB@ HHHH **** "BBB@
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M1110!T7AW_CR?_KH?Y"M2LOP[_QY/_UT/\A6I0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "K2TBTM !1110 458M88IB_
MFNR;5R-HR2:/,6-08T4<XW,=S?EVH'88ENS+N8B-/[S=_H.]9/B*18?LOE@H
M&W?OG'/;.*U9)"SL<E\C :3DUB>((WF:V5%+'YOP'%(?H0>'V_TR4?>RA.X]
M>HKHXH#(I<G9&.K-_GFL#P\L4%Z^XB:3RS\J_='(ZGO^%;LDS2MECG' '0#Z
M4Q$CS@(8X@50]3_$WU_PIL,.]2S'9$O4^OL/>B*(,I=SMC'?N3Z#WI)IC(0
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MBB@ HHHH QO$?_+O_P "_I5+1?\ D)0_\"_]!-7?$7_+O_P+^E4M%_Y"4/\
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M;R6D2.3<K  L!C/0U'24M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!C>(O^7?_ (%_2J6B_P#(2A_X%_Z":N^(O^7?_@7]*I:+
M_P A*'_@7_H)H ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N-KLJXV@#K++_CS@_P"N:_RJ:H;+_CS@_P"N:_RJ:@ I],I] !1110 4
M444 %%%% !1110 4444 %/IE/H **** "N?\0?\ 'XG_ %S'\S705S_B#_C\
M3_KF/YF@ \/_ /'X_P#US/\ ,5T%<_X?_P"/Q_\ KF?YBN@H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!5J*]_P"/.?\ ZYM_*I5J*]_X\Y_^
MN;?RH Y.BBB@ HHHH **** "BBB@ IDW^ID_W3_*GTR;_4R?[I_E0!E4444
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M_"17/]R+\C_C3$=#17/?\)%<_P!R+\C_ (T?\)%<_P!R+\C_ (T =#17/?\
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M_P"- '045S__  D%Q_<B_(_XT?\ "07']R+\C_C0!T%%<_\ \)!<?W(OR/\
MC1_PD%Q_<B_(_P"- '04^N=_X2"X_N1?D?\ &G?\)!<?W(OR/^- '045S_\
MPD%Q_<B_(_XT?\)!<?W(OR/^- '05S_B#_C\3_KF/YFC_A(+C^Y%^1_QJG>7
MCWT@=PH(&WY: +GA_P#X_'_ZYG^8KH*Y.SO'L9"Z!22-OS5<_P"$@N/[D7Y'
M_&@#H**Y_P#X2"X_N1?D?\:/^$@N/[D7Y'_&@#H**Y__ (2"X_N1?D?\:/\
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M5M_<E_(?XT?\)%;?W)?R'^-<[10!T7_"16W]R7\A_C1_PD5M_<E_(?XUSM%
M'1?\)%;?W)?R'^-"^(K;/W)?R'^-<[2KUH T]6U&._\ *\M6&S.=P'?'O[56
MT^X6UO(Y7!*KG.WKT(JO10!T/_"16W]R7\A_C1_PD5M_<E_(?XUSU% '0_\
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M-]NN/^>\O_?9H^W7'_/>7_OLU#10!-]NN/\ GO+_ -]FC[=<?\]Y?^^S4-%
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MH+W2X]:C-UKMA"([.00F.:;?./)#_:80HDVEBQ !*L  >>T5ZO#^S?XILY+
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MKG@.[\%ZSI-MXG=;.PU" 7D=[I$]MJ:R6_F/&9(FBF\N0AXI%*^8,,C X(H
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M'B?QHMEJ4MS=:3XNM7N+=-;T:\:TSILC"1+ QH ?+B?=Y?SX5&"8(1-ODM%
M'OVC_M40^'=676].\*$:]>W6CW&LSW6H++;W8L-C 0Q"%3 TLD:2%B\FUE^0
M**QV^.F@KX?C\,#PMJUSX6>VO8+B._U]9M1)N+BUN,Q7(ME2-4ELHG"&%@3)
M.2<R97QFB@#V+PC\9K&']H+0/%]Y9MI6@P16VC/$9#<26VGI8KI^\L%'F2+
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M$&L^%9;J_P##>KOJWAJ.WU,0P6?R6ZPPW*^0S7*(;2%LJT3,3)DX90G-:/\
M&_1HO%EWK.L^#(-827P[IFAP))+;R26KV=M:6YN$^TVL\),BVK95HB5$N%<8
M);R"G4 ?0&O_ +46G>(O&MSXGN/"%Q%?C6KO5[.*'5D6&+[3:P6\L<B_9\O@
M6Z,I4IC)!#<89X?_ &HK30?%UIXO/A2>[\52G1H]5NI=546UU#I]Q9S@0PK
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3\ZU:RIO]=)_O'^= #**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>prax-20221231_g2.jpg
<TEXT>
begin 644 prax-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3,!O$# 2(  A$! Q$!_\0
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MPSX\T+*Z=KEFMRL+,&:"3)66%B.K)(KH?=37;T %%%% !1110 4444 %%%%
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M\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\
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M_P DT?\ #._C7_HL>O?]\S__ "30![S17@W_  SOXU_Z+'KW_?,__P DT?\
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MZ<[\B([?+\[C_6==QZ>]=[_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\
MHL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S
M_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_P
MSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"B
MQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_
M /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-
M%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^
M-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O
M?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R
M31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU
M_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_
MWS/_ /)- 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)-
M 'O-%>#?\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?
M\,[^-?\ HL>O?]\S_P#R31_PSOXU_P"BQZ]_WS/_ /)- 'O-%>#?\,[^-?\
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M9\;>%](3[9JEU9+?Z6L9&9KB%UGC13T^?9L_X'7A?_#FWX"?\_GC#_P:1?\
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M7/INIVL=[8S@"2"0?*V"&&?Q /X5-ING6VD:?;6-G"MO:6\:Q10IT1%& ![
M4 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!O!_\ R=_XX_[
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M-$MX],[-+<6@C>)1GH7,(3_@9K5_9W_8S^%?[,$<\G@O0/\ B;S@K-K>I/\
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M/)_Z!>5[S7@WC#_D[_P/_P!@>3_T"\H ]YHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!O!_\ R=_XX_[ \?\
MZ!9U[S7@W@__ )._\<?]@>/_ - LZ />:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\&\8?\ )W_@?_L#R?\ H%Y7O->#>,/^3O\ P/\ ]@>3_P!
MO* />:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 ?K517Y*_\ #K_X6?\ 0?\ &'_@9:__ "-1_P .O_A9_P!!_P 8?^!EK_\
M(U 'ZU45^2O_  Z_^%G_ $'_ !A_X&6O_P C5YC^TM^PEX"^"OP3\1>--"UG
MQ+<:KI9MC!'?75NT),ES%$2P2!6X60D88<@?2@#]N*^9_P!O[]J37_V2?@YH
MWB_PYI.FZQ?7NO0Z2\&J"3RUC>WN)2PV,IW9@4=<8)KTK]EV^N=4_9F^$=Y>
M7$MW>7'A#2)IKB9R\DCM91%F9CR22223US7R=_P6K_Y-9\+?]CG:_P#I#?4
M>/:/_P %2/VE_$&F6^HZ5\"+;4M/N%WPW=GHNIRQ2KZJZN01[@TLW_!6#X^>
M&99I?$GP+M[:TMT\R8/8ZA:&->"69GW!1C/)'O7V_P#L!_\ )FWPG_[ R?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'):DZ3#]KTU-L7F-D8E&\?-N^]S7HO\ P@'_  4C_P"AD_\ )[2?_B:^RO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@WC#_
M )._\#_]@>3_ - O*]YKP;QA_P G?^!_^P/)_P"@7E 'O-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'F8'*I<7!QA%Y'EQ<=,.!D']+;.S@T^T@M;6&.VMH$6**&)0J1HHPJJ!P
M !4U% !1110!^9O[3/\ P2EUP_$2?XB_L_\ B*'PMJLEPUZ=#DN'LOLLQY+6
M<\8.P$D_NVVA<G# 84<A:_\ #RWP_;1:-&ES=# 2*ZE.@W#@ GDS,2<GUD.>
MG2OUAHH _+7X4_\ !,GXJ_&KXB6?CK]IOQ?)J$<+([:&+XWEU.JG/D/(A\J"
M+/41%LY;&W.ZOU%M;6&QM8;:VB2"WA18XXHU"JB@8"@#H !C%2T4 ?'?[<7_
M  3M\/\ [5\D7B;1;^+PK\0[>-83J,D;/;W\2C"QSJ.05_AD4$@<$, NWYFT
M/P/_ ,%%O@CI_P#86B7O_"6:-:GRH)I;[3=0^4$*I1[HB?;@# ;@#L*_5VB@
M#\FU_8!_:C_:R\5V-]^T'XX&B:/:880&X@N9%]1!;6N+=&(X+Y!Z<-TK]-?A
M-\*/#/P1^'^D>#?".GKINAZ9%Y<4?5Y&/+22-_$['+,W<G\*Z^B@ KX&_P""
MG'[&_P 1_P!JC7/ %UX#MM.N(M&MKR*[^W7JVY#2-$4VY'/"-7WS10!0T&SD
MT_0].M9@!+!;1Q/M.1N50#^HJ_110 4444 %%%% !1110 4444 %%%% !7@W
M@_\ Y._\<?\ 8'C_ /0+.O>:\&\'_P#)W_CC_L#Q_P#H%G0![S1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5R/CKXP>!?AC&'\7^,M!\+AEW*NKZE#;,XQ_"KL"Q]AG-<=I/[8'P.UN\6TL
M_BYX,DN'^Y&^MVZ%CD# W.,GGH.: /7Z*@LKZVU*TBNK.XBNK:5=T<T+AT<>
MH8<$5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5X-XP_Y._P# _P#V!Y/_ $"\KWFO!O&'
M_)W_ ('_ .P/)_Z!>4 >\T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7@W@_P#Y._\ ''_8'C_] LZ]YKP;P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+^T5X6\$_#;6+:RL]5T"UNA:2Z?;SM)=2W=U#P\BDC(CC&,XX]S7)_\ "?\
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M">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5>4.2/\ IDHZ$B@#VWQ9_P %4OV=O"FN3:8/%EWK+PN8Y+G2=-EGM\C'*R8
M<<]4R#@^U>[?!?\ :"^'W[0GA^76/ 'B>T\06L+!+B.,-'/;L1D"6)P'3/."
M1@X."<5Y)\%_^"=OP5^%OPWL?#VJ^!M#\8:N;<#4=:UNQCNI[B8C+M&SC,2Y
MR%"8P ,DG)/PI\;O!L7_  3)_;<\%>,/!=S<VOP\\29DNM,9V94M3*$N[7/\
M:H&CDC+9(.S.=N2 ?L3134=9%5E8,K#(93D$>M.H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#0F?\ E4O?_CU'_#$_P7_Z$S_RJ7O_ ,>KW"BCZCA?^?4?_ 5_D']O9O\
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M7\ ?C-^VUH'P;\)Z?\/? W]H^"K>R5-*NO[(BE\R')P=Y<$\YYQ78ZM\5/\
M@HKXR@_LJV\)7>B/<JT1N+32[.V89[^;*Q$9P#A@1C/7., '$?M :=9:?_P6
M \-)X,\N&[D\3Z'/?BV/R"=O):YSM/\ $A)<=RSYY)KZ;_X+5_\ )K/A;_L<
M[7_TAOJJ?L$_\$[/$OPF^(EQ\7/C#?V^J^.)1))9V'V@WCVT\O\ K;F><\/.
M074;2P&]FW$D;;?_  6K_P"36?"W_8YVO_I#?4 >Z_\ !/'_ ),M^%7_ &#&
M_P#1\M?15?C-^SQ^P;^T+\4/@MX4\5>$_C5_PCGAW4[4S66E_P!LZC#]G02,
MNW9&NQ>03\OK7HO_  [/_:F_Z.%_\N#5?_B: /U4KX&_X+$_&R^^'G[/^D>#
M-+N#;77C2]>"Y=&(8V4 5Y4&/[SO"I]5+ ]:[3]B/]D_XP?L^>-/$.J_$CXF
M_P#"<Z=?Z>MM:VO]I7EUY,HD5B^)P /E!&1SS7S!_P %R+>Y77OA!.W_ !Z-
M;:HD?^^'M2_Z,E 'UU_P3?\ V=-(^!7[-OAK4%LHQXJ\564.L:K?%/WK"5?,
MA@R>0L<;J-O3<7/>OJJN9^&$D,WPU\)/;%6MVTBT:,KT*F%,8_"NFH ^3_\
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MP*M[F6+1X_LS78A;!62ZE/G28Z$QV\2LN>FYO7G]&Y/%7PU^!.@Z/X;N]?\
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MRIN/VZ/B3X&_:D^'WCSXX> +NTUWPGI-UI4EG'9OIL]['*LB^>4E!7<"Y/R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*H!\'?M_Z7!\%_\ @I1\-OB5K4/_ !3>H7>CZM-<,,J/LLR13 ?[2)%&^/\
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MJ1S+;2MQNACB9FG<#[H(4;L$@@8/Z@UGZ=X?TO1YIIK#3;.REFYDDMX$C9^
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M$&IZ)J_Q-T.PU;3;J6RO+2:1P\,T;E)$;Y>JLI!^E 'XX_\ #KC]IW_HF?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(;B1=RPSJ0\,A'<+(B-^%=IH'A[2O"FCVVDZ)IEGH^EVJ[(+'3[=(((E]$1
M%4>P%:% 'Y#?L1_MGR?L0W&O?!'XY:1J6A66G7LD]G>);M,]D[D;XV1>7A<Y
MD61-W+'[P8%=?]N#]O2S_:LT.R^"/P)T_4O$S^([J*.^OQ:/"UPJR!D@A1P&
M"EE5GD<* JXZ%B/TO^(OP7\!?%R&"/QKX-T3Q2(!B%]5L(YWB!ZA'8;E_ BH
MOAS\#?AY\(O-/@KP3H/A>69!'+/I>GQ0S2J.0'D5=S#ZDT <S^R;\"8?V;_@
M#X3\""1+B^L;<S:C<1G*RW<K&28J>ZAF*K_LJM>O444 %%%% !7Y+_M[>/)?
MVL?VOO#WP8TBX:3P?X+=IM:DA;Y7N>#<$D=T79 O]UWD]:_4;XBW7B"R^'_B
M:X\)VL5]XIATRYDTFUG8*DUV(F,*,3P 7VCD@<]17XT?"7]G;]KGX/ZIK^JZ
M=\'X=7U?7)?-O=0UBXAFG8[F8X9;I?O,Q8\9)QZ"N7%>V]C)4/CZ$RO;0^Q[
M6VBLK:*WMXUA@A01QQH,*J@8  [ "I*^?_L?[;7_ $1+1?\ OI?_ ).K%NO%
M'[8%CXJL_#<_P@T./6[R(SP69^\Z .2V?MN/^6;]3VK\Y_U?QW9?><7L9GTU
M7QGJ&J7?['7[8MAXGT^>33?"7BYB99(SM2!W8>9[?)(5?I]R0KZUZ9]C_;:_
MZ(EHO_?2_P#R=7FWQZ^$/[5_Q6\%K8^+O@O8VEA9SK=)>V#)YT# $$Y-V^%(
M)!R,=/05Z6!RK%X2HW5LH25GKMY^J>II&G*+UV/UM^%GQBM/&T,=A?F.TUM1
M]SHEQ[I[^J_E[>E5^:?[/J^+=+^$_AF#Q? ]AXELH?(D'FAI L;%8F+*2-Q0
M(2<]>>M?8OPG^.":MY.C^(I5BO>$AOFX6;T5_1O?H?KU]#+LY3F\+BI+F3LI
M='_7?J5"IKRR/9Z***^N.D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBLGQ!XKTCPK;I-JU_#9(YPGF'+-ZX4<G\!7,_P#"\O!'_0;_ /)2?_XBN6IB
ML/1ERU*B3\VD2Y);L[RBN#_X7EX(_P"@W_Y*3_\ Q%'_  O+P1_T&_\ R4G_
M /B*R^OX3_G]'_P)?YBYX]SO**X/_A>7@C_H-_\ DI/_ /$5Y?\ M,?MF>$/
M@I\%/$OBC3M36]UV*W,&DVCV\JB:\<%8@=R@%5/SL,_=1JN.-PLY*,:L6WYH
M?-'N;/AK]LSX:^+/VCM8^"=A?73>,--C<M*\2BSGFC7=+;QR;MS2QKN+ J!\
MC8)*D5[G7\]>G?#WQO\ "?P+X1_:)L[^Y?Q5'K8U>?S\L?*=P8II.["1]V_)
M^99U'K7[9?#/]JWX>_$[X?Z!XILM7,$.J6B7!MVMYG:!R/GB8A,%D<,IQQE3
M26,P_*YN:23:U=M5T#FCW/8J*X/_ (7EX(_Z#?\ Y*3_ /Q%'_"\O!'_ $&_
M_)2?_P"(J?K^$_Y_1_\  E_F+GCW.\HK@_\ A>7@C_H-_P#DI/\ _$4H^./@
M@D#^V_\ R5G_ /B*/K^$_P"?T?\ P)?YASQ[G=U\0?\ !7;XA>*OAK^S;X;U
M/PCXEUCPKJ4WBVVMI+S1+^6SF>(V=XQC+QLI*ED0[<XRH/85]GZ+K^G>([,7
M>F7D5[;YQOB;.#Z$=0?8U\(?\%J_^36?"W_8YVO_ *0WU=L9*24HNZ+/FGX4
M_LT_MI_&3X=:#XUT'XW:RFCZU;"ZM5O/'&I1RA"2/F4 @'@]S7:R?LG_ +?7
MAG3S<67Q;N=6EM@7CM%\6SS2RGKMS<(%;_@;8K[@_8#_ .3-OA/_ -@9/_0W
MKZ J@/S7_83_ ."A'CSQ!\8)/@K\<X-OBF262TL=3FM%M;E+N,$M;7,: )DA
M3M< '( .[>"/2?\ @KM\0O%7PU_9M\-ZGX1\2ZQX5U*;Q;;6TEYHE_+9S/$;
M.\8QEXV4E2R(=N<94'L*^0OCI?:?\3/^"OOAM?!\T=P]IXFT6*[NK/#!IK7R
M6N3QU*+$R-[QFOIW_@M7_P FL^%O^QSM?_2&^H ^=O@S^RW^V1\<?ACX?\=:
M%^T+>VFD:W ;BWAU'QKK*3HH=EPZI$R@Y4]&-=Q'^P[^W-HT,TMM^T''>.0/
MW+>,=6E9N?X?-@VCKZBOL;_@GC_R9;\*O^P8W_H^6OH>65(8WDD=8XT!9G8X
M"@=23Z4 ?DC\)OV\/CM^RQ\>+'X;?M&,^I:-/)%%/=7Z0FXLXI"52ZBN(\+-
M%GEMQ8X5@"K*17ZX*P=0RD,I&01T-?C#_P %7OB)H'Q__:*\#>#?AY)#XKUW
M3;8Z9--I;B99KJ>8>7;(ZG#,F.<' ,A!.0P'['>'=,DT7P_I>G2S&YEM+6*W
M>9NLA1 I;\<9H A\7>*-/\#^%=9\1:O,+;2M)LYK^ZF/\$42%W/Y*:_"C3_V
MP_CQIGCC3?CG=^+O%$_@2Y\831MH/]LW#:?\ACGDLO(+>6$\F8*O'&TG@C-?
MH!_P5^^.'_"N?V<[;P78W'EZOXUNQ;.JMAELH2LD[?BWDQX[B1JY+6OV,9?^
M'4EMX1:RSXOL;+_A- FS]X+SYIGCQW?[.[08]0* /T*\.^(+#Q7X?TS6]*N4
MO-+U*VCO+6XC^[+%(@=&'L5(/XU1\?>$AX\\%ZSX?_M74]";4+9X$U/1KM[6
M\M6(^66*5"&5E.#UP<8(()!^-/\ @D/\=_\ A9G[.LO@N_N?-UKP3<"T4,<L
MUC+N>W/_  $B6/V$:^M?=5 'Y&?L]_M0?$W]C7]K35OA5\>O%VL^(_#FH3I:
M#5]=U":Z2VW$_9KV%YF8K X;#@' SD\QD5^N2L'4,I#*1D$=#7R#_P %'OV-
MX_VGOA6=8\/VBGXB>&XGFTUE&&OH/O269/<M]Y,]'&. [&OB;X6?\%2]<^&_
M[(&K^!+\74OQ2TDKH^@ZC-&3MM&5AYLI(QYEN%V '[VZ+@[9#0![9_P4*_;
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MOS5^+'_!&O\ X6A\5/&7C+_A;_\ 9G_"1:U>:O\ 8O\ A&?-^S_:)WE\O?\
M;%W;=^-VT9QG Z5\U?\ #Y+X]_\ /GX/_P#!7+_\?H_X?)?'O_GS\'_^"N7_
M ./T >U_\.,?^JV?^6I_]VUTW@7_ ((B^$M)UBWN/%OQ+U3Q'81R;WLM.TM-
M/\U1CY"YEE(!YR1@X/!!YKYN_P"'R7Q[_P"?/P?_ ."N7_X_1_P^2^/?_/GX
M/_\ !7+_ /'Z /VK\,>&=*\%^'=-T'0["'3-'TVW2UM+.W7:D,2*%50/8"M2
MO%OV-?B]KOQZ_9J\%^//$J6D>MZQ'<O<K8Q&.$&.ZFB7:I9B/EC7N><U[30
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M.K;21]2T54TO5+36K"&]L9TN;69=R21G((_Q]JMU^@IJ2NMCL"BBBF 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S%^T1;WT?CSSK@,;22W06K'.W:!\P'ONR?Q%>7
M5]R:AI=EJ]OY%_9P7L.<^7<1+(N?7!%9?_" ^&/^A<TG_P  8O\ XFOB<9P_
M/$5YUH5-).^IRRHN3O<^+Z*^T/\ A ?#'_0N:3_X Q?_ !-'_" ^&/\ H7-)
M_P# &+_XFN/_ %9K?\_%]S)]@^Y\7U\6_'*ZE_:6_:8T'X8V$C/X:\.N9]6D
MB/&X8,QR.X&V(>CNU?I]^UU\0?!W[-/P#\3>-I?#VBMJ4,/V72;>2QB(GOI
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M<D@4 >-_\$Y?VV+O]K+P/JVF^*(K>W\=>'/*%[);((XKZ"3<$G5/X6RA5U'
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M0 5!?6-OJ5E<6=W"EQ:W$;12PR#*NC AE([@@D5/10!XI_PQ3\!/^B0^#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO^%,,"[4;2VF(_VI)I)&/_?3&NV_:JL8=2_9B^+=M.NZ)_"6JY]B+24@CW!
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MA73[BV>.71-(MDM[6SN4E=9TCC4 *IE#N..0X)Y->V4 %%%% !1110 4444
M?A#_ ,%;/^3TO$'_ &#-/_\ 1 K]0=-_X)Q_LX3:?:R/\+M/9WB5F/VV[Y)
M_P"FU>*_M1?\$ZM"_;"_: \2>*=.^,NGZ/JMM#;65_H%OI27T]DT<2@>:1=(
MRE@0P#(.".O6OT!M(/LMK##NW>6BINQC.!C- 'SA_P .W?V;?^B6Z?\ ^!MW
M_P#'J/\ AV[^S;_T2W3_ /P-N_\ X]7TK10!Y-\'_P!E/X4_ /7+W6/ /@ZU
M\.:E>6_V2>X@N)Y"\6Y6VXD=A]Y5/ [5ZS169K7B?1_#;6*ZMJMEI;7US'9V
MBWEPD1N)W8*D4>XC<[$@!1DDF@#3HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN^#FOW5WK=Z\=Q<:38W!LM0MF2)(]UM*& D!" E<JW8;\X'SOX-_X*B_M'_
MG5)O#GCBW@\0W%D?*FL/%NFO;7T'L73RWS[R!CS]*_<*N1^(7PA\$?%BQ%GX
MS\):-XG@5=J#5+&.=HQ_L,PRA]U(- 'YL:'_ ,%R/W*)K/P?S*%^::Q\085F
M]D:VX'_ C3=;_P""Y$ARFD?!]5/::^\0Y['(V+;#OCG=7TUK_P#P2E_9OUN:
M26'PA?:.TC;B-/UBZ"CUPKNX ]A^&*BT/_@D]^SCH]RDT_A74M7VMN$=]K%S
ML^A$;)D=^?Y<4 ? WB[_ (*P?M%?%C5$T;P39Z;X<N+IO*MK3P[I)O;V7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\&\8?\G?\ @?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFA13\S*, D\]*]EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXRTSQMI*WVFS;UZ20MQ)$W]UAV_D>U;E?H].I&I%3@[IG9>^J"BBBK&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@W@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWU1@&Z#J#TKO/^&UOCW_ -%>\8?^#:7_ !K]J?\ AY#^S;_T5+3_ /P"N_\
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MWQ>_X+%Z5X9\9A;CP_9W]A:P65Y\T1ACL%N4BQT*R3,QV]#YI%?L%0!^/O\
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M'%*DT:21NLD;@,KJ<A@>A!]*_1<%CJ..I\])Z]5U1VQFIJZ'T445Z)84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@W@__ )._\<?]@>/_
M - LZ]YKP;P?_P G?^./^P/'_P"@6= 'O-%%% !1110 4444 %%%% !1110
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M)/VIO%,5N"FG7GANYFO(8E(B#+<VYC..Q!=@/9C7[24 %%%% !1110 4444
M?!7_  4,_89\5_%WQ=HGQ?\ A)=+:?$70TC\VS68027?DMO@EAD/RB=#QAB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK'X6^#O@3P1H,.BZ#X/T/2M+AC$2VMM81*I7'\7R_,3DY)R3DD]:_,[_ (+
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MX*!?\%&8/'UYX';X#_$?Q!I45K'>C6!8K<:?O9C!Y.[<%WX"R^N,GUH H?\
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M_HM^S#^UAX$_:P\'SZUX/N9H;NQ98]1T>^4)=63L,KN )#(V&VNI(.TC@@@
M'L]%%9GB;Q-I?@WP[J6NZW?0Z;I&FV[W5W>7#;4BB0$LQ/L!0!IT5X=^RG^U
MKX9_:X\.:_K?A?2]4TRRTB_^P/\ VHL:O*2@<.H1FP,$=>:]QH **\'_ &D_
MVV/A9^RN+>W\9:M<3ZY<QB:#0M)A%Q>O&21YA4LJHN00"[+G!QG!QXI\/?\
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MWFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M45V6U\2V4TA7H%,4Z9/MEQ^)%>T?\-^?L\_]%8\/_P#?U_\ XFM;]KSX0O\
MM$?LQ^-?".F!+C4-2T];K3"3M#W$3+/ -QZ!F15SZ,: ,/\ X)\W<5[^QC\*
M)(6WHND^63_M)+(K#\"I'X5VO[4UY%8_LR_%N>9MD:>$M6R?K9R@#\Z^'O\
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M;IP =H/.Q5547/9<X!8T >Y4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&_V<;G0?VO?%GQI;78IK76_#L6AKHXMB'B9'A;S#)NP0?)/&T?>Z\5[C110
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M\N&*@XY"@'Z;4444 %%?$O\ P4<_;5US]GNST#P#\.46X^)?B@!H95B6=[&
MOY:,L1!#RRON5 01\C$C.*\2T_\ X)W?M2^)/#\7BG6/VA]5TWQQ(@G72Y-6
MOG6!CAO+-RDF$((481&0$<$@"@#]1Z*_//\ 8!_;*\?ZE\5M8^ /QQW#QUI@
ME&GZA=[5N)WB&Z2WE*_+(WEYD20?>56)+9!/Z&4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA_X*XO\ X_0!]U45\*_\/DO@)_SY^,/_  5Q?_'Z/^'R7P$_Y\_&'_@KB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKC?^"SW_ ":AHG_8VV?_ *2W=>A:?_R#[;_KDO\ (4 5_P#A'M*_Z!EG_P"
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M^X2ZM9AE9$/Z'T(]#TK[_+\RI9A"\=)+=?UT.R$U-%VBBBO7- HHHH ****
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M7GO_  6>_P"34-$_[&VS_P#26[KT+3_^0?;?]<E_D* +%%%% !1110 4444
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M2?\ R+2_\/8O$7_1MGC3_O\ 2?\ R+0!^A]%?GA_P]B\1?\ 1MGC3_O])_\
M(M'_  ]B\1?]&V>-/^_TG_R+0!^A]%?GA_P]B\1?]&V>-/\ O])_\BT?\/8O
M$7_1MGC3_O\ 2?\ R+0!^A]%?GA_P]B\1?\ 1MGC3_O])_\ (M'_  ]B\1?]
M&V>-/^_TG_R+0!^A]%?GA_P]B\1?]&V>-/\ O])_\BT?\/8O$7_1MGC3_O\
M2?\ R+0!^A]%?GA_P]B\1?\ 1MGC3_O])_\ (M'_  ]B\1?]&V>-/^_TG_R+
M0!^A]%?GA_P]B\1?]&V>-/\ O])_\BT?\/8O$7_1MGC3_O\ 2?\ R+0!^A]%
M?GA_P]B\1?\ 1MGC3_O])_\ (M'_  ]B\1?]&V>-/^_TG_R+0!^A]%?GA_P]
MB\1?]&V>-/\ O])_\BT?\/8O$7_1MGC3_O\ 2?\ R+0!^A]%?GA_P]B\1?\
M1MGC3_O])_\ (M'_  ]B\1?]&V>-/^_TG_R+0!^A]%?GA_P]B\1?]&V>-/\
MO])_\BT?\/8O$7_1MGC3_O\ 2?\ R+0!^A]%?G+JW_!7K5-!T^:_U/\ 9Y\6
M:=8PX,ES=W;11)D@#<S6P R2!SW-?>?PO\>6GQ2^&_A;QE86\MI9:_IEMJ<-
MO/CS(EFB60*V.,C=@X]* .GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\&\'_\ )W_CC_L#Q_\ H%G7O->#>#_^3O\ QQ_V!X__ $"SH ]YHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9_Y:G_W;7S)\3/\ @J=^T%\0M2GDL/%,/@W36;,>GZ#9QH$&>,RNK2D],_,
M?0=*^N9OVROB+\/?^"87@CXE_P#"2/?_ ! U;Q ^G)JFHQ).TJK>7+%64C!!
MAMRG3(!X(.#0![9^Q+_P3M_X8Y\?:[XF_P"%@?\ "7?VIIG]G?9?[%^Q>5^]
M23?N^T29^YC&!UZU]E5\P_L(_MIV'[8'P_O9KNSAT?QKH9CCU?3X"?)??NV3
MPY);RVVL-I)*D$$D8)^GJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O!O&'_)W_ ('_ .P/)_Z!>5[S7@WC#_D[_P #_P#8'D_] O*
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MABG:71]_7S_,TIU;Z2/9****^R.D**** "BBB@ HHHH **** "BBB@ HHHH
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M** "O"/VYO\ DU7QY_URM?\ TL@KW>O"/VYO^35?'G_7*U_]+(* /L+]CO\
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M2UB>-1$@0$%N><5\*?MQ?L'_  U_8[^'^FZ@/'6NZ]XHUJ=H-+TJ2VAC1E0
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MU,:C9V#V\>B/O$]P"L^77$9. )&/"G[A_#[%KP;QA_R=_P"!_P#L#R?^@7E
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M'_"P-9_Z%&^_-_\ XW7W)10!\-_\+ UG_H4;[\W_ /C='_"P-9_Z%&^_-_\
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MT4 >#?\ #1'C7_HCFO?]]3__ "-1_P -$>-?^B.:]_WU/_\ (U>\T4 >#?\
M#1'C7_HCFO?]]3__ "-1_P -$>-?^B.:]_WU/_\ (U>\T4 >#?\ #1'C7_HC
MFO?]]3__ "-1_P -$>-?^B.:]_WU/_\ (U>\T4 ?.\?[4_B&;6)=)C^%VIR:
MK"GF26*W,AG1>/F*?9]P'S+R1W'K5_\ X:(\:_\ 1'->_P"^I_\ Y&H\-_\
M)W_BK_L#I_Z!;5[S0!X-_P -$>-?^B.:]_WU/_\ (U'_  T1XU_Z(YKW_?4_
M_P C5[S10!X-_P -$>-?^B.:]_WU/_\ (U'_  T1XU_Z(YKW_?4__P C5[S1
M0!X-_P -$>-?^B.:]_WU/_\ (U'_  T1XU_Z(YKW_?4__P C5[S10!X-_P -
M$>-?^B.:]_WU/_\ (U'_  T1XU_Z(YKW_?4__P C5[S10!X-_P -$>-?^B.:
M]_WU/_\ (U'_  T1XU_Z(YKW_?4__P C5[S10!X-_P -$>-?^B.:]_WU/_\
M(U'_  T1XU_Z(YKW_?4__P C5[S10!X-_P -$>-?^B.:]_WU/_\ (U'_  T1
MXU_Z(YKW_?4__P C5[S10!X-_P -$>-?^B.:]_WU/_\ (U> _MKZ3XP_:Q^$
M-IX0G\$:WX-BL]6AU5M2DLYKM<1Q2Q["ICCQGSL[MW\/3GC[WHH ^%[?QUK-
MO;Q1?\(E?-L4+GYQG Q_SSJ3_A8&L_\ 0HWWYO\ _&Z^Y** /AO_ (6!K/\
MT*-]^;__ !NC_A8&L_\ 0HWWYO\ _&Z^Y** /AO_ (6!K/\ T*-]^;__ !NC
M_A8&L_\ 0HWWYO\ _&Z^Y** /AO_ (6!K/\ T*-]^;__ !NC_A8&L_\ 0HWW
MYO\ _&Z^Y** /AO_ (6!K/\ T*-]^;__ !NC_A8&L_\ 0HWWYO\ _&Z^Y**
M/AO_ (6!K/\ T*-]^;__ !NC_A8&L_\ 0HWWYO\ _&Z^Y** /AO_ (6!K/\
MT*-]^;__ !NC_A8&L_\ 0HWWYO\ _&Z^Y** /AO_ (6!K/\ T*-]^;__ !NC
M_A8&L_\ 0HWWYO\ _&Z^Y** /AO_ (6!K/\ T*-]^;__ !NC_A8&L_\ 0HWW
MYO\ _&Z^Y** /AO_ (6!K/\ T*-]^;__ !NC_A8&L_\ 0HWWYO\ _&Z^Y**
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M_P"&X$_Z$Y?_  ;?_::\]HH_U<I_\_']P?\ $3<3_P! T?\ P)_Y'H7_  W
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M&O\ T1S7O^^I_P#Y&K@_^"5?_)CG@'_KMJ7_ *7W%?6M?$'[P>#?\-$>-?\
MHCFO?]]3_P#R-1_PT1XU_P"B.:]_WU/_ /(U>\T4 >#?\-$>-?\ HCFO?]]3
M_P#R-1_PT1XU_P"B.:]_WU/_ /(U>\T4 >#?\-$>-?\ HCFO?]]3_P#R-1_P
MT1XU_P"B.:]_WU/_ /(U>\T4 >#?\-$>-?\ HCFO?]]3_P#R-1_PT1XU_P"B
M.:]_WU/_ /(U>\T4 >#?\-$>-?\ HCFO?]]3_P#R-1_PT1XU_P"B.:]_WU/_
M /(U>\T4 >#?\-$>-?\ HCFO?]]3_P#R-1_PT1XU_P"B.:]_WU/_ /(U>\T4
M >#?\-$>-?\ HCFO?]]3_P#R-1_PT1XU_P"B.:]_WU/_ /(U>\T4 >#?\-$>
M-?\ HCFO?]]3_P#R-7F>@_%O5]+^/'B/Q+-X)U,ZC>6"6\FB)O,]N L&';,8
M."(U/*C[X_'[%KP;P?\ \G?^./\ L#Q_^@6= !_PTQK7_1,->_)__C5>I_#S
MQA<>./#::I=:-=:%*TKQ_8[O.\!3][E1P?I7344 %%%% !7Q+^UG_P $N?!/
M[1'B2]\9>&]7F\!^-;Q_.NIX81/97DO>22+*E)#QET89/)5B23];_$G7-6\,
M_#OQ1K&@V,>J:YI^EW5W8V,H8K<3QQ,\<9V\X9@%XYYKY4_X)V?MRZO^UW!X
MTLO%MMHVE>(](FBN+6QTF.2-7LG&W=B21RQ5UPS @?.G R* /SU^#NG_ +4O
MP%U;XM7WPHU&ZUVP\)^([G3O%!M(XKT75Q"[JTY@F!D=6"L=R#< <G'6OTF_
M8(_;JLOVOO#>I6.JZ?;Z%X[T1$>^L;>0F&ZA;@7$(;Y@N[Y64EMI*_,=PKF_
M^">K!/BE^U@S$*H^)FHDD]!^_GKY?_X)YO:>(/\ @I=\6M7\'&-?"136YT>W
M4>2]J]]'Y00C@*6*,H_NK[4 6OC"TLG_  6F\,B7[BWVEB+O\OV!#_Z$6K];
M*_)G_@HQ /@7_P % OA!\6KB,QZ'=-I]U=3*#EFM+D)<+QUQ T/Y]/7]7[&^
MM]3LK>\LYX[JTN(UEAGA<.DB,,JRL.""""".N: /R\_X+E?\@OX-GOYVK?\
MH-G7Z3_#995^'?A99\><-*M0^.F[R5S^M?EW_P %4=07X^?M8?"/X.:!(U_J
M=GB"Z2W.[[/+>RQ;@WH5BA20GH%8$]Z_6*UM8[*UAMX5V0PHL:+Z*!@#\J )
M:*** "BBB@ HHHH **** "BBB@ HHHH *_'1?"=C^PO_ ,%.K?Q/X\M7M/ 6
MN7VH7FDZZT9:&!+M)!NR!UB>7RW'55;=C!&?V+K\-_VDOV%OVC/'WQZ^).L:
M;X"U75= U#Q/J=]ITIU"W\MX)+J5HG56FRH*,,# (!H _:C2_B%X5URRCO-.
M\3:/?VD@#)<6M_%)&P(R"&5B#P1^=6O^$LT/_H,Z?_X%1_XU^ /_  [=_:2_
MZ);J'_@;:?\ QZC_ (=N_M)?]$MU#_P-M/\ X]0!_0?:W4-] L]O-'<0M]V2
M)@RGG'!%2UX%^P?\._$7PG_9-\ ^%/%FF2:-X@TZ*[6ZL971VB+WD\BY*$J<
MJZG@]Z]]H **** "BBB@ HHHH *_)#_@M]X8U2/QI\,O$1CD?1I=/NM/60 E
M(YUD60@GL65QCUV'T-?K?7!?&_X(>$OVA?AWJ'@SQGI_V[2;K#J\;;)K:9<[
M)HGQ\KKDX/(()!!!((!\A_LI_P#!4KX0:U\*_#>B^/M;;P5XKTNRAL+E;NUE
M>UN6C4()8I8U8*& !*OM()(&X#<=WX_?\%6/@UX%\":HW@;Q!_PFOBZ6%XK"
MTL;:9(8Y2,+)++(@78I^;"[B<8P,Y'RUX^_X(D^.K75I?^$)\?\ A[4],9\Q
M_P!OI/9S(OH?*CF5B.F>,]<#I47@?_@B3\0;K5HQXP\?^&M+TP,"[:&EQ>S,
MO< 2QPJ">F<G'7!Z4 8O_!%GPSJ^H?M&>*O$$$<@T?3_  Y+:WEQ@[3+-<0F
M*,GU/DR-_P!LS7[05YG^S[^SQX,_9G^'UOX2\%V#6]HK>;=7EP0]S>S$8,LS
M@#<W&       !7IE !1110 4444 %%%% 'A_[6G[)OA3]KCX>+X>\0.^FZI9
M.T^DZW;H'FL92 &^4D;XV  9"1G .00"/B[PW^S/^W?\#]$/@SP+\2M&U+PI
M;IY=E+)/!*8(\\*ANH#)%@#[BDJN?E]:_4&B@#X2_8]_X)PWWPK^)$OQ9^+W
MB6/QQ\2'D:XMQ'(\\%M,X(:=Y9 &FEP< X"IR1N.TK]Q:MI=GKNEWFFZC;17
MNGWD+V]Q;3*&CEC=2KHP/4$$@CWJW10!^8>L_P#!.?XX_LW_ !)U/Q-^S)X_
MM['1]2;#Z3J4P26)-VY8G$D;PSHO.';# '&#R3)HG_!.?XW?M&_$K2_$_P"T
MY\0+;4](TT@QZ1IDH>25-VYX5$:1Q6ZM@9=-S$<<$ C].** *FDZ39Z#I5GI
MFG6L5EI]E"EM;6L"A8X8D4*B*!T    ]!5NBB@ HHHH **** "O!O&'_ "=_
MX'_[ \G_ *!>5[S7@WC#_D[_ ,#_ /8'D_\ 0+R@#WFBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KY?_ ."FG_)CGQ/_ .N-C_Z7VU?4%?+_ /P4
MT_Y,<^)__7&Q_P#2^VH ^>OV??\ DA?P_P#^P#9?^B4KOZX#]GW_ )(7\/\
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ME_Z7W%?6M?C1_;84444 %%%% !1110 4444 %%%% !1110 4444 %>#>#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_QQ_P!@>/\ ] LZ]YKP;P?_ ,G?^./^P/'_ .@6= 'O-%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY?\
M^"FG_)CGQ/\ ^N-C_P"E]M7U!7R__P %-/\ DQSXG_\ 7&Q_]+[:@#YZ_9]_
MY(7\/_\ L V7_HE*[^N _9]_Y(7\/_\ L V7_HE*[^OV/#_P8>B_(_B?,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;84444 %%%% !1110 4444 %%%% !1110 4444 %>#>#_P#D[_QQ_P!@>/\
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M_._ZHG_Y=?\ ]Q4 ?:'[%/[(ND_LA_"U]#BNH]7\2ZI*MUK6K1QE%GD (2-
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\O\ _!33_DQSXG_]<;'_ -+[:OJ"OE__ (*:?\F.?$__ *XV
M/_I?;4 ?/7[/O_)"_A__ -@&R_\ 1*5W]<!^S[_R0OX?_P#8!LO_ $2E=_7[
M'A_X,/1?D?Q/F/\ OM;_ !2_-A11170>>%%%% !1110 4444 %%%% !1110
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M#Q]X=CCDGN(56-=2MF)47 C  5E;"N%^7+(1C=M'VC0 4444 %%%% !1110
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M (,/1?D?Q/F/^^UO\4OS84445T'GA1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** &I&L:X10HR3A1CDG)/YTZBB@
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MD]S0!]*_\$<5>X_:Z\47&EPR0Z5_PC-[N5LG9$UW;&-"?7(7Z[37[45\F?\
M!/G]B4?LB^!=2N==NK;4O'>OF-M1FM26AM8DR8[>-B 6P69F; R2!R%!/UG0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X-XP_Y._\
M _\ V!Y/_0+RO>:\&\8?\G?^!_\ L#R?^@7E 'O-%%% !1110 4444 %%%%
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ME'_#I_\ 9M_Z%#4/_!W=_P#QRC_6.I_S[7WA_P 0RP__ $$R_P# 5_F>7_\
M"V/!'_0X^'__  :0?_%T?\+8\$?]#CX?_P#!I!_\77J'_#I_]FW_ *%#4/\
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M^&->U>Y:\\0Z>TFCZK<,<M+/!@"1CW9XFB=C_><U](4 %%%% !1110 4444
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M?<5X[\9O^2/^.O\ L WW_I.]>Q?\$J_^3'/ /_7;4O\ TON*^$XC_B4_1G]
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MCHKX&_X)O?MG?%O]K#QEXLB\9Z7I,?AC2-/5DOM+L)(5%V\BA8R[2,"2@D;
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M/2M%L5^9V^:2:0_=BB3J\C$<*/<G !(_*F_U;XP_\%;OBDVGZ<LW@GX*Z+=
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M]GOX5Z%X#\,K+_9>E1,OG7!!EN)&8O)*Y'\3,S'C@9 &  * .^HHHH ****
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M#]G_ .#>E_L__!WPOX!TA_/MM&M!%)<[-AN9V)>:8CMOD9VQDXR!GBO0J**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-Y:1:A
M9SVLR[H9HVC=0<94C!Y^AKY%_P"'3_[-O_0H:A_X.[O_ ..5]@44 >(? /\
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M!7GQ4^"_CKP;I]Q!:7VOZ+>:9!<7.[RHWFA9%9MH)V@L,X!- 'Q=_P $3_\
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M\%"/V"O%_P"U]XR\)ZQX;\0Z)HT&CV$MI+'JIFW.S2;P5V(W&/6@#Z)_:O\
MAK-\9/V:_B'X2LHQ<WNI:/,;*,<^9<1@2P#\9$3\Z^+/^"*/Q,T@_#GQS\.9
MIH[?Q'::PVMK;2862:WDAAA8@=3L> ;O3S%]:_1KPOI<FA^&M)TV5UDEL[2&
MW=TSM9D0*2,]N*^&/VEO^"8]WXJ^*4OQ3^"/C(?#?QO-.UW/;L\L-L]PV=\T
M<T(+PE\G>H5E;<>!D@@'V]XW\9Z1\._!^L^)]>NUL=&TBTDO;NX<_=C12QQZ
MDXP!U)( ZU^7_P#P17\-ZAJ_CCXM>.6@^SZ7+'!8)M&$::25YF5>WR*J_3S!
MZULZU^P#^U?^T(;/1OC)\:=/'A&&19)+:TGDN69E^ZWV=(H8W8<X9WR/0U^@
MOP-^"/A;]GGX:Z7X(\(6C6VDV(9FDF8--<RL<O-*V!N=C[         [ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP;P?_ ,G?
M^./^P/'_ .@6=>\UX-X/_P"3O_''_8'C_P#0+.@#WFBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY\OV\/CUXI^(7
M[6GBR^N&M-'U'P=K=YHFEWVBQ-:W*PVMW*L,CRAMS2C;G=D8)X &!7]!M?/M
MO\</V9_A3XL\0PP>+?A_X9\2MJ5R^L%)[:"[:],C^>9V^\9-Y<'<<CD4 ?A'
M\3_VD_B=\:-%L])\<>--3\3:=9S"XMX+]U<1R;2NX'&<[6(Z]ZF_X3#XN?M"
M6/ACP!'?^(O&UII"1VVD:#;AYTME"B--L:C PH"AFZ#/(&:_>W_AM;X"?]%>
M\'_^#:+_ !H_X;6^ G_17O!__@VB_P : %_8U^"-S^SO^S;X,\$:CL.L6=N]
MQJ)C?>HN9I&ED4'H0I?8".H0&O:JX&^^/GPXTOX?V/CJ[\;:';>#KZ7R+77)
M+U!:32;G7:LF<$YC<8_V3Z5H_#KXM>"_BYI]U?\ @KQ1I?BFRM91!//I=RLZ
M12$!MK%3P<$'% '6T444 %%%% !1110 5\M_MZ_MK6_['O@729=/TVWUOQEK
MTLD>F6-TS""..,*99Y=I#%1O10H(+%N#A37U)7Y+_P#!;SP7JR^)OAIXL$,D
MFAM9W.EM,H)2&X#B0*W8%U8X]?*;TH ^=M7_ ."JW[2VI7CSV_CJUTJ)B2+:
MST.Q:-<G. 987;CIRQZ52_X>C?M._P#13/\ R@:7_P#(U?KA^S'^S/\ !C2_
M@/X#N-'\!^&=5BO=&L[YM4O-+AN;B[DDA5VE>2168DLQ.,X7.   !7L?_"I_
M _\ T)OA_P#\%<'_ ,10!^??_!+C]L+XN_M&?%[Q9HGQ#\6_\)#IECH1O+>#
M^S;.VV3?:(DW;H848_*S#!)'/2OTOK%T/P7X>\,W$D^CZ#IFE3R+L>2QLXX6
M9<YP2J@D9 X]JVJ "BBB@ HHHH **** /R._:@^..@_MP?M7:5\*[SQSI/@K
MX+>$;IYM4U;5=3AL4U&:,[)FB:5@&;DQ1 9P"\G(.!]J?%+]H#X$:3^SIXQ\
M+>&/B=\/X[>#PM>Z=INE:?XBLF( M'2*&-%E))^ZH Y/%>4ZS_P1H^"NN:Q?
M:C/XG\>I/>3R7$BQZA9!0SL6(&;,\9/K7%_%/_@CY\&O _PQ\7^(['Q-XZEO
MM'T>\U"".XO[)HVDB@>10X%H"5)49P0<=Q0!QG_!'KXR> ?AE\-_B%:^,/''
MAOPG<W6K0200ZYJ]O9O*@A(+()74L >,BO5/^"U,#7'[,7A&YB_>0IXMM\LO
M(PUG=X/TXZ^XKY,_X)T_L'^ ?VNO!?B_5_&&K^)--N='U"*T@70[FWB1D:/<
M2XE@D).?0BOTD_X*"_!6\^,G[(_B[P_HUM)>ZSIL4.J:? @W/(]NP9E [LT7
MFJ .26'TH Z[]B^Z2\_9*^$$D>-J^%]/C.#GE8%4_J#1^VA=)9_LE?%^23&U
MO"^H1C)QRT#*/U(KYW_X)-_M)>'O'OP!TKX;76IPP>,O"OG1?89V"R7-FTK/
M%+&#]X*'\L@<KL4G[P)7_@K%^TGX=\!_ '5OAK:ZE%<>-/%7DPBP@<-):VBR
MK))+*!]T,$\M0<%MY(R%. ##_P""*%F\?[-OC&Z).R7Q9-&%SQE;.U)/_CX_
M*OT*KYK_ ."=OP9O_@?^R?X0T?5[;[)KFHB36;Z!@0T;W#;D1@>C+$(E8=BI
M%?2E !1110 5S/Q#M_%%SX;=/"%S:VNL^:A62[ *;,_,.5//X5TU% '@W]C_
M !__ .@YH/\ WPG_ ,:KD=#M_&%K^U#X.3QK=6=YJIL)C%)9 !!#Y5S@'"KS
MNW]NXKZGKP;QA_R=_P"!_P#L#R?^@7E 'O-%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7R__ ,%-/^3'/B?_ -<;'_TOMJ^H*^7_ /@II_R8Y\3_
M /KC8_\ I?;4 ?/7[/O_ "0OX?\ _8!LO_1*5W]<!^S[_P D+^'_ /V ;+_T
M2E=_7['A_P"##T7Y'\3YC_OM;_%+\V%%%%=!YX4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!QWQF_Y(_XZ_P"P#??^D[U[%_P2K_Y,<\ _
M]=M2_P#2^XKQWXS?\D?\=?\ 8!OO_2=Z]B_X)5_\F.> ?^NVI?\ I?<5\)Q'
M_$I^C/Z!\,_]UQ/^)?D?6M%%%?'G[.%%%% !1110 4444 %4]6TBSU[3YK&_
MMTNK688>.0<'W]C[CI5RBE**DG&2NF!\K?%#X0WG@:9[VSWWFB,W$V,O#GHK
M_P!&Z'VK@+.\GT^ZBN;:5X+B)@R21L592.X-?<D\$=U#)#-&LL4BE7C< JP/
M!!!ZBOG?XL?!&30_.U?0(VFT[EYK-?F>#U*^J_J/<=/SW-<DE0;Q&%7N]5U7
MIY?D<=2E;6)VOPI^-4'BH1:5K+);:O\ =CFX5+G_  ;VZ'MZ5ZO7PDK%6!!P
M1R"*]V^$_P <O]3H_B6?T2#47/Y+(?\ V;\_6NW*<\4[4,6]>DO\_P#/[RJ=
M7I(]WHI P8 @Y!Z&EK[8Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .7TSX8^%=&\?:QXWLM#M;;Q9K$$=M?ZL@/G7
M$484(C'., (HZ=A74444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@W@__D[_ ,<?
M]@>/_P! LZ]YKP;P?_R=_P"./^P/'_Z!9T >\T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^,OQZ_X):_'7XA?'+X
MB^*=(T_0WTG7/$>HZG9M-JJ(YAFNI)(RRXX.UAD=J_9JOD']M#_@HUX1_91O
M3X8LM.?Q;X^D@$W]FQRB.WLE891KF3D@D881J"2O)*@J2 ?G3_PZ'_:&_P"@
M;X?_ /!PG^%'_#H?]H;_ *!OA_\ \'"?X5;U7_@L+\?]0OI9[9_#.FPL?EM;
M?2BR(/0&21F/XFO8/V?_ /@M!KBZ_9:7\7O#>GS:-,ZQ/KOA^-XI[8'_ ):2
M0,S"0#OLV$#H&/! /6OB!^Q+\3O$7_!.7P!\&K.UTUO&VC:L;R[B>^58!'Y]
MV_RR8P3B>/CZ^E>D_P#!-']F#QS^R[\-_%VB^.K>QM[[4M62\MQ8W0G4QB%4
M.2!P<@\5]<Z+K-CXBT>QU72[N&_TV^@2YM;NW</'-$ZAD=6'!4J00?0U=H *
M*** "BBB@ HHHH _)C_@HE^W-\;O@7^T[K'A+P/XV_L3P_;V-G-'9_V38W&U
MWB#.=\L#L<GU-?'OQ._;T^.7QF\&WWA3QIXRM]?T"\V^=9W&@Z:O*G*LKK;A
MD8'HRD$>M?OYXB^$7@7QAJCZEKW@KP[K>HNJJUYJ.E07$S*!@ NZ$D =.:P8
M/@C\'KJ^N+&'P#X'EO;=5::VCT:S:2,'."RA,@'!QGT- 'X%_!W]LSXT? +0
MGT7P+X\O='T=F+BPFMX+R"-B<DQI/&XCR>3M R<UZ#_P]&_:=_Z*9_Y0-+_^
M1J_:?Q5\*?@?X%T2XUGQ'X-\ :#I-N,RWVI:596\*?5W0 5YIX7^('['OC37
M%T?1I_A1>:F\GE1V_P!AL8S*_.%C+( YX_ASV]10!\Y?\$N/VPOB[^T9\7O%
MFB?$/Q;_ ,)#IECH1O+>#^S;.VV3?:(DW;H848_*S#!)'/2OTOKF?"WPQ\'>
M![R6[\-^$]#\/W4T?E23Z7IL-L[ID':6102,@'!]!734 %%%% !1110 4444
M %8OC;PO;^./!NO>&[N62WM=8T^XT^66'&]$EC:-F7((R Q(R*VJ* /!OV2_
MV0?#?[(/AW7M'\-ZSJNLP:Q=)=S2:J8MR,J;0%V(O&/6O>:** /B+X^?\$G?
MA9\8/%UWXIT'4M2^'VM7DAGN$TE(Y+)YB23*(6 *,3R=CJO'0$DU+\ /^"4?
MPL^#'B^T\5:SJ&I>/]=LY5N+7^U@D=K#,IR)?)7[[ \C>S <'&0#7VQ10 44
M44 %%%% !1110 5X-XP_Y._\#_\ 8'D_] O*]YKP;QA_R=_X'_[ \G_H%Y0!
M[S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\O\ _!33_DQSXG_]
M<;'_ -+[:OJ"OE__ (*:?\F.?$__ *XV/_I?;4 ?/7[/O_)"_A__ -@&R_\
M1*5W]<!^S[_R0OX?_P#8!LO_ $2E=_7['A_X,/1?D?Q/F/\ OM;_ !2_-A11
M170>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <=\9O\
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MPWC'0PVMRR1#+RS,H-Q$".N$50,=3"GK7Z0_L ?M'C]I3]G/0]8OKD3>*=(
MTC6PQ^=KB-1MF/\ UU0H^>FXN!]VOK\'CJ6.C*5/[+:_X/S.F,E+8^D:***]
M L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KP;P?\ \G?^./\ L#Q_^@6=>\UX-X/_ .3O
M_''_ &!X_P#T"SH ]YHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR/XGS'_?:W^*7YL****Z#SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M] O* />:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP;P?\
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ML_W3^.#[5]?A,YPF*LE+EEV>G_ .F-2,CT"BD5@RAE(*D9!'0TM>X:A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>#>#_^3O\ QQ_V
M!X__ $"SKWFO!O!__)W_ (X_[ \?_H%G0![S1110 4444 %%%% !6/XJ\9:!
MX%TEM4\2:YIOA[3%.UKS5;N.VA!ZX+N0.Q[UH:A?0Z98W-Y<OY=O;QM-(Y_A
M5023^0K\;/@?\.->_P""K7[1OC+Q;X^\0:EIW@+P^R-%IMG(-T$4K.+>T@W
MHGRQ,TD@4DE>F7! !^B?P6_;N^%'QL\5>*- T_Q%I^DWVCZJ^F6HU/4;:/\
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M?A#^UY\9K[]KK]K#4R/$6GVOAJ+46T70KS4+H0:?:V*2%1<,YX"O@RLW).X
M9PJT ?N%^S[^T5X/_::\&WWBCP1->7&CVFHR:8TMY;^0SRHD;DJI.=NV5<9P
M>O%=/\0OB=X3^$_A]]<\9>(M.\-:2C!/M6HW"Q*S'HJYY9O]D9-?''[$OB?X
M"?L@?"J]\)M^T'X3\37.H:BVJ7,_VV&WBCE:*.,K&N]CC$2\D\^@Z5^8O[6W
M[0>L?M;?M#:AJ<NJ1IH OFTWP_%>S""VL[/S-L;N6P$WC$CL>F>3A1@ _:GP
M7^WM^S]\1->BT/1?B;I,VHSRB"*&\CFM%E<]%5IHT5B<X&"<GCKQ7J7@_P"$
MO@SX>Z]KVL^&/#.F>']1UXPG4YM-MU@%VT1D*,ZKA2P\V3YL9.[DFOP<^-'[
M)G@7X:_#,>(_#/[0?@GX@:Y;E3>>'M/D2&7:2 3;N96,Q&<D%4. 2,GBOT(_
MX)1_M<6?CSX4VWPV\8^)K1O&&CW9LM$MKN<"ZOK$0^8BJ"<R&()*N1T14],D
M _0BBBB@ HHHH **** /EKX^_P#!.7X4_M(?$B[\;^++CQ%'K-U!#;NNG7T<
M4.V-0JX4Q,<X'/->=?\ #FWX"?\ /YXP_P#!I%_\8K[JKX]_X*0_MFZG^R?\
M/=%M/"D=N_C7Q++*EG/=1B2.S@B"^;,4/#/F1%4,-N2Q.=N" <O_ ,.;?@)_
MS^>,/_!I%_\ &*/^'-OP$_Y_/&'_ (-(O_C%?F1J'_!0K]HK4KI[B;XK:TCM
MU%NL,*?@J1A1^ JO_P -^?M#?]%8\0?]_4_^)H _9[]FG]A'X;?LI^*]4\0^
M"Y]<EO\ 4;+[!,-4O$F3R_,5^ L:X.4'.?6OHNORR_X))^(/BK\3?B]XO\=>
M.;_Q1XBT.;0FL;36]9DGEM6F%S$6BA=_DR K$JG3'-?J;0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5X-XP_P"3O_ __8'D_P#0+RO>
M:\&\8?\ )W_@?_L#R?\ H%Y0![S1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\O_ /!33_DQSXG_ /7&Q_\ 2^VKZ@KY?_X*:?\ )CGQ/_ZXV/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKNP<;L!<X_ XKT'0_P#@G[\9/VT]"M_B'\;OBO>>'[C6%%YI_AF&R:XCLH'
M:,>4942#@_ZL*S8(+-NW"@#Z _;C_P""?*?M4>*O"WBOPQK=CX+\4Z<6BO\
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M?Q*\*S>._ASXI\-V]X^G7&L:5=:?%>1LRM \L+(L@*\@J6!R.>*_*+_@F_\
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M &!Y/_0+R@#WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY?_X*
M:?\ )CGQ/_ZXV/\ Z7VU?4%?+_\ P4T_Y,<^)_\ UQL?_2^VH ^>OV??^2%_
M#_\ [ -E_P"B4KOZX#]GW_DA?P__ .P#9?\ HE*[^OV/#_P8>B_(_B?,?]]K
M?XI?FPHHHKH//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ..^,W_)'_'7_8!OO_2=Z]B_X)5_\F.> ?\ KMJ7_I?<5X[\9O\ DC_CK_L
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!O!_\ R=_XX_[ \?\
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M &!Y/_0+R@#WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY?_X*
M:?\ )CGQ/_ZXV/\ Z7VU?4%?+_\ P4T_Y,<^)_\ UQL?_2^VH ^>OV??^2%_
M#_\ [ -E_P"B4KOZX#]GW_DA?P__ .P#9?\ HE*[^OV/#_P8>B_(_B?,?]]K
M?XI?FPHHHKH//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ..^,W_)'_'7_8!OO_2=Z]B_X)5_\F.> ?\ KMJ7_I?<5X[\9O\ DC_CK_L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_2^XKX3B/^)3]&?T#X9_[KB?\2_(^M:***^//V<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *IZII%CK5JUMJ%I#>0-UCG0,/KST/
MO5RBDTI*S6@'COBO]G'2]0WS:%=/IDW46\V9(3[ _>7]?I7C?BKX:^(?![,V
MH:>YME_Y>H/WD1_X$.GXXK[&I" P((R#U%?-XK(<+B/>IKD?EM]W^5C"5&,M
MM#X2KK?"OQ2\1^#]B65^TMJO_+K=?O(L>@!Y7_@)%?0GBKX*>&?%&^5;7^S+
MMN?/LL("?=/NG\@?>O&O%7P"\1Z!OEL576K5>=UN,2@>\9Y_[Y)KY.ME./R^
M7M*-W;K'_+?]#G=.<-4>B^%/VB]'U39#K5O)I,YX\Y<R0D_@-R_D?K7JFGZE
M::M:K<V5S#=V[=)87#J?Q%?#LT,EO*T4L;12J<,CJ00?0@U>T7Q%J?ARZ^T:
M9?364W<PN0&]B.A'L:[,+Q'6I^[B8\R[[/\ R_(N-9KXC[=HKY]\*?M)7=OL
MA\06*W:=#=6@"2?4H>#^!%>Q>&?'FA>+XP=+U&*>7&3;L=DJ_5#S^/2OL<+F
M>%QFE*>O9Z/^O0Z(U(RV.@HHHKU#0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:?LAUVU34X>AN(<1S#W(^ZWZ?6M?Q7^S6C;YO#U_L/7[+>\CZ!P/YC\:\?\
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M/_Y._P#''_8'C_\ 0+.@#WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!7I]% !1110 4444 %%%% !7@WC#_D[_ ,#_ /8'D_\ 0+RO>:\&\8?\G?\
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MEO[!W[8]M^U]\,KN^O+.'2_&.AR1V^M6-L&\C+AC%-%DDA'"/\I)*E&'(P2
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#IJ*** "BL7QGXRT;X>^%=4\2>(;Y-,T33(&N;R\D5F6*->K$*"3^ ->"?\
M#R']FW_HJ6G_ /@%=_\ QF@#Z$\26-QJ?AW5+.TE\FZN+66&*3^X[(0I_ D5
M^2O_  1U^)7ASX5_$[XD?#_Q=-#X?\5ZPUK#9"_(C,DUL\Z36NXG DS(I"]6
MVMUP*_3?X._M!_#WX_V.I7GP_P#$L'B2VTV1(KN2"&6,1,X)4'S$7.0#T]*^
M?/VL?^"8_P //VEM:N_%&G7L_@;QK='=<ZE90B>VO&_O36Y*Y?C[Z,I/5MU
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X-XP_Y._\
M _\ V!Y/_0+RO>:\&\8?\G?^!_\ L#R?^@7E 'O-%%% !1110 4444 %%%%
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MA!CNIHEVJ68CY8U[GG->TT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>#>,/^3O_ __ &!Y
M/_0+RO>:\&\8?\G?^!_^P/)_Z!>4 >\T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH *\&\'_P#)W_CC_L#Q_P#H%G7O->#>#_\ D[_QQ_V!X_\ T"SH ]YHHHH
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M\A=(V!Y#",IN!Y#;AVKZ3H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[K.G7]WX?D:XA0Z=&EO*\\+^5#Y2,Z+(NU0RY;!('-?3W[%?[>?Q!OOC;=?
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M3\)?@WX3C\??$)9%M[B1DDN(()SDM;I#$0\LBCEOF4(<@Y(8+YMKW[1/[?\
M\,])N/%?B+X5Z+>Z# AFFMH[6*Y,4?<F.VNC,H Y)(. "3P#0!^G=%?./[&/
M[;'AC]L+PG?3V-D_A_Q3I.P:GH<\PD*AA\LT3X&^(D$9(!4C!'*EOHZ@ HHK
MX-_:T_X*2:C\./BB?A+\&_"<?C[XA+(MO<2,DEQ!!.<EK=(8B'ED4<M\RA#D
M')#!0#[RHK\Q->_:)_;_ /AGI-QXK\1?"O1;W08$,TUM':Q7)BC[DQVUT9E
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MP+K?AJS\2S>)TU34O[1-Q/9BV,9\I(]FT.V?N9SGO7T%10 4444 %>#>#_\
MD[_QQ_V!X_\ T"SKWFO!O!__ "=_XX_[ \?_ *!9T >\T444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 5X-XP_Y._\  _\ V!Y/_0+RO>:\&\8?\G?^!_\ L#R?^@7E 'O-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R&
MM?"7PEXB^(WA[QYJ.BQ7/B[P_#-!IFIM)('MDE1DD4*&VG<KL.0>M=?110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10>'M&U6_P##WB*Z;;:Z7XCMUMI+EO[L;H[QLQ[)OW'L#S0!]0T444 %%%%
M!1110 5X-XP_Y._\#_\ 8'D_] O*]YKP;QA_R=_X'_[ \G_H%Y0![S1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7S?\ \%"/CGJ'[/\ ^RWXIU_1;@VFOWYC
MT?3;A6VM#-.2#(A_OI&)'7W45](5^=/_  6TOGC^ O@2S!/ES>)?.8=LI:S
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M3_\ )>7_ .)H ZNBN4_X6EX8_P"@G_Y+R_\ Q-'_  M+PQ_T$_\ R7E_^)H
MZNBN4_X6EX8_Z"?_ )+R_P#Q-'_"TO#'_03_ /)>7_XF@#JZ*Y3_ (6EX8_Z
M"?\ Y+R__$T?\+2\,?\ 03_\EY?_ (F@#JZ*Y3_A:7AC_H)_^2\O_P 31_PM
M+PQ_T$__ "7E_P#B: .KHKE/^%I>&/\ H)_^2\O_ ,31_P +2\,?]!/_ ,EY
M?_B: .KHKE/^%I>&/^@G_P"2\O\ \31_PM+PQ_T$_P#R7E_^)H ZNBN4_P"%
MI>&/^@G_ .2\O_Q-'_"TO#'_ $$__)>7_P")H ZNBN4_X6EX8_Z"?_DO+_\
M$T?\+2\,?]!/_P EY?\ XF@#JZ*Y3_A:7AC_ *"?_DO+_P#$T?\ "TO#'_03
M_P#)>7_XF@#JZ*Y3_A:7AC_H)_\ DO+_ /$T?\+2\,?]!/\ \EY?_B: .KHK
ME/\ A:7AC_H)_P#DO+_\31_PM+PQ_P!!/_R7E_\ B: .KHKE/^%I>&/^@G_Y
M+R__ !-'_"TO#'_03_\ )>7_ .)H ZNBN4_X6EX8_P"@G_Y+R_\ Q-'_  M+
MPQ_T$_\ R7E_^)H ZNBN4_X6EX8_Z"?_ )+R_P#Q-'_"TO#'_03_ /)>7_XF
M@#JZ*Y3_ (6EX8_Z"?\ Y+R__$T?\+2\,?\ 03_\EY?_ (F@#JZ*Y3_A:7AC
M_H)_^2\O_P 31_PM+PQ_T$__ "7E_P#B: .KHKE/^%I>&/\ H)_^2\O_ ,31
M_P +2\,?]!/_ ,EY?_B: .KHKE/^%I>&/^@G_P"2\O\ \31_PM+PQ_T$_P#R
M7E_^)H ZNBN4_P"%I>&/^@G_ .2\O_Q-'_"TO#'_ $$__)>7_P")H ZNBN4_
MX6EX8_Z"?_DO+_\ $T?\+2\,?]!/_P EY?\ XF@#JZ*Y3_A:7AC_ *"?_DO+
M_P#$T?\ "TO#'_03_P#)>7_XF@#JZ*Y3_A:7AC_H)_\ DO+_ /$T?\+2\,?]
M!/\ \EY?_B: .KHKE/\ A:7AC_H)_P#DO+_\31_PM+PQ_P!!/_R7E_\ B: .
MKHKE/^%I>&/^@G_Y+R__ !-'_"TO#'_03_\ )>7_ .)H ZNBN4_X6EX8_P"@
MG_Y+R_\ Q-'_  M+PQ_T$_\ R7E_^)H ZNBN4_X6EX8_Z"?_ )+R_P#Q-'_"
MTO#'_03_ /)>7_XF@#JZ*Y3_ (6EX8_Z"?\ Y+R__$T?\+2\,?\ 03_\EY?_
M (F@#JZ*Y3_A:7AC_H)_^2\O_P 31_PM+PQ_T$__ "7E_P#B: .KHKE/^%I>
M&/\ H)_^2\O_ ,31_P +2\,?]!/_ ,EY?_B: .KHKE/^%I>&/^@G_P"2\O\
M\31_PM+PQ_T$_P#R7E_^)H ZNBN4_P"%I>&/^@G_ .2\O_Q-'_"TO#'_ $$_
M_)>7_P")H ZNBN4_X6EX8_Z"?_DO+_\ $T?\+2\,?]!/_P EY?\ XF@#JZ*Y
M3_A:7AC_ *"?_DO+_P#$T?\ "TO#'_03_P#)>7_XF@#JZ*Y3_A:7AC_H)_\
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M'_03_P#)>7_XF@#JZ*Y3_A:7AC_H)_\ DO+_ /$T?\+2\,?]!/\ \EY?_B:
M.KHKE/\ A:7AC_H)_P#DO+_\31_PM+PQ_P!!/_R7E_\ B: .KHKE/^%I>&/^
M@G_Y+R__ !-'_"TO#'_03_\ )>7_ .)H ZNBN4_X6EX8_P"@G_Y+R_\ Q-'_
M  M+PQ_T$_\ R7E_^)H ZNBN4_X6EX8_Z"?_ )+R_P#Q-'_"TO#'_03_ /)>
M7_XF@#JZ*Y3_ (6EX8_Z"?\ Y+R__$T?\+2\,?\ 03_\EY?_ (F@#JZ*Y3_A
M:7AC_H)_^2\O_P 31_PM+PQ_T$__ "7E_P#B: .KHKE/^%I>&/\ H)_^2\O_
M ,31_P +2\,?]!/_ ,EY?_B: .KKP;P?_P G?^./^P/'_P"@6=>G?\+2\,?]
M!/\ \EY?_B:\*T_XE^&_"W[37BS7]4U VND7FFQP07)MY6#OLMN JJ6_Y9OS
MC'% 'U!17EW_  TW\-/^AD_\D+G_ .-UV_A+QAI'CK1UU30[O[;8,[1B7RGC
M^9>HPX!_2@#:HHHH **** ,WQ)J,VC^'=4O[>,33VMK+/'&W1F5"P'XD5^4/
M_!&_P;HGQ,^*GQ/^(GBGR]<\:Z<UM+:37P$DD<ET\[SW(W?\M"8U7>.0&8?Q
MU^M_7@\BORE^+W[#/QN_92^,^I?%']FNXDU#1[MY)'T6T*-<6T;MN>V>!_EN
M(0V-N,N,#C*[R >P?L>?#GP]\6M<_;&\)^*=-AU71-4^(NI03P3(&QF:?#J3
M]UU.&5ARI (Y%=I_P3U_8R\<_L?Q>,;3Q)XJTG7-*UQH)8;'31,1!-'O!DRZ
MK]Y6 .!_ O/%?"?[+G_!1:__ &9/'OQ._P"%@?#^[N[[Q;XFN-5UD6<ILY].
MNS(_GPK;RJ<E79AL9U*XP37ZW_ SX_>!_P!HSP5'XH\"ZPNJZ?O\J>)E,<]K
M+@$Q2QGE6 (]B.02.: /SW_X+9>/M7C?X8^!8+N2RT*^^TZE> DB*>56CCB+
M8Y(C#2''_30'J!C[H^$W[)/PI^$OP]L/"NF>"M#O[:.W6.ZO-0T^&XGOWVX>
M69V4EBW)QT&<  8%>&_\%3O"?P=\2?!?3[CXF^))/"^NV<TC>'+RQM_M5Y)*
M0OFQ+;[E\R-@$W$LH4A#N' ;Y#_9^_;$_;)TOX1V=EX0^'-S\0?#%C;^1IVO
M:CX;N[B?R$^15CDAD19BH '21N,$G% $OQ+\+:?^QI_P5)\"VWPV\S2]%\07
M6F_:='LV)2.&]G-O/;!3U4[?,53]TE,8VKC]*/VQ/C--\ ?V:_'7C:S*C4[*
MR$%AD]+J9UAA;'?:\@<CT4U^;7_!/Z?P9\:?VL;[QQ\;?&%Y<?&J.^:33/#V
MKV7V2%KB-0JLKYP9(P-J6^U"I0$!L<?47_!8_4&LOV1;:$$@7GB6R@./:*>3
MG_OW0!YQ_P $I_V3?#'BCX:W?QF\>Z/;^+/$?B"_N!ITFM1"Z2**.0I).!)D
M&5YEERYR0$&"-S9ZG_@I]^QEX+UKX&ZO\2?"?AVP\.^+?"X6\GDTFV2W6^M2
MZB42J@ 9D!WASR A&<'CW_\ X)[V<-C^QC\*8X$V(VE>:1_M/-(['\68G\:[
M;]J:TBOOV9?BW!,N^-_"6K9'TLY2#^= 'G'_  3I^.5[\?/V5_#.KZO<O>Z_
MI+R:)J5Q(Q9Y98-NQV)Y+-"\+,3U9F-?3%?G#_P1'OI)/@K\0K,L_E0^($F5
M3]T%[9 2/?\ =C/T%?H]0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? G_  6>\+3:
MQ^S#H6KPJ6_L?Q);R38'"Q203QY)_P!\QC\:^^ZX7XY?"/2?CQ\)/$_@+6V:
M.PUNT-N9D&6@D!#Q2J.Y214<#OMH XC]AWQ+#XL_9"^$=[ X=(O#MI8$K_>M
MD^SL/P:(C\*Y[_@HSXF@\*_L7?$^XFD5&NK".PC5NKM//'%@#UPY/T!/:O@G
MX-_'OXT_\$P[K5OA]\1/A[>^*/ ?VEY[&\MI&C@B9B=TMM<^6R,C@;C$VU@>
M3L)8&?XF?$7XV?\ !5+Q-X?\'>&/ ]YX$^&%G=)=7M]=EI8 WS#[1-,40.50
MML@3DDDDGAE /JO_ ()"^%[CP]^QS8WLZ;4UO6K[4(>.2@*6^?\ OJW:OM:N
M9^&7P]TGX3_#WP[X.T.,Q:3H=C%8V^[[S*B@;V]68Y8GN23734 %%%% !5+5
MM%T_7[,VFIV%KJ5J6#&"[A65"1T.U@1FKM% '+?\*K\%?]"AH/\ X+(/_B:L
MV?P]\*Z<S-:>&='M6889H;")"1[X6N@HH R?^$3T/_H#:?\ ^ L?^%'_  B>
MA_\ 0&T__P !8_\ "M:B@#)_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/
M_"M:B@#)_P"$3T/_ * VG_\ @+'_ (4?\(GH?_0&T_\ \!8_\*UJ* ,G_A$]
M#_Z VG_^ L?^%'_")Z'_ - ;3_\ P%C_ ,*UJ* ,G_A$]#_Z VG_ /@+'_A1
M_P (GH?_ $!M/_\  6/_  K6HH R?^$3T/\ Z VG_P#@+'_A1_PB>A_] ;3_
M /P%C_PK6HH R?\ A$]#_P"@-I__ ("Q_P"%'_")Z'_T!M/_ / 6/_"M:B@#
M)_X1/0_^@-I__@+'_A1_PB>A_P#0&T__ ,!8_P#"M:B@#)_X1/0_^@-I_P#X
M"Q_X4?\ ")Z'_P! ;3__  %C_P *UJ* ,G_A$]#_ .@-I_\ X"Q_X4?\(GH?
M_0&T_P#\!8_\*UJ* ,G_ (1/0_\ H#:?_P" L?\ A1_PB>A_] ;3_P#P%C_P
MK6HH R?^$3T/_H#:?_X"Q_X4?\(GH?\ T!M/_P# 6/\ PK6HH R?^$3T/_H#
M:?\ ^ L?^%'_  B>A_\ 0&T__P !8_\ "M:B@#)_X1/0_P#H#:?_ . L?^%'
M_")Z'_T!M/\ _ 6/_"M:B@#)_P"$3T/_ * VG_\ @+'_ (4?\(GH?_0&T_\
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MB>A_] ;3_P#P%C_PK6HH R?^$3T/_H#:?_X"Q_X4?\(GH?\ T!M/_P# 6/\
MPK6HH R?^$3T/_H#:?\ ^ L?^%'_  B>A_\ 0&T__P !8_\ "M:B@#)_X1/0
M_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"M:B@#)_P"$3T/_ * VG_\ @+'_
M (4?\(GH?_0&T_\ \!8_\*UJ* ,G_A$]#_Z VG_^ L?^%'_")Z'_ - ;3_\
MP%C_ ,*UJ* ,G_A$]#_Z VG_ /@+'_A1_P (GH?_ $!M/_\  6/_  K6HH R
M?^$3T/\ Z VG_P#@+'_A1_PB>A_] ;3_ /P%C_PK6HH R?\ A$]#_P"@-I__
M ("Q_P"%'_")Z'_T!M/_ / 6/_"M:B@#)_X1/0_^@-I__@+'_A1_PB>A_P#0
M&T__ ,!8_P#"M:B@#)_X1/0_^@-I_P#X"Q_X4?\ ")Z'_P! ;3__  %C_P *
MUJ* ,G_A$]#_ .@-I_\ X"Q_X4?\(GH?_0&T_P#\!8_\*UJ* ,G_ (1/0_\
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M/_\  6/_  K6HH R?^$3T/\ Z VG_P#@+'_A1_PB>A_] ;3_ /P%C_PK6HH
MR?\ A$]#_P"@-I__ ("Q_P"%'_")Z'_T!M/_ / 6/_"M:B@#)_X1/0_^@-I_
M_@+'_A1_PB>A_P#0&T__ ,!8_P#"M:B@#)_X1/0_^@-I_P#X"Q_X4?\ ")Z'
M_P! ;3__  %C_P *UJ* ,G_A$]#_ .@-I_\ X"Q_X4?\(GH?_0&T_P#\!8_\
M*UJ* ,G_ (1/0_\ H#:?_P" L?\ A1_PB>A_] ;3_P#P%C_PK6HH R?^$3T/
M_H#:?_X"Q_X4?\(GH?\ T!M/_P# 6/\ PK6HH R?^$3T/_H#:?\ ^ L?^%'_
M  B>A_\ 0&T__P !8_\ "M:B@#)_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\
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M .@-I_\ X"Q_X4?\(GH?_0&T_P#\!8_\*UJ* ,G_ (1/0_\ H#:?_P" L?\
MA1_PB>A_] ;3_P#P%C_PK6HH R?^$3T/_H#:?_X"Q_X4?\(GH?\ T!M/_P#
M6/\ PK6HH R?^$3T/_H#:?\ ^ L?^%'_  B>A_\ 0&T__P !8_\ "M:B@#)_
MX1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"M:B@#)_P"$3T/_ * VG_\
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M\1)N9BN1N(  ![[_ ,$7?"UQI/[-/B36)UV)J_B28P<?>CB@A3=_WWY@_P"
MU^@-<'\"_A#I/P%^$?ACP%HK&6QT6T6 W#+M:XE)+2S,.Q>1G<CMNQ7>4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X=^SC^SC<_ CQ9\7=9GUV+6%\=>*;GQ
M%'#';&(V:RR._E$ECO(WXW#'3I7N-%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0DE(IF0>:BD\D*^Y1GTH [VBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#@J=^V%H_@GPC=W,/PD\+*9)M25&1?)ROVBZ*L.))#B*($= &P 7Q]H?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[1/[5SGQ=-JC?"WPSJ3Z=;:9I)7SGMHY")I4#,%$LS+]\_=4H.=F#]>>!_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTWP]XYT:XMQ%>*C3VZOOC#D*2NY6&X8/4"NB_P"&>_A9_P!$T\'_ /@AM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>prax-20221231_g3.jpg
<TEXT>
begin 644 prax-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3,!O$# 2(  A$! Q$!_\0
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MWC[2/A9X#U_Q?K\_V;1]%LI;VY?OM12=JCNS'"@=R0.] '1T5^0WPYT'X_\
M_!4CQ1XA\47?CV\^&OPNL;I[6TM;%I&A5OE;R$BC>/SW5"I>61NK@*,':L?Q
M2^'?[0?_  3#U71O&OA[XA7GQ!^&SW*6]Y:7ID6V#$\13VS2.(]RC"S1MD$8
M.W@, ?K[17'?!WXI:/\ &SX7^&O'.@L3I>N6:74:,06B8\21-C^)'#(<=U-=
MC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\
M?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT
M >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_
MPSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+
M'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/
M_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#
M._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>
MO?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__
M ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T
M5X-_PSOXU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOX
MU_Z+'KW_ 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_
M 'S/_P#)-'_#._C7_HL>O?\ ?,__ ,DT >\T5X-_PSOXU_Z+'KW_ 'S/_P#)
M-<S\2?A7XU^'O@G4_$/_  M?7M0^Q!#]GWSQ[]TBI][SSC[V>G:@#Z?HKYO\
M(_!?QKXJ\*Z1K/\ PMS7K7^T+2*Z\G,[^7O4-MW?:!G&>N!6O_PSOXU_Z+'K
MW_?,_P#\DT >\T5X-_PSOXU_Z+'KW_?,_P#\DT?\,[^-?^BQZ]_WS/\ _)-
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M_P!\S_\ R31_PSOXU_Z+'KW_ 'S/_P#)- 'O-%>#?\,[^-?^BQZ]_P!\S_\
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MF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2:
M/>:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X
M9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#1
M8]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_
M /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG
M?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%C
MU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\
M^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*
M\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:
M_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_
M[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DF
MC_AG?QK_ -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_
M -%CU[_OF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_O
MF?\ ^2: />:*\&_X9W\:_P#18]>_[YG_ /DFC_AG?QK_ -%CU[_OF?\ ^2:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS/\
M:2_Y(GXF_P!R'_T?'7IE17-K#>0-#<0QSPM]Z.10RGG/(- '+?"/_DEGA'_L
M%6W_ **6NNID,,=O"D42+%$@"JB !5 Z #L*?0 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>#>#_\ D[_QQ_V!X_\ T"SK
MWFO!O!__ "=_XX_[ \?_ *!9T >\T444 %%%% !1110 4444 %%%% !1110
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MOO\ Y/H_X95^-_\ T=K\0/\ P(OO_D^@#]5:*_*K_AE7XW_]':_$#_P(OO\
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M5>'+U-1T/5[5+NTN4_B1AG!'9@<@J>000>163\:_B1_PI[X1^+_'']G?VO\
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MS8S]W\ZZ3X(_\D7\ _\ 8OZ?_P"DT==K0 4444 %%%% !1110 4444 %%%%
M!7@W@_\ Y._\<?\ 8'C_ /0+.O>:\&\'_P#)W_CC_L#Q_P#H%G0![S1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7R%\-?^4E7Q7_[%F'_ -%Z97U[
M7R%\-?\ E)5\5_\ L68?_1>F5Z&$^&M_A?YHXL3O3_Q+\F?7M%%%>>=H4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P! #QA_X!VO_P DT?\ #T#X6?\ 0 \8?^ =K_\ )- 'U_17R!_P] ^%G_0
M\8?^ =K_ /)-'_#T#X6?] #QA_X!VO\ \DT ?7]>?_M"?\D"^)?_ &+.I_\
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MO+GR3[SBND_X*S?#R_T_P7X$^-WAM/+\1_#S68)7F4=+>25"C,1U"3I$ /\
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M .6%>(?\$[?VF?AK^S=\7OC5<_$;Q)_PCL.K74<=DWV&YNO-:.XN"XQ!&^W
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M%%/V>_AW^SK\./#'B'X@_P!GZYI.A6MG>VO]BZC+Y4R1@,N]+<JV".JDCWH
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M_!5GX->,+?6/A_\ 'WP+;27FI^!9$-]'#'YCP11S">"XVCEHTDWA_0.#T#$
M#OBI_P $7_AYX@O);_X?>+]8\#71;S([2Z0:A:Q$<@)EDE7ZF1R.OM7CGBSP
M[^V!_P $[;2+Q9_PF0^(_P .;.5$NH9[N:^M88V8*JRQ3 26X)( :)MH)&6Y
MP?J7X0_\%8?@7X^\+VUUXHUN;P%KZQK]JTS4;2:9 _\ $8IHD973/3.UL=5%
M>1?MO?\ !1WX;_$SX/ZY\,/A3)?>//$OBI1I8EMM/FCAA5G4,%$B*\LC?=0(
MI&3G/ # 'M/QZ^+%E^TY_P $U?&GCGPS%-;0ZKX?DNI;4D/);-!,#<Q,<<A?
M*D&[ RHSQFJ/_!(K5+6__8STF"W93+9:Q?V]P%.2)#() #[[)$_ BO1_V,_V
M>+CX2?LA^'OASXOMEDOKVRNFUFSW A#=.[/ 2"1E4D"$@X)4D=:^$/@S\3/$
M/_!*?X\>)OA]\0=+U#4?A1XBNFNM.UBWC#$A?E2ZC X9BFQ)HL[@54CH X!^
MO59NI^)M(T6^L;+4-5L;"\OBRVEO=7"1R7!7&X1JQ!?&Y<XSC(]:^>KK_@I%
M^SC:Z#_:W_"S;&:(H76WBM+DW+<$[?*\O<"<8Y YQ7PY'<Z__P %6/VO=#UB
MVT*YTWX,>"Y(Q*U^N-\ D$DB.02IGN"H78I.U%!).W) /UZK\ZO^"VG_ "0+
MP+_V,P_])9Z_115"J !@#@ 5^=?_  6T_P"2!>!?^QF'_I+/0!]P?!'_ )(O
MX!_[%_3_ /TFCKM:XKX(_P#)%_ /_8OZ?_Z31UVM !1110 4444 %%%% !11
M10 4444 %>#>#_\ D[_QQ_V!X_\ T"SKWFO!O!__ "=_XX_[ \?_ *!9T >\
MT444 %%%% !112,P12S$*H&23T% "T5P7P?^.'@_X[:/JVJ>#=2;4K/2]2FT
MFZ9X7B*7$84L & )'S###@\X/%=[0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R%\-?^4E7Q
M7_[%F'_T7IE?7M?(7PU_Y25?%?\ [%F'_P!%Z97H83X:W^%_FCBQ.]/_ !+\
MF?7M%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD(R?,MG&]I 3U"G)&03UKP/]GW64_:Z_X*=7OQ8\)V5Q_P *Y\%:>UI;:A)
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MCM[80Q!CQ^\F90=GW@C'(^4U^N] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7R%\-?^4E7Q7_[%F'_T7IE?
M7M?(7PU_Y25?%?\ [%F'_P!%Z97H83X:W^%_FCBQ.]/_ !+\F?7M%%%>>=H4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?)@[F8GY0RDY+ ']'-#_ .".OP#TNP2"\?Q3K%P.6NKK5%1B?I'&J@?AGW-
M'DWPO_X+;Z-?7T-K\0?AW=:3 S8;4M!O1<A0>A,$BH<#N0Y/H.Q_1'X7?%?P
MG\:/!MGXI\%ZY:Z_H=UPEQ;$Y1AC*.APR.,C*L 1D<5\ ?&K_@BUX/O]"O;S
MX7^*=6TG7$5I(=-UV1+FTF(Z1B145X\_WB7^G>OD3_@G[\=O$W[*W[5%GX0U
MT7&FZ-KFIKX>\0:1=':+>X,ABCF(Z*\4I&6_N%QW! !^\]%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ."AUK#??\%&OV9[:YACN+::ZT>.6&50R.IU<@JP/!!!P0:_42OS _X*!_\
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M2*5F:-6PP5XG&"N#C(!['_@A_9Q1_#GXH7:KB>75;.)V]52%RH_-V_.O7/\
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MQB^.</C?PGI/BJ*QN(7M4U6U2<0L]Q<ABNX<9VKGZ"OT0_X8I^ G_1(?!_\
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M&'A?5-6O_#]G<75[=:9$\LTC1 L[,1DDGO0!)_P]@_9M_P"AOU#_ ,$EW_\
M&Z^@+/XT:%XB^!]Q\3_#TK:CH!T>XUBU>6-H3+''&[\JP!7.P]:Y3_ABGX"?
M]$A\'_\ @IB_PKN=6^&.D+\)=5\!:#86NB:-<:3<:7;6=K&(X($EC9,*HZ ;
MCTH _/7_ ((Q^$5\33?%?XK:S_Q,/$NH:@FGB^E&9!OS<7)S_P!-'>(G_<%?
MIY7Y@_\ !&+QC%X9G^*OPJUB06/B6RU!=073Y>';9FWN<>Z,D0/^\/>OT^H
M^?\ ]O3X7Z?\5OV2_B1IU];I+/INE3ZW8R,H+17-K&TR%#V+!6C)_NR,.AKR
M+_@D#X_N_&7[(Z:7>2^8WAG6[K2H-QRWDLL=PN?8-<.H] H':O7?V]OB9IWP
MM_9)^)%_?7:VL^I:3/HMBI/SRW%U&T**@[D!F?V",>U>/_\ !'WP!>>#OV2C
MJM[#Y3>)=<NM4M]W#&!4BMU)'H6@D(]0P/>@#[@K\M_^"Q.LW_C/XF?!7X66
MUSY-KJ4[74B*"=TTTR6T3D=]H\W'^^U?J17Y<_\ !8;1[SP7\3?@E\4X8&GL
M]-N6M92G!$D,T=S$N?\ :'FX_P!PT ?IGX9\-Z=X.\-Z7H.CVJ66DZ7:Q65I
M;1C"Q0QH$11]% %:77@\BJ.@:[8>*-"T[6=*NH[W3-0MH[NUN8CE)8I%#(X/
MH5(/XU?H \I^"O[+GPS_ &>;[6[SP#X;70KO6GWW\JW<\OG89F5=KN555+$
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M_@K7X\^(7PY_9\TG5? _B*\T"QNM5_LS6?L 599()87*?O<;XP&CVDH5)\P
MYKXR_P""7_[%/B#XE_%#0OBIXGTN:P\">'[A;^PDND*G5+Q#F+R@>3'&X#E\
M;24"C/S;0#]K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBOE3]K_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P L:/\ A$_VY_\ HB_A7_P:6O\ \L:_56BC^U,;_P _6'^JF2?] L3\JO\
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M1G*D#;YDLKG'I&E>M?MT_LG0_M;?!MM M+BWT[Q5I<_V_1KZY4^6LNTJ\3D
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M** "BBB@ HHHH **** "O!O!_P#R=_XX_P"P/'_Z!9U[S7@W@_\ Y._\<?\
M8'C_ /0+.@#WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBOG7]O;]I&?]F']G;6/$FF-&/$NH2KI.C^9R$N958^
M;COY:)(X!X)50>M '3?'[XR? WP58KI/Q;U_PJD999DTG6ECNIMPY606^&<8
MX(8+QQS6%X)_;\_9\^(.K)INC_%'1Q>2.8T345FL [>BM<)&I)[8//;-?C#\
M!?V1?C%^VQK>LZ_HVR[A^TG^T?%'B2\=87N& 8J7VO)(^""=JM@$9QD9]/\
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MX$MII]?\&[4U!;2+?.EO'+YT%RH[B&0ON&#Q)GHIKI/AA_P6"^#>N_#^UO\
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MR6I@W*52=X---)._JO-/8VC2<=V?H1\*?C1;^+EBTS5F2UUG&$?HES]/1O\
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M_P"S-\#[/]G/X&^%/A_9W'VTZ3;'[3=XP)[F1VEF<#LID=MH/(7:.U>H444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR[J_[,?P'>W\3Q_9_%OB*[_M/4+,,K?8UV!(H"PX+!06;GAG(YQD_!$7Q?\
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MD:1W$DCPQ7:QL6B;S8P6BF0D[9 #D8!Q@$?/B_M*?MU?LSQB'Q[\._\ A/\
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MQ_\ ^@YH/_?"?_&J]B\)1ZQ#X;T]-?EAGUE8\74EN $9\]1@#CIVH UZ***
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M>K$\7_\ !+G]G+Q3HL]E;^!F\/W3HPBU#2M2N5FA8C[P#R,C8]&4B@#\V_\
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MOXP\2_##XUZ)<6FM>'].2]@U'4K%K2]G0RB/$@P$E'(Q(H&<<ELYKVW]B?\
M:(U;]J+X*GQYJ^F6FC37.JW5M#8V;,ZPPQL @+-RS8ZM@ D\ #BO>]HW!L#<
M!@'O_GB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY"^&O\
MRDJ^*_\ V+,/_HO3*^O:^0OAK_RDJ^*__8LP_P#HO3*]#"?#6_PO\T<6)WI_
MXE^3/KVBBBO/.T**** .?\:>"=,\=:4;+48OF7)AN$_UD3>JG^8Z&OE;QSX!
MU/P%JAMKY-\#D^1=(/DE'MZ'U';]:^R:SM>\/V'B;2Y=/U*W6YMI!RK=0>S
M]B/45X&9Y33Q\>>.DUU[^3,:E-3]3Y-^'_Q&U+X?ZEYMJWGV4A'GV;GY)!ZC
MT;W_ )BOJCPEXPTWQII*7^FS>8G22)N'B;^ZP[']#VKYG^)GPIO_  !=&9-U
MYH\C8BN@.5]%?T/OT/Z#G?"OBW4O!NK)?Z9/Y4@X>-N4D7^ZP[C_ "*^2P68
M8C*:KP^)3Y>W;S7D<\9NF^61]JT5R7P]^)&F_$#3_,MS]GOXQ^_LW;+)[C^\
MOO\ GBNMK]&I5H5X*I3=TSM335T%%%%;#"BBB@ HHHH **** "BBB@ HHHH
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MIR"/6@!U%%4=;US3O#6D7FJZOJ%KI6EV<33W-]?3+#!!&HRSN[$*J@=23@4
M7J*Q_"?C+0/'NAPZSX9US3?$6CS,RQ:AI-W'=6[E258+)&2I(((.#P16Q0 4
M444 %%8'BSX@>%_ 2V#>)O$FD>'%OYQ:VC:M?16HN)CTCC\QAO<_W1DUOT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4L=^/6)3VH _*;X1?L__ !$^/.I7%EX!\(ZEXEEMAF>2UC"PPYZ!Y7(1"<'
M9@3@XS7HOC[_ ()]_M!_#+P]<ZYK_P ,]0CTRV0R33:?=6U^8D'5F2WED8*!
MR21@ $]J_5O_ ()/^(/!^H_L@>'=-\.S6JZS87-T->M8RHN%NFG<K)*.I#1>
M5M;IM4+G*D#Z[UK6-/\ #VDW>IZK>V^G:;:QM+<75W(L<42 9+,S'  ]30!^
M+O\ P2'^#VL:_P#M!V'Q!L;W2YM(T&*ZM]1L_M8%[ 9K>1(G\DC)1F.-PR.#
MW&*_:^OPW_8J^(%K;?\ !3C[5X"W6_A+Q%KNL6\%K OEQR:;()Y8EV8&U5V1
M.%QQL [5^Y% !1110 4444 %%%% !1110!_,U\*_C)XD^ /Q<@\<>$I;>'7M
M.DN5@>ZA$T8$B/$^5/7Y7:O;?B3_ ,%./C?\5O >N>$-?O\ 19-&UFU>SNU@
MTM8W,;==K \'WK]>I/V!_P!GN:1G?X4: SL2Q)C?DG_@5-_X8#_9Y_Z)/X?_
M ._3_P#Q5 'X>?LX_M:>/_V5[G7KCP'/I]O+K20I=M?6:W&5B+E N3\O^L;/
MKQZ5[?\ \/>/VAO^@EX?_P#!.G^-?J+K7[$?[,OANS%WJ_PY\*:7:EM@GO7\
ME-QZ#<S@9X/Y5%X?_8M_9>\769N]#^'_ (0UJU&/W^GR^>G(R/F1R.1S0 O_
M  3[^.WBK]HO]G6S\8^,IK6?6I=2NK9GLX!#'LC8!?E'?FOI.N7^''PP\*_"
M+PRGA[P;H=KX>T5)7F6RLP1&'8Y9N2>3744 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\A?#7_E)5\5_^Q9A_P#1>F5]>U\A?#7_ )25?%?_
M +%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[1117GG:%%%% !1110 4444 %>2
M?%?X)P^)/.U;0T2WU7[TMOPJ7'N/1_?H>_K7K=%<F*PM+&4W2K*Z_+T)E%25
MF?"UU:S6-Q)!<1/!/$Q1XY%*LK#J".QKVGX3_')K/R='\23%[?A(-0<Y,?HL
MA[C_ &NW?CD>@?$_X2V7CRW:ZM]EGK4:X2XQ\LN.BOZCWZCWZ5\OZUHM]X=U
M*:PU"W>UNHCAHW'Z@]P?45^=5J.+R*O[2F[Q?7H_)_UZ'$U*D[H^WD=9$5T8
M,C#(93D$>M.KYA^%7QFN?![1Z;JA>ZT4G"GJ]M[KZKZK^7H?I;3]0MM4LX;N
MSG2YMIEW1RQG*L*^[R_,:.84^:&DENNW_ .N$U-:%BBBBO5- HHHH **** "
MBBB@""^O(].L;B[FSY4$;2OM&3M4$G'X"OQ__8U^$MI_P4B_:&^(_P 4OB])
M-JFDZ2]N(=!AN'BB;SC+Y$&Y2&6&)(C\JD%F8$D_.&_826-9HWCD4,C@JRGH
M0>HK\<UT/XN?\$G_ (W^*->T;PI-XQ^$>M.%>X7>();=79H%DF4-]GN(][+E
MU(8,^ <Y !M_!K]A/P-^T)\&/V@DL='_ +/\:>'_ !SK%EX;OK21U\I(4C:&
MT9,[6C8DKR"PW9!]?K/_ ()CZ?\ %WPK\#;KPC\5_#VIZ,=%N430I=4VB1[)
MT_U. Q8")E;&X#"R*HX7 ^:/^"??[?'PG^'<?Q'T_P <:I<^%+OQ5XRO?$-I
M)<6KS6T<5PL86-Y(P2K JP)*A>ASZ?J1H/B#3/%6BV>KZ+J%KJVE7D8FMKZR
MF6:&9#T9'4D,/<&@#0K\FO\ @JA^U)JWQ0U+6_@W\/O-O/#WA6+^T?&5_:M^
M[,B2(JP,W39'(\88<YE95P#'S]:_\%"/VMI/V<?AK!H7A9FN_B=XLS8Z':6Z
M^9+;AB$:YV#J06"H/XG(X(5A7S[XH_9+C_9?_P""9OQ3?60MU\0O$=G:WVOW
MS-O=7-W"4M@_<1[FR<G<[.<X(P >Y?\ !)__ ),E\(?]?NH_^E<M?8%?'_\
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MXFF6R7,FFWVH9\W5+ZX#)+.-W+H$DER_0NXP25;'Z[4 %%%% !1110 4444
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MK6RE"".W)9%*[=K?*ORC/%?15%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5X-X/_ .3O_''_ &!X_P#T"SKWFO!O!_\
MR=_XX_[ \?\ Z!9T >\T444 %%%% !1110 45S/@+XE^%_BAIM]?^%-:M=<L
M[&]DTZYFM22L5S&%+Q'('S#<N?K734 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5G:WXCTGPS;)<:QJEGI5N[^6LU]<)"C-@G:"Q )P"<>QK1
MKXW_ ."HG[/_ (]_:*^"/AK0/A[H/_"0:M9^(8[Z>W^V6]MLA%M<(7W32(I^
M:1!@'//3K0![S'J/P>@O/$=W!J7@^UN_$D2P:Q<6UY;127ZJKJOG,K N0)7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7@W@_\ Y._\<?\ 8'C_ /0+.O>:\&\'_P#)W_CC_L#Q_P#H
M%G0![S1110 4444 4]9UBS\/Z/?:IJ,ZVNGV,$ES<3R?=CC12SL?8 $_A7Y-
MZ7\;/VC?^"DOQ8U_2?A?XEN/AC\-=(?Y[NUG>U:*)B1'YTL7[R6:0*Q\M2$
M!'&-Q_3KXW^$;SX@?!;Q_P"%].(74-;\/ZAIMLQ;:!+-;21ISVY85^97_!(G
M]HCP=\(_^$V^&/CG4+?PCKM]J:W=I-JY%LDLBIY4ML[O@)(I1<*Q&2S <C!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,&&3]Y!Q7QKJ7A[]KS]D&%K?=X_\*Z+9Y >PN);O24 XSF,O .!WYQ7[^T4
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MNC+< #EI<C]XS<DLV22230!R'[./[6OPW_:FT*:_\#ZN[WMJH:]T74$$-]:
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M_KE:_P#I9!0!]A?L=_\ )J'P>_[%+2__ $ECKV"O'_V._P#DU#X/?]BEI?\
MZ2QU[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]@W6=?\ V5_V\/&'[.4NL2ZMX4OI;D6L<_\ #+%;FZAG4#A': $.!P3C^Z*
M/U@HHHH \Y^*G[17PU^"%YI]KX[\8Z;X8N;^-I;6*^<AI54@,P !X!(KA?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$ @'1_M'?M%^$OV8_AK?>+_%ET%5 8['3HV N-0N,$K#$/4]VZ*,D\"O@/\
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MB@ HHHH ^"O^"SW_ ":AHG_8VV?_ *2W=>A:?_R#[;_KDO\ (5Y[_P %GO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'0-7L-<T]F*"[TVY2XB+#J-Z$C(],UJ4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\A?#7_E)5\5_P#L68?_ $7IE?7M?(7PU_Y25?%?_L68
M?_1>F5Z&$^&M_A?YHXL3O3_Q+\F?7M%%%>>=H4444 %%%% !1110 4444 %%
M%% !1110 4444 ?!7_!9[_DU#1/^QML__26[KT+3_P#D'VW_ %R7^0KSW_@L
M]_R:AHG_ &-MG_Z2W=>A:?\ \@^V_P"N2_R% %BBBB@ HHHH **** "BBB@
MJ"\LXKZ$QRKD=CW'N*GHJ)PC4BX35TQ;[G$ZEI<NFR8;YHS]V0=#_P#7IFGZ
MA+I\V^,Y'\2'H:[::%+B-HY%#HW4&N3U?17T]C(F7@/\7=?8U^=YCE-7+Y_6
ML(WRK[X_\#^F<<Z;@^:)TUAJ$6H0[XSS_$IZBK-<%:W4MG,)(FVL/U]C77:7
MJ\>I1X^Y,!\R?U%?0Y5G$,8E2JZ5/P?IY^1M3J*6CW+]%%%?3&X4444 %%%%
M !7A'[<W_)JOCS_KE:_^ED%>[UX1^W-_R:KX\_ZY6O\ Z604 ?87['?_ ":A
M\'O^Q2TO_P!)8Z]@KQ_]CO\ Y-0^#W_8I:7_ .DL=>P4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5X-X/_Y._P#''_8'C_\ 0+.O>:\&\'_\G?\ CC_L#Q_^@6= 'O-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /&_^'L7B+_HVSQI_P!_I/\ Y%H_X>Q>(O\ HVSQI_W^D_\ D6O9** /&_\
MA[%XB_Z-L\:?]_I/_D6C_A[%XB_Z-L\:?]_I/_D6O9** /&_^'L7B+_HVSQI
M_P!_I/\ Y%H_X>Q>(O\ HVSQI_W^D_\ D6O9** /&_\ A[%XB_Z-L\:?]_I/
M_D6C_A[%XB_Z-L\:?]_I/_D6O9** /&_^'L7B+_HVSQI_P!_I/\ Y%H_X>Q>
M(O\ HVSQI_W^D_\ D6O9** /&_\ A[%XB_Z-L\:?]_I/_D6C_A[%XB_Z-L\:
M?]_I/_D6O9** /$-6_X*]:IH.GS7^I_L\^+-.L8<&2YN[MHHDR0!N9K8 9)
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MP5\0Q(\%O.D;V\-Q,!G[/)#(2T4I7E3N*OT&TE0WWK0 4444 %%%% !1110
M4444 %%%% !1110 5SOC;X=>%/B7IL.G>+_#&C>*M/AF%Q%::WI\5Y%'(%*A
MU216 ;#,,@9PQ'>NBKYU_;V_:1G_ &8?V=M8\2:8T8\2ZA*NDZ/YG(2YE5CY
MN._EHDC@'@E5!ZT 9'Q4T7]CWX(R+#XX\*_";P]=L PLKCP_8O=%2,AO)2(R
M8]]N*XKP3\2_V#?B#JR:;H^F?"<7DCF-$U'PK;V =O16N+>-23VP>>V:_+;X
M"_LB_&+]MC6]9U_1MEW#]I/]H^*/$EXZPO<, Q4OM>21\$$[5; (SC(SZ?\
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M44 %%%% !1110 5\A?#7_E)5\5_^Q9A_]%Z97U[7R%\-?^4E7Q7_ .Q9A_\
M1>F5Z&$^&M_A?YHXL3O3_P 2_)GU[1117GG:%%%% !1110 4444 %%%% !11
M10 4444 %%%% 'P5_P %GO\ DU#1/^QML_\ TENZ]"T__D'VW_7)?Y"O/?\
M@L]_R:AHG_8VV?\ Z2W=>A:?_P @^V_ZY+_(4 6**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!O!_\ R=_XX_[
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M;QDKGMYL<O3N#7W30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7R%\-?^4E7Q7_[%F'_T7IE?7M?(7PU_Y25?%?\ [%F'_P!%Z97H83X:W^%_
MFCBQ.]/_ !+\F?7M%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4444
M?!7_  6>_P"34-$_[&VS_P#26[KT+3_^0?;?]<E_D*\]_P""SW_)J&B?]C;9
M_P#I+=UZ%I__ "#[;_KDO\A0!8HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** *U_I\6H0[)!S_"PZBN/U#3I=.FV2#*G[KCH:[FHKFVCNX6BE7<AK
MP,SRFGCX\\=)KKW\F8U*:GZG':;JDNFRY7YHS]Y#T/\ ]>NOL[V*^A$D39'<
M=Q[&N3U31Y--?/WX2?E?^AJO9WTMC,)(FP>X['V-?)X',:^4U?JV)3Y>W;S7
MD<\9NF^61W=>$?MS?\FJ^//^N5K_ .ED%>UZ;JD6I193Y9!]Y#U'_P!:O%/V
MYO\ DU7QY_URM?\ TL@K]&I585X*I3=TSM335T?87['?_)J'P>_[%+2__26.
MO8*\?_8[_P"34/@]_P!BEI?_ *2QU[!6HPHHHH **** "BBB@ HHHH ****
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ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUK]7OV</V<?"'[+WPW@\'^$(9C;^:;F\OKM@UQ>SL &ED( &<*      /4D
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MK?P-HSQ7]XBI>:Q?RF>]N54Y 9R %7/.U JY .,U[-0 4444 %%%% !1110
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M5Y[_ ,%GO^34-$_[&VS_ /26[KT+3_\ D'VW_7)?Y"@"Q1110 4444 %%%%
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MX'F=<)J:T)Z***]0T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/X5'J23U))YKZ7KS?]GOX"^&OV:_A?IO@;PJ;N33;1GF>XOI?,FGF<Y>1B
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M )!]M_UR7^0JQ5?3_P#D'VW_ %R7^0JQ0 4444 %%%% !1110 4444 %%%%
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M,+6]W9SR*4FC/56^7H: /:?^"6_[+GAK]HWXQ:Q?>,;==2\.^%;6*[?29/\
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M>3U7]1W[$]M7PSI^H7.DWL-W9SO;7,+;HY8S@J:^E_A7\9;;QDD>FZF4M=:
MPO9+CW7T;U7\O0>KE.=1Q-J.(=I]'T?_  32G5YM);GI]%%%?6G0%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\%?\
M%GO^34-$_P"QML__ $ENZ^]:^"O^"SW_ ":AHG_8VV?_ *2W= 'H6G_\@^V_
MZY+_ "%6*KZ?_P @^V_ZY+_(58H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /"/VYO^35?'G_7*U_\ 2R"OL+]CO_DU#X/?]BEI
M?_I+'7Q[^W-_R:KX\_ZY6O\ Z605]A?L=_\ )J'P>_[%+2__ $ECH ]@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&VS_ /26[H ]"T__ )!]M_UR7^0JQ5?3_P#D'VW_ %R7^0JQ0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >$?MS?\FJ^//^N5K_
M .ED%?87['?_ ":A\'O^Q2TO_P!)8Z^/?VYO^35?'G_7*U_]+(*^POV._P#D
MU#X/?]BEI?\ Z2QT >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1A@APQVJ0';[H&>,YP, &;^UQ^UEX7_9'^'*^(M=A?5-4O9#;Z3HL$@26]E
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MX3^!Y=?L/#-_XMN$GCA&FZ;N\U@QP6X5C@?2N[HJXM1DG)71,DVFD[,^0O\
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M/&O_ $1S7O\ OJ?_ .1J/^&B/&O_ $1S7O\ OJ?_ .1J]YHH \&_X:(\:_\
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M8?$4XU:5;FB]4U:S/RNKXCXRA4=*KA%&2T:;=U^!Z%_PW G_ $)R_P#@V_\
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M]S]'X5XBJ<14JM2I34.1I:.^Z.\_X:(\:_\ 1'->_P"^I_\ Y&H_X:(\:_\
M1'->_P"^I_\ Y&KWFBO%/N#P;_AHCQK_ -$<U[_OJ?\ ^1J/^&B/&O\ T1S7
MO^^I_P#Y&KWFB@#P;_AHCQK_ -$<U[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y
M&KWFB@#P;_AHCQK_ -$<U[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P
M;_AHCQK_ -$<U[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P;_AHCQK_
M -$<U[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P;_AHCQK_ -$<U[_O
MJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P;_AHCQK_ -$<U[_OJ?\ ^1J/
M^&B/&O\ T1S7O^^I_P#Y&KWFB@#YWC_:G\0S:Q+I,?PNU.3584\R2Q6YD,Z+
MQ\Q3[/N ^9>2.X]:O_\ #1'C7_HCFO?]]3__ "-1X;_Y._\ %7_8'3_T"VKW
MF@#P;_AHCQK_ -$<U[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P;_AH
MCQK_ -$<U[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P;_AHCQK_ -$<
MU[_OJ?\ ^1J/^&B/&O\ T1S7O^^I_P#Y&KWFB@#P;_AHCQK_ -$<U[_OJ?\
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M'_"P-9_Z%&^_-_\ XW7W)10!\-_\+ UG_H4;[\W_ /C='_"P-9_Z%&^_-_\
MXW7W)10!\-_\+ UG_H4;[\W_ /C='_"P-9_Z%&^_-_\ XW7W)10!^:'[2%]+
M\0/@KXE\/ZS:OX0TR\2$3:U?9,-MMGC<%MP0<E0O+#EA]*]5^"/[5EI\-_@[
MX(\*6FBPZ]:Z)HUII\6J0ZD$2[6*)4$JJ(V #!<X#-UZFNZ_X*:?\F.?$_\
MZXV/_I?;5\]?L^_\D+^'_P#V ;+_ -$I7LY9@(X^<H2E:R/B.*>(:G#U"G6I
MTU/F=M7;I<^@?^&X$_Z$Y?\ P;?_ &FC_AN!/^A.7_P;?_::\]HKZ+_5RG_S
M\?W'YO\ \1-Q/_0-'_P)_P"1Z%_PW G_ $)R_P#@V_\ M-'_  W G_0G+_X-
MO_M->>T4?ZN4_P#GX_N#_B)N)_Z!H_\ @3_R/0O^&X$_Z$Y?_!M_]IH_X;@3
M_H3E_P#!M_\ ::\]HH_U<I_\_']P?\1-Q/\ T#1_\"?^1Z%_PW G_0G+_P"#
M;_[31_PW G_0G+_X-O\ [37GM%'^KE/_ )^/[@_XB;B?^@:/_@3_ ,CT+_AN
M!/\ H3E_\&W_ -IH_P"&X$_Z$Y?_  ;?_::\]HH_U<I_\_']P?\ $3<3_P!
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M>_[ZG_\ D:C_ (:(\:_]$<U[_OJ?_P"1J]YHH \&_P"&B/&O_1'->_[ZG_\
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MF&O?D_\ \:KV+PEKDOB;PWI^J3V$VERW4?F-9W&=\1S]TY Y_"M>B@ HHHH
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MJY^7UK]0J* /A;]C?_@G+>_"+XB3?%?XM>)4\;_$J5GF@\N1YH+65P0\S2R
M-++@D X 7)QDX*_;NL:39>(-)O=,U*UBOM.O87MKFUG4-'+&ZE71@>H()!'O
M5RB@#\O]4_X)R_'7]FOXC:EXD_9G^(-O::/J)VMIFIS!)HTW%ECD62-X9U7L
M[889/'))M>'?^"<?QH_:&^)VE^+?VG?']MJ^F::5V:/ILN]YTW;FA'EI'%;H
MQ W-&"Q''!PP_3:B@"MINFVNCZ=:V%C;QVEE:Q+!!;PJ%2*-0%5% X    'M
M5FBB@ HHHH **** "OD[X=:S>S?\%%OBCILER[6,/AR%XX#]U6\O3N1_WT?S
MKZQKY"^&O_*2KXK_ /8LP_\ HO3*[\+%2C5NOLO\T<F(;3IV_F_1GU[1117
M=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M> ?^NVI?^E]Q7UK7R5_P2K_Y,<\ _P#7;4O_ $ON*^M:_&C^VPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\&\'_P#)W_CC_L#Q_P#H%G7O->#>#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7R_P#\%-/^3'/B?_UQL?\ TOMJ^H*^7_\ @II_
MR8Y\3_\ KC8_^E]M0!\]?L^_\D+^'_\ V ;+_P!$I7?UP'[/O_)"_A__ -@&
MR_\ 1*5W]?L>'_@P]%^1_$^8_P"^UO\ %+\V%%%%=!YX4444 %%%% !1110
M4444 %%%% !363=]:=17GX[ 8?,J$L-BH<T7_5UV?F=^!QV(RZO'$8:7+)?U
M9]UY$!!'!IR2;>#TJ1E#5"RE3S7\\YEE.9<&8Q8S!R;I])?^VS7])[JSV_?<
MNS7+N,,(\'BXI5.L?_;H/^K;.ZWGHJ%7V_2I@<C(K]FX>XEPN?4O=]VJOBC^
MJ[K\NI^09_PYB<CJ^][U)[2_1]G^?0****^P/DCCOC-_R1_QU_V ;[_TG>O8
MO^"5?_)CG@'_ *[:E_Z7W%>._&;_ )(_XZ_[ -]_Z3O7L7_!*O\ Y,<\ _\
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MKT,)\-;_  O\T<6)WI_XE^3/KVBBBO/.T**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^7_P#@II_R8Y\3_P#KC8_^E]M7U!7R_P#\%-/^3'/B?_UQL?\
MTOMJ /GK]GW_ )(7\/\ _L V7_HE*[^N _9]_P"2%_#_ /[ -E_Z)2N_K]CP
M_P#!AZ+\C^)\Q_WVM_BE^;"BBBN@\\**** "BBB@ HHHH **** "BBB@ HHH
MH *&4,,&BBL:U&GB*<J5:*E&6C3V9M1K5,/4C5I2<9+5-;HA92OTH5BM3=:B
M=-O3I7\^\0<+XKA^M_:652?LXN^GQ0_SCY]M'W?[UD/$V&SZC_9V9I>T>FNT
M_P#*7EWU792*P89%+4"L5Z5,K!OK7Z#PQQ?1SF*PV*M&NONEYKS[K[O+X+B7
MA.KE#>)PUY4?QCZ^79_?Y\?\9O\ DC_CK_L WW_I.]>Q?\$J_P#DQSP#_P!=
MM2_]+[BO'?C-_P D?\=?]@&^_P#2=Z]B_P""5?\ R8YX!_Z[:E_Z7W%=G$?\
M2GZ,^^\,_P#=<3_B7Y'UK1117QY^SA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%U;7]2N?$L1N;/2U8@P"UN,M,00JQA]G+D+DKWQ0!1_8N_:<^#?Q1_9#\/\
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MDS65XH$@1F!5N">#7U;29SR.12T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\A?#7_E)5\5_^Q9A_P#1>F5]>U\A?#7_ )25?%?_ +%F'_T7
MIE>AA/AK?X7^:.+$[T_\2_)GU[1117GG:%%%% !1110 4444 %%%% !1110
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M!'_0X^'_ /P:0?\ Q='_  MCP1_T./A__P &D'_Q=>H?\.G_ -FW_H4-0_\
M!W=__'*/^'3_ .S;_P!"AJ'_ (.[O_XY1_K'4_Y]K[P_XAEA_P#H)E_X"O\
M,\O_ .%L>"/^AQ\/_P#@T@_^+H_X6QX(_P"AQ\/_ /@T@_\ BZ]0_P"'3_[-
MO_0H:A_X.[O_ ..4?\.G_P!FW_H4-0_\'=W_ /'*/]8ZG_/M?>'_ !#+#_\
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MC_H<?#__ (-(/_BZ]0_X=/\ [-O_ $*&H?\ @[N__CE'_#I_]FW_ *%#4/\
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M]UKQO]J+]ECPI^UIX)TSPMXOU#6=-T_3]174XI-$FBBE,BQ21@,9(I!MQ*W
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M]F?PK9>/_ .H7USX7ENTLK_3=2<2RV<C@^7(D@4;HR5*D-R"5Y(/R_=GP_\
M^"JW[//C#PW;W^J^*Y_".IM'NN-)U73KEY(6'4"2*-XW&>FULD=5'2OBW_@I
M1_P4,\)?M!>#;3X<?#?[5J&@B]2^U'7+JW>W6X,8/EQ0QOA]NYMS,ZJ<HH Q
MDT ?;7_!+CXOZE\7OV2=$;5[A[S4?#EY-X?DN9&R\B1+&\.3GDB*:-<GD[<^
M]?6]?'W_  2G^%NH?#']D+1I=3A:VNO$U_/KX@D4JRQ2+'%$3_O1P(X]G%?8
M- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(7PU_Y25?%?\
M[%F'_P!%Z97U[7R%\-?^4E7Q7_[%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[1
M117GG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+_\ P4T_Y,<^)_\
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MBBBO/.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^7_^"FG_ "8Y\3_^
MN-C_ .E]M7U!7R__ ,%-/^3'/B?_ -<;'_TOMJ /GK]GW_DA?P__ .P#9?\
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M^%/V7?&MCXWG\6:IXI\76D,L,3B%+6R021E'Q%\[DX8@$R8]J^T:^5/V7_\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?(7PU_Y25?%?_L68?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"VP;BZN6OHX(HX]V ,0))EC@!<GK@'VO5O\ @HE^U7'IK^,[;]G5;/X?[/M
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M]$I7?U^QX?\ @P]%^1_$^8_[[6_Q2_-A11170>>%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <=\9O^2/^.O\ L WW_I.]>Q?\$J_^3'/
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MSVWT]5]NW;T/TE9WD&HVL5S:S)<6\JATEC;*L#W!K[S 9A1S"GS4]&MUU7_
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MKS$4_,(8H/W2$CY]V03MR?TSHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^7_P#@II_R8Y\3_P#KC8_^
ME]M7U!7R_P#\%-/^3'/B?_UQL?\ TOMJ /GK]GW_ )(7\/\ _L V7_HE*[^N
M _9]_P"2%_#_ /[ -E_Z)2N_K]CP_P#!AZ+\C^)\Q_WVM_BE^;"BBBN@\\**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XS?\D?\ '7_8
M!OO_ $G>O8O^"5?_ "8YX!_Z[:E_Z7W%>._&;_DC_CK_ + -]_Z3O7L7_!*O
M_DQSP#_UVU+_ -+[BOA.(_XE/T9_0/AG_NN)_P 2_(^M:***^//V<**** "B
MBB@ KDOB#\.--^(&G^7<KY%]&/W%X@^9/8^J^WY8KK:*RJTH5X.G45TQ-)JS
M/BOQ9X1U+P7JSV&I0&.0<I(O*2K_ 'E/<?R[UT/PS^*U_P" ;H0ONN]'D;,M
MJ3ROJR>A]NA_4?3/BSPAIOC327L-2A\Q.L<B\/$W]Y3V/Z'O7RO\0/ASJ7P_
MU'RKE?/LI"?(O$'R2#T/HWM^6:_.<;E^(RFJL3AF^7OV\GY'%*#IOFB?6.@^
M(+#Q-I<.H:;<+<VL@X9>H/=2.Q'H:T:^-O OC[4_ 6J?:;%_,@<@3VKD[)1[
M^A]#V_2OJGP9XVTSQSI2WNG2_,N!-;O_ *R%O1A_(]#7UF69M3Q\>66DUT[^
M:.BG44_4Z"BBBO?-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!O!
M_P#R=_XX_P"P/'_Z!9U[S7@W@_\ Y._\<?\ 8'C_ /0+.@#WFBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\
M"_\ @HXR:3_P4&\=S2OF*.]TJ=FZ8'V"T8]^V:_?2OQ0_P""Q7P;U?PI^T5#
M\0/LLDGA_P 56,"+>*IV)=P1B)X6/9O+2-AGJ"V/NG !^UV<\CD5^"?QPGCN
M/^"H=\\;!U'Q"L4)'JMS"I'X$$?A7>_#O_@L3\4? _POM/#%YX=T7Q%K%A:+
M:6FOWTDHD*JNU7GC!Q*X&WD%<XYR237C_P"Q7X#\4?M*?MG^%=3N?.U.XCUY
M?%&O:E)'E D4XN)6D(&%\QP(QVW2"@#^A"BBB@ HHHH **** "BBB@ K\&?V
ML?!>H_"/_@H9=:U\1H+ZU\+:IXMAUH:C$' N-*:Y1G\IUY)2+,9"G(*X]*_>
M:OQ._;T^ _[07Q._:2\='3/"/CCQ+X+&I+-I<<4-Q<6*CR44M"O*#G<,J.YH
M _97PAXX\._$#18=7\,ZYI_B#3)E#1W>FW*3QD'I\RD_E[5N5_.#_P ,4_'L
M<CX0^, ?^P3-_A6K_P ,J_M+_P#1.OB!_P" =S0!_1317RE_P3-\%>+_  !^
MRY8Z3XXTG5-&UY=5O)&M=8C=)Q&S#:2'YP>U?5M !1110 4444 ?D;^TM\;O
M#_[<?[66E?#+4/'&D^"_@GX/NGFU+4]6U2&P349HSMF:-I64.Q),4>,[5,DG
M()%?:WQ5_:"^!6F_LZ^,?#'AKXG^ $@A\+7NG:;I=AXBLF.!:/'%#&BRDD_=
M4 <GBO*-9_X(T?!77-8OM1G\3^/4GO)Y+B18]0L@H9V+$#-F>,GUKB_BG_P1
M\^#7@?X8^+_$=CXF\=2WVCZ/>:A!'<7]DT;210/(H<"T!*DJ,X(..XH XS_@
MCU\9/ /PR^&_Q"M?&'CCPWX3N;K5H)((=<U>WLWE00D%D$KJ6 /&17IW_!:R
M%Y_V;?!=S&Q:!?%40.WE3NL[HJ<_@<?6OE+_ ()T_L'^ ?VNO!?B_5_&&K^)
M--N='U"*T@70[FWB1D:/<2XE@D).?0BOT>_X*'?!:[^,7[(GBS1-(MY+S5](
MCBU>PA5=SR-;G+J!W9HO-  Y)(^E '<?L:S1W'[)OP?:-@ZCPIIJ$CU6W0$?
M@01^%5/VW;B.W_9$^+KR,$4^&[Q 3ZM&5 _$D#\:\ _X)/\ [2WA[X@_ '2?
MAO=:E#!XS\*++!]AF<+)=69E9XI8P?O!0XC8#)!0$XW#-7_@K1^TIX?\$_ G
M4?A?8ZC%=>,O%30QO8V[!I+6S259'DDQ]W>8Q& >3N8C[IH K_\ !%>S>']E
MSQ/.Q.)O%]R57/&!9V8S]<Y_(5]_U\Z_\$_?@U?? W]E+P7H&KV_V77+J*35
M=0A((:.6X<R*C#LR1F-&'JAKZ*H **** "N$^-%GX^OO \L7PVO;#3_$_GQE
M)M24&+RL_..5;G&.U=W15QERR4K7L3*/,FCY"_X1O]L?_H:_"'_?J/\ ^1ZX
M_P#9:MO&5G^W1\0H?B!=V=]XN7PR/MMQ8 "%LG3S'M 51Q'L!X'(-?=M?(7P
MU_Y25?%?_L68?_1>F5[%'$.K"K'DBO=>RMU1YM6C[.=-\S?O=7?HSZ]HHHKQ
M#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY?\ ^"FG_)CGQ/\ ^N-C
M_P"E]M7U!7R__P %-/\ DQSXG_\ 7&Q_]+[:@#YZ_9]_Y(7\/_\ L V7_HE*
M[^N _9]_Y(7\/_\ L V7_HE*[^OV/#_P8>B_(_B?,?\ ?:W^*7YL****Z#SP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COC-_P D?\=?
M]@&^_P#2=Z]B_P""5?\ R8YX!_Z[:E_Z7W%>._&;_DC_ (Z_[ -]_P"D[U[%
M_P $J_\ DQSP#_UVU+_TON*^$XC_ (E/T9_0/AG_ +KB?\2_(^M:***^//V<
M**** "BBB@ HHHH *I:QH]EK^G36.H6Z7-K,,/&X_4>A'J*NT5,HJ2<9*Z8'
MRI\4/A'>^!+AKNUWWFBNWRSX^:'/17_HW0^QXKD?#?B;4?">JQ:AIEP8)TX(
MZJZ]U8=P:^U;BWBNX)()XUFAD4J\<BAE8'J"#U%?.GQ8^"<OA_SM7T&-I],Y
M:6U&6>W]QZK^H]^M?G^9Y-/"R^LX/9:V6Z\UY?D<=2FX^]$];^'/Q.T[X@6.
M$(M=3C7,]FQY_P!Y?5?Y=_?M*^&M-U*ZTB^AO+*=[:ZA;<DL9P0:^F?A7\9+
M7QI''I^I%+36U& .B7&.Z^C>J_E[>ME.=1Q5J.(=I]^C_P"":4ZO-H]STRBB
MBOK#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP;P?_P G?^./^P/'_P"@
M6=>\UX-X/_Y._P#''_8'C_\ 0+.@#WFBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBOA?_@KQ\:M=^%O[.^F:'X>O
M9--N?%FI?8+NZ@8K(+1(V>1%8$%=[>6I]5+CO0!]3V_[0WPMNO%"^&X?B1X2
MF\0M)Y2Z7'K=L;DR9QL$8?<6X^[C/M6W\1O /A7XF>#M1\/^--(L=;\.W"9N
M;74%!C '._/5&7J'!!7J"*_GWTG]A[XPZQ\"9_B]:^&<^#X;=[X,URBW3VJ?
M>N%ASN,8 8YZE5+ $8)_1G]E7XL>._VG/^";/C_PUIS2>(?B'IEE>>%X3/<*
MD]U%)"OE.TCD#<(I70,QR3%DG)S0!V=]_P $=_V?[S6#>PGQ396S.7&G6^K*
M8 "00H+Q-)@8Q]_/)Y/&/IOX(?L[_#[]G3PV^B^ ?#EOHEO-M:ZN 3)<W;*#
MAI96)9\9. 3@;C@#-?F1_P $H_VEO&G@_P".,GP+\87E_-I-XEW#9:;J6XRZ
M7?VZEWB!;F-"D4RF/H'"X );=^OU !1110 4444 %%%% !1110 5X[^T!^UO
M\+?V98;,>/?$BZ??WJ&2UTRVA>XNYD!(WB- =JY!&Y]JD@@'(Q7L5?@W^T5X
M:\0?M=?\%(O$W@J'4$MKN\\02:#;3S O'9VUHI1F"\9 6&1]HQEB>><T ??]
MS_P6,^ 4$[QI%XLN%7I+'I485OINF!_,56N/^"RWP'AMY'CT[QE.ZC*Q)ID
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML0VU[Z[8'RH$]R023SM56;HM>E7M[;Z;9SW=W/':VMO&TLT\SA$C11EF9CP
M "23Z5^.OQ_\2:__ ,%&O'7Q.\4:7/<V'P6^%'AW4[ZPF"E5O;J.VEDC?!ZO
M,\:M@CY(4 .&;D ^]?V"OVM-7_:^^'/B'Q)K&@V7A^?3-6_LY(+&5Y%=?)CD
MW$MWRY'X5].5^=7_  1+_P"2!>.O^QF/_I+!7Z*T %%%% !1110 4444 %%%
M% !1110 5\:_\%5_A!9?%+]E^XO9-7TW1M5\-7JZK8OJEW';1W6$=)+97D8#
M>Z,64=6:-5[YK[*KY"_X*7?LY^-_VG/A)X2\+>!;&WO-1@\1QWMS)=W*016\
M MKA#(Q8Y(W2(,*&;GI@' !XY^QO_P %&/@U+^S=X?\ A_\ $[6AX7U?1=*7
M0YX;JRFDM[VU1/*1T>)& )BVA@V#NW8R.:^>/^"9O[4G@#]EWQ_\5-"\8^*%
ML_".H)'-8:L+>:9)Y+:61%VI&A?,D<V[[HXCYP<5H0_\$3?BPT*&;QQX-CEQ
M\RI)=LH/H"8!G\A4\'_!$GXGM,@F\>^$HXL_,T8NF8#V!B&?S% '#_LM^,(O
MC7_P52L/%^@030:;JOB+5-5A#*%=;;[/<,"X[%EQD>K8S7[D5\=_L/\ _!.O
M1/V1]4O_ !/J6NCQ;XTO+?[*EVMKY%O8PD@ND2EF+,Q S(2.!@*,MN^Q* "B
MBB@ HHHH **** "BBB@ K\,/VJK[Q-^QK_P4:U7X@VFG1W!?5F\1:>)@5AO;
M>Y0B=-PZ',DT9/8C.#QG]SZ\[^-7[/OP_P#VAO#<>B>/_#=MKUI"6>VD<M'/
M;,0 6BE0AT)P,X.#@9!H _.[_@K)HM[\3/@1\$?C;::5-I$C0(+RW$GF268O
M((KB%6< ?<>-UW8 W./45YE^T9_P58E^.G[,\_P[C\&R:=XCUBWAMM9U26X5
MK?",KNT" 9R[(.&^Z"1\W!K];O''@CP5XC^'LW@;Q5:Z?<^%[RS%B^G7T@17
MB0*% )((*X4A@<J0""" :^+[#_@DQ^S?9^*1J<OBG7+S35D$@T6;6K80'G)0
MNL0D*8XX<-_M4 ;W_!'/0-2T7]D:>YOHY4M]4\27E[9>8I :$100DKGJOF0R
M\COFON:L;P?I.A>'_#.G:3X9M[.TT+3X5M;2VT_;Y,,:# 1=O' K9H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY"^&O_*2KXK_]BS#_ .B]
M,KZ]KY"^&O\ RDJ^*_\ V+,/_HO3*]#"?#6_PO\ -'%B=Z?^)?DSZ]HHHKSS
MM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXKJ_V)_VNK;]L+X;ZOXF70X_#-]INJ/I\VE+>_:F1/+1XY"^Q.&WL/NCE&H
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M/H&>[ [BL?PU^P[^Q'XTE$7A_3/#>NR%MH33?&UY<$G)&,)>'G((_ T </\
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MXI?FPHHHKH//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTUM?VLUG<+UCF0JWUY[5\P?$?_@G#^UE\6X;"+Q9XE\&ZJM@[26S?:%A:)F
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M^-/BSX??%/1-1O? 6N3++:ZSI]N2LC)Q'=P;B%=&1@)$!W*57NI#>Y_M"?\
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MBC"JHP /04 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (JOU=_:+_X*G?"CX">+;OPK:6VH^-]?L9##?1Z.8UMK609#1M,YY<'@J@8
MY!(((K'^!7_!7#X2_%KQ)::!X@L=1^'VHWCK'!<:H\<MBSG^%IU(V<\9=0OJ
M1TH [?\ X)F_#'Q5\(OV6['P]XRT.Z\/:TFJWDS65XH$@1F!5N">#7U;2*P9
M00<@\@BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY"^&O_
M "DJ^*__ &+,/_HO3*^O:^0OAK_RDJ^*_P#V+,/_ *+TRO0PGPUO\+_-'%B=
MZ?\ B7Y,^O:***\\[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY?_X*
M:?\ )CGQ/_ZXV/\ Z7VU?4%?+_\ P4T_Y,<^)_\ UQL?_2^VH ^>OV??^2%_
M#_\ [ -E_P"B4KOZX#]GW_DA?P__ .P#9?\ HE*[^OV/#_P8>B_(_B?,?]]K
M?XI?FPHHHKH//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ..^,W_)'_'7_8!OO_2=Z]B_X)5_\F.> ?\ KMJ7_I?<5X[\9O\ DC_CK_L
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M2=LJ_5#S^/2OL,+F6%QFE*>O9Z/^O0Z8SC+8WJ***],L**** "BBB@ HHHH
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M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD+X:_\I*OBO\
M]BS#_P"B],KZ]KY"^&O_ "DJ^*__ &+,/_HO3*]#"?#6_P +_-'%B=Z?^)?D
MSZ]HHHKSSM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE_\ X*:?\F.?
M$_\ ZXV/_I?;5]05\O\ _!33_DQSXG_]<;'_ -+[:@#YZ_9]_P"2%_#_ /[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH *^0OAK_P I*OBO_P!BS#_Z+TROKVOD+X:_\I*OBO\
M]BS#_P"B],KT,)\-;_"_S1Q8G>G_ (E^3/KVBBBO/.T**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *^7_^"FG_ "8Y\3_^N-C_ .E]M7U!7R__ ,%-/^3'
M/B?_ -<;'_TOMJ /GK]GW_DA?P__ .P#9?\ HE*[^N _9]_Y(7\/_P#L V7_
M *)2N_K]CP_\&'HOR/XGS'_?:W^*7YL****Z#SPHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !1110 5\A?#7_E)5\5_^Q9A_]%Z97U[7R%\-?^4E7Q7_ .Q9A_\
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M %%%% !1110 4444 %%%% ''?&;_ )(_XZ_[ -]_Z3O7L7_!*O\ Y,<\ _\
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MH,\-_P !)KZ["YMA,9I"5GV>C_X/R.F-2,MCKJ***]@T"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP
M;P?_ ,G?^./^P/'_ .@6=>\UX-X/_P"3O_''_8'C_P#0+.@#WFBBB@ HHHH
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M&/EP5SNQD$5>^.W['OQ:_9NL[.^\?>$Y=*TJ[E\F'4H+B*ZMFDP3L+Q,VQL
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M']F'_@JMKWBSQ7:W TFQ\5W=_<A(]SK;WD;E957^(*MRK@#DA>.:_<ZOD_\
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M%S3_ *!:G_@$O\CV*BO'?^&P/@__ -#O:?\ @//_ /&Z/^&P/@__ -#O:?\
M@//_ /&Z/KF&_P"?L?O0?V+FG_0+4_\  )?Y'L5%>._\-@?!_P#Z'>T_\!Y_
M_C='_#8'P?\ ^AWM/_ >?_XW1]<PW_/V/WH/[%S3_H%J?^ 2_P CV*BO'?\
MAL#X/_\ 0[VG_@//_P#&Z/\ AL#X/_\ 0[VG_@//_P#&Z/KF&_Y^Q^]!_8N:
M?] M3_P"7^1[%17CO_#8'P?_ .AWM/\ P'G_ /C='_#8'P?_ .AWM/\ P'G_
M /C='US#?\_8_>@_L7-/^@6I_P" 2_R/8J*\=_X; ^#_ /T.]I_X#S__ !NC
M_AL#X/\ _0[VG_@//_\ &Z/KF&_Y^Q^]!_8N:?\ 0+4_\ E_D>Q45X[_ ,-@
M?!__ *'>T_\  >?_ .-T?\-@?!__ *'>T_\  >?_ .-T?7,-_P _8_>@_L7-
M/^@6I_X!+_(]BHKQW_AL#X/_ /0[VG_@//\ _&Z/^&P/@_\ ]#O:?^ \_P#\
M;H^N8;_G['[T']BYI_T"U/\ P"7^1[%17CO_  V!\'_^AWM/_ >?_P"-T?\
M#8'P?_Z'>T_\!Y__ (W1]<PW_/V/WH/[%S3_ *!:G_@$O\CV*BO'?^&P/@__
M -#O:?\ @//_ /&Z/^&P/@__ -#O:?\ @//_ /&Z/KF&_P"?L?O0?V+FG_0+
M4_\  )?Y'8_&;_DC_CK_ + -]_Z3O7L7_!*O_DQSP#_UVU+_ -+[BOD7XH?M
M5?"G7?AGXMTVP\8VMQ?7FD7=O!"MO."\CPNJJ"4QR2!S7UU_P2L_Y,<\ _\
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M<UOX0:'+\2O .IMM>UA@-VUQ"I8QI<6\9659HPS8DC&TY]&*4 ?2_P#P3?\
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M".=KL/Q- 'Y$?\/J_C?_ -"M\/\ _P %U]_\F4?\/J_C?_T*WP__ /!=??\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ>"_@KH=MK'CGQ%9^&M,N;@6D-U?,0CS%6<(, \[48_@: /Y\_\ AH3]HO\
MZ*7\4/\ P?:C_P#'*23XU?M$^(HI-.?QY\3]3CN%*/:-K&HS"1<<@IO.1CVK
M]O\ _AOS]GG_ **QX?\ ^_K_ /Q-'_#?G[//_16/#_\ W]?_ .)H _/S_@EG
M^Q3X\A^-&F_%?QEH%]X8\/Z#',VGQZI"T$]_<R1-$"L3 ,(U61FWD $[0N[Y
ML?L'7D?P]_:U^#_Q7\4VWAOPCX_TC7M=N5=X;&T=C(ZHI9B,J.B@G\*AO/VP
M?@QI_CB3P=<?$/1XO$\>H?V6^EL[>:+KS/+\K&W&[?\ +]: /8J*** "BBB@
M HHHH **** "OQO_ ."KW[)?B'P/\5KKXT^%K*XF\,ZRT4VIS6*MNTN^0*OF
MOMY5)-JL'Z!RP."5S][_  <_X*'_  ?^.OQ.L/ 7A6\U>7Q#?>?Y*76G-%&?
M*C>1\N3Q\J-7TI=6L-]:S6US#'<6TR-'+#*H9'4C!5@>""#@@T ?B-\/_P#@
ML5\;O!_ANWTG5;#PUXNEMX_+34]5M9DNWQT,ABE17P.^T$]22>:\8^,_[2'Q
MC_;M\>:%I&IQG5[LS&/2/#'A^U9+>.1P S*A+,QP.7D9MHSR!FOV7\4?\$Z_
MV<O&&L/J>H?"W3(KIW\QAIUS<V,1;_KE!*B8]MN*])^%/[.WPT^!T4B^!?!6
MD>&Y9 5DNK6W!N9%)SM:9LR,O'0MB@#G?V/_ ( K^S3^S]X8\#R/#/JMO&UU
MJEQ#]V6\E8O)@]PN0@/&51>!7L]%% !1110 4444 >3>(OV2_@QXOUZ_UK6_
MAAX7U75[^9I[J]N]-BDEFD8Y9F8C))]:S?\ ABGX"?\ 1(?!_P#X*8O\*]KH
MH \6C_8L^ T<BNGPB\(*ZG(8:3%D'\J]IHHH \L^+'[+?PG^.5]%?>.? FD:
M_J$:A%OY8C%<[1T4S1E7*CLI.!Z5/\)_V:?A=\"YY[CP)X(TGP[=SIY<EY;Q
M%[ADZ[3*Y9]OMG'2O3** "BBB@ HHHH **** "OD+X:_\I*OBO\ ]BS#_P"B
M],KZ]KY"^&O_ "DJ^*__ &+,/_HO3*]#"?#6_P +_-'%B=Z?^)?DSZ]HHHKS
MSM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M#=6<%_;O!<P1W$#C#1RH&5A[@\&IJ*35U9@>5^*_V>]!UK?-I;OHUR>=L?SP
MD_[I.1^! ]J\;\5_!_Q-X3WR2V1O;1?^7FSS(N/4C&Y?Q&/>OKBBOG\7D>$Q
M.L5R2\O\MOR,94HR/A)6*L"#@CD$5WWA3XV>)O#&R)[K^U+1>/)O<L0/9_O#
M\R/:O?\ Q5\*?#?B_?)=V"V]VW_+U:_NY,^I[-^(->-^*_V==:TG?-H\\>KV
MXY\LXCF ^A.#^!S[5\K4RG,,NE[3#NZ[QW^:_P"'.=TYPUB>D^%/CYX<\0;(
MKUVT6Z;C;<G,1/M(./\ OH"O2(9H[B)98G66-AE70@@CU!%?#E]I]UI=T]M>
M6TMI<)]Z*9"C#\#6KX:\<:YX1EW:5J,ULF<M#G=$WU0\?CUKKPO$=2F^3%0O
MYK1_=M^14:S6DC[1HKP_PI^TG!-LA\0V!MVZ&ZL\LGU*'D?@3]*]=T/Q+I?B
M:U^T:7?PWL??RFR5_P!Y>H_$5]AA<?AL8OW,[OMU^XZ8SC+8TZ***] L****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M??%2#Q!X.3P]/XT_X2-;:2]NQ=BW^V^?L*BV*>9MXQOQG^+'-<-_P^\\<?\
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MNSD;N.IKVWX"_ME?#?\ :0\8^)/#7@NZU";4=!B6:Z^W69MU92Y0[-QW':P
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M=_8I^(=Q\:[S]H;X[2;/%]XTEUI^CS$-/%+*I3S9E'RQ!(SMCB!)7(R%* 4
M?HM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O//C9^S_P" OVBO#=GH'Q"T'_A(-)L[L7T%O]LN+;9,$= ^Z&1&/RR.,$XY
MZ=*]#KXG_P""KWAWX@^)O@3X7M_ASI?B75=83Q)%)/#X7M[B:X6#[+<@LX@!
M8)N*#)XR5]J .N_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\
MY)K\@/\ A4_[4W_0F_&#_P %>J__ !%'_"I_VIO^A-^,'_@KU7_XB@#]?_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#&C_A[S^SS_P!!'Q!_X)W_ ,:\ _X<8_\ 5;/_ "U/_NVC_AQC_P!5L_\
M+4_^[: /KOX(_P#!0_X/_M!?$2P\$^$;S5YM=O8Y984N].:&,K'&7;+$\?*I
MJKJG_!2#X,:/\7I_AK<7NL#Q/#K7]@/&NFL8OM7G>3C?G[N_^+TYKRW]D_\
MX)9_\,O_ !MTCXA?\+._X27^SX;B'^S?[ ^R>9YL+1Y\S[2^,;L_=.<8XK/\
M0?\ !)W^W/VEKOXM_P#"T_(^T>*?^$F_L?\ X1[=M_TK[1Y'G?:AG^[OV>^W
MM0!^@M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?(7PU_Y25?%?\ [%F'_P!%Z97U[7R%\-?^
M4E7Q7_[%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[1117GG:%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,H=2K ,I&"".#2T
M4 >?>*_@AX9\3;Y8[8Z5=MSYUGA5)]T^Z?PP?>O&_%7P%\2>'M\MI&NLVB\[
M[4?O />,\_\ ?.:^I:*\/%9-A,5JX\LNZT_#8RE3C(^%)8G@D:.1&CD4X96&
M"#Z$5U/A7XH^(_!^Q++4&DM5_P"76Y_>18] #RO_  $BOJ/Q-X%T+Q?&5U33
MHKB3&!.!ME7Z..?PZ5X[XK_9MN;??-X?OA=)U%K=X5_H''!_$#ZU\G6R7'8&
M7M,++F]-']W_  YSNE*.L3H_"O[1FD:ELAUJW?2ISQYR9DA/Y?,OY'ZUZIIV
MJ6>KVJW-C=0W=NW26%PZG\17Q;KGAW4_#=U]GU2QFLI>PE3 ;W4]"/<4W1?$
M&I>';H7.F7TUE-W:%R WL1T(]C6N'XAQ%!^SQ4;V^3_R_(<:S6DC[>HKY\\*
M_M)7EMLA\06*WD?0W5IA)/J4/RD_0K7L?AGQ]H/B^,'2]1BFEQDV['9*/^ '
MG\1Q7U^%S/"XS2E/7L]'_7H=$:D9;'04445ZAH%%%% !1110!X9^W!\,-6^,
MG[*7Q&\)Z#$]QK%W8)/:V\?WYY()H[@1+_M/Y6T#N6%?GC^R)^V1X&\/?L0_
M$;X+>+=07PUXIL]%UR+2OMB%(K\7$,S"(/C"S"5V7:V,@IM).0/V!KX^_;;_
M &)?A#\1OASX_P#B#>^&$TWQCIFAW^J+JNDR&V>XFBMWD4SHOR2Y9!EF7<1Q
MNH Z7]B?PUX;^(W[#'PST37M+TOQ-HLFE1)=:=J$$=U;N\<Q<+)&P*DJRJ<$
M<$"OHOP_X<TGPGI,.EZ'I=EHVF0Y\JRT^W2"&/)).U$  R23P.I-?B/H?[*_
MQ5^ O[.OA7]I7X4^.[J%'L(M2U33;96AFM4+E68KEDN80>65U&%)R& )K]*/
M@%^VQHWCK]C=_C3XM3^SSH=O+#KD5JF0UW#M4B)<_P#+4O&54G@R $X&: *7
M_!03]K.7]G7X;V_A_P *EKSXH>+B;#0K.W7S)8-Q"-<[!R2"P5!_%(1P0K"O
MSL_;*_9/B_9>_91^&2ZL%N_B!XAUN:_\0W[-O?S3!E;</SE8]Q!.?F=G;H0!
MZG^R%\4O /QC_:'\1_M&_';Q_P"&=$UJ&<VOACPSJ6I1J;!%&%D",>%C5MJ9
M'S.TDA ;:38_X*[_ !X^'7Q>^'/@"S\%>-=$\4W5GJL\MQ#I5ZD[1(80 S!3
MP">* /T[^$W_ "2OP;_V!;+_ -$)75UXQ^SC\>/AU\1_"?AOPYX6\:Z)K^O6
M.@VTMUIVGWJ2SPHD<4;LR@Y #NJGW85[/0 5\UQ^--%\#?M7>-+_ %V_33[2
M33(H$E=68%S':L%^4$]%;\J^E*^<]/\ #.D^*OVLO&MIK&G6^IVR:7%*L-U&
M'4.([0!@#WPQ'XF@#T7_ (:)^'7_ $,]O_WYE_\ B*[G1=:LO$6E6VI:=.MU
M8W*;XIE! 9?7!&:YK_A3/@7_ *%+2/\ P$3_  KJ=-TRTT:P@LK&WCM+2%=D
M4,*A40>@ Z4 6J*** "BO)/VKO@WJO[0'P"\4^ =$UF/P_J>K?9?)U&4.5A\
MJZAF;.SYN5B*\?WJ_/#_ (<W_%3_ *+)I_\ WQ=?_%4 ?K-<6\=U!)!-&LL,
MBE'C<95E(P01W!%?E7\1_P#@GW\<?V5_B=J/C_\ 9DUV2[TJY=F_L2.:-;J"
M(L6\AXYOW5S$O\.3OZ?*2-Q^HOV=_AO=_P#!/']EWQM=^/M>F\9VUAJ4VO33
MZ1"SRK T-M#L597&2#$S?> P:]2_9:_:B\,?M9> =0\6>%K._P!.LK/4I--D
MM=4$:W 94C<,RHS  K(,88]#SQ0!^57[)O\ P47\1_LH:5K>@^*/A\VMZ)JO
MB.\U"\O896M;B*[<1K<1IN5HWV;%.SY2-W+<BOUX^!OQX\&_M%> ;;Q?X'U/
M^T=*D<PRI(ACFM9@ 6AE0_=<!AZ@@@@D$$_*G_!/CX>^'/BE^SO\6_#7BO1[
M37=$OOB'K*36=Y&'4_);X9>ZL.H88(/((-> ?\$>;R\\,_M%_%_P987,UWX:
MBL7E\W?E&D@O!%"^.FYDDD.?:@#V+_@KDOP1O/ NAP>/-3O[+XB0QRR>'TT.
M%)[LQ-PWGQNRK]G+J.2P;<IV9PX/@_PR^+'[?]E\'[*#0_"VIZEHJ6JK9:IJ
M>EP/J*P[<(5$A#R<$$,R,2 .2*?K]I:_%K_@LY%I/C7;<:78:F([2SO#F/%M
MIQFMD Z;6E57V]&+D<[N?U^H _)'_@EE<?#.]^.FLZKX]U?7)_VA;B6ZV0^)
M8A%&'8L)_)8L6>Y*[MPD"D*7"J<,:_6ZOR#_ ."NEG:_"O\ :>^&7C_PH%T[
MQC/:K?3R6PVO)-;3K]GE;'5B/DSW$8':OUZ1BRJ2NTD9*GM[4 .HHHH ****
M "BBB@ HHHH **** "N/^+WQ4T#X)?#?7_&_B:Y^S:-H]L9Y=N-\C<!(D'=W
M<JBCU85V%?G7_P %KO%-_IGP*\%:';R/'9:IKQENMO1Q#"Q1&]MTF['J@]*
M/B[XZ?\ !4OXV_%;7KMO#^OR?#[PX9";;3=$VK,J=O,N=OF,WKM*KS]VO/\
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M4 %%%% !1110 5\A?#7_ )25?%?_ +%F'_T7IE?7M?(7PU_Y25?%?_L68?\
MT7IE>AA/AK?X7^:.+$[T_P#$OR9]>T445YYVA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[0KB?C/\7O#WP'^&>N^.?%$SPZ-I$(DD6%0TLKLP2.) 2,N[LJC) R>2!DT
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M\F?7M%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMPI6Q\)>"+,,A4M):7<K _WA_I(''N#0!^S\$$=K#'##&L4,:A$CC4*JJ!@
M = !7GOQ;_:(^&_P+LTG\<^,-,T&20 PV<LN^[FSP/+@3,CC/<+@=S7XN:C^
MW5^U9^TKJ7_"-^&]=UB2>Y.!IO@K3A!* >,^;$OFJOJ2^!SFO?\ ]FG_ ()'
M^+/&&O1>+_CQK%QIR-*MPVAVMV+C4+IN#FXN,LJ#H"%+,>>4(H _6JBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYK_X*'_'*^^
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M&/\ H)_^2\O_ ,31_P +2\,?]!/_ ,EY?_B: .KHKE/^%I>&/^@G_P"2\O\
M\31_PM+PQ_T$_P#R7E_^)H ZNBN4_P"%I>&/^@G_ .2\O_Q-'_"TO#'_ $$_
M_)>7_P")H ZNBN4_X6EX8_Z"?_DO+_\ $T?\+2\,?]!/_P EY?\ XF@#JZ*Y
M3_A:7AC_ *"?_DO+_P#$T?\ "TO#'_03_P#)>7_XF@#JZ*Y3_A:7AC_H)_\
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M'_03_P#)>7_XF@#JZ*Y3_A:7AC_H)_\ DO+_ /$T?\+2\,?]!/\ \EY?_B:
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M\,?]!/\ \EY?_B: .KHKE/\ A:7AC_H)_P#DO+_\31_PM+PQ_P!!/_R7E_\
MB: .KHKE/^%I>&/^@G_Y+R__ !-'_"TO#'_03_\ )>7_ .)H ZNBN4_X6EX8
M_P"@G_Y+R_\ Q-'_  M+PQ_T$_\ R7E_^)H ZNBN4_X6EX8_Z"?_ )+R_P#Q
M-'_"TO#'_03_ /)>7_XF@#JZ*Y3_ (6EX8_Z"?\ Y+R__$T?\+2\,?\ 03_\
MEY?_ (F@#JZ*Y3_A:7AC_H)_^2\O_P 31_PM+PQ_T$__ "7E_P#B: .KHKE/
M^%I>&/\ H)_^2\O_ ,31_P +2\,?]!/_ ,EY?_B: .KHKE/^%I>&/^@G_P"2
M\O\ \31_PM+PQ_T$_P#R7E_^)H ZNBN4_P"%I>&/^@G_ .2\O_Q-'_"TO#'_
M $$__)>7_P")H ZNBN4_X6EX8_Z"?_DO+_\ $T?\+2\,?]!/_P EY?\ XF@#
MJZ*Y3_A:7AC_ *"?_DO+_P#$T?\ "TO#'_03_P#)>7_XF@#JZ*Y3_A:7AC_H
M)_\ DO+_ /$T?\+2\,?]!/\ \EY?_B: .KHKE/\ A:7AC_H)_P#DO+_\31_P
MM+PQ_P!!/_R7E_\ B: .KHKE/^%I>&/^@G_Y+R__ !-'_"TO#'_03_\ )>7_
M .)H ZNBN4_X6EX8_P"@G_Y+R_\ Q-'_  M+PQ_T$_\ R7E_^)H ZNBN4_X6
MEX8_Z"?_ )+R_P#Q-'_"TO#'_03_ /)>7_XF@#JZ*Y3_ (6EX8_Z"?\ Y+R_
M_$T?\+2\,?\ 03_\EY?_ (F@#JZ*Y3_A:7AC_H)_^2\O_P 31_PM+PQ_T$__
M "7E_P#B: .KHKE/^%I>&/\ H)_^2\O_ ,31_P +2\,?]!/_ ,EY?_B: .KK
MP;P?_P G?^./^P/'_P"@6=>G?\+2\,?]!/\ \EY?_B:\*T_XE^&_"W[37BS7
M]4U VND7FFQP07)MY6#OLMN JJ6_Y9OSC'% 'U!17EW_  TW\-/^AD_\D+G_
M .-UZ%H.NV/B;1[75--G^TV%TGF0S;&3<OKA@"/Q% %^BBB@ HHHH X3X]>)
M-1\'? SXBZ_H[%=6TKPYJ-]9LO4316LCQD?\"45^=_\ P15^&_AG6-/\?_$"
M_@AU+QG:W\=A!<7(\R6SA>/>TB$]&E9F!;J1&1P"<_J)?6-OJ5E<6=W"EQ:W
M$;12PR#*NC AE([@@D5^37BK]C?]HC]AGXH:MXS_ &>9I_%/A&])WZ9 HGG\
MG<2L%S:L<S[,D+)'EN2?DR10!Z]^QO\ !?1/C_\ LD_&[P5KEG;7,>H>/-<6
MUFN$R;2Y\J#RIT."59&P<CMD<@D5['_P3[_93\:_LD^ O$7AKQ7XETO7K34+
MU+^TM]+$I2UD*%)OFD"Y#!8CPHY4^M? O[&G_!2JW_9CTOQ#X5\;> [ZZM]6
M\1W>LWE_ILXCGM9I1&LL0MI0,[3'WD!&<'UK]<_A)\8/"/QS\$V?BSP3K,.M
MZ)<DH)H@5:*0 %HY$8!D<9&58 \@]"#0!YW^V#^UCHO[(7PTMO%.JZ->:_<W
M]W]@L+"T=8U>8QN_[R1L[$PAY"L<X^7N/Q\_:PN_CO\ '_P7#\=OB?8OH?@^
M2_BTG0-+E5H(U69))=UO"WS%-L/S3/RY*8+ 87]V_%/@+PWXXDTM_$6A:?KA
MTNY^V60U&V2=;><*5$J!@0' )PW49XKXH_X+/?\ )J&B?]C;9_\ I+=T ?0'
M["O_ "9_\)/^Q?M_Y5A?\%"_CK??L_\ [+?B?7-'G:UU_4FCT;3;A6VM#-/D
M-(I[,D:RNO\ M**W?V%?^3/_ (2?]B_;_P J^5_^"V^H-'\$_A]8Y.V;Q"\Y
M';*6TB_^U#0!K_\ !+_]CKP5I?P+TGXE^*_#MCXB\7>*#)=Q3:O;+<"RMA(R
MQB)7!"LX7S"X&XAP,X'/+?\ !5/]D'PEX<^&*?&;P)I%OX1\1>'[RW&H?V+$
MMK%<0R2A$F*Q@;9DE>/$@P2"<YPN/MK]D_3X]+_9>^$5M&JJ$\):43MZ%C:1
M%C^))/XUQW_!0:TBO?V,?BO',F]%TGS /]I)8V4_@5!_"@#<_8T^-$_[0'[-
M/@?QI?.'U:ZLS;:BP&-UU [0ROCMN9"^/1Q7M5?"7_!&F]DNOV2=0B<DK;>*
M+R*/GHI@MG_FYK[MH **** "BBB@ HHHH *:ZK(K*RAE88*L,@CTIU% 'E7C
M+]E/X-_$"X>YU_X8>%=0NW&&NFTJ%)V^LBJ&/Y]SZUSVG_L*_L_:7,98?A)X
M7=O2XLA.O7/1\BO=J* ,OPYX5T7P?ID>FZ!I%AHFG1_<M--MDMXE^B( !^5:
ME%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M?O\ P6D\*W&K_LU^&M:@#.FD>(XO/4#A8Y8)DW$]L.(U_P"!U^@5>?\ Q\^#
MNE_'[X/^*/ .L.8;/6K0Q+<*N6@F5@\,H'<I(J-COC'>@#F/V,/$T'B[]DWX
M2:C;R+(H\-6-H[+T\R")8)!^#QL/PKBO^"E7B:#PO^Q3\29)9%22]M[>PA5N
MKM+<Q(0/<*6;_@)KX5^"_P"T3\9_^"9;:G\.?B5\.[[Q)X'CN7FT^\MY6CAA
MW,2\EM<>6R21O]XQ-M96))VDL"_XD>./C;_P56\7>'_"GA_P5=^ OA=872W5
MW>79:6!7PR_:)9BB"1PA8)#&.K')(^90#ZS_ ."1OA6X\._L:Z5>3IY8UK5[
M[48LC!*!Q #^)@/X8K[0KG/ASX!TCX6> ] \(:!!]FT?1;**RMD[[44#<Q[L
MQRQ/<DGO71T %%%% !67XC\+:+XPTUM.U[2+#6]/9@YM-2MDN(BPZ'8X(R/7
M%:E%--IW0GKHS@/^&?/A;_T37PA_X(;7_P"-UKZ)\+?!?AF*6+1_"&@Z5'*V
MZ1+'3(80Y'&2%49-=115RJ3DK.39*A&+ND9/_")Z'_T!M/\ _ 6/_"C_ (1/
M0_\ H#:?_P" L?\ A6M1699D_P#")Z'_ - ;3_\ P%C_ ,*/^$3T/_H#:?\
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M_P#@+'_A6M10!D_\(GH?_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U%
M&3_PB>A_] ;3_P#P%C_PH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\
MP%C_ ,*/^$3T/_H#:?\ ^ L?^%:U% &3_P (GH?_ $!M/_\  6/_  H_X1/0
M_P#H#:?_ . L?^%:U% &3_PB>A_] ;3_ /P%C_PH_P"$3T/_ * VG_\ @+'_
M (5K44 9/_")Z'_T!M/_ / 6/_"C_A$]#_Z VG_^ L?^%:U% &3_ ,(GH?\
MT!M/_P# 6/\ PH_X1/0_^@-I_P#X"Q_X5K44 9/_  B>A_\ 0&T__P !8_\
M"C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\ _ 6/_"C_ (1/0_\ H#:?
M_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/_H#:?_X"Q_X5K44 9/\
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M  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\
M_ 6/_"C_ (1/0_\ H#:?_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/
M_H#:?_X"Q_X5K44 9/\ PB>A_P#0&T__ ,!8_P#"C_A$]#_Z VG_ /@+'_A6
MM10!D_\ ")Z'_P! ;3__  %C_P */^$3T/\ Z VG_P#@+'_A6M10!D_\(GH?
M_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U% &3_PB>A_] ;3_P#P%C_P
MH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\ P%C_ ,*/^$3T/_H#:?\
M^ L?^%:U% &3_P (GH?_ $!M/_\  6/_  H_X1/0_P#H#:?_ . L?^%:U% &
M3_PB>A_] ;3_ /P%C_PH_P"$3T/_ * VG_\ @+'_ (5K44 9/_")Z'_T!M/_
M / 6/_"C_A$]#_Z VG_^ L?^%:U% &3_ ,(GH?\ T!M/_P# 6/\ PH_X1/0_
M^@-I_P#X"Q_X5K44 9/_  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_
MX5K44 9/_")Z'_T!M/\ _ 6/_"C_ (1/0_\ H#:?_P" L?\ A6M10!D_\(GH
M?_0&T_\ \!8_\*/^$3T/_H#:?_X"Q_X5K44 9/\ PB>A_P#0&T__ ,!8_P#"
MC_A$]#_Z VG_ /@+'_A6M10!D_\ ")Z'_P! ;3__  %C_P */^$3T/\ Z VG
M_P#@+'_A6M10!D_\(GH?_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U%
M&3_PB>A_] ;3_P#P%C_PH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\
MP%C_ ,*/^$3T/_H#:?\ ^ L?^%:U% &3_P (GH?_ $!M/_\  6/_  H_X1/0
M_P#H#:?_ . L?^%:U% &3_PB>A_] ;3_ /P%C_PH_P"$3T/_ * VG_\ @+'_
M (5K44 9/_")Z'_T!M/_ / 6/_"C_A$]#_Z VG_^ L?^%:U% &3_ ,(GH?\
MT!M/_P# 6/\ PH_X1/0_^@-I_P#X"Q_X5K44 9/_  B>A_\ 0&T__P !8_\
M"C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\ _ 6/_"C_ (1/0_\ H#:?
M_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/_H#:?_X"Q_X5K44 9/\
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M  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\
M_ 6/_"C_ (1/0_\ H#:?_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/
M_H#:?_X"Q_X5K44 9/\ PB>A_P#0&T__ ,!8_P#"C_A$]#_Z VG_ /@+'_A6
MM10!D_\ ")Z'_P! ;3__  %C_P */^$3T/\ Z VG_P#@+'_A6M10!D_\(GH?
M_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U% &3_PB>A_] ;3_P#P%C_P
MH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\ P%C_ ,*/^$3T/_H#:?\
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MDRRNJR7EM;V$*GJ[2W,2$#WVEC_P$U\+?!W]H3XT?\$Q[C4_AS\2/A]>>)_
M<=R\VGWMM(T<,19B6DMKG8R/&_+&)MK*Q).TE@7?$KQW\:_^"JWB[P]X4\.>
M"KSP)\+;"Z6YN[V[+2P*^&7[1+,402,$+!(4'5CDD?,H!]9_\$C?"MQX=_8U
MTJ\G3RQK6KWVHQ9&"4#B '\3 ?PQ7VA7.?#GP#I'PL\!Z!X0T"#[-H^BV45E
M;)WVHH&YCW9CEB>Y)/>NCH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/]E']
MGFX_9N\'>*=$N=;BUU]:\2WNOK-%;F$1+.L8$1!9LE?+^]QG/2O;*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *2QUZ!7G_[/?_) OAI_V+.F?^DL=>@4 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8X8\^@9IB!Z[3Z5^A&L>(-"^$?P\EU7Q!J<&E:!H-@INKZX.U(XXU"YQR<G
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M/)8DDDU@_M!?M >$OV:_AK?^,_%]V8;.$^5;6D6#/>W!!*01*>K'!/H "20
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M*G^,GBK2-4\ K#.+RUM(M/61G,3>408;='X?:>&^M 'VM1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>prax-20221231_g4.jpg
<TEXT>
begin 644 prax-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2W!W@# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFS_@J]\/_%VD(MA:^(Y=/O[\1\(5N99+*[./5E1W/JS9[T ?KC1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_M"ZI^TA_P3[\3>)-4E6;Q3IVB:KI&HW&,":YAM6*RG'=XWB9L<;F;%:/\
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MM>@44 >?_P!L_$/_ * .G_\ ?P?_ !VC^V?B'_T =/\ ^_@_^.UZ!10!Y_\
MVS\0_P#H Z?_ -_!_P#':/[9^(?_ $ =/_[^#_X[7H%% 'G_ /;/Q#_Z .G_
M /?P?_':/[9^(?\ T =/_P"_@_\ CM>@44 >?_VS\0_^@#I__?P?_':/[9^(
M?_0!T_\ [^#_ ..UZ!10!Y__ &S\0_\ H Z?_P!_!_\ ':/[9^(?_0!T_P#[
M^#_X[7H%% 'G_P#;/Q#_ .@#I_\ W\'_ ,=H_MGXA_\ 0!T__OX/_CM>@44
M>?\ ]L_$/_H Z?\ ]_!_\=H_MGXA_P#0!T__ +^#_P".UZ!10!Y__;/Q#_Z
M.G_]_!_\=H_MGXA_] '3_P#OX/\ X[7H%% 'G_\ ;/Q#_P"@#I__ '\'_P =
MH_MGXA_] '3_ /OX/_CM>@44 >?_ -L_$/\ Z .G_P#?P?\ QVC^V?B'_P!
M'3_^_@_^.UZ!10!Y_P#VS\0_^@#I_P#W\'_QVC^V?B'_ - '3_\ OX/_ ([7
MH%% 'G_]L_$/_H Z?_W\'_QVC^V?B'_T =/_ ._@_P#CM>@44 >?_P!L_$/_
M * .G_\ ?P?_ !VC^V?B'_T =/\ ^_@_^.UZ!10!Y_\ VS\0_P#H Z?_ -_!
M_P#':/[9^(?_ $ =/_[^#_X[7H%% 'G_ /;/Q#_Z .G_ /?P?_':/[9^(?\
MT =/_P"_@_\ CM>@44 >?_VS\0_^@#I__?P?_':/[9^(?_0!T_\ [^#_ ..U
MZ!10!Y__ &S\0_\ H Z?_P!_!_\ ':/[9^(?_0!T_P#[^#_X[7H%% 'G_P#;
M/Q#_ .@#I_\ W\'_ ,=H_MGXA_\ 0!T__OX/_CM>@44 >?\ ]L_$/_H Z?\
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M44 >?_VS\0_^@#I__?P?_':/[9^(?_0!T_\ [^#_ ..UZ!10!Y__ &S\0_\
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M#I__ '\'_P =H_MGXA_] '3_ /OX/_CM>@44 >?_ -L_$/\ Z .G_P#?P?\
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M[7H%% 'G_P#;/Q#_ .@#I_\ W\'_ ,=H_MGXA_\ 0!T__OX/_CM>@44 >?\
M]L_$/_H Z?\ ]_!_\=H_MGXA_P#0!T__ +^#_P".UZ!10!Y__;/Q#_Z .G_]
M_!_\=H_MGXA_] '3_P#OX/\ X[7H%% 'G_\ ;/Q#_P"@#I__ '\'_P =H_MG
MXA_] '3_ /OX/_CM>@44 >?_ -L_$/\ Z .G_P#?P?\ QVC^V?B'_P! '3_^
M_@_^.UZ!10!Y_P#VS\0_^@#I_P#W\'_QVC^V?B'_ - '3_\ OX/_ ([7H%%
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M[-:R0222J^^SD>1Y&R98E&,8#&5<#H*Z_6?^4N&@_P#9,V_]*YJ /-OV*_\
M@H1XZOOB\GP0^/VFG3O&+2M:6>KW%N+2=KG *6]Q$H"$N/N2)@-\@PV\-7U%
M^VG^U)HG[*?P;N?$.I:?'KFJ:E(=.TO1Y2-EU,R,3YO_ $R502W'.0O!8&O@
M#]MBZM?'7_!53X7Z9X0=7UK3[G0K74)K1=S1W27;3L[$#DQP/$3UP$P>A [_
M /X+B:+J5QX1^$VK1*YTBUOM1M;E@/E$TL<#0@^^V&?'T- 'D/[/_P#P3E^(
MW[34+?%JYUO2?@EI?B _:M-LO#VGRAO)/1XK=9D\F)L J#)DCYL8P3G^*O@)
MXZ_X)?\ Q6T#XFZSHGA[XN>%9[I(!JMY;/YMM-RWRAB?(G(5BDGSCCUXK]9O
MV=_&6A_$#X%> ]=\-RQ2:-=:-:B%86!$.R-4:(XZ,C*R$=BI%?/W_!5_QEH/
MAW]C7Q/I.JS1?VEKUS9VFEVS-AY9DNHIG9<<X6.-R3TZ _>H ]&^*'Q1T;XT
M?L,?$#QOX4GDN-*UKP+JUS:E@!(C?8I@T; $@.CAD8 G#*>37R]_P1'/_%F/
MB&.__"01_P#I,E>F_P#!-WX>7VK?\$^].\/ZXC0VOB*+5$ACE7E;6XDD0''H
MV68>H8'O7SW_ ,$=_%@^&OQ.^+7P?\22IIWB/SXY;>SF;:SS6KRQ72+G[S -
M&V!SM1CT!P ?JO7Y'?L*H9/^"JWQG:T&+9;OQ(QX/^K_ +24#Z<E:_5?QGXP
MT?X?>$]6\2:_?1:;HNEVSW5W=3, L<:C)^I[ =22 .37Y@?\$??"]_X]^-GQ
M?^,5[:R1P7(DLHIF^X\]U<"YF4'N4$<>?:0>M 'ZLT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R-^V_\ \$]_#_[6
MQM/$.G:FOA3Q[8P^1'J?D^9!>1 DK'.H(.5).V13D D$,, ?7-% 'XH:M\ _
MVIO#W[6W@[P)+\3;&?XDMX9E&D>(VU&61(=,#S!D,S0>:&R)?X2W(P:^WOV,
M?^"<NG_LZ^*Y_B%XU\0MXY^)=P92M\=QM[0R9$CH7^>25@6!D;'#D!1R3]17
MWPE\):G\3M-^(=UHL4OC/3;%M-M-6,D@>*W8N6C"AMI!,C\D9YZUU] '+_$W
MX;>'_B_X#UKP=XIL%U+0M6MS;W,#<''574_PNK ,K#D%0>U?G3:?\$W/VA?V
M=_$&JS? #XR6UGH%XX<V.JS26\K]AYD8AE@D91_RTPI(' '2OT^HH _-7P#_
M ,$N?'_Q2^(EEXR_:6^)'_"9?9-NW1["YFG\Y VX1/,ZH(H\YRD2\Y.&4\U^
MD6GZ?:Z3I]M8V-O%9V5K$L$%O @2.*-0%5%4<     = *L44 ?$W[9__  3C
M@_:"\:6WQ(\ >(E\#_$F Q/+=/O6WNWBP(I2\?SQ2H%4>8H;(5>,C->'ZW^P
M+^UW\;K.U\,?%'XUZ;)X-BD03QI?3W32JK9#^4(8Q,P/(\UP<X]*_4FB@#S/
M]G?]GWPK^S/\,-/\%>$X&%K 3-=7LP'GWURP >>4CJQP !T"JJC@"N,_;$_8
M[\+_ +7W@2VTG5KA]&\0:8SRZ3KD,8D:V9@ Z.F1OC;:N5R#E001CGW^B@#\
MM=/_ &'/VU/#/AX>!=$^-VEP>#4C%O"PUBZC,4 !41J?LYDC&WC8C;>@S7U)
M^Q'^P;X<_9!TJ^U"2_7Q-XYU2,17FM-#Y:PPY#&"!2253< 68G+E5)Q@ ?4U
M% !1110 4444 %?(7PU_Y25?%?\ [%F'_P!%Z97U[7R%\-?^4E7Q7_[%F'_T
M7IE>AA/AK?X7^:.+$[T_\2_)GU[1117GG:%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?(7[:G_)?/V9?^QF;_ -*M/KZ]KY"_
M;4_Y+Y^S+_V,S?\ I5I]?7M>CB/]WH>C_P#2F<='^-5]5^2"BBBO..P****
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MT_&OXAP_%#X8^)U\!?$='CEGE=I([>YFC $<XDCR\,H"J"RA@V < Y)^XZ*
M/RWUC_@G[^UE\=X['P_\7/C3IS^#H)5,L,-Y/=N^W.U_)$,22L,G#2/D5^A'
MP(^!_AC]G?X8Z3X(\)VQATVQ7=)/)@S74S8\R>4CJ['\   ,  #T"B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD+X:_P#*2KXK
M_P#8LP_^B],KZ]KY"^&O_*2KXK_]BS#_ .B],KT,)\-;_"_S1Q8G>G_B7Y,^
MO:***\\[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#Y"_;4_Y+Y^S+_V,S?\ I5I]?7M?(7[:G_)?/V9?^QF;_P!*M/KZ]KT<
M1_N]#T?_ *4SCH_QJOJOR04445YQV!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;B"+9'!CMH 1\I"MNP3MP=Q /TGT_P#;"^!FJ7@M;?XO>"VG)P%?7+9 QSC
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M7[%/C3_@G]<VGQ@^"OC/67\/V=Q''>B9U%U9!G 3SM@"7$#N0A#(,%E!# Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]+M/K]<J_+\Z_P!_J?+_ -)1_5W _P#R3^&_[?\ _2Y'Y5_\%SO^:)_]QO\
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MKO)GUF!P.'RW#QPN%CRPC>RNWNVWJVWNS\J_^"YW_-$_^XW_ .V%?I3\)O\
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MCFU:_DB7Z(TY7\"/I7T/X/\ !'A[X>Z'#HWAC0].\/:3#_J[+3+5+>)??:@
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MV;QRLL<PUQD;[0'CC6)&SG&0BJO3H* /2**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^0OVU/\ DOG[,O\ V,S?^E6GU]>U\A?MJ?\ )?/V9?\
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MIIOB[08[F(G!>**ZMPR^Q(60?E0!/_PMGP/_ -#EX?\ _!I!_P#%T?\ "V?
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M[T_\2_)GU[1117GG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"74_#7BR\DO_ !?X/>*"2^N&W37MI(&\F1R>6D4QNC-U.$))9B: /MRBBB@
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M #] **_*K_AE7XW_ /1VOQ _\"+[_P"3Z/\ AE7XW_\ 1VOQ _\  B^_^3Z
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M]3G&:^[Z_'SXIV\5W_P6NMH9XDFB?6=)#1R*&5A_9-OP0>M 'HG_  _&T/\
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M=2MM'T73X3/=7UY($BB0=R3^  ZDD <FKUCI]KIL1BL[:&TB+;BD$80$],X
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M17VL1:0+2"[%N4+P3R[]Q1L@>01C'\77BOCC_A^-H?\ T234/_!Y'_\ &*]
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\A?MJ?\E\_9E_[&9O\
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M&7#&I\*?^"N&MZ%X^M?"7Q^^'$G@*>9D234;:WN+8VF[@/+:3YD\O.<LK$@
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MJ /TJK\C?^"<<C>"/^"CWQE\*V^([!AK=GY)XY@U%-A ]0%8?0FOURK\C_\
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M444 ?*O[57_)TW[)7_8YQ?\ I=IU?JK7Y5?M5?\ )TW[)7_8YQ?^EVG5^JM
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M7C;Q+\??VK/ O[.OA_4#::8LMFMS%N(C:^N3D2R@?>6*!D8#MO?U%?=/PO\
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M=9W6DS:78>0T_GSBPM]J>6I!;/H#7[<U^0'QJ_Y32:%_V&=%_P#2&"@#J_\
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M_P""T6G0ZE&!%!XBT?RHY,$#R[&W>,CZL P]S7['5^/W_!2K1[W]GO\ ;N\
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M+H _GXU#X<_M-:3;^??>&/BQ909QYEQI^IQKG!.,E?0'\JY[P+)\8_B9XO\
M^$5\,ZMXIU7Q'B0C2TU25)SL^^ K."649)4<@ G& :_HH_X6SX'_ .AR\/\
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M BX"KD#)^[]'_P""U7PAN/#J7.I^$O&%EK(0>9I]M!;3Q;_1)C,F5Z<E5/\
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M-]O@3XD'Q,^)FIIXD^)4OF/!#'(9H-/>3.^4R,-TTY!8%^ -S8W'#5]WT44
M%?%__!5OX0^,OC5^SOX=T3P/X>O/$NK6_BFWO9;2Q4%TA6TO$+G)' :1!_P(
M5]H44 >0?L@^%-7\"_LQ_#7P_K]A-I>LZ=HL%O=V<X >&0#E6]Q7JVI:;:ZQ
MIUU87]M%>6-U$T$]O.@>.6-@59&4\$$$@@]0:LT4 ?A9^T]_P3+^*'@+XQZU
M9?#CP=J?BOP3<-]KTN[L]KF")R3]GDRV=\9!7/\ $H5NY _=.BB@#\./@/\
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M5"1W(Q7T!^QEX0UGP#^RW\-_#WB'3IM)UK3]*6&ZLK@ 20N&8[6QWY%>T44
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M[T_\2_)GU[1117GG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"B2:?_ .#R3_XQ1_P_&US_ *))I_\ X/)/_C% 'ZT1QI#&L<:JB* JJHP
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MRO0PGPUO\+_-'%B=Z?\ B7Y,^O:***\\[0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M==PP)(R9 5;@[B,@X( /TM'_  1]_9]&DFT\CQ,;@C'V_P#M;]\.#SC9Y?\
MXYVK\]?CQ^S7X5_89_:<T+2O'FD+\3OACJT*W2)-//9W0MB^R0[H)(_W\1!(
MY*.",A2WR_>4G_!9WX%KIYG71O&SS[<BU_LVV#Y],_:=OZU^;G[67[2GB/\
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M.Z,:G/DRXQ+%GU20.A]U-?!'["O[(*>-?^"=OCG3=3MTCU7XE">ZLGE&TQK
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MV_M/?%7]@?XQ1>%?&-OJUGX92X2+6O">JAL11,>;BW4Y"N 2P9/ED  .000
M?O;14-G>0ZA:075M*L]O.BRQ2H<JZL,@@^A!J:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\:/^"EMT/A=_P4/\
M$>--3@FFTF*+1M8("$AX[>Y(D1>Q/[D\?[0]:X/_ (*D?M4>&/VD_BGX6M_
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M_P DL^&G_89N/_1 H ZK]N7Q]?>&O^"8'AA8IRMSXATO0M-FF_B*O#'-(/\
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MP[U^Q5?DK_P1O_Y+]\9/^O)?_2IJ /T/_:\LX+[]E/XQ1W$2RQKX0U:4*PR
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M>UZ.(_W>AZ/_ -*9QT?XU7U7Y(****\X[ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /,/VHM)N]>_9I^*^FV 9KRZ\*:I#"BJ6+LUI( H'OT_&
MOS"_X(S_ !6\ ^ _'7CG0O$FHV>C^)_$,=E#H]S?.L:SA&E\RW21N [,\1"9
M^<J,9*BOV+Z\'D5^;&H?\$J;CP3^U]X,^('@JZL[GX=0>((=7O-'NI-ESIQC
M?SMD>1MEAWJH R& 8##8+4 <58:E::3_ ,%NM7N[ZZALK2(2M)/<2".-!_8
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M")#\ID9HW)+@@ #Y3NROYKW/_!03]HBZG>5_BOKBLW41F*-?P54 'X"OH?\
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M:[\-7EWX>6;2->T[;_:.@WS*9X V0LBL.)(R01N&,'@A<C(![]1110 4444
M%?(7PU_Y25?%?_L68?\ T7IE?7M?(7PU_P"4E7Q7_P"Q9A_]%Z97H83X:W^%
M_FCBQ.]/_$OR9]>T445YYVA1110 4444 %%%% !1110 4444 %>%?'C]B?X1
M_M*>*;+Q'X\\/3ZEK%G9K817-OJ$]L?)5W=5(C< X:1SG&?F^E>ZT4 ?'_\
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M** "BBB@ HHHH ^0OVU/^2^?LR_]C,W_ *5:?7U[7R%^VI_R7S]F7_L9F_\
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MS_@H?X._99UFW\*VNDW/CCQ]<(DBZ'83")+<.0$\^7:Q5F!RJ*C,1@D*&4D
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M/PS^U]:V6K1ZB?"_CG3H3;VVL)!YL<\.2PAG3()4,258'*[FX8<4 <K\0_\
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M,/#WB*>\NM6U6SU*&YDOX9[@RFW1()3N#.%8B3:H"@D$[5/KGQ*_X(G^$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY_CE\>]4CUGXA3.\UKI;R)<M;3L @N)I4)C+J@*HD>50;2#E0%_06@#\J_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y"_;4_Y+Y^S+_V,S?^E6GU
M]>U\A?MJ?\E\_9E_[&9O_2K3Z^O:]'$?[O0]'_Z4SCH_QJOJOR04445YQV!1
M110 5Y?=?L\^'+K]HJT^,[WNJ#Q1;:$?#Z6BRQ_8C;F1I-Q3R]^_+GG?C&.*
M]0HH **** "BBB@ HHHH **** "BBB@ HHHH 1E#J58!E(P0>AK\?OVH_P#@
MD'XXMO'VIZU\'A8:WX9U"9[F/1;FZ2TN+!F8DPH7(1XQGY3N! X(.-S?KMK&
MK6>@:3>ZIJ-Q'9Z?90/<W-Q*<)%$BEG<GT !/X5^-GQI_P""QOQ/USQI>#X<
M6FE^&?"T$Q6T^V68NKNYC5OORE_E7<.=JJ"N<;B>: /I7_@G+_P3GUS]G7Q9
M<_$7XC361\4_9GM-,TFRE$RV*OQ)-)(.#(5R@"Y 5FR26PO5:K_P3*T3QI^V
M/K_QB\4ZQ%=>&9K^WU.R\,V\3;IKA(8]S7$AP GG(S;%!W C+ 9!O?\ !/']
MOJ?]K.UU;PSXKT^STOQWH]NMVS6&Y;>_MMP0RJC$E&5F0,N2#O4C&2JX?A[_
M (*D:#:_M7>)_A)XOT>'3-%MM=FT/3?$UK*Q59DD\H+<1D' :0,/,4X'&5QE
M@ ?=U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?-GBG_@GC\$/&7Q.O/'^J^&[R?Q/=Z@-4ENEU6Y13<!@P;8'V@9
M XQBOI.OPC_;%\-_'.Z_:B^)LWA_2OB%-HKZW.;233;>^:V://!C*#:5^G%
M'ZP_'3]AWX1?M'^,H/%'CO0;K4]9@LDL$FAU&>W40H[NJ[4<#.Z1^>O->=?\
M.G_V;?\ H4-0_P#!W=__ !ROR!_X1/\ :+_Z WQ0_P# 74?\*/\ A$_VB_\
MH#?%#_P%U'_"@#]?O^'3_P"S;_T*&H?^#N[_ /CE>S?L_P#[+7P[_9CL]:M?
MA]I-QI4.L2127BSWLMSO:,,$P9&.,!VZ>M?@W_PB?[1?_0&^*'_@+J/^%?IC
M_P $@=+^(.E^&_B:/'UGXEM)GN[ V@\1Q7",RA)]_E^<.1G;G'M0!^AM%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7R%\-?^4E7Q7_[%F'_T7IE?7M?(7PU_Y25?%?\ [%F'_P!%Z97H83X:
MW^%_FCBQ.]/_ !+\F?7M%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\A?MJ?\E\_9E_[&9O_2K3Z^O:^0OVU/\ DOG[
M,O\ V,S?^E6GU]>UZ.(_W>AZ/_TIG'1_C5?5?D@HHHKSCL"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \[_ &C/#>I^,OV??B7H.BHTFKZGX:U*
MSM(TZR2R6TBH@^I('XU^8O\ P1]^"?PP^)S?$>X\:^&](\4^)-->UBM].UVT
MCN8[>W<2;I%AD!4L74*6P2NT#C<<_J[\1?$5SX1^'WB?7;-(I+O2]+NKV%)P
M3&SQQ,ZA@""1E1G!!QWK^<.3]HGQO9_&+5_B;X=U,>"_%&ISR3SOX;4VD.7P
M9%$>2"K,-Q5L@GDT ?;WA3P;I_[(/_!7+2M T6W&E^$M>F$-E;9.T07UN0L:
MY_A6Z^4>R 5RG_!8+X+>$/A;\8_"^O\ A;3X='O?%-K=7FJ6MJ=L;W"2K_I
M7^%G\PYQ@$IG&2Q/R-\1/VB/B+\6/'.C>,O%?B>XU;Q/HZQ)8:FT,44L BE,
ML>/+11\KLS#(/)KM/#/AWXS_ +>OQ@TV"[N]7\8ZQ.\=I-K%XA:UTVWW$LSE
M0$BC7<S;0!DG@%FP0#^@#X/ZU<>)/A)X(U>[=I+O4-#L;J9Y#EF=[=&8D^N2
M:Z^L[P[H=MX7\/Z7HUD&%GIUK%:0!CDB.- BY_ "M&@ HHHH **** "BBB@
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MW\4G7I[:97@LFMO)\I9 007;.?,]NE 'U51110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\A?#7_E)5\5_^Q9A
M_P#1>F5]>U\A?#7_ )25?%?_ +%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[11
M17GG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:5:I )F0$*6VCG&YL?4T =E1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\A?#7_E)5\5_P#L68?_ $7IE?7M
M?(7PU_Y25?%?_L68?_1>F5Z&$^&M_A?YHXL3O3_Q+\F?7M%%%>>=H4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\A?MJ?\E\_9
ME_[&9O\ TJT^OKVOD+]M3_DOG[,O_8S-_P"E6GU]>UZ.(_W>AZ/_ -*9QT?X
MU7U7Y(****\X[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3QQ
MI&D>(/!?B#2_$#Q1Z#?:?<6VH/,ZI&ML\;+*69N%&PMDG@5\A?LS^#OV2OV4
M=8U/5/!/QI\-R7NI6HM+IM4\;6$RN@<,IVJRJ""#@X_B/K7UG\3-!N_%'PW\
M5Z+8A6OM1TF[LX!(VU3))"Z+D]ADCFOQ0_X=#_M#?] WP_\ ^#A/\* /U_\
M^&L?@A_T63X?_P#A46/_ ,=KYZ_:&\"?L>?M/>-++Q3XX^+/A.?5K/3TTR)K
M'QO9P)Y*222 %1)R=TS\_3TKX%_X=#_M#?\ 0-\/_P#@X3_"C_AT/^T-_P!
MWP__ .#A/\* /V<\2?%KX=_"FUTJR\3>.?#?A=)[<&Q76]8M[0W$2@#<GF.N
M\#CD>M=+X;\3:/XRT.UUG0-6L=<T>[4M;ZAIMREQ;S $J2DB$JP!!'!Z@U\!
M_P#!1;]B7XG?M+7WPUE\%6NFSIH.DRV=[]LOE@Q(QC(VY'(^4\U]4?L<?"W7
M?@I^S3X&\$^)HX(M=TBVFBNDMI1+&&:XE<88=?E<4 >ST444 %%%% !1110
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M=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)+-(6RO&")0/P-?.O_#D/QQ_T4OP_P#^ 4]?K_10!^0'_#D/QQ_T4OP__P"
M4]?9?[ '[%^M?L<Z/XSL]9\1V'B%M>GM9HFL87C$0B64$-NZY\P=/2OK2B@
MHHHH **** "BBB@ HHHH *_*W]OGXK^/?VD/VL]&_9@\":S+H>D;XK?5&AE9
M$NY9(1<2M-MP7BA@Y\OH6#9R=N/U2K\B?VWM.\4?L>_M_:'^T'9Z-)JWAC5)
MHKC<N5C\P6OV6ZM6?!V.T>YU)&/GX!V,  9&O?\ !-GP#X?_ &Q? _P7;Q#X
M@N=-UCPA/K%WJH>%)_MB/<*&C7RRJQ_NE^0[CC/S=ZZ;]C/QA\0/V-_VTK[]
MG/Q'JMQXB\&WMQ]G@<AVBMFDB,UK<PKDB(2;E1T!QN;DDID]7X?_ &OOA?\
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M+-&P.5(^7(#?K7X5\-V/@WPQI&@:9&T6FZ59PV-K&S;BL42!$!/?"J*^ O\
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M^"&O_(5^,G_7'2?_ $*\K]5=4U.TT73;O4+^XCM+&TA>>>XF;:D4:J69F/8
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M6.L2?&'X\?$[1=9^(%Y=O>6>D:M.TQM9-Q/VFYRI#S,?F53D(,'[V-GZ,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<?\ %_P/??$SX8^)?"NF:_<>%=0U:R>U@UJT5FELV8<2*%="2/9E^M?S\^/?
MAM>_!K]KG5?!WBOQ_JFBW.G:YY-UXYM[>22[19,,M\8Q,'RRR*[ 2E@&;!8]
M?Z-J^1/VV_\ @GCX:_:VFMO$5EJA\*>.[2 6RZB(1+;WD0.52X088E<D*ZG(
M!((8!0 #\\/VF?"-I\&OA[]NT7]M#5/BEK%_LB@\/:/<32++$YQ(TTJ7\JQ*
M%W<,I+' QR2.6_8!_8S\4?M1:]XBUG0_'%Y\-X?#:1JFNV-J\TSSS!QY496:
M(K^[#[B&X#*"/FKV_P ,?\$1_'T^O(GB+X@^&[+11(-T^EQ7%Q<LG&<1ND:@
M]?XR!UYZ5^H'P$^ _A/]G#X:Z?X*\'VC0:=:DR2W$Y#7%Y.V-\TS #<YP.P
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_8X_X)YFR?QVLWC_ ,=-&L\5EJ,2ZA<D?WUM1M@B4G[IEYXX8X- 'YP_!/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<>7[YSVQ0!]04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?(7PU_Y25?%?\ [%F'_P!%Z97U[7R%\-?^4E7Q
M7_[%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[1117GG:%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?(7[:G_)?/V9?^QF;_ -*M
M/KZ]KY"_;4_Y+Y^S+_V,S?\ I5I]?7M>CB/]WH>C_P#2F<='^-5]5^2"BBBO
M..P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY&_:D_P"":/PP
M_:8URX\3"6[\%^+YQ^_U/2$1HKMO[\\###M_M*R,>Y.!7TK\2O&UM\-?AWXH
M\77D?G6N@Z7=:G+%NV[UAB:0J#@X)VXZ=Z_ [Q]_P46_:#\?:U<WTGQ&U/0X
M)7+1V.A%;*&!<DA%V ,0,]69B>,DT ?T&Z?80:5I]M96L8BMK:)88HUZ*B@!
M1^  KX8T7X<_LI?L%_&:^UOQ7XG6U^(>K^=J]G)K4,LPL;:>:50+9(HBJ#Y'
M3<27PK<@-BORP_X;6^/?_17O&'_@VE_QKSWXA_%#Q=\6M:AU?QGXCU+Q/JD-
MNMI'>:I<-/(D(9F$89CD*&=SCU8T ?T]VMS%>6T5Q"_F0RH)$8=U(R#^52U^
M _[-O_!0[XH_"WXN>&=4\7>-M?\ %/@V&46VI:3?7CSI]E8;6=$8_?C&'7&,
ME<9P37[VZ1JUGKVDV6IZ=<Q7NGWL"7-M<PL&CFB=0R.I'4$$$'WH MT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^)
MG_!6;1M6\2?MN:1I%U-]GM[_ $G3;739K@D1)')+(I;V E,N?H:^P?"__!&O
MX'Z386R:OJ/BG7;U8\3S/?QP1R/CDJB1@J,]!N/N37G7_!:+Q)\-%\-^%-#U
M&RN+GXI@&[TNYLV5!:V1?;)]H)!WH[(VQ1R&1CD#(?Y<^%__  5H^/'PS\,V
MFB2W&A>,8;6/RHKKQ+:337.T= TL4T9<@<9?)]2: /T%_P"'0W[//_0.\0?^
M#A_\*]Q_9Q_9/\ ?LKV6NVO@.WO[>+69(9;O[==FX):,.$VY''#M7Y=?\/J_
MC?\ ]"M\/_\ P77W_P F5]Q?\$X_VR/&G[7VB^.;SQCIF@Z;+H5Q:16PT.WG
MB#B592V_S9I,D>6,8QU/6@#['HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *^0OAK_P I*OBO_P!BS#_Z+TRO
MKVOD+X:_\I*OBO\ ]BS#_P"B],KT,)\-;_"_S1Q8G>G_ (E^3/KVBBBO/.T*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M? GP!\#[?48/ ?A:P\,1:BR/=I8J0)F0,$+9)Z!F_.OP]_X>C?M._P#13/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%LEY,Q,L]E*K>1O)^\R&*1-W4@)GGD@'W11110 4444 %%%% !1110 4444
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MO#F:^+S[,]K_ .&\O@7_ -#S_P"4B_\ _C%'_#>7P+_Z'G_RD7__ ,8KO_\
MAGSX6_\ 1-?"'_@AM?\ XW1_PSY\+?\ HFOA#_P0VO\ \;KBO@NTOO7^1UVQ
M7>/W/_,X#_AO+X%_]#S_ .4B_P#_ (Q1_P -Y? O_H>?_*1?_P#QBN__ .&?
M/A;_ -$U\(?^"&U_^-T?\,^?"W_HFOA#_P $-K_\;HO@NTOO7^06Q7>/W/\
MS. _X;R^!?\ T//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBN__P"&?/A;_P!$
MU\(?^"&U_P#C='_#/GPM_P"B:^$/_!#:_P#QNB^"[2^]?Y!;%=X_<_\ ,X#_
M (;R^!?_ $//_E(O_P#XQ1_PWE\"_P#H>?\ RD7_ /\ &*[_ /X9\^%O_1-?
M"'_@AM?_ (W1_P ,^?"W_HFOA#_P0VO_ ,;HO@NTOO7^06Q7>/W/_,X#_AO+
MX%_]#S_Y2+__ .,4?\-Y? O_ *'G_P I%_\ _&*[_P#X9\^%O_1-?"'_ ((;
M7_XW1_PSY\+?^B:^$/\ P0VO_P ;HO@NTOO7^06Q7>/W/_,X#_AO+X%_]#S_
M .4B_P#_ (Q1_P -Y? O_H>?_*1?_P#QBOSW^%7@_1=>_:E_:-TF_P!-M[G2
MM(\1R0:=8LN(+./[3=+LB0?*BX51@ #"BO</^%/^"_\ H6K#_OU7T.$R?#XN
MC&M%R2?FN]NQ^;9QQNLGQL\#5I<SC;5;:I/OYGTQ_P -Y? O_H>?_*1?_P#Q
MBC_AO+X%_P#0\_\ E(O_ /XQ7S/_ ,*?\%_]"U8?]^J/^%/^"_\ H6K#_OU7
M9_J[0_F?WK_(\;_B)5/_ )\O^OF?3'_#>7P+_P"AY_\ *1?_ /QBC_AO+X%_
M]#S_ .4B_P#_ (Q7S/\ \*?\%_\ 0M6'_?JC_A3_ (+_ .A:L/\ OU1_J[0_
MF?WK_(/^(E4_^?+_ *^9],?\-Y? O_H>?_*1?_\ QBC_ (;R^!?_ $//_E(O
M_P#XQ7S/_P *?\%_]"U8?]^J/^%/^"_^A:L/^_5'^KM#^9_>O\@_XB53_P"?
M+_KYGTQ_PWE\"_\ H>?_ "D7_P#\8H_X;R^!?_0\_P#E(O\ _P",5\S_ /"G
M_!?_ $+5A_WZH_X4_P""_P#H6K#_ +]4?ZNT/YG]Z_R#_B)5/_GR_P"OF?3'
M_#>7P+_Z'G_RD7__ ,8H_P"&\O@7_P!#S_Y2+_\ ^,5\S_\ "G_!?_0M6'_?
MJC_A3_@O_H6K#_OU1_J[0_F?WK_(/^(E4_\ GR_Z^9],?\-Y? O_ *'G_P I
M%_\ _&*/^&\O@7_T//\ Y2+_ /\ C%?,_P#PI_P7_P!"U8?]^J/^%/\ @O\
MZ%JP_P"_5'^KM#^9_>O\@_XB53_Y\O\ KYGTQ_PWE\"_^AY_\I%__P#&*/\
MAO+X%_\ 0\_^4B__ /C%?,__  I_P7_T+5A_WZH_X4_X+_Z%JP_[]4?ZNT/Y
MG]Z_R#_B)5/_ )\O^OF?3'_#>7P+_P"AY_\ *1?_ /QBC_AO+X%_]#S_ .4B
M_P#_ (Q7S/\ \*?\%_\ 0M6'_?JC_A3_ (+_ .A:L/\ OU1_J[0_F?WK_(/^
M(E4_^?+_ *^9],?\-Y? O_H>?_*1?_\ QBC_ (;R^!?_ $//_E(O_P#XQ7S/
M_P *?\%_]"U8?]^J/^%/^"_^A:L/^_5'^KM#^9_>O\@_XB53_P"?+_KYGTQ_
MPWE\"_\ H>?_ "D7_P#\8H_X;R^!?_0\_P#E(O\ _P",5\S_ /"G_!?_ $+5
MA_WZH_X4_P""_P#H6K#_ +]4?ZNT/YG]Z_R#_B)5/_GR_P"OF?3'_#>7P+_Z
M'G_RD7__ ,8H_P"&\O@7_P!#S_Y2+_\ ^,5\S_\ "G_!?_0M6'_?JC_A3_@O
M_H6K#_OU1_J[0_F?WK_(/^(E4_\ GR_Z^9],?\-Y? O_ *'G_P I%_\ _&*/
M^&\O@7_T//\ Y2+_ /\ C%?,_P#PI_P7_P!"U8?]^J/^%/\ @O\ Z%JP_P"_
M5'^KM#^9_>O\@_XB53_Y\O\ KYGTQ_PWE\"_^AY_\I%__P#&*/\ AO+X%_\
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M_0\_^4B__P#C%'_#>7P+_P"AY_\ *1?_ /QBO&/^%&> /^A2TS_OR*/^%&>
M/^A2TS_OR*+X+M+[U_D%L5WC]S_S/9_^&\O@7_T//_E(O_\ XQ1_PWE\"_\
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M](\4WUOXKGMH;K6K&*\ECB%K;,(U:16(4%F. <98^M?<7_#/GPM_Z)KX0_\
M!#:__&Z+X+M+[U_D%L5WC]S_ ,S@/^&\O@7_ -#S_P"4B_\ _C%'_#>7P+_Z
M'G_RD7__ ,8KO_\ AGSX6_\ 1-?"'_@AM?\ XW1_PSY\+?\ HFOA#_P0VO\
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M9],?\-Y? O\ Z'G_ ,I%_P#_ !BC_AO+X%_]#S_Y2+__ .,5\S_\*?\ !?\
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M_P"A:L/^_5'^KM#^9_>O\@_XB53_ .?+_KYGTQ_PWE\"_P#H>?\ RD7_ /\
M&*/^&\O@7_T//_E(O_\ XQ7S/_PI_P %_P#0M6'_ 'ZH_P"%/^"_^A:L/^_5
M'^KM#^9_>O\ (/\ B)5/_GR_Z^9],?\ #>7P+_Z'G_RD7_\ \8H_X;R^!?\
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MC,+A,%5]E+F;]5_D?H>29O5SS!K&4DHIMJS3OIZ,]M_X;R^!?_0\_P#E(O\
M_P",4?\ #>7P+_Z'G_RD7_\ \8KQC_A1G@#_ *%+3/\ OR*/^%&> /\ H4M,
M_P"_(KAO@NTOO7^1[]L5WC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y?
MO_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5
MWC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&
M> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\
MT//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^
MA2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y?
MO_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5
MWC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&
M> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\
MT//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^
MA2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y?
MO_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5
MWC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&
M> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\
MT//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^
MA2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y?
MO_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5
MWC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&
M> /^A2TS_OR*/^%&> /^A2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\
MT//_ )2+_P#^,4?\-Y? O_H>?_*1?_\ QBO&/^%&> /^A2TS_OR*/^%&> /^
MA2TS_OR*+X+M+[U_D%L5WC]S_P SV?\ X;R^!?\ T//_ )2+_P#^,4?\-Y?
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MGPM_Z)KX0_\ !#:__&Z+X+M+[U_D%L5WC]S_ ,S@/^&\O@7_ -#S_P"4B_\
M_C%'_#>7P+_Z'G_RD7__ ,8KO_\ AGSX6_\ 1-?"'_@AM?\ XW1_PSY\+?\
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MWQW_ -CC<?\ I):U^@5?G[_P1A_Y-]\=_P#8XW'_ *26M?H%0 4444 %%%%
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MP#_T4WQY_P"!-O\ _&J_06B@#\^O^'-O@'_HIOCS_P ";?\ ^-4?\.;? /\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(7PU_Y25?%?\
M[%F'_P!%Z97U[7R%\-?^4E7Q7_[%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[1
M117GG:%%%% !1110 4444 %%%% 'Y(_!/_D[W]J/_L:)?_2N\KZ(KYW^"?\
MR=[^U'_V-$O_ *5WE?1%?I^2_P"XT_G^;/Y3XY_Y*#$?]N?^D1"BBBO</@PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KYM_8?_Y+_P#M&_\ 8<'_ *57E?25?-O[#_\ R7_]HW_L.#_TJO*^0XC_
M (5/U?Y'[+X9_P"]XC_"OS/LVBBBO@S^@PHHHH **** "BBB@ HHHH ****
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MN<'"J"QP<"OC#4_^"T'P1L=<-G;:#XSU&P5BK:A#86ZHWHRH]PK$?[P4^QH
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M:F_Z'+XP?^#35?\ XNOU_P#^'HW[,7_13/\ R@:I_P#(U'_#T;]F+_HIG_E
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M-O\ _&J_06B@#\^O^'-O@'_HIOCS_P ";?\ ^-4?\.;? /\ T4WQY_X$V_\
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M#+'F>/"JN6Y&5ZU[S\.OB-X;^+7@W3/%?A+5H-;T#48S);7EOG#8)5@00"K
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M%:^^!GQU'D>-+=I(+#4KJ)8+B2XCY:UG" (S%06208W;2"6+*3^C- !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7R%\-?^4E7Q7_[%F'_ -%Z97U[7R%\-?\ E)5\5_\ L68?_1>F5Z&$
M^&M_A?YHXL3O3_Q+\F?7M%%%>>=H4444 %%%% !1110 4444 ?DC\$_^3O?V
MH_\ L:)?_2N\KZ(KYW^"?_)WO[4?_8T2_P#I7>5]$5^GY+_N-/Y_FS^4^.?^
M2@Q'_;G_ *1$****]P^#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "N%_X);_ /)Q/[4G_87M?_2B^KNJX7_@EO\
M\G$_M2?]A>U_]*+ZOD>(_P"#3]?T/V3PS_WW$?X5^9^D%%%%?!']"!1110 4
M444 %%%% !1110 45#>7D&GVD]U=31VUM C2RS2L%2-%&69B>   22:_-7XR
M?\%6M8\;:UXA\'_ 3X>ZAXO$%I<"7Q$RS%DC4%7N8H81N2->&$KNO;*B@#],
M**_'S]G#_@J)\1O@C\.O!UK\4O!.M>+?!EX]R+7QI<7%P]_?+]HE,A$TY:.X
M:-BT>T.F%102,<_K'X!\>:%\4/!ND>*O#.H1:IH6JVZW-K=1'AE/8CLP.05/
M(((/(H Z"BO.?CO^T%X(_9O\$2>*?'.K#3;#?Y5O!&OF7%W+@D10QCEFP/8
M<D@<U\.7G_!:K1?M,UWI_P 'O$%UX:CDV-JDVH)&ZYQMW(L;(&/S<>9V'//
M!^E-%>)?LP?M>?#_ /:Q\-W.H>#[N>#4K )_:.BZA&([JS+9VD@$JZ$@X=21
MQS@\5[;0 445XM^TQ^US\._V4O#]MJ'C74)FO[X.=/T;3XO-N[S;C<54D*JC
M(RSLJ]LD\4 >TT5^:\'_  6HT5+J&ZOO@]XAM?#,KA!JD=^CN>N[:AC5"0-O
M'F<Y[=_N'X#_ +07@C]I'P/'XJ\#:K_:&G[_ ";B"5#'<6DV 3%+&?NL 1TR
M#U!(YH ]'HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^7_\ @II_R8Y\3_\ KC8_^E]M7U!7R_\ \%-/^3'/
MB?\ ]<;'_P!+[:@#YZ_9]_Y(7\/_ /L V7_HE*[^N _9]_Y(7\/_ /L V7_H
ME*[^OV/#_P &'HOR/XGS'_?:W^*7YL****Z#SPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y=_P""B7_)"]-_[#UO
M_P"B9Z_7W2?^059?]<4_]!%?D%_P42_Y(7IO_8>M_P#T3/7Z^Z3_ ,@JR_ZX
MI_Z"*_-L^_WQ^B/Z>\/O^1(O\4OT+=%%%?.GZ4%%%% !1110 5X'^VM\&OB'
M\=/@[#X<^&7BB'PCXC75(+MM0FU"XLE,"I('3S($=^2RG&,''L*]\HH _)7_
M (=L_MA?]%TT_P#\*_6/_D>OL;X;ZUJ?["?[(=M>_&_Q#<>)[[1[J3[;JFES
M3ZD\GGW)\E0\RHYQO1?F  Z9Q7U)7#?'#X2Z5\=OA+XH\!:TQBL-<LVMC,JA
MF@D!#12@'@E)%1P/510!@_#'XX^'/VC/@++X\\*K>1:/J%K>QI#J$:QW$;1-
M)$P=59@,E-P^8\,IXZ5\@?L;_ SP;\>?^"9NGZ)XOTRUN8T&L26FHR(!/I\H
MN)BLT4F,H5(!/8@88$$BOG?X;^//CM_P3*N/%O@GQ9X O/%/P[U%Y76\MMZV
M8E9 GVFWN@C*-R!=T3@'Y5SL.<\E\%?VF/B[X@_95L/V?/A'\/-4O[Z^DN[:
M_P#$EFKRDPW$KL\:80)!\K[6E=\ %N%X8 'T9_P0_P#%NJWOACXJ>&YY)I='
MT^ZT^]ME9B4BEF6=90!V+"",\?W>:_3^OF3]@/\ 9);]DOX-MIFJRPW7C'6Y
MQ?:S-;N7B1@"L4"'C*HI.3CEF?MBOIN@#\R_^"X/_(@_"S_L)WO_ **CK[_^
M"/\ R1?P#_V+^G_^DT=?#O\ P67\!^)O'7@;X:1>&O#NK>(9;?4;QIH]*L9;
MEHU,48!8(IP#@]?2ON?X-VL]C\(? ]M<PR6]Q#H5C'+#*I5T86Z JP/(((P0
M: .PHKR#]K?QUXS^&O[/'B_Q)\/;*34?&%C';M86L5DUXSEKF)'Q$H);$;.>
M.F,]JXW]@GXL?$[XQ_!?4-<^+&E3:1XEBUN>TB@FTQ]/8VRPP,C>6P!(W/)\
MW?&.U 'Y^?LM>#;'PK_P5S\3:1KL:"XM]:UV?3EF4?/(ZS2PL >_DN7&/;%?
MLI7YZ?\ !0C]C/QSK?Q*T7X^?!19&\>:289+_3[4@3SM /W5Q$&XD8(!&T?\
M:JH /(/&P_\ !6WXD:7H:Z'J_P"S]JA^(*1F)TWW$$)E /S_ &9H#*!D9*;\
M\'YAV .(_;<MX]-_X*N?"6?P\JC5[FZ\/27>Q0-T_P!M,?S8Y(,*Q D]O85^
MNE?FI^PU^R;\3/'_ .T!?_M(?'6SFTW6Y9'GTK1[V,Q3F9D\M97A/,444?R1
MQM\V0IX"@M^E= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(7
M[:G_ "7S]F7_ +&9O_2K3Z^O:^0OVU/^2^?LR_\ 8S-_Z5:?7U[7HXC_ '>A
MZ/\ ]*9QT?XU7U7Y(****\X[ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\K_:>^!%C^TG\$/$O@"]N!8R:C"KVEZ5+"VN8V#Q2$ C(#* 1W4L.]>J4
M4 ?SH>./@S\>?V*?&$M_<VGB+P5<Q$P1^(]#FE6TN$)'"W,7RL&X.QB#TRH/
M%>.ZEX@OO&/B+^T?$^M:AJ-S=2J;O4KN1KNY*D_,Q+L"Y SP6&?45_49=6L-
M[;RV]Q#'/!*I22*50RNIZ@@\$5\K?&O_ ()D_ GXR_:+I/#1\%:U+D_VAX78
M6HW>K08,)YZX0,?[U 'QK^Q[^RE^QSX^^Q2:M\59/'/B)\9T+5Y#H*%S_ L)
M822$?[$S ^E?J9\//A/X,^$ND_V9X,\+:3X8LN-T>F6B0^81W<J,N?=B37Y!
M?&O_ ((X?%/P1]HO? .JZ=\0M-7++:Y%A?@<G&R1C&V!W$F2>BUX5X9_:$_:
M/_8^UR/0_P"W/%'A)K?IH/B&%Y+4J.#L@N%*A3_>0#M@]#0!_0]15#0;R34-
M#TZZF(,L]M'*^T8&YE!/ZFK] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%?EA^T5_P5I^(OP;^.7C;P1IG@_P +WNGZ
M%J<MC!<78N?-D53P6VR@9^@% '8_\%$/^"?OQ/\ VI/CGIWB[P;<:#%I5OH5
MOIKKJE[)#+YJ33NV%6-AMQ*O.?6OE[_AS;\>_P#G\\'_ /@TE_\ C%=7_P /
MM/BG_P!"+X/_ .^;K_X]1_P^T^*?_0B^#_\ OFZ_^/4 <I_PYM^/?_/YX/\
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MP84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@#\D?@G_ ,G>_M1_]C1+_P"E=Y7T17SO\$_^3O?VH_\
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MH_\ @GG9^./"VG^#I?B#\,=9BN/-N=/MY+JV56B*&[7RLR6TFP ,)%VG;_$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OE_P#X*:?\F.?$_P#ZXV/_ *7VU?4%?+__  4T_P"3'/B?_P!<;'_T
MOMJ /GK]GW_DA?P__P"P#9?^B4KOZX#]GW_DA?P__P"P#9?^B4KOZ_8\/_!A
MZ+\C^)\Q_P!]K?XI?FPHHHKH//"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /EW_@HE_R0O3?^P];_ /HF>OU]TG_D
M%67_ %Q3_P!!%?D%_P %$O\ DA>F_P#8>M__ $3/7Z^Z3_R"K+_KBG_H(K\V
MS[_?'Z(_I[P^_P"1(O\ %+]"W1117SI^E!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'R%^VI_R7S]F7_L9F_]*M/KZ]KY"_;4_P"2^?LR_P#8S-_Z5:?7
MU[7HXC_=Z'H__2F<='^-5]5^2"BBBO..P**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#+\5>(K;PCX8U?7;Q)9+32[.:]F2  R,D:%V"@D G"G&2
M!GO7PI_P^K^"'_0K?$#_ ,%UC_\ )E?<GC?PW_PF7@O7] ^T?8_[5T^XL?M&
MS?Y7FQLF_;D;L;LXR,XZBOS&_P"'&/\ U6S_ ,M3_P"[: /5?^'U?P0_Z%;X
M@?\ @NL?_DRC_A]7\$/^A6^('_@NL?\ Y,KX*_;B_8)_X8QTKPC>_P#"=?\
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M4_$$.W3=7TG2&D:2XAY,4ZQJ>2ARC$<E63LE '6_MN?\%(M2_9'^+MCX+M/
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M .!D?_R51_;F"_F?W,/]0<]_Y]Q_\"1[M17A/_&9'_1!M/\ _ R/_P"2J/\
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M"?M">$SX=\>^'K?7=.5O,A:0M'-;28QOBE4AD;Z'D<'(XH ^0D^*'A/XN?\
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MK>TG37*U[W7T9]VT445XAZ@4444 %%%% !1110 4444 ?DC\$_\ D[W]J/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6_9[T7]G_P".VC>*_"EW>6Y\8M=:S<0RSEWM[Y9P\DD;GY@K-*K $DA@V#C
M !^X-%<Q\+O$4WC#X9^$=>N3NN-4TBSOI&QC+2PHYX[<M73T %%%% !1110
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MJ*KY[IG/E1J!B*/.#M&22!N+8& #Z'HHHH **** "OD+X:_\I*OBO_V+,/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)5+R-ST4' Y.!S7Y%?M9?\%.-:^+WVWP[\,]#@\ ^$I,QM?"",:K>)[R*"(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP0(U)Y; ^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^E/_  WY^SS_ -%8\/\
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M2>!/A@/#>ENQU_Q0S644<7+K;\"5@!W8,L8_WSCI7T7)(D,;R2.L<: LS,<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM];),$)QDKN!QG Z>E7K2T@T^UAM;6&.VMH46.*&% J1H!@*H'     %344
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M@Z@ AE. <BOT);_@M)\$%T\3KX<\<M<D[?LO]GV@8<=2WVK;MSQUS[5\ _M
M_M;:)^V/^T5X:U[XC6E]X5^&FCC[.NFZ2HN[S[.&WR#<2@,DI 4MP$&,!BOS
M '[J?#'Q)<^,OAKX3\07D8BN]5TFTOYHU& KRPH[ #V+&NFKX/L_^"PW[/NG
M6<%I:Z=XMM[:"-8HH8])A5411A5 \_@  "OKWX-_%C1/CE\--#\<^'$NDT76
M(WEMEOHQ',%61HSN4,0.4/<T =G1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R%\-?^4E
M7Q7_ .Q9A_\ 1>F5]>U\A?#7_E)5\5_^Q9A_]%Z97H83X:W^%_FCBQ.]/_$O
MR9]>T445YYVA1110 4444 %%%% !1110!^2/P3_Y.]_:C_[&B7_TKO*^B*^=
M_@G_ ,G>_M1_]C1+_P"E=Y7T17Z?DO\ N-/Y_FS^4^.?^2@Q'_;G_I$0HHHK
MW#X,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MFR2)#&\DCK'&@+,S'  '4D^E 'SI^V_\6I/ GPP'AO2W8Z_XH9K**.+EUM^!
M*P [L&6,?[YQTKN?V=?A/'\&_A3I&A,BC4W7[7J,B_Q7+@%AGN% 5 ?1!7SS
M\+4?]J/]JK5O'MRK2^$?"A6/3%<?*[*6\C@]RV^8^AV@\&OM*OYKXWSCZ]B_
MJ]-^['^E_G\UV/ZJX9RG^QLLA1DK5)>]+U>R^2T];A1117YF?4A7RA^TW'JW
MP!^,W@;X_P#A2(_:]-O(X-4B0[1, "H#D?PR1%X6/8;.YKZOKGOB%X)L/B/X
M)UGPUJ:YL]2MVA9L9,;=4<>ZL%8>ZBO1R_%O!8F-7IU].I<)<LKGWAX!\;Z3
M\2O!.A^*]!N!=Z/K-G%?6LO<QR*& ([,,X([$$=JWZ_-S_@DK\:;_0)/%_[/
M?BV7RM:\-7$U[I"R-]Z OBXB3/4*[+*N.HF<]%K](Z_8XR4DI+9GI!17D7[0
M/[57PY_9AAT.7X@ZO<:4FM-,MD8+*6YWF((7SY:G;CS$Z]<UXY_P]@_9M_Z&
M_4/_  27?_QNF!E?\%=O!^J^*OV/[JYTR&2>/1-:M-3O4CR3]G"RQ,V!U"M,
MC'T )[5XGX+_ &@/!'Q$_P""4?B;PAIFK6=MXK\.^&&L+[0Y)%2XRD@_?(A.
M71QAMRY )(."*_2#P_K6A?%;X?Z;J]K''JWAGQ)I<=U%'=P?)<VEQ$&4/&XZ
M,CC*L.Y!%?FG^W)_P2[^'?@7X;^,OBAX%U6_\,+I%JU_)X>=!=6DAW %8F9@
M\0^;N7 Q@ "@#[(^$?PB\(_&[]BGX0>%O&^C1Z]H,OA+0;A[.262(&2.SA9#
MNC96X(Z9P1D'()%>Q_#_ .'OAWX5^$=/\+^%-*AT30+ .+6QMRQ2+<[.V-Q)
MY9F;KU)K\;O#'C?]J_\ 8A^'?@#X@C6)O%7PFU;3;&[MK.ZN7OK"W@G@1XK:
M16Q):D*X4%,)N& 6'!_6G]G3XZ:+^T?\'_#_ (]T-&MX-2B(N+-VW/:7"';+
M"3@9VL#AL#<-K8&: /EK]MSX#_M#?M._%ZV\">$]>_X1;X,G3()-3OI9EBAF
MN&>3S$9$_?7!"JF(SB/.,D$YKXC_ &M_V7_"W[)_[0WP2\)>&)KJ^-Q#97FH
M:C>MF2[N#?LI?:/E1<*H"CH!R2<D_N77Y*_\%7/^3T/@G_UY6/\ Z<9* /UJ
MK\J/^"JU]>?&#]J[X)_!>"X\NQN/L[R;6QB:^N_();W6.$$>F\^M?JO7XG_\
M%//$GB'PO^W]8ZKX;E>W\06>G::VES1J"Z3'=L9<\;@[<9[T ?I_XM_:8^!/
M[-%OIO@S6?&^A>&/[+MXK.WT6%VGEM(D0"-'BB#M&-H&-X&?>N"^('PA_9\_
MX*,0^']?C\3CQ)_PCOF(DGAW45AF192C>7<(4,BC,>5!"D9;'6N"^#?_  27
M^$^D^#+>;XHVE]X\\<7R?:-3U";5;F&..X< NL7E2(6"MGYY"Q8Y)QD*/DK]
MJ;X'ZG_P3)_: \$_$WX6ZC=R>%M2FDV:?=SDE2A4S6,S#_60R(PVDY88.?F0
M,0#]F[6#[+;10^9)+Y:!/,E;<[8&,D]R:EK(\(>);7QGX3T3Q!99^Q:M8P7\
M&[D^7+&KK^C"O(?VV_CLW[.O[-?B_P 6VDBIK1A&GZ4"<'[7.=B,/78"TF.X
MC- 'P+^V5\1O$'[>7[6^A_L^^ K]D\'Z)>F/4;N+YHGN(\_:KI\?>6%=T: ]
M7W8/SKC]2/AG\-] ^$/@/1?!_ABQ33]#TFW6WMX5ZD#DNQ_B=F)9F/)+$]Z^
M$/\ @CA\ 8_#/PMUGXM:I$9-;\53/96,LHRR6,,F'()YS),K9]H4/K7Z+4 %
M%%% 'YE>(OV&_CG^V-\:M9U?XV>+;KP]\---U>Y71M(AEC,\MH)66,PPIF.$
MM&%S+(#(>,JPY'E_[$O@O2/AS_P50\9>%M!MC9Z+HYUBQLX"[.4BCPJ@LQ))
MP.I.37["U^2O[+O_ "F!^)G_ %^Z[_Z'0!^M5%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2O1J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ?\ B7Y,^O:***\\[0HHHH **** "BBB@ HHHH _)'X)_P#)WO[4?_8T2_\
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M:DG*=)-OR7^1^A_\1 SGM#_P'_@GR-_PA/[6_P#T/7A__OQ;?_(E9?P.TO\
M:M_:"\7^./#?ACQSH<>H>#[A+;4C?V]K%&7=Y4'ED6K;AF%^H':OLVN%_P""
M6_\ R<3^U)_V%[7_ -*+ZOG<WX?RW!4X2I45=OJE_D?H7!G$>-SW$U:6+4;1
MBFK*W4X__AD+]N'_ *'[P?\ ^0/_ )"H_P"&0OVX?^A^\'_^0/\ Y"K]4**^
M6^H83_GS'_P%?Y'ZSR1['Y4_"G_@G[^TYX?_ &F/!_Q3\0>)/"9O].U&W?4+
MVUN"DDMHN$FC\N.W16+0ETYQG(Y&,C]5J**[8QC"*C%62+/+/CE^S#\,_P!I
M*+1H_B/X:_X2)-':9K$?;[JU\DR[!)_J)4W9\M/O9QCC&37E'_#KC]F+_HF?
M_E?U3_Y)KZJHJ@/C+]OOXJ>-_P!C?]G+P=<?!^"STO1=+G@T"075N;PV5JL!
M6V*F1CT\H)N?=DLN>36;\2/CA:?M"?\ !+7Q/XQBOXK[4[CPNL&K^6 IBOXS
M&MPK( -OS@L!@?*RD<$5]=_$?X=Z!\6/ ^L^$?%&GQZGH.K6YM[JVDXRIY#*
M>JLK ,K#D,H(Y%?DY^T9_P $V_'_ .S)\-_B%XC\ ?%1I?ARUFTNK:'>236T
M]S;AL".1(PT5PR[AAF"=20%[@'TK\=?&&@^%/^"2/AR+7)H%?5O 6AZ=86\Q
M^:>Z>UMS&$'<KM,GL(R>U:?_  1[\.ZCH?[(*W-\)5AU77[R]LED4J/)V0P_
M+Z@O#(<^YKP#X _\$S?&/Q^\*?#3Q;\8?BC<:OX(71+*YTCPY83S2R06+P1M
M#;AY J6_R>6&\M6^[@-T:OU+\,^&],\&^'=,T+1+*+3='TVVCM+.S@&$AB10
MJ(/8  4 :=?DK_P5<_Y/0^"?_7E8_P#IQDK]:J^,_P!L3]A/7OVF/CKX"\>:
M9XHT[1;3PY!;PRV=W!(\DQCNFF)4KP,AL<]Z /LROR8_X*\>$+WX=_M#?"KX
MPP6/VK3/+@M9EV_(;FSN#.JN<8!>.3 !ZB)O0U^L]<-\:O@OX4_: ^'>I^"_
M&5A]NT:^ .Z-MDUO*OW)HGP=KJ>AP1U!!!((!N>!?&^B_$GP?H_BCP[?1ZEH
MFK6R75I=1'(=&&>?1@<@@\@@@\BOS7_X+5?$73=6M/AS\,].<7_B5KU]5FL[
M==\D2,AAA4@<YD9WPO4[/<9NZ?\ \$UOVB/@K<7VF?!CX^)I?A:[E+FTO[BY
MLF0-U;RXTE0R !1O786Q_#P*]._99_X)D6WPM^)*?$_XI^+I/B1X^CF^UV[2
M"1K>"Y_Y[O)(2\\@X*LP4*><$A2 #ZU^"7@VY^'7P9\!^%+P[KS0]!L-,G(;
M<#)#;I&V#W&5-?G-_P %LO'EU>W/PM^'-@[2-</<:O/:J>9)"5@MCCUYN!^-
M?J=7Q;^U%^P3KG[17[4G@;XFCQ1IUAH/A^/3X)M+GMY'FFC@NY)Y K#Y06$A
M S0!]2?"+X?VGPH^%OA/P=8HJ6VAZ9;V V=&9(PK/[EF!8GN2:ZZBB@#%U?Q
MMX=\/WR66J:_I>FWCJ'2WO+R.*1E)(!"LP)!((_"MJOA;]M#_@GAXB_:A^/6
MA>/]+\6Z7HEGIVFVMB]G>6\CR.T4\LI8%>,$2@?A7W30 5^2O[+O_*8'XF?]
M?NN_^AU^M5?&?PC_ &$]>^'/[;'BOXX7/BC3KS2M9GU":/2HH)!/&+@Y4%C\
MIQWH ^S**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX^U-4NKW4+<AGTNUSE0,Y EE(XR,A 3@;D- 'W_17SK_ ,$]?'_B+XH?L?\
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M4?\ V-$O_I7>5]$5\[_!/_D[W]J/_L:)?_2N\KZ(K]/R7_<:?S_-G\I\<_\
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MH8 CLPS@CL01VK]CP.*6,P\:RW>_KU/2A+F5S?HHHKO+"BBN:^)7C_3/A7X
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MM_9&;#&/_2$M(%_X# [ >FVOUOK\C?\ @D.WD_M6_&""?Y[O^S;@E]H'W;Y
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MO8Z[HUVNZ"_TZX6>&09P=KJ2#@@@^A!% &O1110 4444 %?(7PU_Y25?%?\
M[%F'_P!%Z97U[7R%\-?^4E7Q7_[%F'_T7IE>AA/AK?X7^:.+$[T_\2_)GU[1
M117GG:%%%% !1110 4444 %%%% 'Y(_!/_D[W]J/_L:)?_2N\KZ(KYW^"?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YS^T/\:-,
M_9\^#/BGQ[JNUX])M&>WMV;'VFY;Y881_O2,HR.@)/:@#\\_^"F/Q*N_VA/V
M@_!O[//ANZ;^R])F74-?FA.0L[)NP>W[J L1ZM-M/(KUC1](M/#^DV6F:? M
MM8V<*6\$*=$C10JJ/H *^:OV*O!6IZO#XD^+OBIVO/$WB^[FE6XF'SF(R%Y'
M]O,DSQZ1KC@U]0U^8Y_C/K&)]E%^[#3Y]?\ (X:TN:5NP4445\P8'/?$+P38
M?$?P3K/AK4US9ZE;M"S8R8VZHX]U8*P]U%9?_!)7XTW^@2>+_P!GOQ;+Y6M>
M&KB:]TA9&^] 7Q<1)GJ%=EE7'43.>BUVM?*'[3<>K? 'XS>!OC_X4B/VO3;R
M.#5(D.T3  J Y'\,D1>%CV&SN:^MX>QGL:SP\GI+;U_X/^1T496=C]G:*P/
M/C?2?B5X)T/Q7H-P+O1]9LXKZUE[F.10P!'9AG!'8@CM6_7Z0=H5E^*/"^E>
M-?#NI:#KEC%J>CZE ]M=V<X)2:)AAD;V(K4HH ^?_P#A@/\ 9Y_Z)/X?_P"_
M3_\ Q5=/HOP&\-?!/X?^,[;X/^&].\(:[J5A*UN]G%E7NTB<6[LKD@[7;H>.
M3FO6:* /SE_X)C_MN>*_C%XU\:>!OBWXG^V^+V9+K2([R"&T9@@9;BW2-%0;
MUPC;0-V/,/137HO[%>K6.@_&7]KS4M2NX-/T^T\://<75S((XH8U$Q9V8\
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M#W35=8L-"TFZU/4KVWL--M8FGN+RYE6.**-1EG9R<!0!DD\5^3W[)3#]J_\
MX*A>-/BYIT37'A;09)[R*YE& Z_9_L-GQV9D4R =O+/ISV?_  Z3^)NL6,7A
MG7?VC-4O/ \#+Y>F^1=2Q[1V%N]SY:'@ ')QUQQ@_<_[.?[-O@O]E_X?Q^%/
M!EG(D+/YUYJ%V5>ZOIL8\R5P #@<  !0.@ZY /4Z*** "BBB@ HHHH ****
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M@60OM&P?-@AAG/V%'&D,:QQJJ(H"JJC  '0 4 .HHHH **** "BBB@ HHHH
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MNG^,O\S+V4.Q^.G_  U1\4_^C;O&'_?-U_\ (='_  U1\4_^C;O&'_?-U_\
M(=?L711_8>7_ //O\9?YA[*'8_'3_AJCXI_]&W>,/^^;K_Y#KGOB#\<OB)\1
M_!6L>&M3_9L\8&SU*W:%FV71,;=5<?Z'U5@K#W45^UE%5')<!"2E&G9KSE_F
M'LH=CX"_X)"ZQ\0],^%/B?P'XV\+:YHFF:!=QW&CW6KV4ML&CN-[2P()%&0C
MH7XS_KCG'%??M%%>V:A1110 4444 %9FD^%]&T&\U&[TS2;'3KK49?/O9[2V
M2)[J3GYY64 NW)Y;)YK3HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX"'GTSZT ?KE1110 45'//':PR332+%#&I=Y)&"JJ@9))/0 5S'_  MGP/\
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MMY=6WAG67MKHV$LAE:.UFN&@NK0D\NFU24+9(RO)9-QZ36_^"C'PR\1?MJ>
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MVI/^PO:_^E%]7R/$?\&GZ_H?LGAG_ON(_P *_,_2"BBBO@C^A HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGDU\N^ _VW++P;^VUKWQZ?PG<75IJ;W3C0UOE62/SHA&/WNP@XZ_=YK]X_\
MA$]#_P"@-I__ ("Q_P"%?E9\$=)LI?\ @L=XVLWL[=[19M2Q;M$IC&+48^7&
M* /M#P[\8%_;(_8=\:>)M-T2703XB\/ZUIL6GRW G96$4\ ^<*N<D9Z=Z^9_
M^"(&MPS_  Y^*&CJ1]HM=5M+MQGG;+"ZKQ]86K]*K6RM[&W$%M!%;P#.(XD"
MJ,]>!7Y!ZI/XK_X)3?M<:]KL?AVYUGX.>+I65&MUPIMV<R+&C_=6XMR74*Y
M=,GC<&4 _8.OR1_X)O*WC?\ X*,?&KQ9;*9=.VZU="?.1FXU*,QC..I7>?P-
M>B?';_@L-X1U3X>W.D_"'1O$%YXXU:+[-:SZC9I%'8L^5+ +(S23#(VJH*Y(
M)8XVMZG_ ,$M_P!E#5/V>?A'J/B+Q99O8^,O%[Q7$UG-D26=H@/DQ.#]V0EW
M=AU&Y5/*F@#[7HHHH Y?XI:+>>)/ACXOTG3H?M&H7^CWEK;0[E7?*\#JBY8@
M#)(&20*_"G_AUQ^T[_T3/_ROZ7_\DU^^FJ:I:Z'I=YJ-_.MK8V<+W$\\GW8X
MT4LS'V !/X5X3_PWY^SS_P!%8\/_ /?U_P#XF@#\=]0_X)D_M,:9;^=-\,)W
M3.,6^KZ?,W0G[J7!/;TKRSPI^SGXU\3?&"+X7W=E#X5\:3/Y,6G>)9#8F24@
M%(P7&-S@Y3L_&TDD _NW_P -^?L\_P#16/#_ /W]?_XFORZ_X*A_M+^ OC=\
M9/!NJ_#+4SJ%SX>L6BG\06L3P[Y?-$D2QLP5CY9W$-C&7.#0!^VV@V<FGZ'I
MUK, )8+:.)]IR-RJ ?U%7ZYCX7Z_>>*OAGX1UO45":AJ6D6EY<J!@"62%'<8
M[<L:Z>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OY]O^"AOPI\9>$/VGOB)XAUGPQJFGZ!J^LS7%AJLUJXM;E&.5V2XV
MD\?=SD=Q7]!-5M2TVSUFPGL=0M(+ZRN$,<UM<QB2.13U5E(((]C0!^!'['?[
M5GPR_9^U"!_&?P2T?Q?=+)D>(XY&EOX!G[RPW!>'<.0#'Y1Z9)K[E_:Z_;D^
M#?[1G[$OQ%TWPEXKBA\03VUF4T#58S:7I(O;=F5$;Y92%!)\MGP 3V->I?''
M_@E3\$?BY]HO=&TR;X=ZW)DBX\.X6U+=MUJW[O'M'Y?UK\]OCA_P28^-/PK\
M^]\-V]K\2-&CRPET7]W>*H[M:N=Q/^S&TAYH ]^_X(8_\UL_[@G_ +?U^JE?
MS?\ P1_:.^*W['?BS6%\+7,GAV^NFBCU;1]6T\,LYBW[$ECD4.A7S'^Z5;YC
MS7['_P#!/O\ ;1U?]L3PGXGN==\-V6@ZIX?FMX99=.G=H+GS5D.5C<%H\>7T
M+MG/44 ?6-%%% !1110 4444 %%%% !4=Q;Q7EO)!/$DT,BE'CD4,K*1@@@]
M0:DHH ^.O%/[#^CZE^VMX2\>67P^\(+\-K3P]+;:E8_V?;*DNH%YRDIM]FUV
M :+]X1D;1Z5]>Z?I]KI-G#9V-M#9VD*[8[>WC$<:#T50, ?2K%% &1KGA#0?
M%#0MK.B:=JS0@B)KZTCF* XR%W XS@=/2LO_ (5/X'_Z$WP__P""N#_XBNKH
MH Y3_A4_@?\ Z$WP_P#^"N#_ .(K>TC1=/\ #]DMGI=A:Z;:*2RV]G"L48)Y
M)"J .:NT4 4-:T'3/$NFRZ?J^G6FJV$O^LM;V!9HG^JL"#^5<GX<^ OPS\'Z
MS_:^@_#KPGHFK;M_V[3=#M;>?=G.?,1 V<D\Y[UW=% !2=>#R*6B@#SZZ_9X
M^%5]K+:O<?#+P=<:LQW&_ET"T:<GU\PQ[OUKOH84MXDBB18XD4*J(,!0.  .
MPI]% !1110 4444 %?(7PU_Y25?%?_L68?\ T7IE?7M?(7PU_P"4E7Q7_P"Q
M9A_]%Z97H83X:W^%_FCBQ.]/_$OR9]>T445YYVA1110 4444 %%%% !1110!
M^2/P3_Y.]_:C_P"QHE_]*[ROHBOG?X)_\G>_M1_]C1+_ .E=Y7T17Z?DO^XT
M_G^;/Y3XY_Y*#$?]N?\ I$0HHHKW#X,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *X7_@EO\ \G$_M2?]A>U_]*+Z
MNZKA?^"6_P#R<3^U)_V%[7_THOJ^1XC_ (-/U_0_9/#/_?<1_A7YGZ04445\
M$?T(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOX?U36KXLMCIUK+>3F-=S".-"[8'<X!XKX[_ .'O/[//_01\0?\ @G?_ !H
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MG[,O_8S-_P"E6GU]>UZ.(_W>AZ/_ -*9QT?XU7U7Y(****\X[ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,3QOX;_X3+P7K^@?:/L?]JZ?<6/V
MC9O\KS8V3?MR-V-V<9&<=17YC?\ #C'_ *K9_P"6I_\ =M?IG\1?$5SX1^'W
MB?7;-(I+O2]+NKV%)P3&SQQ,ZA@""1E1G!!QWK\=_P#A]7\;_P#H5OA__P""
MZ^_^3* /5?\ AQC_ -5L_P#+4_\ NVO3?@/_ ,$<_ ?PQ\96/B'QCXLNOB$U
MA*L]OIK:<MC9M(I!4S)YDK2 $9V[@#W!&0?EW_A]7\;_ /H5OA__ ."Z^_\
MDRC_ (?5_&__ *%;X?\ _@NOO_DR@#]J:*^"?V_?V]_B!^RK>_#N'PGH_AK4
M%\1:7)>W9UFUN)2CJ8P!'Y<\>!\YZY/3FOIG]DOXO:Q\>?V=_!GCW7[:QL]8
MUJWEEN(--C=+=2L\D8V*[NP&$'5CSF@#UVBBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 5\A?#7_E)5\5_^Q9A_]%Z97U[7R%\-?^4E7Q7_ .Q9A_\
M1>F5Z&$^&M_A?YHXL3O3_P 2_)GU[1117GG:%%%% !1110 4444 %%%% 'Y(
M_!/_ ).]_:C_ .QHE_\ 2N\KZ(KYW^"?_)WO[4?_ &-$O_I7>5]$5^GY+_N-
M/Y_FS^4^.?\ DH,1_P!N?^D1"BBBO</@PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?^"6__)Q/[4G_ &%[7_TH
MOJ[JN%_X);_\G$_M2?\ 87M?_2B^KY'B/^#3]?T/V3PS_P!]Q'^%?F?I!111
M7P1_0@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?(7[:G_)?/V9?^QF;_P!*M/KZ]KY"_;4_Y+Y^S+_V,S?^
ME6GU]>UZ.(_W>AZ/_P!*9QT?XU7U7Y(****\X[ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,OQ5XBMO"/AC5]=O$EDM-+LYKV9( #(R1H78*"0
M"<*<9(&>]?"G_#ZOX(?]"M\0/_!=8_\ R97W/XP\.Q^,/".MZ#-,UO#JEC/8
MO-& 6198V0L >X#9K\[?^'(?@C_HI?B#_P  8/\ &@#J_P#A]7\$/^A6^('_
M (+K'_Y,H_X?5_!#_H5OB!_X+K'_ .3*Y3_AR'X(_P"BE^(/_ &#_&C_ (<A
M^"/^BE^(/_ &#_&@#J_^'U?P0_Z%;X@?^"ZQ_P#DROL?X)_%[1_CS\+= \>Z
M!;7UGH^M1/+;P:E&B7"A9'C.]4=U!RAZ,>,5\&_\.0_!'_12_$'_ ( P?XU]
MT_ 'X/6?P!^#_AOP!I^H3ZK9Z)#)#'>7**DD@:5Y,D+P.7(_"@#T&BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OD+X:_\I*OBO_V+,/\ Z+TROKVOD+X:_P#*2KXK_P#8
MLP_^B],KT,)\-;_"_P T<6)WI_XE^3/KVBBBO/.T**** "BBB@ HHHH ****
M /R1^"?_ "=[^U'_ -C1+_Z5WE?1%?._P3_Y.]_:C_[&B7_TKO*^B*_3\E_W
M&G\_S9_*?'/_ "4&(_[<_P#2(A1117N'P84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5PO_!+?_DXG]J3_L+VO_I1
M?5W5<+_P2W_Y.)_:D_["]K_Z47U?(\1_P:?K^A^R>&?^^XC_  K\S](****^
M"/Z$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'#YK+<2H#LC54'RJHX Z5ZOK7@SP_P"(V@.K:%INJ&!=D1O;..;RU]%W X'
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M**]P^#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N%_X);_\ )Q/[4G_87M?_ $HOJ[JN%_X);_\ )Q/[4G_87M?_
M $HOJ^1XC_@T_7]#]D\,_P#?<1_A7YGZ04445\$?T(%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R%^VI_R7
MS]F7_L9F_P#2K3Z^O:^0OVU/^2^?LR_]C,W_ *5:?7U[7HXC_=Z'H_\ TIG'
M1_C5?5?D@HHHKSCL"BBB@ HHHH ***HMKFG+JZZ4=0M1JC1>>+$S+YYCSC>$
MSNVY!YQCB@"]1110 4444 %%%% !1110 4444 9GB;Q%8^#_  WJVO:I+]GT
MS2[2:^NI<9V11(7=OP52:_GUU+_A:O\ P4<_:5OY=-MVU+6M19Y8+>:<I9Z/
M8(<*I8\)&@*@D#+LV<,[\_NK^TKX=OO%W[.OQ0T/2T:34M1\,:E:6T:]9)'M
M9%5/Q) _&OR/_P""1/QT\'_"/XU>(](\6W]KHH\3:?';6.J7KK'"DT<A;R6D
M8@)Y@8X)X+(HZD9 .UD_X(B^/%T;S8_B1X=?5<?\>K6DX@SMZ>;][KQ]SIS[
M5\Y?#CQ;\3/^"<?[3T,&MVT^FW%G+%'K.EQR[[;5+!SDE2#M<;261OX7'."&
M6OZ#'N(H[=IVE18%7>9&8!0N,YSTQCO7X7?\%7/C;X3^-?[2%@G@V\M]:M/#
M^D1Z5/JEFPDBN9_.ED98W!(=$\P#<.K%\9 !(!^YFFZC;:QIUK?V<JSVEU$L
M\,JYPZ, RL/J"#5FN4^$NAWGACX5^#-'U $7^GZ+96EP&Z^9' B-^H-=70 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5\/?M\?M]ZO\  'Q+I/PR^&>D
M1:_\2]82,DR1-.MEYK;($2)>99W/*J>!\I(;<!7W#7X^_%/Q-IGP7_X+'1>*
M?B"RVGAV2[MYX[ZZ_P!5''+I@MX9B3T2.;&6/W?+8]J ./\ $/AK]L2\_:T\
M(3:IK]K!\:KGPS-J&E+NLE$%B&GW6S*(_(#$B7Y6R/F&6]/KG]A?_@H#XG^*
M'Q)OO@U\9=*CT7XCVAFBM;J.W,!NY80S3031#Y4E559@5PK!6X! W;_CBZAO
MO^"K7PGN;::.XMIOAY<R131,&1U,EX0RD<$$'((KVC5/V,_AAK7[02?&>[TV
M^;QU'+#.ES%?R10K)%$L2-Y:$!OD4 AL@\Y% 'I_Q$^(.@_"KP3K'BWQ/J$>
MEZ#I-NUS=74G\*C@*!_$S$A54<LS #DU^=&F_P#!1#]I']I'7M4;]G_X.V5Q
MX7LI!%]NUB-I9=W7#S&:*!6((/EC<0"/F(YK[)_;"_9IE_:O^$H\#+XLF\(0
M-?Q7LUU#9"Z$PC5]L;(73Y=S*_# Y1:Z?]G+X)Z=^SO\%_"_@'39([D:3;!;
MF\CA\K[7<,2TTQ7)QN<DX).!@9XH ^,OA=_P4U\:^ _BE8_#O]I;X?Q^ ]0O
M&2.+6[..2&"/<VU9)$=W#1$YS-&Y4$'Y<9(_0'Q9JEUHOA76=1L+?[9>VEE-
M<6]OM+>;(L995P.3D@# YYK\RO\ @MMXF\,7FF_#?P[%+;7/C6WNKBZ:&)@T
M]O9NBKAP!D"1PNW/7RVX-?HI\#=+U?0_@G\/]-\0;_[>L_#VGV^H>8<M]I2V
MC67)]=X:@#\XO^'F'[4W_1O7_EOZK_\ %4G_  \P_:F')_9ZP/\ L :K_P#%
M5^JM? ?_  53_:RU#X9>$=/^$G@BYE/C?Q?'MNFLLF>UL7;8$3'(DG;*#'.U
M7Z$J: ,3]B7_ (*1_$G]J+X]6/@C5O!6AV&C_9+F[OKW3(KDR6RQH=A8M(RJ
M#(43D=6 ZU[Q^W_^UMJG[(?PNT+7]!TS3M8UK5=76P2UU/?Y0A$,CR2?(RG(
M*QCK_'5O]@W]DVQ_95^#%G8W5M"WC?642\U^]7#-YN"4MU;^Y$&*C'!8NW\5
M?('_  5^NI_B/\=/@;\*K*1A<WA,GEIU+WMU';1''J# ^/J: (;7_@IS^U!?
M6T5Q;_L_QW%O,@DCEBT+5&1U(R&!#8((YR*]*_9X_;R_:%^*'QI\*>%?%GP5
M_P"$<\.ZG=&&]U3^QM1A^SH(V;=OD;8O( ^;UKZ<US]LCX!_#6\B\.7WQ.\-
MV-Q9XM!:078G$&Q<;&,88)@+CYB,'CKQ7K/@_P ;>'_B#H4&M>&-<T_Q#I$V
M1'?:7=)<0L1U ="1D=QU% &U1110 4444 %?(7PU_P"4E7Q7_P"Q9A_]%Z97
MU[7R%\-?^4E7Q7_[%F'_ -%Z97H83X:W^%_FCBQ.]/\ Q+\F?7M%%%>>=H44
M44 %%%% !1110 4444 ?DC\$_P#D[W]J/_L:)?\ TKO*^B*^=_@G_P G>_M1
M_P#8T2_^E=Y7T17Z?DO^XT_G^;/Y3XY_Y*#$?]N?^D1"BBBO</@PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?^
M"6__ "<3^U)_V%[7_P!*+ZNZKA?^"6__ "<3^U)_V%[7_P!*+ZOD>(_X-/U_
M0_9/#/\ WW$?X5^9^D%%%%?!']"!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!\A?MJ?\E\_9E_[&9O\ TJT^
MOKVOD+]M3_DOG[,O_8S-_P"E6GU]>UZ.(_W>AZ/_ -*9QT?XU7U7Y(****\X
M[ HHHH **** /@_]N[_@H%X@^#7C[3_A%\)=&CU_XDWZPB::2$W LWFQY,,<
M(/[R=@5;#?* Z<-N('Q]J'AK]L7_ (:ZL)9]?M?^%WMX2.HVX5K+"Z=YSC[-
MCR_L^[>'.WIS][-=7>>)=+^"/_!8O4M<^(<R6.E7&HRO!J5Z0(H%N;$I;REB
M<!%WJA8G"X).-O'U=JDR7'_!6KP]+$ZR1/\ #$LKH<A@;J8@@]Q0!E_L$?M_
M:[\;_&.J?"GXJZ7'HOQ*TT2^3+#;F 7AA)$\4D1_U<R8)(&%(#<+MP?MKQ)X
MBTSPAX?U'7-9O8=-TC3K>2ZN[R=L)#$BEF=CZ  UX]#^QC\,(/VAI_C4NFWR
M^.I)Q<B>.^DC@CD\CR&(B4@'<F=P;()8GO7SC_P68^*=UX0_9[T#PC93M!)X
MKU;;<[6(WVMNHD=..H,C0'\/>@#D-0_X*2_&C]H/QQJ.A?LT_"J/6M*TY\2Z
MMK,3.SJ20KM^\BBMPV#A7=F(!/'(#/#W_!3;XM_!#XD:;X6_:5^&,'ANQOBH
M35-+@DA>)"P!FP9)8[A%S\PB8$>YX/U'^S+X5\!?L<_LQ^"=*\1:YH?@^2ZL
MXKW4[[6+^&T6YOYD5YOGD90VTD(O^RBBH/CI\*?A+_P4)^&]EH5CXYTW5(-+
MOX]034_#%[;7=Q;?*RM&<%M@=6Y##JJDCY: /H[3=2M=8TZUO["YBO+&ZB6>
M"X@</'+&P#*ZL.""""".H-?%'[8'_!1J;X._$2W^%?PJ\,1^/_B7,\<,L3"2
M6WM)GP4@\N(AYI2""55E"Y&23D#Z6\(^'+']FG]G^#2O[2O=:TKP7HDI2ZOM
MOGO;V\;.JML 'RHH48'117YW?\$<?"+?$;XG?%?XN^) -3\1+)'!#?3KN;S[
MII9;J0$]&(5!D<X=AT/(!J^*/V[?VOO@#'9^)OBO\'-)3P;+(BS-;V[P[-Q^
M5?.2>40L>@\Q3U QDU^@?P#^.GAC]HSX7Z3XX\)SN^G7P*26\X FM)UXDAE
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M /U4HJII-]_:FE65[L\K[1"DVS.=NY0<9[]:MT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5X7K/[<GP%\/:Q?:5J/Q0T*TU"QGDMKFWDD?=%*C%70_+U!!'X
M5[I7Q7XN_P""2?P0\:>*]:\0ZA=^*UO]6O9K^X$.I1*@DED9VV@PG RQP,T
M>\?#W]K7X/\ Q7\4VWAOPCX_TC7M=N5=X;&T=C(ZHI9B,J.B@G\*P/VKOV,/
M /[7&@VMOXFCN-,U[3U9=/U_3MHN8%)R8V!!62,GDJW3G:5))KDO@-_P3?\
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M5\-?MI1? ?Q'X*AT&S:_%BOB6;5]XE\VW$MJPA,*A?,9HTQO."_4XH @M?\
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MG>_M1_\ 8T2_^E=Y7T17SO\ !/\ Y.]_:C_[&B7_ -*[ROHBOT_)?]QI_/\
M-G\I\<_\E!B/^W/_ $B(4445[A\&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<+_ ,$M_P#DXG]J3_L+VO\ Z47U
M=U7"_P#!+?\ Y.)_:D_["]K_ .E%]7R/$?\ !I^OZ'[)X9_[[B/\*_,_2"BB
MBO@C^A HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC9\/-;\%^*K(7VB:M 89E& \9ZI)&<':Z, RGL0*_.G2?V'?VKOV4=2U:W^
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M?VD/#OQ[^)_C#X:>(?",&D^,-7EU+_3Y6\T(\LDBHRM P4J96'RD@\'V$/\
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MUJZ2JS<O5W.["99@<#)RPM&,&]^5)?D%%%%<QZ84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXW, ?*O@BSN/VL_VV=/^T1/<1^,?%YO+F)@24M'N#+*,>B0!OP6OI;_@L?\
M'?PK\2OB-X/\$>';G^T-1\%G4(M6F1&"17$S0+]G4D#+)Y!+$9&6 SD$5]&?
M\$Y?^"<^N?LZ^++GXB_$::R/BG[,]IIFDV4HF6Q5^))I)!P9"N4 7("LV22V
M%ZK5?^"96B>-/VQ]?^,7BG6(KKPS-?V^IV7AFWB;=-<)#'N:XD. $\Y&;8H.
MX$98#((!]9?"'1[GP_\ ";P5I=XKK=V.B65M,LGW@Z0(K ^^0:ZZBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPQ^O] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#Y"_;4_P"2^?LR_P#8S-_Z5:?7U[7R%^VI_P E
M\_9E_P"QF;_TJT^OKVO1Q'^[T/1_^E,XZ/\ &J^J_)!1117G'8%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5\A?#7_ )25?%?_ +%F'_T7IE?7M?(7PU_Y25?%?_L68?\
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MW_\ &J_4ZT22.UA25MTJHH=LYRV.34U% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?(7[:G_)?/V9?^QF;_TJT^OKVOD+]M3_ )+Y^S+_ -C,W_I5I]?7M>CB
M/]WH>C_]*9QT?XU7U7Y(****\X[ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD+X:_P#*
M2KXK_P#8LP_^B],KZ]KY"^&O_*2KXK_]BS#_ .B],KT,)\-;_"_S1Q8G>G_B
M7Y,^O:***\\[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#Y"_;4_Y+Y^S+_V,S?\ I5I]?7M?(7[:G_)?/V9?^QF;_P!*M/KZ
M]KT<1_N]#T?_ *4SCH_QJOJOR04445YQV!1110 4444 %%%% !1110 4444
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M\F?7M%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\
M/UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__
M (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'
M_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\
MC_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ]
MHKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2F
MA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]
M_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^
M%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:
MA_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(
MH ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\
M_A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _
M6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\
MB*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_
M #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/
M_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"B
MO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'
M_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\
MC_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4
MIH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'
M_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@
M#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^
M%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:
MA_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(
MH_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\
M/UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__
M (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\
M_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_
M #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/
M_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2F
MA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]
M_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /
M0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4
MIH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'
M_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC
M_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _
M6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\
MB* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_
M /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\
M/UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__
M (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'
M_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\
MC_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ]
MHKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2F
MA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]
M_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^
M%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:
MA_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(
MH ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\
M_A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _
M6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\
MB*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_
M #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/
M_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"B
MO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'
M_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\
MC_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4
MIH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'
M_?R/_P"(H ] HKS_ /X4IH?_ #]:A_W\C_\ B*/^%*:'_P _6H?]_(__ (B@
M#T"BO/\ _A2FA_\ /UJ'_?R/_P"(H_X4IH?_ #]:A_W\C_\ B* /0**\_P#^
M%*:'_P _6H?]_(__ (BC_A2FA_\ /UJ'_?R/_P"(H ] HKS_ /X4IH?_ #]:
MA_W\C_\ B*/^%*:'_P _6H?]_(__ (B@#T"BO/\ _A2FA_\ /UJ'_?R/_P"(
MH_X4IH?_ #]:A_W\C_\ B* /0**\_P#^%*:'_P _6H?]_(__ (BC_A2FA_\
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ML7R[^_O7Z _"_P"$7@WX+^&UT#P/X<L?#>DAS(UO91X,CGJ[L<L[8P-S$G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC<'K]0/&WQ,T#P#\-=6\=ZK>*GAW3=.;4Y+A.KPA-XV XRS<!1W+ =Z_,_\
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M";'X:^ ?#7A'3);B?3?#^F6VE6LMVRM,\4$2Q(SE54%BJ#)  SG '2N@HHH
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M>7_\.5/@A_T-/Q _\&-C_P#(=??]% 'P!_PY4^"'_0T_$#_P8V/_ ,AU]O\
MP]\$V/PU\ ^&O".F2W$^F^'],MM*M9;ME:9XH(EB1G*JH+%4&2 !G. .E=!1
M0!\6?'W_ ()2_"3XU>++KQ/IMSJ?@36KR4SW8T;RVM)Y"<M(877Y')_N,HSD
ME2234OP _P""5?PC^"/BRT\47T^J>.=<LY%GLVUID6VMY5.5D6% -S ]-Y8
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298762048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRAXIS PRECISION MEDICINES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5195942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">99 High Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">30th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-8460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,393,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001689548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884300477904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298620288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,615<span></span>
</td>
<td class="nump">$ 138,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">38,874<span></span>
</td>
<td class="nump">137,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,351<span></span>
</td>
<td class="nump">11,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">110,840<span></span>
</td>
<td class="nump">287,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">115,128<span></span>
</td>
<td class="nump">292,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,672<span></span>
</td>
<td class="nump">10,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">15,850<span></span>
</td>
<td class="nump">26,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,345<span></span>
</td>
<td class="nump">38,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current portion of deferred revenue</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">41,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized; 49,382,453 shares issued and outstanding as of December&#160;31, 2022, and 45,300,514 shares issued and outstanding as of December&#160;31, 2021</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">606,918<span></span>
</td>
<td class="nump">567,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(530,644)<span></span>
</td>
<td class="num">(316,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">76,106<span></span>
</td>
<td class="nump">250,812<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 115,128<span></span>
</td>
<td class="nump">$ 292,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298475392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">49,382,453<span></span>
</td>
<td class="nump">45,300,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">49,382,453<span></span>
</td>
<td class="nump">45,300,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">46,096,737<span></span>
</td>
<td class="nump">42,454,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">46,096,737<span></span>
</td>
<td class="nump">42,454,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298485808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 155,040<span></span>
</td>
<td class="nump">$ 120,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">59,946<span></span>
</td>
<td class="nump">47,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">214,986<span></span>
</td>
<td class="nump">167,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(214,986)<span></span>
</td>
<td class="num">(167,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Other income, net</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (214,029)<span></span>
</td>
<td class="num">$ (167,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in usd per share)</a></td>
<td class="num">$ (4.64)<span></span>
</td>
<td class="num">$ (3.94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in usd per share)</a></td>
<td class="num">$ (4.64)<span></span>
</td>
<td class="num">$ (3.94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">46,096,737<span></span>
</td>
<td class="nump">42,454,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">46,096,737<span></span>
</td>
<td class="nump">42,454,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884305392912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (214,029)<span></span>
</td>
<td class="num">$ (167,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on marketable securities, net of tax</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (214,026)<span></span>
</td>
<td class="num">$ (167,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303538192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,268,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 287,457<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 437,007<span></span>
</td>
<td class="num">$ (149,554)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,621,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">265,515<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">442,524<span></span>
</td>
<td class="num">(176,927)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,268,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">287,457<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">437,007<span></span>
</td>
<td class="num">(149,554)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (167,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">45,300,514<span></span>
</td>
<td class="nump">45,300,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 250,812<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">567,598<span></span>
</td>
<td class="num">(316,615)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,621,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">265,515<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">442,524<span></span>
</td>
<td class="num">(176,927)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at-the-market public offerings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at-the-market public offerings</a></td>
<td class="nump">98,413<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">98,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,693,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">333,772<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">547,145<span></span>
</td>
<td class="num">(213,328)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,784,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">295,922<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">553,975<span></span>
</td>
<td class="num">(258,033)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at-the-market public offerings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at-the-market public offerings</a></td>
<td class="nump">7,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">45,300,514<span></span>
</td>
<td class="nump">45,300,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 250,812<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">567,598<span></span>
</td>
<td class="num">(316,615)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at-the-market public offerings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at-the-market public offerings</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares witheld for taxes for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units</a></td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,506,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 191,022<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">576,955<span></span>
</td>
<td class="num">(385,332)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">45,300,514<span></span>
</td>
<td class="nump">45,300,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 250,812<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">567,598<span></span>
</td>
<td class="num">(316,615)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">265,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (214,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">49,382,453<span></span>
</td>
<td class="nump">49,382,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 76,106<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">606,918<span></span>
</td>
<td class="num">(530,644)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,506,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">191,022<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">576,955<span></span>
</td>
<td class="num">(385,332)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares witheld for taxes for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,575,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">138,869<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">585,070<span></span>
</td>
<td class="num">(445,526)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at-the-market public offerings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at-the-market public offerings</a></td>
<td class="nump">2,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares witheld for taxes for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,864,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">105,163<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">595,165<span></span>
</td>
<td class="num">(489,471)<span></span>
</td>
<td class="num">(536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at-the-market public offerings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,419,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at-the-market public offerings</a></td>
<td class="nump">5,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares witheld for taxes for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes for vesting of restricted stock units</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">49,382,453<span></span>
</td>
<td class="nump">49,382,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 76,106<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 606,918<span></span>
</td>
<td class="num">$ (530,644)<span></span>
</td>
<td class="num">$ (173)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302968672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prax_A2022OfferingsMember', window );">2022 Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs for at-the-market offerings and initial public offering</a></td>
<td class="nump">$ 598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prax_A2022OfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prax_A2022OfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298997552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (214,029)<span></span>
</td>
<td class="num">$ (167,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">28,593<span></span>
</td>
<td class="nump">22,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities, net</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">547<span></span>
</td>
<td class="num">(5,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,892<span></span>
</td>
<td class="nump">7,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(10,465)<span></span>
</td>
<td class="nump">15,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(811)<span></span>
</td>
<td class="num">(763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">56<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(185,043)<span></span>
</td>
<td class="num">(124,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(83,022)<span></span>
</td>
<td class="num">(164,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">180,355<span></span>
</td>
<td class="nump">24,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">96,889<span></span>
</td>
<td class="num">(140,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts', window );">Proceeds from at-the-market offerings, net of issuance costs</a></td>
<td class="nump">9,561<span></span>
</td>
<td class="nump">7,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on public offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs for at-the-market offerings and initial public offering</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of tax withholdings related to vesting of restricted stock units</a></td>
<td class="num">(260)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and employee stock purchase plan contributions</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">2,447<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,465<span></span>
</td>
<td class="nump">107,586<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(77,689)<span></span>
</td>
<td class="num">(157,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">139,720<span></span>
</td>
<td class="nump">297,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">62,031<span></span>
</td>
<td class="nump">139,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">61,615<span></span>
</td>
<td class="nump">138,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">62,031<span></span>
</td>
<td class="nump">139,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Offering costs included in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from at the market offerings, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884311855440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of the Business<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis Precision Medicines, Inc. (&#8220;Praxis&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Each platform has multiple programs currently, with significant potential for additional program and indication expansion: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Cerebrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, the Company's small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Solidus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, the Company's antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum&#8482; platform, ulixacaltamide (formerly known as PRAX-944), it expects to announce topline results from the Phase 2b Essential1 clinical trial in essential tremor in the first quarter of 2023. The Company also plans to initiate an ulixacaltamide Phase 2 clinical trial in Parkinson's disease in the first quarter of 2023 and expects topline results in the fourth quarter of 2023. The Company plans to initiate</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its PRAX-562 Phase 2 EMBOLD study in the first quarter of 2023, with initial cohorts in SCN2A-DEE and SCN8A-DEE, and expects to announce topline results for both cohorts in the second half of 2023. The Company also initiated a Phase 1 healthy volunteer study of PRAX-628 in the fourth quarter of 2022 and expects to report topline results in mid-2023. For the Company's most advanced product candidate under the Solidus&#8482; platform, PRAX-222, it expects to announce topline results from the first dose cohort of its EMBRAVE study in mid-2023. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, and from the sale of common stock through an initial public offering ("IPO"), a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through December&#160;31, 2022, the Company raised $526.0&#160;million in aggregate cash proceeds from these transactions, net of issuance costs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2014-15, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses since its inception, including a net loss of $214.0 million for the year ended December&#160;31, 2022. In addition, as of December&#160;31, 2022, the Company had an accumulated deficit of $530.6 million. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash, cash equivalents and marketable securities as of December&#160;31, 2022, together with net proceeds raised under the Open Market Sale Agreement ("the Sales Agreement") subsequent to December&#160;31, 2022, may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial statements which raises substantial doubt about the Company's ability to continue as a going concern, and the Company will need to obtain additional funding. The Company expects to finance its operations through potential public or private equity financings, debt financings, collaboration agreements or other capital sources. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884311215088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and ASUs of the FASB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Praxis Security Corporation and Praxis Precision Medicines Australia Pty Ltd. All intercompany transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, stock-based compensation expense and the recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. The majority of the Company&#8217;s long-lived assets are held in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in interest-bearing money market funds. Cash equivalents are carried at cost, which approximates their fair market value.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash comprises letters of credit for the benefit of the landlord in connection with the Company&#8217;s lease facilities. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its marketable securities. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders&#8217; equity. Realized gains and losses are included in the Company's consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. As a result, the Company has categorized all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company's intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in other comprehensive loss, net of applicable taxes unless deemed other than temporary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers and License Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company's investment portfolio comprises money market funds, marketable debt securities, including debt securities issued by U.S. government agencies and corporations, and commercial paper. The Company investments are limited to investment-grade securities with strong credit ratings with the objective of maintaining safety and liquidity. The Company also maintains deposits in </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) up to $250,000. As of December&#160;31, 2022 and 2021, the Company&#8217;s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts or other hedging arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under GAAP. The fair values of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items measured at fair value on a recurring basis include cash equivalents and marketable securities (Note 4 and Note 5). The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal, retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance that do not improve or extend the lives of the respective assets are charged to expense as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842. The Company determines if an arrangement is a lease at contract inception. Operating lease right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable, based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine operating lease right-of-use assets may include lease incentives and stated rent increases. The Company&#8217;s lease agreements may include both lease and non-lease components, which the Company accounts for as a single lease component when the payments are fixed, for all classes of underlying assets. Variable payments included in the lease agreement are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating leases are reflected in operating lease right-of-use assets and in current operating lease liabilities and long-term operating lease liabilities in its consolidated balance sheets. The Company&#8217;s operating lease right-of-use asset as of December&#160;31, 2022 and 2021 did not include any lease incentives. Lease expense for future lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808"), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of ASC 606 under which the Company may license or provide options to license certain development or product candidates and, in certain cases, may perform research and development services. The terms of these agreements may include payment of non-refundable, upfront fees, option exercise fees, development and commercial milestone payments and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for agreements determined to be within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as an option to obtain a license, it evaluates whether such options are material rights that should be treated as separate performance obligations. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received to estimate the amount expected to be received. The amount of variable consideration included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal of the cumulative revenue recognized will not occur in a future period.</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount of the transaction price that it allocated to the respective performance obligation when or as each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an output or input method. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For example, f</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or research and development services that are recognized over time, the Company measures its progress using an input method. The input methods used are based on the effort the Company expends or costs it incurs toward the satisfaction of its performance obligation. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the amount of effort it expends, including the time it estimates it will take to complete the activities, or costs it incurs in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that is multiplied by the transaction price to determine the amount of revenue recognized each period. If the estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that is recognized in the current and future periods.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company performs its obligations under these agreements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had one collaboration, option and license agreement with UCB Biopharma SRL ("UCB"), which it entered into in December 2022. The accounting accounting related to the collaboration agreement is outlined in Note 9, UCB Option and License Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. Costs incurred to obtain licenses are recognized as research and development expense as incurred if the technology licensed has no alternative future uses.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development related contracts with parties both inside and outside of the United States. These agreements are cancellable, and related fees are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent-Related Costs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718"). For stock-based awards issued to employees, non-employees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of the grant. The Company recognizes compensation expense for those awards granted to employees and members of the Board over the requisite service period, which is generally the vesting period of the respective award. For non-employee awards, compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards on a straight-line basis over the vesting period. To date, the Company has not issued any stock-based awards with performance or market-based vesting conditions. The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary or service payments are classified.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs of subjective assumptions, including: (i)&#160;the expected volatility of the Company&#8217;s stock; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; (iv)&#160;expected dividends; and (v)&#160;the fair value of common stock. Due to the lack of Company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline publicly-traded companies that issued options with substantially similar terms. For this analysis, the Company selects companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company determines expected volatility using a weighted average of the historical volatilities of the guideline group of companies. The Company expects to continue to apply this process until such time as it has adequate historical data regarding the volatility of its own traded stock price. As permitted under ASC 718, the Company has elected to use the contractual term as the expected term for certain non-employee awards, on an award-by-award basis. For all other awards, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. The Company utilizes this method as it has insufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for instruments with a term commensurate with the expected term assumption. The expected dividend yield is assumed to be zero as the Company has never paid dividends, and does not have current plans to pay any dividends on its common stock. Subsequent to the IPO, the fair value of the common stock underlying the Company's stock-based awards is the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is estimated based on the fair value of the Company's underlying common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s wholly owned foreign subsidiary in Australia is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss. There were no material foreign currency gains or losses for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent that it believes based upon the weight of available evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss. For the years ended December 31, 2022 and 2021,comprehensive loss consists of net loss and changes in unrealized losses on marketable securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested restricted common stock and potential shares issuable under the employee stock purchase plan are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2019-12"). The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders&#8217; equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. On January 1, 2021, the Company early adopted ASU 2019-12 on a prospective basis, with no material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Financial Instruments&#8212;Credit Losses (Topic&#160;326)&#8212;Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which has been subsequently amended by ASU&#160;No.&#160;2018-19, ASU&#160;No.&#160;2019-04, ASU&#160;No.&#160;2019-05, ASU&#160;No.&#160;2019-10, ASU&#160;No.&#160;2019-11 and ASU&#160;No.&#160;2020-03 (&#8220;ASU&#160;2016-13&#8221;). The provisions of ASU&#160;2016-13&#160;modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. On October 1, 2021, the Company early adopted ASU 2016-13 and its related amendments using a modified retrospective approach. Given the composition of the Company's investment portfolio, there was no material impact on the Company's consolidated financial statements and related disclosures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div>N<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303112928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Restricted Cash</a></td>
<td class="text">Restricted Cash<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company had restricted cash of $0.4 million and $1.0 million, respectively, held as letters of credit for the benefit of its current and former landlords. The Company's Boston, Massachusetts sublease expires on January&#160;31, 2026, and the related letter of credit of $0.4 million was classified within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_21159827-a52f-45e4-914d-16111d124035"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_4c186cd4-1d36-4e49-a94e-eb059faddb23">other non-current assets</span></span> on the consolidated balance sheet as of December&#160;31, 2022 and 2021. The Company's Cambridge, Massachusetts sublease expired on December&#160;31, 2021, and the related letter of credit of $0.6 million was classified within prepaid expenses and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjg_fb095add-7293-4af1-90e2-816d4ff050b8">other current assets</span> on the consolidated balance sheet as of December&#160;31, 2021.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884312432672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesThe following is a summary of the Company's investment portfolio as of December&#160;31, 2022 and 2021 (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,716&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had 7 securities with a total fair market value of $38.9 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and is primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance for credit losses was not recognized.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the years ended December 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302951792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets</a></td>
<td class="text">Fair Value of Financial Assets The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2022 and 2021 (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,104&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its marketable securities classified as Level 2 by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302921344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $0.4 million and $0.2 million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303001888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,850&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302879712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts. The sublease expires on January&#160;31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash (Note 3). This lease qualifies as an operating lease. At inception, the Company recorded an operating lease right-of-use asset and operating lease liability of $4.1 million.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into a sublease agreement for office space located in Cambridge, Massachusetts which expired on December&#160;31, 2021. The base rent increased by approximately 1% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash (Note 3). This lease qualified as an operating lease. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the operating leases in the Company&#8217;s consolidated balance sheets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total lease costs recognized in the Company&#8217;s consolidated statements of operations (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:69.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs were primarily related to operating expenses, taxes and insurance associated with the operating leases, which were assessed based on the Company&#8217;s proportionate share of such costs for the leased premises. As these costs are generally variable in nature, they were not included in the measurement of the operating lease right-of-use asset and related lease liability. Total lease costs are included as operating expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable lease agreements as of&#160;December&#160;31, 2022 were as follows (in&#160;thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future&#160;Lease<br/>Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average incremental borrowing rate of the Company&#8217;s operating lease were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average incremental borrowing rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and no material legal proceedings are currently pending or threatened.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Orders</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with third parties for various services, including services related to research, preclinical and clinical operations and support, for which the Company is not contractually able to terminate for convenience to avoid future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, the Company is contractually obligated to make certain payments to vendors, primarily to reimburse them for their unrecoverable outlays incurred prior to cancellation. The actual amounts the Company could pay in the future to the vendors under such agreements may differ from the purchase order amounts due to cancellation provisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into indemnification agreements and agreements containing indemnification provisions in the ordinary course of business. Pursuant to these agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual upon execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into multiple agreements with third parties under which it may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified product candidates. Payments under these agreements generally become due and payable upon achievement of such milestones and sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303006368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UCB Option and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">UCB Option and License Agreement</a></td>
<td class="text">UCB Option and License Agreement<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into an Option and License Agreement (&#8220;the Collaboration Agreement&#8221;) with UCB for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a $5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to $98.5&#160;million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be $5.0&#160;million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right. </span></div>The Company will recognize revenue for its research services performance obligation over time using an input method over the duration of the research services. During the year ended December&#160;31, 2022, the Company did not recognize any collaboration revenue related to the Collaboration Agreement as no services had been provided. As of December&#160;31, 2022, the $5.0&#160;million upfront payment is included in deferred revenue in the consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302980096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Preferred Stock</a></td>
<td class="text">Common Stock and Preferred Stock<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;18, 2021, the Company completed a follow-on public offering in which the Company issued and sold 5,750,000 shares of its common stock at a public offering price of $18.25 per share, including 750,000 shares of common stock issued and sold pursuant to the underwriters' exercise, in full, of their option to purchase additional shares of common stock, for aggregate gross proceeds of $104.9 million. The Company received approximately $98.4 million in net proceeds after deducting discounts, commissions and offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2021, the Company filed an automatic shelf registration with the Securities and Exchange Commission, which was automatically declared effective on November&#160;3, 2021 in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. The Company also simultaneously entered into the Sales Agreement with Jefferies LLC ("Jefferies"), to provide for the offering, issuance and sale of up to an aggregate amount of $125.0 million of common stock from time to time in at-the-market offerings under the shelf registration and subject to the limitations thereof. Jefferies is entitled to compensation at a commission rate of 3% of the gross sales price of common stock sold under the Sales Agreement. During the year ended December&#160;31, 2022, the Company issued and sold 3,595,273 shares under the Sales Agreement for aggregate net proceeds of $9.6 million after deducting commissions and offering expenses payable by the Company. As of December&#160;31, 2022, the Company issued and sold a total of 3,987,270 shares under the Sales Agreement for net proceeds of $16.6 million after deducting commissions and offering expenses payable by the Company. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value, pursuant to the Amended and Restated Certificate of Incorporation effective upon the completion of the IPO. Holders of such shares of common stock have the exclusive right to vote for the election of the Company's directors and are entitled to one vote per share. In the event of the voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to a pro </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rata distribution of the Company's net assets. Dividends may be declared and paid to such holders only when, as, and if declared by the Board or an authorized committee thereof.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of December&#160;31, 2022, the Company did not hold any treasury shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,838,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,667,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,072,855&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,230,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company was authorized to issue 10,000,000 shares of undesignated preferred stock, $0.0001 par value, in one or more series, and is authorized to fix the powers, designations, preferences and relative participating option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company's shareholders. As of December&#160;31, 2022 and 2021, the Company had no shares of undesignated preferred stock issued or outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302973936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan") as of December&#160;31, 2022 and December&#160;31, 2021 was 7,449,480 shares and 5,184,455 shares, respectively. The total number of shares of common stock authorized for issuance under the 2017 Stock Inventive Plan (the "2017 Plan") as of December&#160;31, 2022 and 2021 was 5,937,763 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.  </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under the 2020 Plan and 2017 Plan expire ten years from the date of grant. Shares that expire, are terminated, surrendered or canceled under the 2020 Plan and 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future awards. Upon stock option exercise, the Company issues new shares and delivers them to the participant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e total shares authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP") as of December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 was 981,306 shares and 654,204 shares, respectively. During the year ended December&#160;31, 2022, the Company issued 141,384 shares under the 2020 ESPP. The Company did not issue any shares under the 2020 ESPP during the year ended December&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(268,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested restricted stock units was $12.4 million, which is expected to be recognized over a weighted-average period of 2.65 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,969,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,334,113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,838,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,315,240&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.86&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,635,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised for the year ended December&#160;31, 2021 was $19.7&#160;million. The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#8217;s common stock at December&#160;31, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#8217;s common stock on the date of exercise for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock on the exercise date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock Options </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees, members of the Board, and non-employees on the date of grant were as follows for the for the years ended December 31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock options was $45.9 million, which is expected to be recognized over a weighted-average period of 2.17 years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302973936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_SignificantAgreementsTextBlock', window );">Significant Agreements</a></td>
<td class="text">Significant Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RogCon and Ionis Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2019, the Company entered into both a Cooperation and License Agreement (the &#8220;License Agreement&#8221;) with RogCon, Inc. ("RogCon"), and a Research, Collaboration, Option and License Agreement (the &#8220;Ionis Collaboration Agreement&#8221;) with Ionis Pharmaceuticals, Inc. ("Ionis"). The agreements were entered into contemporaneously to enable the parties to advance their collective efforts related to SCN2A. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RogCon Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon&#8217;s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Under the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. As part of the agreement, the Company agreed to provide up-front consideration of $2.1 million.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September&#160;11, 2019, the Company will reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. The Company expenses these costs as incurred as research and development. Expenses incurred for all periods presented were not material. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company may pay RogCon a milestone payment of $3.0 million and profit share payments. The $3.0 million milestone payment will become due when the first profit share payment has become due and certain contingent payments have become payable to Ionis under the Ionis Collaboration Agreement, which are subject to the Company exercising its option to obtain license rights to a development candidate, as well as other contingent events. The profit share payments will be based on a low-double-digit percentage of net profits, depending on sales volume. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement, unless earlier terminated, will continue until the latest of: (i)&#160;expiration of all patent rights within RogCon patents, (ii)&#160;the Company and its affiliates certify they have abandoned the research, development and commercialization of product with no intention to re-establish such activities, and (iii)&#160;no third party is obligated to pay the Company or its affiliates any amounts that comprise net sublicense revenue. Either party may terminate the License Agreement for material breach or insolvency of the other party. Additionally, the Company may terminate for convenience with prior written notice to RogCon. Upon termination by either party, all rights and licenses granted by RogCon to the Company will revert back to RogCon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ionis Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ionis Collaboration Agreement, both parties participated in research activities related to the downregulation of SCN2A gene products associated with the treatment of any and all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene, other than one severe type of epilepsy. Ionis was also responsible for identifying a development candidate and conducting an IND-enabling toxicology study. The Company reimbursed Ionis for out-of-pocket costs incurred related to the research activities, identification of a development candidate and conducting an IND-enabling toxicology study. The reimbursement of out-of-pocket costs was recognized as research and development expense as incurred. The Company expensed a total of $0.7 million and $1.9 million, as research and development expense under the Ionis Collaboration Agreement for the years ended December 31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ionis granted the Company an exclusive option to obtain the rights and license to further develop and commercialize a development candidate in the field of epilepsy and neurodevelopmental disorders, other than Dravet Syndrome, following the results of the investigational new drug application-enabling toxicology study. The Company exercised this exclusive option in January 2022, paid a $2.0 million license fee and recognized the license fee in research and development expenses in the consolidated statement of operations during the year ended December&#160;31, 2022. After option exercise, the Company is responsible for clinical development and commercialization of the development candidate. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ionis may be entitled to additional development milestone payments, additional milestone payments, and sales royalties or sublicense fees.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ionis Collaboration Agreement will continue until the expiration of all payment obligations to Ionis, unless earlier terminated. Either party may terminate the Ionis Collaboration Agreement upon material breach or insolvency of the other party. Ionis may terminate if the Company fails to achieve a performance milestone. The Company may terminate for convenience with prior written notice to Ionis. Upon termination by the Company for convenience, the Company will stop selling all products, subject to certain wind-down provisions, and all products will revert back to Ionis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_SignificantAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_SignificantAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302950208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,838,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,865,839&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,942,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303001888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company maintains a full valuation allowance on its U.S. net deferred tax assets due to the uncertainty of future taxable income. The Company did not recognize an income tax benefit in the years ended December&#160;31, <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 or 2021 related to its U.S. operations due to the uncertainty regarding future taxable income. In the years ended December 31, 2022 and 2021, the difference between the statutory tax rate in the U.S. and the Company&#8217;s effective tax rate was due primarily to the valuation allowance recorded to offset any potential tax benefit. The income tax benefit (provision) recognized for the years ended December 31, 2022 and 2021 was not material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal and state research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(959)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had U.S. federal net operating loss carryforwards which may be able to offset future income tax liabilities of approximately $226.3 million and $212.3 million, respectively. Federal net operating loss carryforwards of $7.7 million will expire at various dates from 2035 through 2037 and approximately $218.6 million may be carried forward indefinitely.&#160;As of December 31, 2022 and 2021, the Company also had state net operating loss carryforwards of approximately $197.4 million and $187.6 million, respectively, which may be available to offset future income tax liabilities and expire at various dates from 2036 through 2042.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $14.4 million and $7.3 million, respectively, available to reduce future tax liabilities which expire at various dates from 2039 through 2042.&#160;As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $3.5 million and $2.5 million, respectively, available to reduce future tax liabilities which expire at various dates from 2031 through 2037.&#160;The Company has </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generated research credits but has not conducted a study to document the qualified activity.&#160;This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.&#160;A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.&#160;Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change.&#160;Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study.&#160;If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all of the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2022 and 2021 because management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception. As a result, a valuation allowance of $143.9 million and $86.0 million has been established at December 31, 2022 and 2021, respectively.&#160;Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $58.0 million and $49.1 million during the years ended December 31, 2022 and 2021, respectively, due primarily to the generation of net operating losses.</span></div>The Company has not recorded any amounts for unrecognized tax benefits as of December 31, 2022 and 2021.&#160;The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision.&#160;As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s consolidated statement of operations for either year ended December&#160;31, 2022 or 2021.&#160;The statute of limitations for federal and state tax authorities is open for tax years ended December&#160;31, 2019 through December&#160;31, 2022. Since the Company is in a net loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302951792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsOne of the founders of RogCon is the Company's General Counsel. During the years ended December 31, 2022 and 2021, the Company reimbursed RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement (Note 12).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884299825440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code for eligible employees. The plan covers substantially all employees who meet a minimum age requirement and allows participants to defer a portion of their annual compensation on a pre-tax basis. Under the plan, the Company is not obligated to match any participant contributions. The Company made contributions of $1.5&#160;million and $1.0 million during the years ended December&#160;31, 2022 and 2021, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303108320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Company began a strategic realignment to focus resources on its ulixacaltamide, PRAX-562, PRAX-222 and PRAX-628 product candidates, as well as its preclinical programs across our Cerebrum&#8482; and Solidus&#8482; platforms, which resulted in a reduction of the Company&#8217;s workforce. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTU5_f31a878b-51d8-49e1-8652-9a345f90aac3">research and development expenses</span> and $0.4 million has been recognized in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTYw_c651d9dc-e4c5-4069-8a23-904dc552dfc6">general and administrative expenses</span> in the consolidated statement of operations during the year ended December&#160;31, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment. </span></div>As of December&#160;31, 2022, all costs related to the strategic realignment have been paid.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302948208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsSubsequent to December&#160;31, 2022, the Company issued and sold a total of 2,942,083 shares under the Sales Agreement for aggregate net proceeds of $11.2 million after deducting commissions and offering expenses payable by the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884299853712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and ASUs of the FASB.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Praxis Security Corporation and Praxis Precision Medicines Australia Pty Ltd. All intercompany transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, stock-based compensation expense and the recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">SegmentsThe Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. The majority of the Company&#8217;s long-lived assets are held in the United States.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in interest-bearing money market funds. Cash equivalents are carried at cost, which approximates their fair market value.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash comprises letters of credit for the benefit of the landlord in connection with the Company&#8217;s lease facilities. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its marketable securities. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders&#8217; equity. Realized gains and losses are included in the Company's consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. As a result, the Company has categorized all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company's intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in other comprehensive loss, net of applicable taxes unless deemed other than temporary.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Significant Suppliers and License Agreements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Significant Suppliers and License Agreements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company's investment portfolio comprises money market funds, marketable debt securities, including debt securities issued by U.S. government agencies and corporations, and commercial paper. The Company investments are limited to investment-grade securities with strong credit ratings with the objective of maintaining safety and liquidity. The Company also maintains deposits in </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) up to $250,000. As of December&#160;31, 2022 and 2021, the Company&#8217;s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-Balance-Sheet Risk</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts or other hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities of the Company are carried at fair value under GAAP. The fair values of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items measured at fair value on a recurring basis include cash equivalents and marketable securities (Note 4 and Note 5). The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal, retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance that do not improve or extend the lives of the respective assets are charged to expense as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842. The Company determines if an arrangement is a lease at contract inception. Operating lease right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable, based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine operating lease right-of-use assets may include lease incentives and stated rent increases. The Company&#8217;s lease agreements may include both lease and non-lease components, which the Company accounts for as a single lease component when the payments are fixed, for all classes of underlying assets. Variable payments included in the lease agreement are expensed as incurred.</span></div>The Company&#8217;s operating leases are reflected in operating lease right-of-use assets and in current operating lease liabilities and long-term operating lease liabilities in its consolidated balance sheets. The Company&#8217;s operating lease right-of-use asset as of December&#160;31, 2022 and 2021 did not include any lease incentives. Lease expense for future lease payments is recognized on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements and Revenue Recognition</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808"), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of ASC 606 under which the Company may license or provide options to license certain development or product candidates and, in certain cases, may perform research and development services. The terms of these agreements may include payment of non-refundable, upfront fees, option exercise fees, development and commercial milestone payments and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for agreements determined to be within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as an option to obtain a license, it evaluates whether such options are material rights that should be treated as separate performance obligations. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received to estimate the amount expected to be received. The amount of variable consideration included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal of the cumulative revenue recognized will not occur in a future period.</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes as revenue the amount of the transaction price that it allocated to the respective performance obligation when or as each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an output or input method. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For example, f</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or research and development services that are recognized over time, the Company measures its progress using an input method. The input methods used are based on the effort the Company expends or costs it incurs toward the satisfaction of its performance obligation. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the amount of effort it expends, including the time it estimates it will take to complete the activities, or costs it incurs in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that is multiplied by the transaction price to determine the amount of revenue recognized each period. If the estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that is recognized in the current and future periods.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company performs its obligations under these agreements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had one collaboration, option and license agreement with UCB Biopharma SRL ("UCB"), which it entered into in December 2022. The accounting accounting related to the collaboration agreement is outlined in Note 9, UCB Option and License Agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. Costs incurred to obtain licenses are recognized as research and development expense as incurred if the technology licensed has no alternative future uses.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development related contracts with parties both inside and outside of the United States. These agreements are cancellable, and related fees are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent-Related Costs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation ("</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718"). For stock-based awards issued to employees, non-employees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of the grant. The Company recognizes compensation expense for those awards granted to employees and members of the Board over the requisite service period, which is generally the vesting period of the respective award. For non-employee awards, compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards on a straight-line basis over the vesting period. To date, the Company has not issued any stock-based awards with performance or market-based vesting conditions. The Company accounts for forfeitures as they occur.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary or service payments are classified.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs of subjective assumptions, including: (i)&#160;the expected volatility of the Company&#8217;s stock; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; (iv)&#160;expected dividends; and (v)&#160;the fair value of common stock. Due to the lack of Company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline publicly-traded companies that issued options with substantially similar terms. For this analysis, the Company selects companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company determines expected volatility using a weighted average of the historical volatilities of the guideline group of companies. The Company expects to continue to apply this process until such time as it has adequate historical data regarding the volatility of its own traded stock price. As permitted under ASC 718, the Company has elected to use the contractual term as the expected term for certain non-employee awards, on an award-by-award basis. For all other awards, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. The Company utilizes this method as it has insufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for instruments with a term commensurate with the expected term assumption. The expected dividend yield is assumed to be zero as the Company has never paid dividends, and does not have current plans to pay any dividends on its common stock. Subsequent to the IPO, the fair value of the common stock underlying the Company's stock-based awards is the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is estimated based on the fair value of the Company's underlying common stock on the date of grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign CurrencyThe functional currency of the Company&#8217;s wholly owned foreign subsidiary in Australia is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent that it believes based upon the weight of available evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss. For the years ended December 31, 2022 and 2021,comprehensive loss consists of net loss and changes in unrealized losses on marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested restricted common stock and potential shares issuable under the employee stock purchase plan are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2019-12"). The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders&#8217; equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. On January 1, 2021, the Company early adopted ASU 2019-12 on a prospective basis, with no material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Financial Instruments&#8212;Credit Losses (Topic&#160;326)&#8212;Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which has been subsequently amended by ASU&#160;No.&#160;2018-19, ASU&#160;No.&#160;2019-04, ASU&#160;No.&#160;2019-05, ASU&#160;No.&#160;2019-10, ASU&#160;No.&#160;2019-11 and ASU&#160;No.&#160;2020-03 (&#8220;ASU&#160;2016-13&#8221;). The provisions of ASU&#160;2016-13&#160;modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. On October 1, 2021, the Company early adopted ASU 2016-13 and its related amendments using a modified retrospective approach. Given the composition of the Company's investment portfolio, there was no material impact on the Company's consolidated financial statements and related disclosures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements</span></div>None.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884306592976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884311849984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text">The following is a summary of the Company's investment portfolio as of December&#160;31, 2022 and 2021 (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one year or less</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,716&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total securities with a maturity of one to two years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884306086480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2022 and 2021 (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities issued by U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,104&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884306063472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884311849984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued external research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,850&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303131904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Operating Lease, Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the presentation of the operating leases in the Company&#8217;s consolidated balance sheets (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease cost</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total lease costs recognized in the Company&#8217;s consolidated statements of operations (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:69.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average incremental borrowing rate of the Company&#8217;s operating lease were as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average incremental borrowing rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable lease agreements as of&#160;December&#160;31, 2022 were as follows (in&#160;thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future&#160;Lease<br/>Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298688848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Summary of common stock reserved for future issuance</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved the following shares of common stock for future issuance:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,838,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,667,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for future awards under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares reserved for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shares of authorized common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,072,855&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,230,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884306306544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted stock activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock unit activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(268,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,969,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,334,113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,838,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,315,240&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.86&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,635,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of stock option awards on the grant date using the Black-Scholes option valuation model</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average grant-date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was allocated as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303056384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,838,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,468,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potential shares issuable under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,865,839&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,942,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298503152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal and state research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(959)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298544368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 41,173<span></span>
</td>
<td class="nump">$ 43,945<span></span>
</td>
<td class="nump">$ 60,194<span></span>
</td>
<td class="nump">$ 68,717<span></span>
</td>
<td class="nump">$ 58,582<span></span>
</td>
<td class="nump">$ 44,705<span></span>
</td>
<td class="nump">$ 36,401<span></span>
</td>
<td class="nump">$ 27,373<span></span>
</td>
<td class="nump">214,029<span></span>
</td>
<td class="nump">$ 167,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 530,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,644<span></span>
</td>
<td class="nump">$ 316,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884300475216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298548416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,615<span></span>
</td>
<td class="nump">$ 138,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows</a></td>
<td class="nump">$ 62,031<span></span>
</td>
<td class="nump">$ 139,720<span></span>
</td>
<td class="nump">$ 297,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303482176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_OfficeFurnitureAndEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298542816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prepaid expenses and other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_LettersOfCreditReceivableCurrent', window );">Letters Of Credit Receivable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_LettersOfCreditReceivableNoncurrent', window );">Letters of Credit Receivable, Noncurrent</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_LettersOfCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Letters Of Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_LettersOfCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_LettersOfCreditReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Letters of Credit Receivable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_LettersOfCreditReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302170080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Investment Profile (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Available-for-sale, amortized cost, current</a></td>
<td class="nump">$ 39,047<span></span>
</td>
<td class="nump">$ 105,716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Available-for-sale, amortized cost, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, amortized cost</a></td>
<td class="nump">39,047<span></span>
</td>
<td class="nump">137,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, current, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, noncurrent, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, current, before tax</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, noncurrent, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total available-for-sale securities, gross unrealized losses</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Available-for-sale, current</a></td>
<td class="nump">38,874<span></span>
</td>
<td class="nump">105,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated Fair Value, Available-for-sale, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities, estimated fair value</a></td>
<td class="nump">38,874<span></span>
</td>
<td class="nump">137,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Available-for-sale, amortized cost, current</a></td>
<td class="nump">35,042<span></span>
</td>
<td class="nump">52,214<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Available-for-sale, amortized cost, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, current, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, noncurrent, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, current, before tax</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, noncurrent, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Available-for-sale, current</a></td>
<td class="nump">34,879<span></span>
</td>
<td class="nump">52,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated Fair Value, Available-for-sale, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Available-for-sale, amortized cost, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, current, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, current, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Available-for-sale, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt securities issued by U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Available-for-sale, amortized cost, current</a></td>
<td class="nump">4,005<span></span>
</td>
<td class="nump">12,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, current, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, current, before tax</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Available-for-sale, current</a></td>
<td class="nump">$ 3,995<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Available-for-sale, amortized cost, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized gain, current, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax', window );">Available-for-sale, accumulated gross unrealized loss, current, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Available-for-sale, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884299715120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>program</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities | program</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Securities, unrealized loss position, fair value | $</a></td>
<td class="nump">$ 38.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303366688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 73,055<span></span>
</td>
<td class="nump">$ 268,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">38,176<span></span>
</td>
<td class="nump">143,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">34,879<span></span>
</td>
<td class="nump">125,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">34,181<span></span>
</td>
<td class="nump">131,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">34,181<span></span>
</td>
<td class="nump">131,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">34,879<span></span>
</td>
<td class="nump">83,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">34,879<span></span>
</td>
<td class="nump">83,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt securities issued by U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt securities issued by U.S. government agencies | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt securities issued by U.S. government agencies | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt securities issued by U.S. government agencies | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other debt securities | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other debt securities | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other debt securities | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303169712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="nump">$ 1,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(572)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_OfficeFurnitureAndEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=prax_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884306465344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent', window );">Accrued external research and development expenses</a></td>
<td class="nump">$ 10,734<span></span>
</td>
<td class="nump">$ 17,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_AccruedPersonnelRelatedExpensesCurrent', window );">Accrued personnel-related expenses</a></td>
<td class="nump">2,803<span></span>
</td>
<td class="nump">7,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">2,313<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 15,850<span></span>
</td>
<td class="nump">$ 26,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_AccruedExternalResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued External Research And Development Expenses, Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_AccruedExternalResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_AccruedPersonnelRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Personnel Related Expenses, Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_AccruedPersonnelRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298512080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_PercentageIncreaseInAnnualBaseRent', window );">Percentage increase in annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,901<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 4,311<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_PercentageIncreaseInAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase In Annual Base Rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_PercentageIncreaseInAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298996896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease, Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,901<span></span>
</td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 4,311<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884306149968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Total Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303322736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 4,311<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303074944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Incremental Borrowing Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298501488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UCB Option and License Agreement (Details) - UCB - License<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront Payment</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Milestone Payments</a></td>
<td class="nump">98.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Upfront payment</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=prax_UCBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=prax_UCBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301917376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 08, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 20, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_SaleOfStockConsiderationReceivedGrossAmount', window );">Sale of stock, consideration received, gross amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, net of discounts, commissions and offering expenses | $</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="nump">$ 98.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Jefferies Open Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,595,273<span></span>
</td>
<td class="nump">3,987,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, net of discounts, commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_SaleOfStockConsiderationReceivedGrossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received, Gross Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_SaleOfStockConsiderationReceivedGrossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance Line items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prax_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prax_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prax_JefferiesOpenMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prax_JefferiesOpenMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884303188032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">12,072,855<span></span>
</td>
<td class="nump">10,230,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">8,838,028<span></span>
</td>
<td class="nump">6,468,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Future Share-based Awards | 2020 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,650,955<span></span>
</td>
<td class="nump">2,667,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Future Share-based Awards | 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">839,922<span></span>
</td>
<td class="nump">654,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems', window );"><strong>Schedule Of Common Stock Reserved For Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">743,950<span></span>
</td>
<td class="nump">440,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance Line items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301831632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value exercised</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=prax_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested restricted stock units</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense expected to be recognised (in years)</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">7,449,480<span></span>
</td>
<td class="nump">5,184,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prax_TwentySeventeenEmployeeStockIncentivePlanMember', window );">2017 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">5,937,763<span></span>
</td>
<td class="nump">5,937,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">981,306<span></span>
</td>
<td class="nump">654,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">141,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=prax_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=prax_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prax_TwentySeventeenEmployeeStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prax_TwentySeventeenEmployeeStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prax_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302157552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares beginning balance | shares</a></td>
<td class="nump">440,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Issued Shares | shares</a></td>
<td class="nump">676,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested Shares | shares</a></td>
<td class="num">(104,803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited Shares | shares</a></td>
<td class="num">(268,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares ending balance | shares</a></td>
<td class="nump">743,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Issued (in usd per share) | $ / shares</a></td>
<td class="nump">14.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">44.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">22.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 23.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, issued in period, weighted average grant date fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884300718064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding beginning balance</a></td>
<td class="nump">6,468,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="nump">3,969,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares exercised</a></td>
<td class="num">(265,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares canceled or forfeited</a></td>
<td class="num">(1,334,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding ending balance</a></td>
<td class="nump">8,838,028<span></span>
</td>
<td class="nump">6,468,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable</a></td>
<td class="nump">3,315,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares vested and expected to vest</a></td>
<td class="nump">8,635,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price beginning balance</a></td>
<td class="nump">$ 16.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price granted</a></td>
<td class="nump">9.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price exercised</a></td>
<td class="nump">3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price cancelled or forfeited</a></td>
<td class="nump">16.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price ending balance</a></td>
<td class="nump">13.93<span></span>
</td>
<td class="nump">$ 16.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">14.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price vested and expected to vest</a></td>
<td class="nump">$ 13.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term outstanding</a></td>
<td class="text">8 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term vested and expected to vest</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value exercised</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding</a></td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value exercisable</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value vested and expected to vest</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301851872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.52%<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.20%<span></span>
</td>
<td class="nump">85.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share</a></td>
<td class="nump">$ 6.65<span></span>
</td>
<td class="nump">$ 27.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock based awards</a></td>
<td class="nump">$ 45.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense expected to be recognised (in years)</a></td>
<td class="text">2 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301850048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 28,593<span></span>
</td>
<td class="nump">$ 22,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">9,972<span></span>
</td>
<td class="nump">9,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 18,621<span></span>
</td>
<td class="nump">$ 13,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884302171456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 10, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">155,040,000<span></span>
</td>
<td class="nump">$ 120,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prax_IonisMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LicensingAgreementsMember', window );">License agreement | RogCon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LicensingAgreementsMember', window );">License agreement | Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=prax_LicensingAgreementsProfitSharePaymentsMember', window );">License agreement, profit share payments | RogCon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=prax_IonisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=prax_IonisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=prax_RogconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=prax_RogconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=prax_LicensingAgreementsProfitSharePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=prax_LicensingAgreementsProfitSharePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884304724720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,865,839<span></span>
</td>
<td class="nump">6,942,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,838,028<span></span>
</td>
<td class="nump">6,468,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">743,950<span></span>
</td>
<td class="nump">440,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Potential shares issuable under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">283,861<span></span>
</td>
<td class="nump">33,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884304732768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development credits</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(27.20%)<span></span>
</td>
<td class="num">(29.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298602208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 60,047<span></span>
</td>
<td class="nump">$ 56,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenditures</a></td>
<td class="nump">34,947<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization', window );">Amortization</a></td>
<td class="nump">24,262<span></span>
</td>
<td class="nump">14,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">9,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,422<span></span>
</td>
<td class="nump">3,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset', window );">Leases</a></td>
<td class="nump">898<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">144,674<span></span>
</td>
<td class="nump">86,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(143,930)<span></span>
</td>
<td class="num">(85,957)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DeferredTaxAssetsTaxDeferredExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DeferredTaxAssetsTaxDeferredExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301664800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, domestic</a></td>
<td class="nump">$ 226,300<span></span>
</td>
<td class="nump">$ 212,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">218,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Operating loss carryforwards, state and local</a></td>
<td class="nump">197,400<span></span>
</td>
<td class="nump">187,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">9,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="nump">143,930<span></span>
</td>
<td class="nump">85,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase (decrease), amount</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301348880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884301982960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">General and administrative<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139884298718256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 07, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in follow-on public offering (in shares) | shares</a></td>
<td class="nump">2,942,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, gross proceeds | $</a></td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>prax-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:prax="http://praxismedicines.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="prax-20221231.xsd" xlink:type="simple"/>
    <context id="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a728182f04043d39d4792ebfafe466a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ice112e6c2ffe47f9a03da78fda972c84_I20230203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="ica6b7381be214302904bad838ac442b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica5b4ea7f3da432faad4765b7291efb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2344b1ab9c3a4878a68866f2972e66c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ad98315af3d41a282deab5221cf97e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3be9750a865b4e6e91d05a084c54ac34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6eba7ebb706b4dfa80a4a7810dd535c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic09992728bef4f0bae174a9c6128fa25_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b0b9cad54eb49588e17c54b674ca49b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida8c1ac19c834c578b8b2ece2ac3cb77_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic74d74d369a54b27a1f0a0997271d1da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7789b54e2a114c39b31e80ed274bb4dd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2585ba6f7d1140968c2b676bef9b6a76_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i37b99720f46e48d785dd30506df4095a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8e08f1293150426397b0487ecffc04ea_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8af8704c56174ca1b37faec33a912463_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3ba601030eba426189040ccc2833c493_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65bc52cfad8d4c54b16d280f13ff2223_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a93c7b7231e485d9dcb693c55f01c36_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i196d0f35a1c74e6e8d4415c7632ab49f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2f912841859b41cabd50be81996afef1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4bc40af393984b69a6f339c706f7a8cc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85b46df47ce94205bcab6f972efaee12_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie93ce564963d491aba684e9adfb498e6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac0a8e5710134eb08c67c0c06b7b24da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i70c148e140a84df0a85d7419acf357d6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibea6fb2e7f9c4653980110ad0997c840_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i37e0cde373b74b1fbcdea62d3b9b067d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf0b11d79884461a83cccb8dc6bbcdd3_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3477c218f40b4c7c970a4c3f3626732d_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51354d96fa5d42aca6c0254acaecbeed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9b3da6cf3fb4b80b31db69d5e75e733_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id33de74923df41ec83c75880cf5f279b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2656057b4b1f4ddab56bd4e68b9a8313_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53d1517befc54004869962cb5db5d4db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5685a97c7eb649f18683911595830a0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c72dd27f4db45c5a09009b132c11e0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice2015d475fd417da87c4d8147258dc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a2ef18fc101489483b20f45d8d64499_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0cc21efa6afc42e49f591f790c790431_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9132bcbc9a0e463d891bcdf0f039bb90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i186b0778379c4993937fb55c38327183_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9293a98a8dd4a93a09eb1a71841867b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e4c52a182b04c4ab5d1d08a712e89e9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i28901937c12f479a8152673d4168671a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib7be4e0e05564f3fafa58c61f9b1fd10_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab0b74c530d04342bf1f589de16e0e3a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if2685775b6e74db4912d26db6ca928e3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70ce13338d7446b8bdc23590e058954d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17ab2e142b2d4fd391309d3aeb7a644b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i53f78ffae117408b9d174f79b6dadfc4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61be35db0ffd454eb578dd8a53db2fdc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iabb872f5f3514052982389e3861ab98b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic2628ce7abeb41ba95f3481aac7564a5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f2b8a2121cf494bb5534c112dd72a9e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba3004733fd54cbaa6eaea0ca6842030_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifefc7fcacec24cc2a304b8269c3aab86_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78de702859e243238daafb422255ef7f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i83f734a83c044c69af0d89604a75b839_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if3238b6279a242f289e5ffa4033bab55_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic0eb91dd5deb4936a88808d25a6364c8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie3418d0f46f24a79a25d7259e2c96794_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7a5663f6ee44464a959cce62a6559179_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f0624b7d6cc44bcb25109c266ffa6b8_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:A2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f20c793f4244b09a0b12e6890ea02f5_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05cebf03629447b68ee074d4fbbd0250_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i632d279a2efe44aea3fdf28603091934_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2d950c598cd455e8bb7e9014cef8268_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia737e914cf5e40249acbf0bf1ee2f218_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id5fa9a695a6e4fb0ba67088018be15ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4a71c9652034aa088cfbfe7454ba32b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2cdab54eb0dc4fe59c45617c2005234f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55923be6a1c64b7eaac49c978815f27c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie24f78a034d8434ea805bba77e18db42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if74bbcf7115f440d8a7727a6bd51c63f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4155d454f999412a8921a320b1dac7b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i863005b39586407793ad56aa5956d85b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i602db591ac4e4681915e753d9c9f647b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b26d9edbae245159b56fa3a00570a2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57f52406efb649548003a483847ad691_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1e5a8fc79f44e908279f9f4451ffcbf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b7963bf676f4ac8a945b019d828f54d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3294a9a7ece4c74870e2e39a7c3d8c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4d0ac36134f4884ba2a77e339a74cf2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i067bfcb424b847af96504067bd13ea3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c9179d2848e4437a83ec90af5318502_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14f74f35a8bd4e0d88f85f5805b2b164_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72ba78adb17f4a0397707c92359e2504_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if58d705233dd47d8aee4f5ab6cfb7200_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27a0c3d7a4f446ce8e8a686a819a00e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e26ad8bb6f04d92a24db27f1e62aee2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc35a88c136a419baf53d23fb148a052_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3aa83e6bc8e4ae9b4d9cbb367c26259_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e590dbad5c94c6bb050a64eccee552f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a98be32db89466fb3fa4f64deb01f21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb01972b2a0f443d89fb162c0416b297_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bd8cd471062406d938bc8f398785ba9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id43b84cc8f724c1790306900f9eab5c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i244c9b8a8bc64d05805e6f9efdd28890_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28ab65adfac24345b56927930bd81e0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09d1356850af46b7a820dcbe285a8867_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47fa3e30c05c4125a934754580ac61d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62409ab1a9324ce686d28857f3d25ed8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1040caddcfac467f932bd93ddc355481_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00b254a6d21743ceb007eeb41999093b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6eb6df78b28c4de8a6b362faa5295589_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a3ad0541c6044f3af2172c901923f02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1964efc982e4dd5bfee80bfedb3be00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cbc72ab825d46fbb9a436e63f3c57ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e19833c70214691b2d072f303950003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee5a509f1d7046e5a8180c53dbfa8c7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6bcfca8aec14570ad5ec15d6bc82cc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i136b3f69ecaa46faa9ac4cd6b513328e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia93a96f76f6246f2aae4871e03bbf942_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i003402f9a7274f688237578608beb52e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if42340b78da843ad9d0bb3e0bc2a70c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i933e341b21264671b5246e7e4b47974b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66ec332f151445f7b78b848590737181_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8742d8224d8c45c5bdaf37d3f6ba1094_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fcf4921a72b4aab9503d8d482d73745_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prax:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i716e562883f3424aaef16a9b22f5c8e7_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="if36d77c9c53144d09601968a0865fbce_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i1738436c1e4a4aaabe1692876228c53a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:UCBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-18</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="ia8aa498682824f9bb5c5eed3af34a7de_I20210518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-18</instant>
        </period>
    </context>
    <context id="ie851e6aa9211407fbf15412951580a0b_D20210518-20210518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-18</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="iac3370fe8f2b42789eb23526e5ecb703_D20211103-20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="i921f704070724adca8d013ad9ca44f7a_D20211103-20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="ic6c285fb70c14984a035bed8222bb71a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:JefferiesOpenMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82a93dc661184757b579f3d8def24296_D20211103-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prax:JefferiesOpenMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e73530e136b479c80208cb925bbade7_I20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <instant>2020-10-20</instant>
        </period>
    </context>
    <context id="ia026dc966a754812a61ad0c096814457_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5afc5d945ba4bafadfb0d0c3dac741e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66f40fdf3e9849dc95aff9107e6a2abc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib353ee652a0c4a69b3370039987754bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc86f7ac19204f0e8a499e53f47bb1fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00847cec0267471db96ca9e81a3449ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfec095cffc9489f9b959bfbd8233e2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentyTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibab1d12675f44c9183ae81a1c19d02b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7da243485d114cb4884c5da895b1ce3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibba3fdb81c274cda9b548a2f92b2852d_D20201008-20201008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-08</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <context id="ia2ab45cd01a247ec83adf3c948df3f0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bd4bd8649214980a4a5f8233252d50e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentySeventeenEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2996ff42e2cd4a599e5553a465ddee81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwentySeventeenEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73413d9e77ac43d0ba5a6eb2639a610b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1f0a02e5c3f43b595b8742c748bc727_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09eef053696d47e58b2abf3b796af5de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90c01ec3e3ba4a2980aae7d5fa413eb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99f60c5a963444cba12bc6600fceeae2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prax:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i75efa4697b4345348551061c24679c66_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i92a1b80e6fa1480abd9c373178bf12e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prax:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b5c9571e9f8424ab4b2a1bb9d76588f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prax:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae5ce00fe1944639b5669f121145e350_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01b521b0c1334a6d99bffb35ef881760_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i086cadcb8e4b43b0b1cf5d9e023a28e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59d22bb870c64b27b65b8cba9ec3536b_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:RogconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="id08d935b650f48b894cff86c998390d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:RogconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">prax:LicensingAgreementsProfitSharePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e78b82d33fe4b7ea06ff1555beedb9f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:IonisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3928d36a17d4572b98fb4d36c5bc667_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:IonisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6db4fda94de8472aa375ed40f41dd0c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prax:IonisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb80111739064117857d8ff63d282ee7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c1e903808d0417082b7ca141017b6d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3beb3fccfcac48b1a1b2abcb40888aa0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ce3a4228571459f975e7c892d40666b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a68deb4cf0f483abe816b51999d287c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb0e4722ba7b4b88b3538c783c5b2e05_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic56cac62e36f40bcb5f9287718900ca1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6ff1ec2beed4170862a47ce96834fcd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27c24e65906d4987bf2662bc0bef89a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cd10fe8bfcc4606aabb82073574d6fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>prax:segment</measure>
    </unit>
    <unit id="program">
        <measure>prax:program</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV8xLTEtMS0xLTU5NTg0_a37bbcec-fd4a-40f1-b0ba-59e56a81d6ab">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV8yLTEtMS0xLTU5NTg0_ed8effe1-6f43-4e34-9278-828cd8e92cfd">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV8zLTEtMS0xLTU5NTg0_81019ee5-e9b6-482f-91ec-226f18d26c68">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N180L2ZyYWc6NGZkZjMyMTNlYmY2NDJjYmFlNjY5ODZjN2FiYjE2Y2EvdGFibGU6M2NjODI3ZTY0M2FlNDQ1YjhiOWExZmNiN2Q4YzU2ZGUvdGFibGVyYW5nZTozY2M4MjdlNjQzYWU0NDViOGI5YTFmY2I3ZDhjNTZkZV81LTEtMS0xLTU5NTg0_c1479157-4094-4a6a-b5c6-ef7da5eef031">0001689548</dei:EntityCentralIndexKey>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_21159827-a52f-45e4-914d-16111d124035">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_4c186cd4-1d36-4e49-a94e-eb059faddb23">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjg_fb095add-7293-4af1-90e2-816d4ff050b8">http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ibba3fdb81c274cda9b548a2f92b2852d_D20201008-20201008"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzMvZnJhZzoxMDEyMDI0ZmFjZjc0YWIzOWZjNDBmMWJjYzA0NDExZS90ZXh0cmVnaW9uOjEwMTIwMjRmYWNmNzRhYjM5ZmM0MGYxYmNjMDQ0MTFlXzIzOA_ce82ec93-1a90-4e6f-a7d3-4e0b8a78edce"
      unitRef="number">0.4673</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTU5_f31a878b-51d8-49e1-8652-9a345f90aac3">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTYw_c651d9dc-e4c5-4069-8a23-904dc552dfc6">http://fasb.org/us-gaap/2022#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYw_e721d28e-e719-4a46-a17b-ebcc1117ff3f">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6MTY1MDA0MmE4MmI2NGUwYzg1ZWE1MzUxYzYwZjAzMDkvdGFibGVyYW5nZToxNjUwMDQyYTgyYjY0ZTBjODVlYTUzNTFjNjBmMDMwOV8wLTAtMS0xLTU5NTg0_89453502-08c6-4590-8a16-f7dfadb3511a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xMjk_e1c01433-482c-4b3a-aeb6-507104ecf671">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xMjk_05fe4cca-a96d-4d43-9012-3b24fdab9f8e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjE5ZTk5MjFhZTBmNDJkMThjYjg2ZmEwOTExNzQ4YjgvdGFibGVyYW5nZTo2MTllOTkyMWFlMGY0MmQxOGNiODZmYTA5MTE3NDhiOF8wLTAtMS0xLTU5NTg0_27ff7242-ca14-444f-8e7c-71ab7f7c3cd7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYz_971e25ae-708d-4cf7-abb0-851ec4118932">001-39620</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjY3_3e9870b9-ef95-4126-9d1c-728c96fcb9fc">PRAXIS PRECISION MEDICINES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8wLTAtMS0xLTU5NTg0_b0e04c9d-fb8e-4652-943a-47349bf1e37a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8wLTItMS0xLTU5NTg0_35e69191-f1dd-4f88-b7c7-25ce50909461">47-5195942</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8zLTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTgxYzk0MTY0YzlmNGRiZGIxZWI3ODMyM2IzZTc3ZTBfNA_9e666ced-e35b-4c2c-97cd-3b09936ec695">99 High Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl8zLTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTgxYzk0MTY0YzlmNGRiZGIxZWI3ODMyM2IzZTc3ZTBfOA_b8eacab9-c20d-4088-86dd-46cb8f26de61">30th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl80LTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTc4YzFiYThjMTU3NGEwNWEzZWJhODJlZWEyYjAwNmZfNA_5d3f5a78-a7d0-4bdd-a1d0-890448287f9e">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl80LTAtMS0xLTU5NTg0L3RleHRyZWdpb246OTc4YzFiYThjMTU3NGEwNWEzZWJhODJlZWEyYjAwNmZfOA_9bd2d96f-b92c-416b-ada6-be76ced7c4de">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6NjI1YzI3YzZiMmQxNGYwNWEwMDI5N2JjZjkyNmNlMjYvdGFibGVyYW5nZTo2MjVjMjdjNmIyZDE0ZjA1YTAwMjk3YmNmOTI2Y2UyNl80LTItMS0xLTU5NTg0_bffacc3d-a736-44c8-8d80-5e86c4a1d7f8">02110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjU2_423456b6-0f3b-48ee-b5e8-da0391bac60f">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjU3_0912625d-af53-4d9c-945a-0ac4829ee514">300-8460</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6ZTVmODlmMDc1OTU4NDBmMTgxMjE0Yjg3YjA2NmM5MmIvdGFibGVyYW5nZTplNWY4OWYwNzU5NTg0MGYxODEyMTRiODdiMDY2YzkyYl8xLTAtMS0xLTU5NTg0_ed4735bd-3821-4564-87b4-d00938410d99">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6ZTVmODlmMDc1OTU4NDBmMTgxMjE0Yjg3YjA2NmM5MmIvdGFibGVyYW5nZTplNWY4OWYwNzU5NTg0MGYxODEyMTRiODdiMDY2YzkyYl8xLTItMS0xLTU5NTg0_8a36999d-1fa9-4e9a-b73d-3bab591e738e">PRAX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6ZTVmODlmMDc1OTU4NDBmMTgxMjE0Yjg3YjA2NmM5MmIvdGFibGVyYW5nZTplNWY4OWYwNzU5NTg0MGYxODEyMTRiODdiMDY2YzkyYl8xLTQtMS0xLTU5NTg0_fc797df6-a7f8-46c4-8220-95f0dbb8ba0c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY183MTQ2ODI1NTg0ODc3_d10aa3f4-43c0-4dbf-9e42-369fe1cdeb3f">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjU4_ca1205f2-d9a5-446d-a95c-cc5e96a06525">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYx_195a9de8-18fc-4290-8f6f-ef87b681f44f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjYy_24e04e91-fd7c-4ad9-ab05-467111406383">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6OGRiMDA0ZmMzZjEwNDExYmI0YWI1NDFiZjliMWU1MzAvdGFibGVyYW5nZTo4ZGIwMDRmYzNmMTA0MTFiYjRhYjU0MWJmOWIxZTUzMF8yLTAtMS0xLTcwNDk1_f0e9762e-17ad-4b60-b21f-59e3bf4de85e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6OGRiMDA0ZmMzZjEwNDExYmI0YWI1NDFiZjliMWU1MzAvdGFibGVyYW5nZTo4ZGIwMDRmYzNmMTA0MTFiYjRhYjU0MWJmOWIxZTUzMF8yLTMtMS0xLTU5NTg0_226ca2ef-b1b2-4107-a3f1-31bd5b31710e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGFibGU6OGRiMDA0ZmMzZjEwNDExYmI0YWI1NDFiZjliMWU1MzAvdGFibGVyYW5nZTo4ZGIwMDRmYzNmMTA0MTFiYjRhYjU0MWJmOWIxZTUzMF80LTMtMS0xLTU5NTg0_84a4ca74-c75a-42e7-901d-f46d1fd3ff47">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xMTU0NDg3MjA5NTk5Nw_553674f8-2ec8-4fe0-8ee3-e5b52bb5cb4f">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18zMjY2_2d53b51a-5d34-4d9a-b593-b6275177c465">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i0a728182f04043d39d4792ebfafe466a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18xNjQ5MjY3NDQ2MDAw_65f4dd52-145e-4dd5-9b7f-551d67c6652d"
      unitRef="usd">103800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ice112e6c2ffe47f9a03da78fda972c84_I20230203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xL2ZyYWc6ODhlNWE2MGU4OWZmNDRmMDhlNGVkMTg0MjEwNDczYmMvdGV4dHJlZ2lvbjo4OGU1YTYwZTg5ZmY0NGYwOGU0ZWQxODQyMTA0NzNiY18yODky_426161a2-1415-4c70-bb0c-78fe94f2ba39"
      unitRef="shares">52393118</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N183OS9mcmFnOjJlMjNiZTZjNWVjOTRmZmNiYzBkODQzMjk1ZGRjMjQwL3RhYmxlOjc5NmNlZWUyMTMxYzRiNTFiYWRmM2Q3NDUwNzdjOWYxL3RhYmxlcmFuZ2U6Nzk2Y2VlZTIxMzFjNGI1MWJhZGYzZDc0NTA3N2M5ZjFfMi0wLTEtMS01OTU4NC90ZXh0cmVnaW9uOmM1MTc0ZDE0MmVlYjRlODM5YjQ1ZGVlYzNjNDgyZGUyXzcx_78dbd9cc-e07d-45d3-a2af-307a524d2650">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184Mi9mcmFnOjZiNjc3YWE0NjY3ZTQ2NTc5YmU3ZDZkNTM5YmI0NTI1L3RleHRyZWdpb246NmI2NzdhYTQ2NjdlNDY1NzliZTdkNmQ1MzliYjQ1MjVfMzY3Nw_5b8f63ca-b419-401c-994d-bef862a3ade1">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184Mi9mcmFnOjZiNjc3YWE0NjY3ZTQ2NTc5YmU3ZDZkNTM5YmI0NTI1L3RleHRyZWdpb246NmI2NzdhYTQ2NjdlNDY1NzliZTdkNmQ1MzliYjQ1MjVfMzY3OA_6311d1d7-d308-4771-969a-2af13e11e114">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNC0xLTEtMS01OTU4NA_567f17de-1086-457e-b7de-c804e56b4eb7"
      unitRef="usd">61615000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNC0zLTEtMS01OTU4NA_dc8db2b0-0181-4169-903c-d9d0f83109a5"
      unitRef="usd">138704000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNS0xLTEtMS01OTU4NA_f92250ac-f5de-4819-96f8-011b7bf0da52"
      unitRef="usd">38874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNS0zLTEtMS01OTU4NA_ce0b1d2f-d45c-4358-9c14-6ac159278f54"
      unitRef="usd">137207000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNi0xLTEtMS01OTU4NA_55d9d57d-b4f9-42e6-aa72-2cb82114c666"
      unitRef="usd">10351000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNi0zLTEtMS01OTU4NA_27ca927f-635a-42c1-9fe5-b905cdbb5b7f"
      unitRef="usd">11498000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNy0xLTEtMS01OTU4NA_6f3480a9-bb99-47f1-9c13-3c493f9c0b6f"
      unitRef="usd">110840000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfNy0zLTEtMS01OTU4NA_0cb8165a-fd6a-4594-9a23-bf4dcbe3490b"
      unitRef="usd">287409000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOC0xLTEtMS01OTU4NA_e1d78539-c7d6-48e0-99bf-a428023fde50"
      unitRef="usd">971000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOC0zLTEtMS01OTU4NA_c2d9dd19-63e7-440b-b139-a4fc1cfb764e"
      unitRef="usd">1213000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOS0xLTEtMS01OTU4NA_defd8a5b-ef04-41de-9287-e13271eef036"
      unitRef="usd">2901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfOS0zLTEtMS01OTU4NA_dda760f2-6f7d-4dfa-b388-c269b6a67397"
      unitRef="usd">3653000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTAtMS0xLTEtNTk1ODQ_65bc9841-ebc8-4687-a30a-06f0d8b89608"
      unitRef="usd">416000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTAtMy0xLTEtNTk1ODQ_1809616c-70fc-4c66-b3df-adaf995ced3d"
      unitRef="usd">472000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTEtMS0xLTEtNTk1ODQ_a8596a69-ad23-47e2-97bb-e497c029091a"
      unitRef="usd">115128000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTEtMy0xLTEtNTk1ODQ_d0829b9e-eb2c-4dfa-8b9e-3d83cdff4b38"
      unitRef="usd">292747000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTQtMS0xLTEtNTk1ODQ_09fae10c-76e7-49ff-a966-19015a4a7536"
      unitRef="usd">14672000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTQtMy0xLTEtNTk1ODQ_6d656a7d-9c27-4641-8373-faf7d3c03545"
      unitRef="usd">10780000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTUtMS0xLTEtNTk1ODQ_82229d10-90ad-4cfb-8cf9-2bc9c49991b1"
      unitRef="usd">15850000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTUtMy0xLTEtNTk1ODQ_8f9e542a-20e9-46d8-bb9f-fedb679fb40d"
      unitRef="usd">26844000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTYtMS0xLTEtNTk1ODQ_796353d4-5015-45c8-9911-68940bb59155"
      unitRef="usd">1005000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTYtMy0xLTEtNTk1ODQ_345eea4f-7014-4395-9a70-3eb394cff1dc"
      unitRef="usd">810000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMS0xLTEtNjkyNzI_45a0e60e-d4e2-4f29-8aa3-655f2573ddb5"
      unitRef="usd">2818000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMy0xLTEtNjkyNzI_b38ad462-507e-46b7-9170-3a94739a9fd4"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMS0xLTEtNTk1ODQ_c1c0cef5-b67c-43c6-b26c-d02f9b959002"
      unitRef="usd">34345000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTctMy0xLTEtNTk1ODQ_f6d6f9ae-186b-422b-a529-1f82c378d39e"
      unitRef="usd">38434000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTktMS0xLTEtNTk1ODQ_379eb16c-8a8f-48a7-9d6c-84a5fd61d9cb"
      unitRef="usd">2495000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMTktMy0xLTEtNTk1ODQ_c247e592-e2ed-473f-a222-752b7a62a493"
      unitRef="usd">3501000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMS0xLTEtNjY5MzY_54dc78ad-70c7-44a1-a391-bf6bc1edb4f3"
      unitRef="usd">2182000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMy0xLTEtNjY5MzY_97124898-4c5c-4d2f-bfe8-df64508dca7b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMS0xLTEtNTk1ODQ_a39f7675-9039-4b17-a566-1b6becb3963f"
      unitRef="usd">39022000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjAtMy0xLTEtNTk1ODQ_35ec9193-6c6c-43db-8f8d-08f055fb293a"
      unitRef="usd">41935000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjEtMS0xLTEtNTk1ODQ_4a47c460-777a-4a00-9ae6-7b1d444729e9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjEtMy0xLTEtNTk1ODQ_d688a27b-9f05-419d-a060-6a7e687c32b7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8yMQ_a6b4fe0d-23d5-4e3f-8a43-3e85ac90f356"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8yMQ_c98eeccd-d6a5-4011-9317-ad8b0d052173"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8zNQ_37322fd1-4e5b-4c1e-9ff6-068968186c0a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl8zNQ_d3845336-e962-405b-849f-54610cef59de"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_2fb64e20-d5c0-44dc-8671-70bc695d0a59"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_375baf63-85ed-4abc-aafb-dca7d50968ad"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_5acfa803-7fc5-4554-9d6d-0b1dc9138544"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo3OTFkMzA2YmFjYmI0ODcyOWU0NDdiNjI4MWM5NmUwYl82MA_9b75cc53-1ebd-4422-9646-fae92ded8291"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMS0xLTEtNTk1ODQ_883ec23c-f41d-43f9-aa7d-f2075110432d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjMtMy0xLTEtNTk1ODQ_fd848b2e-7275-47b2-b161-d534664ec58a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjIz_14130309-9e71-4b2d-91c9-e40c3d1f702a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjIz_f080d998-ff71-4f17-96e3-070e4e5f3212"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjU1_3e23f15b-4601-46d4-a75a-406109ceb789"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMjU1_dff220f5-7c60-4f7c-bf4c-99521c968180"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzUz_1fe67ca3-3c18-43f3-8117-e67fed18256e"
      unitRef="shares">49382453</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzUz_8a917dce-bcbb-4015-a7ea-117f64ec3736"
      unitRef="shares">49382453</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzIy_8b595ef3-3857-4921-a476-6cb6e6f1d99d"
      unitRef="shares">45300514</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjo5ZTQ5NWRlMDIxMmE0MjE4YjRkODhlZmRiMjdmMzNhYV8xNjQ5MjY3NDQyMzIy_d3dabcf3-cec1-4747-b3b0-aea92e27a832"
      unitRef="shares">45300514</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMS0xLTEtNTk1ODQ_54da305e-1632-4a55-8f4e-12e71c560dbb"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjQtMy0xLTEtNTk1ODQ_efa9752e-cfc5-47a7-b309-add42215d90c"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjUtMS0xLTEtNTk1ODQ_f5661d40-8ef8-4671-99ba-95d9977275cf"
      unitRef="usd">606918000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjUtMy0xLTEtNTk1ODQ_6a6b4817-e7db-4e39-9fec-2c88a5f1b339"
      unitRef="usd">567598000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjYtMS0xLTEtNTk1ODQ_95421f9b-96cb-4f7e-b050-35c80185474e"
      unitRef="usd">-173000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjYtMy0xLTEtNTk1ODQ_df76f7a3-f8de-49a1-bd3f-607c01f014eb"
      unitRef="usd">-176000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjctMS0xLTEtNTk1ODQ_163eaac8-5675-488e-a7e3-42ea1d9c8df6"
      unitRef="usd">-530644000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjctMy0xLTEtNTk1ODQ_5c634938-cd0e-4f6d-9d3a-3de637cd314d"
      unitRef="usd">-316615000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjgtMS0xLTEtNTk1ODQ_2a24d079-2435-43c1-90af-795bbe39680d"
      unitRef="usd">76106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjgtMy0xLTEtNTk1ODQ_915f256f-7bcb-44f6-9eea-1bd30296ab50"
      unitRef="usd">250812000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjktMS0xLTEtNTk1ODQ_9b709b77-42a9-4c8a-b56f-b6cd916b1eb1"
      unitRef="usd">115128000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184NS9mcmFnOmVlOTMzMTMyZTIxZjRhNTA4NzA4MzJmNDgwMTU3MWMxL3RhYmxlOmI5ZTExOTQ2YmI1ZjQ5Njc4Yzk1NmQ4MjY3Y2Y3NWNlL3RhYmxlcmFuZ2U6YjllMTE5NDZiYjVmNDk2NzhjOTU2ZDgyNjdjZjc1Y2VfMjktMy0xLTEtNTk1ODQ_2445311b-e189-4552-92fb-4d9e9d565d93"
      unitRef="usd">292747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMy0xLTEtMS01OTU4NA_46b5e9b3-a914-4312-971a-d71729f88be0"
      unitRef="usd">155040000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMy0zLTEtMS01OTU4NA_73f9604b-5cfb-4fdf-aa54-2160d12eba46"
      unitRef="usd">120257000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNC0xLTEtMS01OTU4NA_efd6411c-1c4e-407c-9d8a-19f8c9a1e076"
      unitRef="usd">59946000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNC0zLTEtMS01OTU4NA_8325fd6c-a11c-4482-9966-852197005a27"
      unitRef="usd">47075000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNS0xLTEtMS01OTU4NA_f84ee78e-e624-4a03-8dac-c41d227996df"
      unitRef="usd">214986000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNS0zLTEtMS01OTU4NA_53a9fcf5-e270-4eda-bcbb-e5c0bb6556f7"
      unitRef="usd">167332000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNi0xLTEtMS01OTU4NA_d7f771cc-0f23-4911-a93b-67395f6b96b5"
      unitRef="usd">-214986000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfNi0zLTEtMS01OTU4NA_f4a20f6a-e01e-4659-85f3-0321cb963379"
      unitRef="usd">-167332000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfOC0xLTEtMS01OTU4NA_e3424f58-4929-4c1c-87db-46de44d11b77"
      unitRef="usd">957000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfOC0zLTEtMS01OTU4NA_62223d1e-4d98-4549-8798-7090d556d872"
      unitRef="usd">271000</us-gaap:InterestIncomeOther>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTEtMS0xLTEtNTk1ODQ_e19d6d77-7a4d-472a-a074-1445ae854911"
      unitRef="usd">957000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTEtMy0xLTEtNTk1ODQ_6943e0fc-b8e5-4ded-829d-103b43b2a085"
      unitRef="usd">271000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTQtMS0xLTEtNTk1ODQ_4e4ab308-1182-4a04-9330-2edf917f2c25"
      unitRef="usd">-214029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTQtMy0xLTEtNTk1ODQ_10ca4967-5de2-470c-8cea-44dc0b3a6442"
      unitRef="usd">-167061000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMS0xLTEtNTk1ODQ_138411af-4657-42b4-b674-78eb96250fee"
      unitRef="usdPerShare">-4.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMS0xLTEtNTk1ODQ_284fd66b-c421-4de8-9d5f-8d65c491bfa9"
      unitRef="usdPerShare">-4.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMy0xLTEtNTk1ODQ_25741e6e-c942-4849-8a51-8e6a79cdfcb6"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTgtMy0xLTEtNTk1ODQ_5844f63c-61db-46b9-a88b-3de903962925"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMS0xLTEtNTk1ODQ_2ba6be67-02f3-44ac-abbc-67694fa0006f"
      unitRef="shares">46096737</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMS0xLTEtNTk1ODQ_f738c9cb-bf35-44e9-9616-7cabc71b7c60"
      unitRef="shares">46096737</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMy0xLTEtNTk1ODQ_023ea646-7783-4ccf-b099-3a173050c943"
      unitRef="shares">42454055</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N184OC9mcmFnOjc4MjE5ODcyYzUyNzQ4NTZiM2YwMmFjNjRhOTMxNzA1L3RhYmxlOjI3YWNlNGNjMTA1ODRhYmE5MTg3MDBjYWRjNzAyOGJiL3RhYmxlcmFuZ2U6MjdhY2U0Y2MxMDU4NGFiYTkxODcwMGNhZGM3MDI4YmJfMTktMy0xLTEtNTk1ODQ_d5875df9-2864-49ad-8a0a-9128e2f2728f"
      unitRef="shares">42454055</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMi0xLTEtMS01OTU4NA_2da21731-6697-4ba6-bcb2-8d9ecb526c3d"
      unitRef="usd">-214029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMi0zLTEtMS01OTU4NA_9fcfed17-cc5e-4490-97b6-b390cdae4099"
      unitRef="usd">-167061000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMy0xLTEtMS01OTU4NA_d961a613-6456-4f2c-8b9b-3502e8d2b1ac"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfMy0zLTEtMS01OTU4NA_5d4918f9-d901-4c24-a0a9-c72d57a279ea"
      unitRef="usd">-176000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfNC0xLTEtMS01OTU4NA_5f5e5f19-06cc-4925-9c1a-27646947d5eb"
      unitRef="usd">-214026000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185MS9mcmFnOjM3ZTc5YTM1ZWUwZTQ2OTk5MmI3YzAyZmY0NDEzNzIzL3RhYmxlOmZkNDhiZTJjZjI1YzRiNDliMjZmODE3YTY0NWY4ODg4L3RhYmxlcmFuZ2U6ZmQ0OGJlMmNmMjVjNGI0OWIyNmY4MTdhNjQ1Zjg4ODhfNC0zLTEtMS01OTU4NA_d230f373-6ecf-496b-8abc-7d6011f7c7d9"
      unitRef="usd">-167237000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi0xLTEtMS01OTU4NA_35569e8c-bd9d-4a9b-9d04-2a9c0ed1c4c8"
      unitRef="shares">45300514</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi0zLTEtMS01OTU4NA_49970f06-3a12-4431-9f9b-8a1d9a4b5d8c"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2344b1ab9c3a4878a68866f2972e66c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi01LTEtMS01OTU4NA_2cc769f2-029c-41b1-957b-995e0a774218"
      unitRef="usd">567598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ad98315af3d41a282deab5221cf97e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi03LTEtMS01OTU4NA_f2c55fea-ee15-4ef0-a3d8-ba6ecc6c887d"
      unitRef="usd">-316615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3be9750a865b4e6e91d05a084c54ac34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi05LTEtMS01OTU4NA_b9a4afc9-44f4-4964-90bf-1183471eece6"
      unitRef="usd">-176000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMi0xMS0xLTEtNTk1ODQ_961d8c2a-6583-4ab8-aae6-69e83f507941"
      unitRef="usd">250812000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMy01LTEtMS01OTU4NA_c77cb19a-edae-49a3-b02e-78d37819dc63"
      unitRef="usd">7886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMy0xMS0xLTEtNTk1ODQ_fadaa639-4c43-490a-9d06-1fc99760f62a"
      unitRef="usd">7886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNC0xLTEtMS01OTU4NA_76b7e50b-1bd3-4c24-909d-a0250fa48a54"
      unitRef="shares">70410</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNC01LTEtMS01OTU4NA_25d518a7-7f09-4ce0-8e09-9fc88d42587c"
      unitRef="usd">1368000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNC0xMS0xLTEtNTk1ODQ_08712020-1d18-426b-8b4a-e70465bda743"
      unitRef="usd">1368000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNS0xLTEtMS01OTU4NA_b890486d-5211-4e41-ae4e-f5232edea311"
      unitRef="shares">81130</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNi0xLTEtMS01OTU4NA_5cbb9372-0180-48ed-ad5c-f41dd6e76d3a"
      unitRef="shares">17850</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNi01LTEtMS01OTU4NA_092d508b-f5cd-4ba2-8688-8fd20597ca08"
      unitRef="usd">230000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNi0xMS0xLTEtNTk1ODQ_21b5a4aa-2608-4afe-b6e4-3ff6a3566453"
      unitRef="usd">230000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8171b575186d4b1f86729875f2a8326e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNy0xLTEtMS01OTU4NA_d320c35a-ed1c-430e-8670-84f4d530fa80"
      unitRef="shares">72278</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i500a25e7f1fb461ab5fa31cd8201c6f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNy01LTEtMS01OTU4NA_fb2c101a-2825-4205-bd46-9e9e9deb5e0c"
      unitRef="usd">333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfNy0xMS0xLTEtNTk1ODQ_b47c05e1-523c-4aa1-92a7-30aec824bdf3"
      unitRef="usd">333000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6eba7ebb706b4dfa80a4a7810dd535c9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOC05LTEtMS01OTU4NA_bb98ba68-0483-46ca-9dff-7fd3a450c025"
      unitRef="usd">-430000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOC0xMS0xLTEtNTk1ODQ_a8962d9f-b98a-4fe2-bbb8-405ca6876b66"
      unitRef="usd">-430000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic09992728bef4f0bae174a9c6128fa25_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOS03LTEtMS01OTU4NA_143b89a2-c1a4-4cc8-b234-0dcd64dd52a3"
      unitRef="usd">-68717000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c059605ba9d491da2aa09c9550c382e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfOS0xMS0xLTEtNTk1ODQ_f4a2ced3-14e7-4670-9566-3ca668cc11c4"
      unitRef="usd">-68717000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b0b9cad54eb49588e17c54b674ca49b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtMS0xLTEtNTk1ODQ_c0385960-913b-4a28-a513-1cdcdd0ba771"
      unitRef="shares">45506482</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2b0b9cad54eb49588e17c54b674ca49b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtMy0xLTEtNTk1ODQ_af4537a8-be31-41cb-a258-e224c364d0f3"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida8c1ac19c834c578b8b2ece2ac3cb77_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtNS0xLTEtNTk1ODQ_b76f5976-3a39-4154-9b49-2306ad26fcad"
      unitRef="usd">576955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic74d74d369a54b27a1f0a0997271d1da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtNy0xLTEtNTk1ODQ_577756e2-ab3e-4ab4-82d9-c942a8a335f3"
      unitRef="usd">-385332000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7789b54e2a114c39b31e80ed274bb4dd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtOS0xLTEtNTk1ODQ_0a5be613-4243-4c5b-af43-835d38b7a404"
      unitRef="usd">-606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2585ba6f7d1140968c2b676bef9b6a76_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTAtMTEtMS0xLTU5NTg0_9cf34c71-14a3-4683-8d07-3e307f98711b"
      unitRef="usd">191022000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTEtNS0xLTEtNTk1ODQ_890e476b-3154-4c6c-a009-a616d151597f"
      unitRef="usd">7611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTEtMTEtMS0xLTU5NTg0_57c25a89-4ae7-444c-8b53-79fcbfa34425"
      unitRef="usd">7611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTItMS0xLTEtNTk1ODQ_80f770e1-51b1-4996-91f8-6cf841d2e439"
      unitRef="shares">51645</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTItNS0xLTEtNTk1ODQ_ed542de1-4b8c-4036-a95c-76901a0a6d50"
      unitRef="usd">454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTItMTEtMS0xLTU5NTg0_c0d60df7-6313-4f00-a9bf-9b7494571e9e"
      unitRef="usd">454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTMtMS0xLTEtNTk1ODQ_065f7ea3-697f-4673-a3ea-addfe4a128df"
      unitRef="shares">6361</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTQtMS0xLTEtNTk1ODQ_cde957af-9481-40f7-b6dc-b360cb2b6f4a"
      unitRef="shares">2225</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTQtNS0xLTEtNTk1ODQ_5b46a6d6-9b1c-49bb-9c74-a901ed0b22cb"
      unitRef="usd">17000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTQtMTEtMS0xLTU5NTg0_952ce428-0d66-44f0-ada5-4a51fd670e62"
      unitRef="usd">17000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i37b99720f46e48d785dd30506df4095a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTUtMS0xLTEtNTk1ODQ_390e9d27-8c7b-497a-902a-ecf46f7fd0e0"
      unitRef="shares">13143</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3066c9dc057e47028e1858cfdc0c8acb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTUtNS0xLTEtNTk1ODQ_1060cd98-9911-4924-a31b-03b6b67f325d"
      unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTUtMTEtMS0xLTU5NTg0_6260da18-e642-4f7d-bb4a-6822705cfeb4"
      unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8e08f1293150426397b0487ecffc04ea_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTYtOS0xLTEtNTk1ODQ_7cf80ca0-1bf8-448e-b6e3-2c9299645077"
      unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTYtMTEtMS0xLTU5NTg0_7a0b7e9b-781c-4cb9-aa12-b247e49c2c57"
      unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8af8704c56174ca1b37faec33a912463_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTctNy0xLTEtNTk1ODQ_83bd9148-8aea-44f1-b580-920dd4087620"
      unitRef="usd">-60194000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e44a1a83157455886edd1831c1b71ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTctMTEtMS0xLTU5NTg0_d71e0ba0-2ab4-49d8-8745-ddfae791def6"
      unitRef="usd">-60194000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3ba601030eba426189040ccc2833c493_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtMS0xLTEtNTk1ODQ_057b8f82-ead7-4e6c-9c0e-4c47481f2033"
      unitRef="shares">45575406</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ba601030eba426189040ccc2833c493_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtMy0xLTEtNTk1ODQ_eee60861-7d80-45e6-b426-566cb9f5936f"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65bc52cfad8d4c54b16d280f13ff2223_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtNS0xLTEtNTk1ODQ_0260972e-389e-4102-9137-5537cb3e26a9"
      unitRef="usd">585070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a93c7b7231e485d9dcb693c55f01c36_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtNy0xLTEtNTk1ODQ_7bca62ad-65a3-4656-b7de-1157ce0953af"
      unitRef="usd">-445526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i196d0f35a1c74e6e8d4415c7632ab49f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtOS0xLTEtNTk1ODQ_5e25d635-c2e5-4808-85e3-1cab8db56d5a"
      unitRef="usd">-680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a728182f04043d39d4792ebfafe466a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTgtMTEtMS0xLTU5NTg0_3493974d-401f-45fa-96e1-662305830088"
      unitRef="usd">138869000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTktNS0xLTEtNTk1ODQ_0aed566d-ad47-46e2-b5ab-7eaccd3bc11f"
      unitRef="usd">6730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMTktMTEtMS0xLTU5NTg0_2a90e06e-0e25-4ad8-a6bb-d364992c6e70"
      unitRef="usd">6730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtMC0xLTEtNTk1ODQvdGV4dHJlZ2lvbjplZGM5YjY2YTk4ODk0YzFhODE2OWFlNzEzOGNjODlkNl8xNjQ5MjY3NDQxNzYy_f820b64d-abf1-4ca5-a208-69fdb15e2775"
      unitRef="usd">109000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtMS0xLTEtNTk1ODQ_cd8c3bc7-13e9-4dc3-a459-c461bd0c2f3b"
      unitRef="shares">1105006</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtNS0xLTEtNTk1ODQ_af1c278c-f460-4c02-b874-2e6597957e5b"
      unitRef="usd">2962000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjAtMTEtMS0xLTU5NTg0_6aa4881a-2394-4fac-acea-8dba1850729e"
      unitRef="usd">2962000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtMS0xLTEtNjQyNjI_b77368fe-48fa-47d2-aec5-82aff5066746"
      unitRef="shares">5312</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItMS0xLTEtNjQyNjI_eebadb6f-a8a2-4b2d-8ea3-b2efb24ec601"
      unitRef="shares">1638</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItNS0xLTEtNjQyNjI_05e4a8b1-d672-44ca-a945-57280d822cd0"
      unitRef="usd">6000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItMTEtMS0xLTY0MjYy_3cf981bc-69d6-4bb4-83fe-60bba323f165"
      unitRef="usd">6000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i64662d278b9e4bfe8142a950b42e7bb3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtMS0xLTEtNTk1ODQ_d5f562de-391a-4752-a8b2-39e244aaceb9"
      unitRef="shares">180241</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5832096e685741ae9e6cc8e15bcdcc05_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtNS0xLTEtNTk1ODQ_4d8c547c-d4cb-461f-9d1e-93073f35416a"
      unitRef="usd">409000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjEtMTEtMS0xLTU5NTg0_008ef4a7-fafe-46de-9f42-0df4d1ebde94"
      unitRef="usd">409000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4bc40af393984b69a6f339c706f7a8cc_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItOS0xLTEtNTk1ODQ_354c02c8-c0c0-431e-8e7f-739546c81e48"
      unitRef="usd">144000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjItMTEtMS0xLTU5NTg0_d01d59bc-228e-4657-b830-d3c62962f325"
      unitRef="usd">144000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i85b46df47ce94205bcab6f972efaee12_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjMtNy0xLTEtNTk1ODQ_c29a15c7-8b71-4979-b521-c84735aa509e"
      unitRef="usd">-43945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2f912841859b41cabd50be81996afef1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjMtMTEtMS0xLTU5NTg0_c9d28aca-445a-4f62-9a27-c61466931ac6"
      unitRef="usd">-43945000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie93ce564963d491aba684e9adfb498e6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtMS0xLTEtNTk1ODQ_2be79eaa-6455-4d0a-8d7b-3bc8699abd58"
      unitRef="shares">46864327</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie93ce564963d491aba684e9adfb498e6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtMy0xLTEtNTk1ODQ_0238b9c9-88a3-4fd4-8e3e-d2e34136491b"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac0a8e5710134eb08c67c0c06b7b24da_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtNS0xLTEtNTk1ODQ_d452c787-a652-493a-b63d-1fdb72fb5f12"
      unitRef="usd">595165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70c148e140a84df0a85d7419acf357d6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtNy0xLTEtNTk1ODQ_2869e6dd-a5eb-4bc1-8576-7e730ce20781"
      unitRef="usd">-489471000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibea6fb2e7f9c4653980110ad0997c840_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtOS0xLTEtNTk1ODQ_93569786-e435-4541-8a9a-b8472182274d"
      unitRef="usd">-536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37e0cde373b74b1fbcdea62d3b9b067d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjQtMTEtMS0xLTU5NTg0_07266d70-eee2-4904-acde-76c4dda6fc42"
      unitRef="usd">105163000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjctNS0xLTEtNjQyNjI_71126ef9-6a43-4501-bd01-d090fb4af393"
      unitRef="usd">6366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjctMTEtMS0xLTY0MjYy_07c0729e-5dc7-4d83-9312-7ce6f55dbf8a"
      unitRef="usd">6366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMS0xLTEtNjY5ODU_a3cda1a2-c63b-4611-b6af-377ecabbfdb1"
      unitRef="shares">89739</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtNS0xLTEtNjY5ODU_935b3c28-f831-42d1-84cb-4a833d8c510e"
      unitRef="usd">163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMTEtMS0xLTY2OTg1_48d825b4-b857-4833-a7f6-553a7869eece"
      unitRef="usd">163000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMS0xLTEtNjQyNjI_5b5a7b01-5e07-4abe-8933-45591ac000f8"
      unitRef="shares">2419857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtNS0xLTEtNjQyNjI_e5af9066-95c8-4058-80a3-02f919a59464"
      unitRef="usd">5231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjgtMTEtMS0xLTY0MjYy_e9930182-1ee5-40c9-bb28-263a67509db8"
      unitRef="usd">5231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMjktMS0xLTEtNjQyNjI_28942f6e-7eca-4b66-828a-55fffc84f2bb"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ie470e6c58e7546639e4581f5924cc9e6_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzAtMS0xLTEtNjQyNjI_bb5254f5-0c3a-473f-b370-19d9e0c2a6a7"
      unitRef="shares">3470</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0a1fa0a9f4864073b2b00c466bea50e5_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzAtNS0xLTEtNjQyNjI_90c00d38-4c87-438a-bc4e-d465edbba766"
      unitRef="usd">7000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzAtMTEtMS0xLTY0MjYy_2d769e4f-37af-4d40-81da-2d28d2a3f19b"
      unitRef="usd">7000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icf0b11d79884461a83cccb8dc6bbcdd3_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzItOS0xLTEtNjQyNjI_af19a7c5-a8cb-4d75-9cba-c86e62fa0a11"
      unitRef="usd">363000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzItMTEtMS0xLTY0MjYy_5c6a0ebe-176b-4c45-abb3-b72204d781f3"
      unitRef="usd">363000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3477c218f40b4c7c970a4c3f3626732d_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzMtNy0xLTEtNjQyNjI_06c585af-b077-447b-b916-d7a028aea24f"
      unitRef="usd">-41173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff86badfa9df415dacce8a1cdb27f71e_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzMtMTEtMS0xLTY0MjYy_086f2355-6d15-4f1c-9e42-72c1f1bb1d39"
      unitRef="usd">-41173000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i51354d96fa5d42aca6c0254acaecbeed_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtMS0xLTEtNjQyNjI_f81dbc51-d9f3-42e4-a327-c56299809bff"
      unitRef="shares">49382453</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i51354d96fa5d42aca6c0254acaecbeed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtMy0xLTEtNjQyNjI_6bc75bcc-ae80-4af1-aba3-876b1a6728ea"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9b3da6cf3fb4b80b31db69d5e75e733_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtNS0xLTEtNjQyNjI_785e886c-b924-4f16-ae95-6bf2e5eb5bb1"
      unitRef="usd">606918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id33de74923df41ec83c75880cf5f279b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtNy0xLTEtNjQyNjI_713d4301-62b2-4afb-b285-33b80b15908f"
      unitRef="usd">-530644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2656057b4b1f4ddab56bd4e68b9a8313_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtOS0xLTEtNjQyNjI_2febdbd4-5968-40bf-8ebc-394ce5fe59f1"
      unitRef="usd">-173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOmQzODZiYTJhMjM0ZDQ2ODFhNmNhMzk2NTYwOTU4NjMyL3RhYmxlcmFuZ2U6ZDM4NmJhMmEyMzRkNDY4MWE2Y2EzOTY1NjA5NTg2MzJfMzQtMTEtMS0xLTY0MjYy_33e023de-5e7a-4c10-8e29-80d3e08f937c"
      unitRef="usd">76106000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi0xLTEtMS02NDMyOA_7e4d9430-c04a-427c-9621-5b59f728abc6"
      unitRef="shares">38268543</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi0zLTEtMS02NDMyOA_44271227-3fa6-4243-ac10-d255680e8031"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53d1517befc54004869962cb5db5d4db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi01LTEtMS02NDMyOA_a69cdea1-fe4a-4518-8689-97633480c261"
      unitRef="usd">437007000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5685a97c7eb649f18683911595830a0d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi03LTEtMS02NDMyOA_a26dcf25-8ef2-4555-8d86-44a2643e4af0"
      unitRef="usd">-149554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c72dd27f4db45c5a09009b132c11e0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi05LTEtMS02NDMyOA_9cfd3765-75d2-4425-abfd-6d301a6e2002"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice2015d475fd417da87c4d8147258dc6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMi0xMS0xLTEtNjQzMjg_ae046cdd-6d2f-4540-a740-e65981431a92"
      unitRef="usd">287457000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8a2ef18fc101489483b20f45d8d64499_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMy01LTEtMS02NDMyOA_03c9eeff-03eb-4a1c-af52-2de164a003fc"
      unitRef="usd">4666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMy0xMS0xLTEtNjQzMjg_33ae1221-d212-43c1-ae2d-6fdd7f9f3c22"
      unitRef="usd">4666000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0cc21efa6afc42e49f591f790c790431_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNC0xLTEtMS02NDMyOA_eab62558-57ca-41f4-9dfe-a01341aa8166"
      unitRef="shares">352506</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8a2ef18fc101489483b20f45d8d64499_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNC01LTEtMS02NDMyOA_9aab9c70-6538-4b42-8224-42e57a6babd0"
      unitRef="usd">851000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNC0xMS0xLTEtNjQzMjg_8e991790-61e8-4e5a-9d9b-16955871e624"
      unitRef="usd">851000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9132bcbc9a0e463d891bcdf0f039bb90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNS05LTEtMS02NDMyOA_7a5384ce-c1bb-42c0-83e8-ed89e96b5d1c"
      unitRef="usd">-86000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNS0xMS0xLTEtNjQzMjg_32688e92-ccef-4e54-9674-a0d129a44072"
      unitRef="usd">-86000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i186b0778379c4993937fb55c38327183_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNi03LTEtMS02NDMyOA_fe849bb3-85af-4c13-8164-135bea6cd02d"
      unitRef="usd">-27373000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNi0xMS0xLTEtNjQzMjg_e50141c5-f5f7-41b5-8407-be70f7124b0e"
      unitRef="usd">-27373000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib9293a98a8dd4a93a09eb1a71841867b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy0xLTEtMS02NDMyOA_56092ad9-2b2e-41c3-8fe0-a9ff886a8304"
      unitRef="shares">38621049</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib9293a98a8dd4a93a09eb1a71841867b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy0zLTEtMS02NDMyOA_75873ad4-032c-48d7-844e-ed84363a03e8"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e4c52a182b04c4ab5d1d08a712e89e9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy01LTEtMS02NDMyOA_5ef19886-972d-440b-b177-34bb047a73ab"
      unitRef="usd">442524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28901937c12f479a8152673d4168671a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy03LTEtMS02NDMyOA_c4025092-bcdc-400b-bbd6-405a2673f1cb"
      unitRef="usd">-176927000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7be4e0e05564f3fafa58c61f9b1fd10_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy05LTEtMS02NDMyOA_f5d85d36-6a45-45e1-8a65-97abfedeaad1"
      unitRef="usd">-86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab0b74c530d04342bf1f589de16e0e3a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfNy0xMS0xLTEtNjQzMjg_6e356336-294f-49e9-9885-43de4606f593"
      unitRef="usd">265515000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOC01LTEtMS02NDMyOA_6254f499-c8d0-498a-a45a-2c2c4ed30825"
      unitRef="usd">5400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOC0xMS0xLTEtNjQzMjg_071b2973-22a1-468a-a32e-be75ce462e78"
      unitRef="usd">5400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0wLTEtMS02NDMyOC90ZXh0cmVnaW9uOmQxZDEyZDM5OGY5NjQwODc4OTkzYmU1NmEyNGY5NmU2XzE2NDkyNjc0NDE3NTc_584224e5-11aa-4b14-ae0b-376afd919b9d"
      unitRef="usd">229000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0xLTEtMS02NDMyOA_a0aa4134-f68c-405b-95e0-1f851cd87a28"
      unitRef="shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0zLTEtMS02NDMyOA_bfeeced4-efaf-4083-bb38-1091eb8f0394"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS01LTEtMS02NDMyOA_3dc64de2-ffba-4a1a-9edf-939862c1e726"
      unitRef="usd">98412000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfOS0xMS0xLTEtNjQzMjg_8540bb6c-f369-422a-b5d5-da8919af4afd"
      unitRef="usd">98413000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i10125ac1438b4ebf997c096976d80d2a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTAtMS0xLTEtNjQzMjg_b12556f5-0af2-4c0c-94eb-5b7988e5120c"
      unitRef="shares">322113</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i37a0988b06d0421295808ca56e48d86f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTAtNS0xLTEtNjQzMjg_032a9f4b-7cbe-4337-a3ec-6ef701f37fb1"
      unitRef="usd">809000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTAtMTEtMS0xLTY0MzI4_761312e0-3a7e-41fd-b6bd-569644f23935"
      unitRef="usd">809000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if2685775b6e74db4912d26db6ca928e3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTEtOS0xLTEtNjQzMjg_ab5569ff-9b6d-4141-90cb-c9f6660df8f8"
      unitRef="usd">36000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTEtMTEtMS0xLTY0MzI4_c19eda55-3970-4cdd-a528-1eea3f86fa8e"
      unitRef="usd">36000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i70ce13338d7446b8bdc23590e058954d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTItNy0xLTEtNjQzMjg_32e5b613-d660-42d5-9132-248464580585"
      unitRef="usd">-36401000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b7f2b2d225f4a0b8d1c39001a08205d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTItMTEtMS0xLTY0MzI4_ee2b6027-ad54-4c42-b2fa-ae978f1ae400"
      unitRef="usd">-36401000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i17ab2e142b2d4fd391309d3aeb7a644b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtMS0xLTEtNjQzMjg_7f414f06-8693-48ae-a3f5-1eea2fcc5757"
      unitRef="shares">44693162</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i17ab2e142b2d4fd391309d3aeb7a644b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtMy0xLTEtNjQzMjg_28e4325e-2251-43dc-aa45-711b61d9d3e0"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53f78ffae117408b9d174f79b6dadfc4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtNS0xLTEtNjQzMjg_ff579083-46d8-4003-87fb-25a58d44eca5"
      unitRef="usd">547145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61be35db0ffd454eb578dd8a53db2fdc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtNy0xLTEtNjQzMjg_d5ccf04d-fb7d-4739-80f5-7bab5b0573dc"
      unitRef="usd">-213328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabb872f5f3514052982389e3861ab98b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtOS0xLTEtNjQzMjg_5797cf39-ded7-428f-baba-155953f306b1"
      unitRef="usd">-50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2628ce7abeb41ba95f3481aac7564a5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTMtMTEtMS0xLTY0MzI4_533f6616-d7c8-4606-8152-1b16da30c067"
      unitRef="usd">333772000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0f2b8a2121cf494bb5534c112dd72a9e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTQtNS0xLTEtNjQzMjg_94c5aeb7-4a33-48c1-ae47-c49561c764a5"
      unitRef="usd">6521000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTQtMTEtMS0xLTY0MzI4_ee855cca-4806-4e29-80fb-55d7e462f527"
      unitRef="usd">6521000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iba3004733fd54cbaa6eaea0ca6842030_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTUtMS0xLTEtNjQzMjg_31da0663-db8c-4d2e-bc84-ef161e9ba5bd"
      unitRef="shares">90909</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0f2b8a2121cf494bb5534c112dd72a9e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTUtNS0xLTEtNjQzMjg_1af62f5d-7e8f-4ee8-81dc-cf58c2ff1623"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTUtMTEtMS0xLTY0MzI4_b62e30ea-ab4d-4e2f-8224-885dab018088"
      unitRef="usd">309000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifefc7fcacec24cc2a304b8269c3aab86_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTYtOS0xLTEtNjQzMjg_52d413a0-7abb-42f9-94dc-a9e4d2fa1bd9"
      unitRef="usd">25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTYtMTEtMS0xLTY0MzI4_b3e5b62b-f52e-4ce5-9a40-df9ae89ca677"
      unitRef="usd">25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i78de702859e243238daafb422255ef7f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTctNy0xLTEtNjQzMjg_b578923b-9bd3-4b64-9dea-25e9a73d87df"
      unitRef="usd">-44705000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0fdd2e59380342fd9f8403563654886e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTctMTEtMS0xLTY0MzI4_9b485d78-6ff3-490e-88ef-d0a783aa3b58"
      unitRef="usd">-44705000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i83f734a83c044c69af0d89604a75b839_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtMS0xLTEtNjQzMjg_090970b5-7cc5-4e73-a121-fddf0205a1f4"
      unitRef="shares">44784071</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i83f734a83c044c69af0d89604a75b839_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtMy0xLTEtNjQzMjg_ed3cee22-e044-4465-ad8f-fea1581a22a6"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3238b6279a242f289e5ffa4033bab55_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtNS0xLTEtNjQzMjg_acb573ad-882b-4f78-919b-1cd71ae013c3"
      unitRef="usd">553975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0eb91dd5deb4936a88808d25a6364c8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtNy0xLTEtNjQzMjg_38c5afaa-a628-4c4d-8594-6fd8db926f47"
      unitRef="usd">-258033000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3418d0f46f24a79a25d7259e2c96794_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtOS0xLTEtNjQzMjg_c9adb31c-4ef9-4fc4-b535-e297b9af137e"
      unitRef="usd">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a5663f6ee44464a959cce62a6559179_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTgtMTEtMS0xLTY0MzI4_b9b5bdbe-abd2-4ae3-82b2-e53181374267"
      unitRef="usd">295922000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTktNS0xLTEtNjQzMjg_bf9f190d-c5a6-41de-a0d8-635bc376c551"
      unitRef="usd">6106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMTktMTEtMS0xLTY0MzI4_945fb8ba-b03a-4816-b4a4-8b82eb3bb43d"
      unitRef="usd">6106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0f0624b7d6cc44bcb25109c266ffa6b8_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtMC0xLTEtNjQzMjgvdGV4dHJlZ2lvbjozMjBiZTJlYWUwZWQ0YWE3YWVmOWY2M2NlMTg0YTE3OF8xNjQ5MjY3NDQxNzYy_f66f67a5-f8c3-43ca-98b2-2cf695e215f2"
      unitRef="usd">598000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7f20c793f4244b09a0b12e6890ea02f5_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtMS0xLTEtNjQzMjg_7fb7c95f-20bf-40b3-bb04-6c651a307ddf"
      unitRef="shares">391997</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtNS0xLTEtNjQzMjg_96dc1aa7-6400-4c80-a67e-c59295de2bd2"
      unitRef="usd">7039000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjAtMTEtMS0xLTY0MzI4_c6809a4a-4674-4267-874f-415b04247baf"
      unitRef="usd">7039000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7f20c793f4244b09a0b12e6890ea02f5_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjEtMS0xLTEtNjQzMjg_dfe887b0-3977-4754-8495-0b038d5b11c9"
      unitRef="shares">124446</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idc63b94c7b1d4742bf570e4561837b6f_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjEtNS0xLTEtNjQzMjg_65fc4113-a21f-4a0e-bfa6-51a2a42a7bb9"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjEtMTEtMS0xLTY0MzI4_4e517e0b-8ba1-475b-9b48-39b1d8897a49"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i05cebf03629447b68ee074d4fbbd0250_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjItOS0xLTEtNjQzMjg_31e67b1f-4676-4dbd-9365-e4a829144fbc"
      unitRef="usd">-151000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjItMTEtMS0xLTY0MzI4_41f1cfc6-f8ec-423f-918f-9c817b524b6d"
      unitRef="usd">-151000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i632d279a2efe44aea3fdf28603091934_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjMtNy0xLTEtNjQzMjg_d8ef7b56-a83b-44f2-a114-ea4d487eb746"
      unitRef="usd">-58582000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic906ca32fa12476f8b0f0f36982827da_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjMtMTEtMS0xLTY0MzI4_56796554-301b-4d4f-aca1-63a9a4b1db2b"
      unitRef="usd">-58582000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtMS0xLTEtNjQzMjg_36d675a8-e0ab-4beb-bee7-5a32b6fd68d5"
      unitRef="shares">45300514</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie7c13a7ad8a14c11b75ab5942b1ade28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtMy0xLTEtNjQzMjg_290e07f6-112b-49de-a048-372e913f6c13"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2344b1ab9c3a4878a68866f2972e66c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtNS0xLTEtNjQzMjg_b6b514e0-3921-4997-97fe-2598e7515aaa"
      unitRef="usd">567598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ad98315af3d41a282deab5221cf97e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtNy0xLTEtNjQzMjg_aff6a9ae-ce8d-4fde-80d4-339568299a7a"
      unitRef="usd">-316615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3be9750a865b4e6e91d05a084c54ac34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtOS0xLTEtNjQzMjg_4dc7387e-2817-46a0-af6c-90b4d2808d25"
      unitRef="usd">-176000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185NC9mcmFnOjAzM2FkZGEwNGJmNzQ4NmQ4OTAwNDA4OWZiY2RhYzE4L3RhYmxlOjEwMDhjN2E1MjJhNzQ0OWE5YjEyYTg0OGViOWNlOGEzL3RhYmxlcmFuZ2U6MTAwOGM3YTUyMmE3NDQ5YTliMTJhODQ4ZWI5Y2U4YTNfMjQtMTEtMS0xLTY0MzI4_51f4f7f1-d513-4e41-a047-698f8b185c33"
      unitRef="usd">250812000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMy0xLTEtMS01OTU4NA_d5223313-dac7-4675-b615-bbbfdcdcdf6c"
      unitRef="usd">-214029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMy0zLTEtMS01OTU4NA_e2906acf-baf7-4d1f-882b-6f8a7ed65bc3"
      unitRef="usd">-167061000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNS0xLTEtMS01OTU4NA_429a1ed3-7472-44fb-84aa-addf35ef9122"
      unitRef="usd">419000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNS0zLTEtMS01OTU4NA_f9e32521-f7f2-4505-b428-9dcf291755d8"
      unitRef="usd">182000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNi0xLTEtMS01OTU4NA_263dbd65-8c96-4071-8510-cc5c9768a341"
      unitRef="usd">28593000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNi0zLTEtMS01OTU4NA_7e811cd3-f4d7-4948-a179-a99bbcb4d8ee"
      unitRef="usd">22693000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNy0xLTEtMS01OTU4NA_5610a555-e346-4cb0-b357-ba6a2f122a4a"
      unitRef="usd">752000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNy0zLTEtMS01OTU4NA_7db28104-a3de-49cc-8e6b-2b6565f4da11"
      unitRef="usd">1412000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfOC0xLTEtMS01OTU4NA_aca85c4d-59f3-476d-99f9-81c5fdbee658"
      unitRef="usd">-1003000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfOC0zLTEtMS01OTU4NA_88d11ce4-6b65-44d5-85c2-fd885eddf27c"
      unitRef="usd">-2087000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTAtMS0xLTEtNTk1ODQ_9eda9850-b53c-46fa-b761-fe0e157d17d5"
      unitRef="usd">-547000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTAtMy0xLTEtNTk1ODQ_389d895f-9089-4e7c-96dd-519ea4b84ece"
      unitRef="usd">5780000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTEtMS0xLTEtNTk1ODQ_aa28707b-acb4-4453-936a-f5a94f6be633"
      unitRef="usd">3892000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTEtMy0xLTEtNTk1ODQ_34f8db06-014d-4449-b380-4ea4ad82490d"
      unitRef="usd">7267000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTItMS0xLTEtNTk1ODQ_cbc3b88d-32f9-4e17-bf8d-51aa7cfa564f"
      unitRef="usd">-10465000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTItMy0xLTEtNTk1ODQ_be2874de-1adc-4694-bded-b6c30caefb04"
      unitRef="usd">15450000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <prax:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTMtMS0xLTEtNTk1ODQ_be4f741e-8568-47dc-a048-d2690c5e1e6b"
      unitRef="usd">-811000</prax:IncreaseDecreaseInOperatingLeaseLiabilities>
    <prax:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTMtMy0xLTEtNTk1ODQ_1dcf89f4-4371-4852-a4c6-3e0afd116ec1"
      unitRef="usd">-763000</prax:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMS0xLTEtNjcwMTc_dacb31f8-f40b-4adc-b0bf-6b5dbb9ae93b"
      unitRef="usd">5000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMy0xLTEtNjcwMTc_26ad4fd5-7fdd-462f-81cd-096fdd96b6e2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMS0xLTEtNTk1ODQ_2e53b816-190f-458f-b25e-32ccae4ecf5a"
      unitRef="usd">56000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTQtMy0xLTEtNTk1ODQ_892aa124-600c-41e3-81f2-059e873fc98b"
      unitRef="usd">-41000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTUtMS0xLTEtNTk1ODQ_c4ee247a-1c93-48f4-bfbf-5ccaae3fccd5"
      unitRef="usd">-185043000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTUtMy0xLTEtNTk1ODQ_adbb5b7e-ee71-486d-8fb3-51607b017ca6"
      unitRef="usd">-124554000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTctMS0xLTEtNTk1ODQ_861e7501-683f-4ae1-8ac2-80dda48b19d7"
      unitRef="usd">444000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTctMy0xLTEtNTk1ODQ_1b9daab2-af6c-40bc-8d8e-5a47564f09ff"
      unitRef="usd">1050000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTgtMS0xLTEtNTk1ODQ_dec503a8-e1c3-42c1-b014-b1d085bc2385"
      unitRef="usd">83022000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTgtMy0xLTEtNTk1ODQ_b8a15fb9-d14e-4268-92d4-3ea27e2f5eb9"
      unitRef="usd">164170000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTktMS0xLTEtNTk1ODQ_6a3e1793-e305-41ce-b7d4-831328144db9"
      unitRef="usd">180355000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMTktMy0xLTEtNTk1ODQ_5d13b2f8-8da5-4d67-9102-9f4afd9c2678"
      unitRef="usd">24700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjAtMS0xLTEtNTk1ODQ_7ce25c7c-33d7-4e51-9872-0ed96dce2e8f"
      unitRef="usd">96889000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjAtMy0xLTEtNTk1ODQ_cf524a0b-d422-4579-858c-4b98d08fcaf3"
      unitRef="usd">-140520000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <prax:ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjItMS0xLTEtNTk1ODQ_b3a7d059-9ffa-4ac0-ac8a-8ebb0bc9258b"
      unitRef="usd">9561000</prax:ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts>
    <prax:ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjItMy0xLTEtNTk1ODQ_546b8df8-15d7-4b8c-972f-5ecc88c5544c"
      unitRef="usd">7301000</prax:ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjMtMS0xLTEtNTk1ODQ_42d8690c-afba-4640-ae20-635f3469cfe6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjMtMy0xLTEtNTk1ODQ_f0af9171-6c9e-4e9c-99f3-5fc59fd0c83b"
      unitRef="usd">98413000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjUtMS0xLTEtNjcwNjA_8ebafee8-596b-4667-ba3e-e8e061af0627"
      unitRef="usd">262000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjUtMy0xLTEtNjcwNjA_8617accc-cac5-4c47-9ef6-d83594fd4d0e"
      unitRef="usd">575000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMS0xLTEtNjcxMTc_24150d4d-a3f0-40e9-affc-f89584314b5f"
      unitRef="usd">260000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMy0xLTEtNjcxMTc_0f48794c-c10b-4cdf-be77-65ee2c3d70a3"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMS0xLTEtNTk1ODQ_e15a16f3-95c1-4526-8d50-beb54ae9c955"
      unitRef="usd">1426000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjYtMy0xLTEtNTk1ODQ_07f4ebaf-6ac6-4339-b9f4-dc76a73c1549"
      unitRef="usd">2447000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjktMS0xLTEtNTk1ODQ_56dbb2fd-75bd-4a0f-8406-b509091c5920"
      unitRef="usd">10465000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMjktMy0xLTEtNTk1ODQ_244b2b8d-1bf8-4050-a424-0ea9611db66a"
      unitRef="usd">107586000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzAtMS0xLTEtNTk1ODQ_8094d76c-2910-4164-9b69-ed3477d355c0"
      unitRef="usd">-77689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzAtMy0xLTEtNTk1ODQ_428266e7-d42c-4708-9900-eef041ab85ae"
      unitRef="usd">-157488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzEtMS0xLTEtNTk1ODQ_f2ca308a-872a-4e44-b71d-28bffaa0a02f"
      unitRef="usd">139720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ice2015d475fd417da87c4d8147258dc6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzEtMy0xLTEtNTk1ODQ_0b5fcadc-1b57-4070-8a28-b76e99195fd7"
      unitRef="usd">297208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzItMS0xLTEtNTk1ODQ_8dd7b7ee-512c-4453-a4bc-bff240efab53"
      unitRef="usd">62031000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzItMy0xLTEtNTk1ODQ_750aec58-d4e3-4091-894a-d301a2720d17"
      unitRef="usd">139720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzQtMS0xLTEtNTk1ODQ_0b2eff26-a897-49db-acda-0fbe1d7ed619"
      unitRef="usd">61615000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzQtMy0xLTEtNTk1ODQ_9bdfc509-c4a0-475c-bb56-da2a42eade48"
      unitRef="usd">138704000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzUtMS0xLTEtNTk1ODQ_15e9e2a0-fbd7-41be-a129-d349e57cb6e9"
      unitRef="usd">416000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzUtMy0xLTEtNTk1ODQ_85c42962-7dbe-4f08-b770-f856d75f3077"
      unitRef="usd">1016000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzYtMS0xLTEtNTk1ODQ_eafe9adc-81b3-4b68-b0e8-68bb631b0763"
      unitRef="usd">62031000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzYtMy0xLTEtNTk1ODQ_6c64700c-e001-4821-9ff7-dbbee731adf0"
      unitRef="usd">139720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzgtMS0xLTEtNTk1ODQ_6237b0d2-af57-492e-8978-2e73c0144ca4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzgtMy0xLTEtNTk1ODQ_b9ebad16-f11a-4c2d-9153-4b5e1932789a"
      unitRef="usd">4068000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <prax:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzktMS0xLTEtNTk1ODQ_7d1ce427-aeec-4f20-b2c3-5f84f1f969a9"
      unitRef="usd">0</prax:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <prax:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfMzktMy0xLTEtNTk1ODQ_c26b4df6-b8e3-4eac-abfc-5213b48457b7"
      unitRef="usd">262000</prax:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNDAtMS0xLTEtNTk1ODQ_83b64f2e-b4d6-4a51-81ce-6661a35dd055"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N185Ny9mcmFnOjE5NmU2YWM4MjRmNTQ1MmQ5MGE0ZTBhNzgyYjA5OGVjL3RhYmxlOjc5OGY1YTg1YTk1MTQ4ODRiNWFlYzE2YjFjMTc4Y2Q3L3RhYmxlcmFuZ2U6Nzk4ZjVhODVhOTUxNDg4NGI1YWVjMTZiMWMxNzhjZDdfNDAtMy0xLTEtNTk1ODQ_027165a1-50f4-4728-adf1-ee804cf2d917"
      unitRef="usd">267000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzc0Njg_12e086bf-e73a-4c52-bcd1-41d9ef121133">Nature of the Business&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Praxis Precision Medicines, Inc. (&#x201c;Praxis&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using its understanding of shared biological targets and circuits in the brain. Each platform has multiple programs currently, with significant potential for additional program and indication expansion: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt"&gt;Cerebrum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2122;, the Company's small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Solidus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2122;, the Company's antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum&#x2122; platform, ulixacaltamide (formerly known as PRAX-944), it expects to announce topline results from the Phase 2b Essential1 clinical trial in essential tremor in the first quarter of 2023. The Company also plans to initiate an ulixacaltamide Phase 2 clinical trial in Parkinson's disease in the first quarter of 2023 and expects topline results in the fourth quarter of 2023. The Company plans to initiate&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its PRAX-562 Phase 2 EMBOLD study in the first quarter of 2023, with initial cohorts in SCN2A-DEE and SCN8A-DEE, and expects to announce topline results for both cohorts in the second half of 2023. The Company also initiated a Phase 1 healthy volunteer study of PRAX-628 in the fourth quarter of 2022 and expects to report topline results in mid-2023. For the Company's most advanced product candidate under the Solidus&#x2122; platform, PRAX-222, it expects to announce topline results from the first dose cohort of its EMBRAVE study in mid-2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, and from the sale of common stock through an initial public offering ("IPO"), a follow-on public offering and at-the-market offerings under its shelf registration statement. From inception through December&#160;31, 2022, the Company raised $526.0&#160;million in aggregate cash proceeds from these transactions, net of issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2014-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring losses since its inception, including a net loss of $214.0 million for the year ended December&#160;31, 2022. In addition, as of December&#160;31, 2022, the Company had an accumulated deficit of $530.6 million. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that its cash, cash equivalents and marketable securities as of December&#160;31, 2022, together with net proceeds raised under the Open Market Sale Agreement ("the Sales Agreement") subsequent to December&#160;31, 2022, may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial statements which raises substantial doubt about the Company's ability to continue as a going concern, and the Company will need to obtain additional funding. The Company expects to finance its operations through potential public or private equity financings, debt financings, collaboration agreements or other capital sources. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#x2019;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzQ4MjM_fadc8cfb-0ecf-4b45-aa6c-4a3f2dd940f7"
      unitRef="usd">526000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzY0OTc_54929b40-8ca9-4c49-8de1-d7d5d4ecec0a"
      unitRef="usd">-214000000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDMvZnJhZzozYTc4NjQ1MTIwOWI0ZGY2OTM5MGVmNTI1NWQ4ZDMwYi90ZXh0cmVnaW9uOjNhNzg2NDUxMjA5YjRkZjY5MzkwZWY1MjU1ZDhkMzBiXzY1ODg_9e54ce92-eed8-45b1-8961-a6fd98b8a9e0"
      unitRef="usd">-530600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIy_e35b3393-85a0-4a19-b834-edb502232df8">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and ASUs of the FASB.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Praxis Security Corporation and Praxis Precision Medicines Australia Pty Ltd. All intercompany transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, stock-based compensation expense and the recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. The majority of the Company&#x2019;s long-lived assets are held in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in interest-bearing money market funds. Cash equivalents are carried at cost, which approximates their fair market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash comprises letters of credit for the benefit of the landlord in connection with the Company&#x2019;s lease facilities. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its marketable securities. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders&#x2019; equity. Realized gains and losses are included in the Company's consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. As a result, the Company has categorized all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company's intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in other comprehensive loss, net of applicable taxes unless deemed other than temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Significant Suppliers and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company's investment portfolio comprises money market funds, marketable debt securities, including debt securities issued by U.S. government agencies and corporations, and commercial paper. The Company investments are limited to investment-grade securities with strong credit ratings with the objective of maintaining safety and liquidity. The Company also maintains deposits in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the &#x201c;FDIC&#x201d;) up to $250,000. As of December&#160;31, 2022 and 2021, the Company&#x2019;s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. The fair values of the Company&#x2019;s financial assets and liabilities reflects the Company&#x2019;s estimate of the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Items measured at fair value on a recurring basis include cash equivalents and marketable securities (Note 4 and Note 5). The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon disposal, retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance that do not improve or extend the lives of the respective assets are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases in accordance with ASC 842. The Company determines if an arrangement is a lease at contract inception. Operating lease right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable, based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease payments used to determine operating lease right-of-use assets may include lease incentives and stated rent increases. The Company&#x2019;s lease agreements may include both lease and non-lease components, which the Company accounts for as a single lease component when the payments are fixed, for all classes of underlying assets. Variable payments included in the lease agreement are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating leases are reflected in operating lease right-of-use assets and in current operating lease liabilities and long-term operating lease liabilities in its consolidated balance sheets. The Company&#x2019;s operating lease right-of-use asset as of December&#160;31, 2022 and 2021 did not include any lease incentives. Lease expense for future lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 808"), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#x2019;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements which are within the scope of ASC 606 under which the Company may license or provide options to license certain development or product candidates and, in certain cases, may perform research and development services. The terms of these agreements may include payment of non-refundable, upfront fees, option exercise fees, development and commercial milestone payments and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for agreements determined to be within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as an option to obtain a license, it evaluates whether such options are material rights that should be treated as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received to estimate the amount expected to be received. The amount of variable consideration included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes as revenue the amount of the transaction price that it allocated to the respective performance obligation when or as each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an output or input method. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For example, f&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or research and development services that are recognized over time, the Company measures its progress using an input method. The input methods used are based on the effort the Company expends or costs it incurs toward the satisfaction of its performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the amount of effort it expends, including the time it estimates it will take to complete the activities, or costs it incurs in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that is multiplied by the transaction price to determine the amount of revenue recognized each period. If the estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that is recognized in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company performs its obligations under these agreements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had one collaboration, option and license agreement with UCB Biopharma SRL ("UCB"), which it entered into in December 2022. The accounting accounting related to the collaboration agreement is outlined in Note 9, UCB Option and License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. Costs incurred to obtain licenses are recognized as research and development expense as incurred if the technology licensed has no alternative future uses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development related contracts with parties both inside and outside of the United States. These agreements are cancellable, and related fees are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent-Related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718"). For stock-based awards issued to employees, non-employees and members of the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of the grant. The Company recognizes compensation expense for those awards granted to employees and members of the Board over the requisite service period, which is generally the vesting period of the respective award. For non-employee awards, compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards on a straight-line basis over the vesting period. To date, the Company has not issued any stock-based awards with performance or market-based vesting conditions. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s salary or service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs of subjective assumptions, including: (i)&#160;the expected volatility of the Company&#x2019;s stock; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; (iv)&#160;expected dividends; and (v)&#160;the fair value of common stock. Due to the lack of Company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline publicly-traded companies that issued options with substantially similar terms. For this analysis, the Company selects companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company determines expected volatility using a weighted average of the historical volatilities of the guideline group of companies. The Company expects to continue to apply this process until such time as it has adequate historical data regarding the volatility of its own traded stock price. As permitted under ASC 718, the Company has elected to use the contractual term as the expected term for certain non-employee awards, on an award-by-award basis. For all other awards, the expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. The Company utilizes this method as it has insufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for instruments with a term commensurate with the expected term assumption. The expected dividend yield is assumed to be zero as the Company has never paid dividends, and does not have current plans to pay any dividends on its common stock. Subsequent to the IPO, the fair value of the common stock underlying the Company's stock-based awards is the closing price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of restricted stock units is estimated based on the fair value of the Company's underlying common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s wholly owned foreign subsidiary in Australia is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss. There were no material foreign currency gains or losses for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent that it believes based upon the weight of available evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss. For the years ended December 31, 2022 and 2021,comprehensive loss consists of net loss and changes in unrealized losses on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested restricted common stock and potential shares issuable under the employee stock purchase plan are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2019-12"). The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders&#x2019; equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. On January 1, 2021, the Company early adopted ASU 2019-12 on a prospective basis, with no material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Financial Instruments&#x2014;Credit Losses (Topic&#160;326)&#x2014;Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;which has been subsequently amended by ASU&#160;No.&#160;2018-19, ASU&#160;No.&#160;2019-04, ASU&#160;No.&#160;2019-05, ASU&#160;No.&#160;2019-10, ASU&#160;No.&#160;2019-11 and ASU&#160;No.&#160;2020-03 (&#x201c;ASU&#160;2016-13&#x201d;). The provisions of ASU&#160;2016-13&#160;modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. On October 1, 2021, the Company early adopted ASU 2016-13 and its related amendments using a modified retrospective approach. Given the composition of the Company's investment portfolio, there was no material impact on the Company's consolidated financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;N</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM2_e3aebaf7-e88e-42b8-bb69-b4aadb343860">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and ASUs of the FASB.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMy_e3096931-db1c-4b66-b4d3-c128d7462b55">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Praxis Security Corporation and Praxis Precision Medicines Australia Pty Ltd. All intercompany transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM3_a5beeafe-e2c4-4122-b6a2-af2dd2154fb9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, stock-based compensation expense and the recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM4_cd244612-3296-4282-8493-c940e120fb0e">SegmentsThe Company has one operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of assessing performance and allocating resources. The majority of the Company&#x2019;s long-lived assets are held in the United States.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzE2NTI_1eb7677b-1d41-4195-946f-e347d5cde866"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMz_84ebad87-358e-40a6-90a7-d2e56d69c1db">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in interest-bearing money market funds. Cash equivalents are carried at cost, which approximates their fair market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash comprises letters of credit for the benefit of the landlord in connection with the Company&#x2019;s lease facilities. Restricted cash is classified as either current or non-current based on the terms of the underlying lease arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIw_6a5be7ee-4a73-4638-b830-8f1a6ff5d8f6">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIw_f3245853-719f-44be-844a-9e105628b45e">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents cash and cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzItMS0xLTEtNTk1ODQ_3d46a881-9b3f-4eb2-8773-19915d628563"
      unitRef="usd">61615000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzItMy0xLTEtNTk1ODQ_f4c91977-67f8-4e47-9569-0a7749ca3282"
      unitRef="usd">138704000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzMtMS0xLTEtNTk1ODQ_a1868495-68fd-44ad-af59-4173389de61e"
      unitRef="usd">416000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzMtMy0xLTEtNTk1ODQ_e12d6bf2-8cf4-4e42-a05d-6a1cae942462"
      unitRef="usd">1016000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzQtMS0xLTEtNTk1ODQ_030a507c-5d12-4728-b5eb-37b29e450632"
      unitRef="usd">62031000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphNTc5OTgzOGFmNzU0MTIyYjVjYWRmOTY5M2U5NmFlYy90YWJsZXJhbmdlOmE1Nzk5ODM4YWY3NTQxMjJiNWNhZGY5NjkzZTk2YWVjXzQtMy0xLTEtNTk1ODQ_19c5c96f-9ffb-4aa2-9307-89cb18baacfd"
      unitRef="usd">139720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM0_a04ab904-bb0e-4fe2-8b4d-e08fa60faa0f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its marketable securities. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders&#x2019; equity. Realized gains and losses are included in the Company's consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. As a result, the Company has categorized all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the Company, and the Company's intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit-related is recognized in other comprehensive loss, net of applicable taxes unless deemed other than temporary.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIx_74a7c947-e783-4c13-97aa-e54dbc971939">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Significant Suppliers and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company's investment portfolio comprises money market funds, marketable debt securities, including debt securities issued by U.S. government agencies and corporations, and commercial paper. The Company investments are limited to investment-grade securities with strong credit ratings with the objective of maintaining safety and liquidity. The Company also maintains deposits in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the &#x201c;FDIC&#x201d;) up to $250,000. As of December&#160;31, 2022 and 2021, the Company&#x2019;s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzIz_00af3087-39cc-48e9-be3c-afc7b62cba34">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMw_2f70f18b-336d-46af-b96c-18bd8ef52127">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. The fair values of the Company&#x2019;s financial assets and liabilities reflects the Company&#x2019;s estimate of the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Items measured at fair value on a recurring basis include cash equivalents and marketable securities (Note 4 and Note 5). The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzcxNDY4MjU2MjU2MTE_5ad667ae-3a2b-47a3-a5e4-a9432a05598e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon disposal, retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance that do not improve or extend the lives of the respective assets are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzQw_979141f7-97ff-46a2-8c1f-1387db50fc85">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia2d950c598cd455e8bb7e9014cef8268_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphMzA5NDk1ZmRhNWM0Y2EzYmIzZWI0NWZlNDU3NzJlZi90YWJsZXJhbmdlOmEzMDk0OTVmZGE1YzRjYTNiYjNlYjQ1ZmU0NTc3MmVmXzEtMS0xLTEtNTk1ODQ_12b3ab90-f84b-4833-920d-1acc7d858993">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia737e914cf5e40249acbf0bf1ee2f218_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphMzA5NDk1ZmRhNWM0Y2EzYmIzZWI0NWZlNDU3NzJlZi90YWJsZXJhbmdlOmEzMDk0OTVmZGE1YzRjYTNiYjNlYjQ1ZmU0NTc3MmVmXzItMS0xLTEtNTk1ODQ_5729152f-f016-4a37-9be4-c678912c4d68">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id5fa9a695a6e4fb0ba67088018be15ca_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90YWJsZTphMzA5NDk1ZmRhNWM0Y2EzYmIzZWI0NWZlNDU3NzJlZi90YWJsZXJhbmdlOmEzMDk0OTVmZGE1YzRjYTNiYjNlYjQ1ZmU0NTc3MmVmXzMtMS0xLTEtNTk1ODQ_6609bbf8-b17c-4b6d-b9f4-87ae902fad09">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzQx_299384ca-6cd0-4d18-b8fe-1dcb12a03c88">Impairment of Long-Lived AssetsLong-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzExNzA5_11fa59f3-a1b6-4b78-be17-eaa1d19874fd"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzExNzA5_d1cf0547-837b-44dc-9af3-d62a28b82c72"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI0_a0f8d94c-2408-49a2-ae61-48841091c59e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases in accordance with ASC 842. The Company determines if an arrangement is a lease at contract inception. Operating lease right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable, based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease payments used to determine operating lease right-of-use assets may include lease incentives and stated rent increases. The Company&#x2019;s lease agreements may include both lease and non-lease components, which the Company accounts for as a single lease component when the payments are fixed, for all classes of underlying assets. Variable payments included in the lease agreement are expensed as incurred.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s operating leases are reflected in operating lease right-of-use assets and in current operating lease liabilities and long-term operating lease liabilities in its consolidated balance sheets. The Company&#x2019;s operating lease right-of-use asset as of December&#160;31, 2022 and 2021 did not include any lease incentives. Lease expense for future lease payments is recognized on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzcxNDY4MjU2MjU2MDk_79f0e566-2dff-4b73-bfa9-f72ae8ae5576">Collaboration Agreements&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 808"), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#x2019;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements which are within the scope of ASC 606 under which the Company may license or provide options to license certain development or product candidates and, in certain cases, may perform research and development services. The terms of these agreements may include payment of non-refundable, upfront fees, option exercise fees, development and commercial milestone payments and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for agreements determined to be within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as an option to obtain a license, it evaluates whether such options are material rights that should be treated as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payments and the likelihood that the payments will be received to estimate the amount expected to be received. The amount of variable consideration included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes as revenue the amount of the transaction price that it allocated to the respective performance obligation when or as each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an output or input method. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. For example, f&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or research and development services that are recognized over time, the Company measures its progress using an input method. The input methods used are based on the effort the Company expends or costs it incurs toward the satisfaction of its performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the amount of effort it expends, including the time it estimates it will take to complete the activities, or costs it incurs in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that is multiplied by the transaction price to determine the amount of revenue recognized each period. If the estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that is recognized in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company performs its obligations under these agreements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had one collaboration, option and license agreement with UCB Biopharma SRL ("UCB"), which it entered into in December 2022. The accounting accounting related to the collaboration agreement is outlined in Note 9, UCB Option and License Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI2_c7a7a128-ac8b-460f-8926-115c6e3e213e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. Costs incurred to obtain licenses are recognized as research and development expense as incurred if the technology licensed has no alternative future uses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development related contracts with parties both inside and outside of the United States. These agreements are cancellable, and related fees are recorded as research and development expenses as incurred. The Company records accrued liabilities and prepaid expenses for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent-Related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM1_b4af67c0-f545-4bf5-87cd-b813b75420d2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718"). For stock-based awards issued to employees, non-employees and members of the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of the grant. The Company recognizes compensation expense for those awards granted to employees and members of the Board over the requisite service period, which is generally the vesting period of the respective award. For non-employee awards, compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. The Company issues stock-based awards with service-based vesting conditions and records the expense for these awards on a straight-line basis over the vesting period. To date, the Company has not issued any stock-based awards with performance or market-based vesting conditions. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s salary or service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs of subjective assumptions, including: (i)&#160;the expected volatility of the Company&#x2019;s stock; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; (iv)&#160;expected dividends; and (v)&#160;the fair value of common stock. Due to the lack of Company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline publicly-traded companies that issued options with substantially similar terms. For this analysis, the Company selects companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company determines expected volatility using a weighted average of the historical volatilities of the guideline group of companies. The Company expects to continue to apply this process until such time as it has adequate historical data regarding the volatility of its own traded stock price. As permitted under ASC 718, the Company has elected to use the contractual term as the expected term for certain non-employee awards, on an award-by-award basis. For all other awards, the expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. The Company utilizes this method as it has insufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for instruments with a term commensurate with the expected term assumption. The expected dividend yield is assumed to be zero as the Company has never paid dividends, and does not have current plans to pay any dividends on its common stock. Subsequent to the IPO, the fair value of the common stock underlying the Company's stock-based awards is the closing price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of restricted stock units is estimated based on the fair value of the Company's underlying common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DividendsStock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzIxOTkwMjMzMDgxNjg_a4c1c446-0401-4974-83e6-b4dab7069304"
      unitRef="usd">0</us-gaap:DividendsStock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzMx_75a2fbb4-6f0e-4469-a359-c06f099aff9a">Foreign CurrencyThe functional currency of the Company&#x2019;s wholly owned foreign subsidiary in Australia is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzIxOTQ5_25170d95-de8d-4969-b590-7d0e2fdf21cb"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzIxOTQ5_5bf87f9c-dcfe-4f95-9334-2dfd3e1b2a38"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI5_cc54917e-87c0-4c2c-aa9d-5ee0599589a0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent that it believes based upon the weight of available evidence it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI1_47047026-5292-4436-b642-8aa693968871">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss. For the years ended December 31, 2022 and 2021,comprehensive loss consists of net loss and changes in unrealized losses on marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzI3_59ba0adc-de58-4f5d-9e5a-b7a4ded53604">Net Loss per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested restricted common stock and potential shares issuable under the employee stock purchase plan are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDYvZnJhZzphYmNhNmQ2ZjIxMGQ0ZTYyYWNiYzg2ZWI1Nzg3ODEzMy90ZXh0cmVnaW9uOmFiY2E2ZDZmMjEwZDRlNjJhY2JjODZlYjU3ODc4MTMzXzI3NzM5_3f1cf0bc-acb4-4eb8-acea-e772fccb7285">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2019-12"). The ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740, Income Taxes, related to the approach for allocating income tax expense or benefit for the year to continuing operations, discontinued operations, other comprehensive income, and other charges or credits recorded directly to shareholders&#x2019; equity; the methodology for calculating income taxes in an interim period; and the recognition of deferred tax liabilities for outside basis differences. On January 1, 2021, the Company early adopted ASU 2019-12 on a prospective basis, with no material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU&#160;No.&#160;2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Financial Instruments&#x2014;Credit Losses (Topic&#160;326)&#x2014;Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;which has been subsequently amended by ASU&#160;No.&#160;2018-19, ASU&#160;No.&#160;2019-04, ASU&#160;No.&#160;2019-05, ASU&#160;No.&#160;2019-10, ASU&#160;No.&#160;2019-11 and ASU&#160;No.&#160;2020-03 (&#x201c;ASU&#160;2016-13&#x201d;). The provisions of ASU&#160;2016-13&#160;modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. On October 1, 2021, the Company early adopted ASU 2016-13 and its related amendments using a modified retrospective approach. Given the composition of the Company's investment portfolio, there was no material impact on the Company's consolidated financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;None.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzU4Mw_ff8a8110-25e3-49bf-8102-8b372e21cc67">Restricted Cash&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company had restricted cash of $0.4 million and $1.0 million, respectively, held as letters of credit for the benefit of its current and former landlords. The Company's Boston, Massachusetts sublease expires on January&#160;31, 2026, and the related letter of credit of $0.4 million was classified within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_21159827-a52f-45e4-914d-16111d124035"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjY_4c186cd4-1d36-4e49-a94e-eb059faddb23"&gt;other non-current assets&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet as of December&#160;31, 2022 and 2021. The Company's Cambridge, Massachusetts sublease expired on December&#160;31, 2021, and the related letter of credit of $0.6 million was classified within prepaid expenses and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzIxOTkwMjMyNTYzMjg_fb095add-7293-4af1-90e2-816d4ff050b8"&gt;other current assets&lt;/span&gt; on the consolidated balance sheet as of December&#160;31, 2021.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:RestrictedCash
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1Xzc1_92bf3e5c-35af-41c6-a94a-e0e2fa060780"
      unitRef="usd">400000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NDg3NzkwNzAwOTQ_621c7924-a5fa-4dbd-9d38-2dd419491a08"
      unitRef="usd">1000000.0</us-gaap:RestrictedCash>
    <prax:LettersOfCreditReceivableNoncurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NQ_2f24d64c-25e7-4a3f-b8c7-ff4854298929"
      unitRef="usd">400000</prax:LettersOfCreditReceivableNoncurrent>
    <prax:LettersOfCreditReceivableNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NQ_83aed366-f6fb-43d1-992d-570fdd8edb30"
      unitRef="usd">400000</prax:LettersOfCreditReceivableNoncurrent>
    <prax:LettersOfCreditReceivableCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDkvZnJhZzo5ZTkwYjQ2MzllNmQ0ODFlYjRjMTY0MDE1YTAyYzU4NS90ZXh0cmVnaW9uOjllOTBiNDYzOWU2ZDQ4MWViNGMxNjQwMTVhMDJjNTg1XzI3NDg3NzkwNzAxMjM_5b7f8e18-efa5-4f8b-8911-b7bf1d59d120"
      unitRef="usd">600000</prax:LettersOfCreditReceivableCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzk0Mg_e8ca6ded-7b05-444d-8d80-e2511ff0d174">Marketable SecuritiesThe following is a summary of the Company's investment portfolio as of December&#160;31, 2022 and 2021 (in thousands):&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total securities with a maturity of one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total securities with a maturity of one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total securities with a maturity of one to two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had 7 securities with a total fair market value of $38.9 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and is primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. Therefore, the Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance for credit losses was not recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzk0Mw_05ae463e-4a16-40bc-8bf6-06c3b89ae45a">The following is a summary of the Company's investment portfolio as of December&#160;31, 2022 and 2021 (in thousands):&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total securities with a maturity of one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total securities with a maturity of one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total securities with a maturity of one to two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtMi0xLTEtNTk1ODQ_b7099060-804a-4bdc-9dda-6489ff962bd3"
      unitRef="usd">35042000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtNC0xLTEtNTk1ODQ_7f478d11-f6e2-4a20-911d-36860a87fb7a"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtNi0xLTEtNTk1ODQ_e2771983-877c-43b5-8c73-96560829a10d"
      unitRef="usd">163000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia7e674169ddd4e6eb0e5b8b1e643177b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzMtOC0xLTEtNTk1ODQ_0f03c5f1-c9a7-48db-916a-0596f155eb3c"
      unitRef="usd">34879000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtMi0xLTEtNTk1ODQ_3042495a-7f68-4ce9-89d8-ffa2a3d4c527"
      unitRef="usd">4005000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtNC0xLTEtNTk1ODQ_3ef61a75-a038-498e-b7b3-5d3bac5f7f3c"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtNi0xLTEtNTk1ODQ_2f3d50a1-bc4c-4431-99ca-f747a75b1ed7"
      unitRef="usd">10000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie4a71c9652034aa088cfbfe7454ba32b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzUtOC0xLTEtNTk1ODQ_55ae0c6e-07e4-403b-a4d6-cfe767564f3e"
      unitRef="usd">3995000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctMi0xLTEtNTk1ODQ_d598f868-dbf2-41f5-b3b6-9bca9b51ddfe"
      unitRef="usd">39047000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctNC0xLTEtNTk1ODQ_7c92482a-3211-458d-9f9d-4a4f26dfdb8f"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctNi0xLTEtNTk1ODQ_527b22bd-d1d7-4835-8bb5-612fc7447138"
      unitRef="usd">173000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzctOC0xLTEtNTk1ODQ_50e26bb7-5ac4-4f74-b447-a335c20f40fa"
      unitRef="usd">38874000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTItMS0xLTU5NTg0_1dc329f0-b607-463f-83bd-593e76aecb61"
      unitRef="usd">39047000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTQtMS0xLTU5NTg0_cd5beeb7-b205-4bff-b5a7-c8858498d708"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTYtMS0xLTU5NTg0_856c308a-99c0-4897-b4ca-c28025d28b1c"
      unitRef="usd">173000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZTo0NGJlZDYzMDYxZDM0Y2MxYTcyOWYxNTkxZmQ0ZTdiZC90YWJsZXJhbmdlOjQ0YmVkNjMwNjFkMzRjYzFhNzI5ZjE1OTFmZDRlN2JkXzExLTgtMS0xLTU5NTg0_f4743a1d-d11a-4151-bce9-5593b94a3193"
      unitRef="usd">38874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtMi0xLTEtNjcyOTI_7738b28b-3be3-4268-ab09-bdd39679fb50"
      unitRef="usd">52214000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtNC0xLTEtNjcyOTI_2a0091e6-1bd5-48bb-9f94-9dc342365c28"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtNi0xLTEtNjcyOTI_f6be2e58-d5de-4532-bf13-db7673a4d05b"
      unitRef="usd">31000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzQtOC0xLTEtNjcyOTI_0cf9f2c6-357e-4567-b02c-a647737376fb"
      unitRef="usd">52183000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtMi0xLTEtNjcyOTI_24a98403-4ea9-4ccd-bc51-1d02859a3602"
      unitRef="usd">34993000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtNC0xLTEtNjcyOTI_9b31dd07-52df-4963-80bb-574b1160449a"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtNi0xLTEtNjcyOTI_98c017a0-57a5-4173-ba4e-c805695ebd2b"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib4245c83788c4fad96f5b6d1db44c9fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzUtOC0xLTEtNjcyOTI_787b882f-3456-4af0-9b85-4c3df1284fee"
      unitRef="usd">34993000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtMi0xLTEtNjcyOTI_9efe5e7a-c7d9-4855-87db-7b99ecc83258"
      unitRef="usd">12111000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtNC0xLTEtNjcyOTI_a680649d-6434-4708-b1f3-7d0c86ff315f"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtNi0xLTEtNjcyOTI_3dcf0102-9e01-465e-ab25-d8845910c9f8"
      unitRef="usd">8000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i55923be6a1c64b7eaac49c978815f27c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzYtOC0xLTEtNjcyOTI_1898363f-7812-4dc0-94a0-a69356232f93"
      unitRef="usd">12103000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctMi0xLTEtNjcyOTI_02b2f36c-b92d-4856-89a1-4846416c371b"
      unitRef="usd">6398000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctNC0xLTEtNjcyOTI_11bae626-c4ae-4ad4-995a-cf85546e2459"
      unitRef="usd">1000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctNi0xLTEtNjcyOTI_4efa7866-eefa-4fa8-b828-5b201e3651e1"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie24f78a034d8434ea805bba77e18db42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzctOC0xLTEtNjcyOTI_2c4cf168-842d-44f4-8c0a-8dbc9ee2fd36"
      unitRef="usd">6399000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtMi0xLTEtNjcyOTI_05eff959-8ff9-4215-a42c-9224e0e682db"
      unitRef="usd">105716000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtNC0xLTEtNjcyOTI_d29f239c-16b1-45ba-836c-e667927872fe"
      unitRef="usd">1000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtNi0xLTEtNjcyOTI_d041bde5-165d-40fc-a37e-a9e3811d984b"
      unitRef="usd">39000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzgtOC0xLTEtNjcyOTI_89351ab1-b39b-4e26-9817-c0eb628ed3f9"
      unitRef="usd">105678000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTItMS0xLTY3Mjky_ba7ab358-12b8-4e36-aace-fe0995175cb9"
      unitRef="usd">31667000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTQtMS0xLTY3Mjky_873b375b-92ec-4c53-96ce-3762db159140"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTYtMS0xLTY3Mjky_1fb068d5-7f7f-4846-bded-f947c8d4b0b4"
      unitRef="usd">138000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2cdab54eb0dc4fe59c45617c2005234f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEwLTgtMS0xLTY3Mjky_1d430f83-b8d4-46e3-993b-d18d498458e7"
      unitRef="usd">31529000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTItMS0xLTY3Mjky_96bcbfee-ed32-443c-aa8b-8c7fe837fcee"
      unitRef="usd">31667000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTQtMS0xLTY3Mjky_2ea35a09-2e4a-4f04-8403-d0a7220d3162"
      unitRef="usd">0</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax>
    <prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTYtMS0xLTY3Mjky_df464411-cc0d-4bb2-9c73-a173b2d7014e"
      unitRef="usd">138000</prax:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzExLTgtMS0xLTY3Mjky_b12584d5-473c-4b9e-a42d-ad84a4048f55"
      unitRef="usd">31529000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTItMS0xLTY3Mjky_703c0a58-a4dc-4a1d-b6af-ab5d2a81903f"
      unitRef="usd">137383000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTQtMS0xLTY3Mjky_e59454b4-40cc-429c-b4ed-31b8311d0704"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTYtMS0xLTY3Mjky_31fceb50-ded4-486e-ad4e-35a905cc9231"
      unitRef="usd">177000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90YWJsZToxNGJmNzE3OGRjNGU0ZTYyYmQzY2RhZTEwMzBjMDIzZC90YWJsZXJhbmdlOjE0YmY3MTc4ZGM0ZTRlNjJiZDNjZGFlMTAzMGMwMjNkXzEyLTgtMS0xLTY3Mjky_940472d7-2921-427d-ab71-ea973ff5df36"
      unitRef="usd">137207000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzIwNw_697887c3-35ac-4a51-8a8e-bf2a4f5cf480"
      unitRef="program">7</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTIvZnJhZzo2MDNiMWRmNmY4M2E0M2Q0YTE4YzMzNzNhMjA0ZjdkZC90ZXh0cmVnaW9uOjYwM2IxZGY2ZjgzYTQzZDRhMThjMzM3M2EyMDRmN2RkXzI1NQ_170f307d-3da2-439b-b1a5-621e979f05d8"
      unitRef="usd">38900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90ZXh0cmVnaW9uOmYxNDhlZDgzOWQ0ZTRhMDdiMjM5YjlmNGJjMmIwMmI2XzEwNDg_db1c60a1-7f28-4e3b-b009-420c3b7f852e">Fair Value of Financial Assets The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2022 and 2021 (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its marketable securities classified as Level 2 by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90ZXh0cmVnaW9uOmYxNDhlZDgzOWQ0ZTRhMDdiMjM5YjlmNGJjMmIwMmI2XzEwNDk_50dbd477-5133-451a-ae68-57f928db0736">The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2022 and 2021 (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities issued by U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if74bbcf7115f440d8a7727a6bd51c63f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtMS0xLTEtNTk1ODQ_a0489a22-deb1-4f9c-beda-9a906576c3b6"
      unitRef="usd">34181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4155d454f999412a8921a320b1dac7b8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtMy0xLTEtNTk1ODQ_e64993f8-76e3-4dcf-a6d6-e4c033b217f7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i863005b39586407793ad56aa5956d85b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtNS0xLTEtNTk1ODQ_f0bccc4b-a74b-4c77-9434-f975089f460f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i602db591ac4e4681915e753d9c9f647b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzQtNy0xLTEtNTk1ODQ_cf805a5b-93ef-4c6e-b221-d88d409761de"
      unitRef="usd">34181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1b26d9edbae245159b56fa3a00570a2d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtMS0xLTEtNTk1ODQ_9ab6b8ed-6116-434a-b8b9-aa7ba7d0d10b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i57f52406efb649548003a483847ad691_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtMy0xLTEtNTk1ODQ_39669230-6c76-411d-99af-b326f2182448"
      unitRef="usd">34879000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib1e5a8fc79f44e908279f9f4451ffcbf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtNS0xLTEtNTk1ODQ_a6f6fd57-220f-4152-9db9-f56a5aed2b79"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3b7963bf676f4ac8a945b019d828f54d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzYtNy0xLTEtNTk1ODQ_a1b6c73a-6cb1-4e37-9586-4ab1dfa48f26"
      unitRef="usd">34879000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic3294a9a7ece4c74870e2e39a7c3d8c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtMS0xLTEtNTk1ODQ_3c189bfc-df2b-444d-9cce-bdb03133e102"
      unitRef="usd">3995000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia4d0ac36134f4884ba2a77e339a74cf2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtMy0xLTEtNTk1ODQ_e5b1d10e-0ef5-47a0-a9d4-d29cf1b61646"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i067bfcb424b847af96504067bd13ea3b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtNS0xLTEtNTk1ODQ_0b45b00f-d327-4afd-85fc-ba932c42dd04"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7c9179d2848e4437a83ec90af5318502_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzgtNy0xLTEtNTk1ODQ_6dbc4a42-1f46-467d-b035-f5fb55d7260b"
      unitRef="usd">3995000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14f74f35a8bd4e0d88f85f5805b2b164_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTEtMS0xLTU5NTg0_3d512c6b-464b-4720-be4d-e101f0237e9b"
      unitRef="usd">38176000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i72ba78adb17f4a0397707c92359e2504_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTMtMS0xLTU5NTg0_b7af03de-c083-43b4-9b2e-b49ceca8a775"
      unitRef="usd">34879000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if58d705233dd47d8aee4f5ab6cfb7200_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTUtMS0xLTU5NTg0_6f99a1df-8b0a-4e21-9039-49fa00a97254"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i27a0c3d7a4f446ce8e8a686a819a00e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTpkY2MyMGQ5ZmE2ZDg0ZDA1ODk1ZGQ2ZmNmNDE1NDNkOC90YWJsZXJhbmdlOmRjYzIwZDlmYTZkODRkMDU4OTVkZDZmY2Y0MTU0M2Q4XzEwLTctMS0xLTU5NTg0_4fb629a6-ae04-4fd0-a50a-e6625b3a8642"
      unitRef="usd">73055000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5e26ad8bb6f04d92a24db27f1e62aee2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMS0xLTEtNjQxMTM_c9df0be8-08c1-484f-a977-fe228164f4cb"
      unitRef="usd">131372000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifc35a88c136a419baf53d23fb148a052_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMy0xLTEtNjQxMTM_795142f3-30b6-4847-98e3-1dedebe711f4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3aa83e6bc8e4ae9b4d9cbb367c26259_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNS0xLTEtNjQxMTM_514f7287-349b-4188-8113-0b36ac22197e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e590dbad5c94c6bb050a64eccee552f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNy0xLTEtNjQxMTM_9bf23198-d555-4d32-8881-5c6133b51991"
      unitRef="usd">131372000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7a98be32db89466fb3fa4f64deb01f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtMS0xLTEtNjQxMTM_80fef839-c587-4f84-8c69-bc1754ba1d7f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibb01972b2a0f443d89fb162c0416b297_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtMy0xLTEtNjQxMTM_23cd1e69-fc9c-4764-b2f9-1f4711cab70d"
      unitRef="usd">83712000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7bd8cd471062406d938bc8f398785ba9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtNS0xLTEtNjQxMTM_0d899161-2b18-4623-b4e4-2547ca67b1ad"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id43b84cc8f724c1790306900f9eab5c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzYtNy0xLTEtNjQxMTM_68a1b914-ebb6-4327-809d-5bf5ac2ee9d5"
      unitRef="usd">83712000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i244c9b8a8bc64d05805e6f9efdd28890_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctMS0xLTEtNjQxMTM_6ccadbd8-7515-41eb-ba44-e0b859608292"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i28ab65adfac24345b56927930bd81e0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctMy0xLTEtNjQxMTM_29a8d1fc-4834-46a4-a752-8e9034a4f403"
      unitRef="usd">34993000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i09d1356850af46b7a820dcbe285a8867_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctNS0xLTEtNjQxMTM_f7213f4f-6b3f-4757-961c-91a62509b72a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i47fa3e30c05c4125a934754580ac61d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzctNy0xLTEtNjQxMTM_1d05bae7-70b6-4447-aba0-49e456c599da"
      unitRef="usd">34993000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i62409ab1a9324ce686d28857f3d25ed8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtMS0xLTEtNjQxMTM_6da5a58a-94ea-445c-848a-d0f5fa9db718"
      unitRef="usd">12103000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1040caddcfac467f932bd93ddc355481_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtMy0xLTEtNjQxMTM_f3ec90ef-c7cb-44fc-a37b-d23def8b6a34"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i00b254a6d21743ceb007eeb41999093b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtNS0xLTEtNjQxMTM_06e6104f-35ec-43f0-80f2-27c90c90ac37"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6eb6df78b28c4de8a6b362faa5295589_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzgtNy0xLTEtNjQxMTM_54373f93-6e76-4836-8ca9-99d916a7ea03"
      unitRef="usd">12103000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3a3ad0541c6044f3af2172c901923f02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMS0xLTEtNTk1ODQ_a3febcac-ee46-462e-b6e5-deff5c20128c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia1964efc982e4dd5bfee80bfedb3be00_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtMy0xLTEtNTk1ODQ_7bbe5bc5-0d99-44da-a241-1569148662ce"
      unitRef="usd">6399000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1cbc72ab825d46fbb9a436e63f3c57ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNS0xLTEtNTk1ODQ_4a3dba52-8d5a-4244-bb20-bb8cd57884c7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8e19833c70214691b2d072f303950003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzQtNy0xLTEtNTk1ODQ_fc522c1c-fed8-4b82-ac48-9019b0e3a2a9"
      unitRef="usd">6399000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee5a509f1d7046e5a8180c53dbfa8c7b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtMS0xLTEtNTk1ODQ_59a30b36-60f9-4433-af9e-e6ae0c1ca7a4"
      unitRef="usd">143475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6bcfca8aec14570ad5ec15d6bc82cc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtMy0xLTEtNTk1ODQ_9ef219a7-a383-4fb6-8877-09e87e1d5abe"
      unitRef="usd">125104000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i136b3f69ecaa46faa9ac4cd6b513328e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtNS0xLTEtNTk1ODQ_c318d09c-a83f-4b89-a6bb-97459ee5376e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia93a96f76f6246f2aae4871e03bbf942_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTUvZnJhZzpmMTQ4ZWQ4MzlkNGU0YTA3YjIzOWI5ZjRiYzJiMDJiNi90YWJsZTphYTY5ZTAwMDk0ODI0ODRmODBiNzVkOGUwYWZjZGM1MC90YWJsZXJhbmdlOmFhNjllMDAwOTQ4MjQ4NGY4MGI3NWQ4ZTBhZmNkYzUwXzUtNy0xLTEtNTk1ODQ_151568ec-2547-4623-9908-c154e642a20e"
      unitRef="usd">268579000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90ZXh0cmVnaW9uOjJjOWY4ZjQ4OTdmZDRlNGZhMWZiMTU1ZmM1NmIwMjViXzE3MA_bedc69ac-e329-4ce0-a719-b17102e4cf25">Property and Equipment, Net&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $0.4 million and $0.2 million for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i003402f9a7274f688237578608beb52e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzItMS0xLTEtNTk1ODQ_5dbc7d52-bc21-412a-979b-377d2fcff020"
      unitRef="usd">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if42340b78da843ad9d0bb3e0bc2a70c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzItMy0xLTEtNTk1ODQ_c6b081e1-7e4b-419e-839c-b4dd6c5a7a41"
      unitRef="usd">579000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i933e341b21264671b5246e7e4b47974b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzMtMS0xLTEtNTk1ODQ_005f6a51-a39f-469a-8f01-403eefc82c29"
      unitRef="usd">545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i66ec332f151445f7b78b848590737181_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzMtMy0xLTEtNTk1ODQ_850b9b5c-7523-413c-bfd5-f8d5368ba7ba"
      unitRef="usd">545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8742d8224d8c45c5bdaf37d3f6ba1094_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzQtMS0xLTEtNTk1ODQ_f981adcc-b843-4fbc-8e28-e7aecebadd2e"
      unitRef="usd">309000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fcf4921a72b4aab9503d8d482d73745_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzQtMy0xLTEtNTk1ODQ_3bd599ac-fc5f-4ce3-970e-63808260229e"
      unitRef="usd">242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzUtMS0xLTEtNTk1ODQ_b02d0c1d-0e1e-42a4-9bc9-b0bede7bd0a5"
      unitRef="usd">1543000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzUtMy0xLTEtNTk1ODQ_8105f8ac-ddae-4e01-ad64-6cc353a2ccf7"
      unitRef="usd">1366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzYtMS0xLTEtNTk1ODQ_df182ced-d736-42fa-8d0e-1f16e5be7721"
      unitRef="usd">572000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzYtMy0xLTEtNTk1ODQ_1a8054cf-c2c3-4ff8-84a6-00da565503ff"
      unitRef="usd">153000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzctMS0xLTEtNTk1ODQ_718150b2-cd7f-4b9b-b3ea-f965c6ca937d"
      unitRef="usd">971000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90YWJsZToxZTA5MjYyY2JmZmQ0YzIwYmNhYmQxNzM2NWY2ZmRjNC90YWJsZXJhbmdlOjFlMDkyNjJjYmZmZDRjMjBiY2FiZDE3MzY1ZjZmZGM0XzctMy0xLTEtNTk1ODQ_8bd60ed5-e408-4a2d-a04e-079335d413ae"
      unitRef="usd">1213000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90ZXh0cmVnaW9uOjJjOWY4ZjQ4OTdmZDRlNGZhMWZiMTU1ZmM1NmIwMjViXzEwOTk1MTE2MjgwOTA_8b9883e4-be2a-426a-9385-a01584a2bf0d"
      unitRef="usd">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMTgvZnJhZzoyYzlmOGY0ODk3ZmQ0ZTRmYTFmYjE1NWZjNTZiMDI1Yi90ZXh0cmVnaW9uOjJjOWY4ZjQ4OTdmZDRlNGZhMWZiMTU1ZmM1NmIwMjViXzE2NDkyNjc0NDE5MjY_19cff90c-eb7d-441a-beb9-75fa2f3803cb"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90ZXh0cmVnaW9uOmNjZDJkYWQzNzg4MzQ2Zjg5MGRhMjZiNGQ2MDhlOTNjXzg1_c5f761de-05e3-4be0-8837-7b0570324e3b">Accrued Expenses&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90ZXh0cmVnaW9uOmNjZDJkYWQzNzg4MzQ2Zjg5MGRhMjZiNGQ2MDhlOTNjXzg2_78c534c6-f167-463e-9b35-9a8b6630f1cb">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <prax:AccruedExternalResearchAndDevelopmentExpensesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzItMS0xLTEtNTk1ODQ_8b656dd7-5d85-41f5-b302-6a7173b11f0b"
      unitRef="usd">10734000</prax:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <prax:AccruedExternalResearchAndDevelopmentExpensesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzItMy0xLTEtNTk1ODQ_972c1261-3390-45a3-a055-684ee43b6d8a"
      unitRef="usd">17763000</prax:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <prax:AccruedPersonnelRelatedExpensesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzMtMS0xLTEtNTk1ODQ_bf097ed8-25ff-41c2-9757-8cf846fecad0"
      unitRef="usd">2803000</prax:AccruedPersonnelRelatedExpensesCurrent>
    <prax:AccruedPersonnelRelatedExpensesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzMtMy0xLTEtNTk1ODQ_fb0bd35b-8141-4471-ad20-b429e120aace"
      unitRef="usd">7180000</prax:AccruedPersonnelRelatedExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzUtMS0xLTEtNTk1ODQ_f5573289-38ee-4ab1-82a8-689258dc0399"
      unitRef="usd">2313000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzUtMy0xLTEtNTk1ODQ_7de009d3-a825-4493-88bf-591acfc18006"
      unitRef="usd">1901000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzYtMS0xLTEtNTk1ODQ_0fd00ed0-1eef-4edb-8740-db3cb66b01c5"
      unitRef="usd">15850000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjEvZnJhZzpjY2QyZGFkMzc4ODM0NmY4OTBkYTI2YjRkNjA4ZTkzYy90YWJsZTpkMjFkOWMxNTMyNTg0MjE5OGZlOWFhMjM3ZjM0MjliOS90YWJsZXJhbmdlOmQyMWQ5YzE1MzI1ODQyMTk4ZmU5YWEyMzdmMzQyOWI5XzYtMy0xLTEtNTk1ODQ_d99c59c4-dd49-4c5d-b5fa-94233f730b55"
      unitRef="usd">26844000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDY_1f5ff631-d3a7-4174-bb3f-8f2d1fa22c84">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts. The sublease expires on January&#160;31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash (Note 3). This lease qualifies as an operating lease. At inception, the Company recorded an operating lease right-of-use asset and operating lease liability of $4.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into a sublease agreement for office space located in Cambridge, Massachusetts which expired on December&#160;31, 2021. The base rent increased by approximately 1% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash (Note 3). This lease qualified as an operating lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the operating leases in the Company&#x2019;s consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total lease costs recognized in the Company&#x2019;s consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease costs were primarily related to operating expenses, taxes and insurance associated with the operating leases, which were assessed based on the Company&#x2019;s proportionate share of such costs for the leased premises. As these costs are generally variable in nature, they were not included in the measurement of the operating lease right-of-use asset and related lease liability. Total lease costs are included as operating expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancelable lease agreements as of&#160;December&#160;31, 2022 were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Future&#160;Lease&lt;br/&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and weighted average incremental borrowing rate of the Company&#x2019;s operating lease were as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average incremental borrowing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the years ended December 31, 2022 and 2021, and no material legal proceedings are currently pending or threatened.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Orders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with third parties for various services, including services related to research, preclinical and clinical operations and support, for which the Company is not contractually able to terminate for convenience to avoid future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, the Company is contractually obligated to make certain payments to vendors, primarily to reimburse them for their unrecoverable outlays incurred prior to cancellation. The actual amounts the Company could pay in the future to the vendors under such agreements may differ from the purchase order amounts due to cancellation provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into indemnification agreements and agreements containing indemnification provisions in the ordinary course of business. Pursuant to these agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#x2019;s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#x2019;s products. The term of these indemnification agreements is generally perpetual upon execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into multiple agreements with third parties under which it may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified product candidates. Payments under these agreements generally become due and payable upon achievement of such milestones and sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <prax:PercentageIncreaseInAnnualBaseRent
      contextRef="i716e562883f3424aaef16a9b22f5c8e7_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzM0OA_be445bdb-c3eb-4b02-b956-a843865b2903"
      unitRef="number">0.02</prax:PercentageIncreaseInAnnualBaseRent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i716e562883f3424aaef16a9b22f5c8e7_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzYzNQ_559b3142-1ac9-4477-9218-f382ab5e5212"
      unitRef="usd">4100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i716e562883f3424aaef16a9b22f5c8e7_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzYzNQ_87db63cf-b542-4619-af6c-fcdfa5f4fe81"
      unitRef="usd">4100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <prax:PercentageIncreaseInAnnualBaseRent
      contextRef="if36d77c9c53144d09601968a0865fbce_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzE2NDkyNjc0NDcwMjM_e43b9341-3307-43f7-8b29-0e787e7d4acb"
      unitRef="number">0.01</prax:PercentageIncreaseInAnnualBaseRent>
    <prax:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDc_16063b85-3789-482b-9f54-a64fdb61541a">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the presentation of the operating leases in the Company&#x2019;s consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</prax:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzMtMS0xLTEtNTk1ODQ_e7f3cbfb-512f-4a12-a5b2-9ffd9f65b61e"
      unitRef="usd">2901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzMtMy0xLTEtNTk1ODQ_d9cbf5e9-67ad-40c7-b6ab-30093f216912"
      unitRef="usd">3653000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzUtMS0xLTEtNTk1ODQ_a6f75a18-7ff0-4d02-b8db-4b9c841c3622"
      unitRef="usd">1005000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzUtMy0xLTEtNTk1ODQ_b9fbd556-54e2-4696-a982-82ff8bbd52d2"
      unitRef="usd">810000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzYtMS0xLTEtNTk1ODQ_fb603303-a588-4cea-b0f7-26f80acaec5d"
      unitRef="usd">2495000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzYtMy0xLTEtNTk1ODQ_250f7284-0f9a-42a5-b22b-a9b1bff4c928"
      unitRef="usd">3501000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzctMS0xLTEtNTk1ODQ_bca8e18f-8daa-4bd2-be44-cbdf00c54c2c"
      unitRef="usd">3500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo0NGIyN2FlMGY3ZDM0NTliYjZiNThlZDVkYjA2ZWJlYS90YWJsZXJhbmdlOjQ0YjI3YWUwZjdkMzQ1OWJiNmI1OGVkNWRiMDZlYmVhXzctMy0xLTEtNTk1ODQ_0f4e44f2-3959-4f01-a58e-f74f3b4c70ce"
      unitRef="usd">4311000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDQ_6e8beb39-154c-4003-9844-097020e96dda">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total lease costs recognized in the Company&#x2019;s consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and weighted average incremental borrowing rate of the Company&#x2019;s operating lease were as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average incremental borrowing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzItMS0xLTEtNTk1ODQ_78165e01-52dc-4913-b422-f6e67746c076"
      unitRef="usd">1102000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzItMy0xLTEtNTk1ODQ_45e24a3d-390f-43e8-a79f-ab04a33ca88d"
      unitRef="usd">1412000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzMtMS0xLTEtNTk1ODQ_02c544ef-6ccc-4dab-a2e8-d377d55ce75e"
      unitRef="usd">37000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzMtMy0xLTEtNTk1ODQ_b7ec3932-822f-441f-af9c-3fb8fb1879aa"
      unitRef="usd">34000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzQtMS0xLTEtNTk1ODQ_47dc4a27-4dbe-4d18-92fd-f325e42d5306"
      unitRef="usd">1139000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo2ZDg2ODBkNzZkNzg0MjZmOWM5YWE0OGIyMWJjOTRmZi90YWJsZXJhbmdlOjZkODY4MGQ3NmQ3ODQyNmY5YzlhYTQ4YjIxYmM5NGZmXzQtMy0xLTEtNTk1ODQ_748e83d6-8527-4e58-8ecb-0238c863fec6"
      unitRef="usd">1446000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90ZXh0cmVnaW9uOmUxNGNlNGFkMDkzMzQ1NTE5ODYxNjdiNmZjYTViMjhhXzQ1MDk_3bc6b72c-38fa-4c17-aac6-f9c61f5293f6">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancelable lease agreements as of&#160;December&#160;31, 2022 were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Future&#160;Lease&lt;br/&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzEtMS0xLTEtNTk1ODQ_411b16b8-eefc-4242-ab9e-0740cec58adf"
      unitRef="usd">1270000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzItMS0xLTEtNTk1ODQ_20ba85e8-70f2-4d43-bb1c-2db350821ff2"
      unitRef="usd">1296000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzMtMS0xLTEtNTk1ODQ_34c650ae-74fd-4f35-8694-441401311cec"
      unitRef="usd">1321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzQtMS0xLTEtNTk1ODQ_fe0e39e6-5176-4b1b-bc87-85e17b15539c"
      unitRef="usd">110000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzYtMS0xLTEtNTk1ODQ_78d97b9b-c54c-4c1b-80d1-aef73c52d9d7"
      unitRef="usd">3997000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzctMS0xLTEtNTk1ODQ_ec8e5102-41b4-4f91-9f95-7d3d37840974"
      unitRef="usd">497000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTphYTQ2NzNhM2FhYjk0M2MyOGI2MWY2OWQ4OTg3ZTI5Ny90YWJsZXJhbmdlOmFhNDY3M2EzYWFiOTQzYzI4YjYxZjY5ZDg5ODdlMjk3XzgtMS0xLTEtNTk1ODQ_df1fb59d-a77c-4144-b08c-fbac39d0038b"
      unitRef="usd">3500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzItMS0xLTEtNTk1ODQ_89f80d52-56fa-494b-b63e-92d1221dad5e">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzItMy0xLTEtNTk1ODQ_e1a7b7f5-02d9-4bba-aa12-3413d57217ad">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzMtMS0xLTEtNTk1ODQ_21d1b27f-ba03-48ea-a8b3-442213cb888d"
      unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMjQvZnJhZzplMTRjZTRhZDA5MzM0NTUxOTg2MTY3YjZmY2E1YjI4YS90YWJsZTo4MTUzMDgzN2JhMmQ0NTdjYWM3OGVhZjkxMzI4YTU5Yi90YWJsZXJhbmdlOjgxNTMwODM3YmEyZDQ1N2NhYzc4ZWFmOTEzMjhhNTliXzMtMy0xLTEtNTk1ODQ_31db6850-ebd2-447d-8eb8-09efa9aa4d53"
      unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV83Njk2NTgxNDExOTk2_c8900ffd-f8a5-4b60-893b-1a2bc4958526">UCB Option and License Agreement&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company entered into an Option and License Agreement (&#x201c;the Collaboration Agreement&#x201d;) with UCB for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a $5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to $98.5&#160;million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be $5.0&#160;million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right. &lt;/span&gt;&lt;/div&gt;The Company will recognize revenue for its research services performance obligation over time using an input method over the duration of the research services. During the year ended December&#160;31, 2022, the Company did not recognize any collaboration revenue related to the Collaboration Agreement as no services had been provided. As of December&#160;31, 2022, the $5.0&#160;million upfront payment is included in deferred revenue in the consolidated balance sheet.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjUzODIw_0486b902-9852-4738-8f64-0c2fafa1bbb1"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiability>
    <prax:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjU2MDM4_f457e6f9-a5f0-441d-aacd-b45968ef14c4"
      unitRef="usd">98500000</prax:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjU2MTU1_dafe8376-1b50-4e9b-a999-58a2ed4dd845"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1738436c1e4a4aaabe1692876228c53a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMDk5NTExNjI5NDIxL2ZyYWc6Y2Y2MzQxNmU2YTA5NGZmNWIzMzkwN2VhOGMzYmJlZGUvdGV4dHJlZ2lvbjpjZjYzNDE2ZTZhMDk0ZmY1YjMzOTA3ZWE4YzNiYmVkZV8xMDk5NTExNjU2MTYz_aa0c434e-6e6e-44d6-a643-b7d1751eb78f"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzQzMTk_23c82157-bf27-4e1b-9a55-f2c58147e077">Common Stock and Preferred Stock&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;18, 2021, the Company completed a follow-on public offering in which the Company issued and sold 5,750,000 shares of its common stock at a public offering price of $18.25 per share, including 750,000 shares of common stock issued and sold pursuant to the underwriters' exercise, in full, of their option to purchase additional shares of common stock, for aggregate gross proceeds of $104.9 million. The Company received approximately $98.4 million in net proceeds after deducting discounts, commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2021, the Company filed an automatic shelf registration with the Securities and Exchange Commission, which was automatically declared effective on November&#160;3, 2021 in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof. The Company also simultaneously entered into the Sales Agreement with Jefferies LLC ("Jefferies"), to provide for the offering, issuance and sale of up to an aggregate amount of $125.0 million of common stock from time to time in at-the-market offerings under the shelf registration and subject to the limitations thereof. Jefferies is entitled to compensation at a commission rate of 3% of the gross sales price of common stock sold under the Sales Agreement. During the year ended December&#160;31, 2022, the Company issued and sold 3,595,273 shares under the Sales Agreement for aggregate net proceeds of $9.6 million after deducting commissions and offering expenses payable by the Company. As of December&#160;31, 2022, the Company issued and sold a total of 3,987,270 shares under the Sales Agreement for net proceeds of $16.6 million after deducting commissions and offering expenses payable by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the authorized capital stock of the Company included 150,000,000 shares of common stock, $0.0001 par value, pursuant to the Amended and Restated Certificate of Incorporation effective upon the completion of the IPO. Holders of such shares of common stock have the exclusive right to vote for the election of the Company's directors and are entitled to one vote per share. In the event of the voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to a pro &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rata distribution of the Company's net assets. Dividends may be declared and paid to such holders only when, as, and if declared by the Board or an authorized committee thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s of December&#160;31, 2022, the Company did not hold any treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shares Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved the following shares of common stock for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for exercise of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,838,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,468,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for future awards under the 2020 Stock Option and Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,650,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,667,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for future awards under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;839,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;654,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for vesting of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of authorized common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,072,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,230,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company was authorized to issue 10,000,000 shares of undesignated preferred stock, $0.0001 par value, in one or more series, and is authorized to fix the powers, designations, preferences and relative participating option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company's shareholders. As of December&#160;31, 2022 and 2021, the Company had no shares of undesignated preferred stock issued or outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE0MjY_8cec359a-3608-4aa6-969a-bd9119a83091"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia8aa498682824f9bb5c5eed3af34a7de_I20210518"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE0ODY_47489544-d0f1-4052-bb46-de10c9f27503"
      unitRef="usdPerShare">18.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie851e6aa9211407fbf15412951580a0b_D20210518-20210518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE1MTA_68786673-5934-451a-8e5c-18aa800d4718"
      unitRef="shares">750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <prax:SaleOfStockConsiderationReceivedGrossAmount
      contextRef="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2OTY_956b1453-691e-4b6a-89c9-81e6290bc70e"
      unitRef="usd">104900000</prax:SaleOfStockConsiderationReceivedGrossAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i91a1170c8d14496e991f8d1ea2f9b31d_D20210518-20210518"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE3MzU_b28627e4-b189-4e06-93b8-c25d193ea5ac"
      unitRef="usd">98400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iac3370fe8f2b42789eb23526e5ecb703_D20211103-20211103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTE0MDk_a859fdfe-5d18-45c0-a7a0-af591f586352"
      unitRef="usd">125000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i921f704070724adca8d013ad9ca44f7a_D20211103-20211103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTE0MTk_92209d52-44a2-441c-9213-7bb4fe38387c"
      unitRef="number">0.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic6c285fb70c14984a035bed8222bb71a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMxNzk_1af28109-5599-4784-b347-bc08315b5440"
      unitRef="shares">3595273</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic6c285fb70c14984a035bed8222bb71a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMzMzg_f3d2ac28-f3de-4545-af88-72f35ffd3468"
      unitRef="usd">9600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i82a93dc661184757b579f3d8def24296_D20211103-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMzNjE_50b993ee-c34e-4eca-9ccf-e838ca47e2d7"
      unitRef="shares">3987270</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i82a93dc661184757b579f3d8def24296_D20211103-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzE2NDkyNjc0NTMzNjg_69f69c92-48ab-4413-8583-a96665d077a9"
      unitRef="usd">16600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzI5MjE_b0cafa75-bbd9-41b4-9d64-1f0642afc6e4"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzI5MjE_c9f500cb-ded6-4acf-afca-c58ba8563663"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9e73530e136b479c80208cb925bbade7_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzI5NDg_b1730168-7205-4c13-86e7-a1dd9d831bcb"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TreasuryStockShares
      contextRef="ia026dc966a754812a61ad0c096814457_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM1ODA_b531c926-7993-49ae-bb04-2234165673b8"
      unitRef="shares">0</us-gaap:TreasuryStockShares>
    <prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzQzMjE_c82b3a12-bbcc-4296-90e4-3ba149fff40e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved the following shares of common stock for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for exercise of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,838,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,468,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for future awards under the 2020 Stock Option and Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,650,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,667,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for future awards under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;839,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;654,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares reserved for vesting of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shares of authorized common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,072,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,230,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib5afc5d945ba4bafadfb0d0c3dac741e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzItMS0xLTEtNTk1ODQ_43a3b76a-12c9-490d-8a69-fca8572e8382"
      unitRef="shares">8838028</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i66f40fdf3e9849dc95aff9107e6a2abc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzItMy0xLTEtNTk1ODQ_e2f5a211-c421-48e1-a5c0-874f2ea3aeff"
      unitRef="shares">6468501</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib353ee652a0c4a69b3370039987754bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzMtMS0xLTEtNTk1ODQ_4430d965-24cf-4500-9323-c4daa874c969"
      unitRef="shares">1650955</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="icc86f7ac19204f0e8a499e53f47bb1fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzMtMy0xLTEtNTk1ODQ_0d29adaa-1584-4234-88fd-67f94e887f4c"
      unitRef="shares">2667780</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i00847cec0267471db96ca9e81a3449ce_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzQtMS0xLTEtNTk1ODQ_f7ee6f57-fc91-433f-9334-0ee869be0dd7"
      unitRef="shares">839922</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idfec095cffc9489f9b959bfbd8233e2c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzQtMy0xLTEtNTk1ODQ_377172ac-b833-42a9-89cd-ec19f4dbdc08"
      unitRef="shares">654204</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibab1d12675f44c9183ae81a1c19d02b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzUtMS0xLTEtNTk1ODQ_736b2dca-9de0-4dab-8bc7-6244dffd8ee8"
      unitRef="shares">743950</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7da243485d114cb4884c5da895b1ce3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzUtMy0xLTEtNTk1ODQ_04ff93ac-5a3c-4804-9b11-d52c7049c799"
      unitRef="shares">440079</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzYtMS0xLTEtNTk1ODQ_dd989c35-574e-4ded-9768-af40b019544c"
      unitRef="shares">12072855</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90YWJsZTpmZDQ4NjIzNWQwOTU0ZjA0YmJhOWJhZTI5NTg2NTY4Yi90YWJsZXJhbmdlOmZkNDg2MjM1ZDA5NTRmMDRiYmE5YmFlMjk1ODY1NjhiXzYtMy0xLTEtNTk1ODQ_e93f6458-89d7-4316-8999-ff73af4c87f8"
      unitRef="shares">10230564</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM4MDA_71487a5f-77df-44fb-84b7-ccf9cb1dc59c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM4MDA_af4680b9-3302-466a-96ac-4c7c6a45b63d"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzM4NDM_48ef9648-ac20-415d-a480-eec34bbaf952"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_371491e4-c2b2-4269-b34c-50d1e8233c53"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_37695702-e616-4dac-8097-c7571d0e5125"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_9a433e05-909a-402a-9e69-dea9161449e2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzAvZnJhZzplZjg4Y2EyYjgzMTA0ZjQ0YjIxNzNhZmVjZDNiZTBkNy90ZXh0cmVnaW9uOmVmODhjYTJiODMxMDRmNDRiMjE3M2FmZWNkM2JlMGQ3XzcxNDY4MjU1OTI0OTg_d4b1d425-2f2b-440c-894f-1caf377c7b5e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNTY_4190116c-3bad-423c-b352-8b549015f929">Stock-Based Compensation&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares of common stock authorized for issuance under the 2020 Stock Option and Incentive Plan (the "2020 Plan") as of December&#160;31, 2022 and December&#160;31, 2021 was 7,449,480 shares and 5,184,455 shares, respectively. The total number of shares of common stock authorized for issuance under the 2017 Stock Inventive Plan (the "2017 Plan") as of December&#160;31, 2022 and 2021 was 5,937,763 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options issued under the 2020 Plan and 2017 Plan expire ten years from the date of grant. Shares that expire, are terminated, surrendered or canceled under the 2020 Plan and 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for future awards. Upon stock option exercise, the Company issues new shares and delivers them to the participant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e total shares authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP") as of December&#160;31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 was 981,306 shares and 654,204 shares, respectively. During the year ended December&#160;31, 2022, the Company issued 141,384 shares under the 2020 ESPP. The Company did not issue any shares under the 2020 ESPP during the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock unit activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;676,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(268,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation cost related to unvested restricted stock units was $12.4 million, which is expected to be recognized over a weighted-average period of 2.65 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,468,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,969,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(265,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,334,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,838,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,315,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,635,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised for the year ended December&#160;31, 2021 was $19.7&#160;million. The aggregate intrinsic value of stock options outstanding, exercisable, and vested and expected to vest is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#x2019;s common stock at December&#160;31, 2022. The aggregate intrinsic value of stock options exercised is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company&#x2019;s common stock on the date of exercise for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock on the exercise date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees, members of the Board, and non-employees on the date of grant were as follows for the for the years ended December 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation cost related to unvested stock options was $45.9 million, which is expected to be recognized over a weighted-average period of 2.17 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was allocated as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia026dc966a754812a61ad0c096814457_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNzk_f096130b-e642-49fe-955a-3c4d68142d5f"
      unitRef="shares">7449480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia2ab45cd01a247ec83adf3c948df3f0f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNzI_158aa10b-2452-4eef-95a5-6e1497248adb"
      unitRef="shares">5184455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8bd4bd8649214980a4a5f8233252d50e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNjU_10ca8551-b111-4e82-8d0e-c024411902eb"
      unitRef="shares">5937763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2996ff42e2cd4a599e5553a465ddee81_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTAwNjU_a0b669de-eb12-4a81-8822-5e49d100874b"
      unitRef="shares">5937763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i73413d9e77ac43d0ba5a6eb2639a610b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzg4OA_439fbd54-fac9-4987-962a-3d11bf81b580">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id1f0a02e5c3f43b595b8742c748bc727_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTA5NTU_3f96eb3f-4b0d-4d6a-917d-de8155ae1434"
      unitRef="shares">981306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i09eef053696d47e58b2abf3b796af5de_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE4MTQ_7e76d058-d74d-4105-ad07-c237dd2533e8"
      unitRef="shares">654204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i90c01ec3e3ba4a2980aae7d5fa413eb1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzE2NDkyNjc0NTEyMzA_01e1877c-e0a5-42a6-8a5c-5a151287a9c0"
      unitRef="shares">141384</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i99f60c5a963444cba12bc6600fceeae2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzIxOTkwMjMyNjU5ODc_02b4d96d-c384-424d-87af-03ceaa017f25"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNjE_c805f162-feda-4363-aceb-201f3dc8d31e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock unit activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;676,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(268,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7da243485d114cb4884c5da895b1ce3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzEtMS0xLTEtNTk1ODQ_aab3cdf5-5c70-4f43-90fd-a7a8e355922f"
      unitRef="shares">440079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7da243485d114cb4884c5da895b1ce3b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzEtMy0xLTEtNTk1ODQ_c135d00a-4352-4121-b5e3-c9f976c3ce6e"
      unitRef="usdPerShare">41.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <prax:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
      contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzItMS0xLTEtNTk1ODQ_68db6424-8d8d-46d2-b560-717e9e7741d7"
      unitRef="shares">676828</prax:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <prax:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzItMy0xLTEtNTk1ODQ_011a03ac-fd22-4b83-b165-dfa63b94c7fa"
      unitRef="usdPerShare">14.54</prax:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzMtMS0xLTEtNTk1ODQ_1d4a445e-69e2-4f2c-bc93-b773864c18dc"
      unitRef="shares">104803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzMtMy0xLTEtNTk1ODQ_4d73b9a4-f0b3-418a-9f5e-3f193eaf644c"
      unitRef="usdPerShare">44.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzQtMS0xLTEtNTk1ODQ_75936d57-5597-440c-8ea8-f96a1bcd1bee"
      unitRef="shares">268154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i75efa4697b4345348551061c24679c66_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzQtMy0xLTEtNTk1ODQ_da6ce4f6-3799-424d-8f26-505cd560d188"
      unitRef="usdPerShare">22.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibab1d12675f44c9183ae81a1c19d02b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzUtMS0xLTEtNTk1ODQ_48bc0b40-1d76-4243-a787-5f1cc91730da"
      unitRef="shares">743950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibab1d12675f44c9183ae81a1c19d02b4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTplNmQ2MDBlMjJjOTY0ZTE5YTIxZTYwZTk2YjAwNTZjNy90YWJsZXJhbmdlOmU2ZDYwMGUyMmM5NjRlMTlhMjFlNjBlOTZiMDA1NmM3XzUtMy0xLTEtNTk1ODQ_9c3c771d-aed9-4bef-b31b-2b31978f2627"
      unitRef="usdPerShare">23.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i92a1b80e6fa1480abd9c373178bf12e6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzI1MDc_ad780c51-594b-4f47-99a7-fe338f386de3"
      unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8b5c9571e9f8424ab4b2a1bb9d76588f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzI1ODA_988a31d9-1a89-4d2a-9e3b-668714939f63">P2Y7M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNTk_b246673d-b322-4d31-a6ec-f1ba6eade15b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,468,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,969,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(265,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,334,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,838,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,315,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,635,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzItMS0xLTEtNTk1ODQ_743242ce-07db-4f82-babd-5054e23b1af1"
      unitRef="shares">6468501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzItMy0xLTEtNTk1ODQ_9e3ea303-065d-4978-9dd9-4a2ed4bbaea2"
      unitRef="usdPerShare">16.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzMtMS0xLTEtNTk1ODQ_bacfb6af-cb77-48ba-8abf-0421e78f9161"
      unitRef="shares">3969302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzMtMy0xLTEtNTk1ODQ_bf8bb945-1cd5-47a0-96d7-1a15512a39cc"
      unitRef="usdPerShare">9.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzQtMS0xLTEtNTk1ODQ_7ac38916-44ad-4544-b218-325af32cfd31"
      unitRef="shares">265662</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzQtMy0xLTEtNTk1ODQ_a202e2d1-d6d6-40dd-99b6-e92701128b6e"
      unitRef="usdPerShare">3.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzQtNy0xLTEtNTk1ODQ_89142563-d7ee-44e6-9e90-fdc1a17068d2"
      unitRef="usd">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzUtMS0xLTEtNTk1ODQ_0005b852-819d-46da-a4ae-73bb55629a61"
      unitRef="shares">1334113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzUtMy0xLTEtNTk1ODQ_4df35692-2bcb-4307-8943-84014506a721"
      unitRef="usdPerShare">16.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtMS0xLTEtNTk1ODQ_741a9e14-ee92-4c51-8496-bef4d7cbeac8"
      unitRef="shares">8838028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtMy0xLTEtNTk1ODQ_f7b87120-6216-45c8-b7ba-cde7395164c0"
      unitRef="usdPerShare">13.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtNS0xLTEtNTk1ODQ_7ec75c02-7fdc-416c-9fdc-3dcadfd33dbe">P8Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzYtNy0xLTEtNTk1ODQ_77b4b404-46a2-4930-bae1-ba4fd5a37471"
      unitRef="usd">514000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctMS0xLTEtNTk1ODQ_8a118269-a0ef-4b6a-92ab-7b8e9f5e8ff9"
      unitRef="shares">3315240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctMy0xLTEtNTk1ODQ_5b8e32cd-dd38-45bd-a32e-a839ed67f9dd"
      unitRef="usdPerShare">14.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctNS0xLTEtNTk1ODQ_bf758d89-1734-442c-a261-0a3f9eb4d027">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzctNy0xLTEtNTk1ODQ_c582239a-2866-4d92-8e63-e0f9271522e6"
      unitRef="usd">95000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtMS0xLTEtNTk1ODQ_e005a0b2-eb42-4100-a063-2acf6541cc06"
      unitRef="shares">8635022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtMy0xLTEtNTk1ODQ_57e92a56-283a-46ad-b956-a64fbb1fe08f"
      unitRef="usdPerShare">13.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtNS0xLTEtNTk1ODQ_50a54f98-611a-4211-8236-bf29454692f0">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1YWEwNGE2MWQxM2Q0NWJjODU5ZTQyMDk4MTkwNzBhNS90YWJsZXJhbmdlOjVhYTA0YTYxZDEzZDQ1YmM4NTllNDIwOTgxOTA3MGE1XzgtNy0xLTEtNTk1ODQ_0f43233e-c3a6-4b89-a9f5-b86a4d609b77"
      unitRef="usd">497000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzEwOTk1MTE2MzgxODg_b53e561a-8a3a-4286-975a-fe6ed5ac907f"
      unitRef="usd">19700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNjA_9b1bffeb-5356-4e3a-9c1c-90e9b18c5d3a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average grant-date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzMtMS0xLTEtNTk1ODQ_4d645ea8-6bb5-4f7f-bca5-9ffd4b473ccc"
      unitRef="number">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzMtMy0xLTEtNTk1ODQ_3b7b6e10-b839-4980-b284-57cd6ff7f1d6"
      unitRef="number">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzQtMS0xLTEtNTk1ODQ_4032e384-cb70-495d-a450-bf048da7100d">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzQtMy0xLTEtNTk1ODQ_7a67e7f6-80e3-4e0f-9d68-297091022133">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzUtMS0xLTEtNTk1ODQ_e8d8441c-e6d5-416b-91ee-a3c3bd8ea454"
      unitRef="number">0.8920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzUtMy0xLTEtNTk1ODQ_418f7bda-f03f-42f4-b63d-e7ec6950c16d"
      unitRef="number">0.8552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzYtMS0xLTEtNTk1ODQ_448703a8-f06c-4f9b-ac14-7db5c6d54db0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzYtMy0xLTEtNTk1ODQ_631cf43b-95c1-4890-a2d0-b7d6c8c33a79"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzctMS0xLTEtNTk1ODQ_633bbd40-82c3-4c29-8763-3da6a5fbffa3"
      unitRef="usdPerShare">6.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae5ce00fe1944639b5669f121145e350_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo1OTI4NjVmZDRkZGM0ZDE3YjkzZmVkZmUzMWQ5NmVhZC90YWJsZXJhbmdlOjU5Mjg2NWZkNGRkYzRkMTdiOTNmZWRmZTMxZDk2ZWFkXzctMy0xLTEtNTk1ODQ_9285bcbd-0141-438e-9360-566f96ee8db4"
      unitRef="usdPerShare">27.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ib5afc5d945ba4bafadfb0d0c3dac741e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzM4OTk_ecd3b3c3-c15b-4dd1-a34b-515e531cddf2"
      unitRef="usd">45900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzM5NzI_6650130b-437c-4bb9-bc25-358131cef182">P2Y2M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90ZXh0cmVnaW9uOjQxNTcyNDYyMzA2ZTQwZGViZWQ5MmQ5NTYzMzk1YjJjXzQzNTc_3ef4f58f-c6a0-47dc-ac87-db8507bf3c47">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was allocated as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzItMS0xLTEtNTk1ODQ_43ddf134-658b-4237-ba26-9fe8a9d663e5"
      unitRef="usd">9972000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01b521b0c1334a6d99bffb35ef881760_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzItMy0xLTEtNTk1ODQ_eef1d59f-7ebd-45de-b584-158bca315844"
      unitRef="usd">9350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzMtMS0xLTEtNTk1ODQ_adf69449-959f-421f-93b4-44a92f60c3fd"
      unitRef="usd">18621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i086cadcb8e4b43b0b1cf5d9e023a28e9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzMtMy0xLTEtNTk1ODQ_1fe1da6b-1edc-414c-964d-8bae8ea71cd0"
      unitRef="usd">13343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzQtMS0xLTEtNTk1ODQ_6ef5458a-9961-443c-a6e9-b54a629e834d"
      unitRef="usd">28593000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzYvZnJhZzo0MTU3MjQ2MjMwNmU0MGRlYmVkOTJkOTU2MzM5NWIyYy90YWJsZTo0NmM0NjBlMzE1OWM0MTBhOTQwNzE5ZTc5M2M2MjdlMC90YWJsZXJhbmdlOjQ2YzQ2MGUzMTU5YzQxMGE5NDA3MTllNzkzYzYyN2UwXzQtMy0xLTEtNTk1ODQ_3561f812-d5b0-4661-8c80-808750b89812"
      unitRef="usd">22693000</us-gaap:AllocatedShareBasedCompensationExpense>
    <prax:SignificantAgreementsTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzgyMzQ_ecbcfbc0-6be9-40a1-90d0-dcb2c3346db2">Significant Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RogCon and Ionis Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11, 2019, the Company entered into both a Cooperation and License Agreement (the &#x201c;License Agreement&#x201d;) with RogCon, Inc. ("RogCon"), and a Research, Collaboration, Option and License Agreement (the &#x201c;Ionis Collaboration Agreement&#x201d;) with Ionis Pharmaceuticals, Inc. ("Ionis"). The agreements were entered into contemporaneously to enable the parties to advance their collective efforts related to SCN2A. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RogCon Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon&#x2019;s intellectual property to research, develop and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Under the License Agreement, the Company will conduct, at its own cost and expense, the research and development activities assigned to it under the research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the Company. As part of the agreement, the Company agreed to provide up-front consideration of $2.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to September&#160;11, 2019, the Company will reimburse RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement. The Company expenses these costs as incurred as research and development. Expenses incurred for all periods presented were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company may pay RogCon a milestone payment of $3.0 million and profit share payments. The $3.0 million milestone payment will become due when the first profit share payment has become due and certain contingent payments have become payable to Ionis under the Ionis Collaboration Agreement, which are subject to the Company exercising its option to obtain license rights to a development candidate, as well as other contingent events. The profit share payments will be based on a low-double-digit percentage of net profits, depending on sales volume. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The License Agreement, unless earlier terminated, will continue until the latest of: (i)&#160;expiration of all patent rights within RogCon patents, (ii)&#160;the Company and its affiliates certify they have abandoned the research, development and commercialization of product with no intention to re-establish such activities, and (iii)&#160;no third party is obligated to pay the Company or its affiliates any amounts that comprise net sublicense revenue. Either party may terminate the License Agreement for material breach or insolvency of the other party. Additionally, the Company may terminate for convenience with prior written notice to RogCon. Upon termination by either party, all rights and licenses granted by RogCon to the Company will revert back to RogCon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ionis Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Ionis Collaboration Agreement, both parties participated in research activities related to the downregulation of SCN2A gene products associated with the treatment of any and all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene, other than one severe type of epilepsy. Ionis was also responsible for identifying a development candidate and conducting an IND-enabling toxicology study. The Company reimbursed Ionis for out-of-pocket costs incurred related to the research activities, identification of a development candidate and conducting an IND-enabling toxicology study. The reimbursement of out-of-pocket costs was recognized as research and development expense as incurred. The Company expensed a total of $0.7 million and $1.9 million, as research and development expense under the Ionis Collaboration Agreement for the years ended December 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Ionis granted the Company an exclusive option to obtain the rights and license to further develop and commercialize a development candidate in the field of epilepsy and neurodevelopmental disorders, other than Dravet Syndrome, following the results of the investigational new drug application-enabling toxicology study. The Company exercised this exclusive option in January 2022, paid a $2.0 million license fee and recognized the license fee in research and development expenses in the consolidated statement of operations during the year ended December&#160;31, 2022. After option exercise, the Company is responsible for clinical development and commercialization of the development candidate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ionis may be entitled to additional development milestone payments, additional milestone payments, and sales royalties or sublicense fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ionis Collaboration Agreement will continue until the expiration of all payment obligations to Ionis, unless earlier terminated. Either party may terminate the Ionis Collaboration Agreement upon material breach or insolvency of the other party. Ionis may terminate if the Company fails to achieve a performance milestone. The Company may terminate for convenience with prior written notice to Ionis. Upon termination by the Company for convenience, the Company will stop selling all products, subject to certain wind-down provisions, and all products will revert back to Ionis.&lt;/span&gt;&lt;/div&gt;</prax:SignificantAgreementsTextBlock>
    <us-gaap:OtherCommitment
      contextRef="i59d22bb870c64b27b65b8cba9ec3536b_I20190910"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc2OTg_082b6c7c-8e20-4a62-a60b-aabeac8d0332"
      unitRef="usd">2100000</us-gaap:OtherCommitment>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzExNTQ0ODcyMTAxNDQ4_59f01f6c-34b3-4597-b196-e7648398f682"
      unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherCommitment
      contextRef="id08d935b650f48b894cff86c998390d7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc3NDY_d30013a9-5869-4aa6-8d36-ae2a0b582e6a"
      unitRef="usd">3000000.0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="id08d935b650f48b894cff86c998390d7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc3NTE_d30013a9-5869-4aa6-8d36-ae2a0b582e6a"
      unitRef="usd">3000000.0</us-gaap:OtherCommitment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8e78b82d33fe4b7ea06ff1555beedb9f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzY2NDE_bf8a82aa-5872-41c3-b0c0-0320039077fa"
      unitRef="usd">700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if3928d36a17d4572b98fb4d36c5bc667_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzY2NDg_30a0d4a4-9bba-4fa1-8c4c-dfb2e3fb71a7"
      unitRef="usd">1900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="i6db4fda94de8472aa375ed40f41dd0c4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xMzkvZnJhZzo2YjI2Mzc5NTcyZDE0ZDM1ODU3MjEwMTFmMDhhOTk5OC90ZXh0cmVnaW9uOjZiMjYzNzk1NzJkMTRkMzU4NTcyMTAxMWYwOGE5OTk4XzI3NDg3NzkwNzc3NTk_ea85230e-f8e9-4215-aef4-6703f58a6757"
      unitRef="usd">2000000.0</us-gaap:OtherCommitment>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90ZXh0cmVnaW9uOjAxNDcwMDZkMTdkODQwMmU4NDgxM2IxNTU3YTZjMDU5XzQ1OA_9021748a-5104-4eac-a558-470ab3a9d13d">Net Loss per Share&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,838,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,468,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Potential shares issuable under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,865,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,942,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90ZXh0cmVnaW9uOjAxNDcwMDZkMTdkODQwMmU4NDgxM2IxNTU3YTZjMDU5XzQ2MA_0fb3dde8-1990-4f33-a66c-73c9ede0d3ff">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,838,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,468,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Potential shares issuable under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,865,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,942,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb80111739064117857d8ff63d282ee7_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzItMS0xLTEtNTk1ODQ_9cef6e02-5658-485a-9e3e-d27342288602"
      unitRef="shares">8838028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c1e903808d0417082b7ca141017b6d2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzItMy0xLTEtNTk1ODQ_1586fff3-7d66-4b01-98b6-2768f3521ff4"
      unitRef="shares">6468501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3beb3fccfcac48b1a1b2abcb40888aa0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzMtMS0xLTEtNTk1ODQ_0ca4043e-485d-4895-b38d-9ad12e73b08e"
      unitRef="shares">743950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ce3a4228571459f975e7c892d40666b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzMtMy0xLTEtNTk1ODQ_bcc448a4-3e86-4db7-86e2-6525cc86a06e"
      unitRef="shares">440079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a68deb4cf0f483abe816b51999d287c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzQtMS0xLTEtNTk1ODQ_34930828-ff2b-4ed6-a861-4eb26b098d2c"
      unitRef="shares">283861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb0e4722ba7b4b88b3538c783c5b2e05_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzQtMy0xLTEtNTk1ODQ_8440e4d1-66c6-44ad-99ac-b60d59653b0b"
      unitRef="shares">33425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzUtMS0xLTEtNTk1ODQ_00401d13-ed91-4d44-b695-03864e06719c"
      unitRef="shares">9865839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDIvZnJhZzowMTQ3MDA2ZDE3ZDg0MDJlODQ4MTNiMTU1N2E2YzA1OS90YWJsZTowMzdkOTAxNDllNzI0N2E4Yjg1ZTY5Yjg4NDU1ZjAxYy90YWJsZXJhbmdlOjAzN2Q5MDE0OWU3MjQ3YThiODVlNjliODg0NTVmMDFjXzUtMy0xLTEtNTk1ODQ_e9346874-edfb-4def-ac3e-a0964c5bb9fe"
      unitRef="shares">6942005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzYxNzE_b1d933a0-acb4-460c-b481-f58894bdec05">Income TaxesThe Company maintains a full valuation allowance on its U.S. net deferred tax assets due to the uncertainty of future taxable income. The Company did not recognize an income tax benefit in the years ended December&#160;31, &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 or 2021 related to its U.S. operations due to the uncertainty regarding future taxable income. In the years ended December 31, 2022 and 2021, the difference between the statutory tax rate in the U.S. and the Company&#x2019;s effective tax rate was due primarily to the valuation allowance recorded to offset any potential tax benefit. The income tax benefit (provision) recognized for the years ended December 31, 2022 and 2021 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. statutory income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal and state research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had U.S. federal net operating loss carryforwards which may be able to offset future income tax liabilities of approximately $226.3 million and $212.3 million, respectively. Federal net operating loss carryforwards of $7.7 million will expire at various dates from 2035 through 2037 and approximately $218.6 million may be carried forward indefinitely.&#160;As of December 31, 2022 and 2021, the Company also had state net operating loss carryforwards of approximately $197.4 million and $187.6 million, respectively, which may be available to offset future income tax liabilities and expire at various dates from 2036 through 2042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had federal research and development tax credit carryforwards of approximately $14.4 million and $7.3 million, respectively, available to reduce future tax liabilities which expire at various dates from 2039 through 2042.&#160;As of December 31, 2022 and 2021, the Company had state research and development tax credit carryforwards of approximately $3.5 million and $2.5 million, respectively, available to reduce future tax liabilities which expire at various dates from 2031 through 2037.&#160;The Company has &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;generated research credits but has not conducted a study to document the qualified activity.&#160;This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.&#160;A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.&#160;Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change.&#160;Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study.&#160;If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all of the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2022 and 2021 because management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception. As a result, a valuation allowance of $143.9 million and $86.0 million has been established at December 31, 2022 and 2021, respectively.&#160;Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $58.0 million and $49.1 million during the years ended December 31, 2022 and 2021, respectively, due primarily to the generation of net operating losses.&lt;/span&gt;&lt;/div&gt;The Company has not recorded any amounts for unrecognized tax benefits as of December 31, 2022 and 2021.&#160;The Company&#x2019;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision.&#160;As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#x2019;s consolidated statement of operations for either year ended December&#160;31, 2022 or 2021.&#160;The statute of limitations for federal and state tax authorities is open for tax years ended December&#160;31, 2019 through December&#160;31, 2022. Since the Company is in a net loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzYxNzI_08272650-3a2e-4ee5-b9c3-594a37953f10">&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. statutory income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal and state research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzItMS0xLTEtNTk1ODQ_639366da-97af-4f40-9dc6-ca63bd9e92bf"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzItMy0xLTEtNTk1ODQ_f43a71d6-ee88-4a99-aa9c-b317f295b128"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzMtMS0xLTEtNTk1ODQ_131a7853-ae01-48e0-94f2-0482c897a2c9"
      unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzMtMy0xLTEtNTk1ODQ_ac8c8771-b7fa-4ef8-baa6-d205f9b7b0af"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzQtMS0xLTEtNTk1ODQ_09b32766-5a3f-423b-b0a6-5a8c1116686b"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzQtMy0xLTEtNTk1ODQ_1ef8746a-d1fc-4c97-b4cf-c3a102e545fd"
      unitRef="number">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzUtMS0xLTEtNTk1ODQ_98ced08a-287b-4761-8d99-013d2efda0e2"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzUtMy0xLTEtNTk1ODQ_ed328b66-cccc-4966-8f93-f4ec29522203"
      unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMS0xLTEtNzU5MjY_ce4d8bf8-2f95-4518-a929-9bce0fed137b"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMy0xLTEtNzU5MjY_19322df9-0680-4c9c-be40-d00aaa5f6e4f"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMS0xLTEtNTk1ODQ_6f876d97-5ad3-4e52-9c0c-2f9797cb76fe"
      unitRef="number">-0.272</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzYtMy0xLTEtNTk1ODQ_c103c735-35bf-4d83-8927-0ba6b9e469ca"
      unitRef="number">-0.294</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzctMS0xLTEtNTk1ODQ_bc64b75c-b159-4719-a966-30d582365b2a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzctMy0xLTEtNTk1ODQ_9eca14c7-b598-4a81-89d4-b35acce8888b"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzgtMS0xLTEtNTk1ODQ_1124e8de-dc82-41d6-b508-01111663b677"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTphMWFlM2JiNjUxZjM0MjMzODZiYjA4MjRhOGM3MDQ3NS90YWJsZXJhbmdlOmExYWUzYmI2NTFmMzQyMzM4NmJiMDgyNGE4YzcwNDc1XzgtMy0xLTEtNTk1ODQ_7ea4559d-683c-424d-a452-82ec86d9dbeb"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzYxNzM_a00f0660-2afa-4285-9d61-a2ce93283bcc">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzMtMS0xLTEtNTk1ODQ_06e9a8ca-5e30-4d9e-8221-e252d7e268fa"
      unitRef="usd">60047000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzMtMy0xLTEtNTk1ODQ_122f2d88-cdd5-4d17-9504-7ddba09d043a"
      unitRef="usd">56482000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMS0xLTEtNzUxNzY_47bdc7c7-7b34-4280-b563-37be88ff37c0"
      unitRef="usd">34947000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMy0xLTEtNzUxNzY_0cc20a0b-9497-4a6c-9bf8-ffb4fb521a3d"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <prax:DeferredTaxAssetsTaxDeferredExpenseAmortization
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMS0xLTEtNTk1ODQ_c275a293-453f-42a8-8906-7bbaac0107cd"
      unitRef="usd">24262000</prax:DeferredTaxAssetsTaxDeferredExpenseAmortization>
    <prax:DeferredTaxAssetsTaxDeferredExpenseAmortization
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzQtMy0xLTEtNTk1ODQ_e7d43251-a0c5-4db6-97d6-e1583788c700"
      unitRef="usd">14295000</prax:DeferredTaxAssetsTaxDeferredExpenseAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzUtMS0xLTEtNTk1ODQ_6c67c6f6-88b9-4d3a-89ad-aea28255552f"
      unitRef="usd">17205000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzUtMy0xLTEtNTk1ODQ_bcb4a25f-00e5-4bcb-9c14-2799b069e287"
      unitRef="usd">9296000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzYtMS0xLTEtNTk1ODQ_8f51b605-a6ca-4a2c-832b-97aeb00ebb9f"
      unitRef="usd">6422000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzYtMy0xLTEtNTk1ODQ_80d9fd5f-d04b-4ad3-b21c-9ad64b02a1a4"
      unitRef="usd">3759000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <prax:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzctMS0xLTEtNTk1ODQ_d6b47a44-f527-445e-8376-51be1a82139f"
      unitRef="usd">898000</prax:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <prax:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzctMy0xLTEtNTk1ODQ_72197af2-8919-4520-ba3a-a70132fb3df2"
      unitRef="usd">1132000</prax:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzgtMS0xLTEtNTk1ODQ_060de93d-3561-4d93-b171-9b3452bb6071"
      unitRef="usd">893000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzgtMy0xLTEtNTk1ODQ_540f6b4c-cb1f-4610-874f-4fa33d8e146a"
      unitRef="usd">1952000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzktMS0xLTEtNTk1ODQ_ac28fe33-6de6-4d45-a6ee-70012af7c106"
      unitRef="usd">144674000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzktMy0xLTEtNTk1ODQ_01bc02f1-89f8-4c13-9dba-885919d211cc"
      unitRef="usd">86916000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEwLTEtMS0xLTU5NTg0_3876f0a1-1120-49a2-bba4-29822a24f2f9"
      unitRef="usd">143930000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEwLTMtMS0xLTU5NTg0_64371613-23a5-4fcd-a69a-f93e87411b08"
      unitRef="usd">85957000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzExLTEtMS0xLTU5NTg0_2632199f-ab4c-4262-bd4c-d50181407ef1"
      unitRef="usd">744000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzExLTMtMS0xLTU5NTg0_da0a16c8-b1e4-4c3c-aeea-1b2c4477f29b"
      unitRef="usd">959000</us-gaap:DeferredTaxAssetsNet>
    <prax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEzLTEtMS0xLTU5NTg0_17db5b71-694e-4890-94f4-832287f2d89d"
      unitRef="usd">744000</prax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <prax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzEzLTMtMS0xLTU5NTg0_19015eda-bf58-4793-aa59-0e70fc1f2db7"
      unitRef="usd">959000</prax:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE0LTEtMS0xLTU5NTg0_8095bf4e-da33-4760-a3da-4e94ab9d57dc"
      unitRef="usd">744000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE0LTMtMS0xLTU5NTg0_b7da6732-db7e-4329-af42-c423cc9f2583"
      unitRef="usd">959000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE1LTEtMS0xLTU5NTg0_b8fc7533-b326-4fb0-9b07-1c2646533451"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90YWJsZTozNTFiN2M2OTNiZjI0NjlmYmE0N2NkYTJlNzEzMjg4Zi90YWJsZXJhbmdlOjM1MWI3YzY5M2JmMjQ2OWZiYTQ3Y2RhMmU3MTMyODhmXzE1LTMtMS0xLTU5NTg0_fab37030-0513-4f29-ae6f-3649effc650a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzkyMA_18c4f83b-fa67-4698-94fe-73b787dbc6b4"
      unitRef="usd">226300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzkyNw_2ff9994b-110f-4cf4-944e-493434db77ed"
      unitRef="usd">212300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzk4OQ_fe58c35f-4e4d-4073-bd12-2c953c6e111c"
      unitRef="usd">7700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzEwNTg_7bda9a73-3fe0-4d62-a900-4f606c4d25a0"
      unitRef="usd">218600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzExODU_8727425f-fed8-436f-91cd-2e6e3d954b12"
      unitRef="usd">197400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzExOTI_8ac76156-f763-4ab8-8a77-bbb132a31784"
      unitRef="usd">187600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ic56cac62e36f40bcb5f9287718900ca1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE0MjI_644bd8b5-b4d6-43e4-8e2f-b0fed45a8262"
      unitRef="usd">14400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="id6ff1ec2beed4170862a47ce96834fcd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE0Mjk_d77b0b11-3883-4e8b-8306-627a76ea9037"
      unitRef="usd">7300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i27c24e65906d4987bf2662bc0bef89a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE2Mzk_22e7f9cc-9de6-4899-91a6-23dd5518a5d7"
      unitRef="usd">3500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i1cd10fe8bfcc4606aabb82073574d6fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzE2NDY_bf0de2a4-a225-49fa-a885-9c245590a447"
      unitRef="usd">2500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ica6b7381be214302904bad838ac442b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUwOTg_491ef594-3cd7-48c5-bdd8-62427a8c3cdb"
      unitRef="usd">143900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ica5b4ea7f3da432faad4765b7291efb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUxMDU_962c5297-ca74-404d-bf73-c2aa7183ca55"
      unitRef="usd">86000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUyODU_290e109c-8716-4c7a-a546-0ea8c46c87a1"
      unitRef="usd">58000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDUvZnJhZzo1N2JmOGZiNTMzYWU0YTMxOTgzZTEzODBjMzc2OWU1Yy90ZXh0cmVnaW9uOjU3YmY4ZmI1MzNhZTRhMzE5ODNlMTM4MGMzNzY5ZTVjXzUyOTI_88c09bc8-31ae-416a-9060-e06be23cfc49"
      unitRef="usd">49100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNDgvZnJhZzpjMjhjYTIxM2Y3MGQ0NWY3YjBiNWVjMjdmNTMyZWUwYS90ZXh0cmVnaW9uOmMyOGNhMjEzZjcwZDQ1ZjdiMGI1ZWMyN2Y1MzJlZTBhXzYyMg_f5cc2ca5-9b07-42f4-8d20-10caea857190">Related Party TransactionsOne of the founders of RogCon is the Company's General Counsel. During the years ended December 31, 2022 and 2021, the Company reimbursed RogCon for its out-of-pocket costs incurred for activities performed under the License Agreement (Note 12).</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTEvZnJhZzo0YWY5YTc5OWI3ZmE0YmZmOTE1OGViOWRlNGZhZWZiMC90ZXh0cmVnaW9uOjRhZjlhNzk5YjdmYTRiZmY5MTU4ZWI5ZGU0ZmFlZmIwXzUwMw_a5438428-efb7-4808-849f-46faac5c6e51">Employee Benefit Plan&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code for eligible employees. The plan covers substantially all employees who meet a minimum age requirement and allows participants to defer a portion of their annual compensation on a pre-tax basis. Under the plan, the Company is not obligated to match any participant contributions. The Company made contributions of $1.5&#160;million and $1.0 million during the years ended December&#160;31, 2022 and 2021, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTEvZnJhZzo0YWY5YTc5OWI3ZmE0YmZmOTE1OGViOWRlNGZhZWZiMC90ZXh0cmVnaW9uOjRhZjlhNzk5YjdmYTRiZmY5MTU4ZWI5ZGU0ZmFlZmIwXzQ0Nw_be4ee9e5-d077-4cbb-b66a-340cf79676da"
      unitRef="usd">1500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6cdaa96e1f1b4314a9084a09a2bdb55c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTEvZnJhZzo0YWY5YTc5OWI3ZmE0YmZmOTE1OGViOWRlNGZhZWZiMC90ZXh0cmVnaW9uOjRhZjlhNzk5YjdmYTRiZmY5MTU4ZWI5ZGU0ZmFlZmIwXzQ1NA_31799571-1bbd-459e-80a6-497bd1a1f7ea"
      unitRef="usd">1000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83Njk2NTgxMzk1ODQ2_a78069ee-a0bf-4f19-aeaa-c00fc93c0b89">Restructuring&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2022, the Company began a strategic realignment to focus resources on its ulixacaltamide, PRAX-562, PRAX-222 and PRAX-628 product candidates, as well as its preclinical programs across our Cerebrum&#x2122; and Solidus&#x2122; platforms, which resulted in a reduction of the Company&#x2019;s workforce. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $1.0 million of costs related to the realignment, of which $0.6 million has been recognized in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTU5_f31a878b-51d8-49e1-8652-9a345f90aac3"&gt;research and development expenses&lt;/span&gt; and $0.4 million has been recognized in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl83MTQ2ODI1NTgxOTYw_c651d9dc-e4c5-4069-8a23-904dc552dfc6"&gt;general and administrative expenses&lt;/span&gt; in the consolidated statement of operations during the year ended December&#160;31, 2022. These costs relate to employee severance, benefits and related costs. The Company does not expect to incur any additional significant costs related to the strategic realignment. &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2022, all costs related to the strategic realignment have been paid.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl8xNjQ5MjY3NDQyOTQ0_d8c52f33-0158-4439-8abb-bfab03e7e8e0"
      unitRef="usd">1000000.0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idc64fb1922be4dafa32214be1424bcea_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl8xNjQ5MjY3NDQyOTUx_79dc2343-ec58-4c91-9e0c-aa9bb53d3518"
      unitRef="usd">600000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic871a4e6f88a41a5ae62c882d6ad286b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNjQ5MjY3NDQzMjcwL2ZyYWc6ZmE1ZWYxY2U5ZmNiNDg4YTg5OGY5NTk4ODJlMDg2MGIvdGV4dHJlZ2lvbjpmYTVlZjFjZTlmY2I0ODhhODk4Zjk1OTg4MmUwODYwYl8xNjQ5MjY3NDQyOTU5_1dc171e9-d042-4282-963d-0a2225024834"
      unitRef="usd">400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTQvZnJhZzozODAwNjYyNmM5ZDU0NTNiOTc5ZWUxNDliZDFmMTU2MS90ZXh0cmVnaW9uOjM4MDA2NjI2YzlkNTQ1M2I5NzllZTE0OWJkMWYxNTYxXzI5NQ_4cc8e5c1-b366-482a-8436-80b0f2cb92fb">Subsequent EventsSubsequent to December&#160;31, 2022, the Company issued and sold a total of 2,942,083 shares under the Sales Agreement for aggregate net proceeds of $11.2 million after deducting commissions and offering expenses payable by the Company.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTQvZnJhZzozODAwNjYyNmM5ZDU0NTNiOTc5ZWUxNDliZDFmMTU2MS90ZXh0cmVnaW9uOjM4MDA2NjI2YzlkNTQ1M2I5NzllZTE0OWJkMWYxNTYxXzEwOTk1MTE2MjgyNDI_3fafc06b-e851-4129-98b1-fcf73b605cc2"
      unitRef="shares">2942083</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM2MDM2Njk0MDRmZTRmYzhiNTlkMzFiMzFlMjZlNDY3L3NlYzozNjAzNjY5NDA0ZmU0ZmM4YjU5ZDMxYjMxZTI2ZTQ2N18xNTQvZnJhZzozODAwNjYyNmM5ZDU0NTNiOTc5ZWUxNDliZDFmMTU2MS90ZXh0cmVnaW9uOjM4MDA2NjI2YzlkNTQ1M2I5NzllZTE0OWJkMWYxNTYxXzEwOTk1MTE2MjgzMDk_fca9e9e2-44bf-4fdc-a560-ff023cb144d9"
      unitRef="usd">11200000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MB>-$/<V=T)RJ7+$#%]7&=HY88.6QP*H4"[[30 1XS++G2DSY.NN$4@DLK2E
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M:YFS#4XWZ>K>!>6<ANG7-<$>8?( \?N24K[?D"<XK"CO_P]02P,$%     @
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MEN_>H!">N;Q[)6,'OGJ-K]Z8]>4%D1N@9PVDYH+^+-F.9-IYYRSN3465*9,
M=LL0A2A8S'===VPIY,41]!NQ Z!^ ]0?!?J%B#NJR$U&@:1I*9ABU ER;R;L
M#._%<>3W0-I2R(LPC-P@@P9D, KR2M M82M 'W0>E516D>5J0X7>K-U%Y0(>
MV)"@%Z ><(<4\I/8C3ML<(>CN+]S1;(C((:.P6'LPQY&6PSK&8")&V34@(R>
M":YF)Z$>JZ":E;K5?*&FH*#*A36R0"11/YBV#,+(<\.,&YCQ*,P_-4BB6'$+
M,JH)! C#%#.^GI7Z9CBTL1VS!/;QVD)>& S@31J\R3C>:GD6O)@]/_^)-;Z/
MPAY&ATR$W1 1;&D('K% AX'5ZH<K,T X[H%SR.$$1_[ OD<=GD1'<4;&R W+
MJN3D)([:S"LQQVM9.W2ZY4DT2DW+CVG*2\T58$L>369V.HSMF?'#SHJH/7&(
MP2B& _/2TAL:YS<-492TS<A.B)X]=A '_:SF$,-A[ _P&FJ)#8TSV]/2X;W$
MT5E*3M0."H.P3\8.J1@-1;6E.33.<T^0MUQ4U39?F]J8ZH<K7;SO:%&ZUX)-
M7CA&UAZUI88 M_R&7D)PST76YB_/]WPKM ZQ6,L-8&UI#D6CJ>0/7MS.%!7Y
M\\EDE#!?G$Q>R=JAVRUMHG'>_-IAH,ZZ>NFN</"HGUA3YR#2H,.VARZT3(K&
MJ73 A:.VADV;&,56EK2E!K8&;JD5'T.MSX05V[SI)56S=H#/(>:CQ L&,+;L
MBD>)3+>A><Z4*??V)77*"[,D:)%JO.#]5ZXHB#\X@?\"0P)GD_;?#1TZW^E&
MQ]O1:\73NPW/5E3(=V]BC**SJOQ5C^[6]'5[T_^C.<4M?>-Q^M8-5;UWI(G"
M%+R%)Q!"I"L. 72G6M(S@.!4/S(?(#=$F*ZK5!LNV#]:S:R6@C^]8%*:8H +
MP$LEE7YI$@N19I=>TI3F-U3LT3^=1E0&G*^0,_AVC= O(T9%#L/4EA#XF1)"
M[P^=:T9B%(P$Z0SXR=2+\=0/O%ZDJO[UR%!-*VD_F'IZH #YOV[*'5J[DNFG
M]5&1P]"VI0X>+W4^KE;,)'*=(TUK/V,%2,F6Z9SI!&G7+B$,$ZO&<<@%810,
M]?&X+73P>*&CZ]TR+[/JO*X^>."YWIH;<[2ZT_3)I3O!V\7,#$5>'[93*AP
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M+'!,YA;L5DG$CEC1/Z_<T'G?%?A?$CM(PZA)PZA//5K!/B1"0#E!\<:/5ZC
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M<&6 []>,R>.-^D!WIEO\"U!+ P04    " !Q04=6;O9)FK\"   K!P  &
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MWDFN?J5JG-Q<LUJPDA98D@+<2?5/S9$4@.W -19[\$'-LP!+\/O=#?C^VQ_
MMX#6X+<]:P6N"W&YD@J#]K3*^_N][^Z'9NX'$?C(:KD7X*>Z(,6Q@Y4"/T2
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M]])"]T6RQCSWWS(I664^[@DN"-<&ZO<=8_+EB[[!\.K(YE]02P,$%     @
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M'IE@"-QV3YZX9IS%N DO.;3"=2/QBC+7"-.1AQ(01W2S6=B?=?M7HM/$&YS
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MZQNUZ)T![QVVE-X&J_6\Q"&XJR+%0[(&+JPA ^M]2&?P\DN2V2O$H$(V!D$
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M;XY?E2K!34 H#])1J-PZW>!:9](V$$-N'X<YN%,;@G":U;R5MU/$(F&/IC
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M-Z&F+SWNH#EE/Q-5I9!!V&*HSU3_;KIV7'C#IA??%&5?W6N[5=K3C+UEEZ/
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MXK507.-/D2HRC1:@UHIKW_4QAJ]>WG'-JPHEFQD\\CF*.?051@TK),S*8ZZ
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M.A[.I@-AVV&RW7A3AP$.:8EQ,"P+A(8L7\#WM3%^OV$%_42__!M02P,$%
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MX%L>?]:XKI+C#5@O+;X"PP,'V%V EW\"4$L#!!0    ( '%!1U88-!,IAP<
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M].1T'('I6V%O.-V&]K/2CII9&#;T>J#Q#K2^UB1V9_@$PWNT^ U02P,$%
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M=A T? (;]H\B"MMMR,G\(6XYZJR26.K)#.S4B-[AE\)*0SOI01-6(PM%!CU
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MN1J\PU9:=,/X)[Q;:5<2"\7_5@4Y0Z/1J]- 8+<F.H-,XT=S:X@'W1]+WJR
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M:38>ZI#3\+4ZN.EZ:9J-W]Z] [L&8JP+0^B,4'"-6S1- "\1V#  E=S(E4+
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M;,5=ZW/;1I+_5U"ZJXU=1<J2_(AC)ZZ2Y7C/6\[&9\6['Z[N P@,1<0@P&
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MF80&H97\"P,BHBWV%0DI>=6)*>!9+[T=>A$;A"16=%,0I7CPW"V4'$MKVNZ
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M;F,: _Y!3E8LH*CH<07.X_J4N/J1\[*%"#7-DHY$\,BL@D:48&DFT0\/!"H
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MUO8_O(9D<*-%:1/IRL-W62CV(P?2]PVGDB^MJ(: [FSNVRTUXPJ-Y61WG(D
MKF"NMT4Q=*SS70;"=0[&E!V9&7FP--)KF]$\"KU34*4[790[G6:N6-4<42I<
M!:/:AXQ&[>%G].PXM !<5^)/2GB7_F#7<UXC)FN&M[YJ>B4,'E(T[="C9L?5
M26E5P%S#)]YU-3EBJ1&/63O=X*F6\CJ4RR^TE^]PH=%@$)><'U&'=F]RUCO?
M[F "K[-CC1=>!'FE$M'9#.X4+!OJXW%"#<8V$VB*/[$A;9PFK-9TOM0@X."?
M2$J4*[ ZYR @=#G"/1K=Q54KV;JB_7M8,*F\#YR@@%2]VS\.FS";@!ZK>#92
MU0M+]DB?]-+\5ALGMWQP:3%U$F;>FPHMRT(4BZ3-GU'C<XY]BYBX0N@70U",
MD7#,/L7A.4DA-1:\+3V)<'1^XSB=_"K4:L"J\Q5WD_;HR- _,.XC(G+<+PW-
MZ^1$?+<H]E.;7PTZG\@I6D)1-/TJ<H$7$O^$N(YF<O68:W83#4])/ X]8]KI
M*N(VM-<D@A3^F[J02>@[U!?98*S%^2ZUYOP8*0>##T;.5XPA;%)/.S1IQBZ*
M=R3.,6E\K50;@^H#_J(V61O=C<R[P^3C2(5B6]]WG=>S'7R'?1API$>7J/:@
MI M'#37BBWVZ>IV]KMK=)B>:SJX_OL\>G-!G"%:+_PI6Y(D3I41*".T>%L"A
MID$(2$7_=&+4^0;301:<66>[,LEP>>!W"P;MYW" @^;>HYF*,"GK_/C JX^Q
M['X3R>XK</]D7N)?63#[.*<K1-K,IF7F7_05BU'5D<I!?1E852K765=?ZQ.,
MI3(93CI.<782'!;2F40R7LTW)P".15+8!L(-W7Z.+"58),D(HK:&IP]H'0L1
M!S@D(QXO46MDFIM<B\C *8B/Q4UY,YV/:4NC=$T2@N\,!]+'#8*S.(HZ[OZ>
MA,.D E6E&%R40T=$VF?4%&=%S<9#(QT0>$?%XWTZ.24-HP)0YE_MJEZ*AU%3
MC+='@BH9A1#5WP7?619%;4\GT(DY*FSLSQ%YQ_*4"-5*YQ]P@1"\8.],.']$
M-G$8.-C(;^!P<JI,XPDY>+9*.%.'^]I(PYBO7+R?:_Q;#I7[**/T%I-YS@0I
M+1AR/\,XD2QSA6(Y"1<)C4NSP#BL%FD^R.7R.(57L6J0HA-E C<\*ADOI_VF
MHV9)GD=2UQ*KC<U:,-N!]OH:UFPJCL8N$-*#KH8Z*4V)9DWZE4#JP>XB:FD3
MN<2<KZ$1-?Z=>9B7YK<A+WPK['VW'$6-7%K8V]>ZG.U)YHGA-)(58SMUAX%V
M8B6R.>H\_UM)1R&%JZ2L'G><]#"E.V,\S,+U96A2-IE!N<5\A(FRCZF1GFKQ
MV-$4'+FI\1"<8Y,J?5'27)O@3#4%F<)]VS'RPBFXCU\*2;D7SP_!E,U :5&9
M,P.E./J0P]E??E3J%9&@'P8N&BN\\2"\72Z#:"1#%B)>4]HV+N\G<TPR+:CA
M7;6#&T^K VE\HZ0OHPX&HE^.N3&9IZ?#K,66+G&AW$D,&>.YQ"?KYX9I^]E2
MHZ+N8X91&#=Y?GPFY#4K^]>L[*\B93]I$OVYI>9+"9'=CJV-7.H/;LA;4H/2
M$->U>Z/LCLQ4](F]Q]#:I,UEHF81D[6C1/ZWYUSH$59B:K]XR6=+3Z6)?'H#
MB7R$"R:.HN-6XI,LQL= !3Y;VK/=OJL6CCI]659$D5R)'8\&>8VO_6P0C>17
MD46B#A,_-Q.&2'WDP^Z[@[.Y1>.*0[ZXV;C9Y 5%]0=?N?P1CEX+3IR7RPUR
MEK2EC[^[2( Z.#::+(\7;F7<A8LB3?0S !ZYV/C"%,[%]'$.IE$E!@];5)(=
MG@:,6)MK'_VQ4BC'XQ\L>I0FJ$[&ZLBN^HU;R#N=KN1'=+H7;OY*3+@2&>:1
MM/5(A]@\F*T.^4N]5ZF=4)[@I-D,[$GXQ8U2G3W)Z;R$H?^MC;:]R&WL)> [
M.R?QJR+%S>&[AXCV<SU0/+E%0P$'FD/*6#@)3M.NBILEV1G;Q]FD)'(2E,QX
M8(!/2_ Q?&2 MZEL8HTEW,M<%S5QO:YSPL)UL6EK7\F;-M@Z^O6=J=H!R_5@
M?F13-.T\,JU>9 ^JAY[FV%"Z;1&O.S91G$_TDMX<O\J%J,Y0Q$GY(7T*U6W+
M-5IBDXF:>.3V85B#AQ@B4*F9WUMY.T4LBAHP:@B G&9O@O$ 9/$,,P%YJ4V@
M16PB<0)D*U'!Z+#HMD[9)$E5FOA95IFIE/3A7YZD1^:N_KB'[P'%^O*BZTU8
MASFDV6Y8D9E4[Y<])G,)P>>-+S)43G690Q$KPPH]1CI1+31/=Q@3\Y9%!ZKZ
M%9;T:/*3.C;:QDU00I*1,TV;G"WGCL?,VL@:9[>+QZ&YA@H>/D+B=(T"$W%]
M>+D(Z78C(I?SL5'QM1W00%@9_<T"-TK&DT.-)L,YS7<P]LK?UQ0UN_KJ._Z5
M'ZR!]IX;OWP$K7\KFAX2[LI?G\?>*!8_/8\IYY%"?"ENK)+X\5(<ACA\SK%T
MB&?QN_H$*J:@SMSDG?>*4F;E@.I=DRD-B>1AG'-8<P?L]-KMHU4\;&:-=8/K
M8]96C3B9Z\K'G$9->9_;@[5.:E)5*W_@K^5JOQ1QR"I,2);'HDK63-^8%3"3
M4LESB._)C@OL@:G?'>K49+,L"B#!U6YSC;)WJ%'4K$$* &ZFUD1+2D).(_K6
M%7SHQZ\?X- 7UKE2C9@Z1;$G626WO%,M2&84F]&X5CDE"P[^N1P^3" LC+_S
M+!<[CJZ,C*FL#\.J\M *XJP-;J-0W3G*:R>8$L!F!/^X;C'^-2"5YLG$;IG)
MC.2&EG%)GB3WJ9)(?<8ZZ&!L@M9$\0U(JP<F_O4FU#VFUQTTIYSG0%4I9!"V
M>-1G\W\W73LN3F+3BWM(.73@M=TBG93'SKO+XZ #4B:S(3T$0>?>DAD%=J0/
MH_D&BLAW'WY>3*A18>SP:MSI$ ']S:1I6VD-7MU:-_/#C'CSFQ2R25-'<"K7
MQE^D($9S/!V(E=2\!@LJX9'#$P9@HN-]':YC3GV8EG]^?+[]6YW$=:7].I/.
M_!];@LW,H2FT0,EW LV(Q>37FMQ@,/^K33QZ)/STDMXI\UV)[!%9YS^UC>GQ
MY.Q\*]<1+^&DN(*9B+2-?YI)8&6EVH>)NC,'TH9\-R>#H[RSS_:A@$[FM.\Z
M@[XNG;:/]Z;F7".EL/W* 4>'<#B,#L,!0P>GF!F)9/T*8+'C'N>G.5:E(XFL
MYVGN"'>[89Z KB[S2W0@@1EU.HZ 'OV4UM1X]8,9.*@,QM+'&.,BS#V^.#YV
M^%U3H+'BE_S+%$O<^V4ZYYN9WS8:]VM&NL;/HE8;G<^K45%$!^+^E7O^2!7M
M[9>; 4((PS02C\8;0A!!E[G23Y[4GKBG,70NB!KZL7G&9?*#2G,_^#35Q)K\
MU!*4/O]XD&A-QC-/Q!ZY]G$9Z+@2KN)ZYT, HJ*X5O)00IN2XZ$'=1X3;\K%
M1-/59WY4[:BI4TPGO@'?TFE84Q9NYBP/;6)X]R)\P%M2+%3SB*^<ISY'S?>S
M!]$9#6Y^$'[I8.)GM%13N=^_.!(@\7%OWLG- )BL[_@J2:)'C>1RT54K\7EP
M[J6<>XES+^7<] Q/AN< S>%"23./1/Y"-P_0G(#*!4.-S"A)JAKE<Z[18:HW
M=-]J2\W36ZC?9 I@!K$AK>)TCBS(/\TI%4F8Z.01QFSI\^2^*"P:@Y=4]4?9
MZ2@-"\'G+5?YE9%&&B:.BL(P8?3B^&#0JV0L_7L2L9,B\8\NDJ4?R9@:AU,G
MS)-Q6M&$C?F?Z0A8)+TF&H.YV*L'#3T8G>"#S')Y;+[IX51^5UAA8[4CD 8(
MH\E=85[7](3W8[<49IA>'!\]^G>"@]%*7G1VC6C&Y"W]T47P([!%."0^EU!)
M)<&904?YL<G//Y#A'E77]"":$:8\.QMWPZ-*D-#&[YZR3>#Z 9/(O%ZH]6\D
MYG=B,2?C$F]Y8,YI]J:J!\<P_Y^GR=<8)G5#>V@"+Y1[J4(I 2GG_D3QQI7>
MG"'5KY,]A;+C7[IC#]N-WA(7/@(KZCIS/\@6839&YX*H69 XB_!T5+8N@Z@@
M$WOH%/01%PW^N(WA0XYEWWV.'*NKC<^C\@V%RZM8X;DB0]=E"I>M]896H?VF
MLR3"HY=<B%Y%,,LK&VGC29#CGS'P@[_IJ:5[XJ@$" /@+H[/;?MH4%Z:_*QV
MUS;MH),BIJ7VO[9D)@_082_+EG^!>?[1=TFAX/EWXO!S5E6CQY?7G\CA.>5O
ME^<7BRRQHQ]HWO7)V4.7:I70F \'1'N#Y=*W3["ZKGRBLP;QD8^O69]<C]9(
M-#[) /=3OLRYJI8P_">PD@O%N@9=#F(^.4L/LQB70K*:1\A,D]WN9RC#_CZK
MA#Y>_;F_Q!X/T5QA;I=:TO&F$N<MDR^F?G9&=ES$XQ)Y1IO4P/"O&]A@EDN:
M6?HPF$TF=?)+AC(,5-WKG$853,DY?5<EFS355KGV930H+VK@7J?V;^P^8 M7
M)"6N3^2DG&8_-]G?\F: 7RTJ?S3)G%"*GCM'UH%X) SJ?O((*./5%Q*>XT&V
MVC*%B4]%'V)@]W'4'%V$QG?+O[/PMZ$Q@.#94;9YMCQ_O(A&1+\+847E&?WQ
MG/=BDBA//;YXYGCJI]2"3A^GDTRN[12T#VHGT0"2EVQC$?M$H#Y?0@0D+'_V
M9/S!T]$'YV?C#\X9:^&SB[/EV>/HE](_.;2$'W9/['KY(?CPF/P2GRC[:/:7
M[[+4Z+4KF)0<$!1%3-THKZWS$&[40&F]=S^EH&5 !R\*!7":5'_/-FHY@S^S
M(BD!5=I)Y?XZCGWSB!L9KZR.:DAC<:$V]X+K#Y3PUE'9%K'#ST7?0CC?GQT8
M86YPAA]@B>MV<WR<=U=*H1.Y5A'?.*%WFOVUNO7AC.UXO%R(CT[]]A&#B79\
M*<Z<8+YQP/=/LZ%7=N^4\>ZG:46=/^*PWIN\SU]]OS4D4*_(E;,R0^*'$SAC
M_E,D&A"Z?7%Y<?*(W@R/O_I^1T;G3R2/$4NKS9I>/3O]]NF)M ^X/_IVAR51
M,]JW6_[GQH!N\ !]OV[)3-$_L,%=VWUF\%[]#U!+ P04    " !Q04=6(,8O
M)/,#  #W"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6SM5MMNXS80
M_96!NB@20(TNMNS$M0TDV2Q:((L:2;9]*/I 2R.;6(K4DE2\^?L.*5MQLHJZ
M?2WZ8(J7N9R9.31GOE/ZL]DB6OA:"6D6P=;:>A9%)M]BQ<R9JE'22:ETQ2PM
M]28RM496>*5*1&D<3Z**<1DLYWYOI9=SU5C!):XTF*:JF'ZZ0J%VBR )#AMW
M?+.U;B-:SFNVP7NTG^J5IE7462EXA=)P)4%CN0@ND]G5Q,E[@=\Y[LS1'%PD
M:Z4^N\6OQ2*('2 4F%MG@='G$:]1"&>(8'S9VPPZET[Q>'ZP_L''3K&LF<%K
M)?[@A=TN@O, "BQ9(^R=VOV"^W@R9R]7PO@1=JUL-@X@;XQ5U5Z9$%1<ME_V
M=9^'(X7S^ V%=*^0>MRM(X_R/;-L.==J!]I)DS4W\:%Z;0+'I2O*O=5TRDG/
M+N_;8H JX9YO)"]YSJ2%RSQ7C;1<;F"E!,\Y&CAY8&N!YG0>67+LU*-\[^2J
M=9*^X21)X:.2=FO@1A98O#00$>(.=GJ ?94.6GR/^1F,DA#2.$T'[(VZ-(R\
MO=$;]OKB_?-R;:PFVOS5%W%K;]QOSUVEF:E9CHN [HI!_8C!\L<?DDG\\P#:
M<8=V/&3]N&C7S&Q#/\+-EX8_,H'2&F"R@#LD^#RW6/CSOB &W?0'\;!%*)6@
MR^R291TEP)\ZM[G#X7S[";X"I)\!M8*&MFJEW09=4$N6<R4-Y;]@;F_-!),Y
M@F>WH7-FG4TFO*A5EF:L<G4SO?K&TJ?R[BE3WF5)N(G)W$FKQA J<SH#8A-6
M:]0=H]R0M%GMC>8=3))PDF0T24;GX30>'V?;BX^3"21A3..#!YK[0GUO7LQ6
M[>2_"XHPI6$\2CRFBW":QC! M:RC6C9,-7H%BH9J3,Y>$<IC?\V\/I8->OB?
M9?]AEDTZEDT&6;;2U&5H^Q3"2KCGQ^%UI*H=A#Y*#9KKI]3!AS>.!^/ -%)J
M<J7I80(J?:Z,/:-:D6+.F>\<N*.<R!OA4],83TG*F'L=W*/_D_,/%5*QB6*/
M5&'[@KZ4>%[M=;%L! AJ1'QBG1PSAG@W@YM.ZE,K=<M+A-]*>I')6*,EMPUA
M?8D^@R=DVL M6RO-K*)'X?EPM#^\5E7=6(+U[5%_4D*0:#TAN/'7IGP5T?=2
M^UO'Q)_S"QJSZ<4_QC;._*\_MO@"TG&ZIWW=7]LDS,8C&D>3"=RBH233.]]4
M^T(6QS4^R:;I*9PDV>AT,"GOX&+JR1^FR:B7^M%1,U:AWOB6DQCD_D':OJS;
M[;K:R[:9>Q9O6^*/3&^X-""P)-7X;$K_I+IM,]N%5;5O[=;*4J/HIUOJS%$[
M 3HOE;*'A7/0]?K+OP%02P,$%     @ <4%'5MSQ3H&Z P  <PD  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S N>&ULQ59MC^(V$/XKH]SIND@Y\@H!#I#8
MW7N3>NIJV;U^J/K!A &L3>*<[<#17]^Q$[+0LO1T7_HE&8]G'C_S%F>\$_))
M;1 U?,^S0DV<C=;ER/-4NL&<J:XHL:"=E9 YT[24:T^5$MG2.N69%_I^W\L9
M+YSIV.KNY'0L*IWQ N\DJ"K/F=Q?8R9V$R=P#HI[OMYHH_"FXY*M<8[ZL;R3
MM/):E"7/L5!<%"!Q-7%FP>@Z-O;6X"O'G3J2P42R$.+)+#XO)XYO"&&&J38(
MC%Y;O,$L,T!$XUN#Z;1'&L=C^8#^P<9.L2R8PAN1_<Z7>C-Q!@XL<<6J3-^+
MW2=LXND9O%1DRCYA5]OV$@?22FF1-\[$(.=%_6;?FSP<.0S\%QS"QB&TO.N#
M+,M;IMET+,4.I+$F-"/84*TWD>.%*<I<2]KEY*>G7YA\0LT6&<(<TTIRS5'!
MU8/1J,[8TW2&L?32!N^ZQ@M?P M"^"(*O5'POECB\A3 (W(MP_# \#J\B'B+
M:1>BP(70#\,+>%$;<63QHA?P/A=;5)KZ2BL7;G&A@15+>/^MXGI_G(,_9@NE
M)77-G^>R4)\1GS_#3-)(E2S%B4.CHE!NT9F^>17T_7<7(HC;".)+Z-,Y3>:R
MHHJ)%<RVC&>F6&]I0-\J=EK'>TQ%D?*,,S,"Y^*X>-+Y.!XV""N1T3CS8@U<
M 3N,M"&D:?=&Y"4K]K\HX&VRH112DQL7P)0QI+IBOD#9UM;6@80 KGA!.*)2
MI%&=$<Q></@HA5+P6-#7*.-_(551:4Z32M*-4!H^TD=)P:]D1+GXP+B$KRRK
M\%S25)NT$?E*(DLP--[4'L];\!JBGNO'(0EO7@W"('Q'TE70CSIF*W8'R;!N
MJ2,?KE1%A!9[>.S.N[ 66Y2%S0A]]*@X9!*[OM]K$:\"OP.1.QSVX$%HEAV#
M[;C>4+XI1J.Q"1<%PAZ9!"&!9M:2'!+)Y!\DDYKD@$C&#3"[E(<?PCE?F>#_
MJ$PO=,,@/B4;!9UZ)QA$IBMSE"FGP$M6&K8Q)3EJ[0_O1OT3=0SHH"!X+N2@
M8U5^!+_16,A_D>Z[T7  SPYF/?S9H@=^STV"OI%LZ,-.H^PG@PN)HY+U^\E1
M\T7$FI2]\,>9: %Z)RPAVS8UY&G;&-C7I\#_U7Y!E+@1%:Z)*$B23J,-_03.
M?4B]HXN0:KVVU[V"5%2%KN_$5MO^4<SJB_39O/X=H8MQ;7HTPQ6Y^MVDYX"L
MK_AZH45IK]6%T'1)6W%#?T4HC0'MKX30AX4YH/W/FOX-4$L#!!0    ( '%!
M1U9(<B)HH ,  .8(   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*U6
M;6_;-A#^*P=U*%I L"S)[[$-Q,F"#EC0($F[#\,^4-+9(B*1*DG9]7[]CI2M
M*I[C <6^V#SR[KGGCG<\S7=2O>@<T<#WLA!ZX>7&5+,@T&F.)=,]6:&@D[54
M)3,DJDV@*X4L<T9E$43]_B@H&1?><N[V'M1R+FM3<($/"G1=EDSM5UC(W<(+
MO>/&(]_DQFX$RWG%-OB$YDOUH$@*6I2,ER@TEP(4KA?>=3A;#:R^4_C*<:<[
M:["1)%*^6.&W;.'U+2$L,#46@='?%F^P*"P0T?AVP/1:E]:PNSZBW[G8*9:$
M:;R1Q1\\,_G"FWB0X9K5A7F4NT]XB&=H\5)9:/<+NT9W,/8@K;61Y<&8&)1<
M-/_L^R$/'8-)_PV#Z& 0.=Z-(\?REAFVG"NY V6U"<TN7*C.FLAQ82_ER2@Z
MY61GEG>,*_C*BAI!KN&."R92S@JXUAJ-A@_/+"E0?YP'AIQ9DR ] *\:X.@-
MX#"">RE,KN%7D6'V&B @EBW5Z$AU%5U$O,6T!W'H0]2/H@MX<1MZ[/#B_P[]
MENNTD+I6J.'/ZT0;1=7RU[F@&\C!>4C;03-=L107'K6(1K5%;_G^73CJ7UT@
M/&@)#RZA=PC[Q_NY1V999T %_HAIK107&U@QS?4Y]A?QS[-_SA'6LJ#FM<C&
ME0.X8V& B^99</V54,^#(?4;659,[-^_FT3A^$K#NJTJUK NCZR9@;4-:ML4
M((%0HQ^C2&P4P$1&;C*>,D..+7R!6RQLM5JA8YYS5$RE^1YJPPO^-^$;21UJ
M4%'C(+T[:=[1)VAM4:BLL$Q0M:7E7-(BA ]<D!-9:]K1'V>4]/,&OSM&X>'_
M*,?P+$W;2C.X83H'_%9S<D_)HQUJ$-Q3-ZL7>GW7-3F!7R >^.$DI(7+7W3U
M:G4XO'<F]BY VWQQP]%ZD*J2BA)%42>F<]0BD/UD/#T5;T^TN=8U92_9PY?>
M4P\V<HM*E/;"Z9VFFR25V)].ARU.B^=VB>;$#\>CAJ]UT UA'/O]X?"-7(;_
M;RY#@HW'T1O)/)[^=#8GL3^F=^Y$I/(O4;EZKUA%L76R/9W&I^)/)#^,_+ ?
M_RO[A^W/U!?J3<XC/YY.3R1*Q2#V!V-[=6$T))3!JT1%HXD_I&L\]X8%G=E#
M86_<A-60REJ89@RUN^T0OVYFUP_UY@N [F'#A:8&7Y-IOS<>>J":J=H(1E9N
MDB72T%QTRYP^1%!9!3I?2VF.@G70?MHL_P%02P,$%     @ <4%'5N\U5P0*
M P  (0<  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULA55;;]LZ#/XK
MA#<,+9!3QW:2MED2H+=A [IS@ET?ACTH-AT+DR5/HIOVWQ_*=KP4\[('RY)(
M?OQ(4=1B9^P/5R 2/)9*NV50$%7S,'1I@:5P9Z9"S9+<V%(0+^TV=)5%D35&
MI0KC\7@6ED+J8+5H]M9VM3 U*:EQ;<'592GLTS4JLUL&4;#?^""W!?F-<+6H
MQ!8_(GVNUI9788^2R1*UDT:#Q7P97$7SZXG7;Q2^2-RY@SGX2#;&_/"+=]DR
M&'M"J# ECR#X]X WJ)0'8AH_.\R@=^D-#^=[]#=-[!S+1CB\,>JKS*A8!A<!
M9)B+6M$'LWN+73Q3CY<:Y9H1=JWNA#VFM2-3=L:\+J5N_^*QR\.!P<7X#P9Q
M9Q WO%M'#<M;06*UL&8'UFLSFI\TH3;63$YJ?R@?R;)4LAVMUI;/U](3")W!
MW<]:5IQQ&L&_7 \GG\1&H3M=A,2>O'Z8=JC7+6K\!]0HAO=&4^'@3F>8/0<(
MF6+/,][SO(Z/(MYB>@9)-()X',='\)(^[J3!2_X2]PC62FAZ'CY\N]HXLEPQ
MWX=B;Y$GP\C^%LU=)5)<!GQ-'-H'#%:O7D2S\>LCO"<][\DQ]..\A\@>A1LF
M^ZPFL$^*L,C7,#663Q0$06H<G<$MLF$J17/'I(-4J+16@EBG=E)O@0H$GTQ_
M/?[Q_J%$*DP&Y@%M(\V-XM[@==&1+#M;S&L%BJ^L Y,W>L(Y)#>'NU[K<ZMU
M+W.$__)<I@Q66RVI9J[/V4_A"85U<"\VQ@HR]NE F'3"&U-6-3&MWT7#21F!
M1I\);E+.$^J8_HKH1&K>,;5C,W<ZYW2E6&[8P[Z6_1 -.7X)LXM+'J?GEW^-
M;3)MON'8QI<03V+X9$@HJ(;/-AI-)PF/R6P&]^@XR5=I6I?=06:'9WPR/8]/
MX22:)J='D_(2+L\C'J-1'"4P5/KA0=LJT6Z;YLP59&I-;0?K=_O^?]6VO5_J
M[>/Q7MBMU X4YFPZ/CN?!F#;AMPNR%1-$]P8XI;:3 M^P]!Z!9;GQM!^X1WT
MK^+J?U!+ P04    " !Q04=6-2YO+IL"  #,!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q]5-MNVS ,_17"&X86\.IK+LL2 TDOV!X*!&VW/0Q[
M4&PF-BI+GB0W[=^/DA,W*]*\V!1-'AZ*/IQNI7K4):*!YYH+/?-*8YI)$.B\
MQ)KI"]F@H"]KJ6IFZ*@V@6X4LL(EU3R(PW 8U*P27C9UOJ7*IK(UO!*X5*#;
MNF;J98%<;F=>Y.T==]6F--819-.&;? >S8]FJ>@4]"A%5:/0E12@<#WSYM%D
MD=IX%_"SPJT^L,%VLI+RT1Z^%S,OM(208VXL J/7$UXBYQ:(:/S=87I]29MX
M:._1;USOU,N*:;R4_%=5F'+FC3TH<,U:;N[D]AON^AE8O%QR[9ZP[6*3Q(.\
MU4;6NV1B4%>B>[/GW3T<)(S#=Q+B74+L>'>%',LK9E@V57(+RD83FC5<JRZ;
MR%7"#N7>*/I:49[)YGFN6BS@^IG&K%'#V0-;<=3GT\ 0O T*\AW4HH.*WX&*
M8KB5PI0:KD6!Q?\  ?'JR<5[<HOX).(5YA>01#[$81R?P$OZ9A.'E[R#MV0O
MKCE@H@#7.>,:?L]7VBCZ/?X<Z[E#3(\C6LE,=,-RG'FD"8WJ";WLTX=H&'X]
MP3?M^::GT+-[DF#1<@2YAK>#.L;U)-IQKGM8W,\_ER0X;<A%14V)L):<E%N)
M#9Q5@CRRU71]^GP"-!ZL5ZCZ$=E'!*^0!I5@'&PQIO+277N!3[0)&M*U>2WZ
M$:+0'R6I-4;^:)CT( TJ+85 _EDA9^:0:>R/PP1&?C0.^W!)C-5A2!(E$/E?
MP@@>I"$N[&V_5''@CP<A&?'0'Z<I'!M<<*"P&M7&[1%[6:TPG=AZ;[^JYIU"
M7\.[/7?+U*82&CBN*36\& T\4-WNZ Y&-DZO*VE(_<XL:=VBL@'T?2VEV1]L
M@7Z!9_\ 4$L#!!0    ( '%!1U8A3UU/* 0   X+   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,T+GAM;(U6ZV_;-A#_5PAU*QK L9ZV8]<VD$>+#6C6H,E:
M#,,^T-+9)DJ)&DG%]?[ZW5&RXB2*TB_BZ][WN]/-=TI_-UL RW[DLC +;VMM
M.?-]DVXAYV:H2BCP9:UTSBT>]<8WI0:>.:9<^E$0C/V<B\);SMW=C5[.566E
M*.!&,U/E.=?["Y!JM_!"[W#Q16RVEB[\Y;SD&[@%^V=YH_'DMU(RD4-AA"J8
MAO7".P]G%V.B=P1?!>S,T9Z1)RNEOM/A]VSA!6002$@M2>"XW,,E2$F"T(Q_
M&YE>JY(8C_<'Z1^=[^C+BANX5/*;R.QVX9UY+(,UKZ3]HG:_0>//B.2E2AKW
M9;N:=A1Y+*V,57G#C!;DHJA7_J.)PQ'#6? "0]0P1,[N6I&S\HI;OIQKM6.:
MJ%$:;9RKCAN-$P4EY=9J?!7(9Y>7*L^%Q2A;QHN,7:K"BF(#12K L'=W?"7!
MG,Q]BZJ(P4\;L1>UV.@%L6'$KE'4UK /10;98P$^VM@:&AT,O8AZ)5Y!.F1Q
M.&!1$$4]\N+6\=C)BU]UW'1X?B5,*I6I-+"_SU?&:D3//UUAJ)4DW4JHHF:F
MY"DL/"P9 _H>O.7;-^$X>-_C0M*ZD/1)7WXN07,RFGT"!.: ?#!*BHQ;R-@%
ME[Q(@=T2-DR7[;W2NVV_VP);*XFE3&HMP:.I9_$?ALWBLR,N+'=%I];N3K66
M2K+4,%&X>TQ"R8O]VS=G43AY;UAZ[,"J<<"!&\'H>%1E,%OF9,;.#4E'6$"^
M MU"@SXA/AKDF;'/CQ4S345ZJM:G%1ZX(V*_L&@P#4)<X\%X%+-/@J^$%!9Q
M,&.7E=94'$\\8/*!"!G#01",<#T+ _:'*D[3AJM4^A"&/@'1()F.4/L(K;A3
MELM.)?0>X)H,XC!D/?@9M?@9]>+'H09C;FP7.OIY7P/"D1>DP& #3]6FP,?L
MIY)O$$!05^=#\)#@&0RP-SMI>^": 36;ES#Q% MDE\M=&$1N3;!K?44'G#/'
MML<3%B>/,E/?.^9X6C,G8T9!V;G_ %K![U'=!B$']&]\4&M!YZ[C/*,41:J=
MSZAFI;2N8XLVPZ&.GH;L*:AVH G636;,*T7R[:=,I8!3<,T)BX<A2X8=C#V6
M3X<!^[7^]D!VW$)V_ IDL6:QTSUK?8>BW0_8-;>5QET7J'NE=[>\CY6EWT =
MD9+O:U!6B#3-"JIU:E+R"#-\HZ&!+G\A_$_R] S4?Q&8/SP'<V-+7;@H*7;0
MBR8!'1+:3L>T'>$VQ@SC=LQ";$HU=M>=KE!GF4XGC&([PU1BU@$KXUTRG9RP
MF[J;LWLN*WBMCQUZ5%>B_:,9)0>]<9,8%7U5V'I<:6_;8>^\GG$>R.M)\9KK
MC<!6(&&-K,%P@JU*U]-7?;"J=!//2EF<G]QVBP,K:"+ ][52]G @!>T(O/P?
M4$L#!!0    ( '%!1U;:89DL'0,   $'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;)55WV_;-A#^5PXJT+6 $%&R)"N9;2!)4ZP/78TZVQZ&/=#2
MV2(BD2I)Q<G^^ATI174QQ]A>)/+(^^Z[GUP<E'XP-:*%I[:19AG4UG97463*
M&EMN+E2'DDYV2K?<TE;O(]-IY)57:ILH82R/6BYDL%IXV5JO%JJWC9"XUF#Z
MMN7Z^08;=5@&<? B^"KVM76":+7H^!XW:'_KUIIVT812B1:E$4J"QMTRN(ZO
M;E)WWU_X7>#!'*W!>;)5ZL%M/E7+@#E"V&!I'0*GWR/>8M,X(*+Q;<0,)I-.
M\7C]@O[1^TZ^;+G!6]7\(2I;+X,B@ IWO&_L5W7X!4=_,H=7JL;X+QR&N]DL
M@+(W5K6C,C%HA1S^_&F,PY%"P5Y12$:%Q/,>#'F6'[CEJX56!]#N-J&YA7?5
M:Q,Y(5U2-E;3J2 ]N[I5;4O!V5A5/@"7%:PI*J@U5J/LW3W?-FC>+R)+YIQ2
M5([0-P-T\@ITG,!G)6UMX$Y66/T($!'/B6SR0O8F.8OX <L+F,4A)"Q)SN#-
M)N=G'F_V"I[WL%9-A=K\!'??>F&?X5=E$?Z\WAJKJ63^.N7W@)J>1G5M=&4Z
M7N(RH#XQJ!\Q6+U]$^?LYS.<TXES>@Y]M1FZ!]0.RB%WQN=IM%0!-2KL>MMK
M!&%,SV6)IWPX:^6T#_<U M5+Q^4SU+SZ;M+2P4XUU.!"[L'4G$[^1? $KRN@
MC&*[13UEU7UBV P0/_B$3ZA+8= !TW0QEJK5F_/HJG--;J (BUD1LJ2 /$SS
M(LS8:;21"3]P71GHJ4"U=X/,L['ROW3#W*"F^$1DI1L?L&ZXA#C,,Q9>9ADD
M89[/PWG!_K^1N[9KU#/B:&W=Z[*F\3)8*&:7X25%(\_2,&'I2?1'--8%@.)!
M<JM%:>ED"$<OA34P3V?$DD&:LI#-+^%>6=X<Y8?WME9:_$UJ_[F6($X(*PD+
M\CYF83)C89:G<*JRHZ.QU*+>^^%KR%0O[3"A)NDTWZ^'L?;]^O X?.9Z+RB]
M#>Y(E5W,LP#T,'"'C56='W);96ED^F5-;Q1J=X'.=XK:>MPX ].KM_H'4$L#
M!!0    ( '%!1U;>A+OIR00  !D,   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;*U7[V_;-A#]5P[N6B2 (DO4#\N.;2!.NRX?N@5)VF(8]H&6SK80
M2?1(RH[WU^](V8J'.DH&[$M,2<?'=WSOR,MX*^2C6B%J>"J+2DUZ*ZW7HWY?
MI2LLN7+%&BOZLA"RY)H>Y;*OUA)Y9B>519]Y7MPO>5[UIF/[[E9.QZ+615[A
MK015ER67NQD68COI^;W#B[M\N=+F17\Z7O,EWJ/^NKZ5]-1O4;*\Q$KEH@*)
MBTGORA_-!B;>!GS+<:N.QF RF0OQ:!YNLDG/,X2PP%0;!$X_&[S&HC! 1..O
M/6:O7=),/!X?T'^VN5,N<Z[P6A3?\TRO)KVD!QDN>%WH.[']!??Y1 8O%86R
M?V&[C_5ZD-9*BW(_F1B4>=7\\J?]/KQE MM/8)9WLY!E^9%K/AU+L05IH@G-
M#&RJ=C:1RRLCRKV6]#6G>7IZKT7Z>#&CO#*X%B5IK;C=KK,'/B]0G8_[FI8Q
MP?UT#SEK(-D+D#Z#+Z+2*P6?J@RS?P/TB5]+DAU(SE@GXD=,70A\!YC'6 =>
MT"8=6+S@I:177.(^Z5N^(X]IN)*25TNTXS^NYDI+,LR?I[)OL,/3V*:(1FK-
M4YSTJ$H4R@WVIA_>^;%WV<$\;)F'7>C3^Z9V0"RH(HACGFK*01D1&X/G>G>*
M<R?J:<X/*X2%**AJ\VH)VKAA7[KYWZA TV=C&%[M/KQ+F#^X5#]2JJM<M[Q&
M8/==P7=;*A3TM=K0#!IP93(BF;&<HSQ([4,8>HXW&,)/$/IN$L.-4C6%QX/8
M25@"?NA&(7QK,,Y\+W02+SBG66XR!"K:!>;V"XL3QX_"<V#,]9+7EF4P" -G
M&'FT+ M<;P =PD6M<-%;A6NV1JR?3Z471.M$_-]$.TEG!+_6=D^(;RM7.[A:
M+B4NN48XNZE@AURJ<SO4*U$K7F7T^%NME::AX?&2O+$3DC*1Y]-.^[$[9/"9
MBM"L0/L?#YW 8S!T60"?GE"FN6JTC)PX9N= RH0T+R&=KGF5TKE.GX4\UMUW
M@B!T?)\\0?!Q^ 92#!(G"1+'(WL1J< =!I"X+*:'R \/1.R^O@00.($?.2PT
M_B&'DFT'KC73,#IXE2@ /JW1EHH68/S802@.(L>,&D(>$0H,7CCLM&;<6C/N
MMB9=]%E-"='J"YY+V/"BQA^=NN4R(XJ5=='2" 69\4"MK-?HY:S@=)D0GJ";
MXS#/H#572BDR+$X9O9/?::/#[^2ZYH(YL67677>Y>KQ82$3(R5/F; )I^#(W
M8O >/*/,>U+T( /*$L[RUL^QJ?S8G!=MR$84E$E!]0$)^=*CZ4G4H+4Q&=5/
MAJ3O+L<B UMF[)(BGD=M'?$-2NI\FLV\L)MY),":,E+FQ"2IR;V1.8[(24F7
MYH-6\\%_.HXNYO8R3(\[ &/02N$IP3K!3PMV_\HRL"7_<SJY4KX_FIMS3%E-
MG@^6T5N4IT6Y3%>VSC+<4.NYMA<[U: S'##[&U!-?L:*%"AL',^HO<K-O6_Z
M1/"I[ C*IVH. W@0FL)>VRJC$)UG=&30@#DQ#4YIU3]JUTJ42]N4*D*L*]UT
M;NW;MN^]:MJ]Y_"F:?["Y3*O%!2XH*F>.Z [0S:-:/.@Q=HV?W.AJ96TPQ7U
M[BA- 'U?"*$/#V:!]K^!Z3]02P,$%     @ <4%'5NCTE>([ P  T08  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULC55M;]LV$/XK!PTH-D"-9$EV
M[-0VD+09-J#9C+A=413[0%-GBPA?-)**TW_?(V6K+N :^R*1U-USSW-W/,WW
MQCZY!M'#BY+:+9+&^_8FRQQO4#%W95K4]&5KK&*>MG:7N=8BJZ.3DEF1YY-,
M,:&3Y3R>K>QR;CHOA<:5!=<IQ>S7.Y1FOTA&R?'@4>P:'PZRY;QE.URC_]BN
M+.VR :46"K431H/%[2*Y'=W<5<$^&OPC<.].UA"4;(QY"IL_ZT62!T(HD?N
MP.CUC&]1R@!$-/X[8"9#R.!XNCZB_QZUDY8-<_C6R$^B]LTBF290XY9UTC^:
M_1]XT#,.>-Q(%Y^P/]CF"?#.>:,.SL1 "=V_V<LA#__'H3@X%)%W'RBR?,<\
M6\ZMV8,-UH06%E%J]"9R0H>BK+VEKX+\_/(OJOM[XQRT:&'=,(OPZP>VD>A^
MFV>> @2SC!_ [GJPXB=@HP(>C/:-@WM=8_TC0$;,!GK%D=Y=<1'Q'?(K*$<I
M%'E17, K![EEQ"M_@G?/K!9ZYV UR/URNW'>4G?\>TYP#U>=APLWYL:UC.,B
MH2OAT#YCLGSURVB2O[E MAK(5I?0E^O^HH#9 M->U$)VH87!(>^L\ (=X N7
M':4:MM8HX$:UG6>QW<D)CV)#;5T0>T[A10[G%7YH$+9&TH4F>&B-1Z+'9(BO
M*'0,Y5*(#MH3NW!O:@B74)E.>P<T'IQGN@[^S!-3W@26PM2 NDYACU29'\5Y
M"LJ9Y)T<!,:,T'=-32R/31RC$ZBW8D/)H%8&;P9JWO"GQL@:K2,)-J+V@1T(
MXL-9Y(N<=0[I)# (),E.T8#I9 T-HQIL$'6LRNMC66[@,R6\[WR@OD6U(3;'
MW@V/$?Q](CM2 =,&,0ZFZ;2<IGDQA4E:3:;I.!_!1_V,+M"A/)(:'I:]5Z<%
M)?&Z*M/9.(>JRM/\>@:KH1!]!4 XU\4$=$2JUWJ_7JV@F);I=#*"LDRK8@PS
MVHPI_HQBSZHBS?,QG&O?[&3,*+2[.$P=I99*VD^<X728U[?]F/INW@_[!V9W
M@F1+W))K?G4]3L#V [3?>-/&H;4QGD9@7#;TST$;#.C[UI#8PR8$&/YBRV]0
M2P,$%     @ <4%'5C8X5 9,!   _ D  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&ULC5;;;MLX$/V5@9HM'$"1)5J^QC;@)"VV0"]!G':Q6.P#+8UL
MHI+HDE2<].MW2-FRLVN[^R+Q,G/F=H;D>"/5=[U"-/!<Y*6>>"MCUJ-V6R<K
M++@.Y!I+VLFD*KBAJ5JV]5HA3YU2D;=9&/;:!1>E-QV[M7LU'<O*Y*+$>P6Z
M*@JN7FXPEYN)%WF[A0>Q7!F[T)Z.UWR)<S1?U_>*9NT&)14%EEK($A1F$V\6
MC6ZZ5MX)?!.XT0=CL)$LI/QN)Q_2B1=:AS#'Q%@$3K\GO,4\MT#DQH\MIM>8
MM(J'XQWZ>Q<[Q;+@&F]E_H=(S6KB#3Q(,>-5;A[DYG?<QN,<3&2NW1<VM6RW
MXT%2:2.+K3)Y4(BR_O/G;1X.% ;A"06V56#.[]J0\_*.&SX=*[D!9:4)S0Y<
MJ$Z;G!.E+<K<*-H5I&>F'\I$%@B/_!DUM![Y(D=].6X;@K8"[60+<U/#L!,P
M$8-/LC0K#>_*%-/7 &WRJ7&,[1R[86<1[S )H!/YP$+&SN!UFD [#J_SRT#A
M3N@DE[I2"'_-%MHHHL;?QV*N$>/CB+9=1GK-$YQXU \:U1-ZT[=OHEYX?<;?
MN/$W/H<^G5/[I56.(#-XEV7HV L'43QP@_" B2P3D0MN.7XLAO-6'E=(K76(
M8>T96OT:S /0AIO*2/4"HC9LR+"RAHUT4K>R6//RY>V; 8OZUQJP\;21%!JX
MADSFU/]Z!'\B5S5)@$J,Q0)54V;[B> ]IJAX?L8XBX(0?MO]=O*\3)V.C4B3
ME63EEE)\HJ-G30>)@41A*HR&3M GQ4XPH._<J1C; #Z4= Q2 K(MY )+S(2!
M.& D&3OYS[*\(N\K"I.:!83!@CHG#/J7M-F*ZO_<R.3[E3TN4B#?Z0C5=79)
M(+0"4="C[^V*ETO"*.&)YU4MP6VB>)D@M%@_8 Z5#8/8#KY0SA6X;+-KNQ$&
MD5W?$^3?J=K+-J,SY.PVY.S^;W+>88:*\NI(.=,:*;\V[Q\%7Q"IC$!]C)=G
M#1SOK<]4G'1GS4;(:VM$7RVTH<4M=VNRB7()+4JM6<E*DT?Z<G2*<G?_11V!
M-4>7'Z71(M&!09:X4B]T$VZX2C5<0"_TP[A/@V[/CP<,;OE:&)Z+GP35D!"?
MJ?Q$.SIOB'FQ/R2-73%FA51&_*PKSV*?]1A$]!MVJ;5_0>*H[[.P"T.2[ITF
M'#E&47;\?G<('Y'V-0R& XC\J,-@EB2J(@WG8KW5H:UAE\&CI$!@J6S8QY)^
M07[&?J\?TVC0\X=1C^ UI>W;,29'<<<?=HCYK4&7X*E'3A7S OJQQ1R2OZ_*
MDN_Y-((O^[K8F$#9R_=*9E<531P2M B'[!'.Y>E@#D!?*9SV;E>Y_>A8/[4/
M;N0"U=*].RQ3J]+4EW.SVCQM9O6-OA>OWT6?N%J*4E.@&:G2.4.=H^JW1CTQ
M<NWN]X4T]%IPPQ4]SU!9 =K/I#2[B370//BF_P!02P,$%     @ <4%'5CA^
MH<3; P  <1,  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULM9AMD]HV
M$,>_BL;-=)*9]/QL P5F[GB&27L3FO9%IR]TM@!-;(E(\I'DTU>RC8/!YSJM
M^@9L>?^_76EWP=+P1-E'?D!(@,]I0OC(. AQ')@FCPXHA?R.'A&13W:4I5#(
M6[8W^9$A&.>B-#$=RPK,%&)BC(?YV",;#VDF$DS0(P,\2U/(OCR@A)Y&AFV<
M!][C_4&H 7,\/,(]VB+QX?C(Y)U946*<(L(Q)8"AW<BXMP>;0-GG!K]C=.(7
MUT#-Y(G2C^IF%8\,2P6$$A0)18#RZQE-4)(HD SC4\DT*I=*>'E]IL_SN<NY
M/$&.)C3Y \?B,#)Z!HC1#F:)>$]/2U3.QU>\B"8\_P2GTM8R0)1Q0=-2+"-(
M,2F^X>=R'2X$DM,L<$J!<RWP7A"XI<#M*O!*@==5X)<"OZL@* 5!5T%8"L*N
M@EXIZ'45]$M!_UH0O)0XZYPYJZL/NTIV471%E>0E-H4"CH>,G@!3]I*G+O(Z
MS?6RLC!1';453#[%4B?&O[(])/@K5/7]%DPHX33!,2S*G<3@D2&.B"@&Z [,
M,8$DPC !6SF(9&\)#EY/D8 XX6_ 3^##=@I>OWH#7@%,P&\'FG&)X4-3R&"5
M2S,J WLH G->",P%[R@1!PYF)$9Q@W[=KK>=%H I5ZE:*N>\5 ].*W&*HCO@
MVF^!8SE.0T"3=OD6':7<>E$^;9>O,](JG[7+WT'6&OR\^]SM!OFB^]R;Y,ON
M<V^2K[K/O4F^_F]YW_SKI:N5H5MUK)OSW/^S8_^\?^*"R?^SOYHZLPC :PY
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M*&AUA_YZ5T(9,]B):=<1K^KJUG5UCZUK[QZ=PW?!DY649G(.,TTTFB-%@UC
M+>6$)Y0PF A%W1GQ>+/5]L"9,X0;OLI1$KO>N+V':[O7&4K@@E]4R8$HA;JI
M&^+W8'IE8*\VL/<.!L;_P[V#A;VU.0ZKG$@L"$T!M^8F4ZB<3.%</=K1?NUH
M_V"N;Z@U2@7W"X@EIE3#%!,T7AI/:B>;_#A(^U8_^@W=V&_NM4$M;'"4,-$H
M[&^/-6D;''$X'(XI2_9W;BW[Q7!'Y))R!0P7!A6T!@8NRUNXG&A1N(ML+K2Y
M%MTP,Q\N*&V >;\00K],[-U8?PI%?P!02P,$%     @ <4%'5KA Z%3L!0
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MHWWX#[OPJ";\#8TN (9G 'D(69I?G]X<5IOW52+*;* R&ZCPAVO]3>5!'L[
M^XU2G&?G7-TQYX*H-/SUNVH$;B5-Q=\VP;L(OCU"?E=>BA6)Z%5/W7:"\@WM
M37[^"0;>+S;Y+3FK) .7R< N[Q-3^QD@*>,R_I?.0,2$/%,5RKFJ$5L>=L[#
MPGD^F6PF>.3YX;B_.11H6D%O$,*@-*MTW2^[[K^ZZQG+'+UW^F\ZBCMGP6$J
M8!"$=HV#4N/ J?$+DR0!Q"Q0<5"_5=$VH0.S;Y9A,JT@#O$0VR4$I82@^3!%
MT3I=)T2J/B\X$P*L,[4^)86(A5J7RJ([ U.JVE$@R:--66#TV3M295I NZ"P
M%!1V(4B7XG.:G.&;EF7H2%!%_K"4/WQ]25IS8%TZAL\.H&E1,X"C4L&HW0%,
MU/7)%3DRNGL.0WRDR6*$1W95T-.KO->%KM,+TQV_:67NO54SA8<U63A@'=A!
M?>:IH':V@:<,J-VJ9O:'&E6@<_&?_"IDG!:#]Y'$''PER9K:@,6Y2.]C5*;_
MX3#TCR689FJ9#L*Z$=&( =V,<;H(]W+M#M.X_+!EP1Z@NKM04PET8\E)]4?+
ME,SSE&SRE%@E6ZC"-G2FF5JZD5=7?QH_H)L_KAE?,:XZJG9-BIJU!&MGG;X:
MCT]+WJK*-;7 H/-= G224>.$M.2MFA!-/? %V'/Z3@&:((('GH^.*]DT&R $
M_9I"UM "W=3R^LV".T#CP32IQK%=@!IM8,MLTXBVH<DMQ[3F-*GNUS78H);!
MIBEQN^,WWL^;8%.7 DTUR$TUW3(KLM%+<,PX-BM<P^+HX&F,&W$ZIU9W_,:#
M:U)2/;4BS4BH+49R3%'(@C3^,!P=CZ-I-D"P;I^/-/D@-_FTQ7GN,(T'S/9@
MII;SD$8C]!P:I2GE4:Q@;T56E%N5M$I$;7FK"M9$A+HG(M0J$;7EK9H0342H
M4R)R>V^<"PM?^:-1W4VMP0F] )Q: PIW\,8Y<#U,JNK70(5^Y,,B=_#&^D]F
M+ZS9"[O9JY6%R1VCJ4QL\I6CU+%F+.QFK)OJ%A?$0JR5[NEW\'!Q?P$6;$-Y
M5IR6D07-HII=L#M(8ZTM>:NF1,,9[OZL#+?*7VUYJR;DX+BLV_,R$[U\SQL<
MGY>95A!!6(/:6 ,:?L&)66MS.39!ZWASZ#2IBM(<AMT<UNT$C<U#L7-HR+(8
MU>P(L,8M[#XW:V?B#2P'M".CWBQG9 AZ=1.J!B3L!J0_Y)+R4YX<NOTTGB):
M\E95K8D)#[N?,UOEHK:\51.B$0J_ *$:S)FM,A(V&2G HYJ[U=>8Y'?RB.K$
M6<@=O/&;"B8_U2PMOF8G_T<^GW(';ZS??(Y5LPKY&I3\_^&@SAVCL4QDS/VJ
MTH^?>_0/7BO+W^G[1/@BS@1(Z%PU\RY"M;;QW6MRNPO)5L6;9E,F)4N+CTM*
M9I3G!NKW.6/RZ2)_>:U\67'R'U!+ P04    " !Q04=69U!P!5H"  #T!
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M2G=2LJ-2T[LJ0'8<KZ=U3_>M$'8:1X?H!@(]\2/TU"W-C0R.2]NN%)6:'@A
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MJ[(IT4U'B]I6N8706#-ML\!7#:0)P/FE$/JE8PIG]TZF_P!02P,$%     @
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M^GN%<5<.-GMM^4'5C F-=4^1WNN=X6JJO@K4$R.+ZJR;2(,G9S6<X^T)E W
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M5Z?DZF1^[G]Q#8F(*!.:[.^KF9!<O?Y_ZI#E@WCU@^@E82A2','84'-> -^
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M$X20;5>V$RUJVPE;H;&O[+# APRD"<#]3 A]F)CFZI_&^ ]02P,$%     @
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M#>1]<%Y _G_%F'AZDS>P>VS/XA]02P,$%     @ <4%'5FJ;Q<:& P  /1$
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MA[P9D5-#=(T<VW&JB+1S=D0T+! -ST/DI_D6R05,&9!E>$'"$_$:UM%!RQI
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M E39Y943(]>N49I+0VV7&ZZH,T9E#>C[0DISG-@ 5:\]_@M02P,$%     @
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M4::Y54&U "&WJ$E\CMC3B.HVV_I.OSMPA^:VJJHARO$J436ZW9)N]R3=!VD
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MR["@,2SH0V\;]B.[D]!Z5W[H\JLB$1H2^ES<SB=1.(K\R=3>'EIQ.B^<!.I
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MLH)JGR#&K/O4LVWJD^Q=QAF4 S),STF69-F!A*;_#D_?26?85W+H^89'^![
M,@WXP.VVEH;\O%D8J_&I_CI4L, W.LSGVO?:M+2$<83]:4"O(2H^?D@ODR^'
MQ/XGLCWIHU[ZZ#UV+&6-EHJ4^(,U6ZQ\@[;XD,X)A/>E2<5,J<'=X+#8]Z1"
MK:0]5*$0]L*'=?-H7:2#BSQ>[PH//E>[/KU'4!/OM(< O?13PV .&#4\M][:
M#Z8;WX]O[!,<6&&^_*4)T^Z>ZB63AG"HD3(97&'..DR0<+"J]4VX4!9;VF\;
M'+J@G0/>UTK9[<$%Z,=X\0=02P,$%     @ <4%'5BM; _;W @  8 H  !D
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MW(TX@CD #Q@21>8]N/4^"I;OJ6#U&^W@"5!+ P04    " !Q04=6EXJ[',
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M=_RDWG7XVI=Z[?E>XT]!/TGU<+ZW7!]_67Z?1)P7%YS3;45]^@M02P,$%
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M_Q%<O !02P$"% ,4    " !Q04=6!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '%!1U9Y[]X1[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( '%!1U:97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ <4%'5M9R9V L!P  72X  !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( '%!1U;C)GG,.P(  +T%   8              " @6X/  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !Q04=6BU2;!=\%  #T
M&   &               @('?$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ <4%'5BE% 0YO P  @ P  !@              ("!]!<
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '%!1U9<>F6H
MY0,  -\-   8              " @9D;  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !Q04=6;O9)FK\"   K!P  &
M@(&T'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ <4%'
M5JSPE;+Q$   6KD  !@              ("!J2(  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( '%!1U8!$NL060(  /4$   8
M      " @= S  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !Q04=6K/47:YL'  !&(@  &               @(%?-@  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ <4%'5AA]A!:&#   =Q\  !D
M             ("!,#X  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !Q04=6[?!,#7DG  ""?P  &0              @('M2@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( '%!1U;$+19LP0(
M !\&   9              " @9UR  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ <4%'5N=#Y8SG!   >PP  !D              ("!
ME74  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !Q04=6
M.6&4,MH$  #="P  &0              @(&S>@  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( '%!1U:%T%OCU@(  'P&   9
M      " @<1_  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ <4%'5FO%#<Z. @  R 4  !D              ("!T8(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !Q04=6ER<^ZCL)   H&0
M&0              @(&6A0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( '%!1U9.*R+-@00   P+   9              " @0B/  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ <4%'5A@T$RF'
M!P  K!,  !D              ("!P),  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !Q04=6.9O%G<0'  !D%@  &0
M@(%^FP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '%!
M1U836)18PP@  $49   9              " @7FC  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ <4%'5KAJQL$7 P  FP8  !D
M         ("!<ZP  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !Q04=6:=S?:'P*   P'P  &0              @('!KP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( '%!1U9:51]XAP(  +<%
M   9              " @72Z  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ <4%'5GY_WP(' P  K 8  !D              ("!,KT
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !Q04=6IH7Z
M&1,#  "2!@  &0              @(%PP   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( '%!1U9I@RW9>P(  (L%   9
M  " @;K#  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M<4%'5G=<XM "*   JX4  !D              ("!;,8  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !Q04=6(,8O)/,#  #W"P  &0
M            @(&E[@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( '%!1U;<\4Z!N@,  ',)   9              " @<_R  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ <4%'5DAR(FB@ P
MY@@  !D              ("!P/8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !Q04=6[S57! H#   A!P  &0              @(&7
M^@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( '%!1U8U
M+F\NFP(  ,P%   9              " @=C]  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ <4%'5B%/74\H!   #@L  !D
M     ("!J@ ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M" !Q04=6VF&9+!T#   !!P  &0              @($)!0$ >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( '%!1U;>A+OIR00  !D,   9
M              " @5T( 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M A0#%     @ <4%'5NCTE>([ P  T08  !D              ("!70T! 'AL
M+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !Q04=6-CA4!DP$
M  #\"0  &0              @('/$ $ >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;%!+ 0(4 Q0    ( '%!1U8X?J'$VP,  '$3   9              "
M@5(5 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ <4%'
M5AMVQ?RG @  "@<  !D              ("!9!D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !Q04=6SI\;0],"  !E"   &0
M        @(%"' $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( '%!1U8X88/ N0(  ,@)   9              " @4P? 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ <4%'5L^>N/C8 @  %@D
M !D              ("!/"(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !Q04=6N$#H5.P%  "X*   &0              @(%+)0$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( '%!1U9G4' %
M6@(  /0$   9              " @6XK 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ <4%'5NCRX+R,!P  (DD  !D
M ("!_RT! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !Q
M04=6("'#HXP#  "O#P  &0              @('"-0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( '%!1U98/.;WH@(  #,'   9
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M970U,BYX;6Q02P$"% ,4    " !Q04=6\J?OHG4"  !Y!@  &0
M    @(&D2 $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M '%!1U:84VE2/@(  "8%   9              " @5!+ 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ <4%'5@VWZ&.C!P  PD<  !D
M             ("!Q4T! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " !Q04=6:IO%QH8#   ]$0  &0              @(&?50$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( '%!1U92],A0B00
M )<4   9              " @5Q9 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ <4%'5G:-A590 P  XPH  !D              ("!
M'%X! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !Q04=6
M@^DZ_F0%   (&P  &0              @(&C80$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( '%!1U;?-V!FV ,  '<+   9
M      " @3YG 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ <4%'5A;^?4XE P  N L  !D              ("!36L! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !Q04=6F],6#]8#  !-%@
M&0              @(&I;@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( '%!1U8*$=<SBP,  *L/   9              " @;9R 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ <4%'5DP7L6%H
M P  Z@H  !D              ("!>'8! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " !Q04=6;8]ZJ-P#  #K#0  &0
M@($7>@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( '%!
M1U8G4 IHW ,  ,L/   9              " @2I^ 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ <4%'5BN^8%1Q @  T@4  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !Q04=6EXJ[',     3 @  "P
M            @ $^C@$ 7W)E;',O+G)E;'-02P$"% ,4    " !Q04=6-@Q
MP5T%  "B+0  #P              @ $GCP$ >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ <4%'5I=W<N0L @  ]B@  !H              ( !L90! 'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ <4%'5M9((R[W
M 0  *R@  !,              ( !%9<! %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&     $T 30 2%0  /9D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>198</ContextCount>
  <ElementCount>301</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/NatureoftheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/RestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value of Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/FairValueofFinancialAssets</Role>
      <ShortName>Fair Value of Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - UCB Option and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/UCBOptionandLicenseAgreement</Role>
      <ShortName>UCB Option and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Common Stock and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommonStockandPreferredStock</Role>
      <ShortName>Common Stock and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/MarketableSecurities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Value of Financial Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/FairValueofFinancialAssetsTables</Role>
      <ShortName>Fair Value of Financial Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/FairValueofFinancialAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/AccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Common Stock and Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommonStockandPreferredStockTables</Role>
      <ShortName>Common Stock and Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/CommonStockandPreferredStock</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/NetLossperShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/RestrictedCashDetails</Role>
      <ShortName>Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/RestrictedCash</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Marketable Securities - Investment Profile (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails</Role>
      <ShortName>Marketable Securities - Investment Profile (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Commitments and Contingencies - Operating Lease, Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease, Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Commitments and Contingencies - Total Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Total Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Commitments and Contingencies - Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Incremental Borrowing Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails</Role>
      <ShortName>Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Incremental Borrowing Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - UCB Option and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails</Role>
      <ShortName>UCB Option and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/UCBOptionandLicenseAgreement</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock and Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SignificantAgreementsDetails</Role>
      <ShortName>Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/SignificantAgreements</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails</Role>
      <ShortName>Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/RestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/Restructuring</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="prax-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://praxismedicines.com/role/SubsequentEvents</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  prax-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="prax-20221231.htm">prax-20221231.htm</File>
    <File>exhibit1013-cfoemploymenta.htm</File>
    <File>exhibit231-eyconsent2022.htm</File>
    <File>exhibit311-peo302certifica.htm</File>
    <File>exhibit312-pfo302certifica.htm</File>
    <File>exhibit321-peoandpfo906cer.htm</File>
    <File>prax-20221231.xsd</File>
    <File>prax-20221231_cal.xml</File>
    <File>prax-20221231_def.xml</File>
    <File>prax-20221231_lab.xml</File>
    <File>prax-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>prax-20221231_g1.jpg</File>
    <File>prax-20221231_g2.jpg</File>
    <File>prax-20221231_g3.jpg</File>
    <File>prax-20221231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="676">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "prax-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 676,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 198,
   "dts": {
    "calculationLink": {
     "local": [
      "prax-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "prax-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "prax-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prax-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prax-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "prax-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 446,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 10
   },
   "keyCustom": 22,
   "keyStandard": 279,
   "memberCustom": 15,
   "memberStandard": 26,
   "nsprefix": "prax",
   "nsuri": "http://praxismedicines.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://praxismedicines.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Nature of the Business",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://praxismedicines.com/role/NatureoftheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Restricted Cash",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://praxismedicines.com/role/RestrictedCash",
     "shortName": "Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://praxismedicines.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value of Financial Assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://praxismedicines.com/role/FairValueofFinancialAssets",
     "shortName": "Fair Value of Financial Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://praxismedicines.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://praxismedicines.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://praxismedicines.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - UCB Option and License Agreement",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://praxismedicines.com/role/UCBOptionandLicenseAgreement",
     "shortName": "UCB Option and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Common Stock and Preferred Stock",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://praxismedicines.com/role/CommonStockandPreferredStock",
     "shortName": "Common Stock and Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://praxismedicines.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://praxismedicines.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prax:SignificantAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Significant Agreements",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://praxismedicines.com/role/SignificantAgreements",
     "shortName": "Significant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prax:SignificantAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://praxismedicines.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://praxismedicines.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://praxismedicines.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://praxismedicines.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://praxismedicines.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://praxismedicines.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://praxismedicines.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://praxismedicines.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fair Value of Financial Assets (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://praxismedicines.com/role/FairValueofFinancialAssetsTables",
     "shortName": "Fair Value of Financial Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://praxismedicines.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://praxismedicines.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prax:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitment and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://praxismedicines.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prax:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Common Stock and Preferred Stock (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://praxismedicines.com/role/CommonStockandPreferredStockTables",
     "shortName": "Common Stock and Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://praxismedicines.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://praxismedicines.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://praxismedicines.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ia2d950c598cd455e8bb7e9014cef8268_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Life (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ia2d950c598cd455e8bb7e9014cef8268_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://praxismedicines.com/role/RestrictedCashDetails",
     "shortName": "Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Marketable Securities - Investment Profile (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails",
     "shortName": "Marketable Securities - Investment Profile (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Marketable Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i27a0c3d7a4f446ce8e8a686a819a00e1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i27a0c3d7a4f446ce8e8a686a819a00e1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i716e562883f3424aaef16a9b22f5c8e7_I20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "prax:PercentageIncreaseInAnnualBaseRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i716e562883f3424aaef16a9b22f5c8e7_I20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "prax:PercentageIncreaseInAnnualBaseRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://praxismedicines.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "prax:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Commitments and Contingencies - Operating Lease, Consolidated Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails",
     "shortName": "Commitments and Contingencies - Operating Lease, Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Commitments and Contingencies - Total Lease Costs (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Total Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Commitments and Contingencies - Future Lease Payments (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Future Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Incremental Borrowing Rate (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails",
     "shortName": "Commitments and Contingencies - Weighted Average Remaining Lease Term and Weighted Average Incremental Borrowing Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i1738436c1e4a4aaabe1692876228c53a_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - UCB Option and License Agreement (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails",
     "shortName": "UCB Option and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i1738436c1e4a4aaabe1692876228c53a_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i921f704070724adca8d013ad9ca44f7a_D20211103-20211103",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
     "shortName": "Common Stock and Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i921f704070724adca8d013ad9ca44f7a_D20211103-20211103",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "prax:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i92a1b80e6fa1480abd9c373178bf12e6_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i7da243485d114cb4884c5da895b1ce3b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i7da243485d114cb4884c5da895b1ce3b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica5b4ea7f3da432faad4765b7291efb5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i8d8ba7b8d8e04f518989ee07c35fa85f_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Significant Agreements (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://praxismedicines.com/role/SignificantAgreementsDetails",
     "shortName": "Significant Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails",
     "shortName": "Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Income Taxes - Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "ica6b7381be214302904bad838ac442b9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Employee Benefit Plan (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://praxismedicines.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Restructuring (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://praxismedicines.com/role/RestructuringDetails",
     "shortName": "Restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://praxismedicines.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i5c431d3320c046b7aae0d9ca6185c293_D20230101-20230207",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i7981ea2568c04a67a4ac7e9b7f44ffa8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i78379e54ba7f4f74ae54e573dcb1f8b6_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0f0624b7d6cc44bcb25109c266ffa6b8_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0f0624b7d6cc44bcb25109c266ffa6b8_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prax-20221231.htm",
      "contextRef": "i0c40d3a2410c4fde899c8c10df92352b_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://praxismedicines.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "prax_A2022OfferingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Offerings",
        "label": "2022 Offerings [Member]",
        "terseLabel": "2022 Offerings"
       }
      }
     },
     "localname": "A2022OfferingsMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_AccruedExternalResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued External Research And Development Expenses, Current.",
        "label": "Accrued External Research And Development Expenses Current",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_AccruedPersonnelRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Personnel Related Expenses, Current.",
        "label": "Accrued Personnel Related Expenses Current",
        "terseLabel": "Accrued personnel-related expenses"
       }
      }
     },
     "localname": "AccruedPersonnelRelatedExpensesCurrent",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Operating Lease, Consolidated Balance Sheets"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prax_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://praxismedicines.com/20221231",
     "xbrltype": "stringItemType"
    },
    "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax",
        "terseLabel": "Available-for-sale, accumulated gross unrealized gain, current, before tax"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Noncurrent, before Tax",
        "terseLabel": "Available-for-sale, accumulated gross unrealized gain, noncurrent, before tax"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax",
        "negatedLabel": "Available-for-sale, accumulated gross unrealized loss, current, before tax"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Noncurrent, before Tax",
        "negatedLabel": "Available-for-sale, accumulated gross unrealized loss, noncurrent, before tax"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Offering costs included in accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DeferredTaxAssetsOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Assets, Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseAsset",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DeferredTaxAssetsTaxDeferredExpenseAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Amortization",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAmortization",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offering",
        "label": "Follow on public offering [Member]",
        "terseLabel": "Follow on public offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liabilities.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_IonisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis",
        "label": "Ionis [Member]",
        "terseLabel": "Ionis"
       }
      }
     },
     "localname": "IonisMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_JefferiesOpenMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies Open Market Agreement",
        "label": "Jefferies Open Market Agreement [Member]",
        "terseLabel": "Jefferies Open Market Agreement"
       }
      }
     },
     "localname": "JefferiesOpenMarketAgreementMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_LettersOfCreditReceivableCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letters Of Credit Receivable, Current",
        "label": "Letters Of Credit Receivable, Current",
        "terseLabel": "Letters Of Credit Receivable, Current"
       }
      }
     },
     "localname": "LettersOfCreditReceivableCurrent",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/RestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_LettersOfCreditReceivableNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letters of Credit Receivable, Noncurrent",
        "label": "Letters of Credit Receivable, Noncurrent",
        "terseLabel": "Letters of Credit Receivable, Noncurrent"
       }
      }
     },
     "localname": "LettersOfCreditReceivableNoncurrent",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/RestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_LicensingAgreementsProfitSharePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements, Profit Share Payments",
        "label": "Licensing Agreements, Profit Share Payments [Member]",
        "terseLabel": "License agreement, profit share payments"
       }
      }
     },
     "localname": "LicensingAgreementsProfitSharePaymentsMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_OfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Furniture and Equipment",
        "label": "Office Furniture and Equipment [Member]",
        "terseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_PercentageIncreaseInAnnualBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase In Annual Base Rent.",
        "label": "Percentage Increase In Annual Base Rent",
        "terseLabel": "Percentage increase in annual base rent"
       }
      }
     },
     "localname": "PercentageIncreaseInAnnualBaseRent",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prax_ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from at the market offerings, net of issuance costs",
        "label": "Proceeds from at the market offerings, net of issuance costs",
        "terseLabel": "Proceeds from at-the-market offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromAtTheMarketOfferingsNetOfIssuanceCosts",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Milestone Payments"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_RogconMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RogCon [Member]",
        "terseLabel": "RogCon"
       }
      }
     },
     "localname": "RogconMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_SaleOfStockConsiderationReceivedGrossAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received, Gross Amount",
        "label": "Sale of Stock, Consideration Received, Gross Amount",
        "terseLabel": "Sale of stock, consideration received, gross amount"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedGrossAmount",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance Line items",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceLineItems",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prax_ScheduleOfCommonStockReservedForFutureIssuanceTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance Table",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]",
        "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTable",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Summary of common stock reserved for future issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period",
        "label": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period",
        "terseLabel": "Issued Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, issued in period, weighted average grant date fair value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "prax_SignificantAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Agreements",
        "label": "Significant Agreements [Text Block]",
        "terseLabel": "Significant Agreements"
       }
      }
     },
     "localname": "SignificantAgreementsTextBlock",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prax_TwentySeventeenEmployeeStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Seventeen Employee Stock Incentive Plan",
        "label": "Twenty Seventeen Employee Stock Incentive Plan [Member]",
        "terseLabel": "2017 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwentySeventeenEmployeeStockIncentivePlanMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_TwentyTwentyEmployeeStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Employee Stock Incentive Plan",
        "label": "Twenty Twenty Employee Stock Incentive Plan [Member]",
        "terseLabel": "2020 Employee Stock Incentive Plan"
       }
      }
     },
     "localname": "TwentyTwentyEmployeeStockIncentivePlanMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_TwentyTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Employee Stock Purchase Plan",
        "label": "Twenty Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwentyTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_TwoThousandTwentyEmployeeStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Employee Stock Incentive Plan",
        "label": "Two Thousand Twenty Employee Stock Incentive Plan [Member]",
        "terseLabel": "2021 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockIncentivePlanMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Employee Stock Purchase Plan",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_UCBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB",
        "label": "UCB [Member]",
        "terseLabel": "UCB"
       }
      }
     },
     "localname": "UCBMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prax_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Units",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Unvested Restricted Stock Units"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://praxismedicines.com/20221231",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r247",
      "r252",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails",
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r201",
      "r432",
      "r463",
      "r478",
      "r511",
      "r512",
      "r516",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r201",
      "r432",
      "r463",
      "r478",
      "r511",
      "r512",
      "r516",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r247",
      "r252",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails",
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r477"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r104",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r60",
      "r129"
     ],
     "calculation": {
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r132",
      "r437",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r18",
      "r21",
      "r93",
      "r392",
      "r440",
      "r441",
      "r492",
      "r493",
      "r494",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r477"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r499",
      "r500",
      "r501",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r82",
      "r83",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r112",
      "r131",
      "r152",
      "r189",
      "r197",
      "r199",
      "r210",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r357",
      "r359",
      "r373",
      "r477",
      "r514",
      "r515",
      "r558"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r124",
      "r133",
      "r152",
      "r210",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r357",
      "r359",
      "r373",
      "r477",
      "r514",
      "r515",
      "r558"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "totalLabel": "Total available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTotalLabel": "Total available-for-sale securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r204",
      "r218"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Total available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r52",
      "r203",
      "r218",
      "r433"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Total available-for-sale securities, estimated fair value",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets",
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r51",
      "r218"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Estimated Fair Value, Available-for-sale, current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r51",
      "r127",
      "r218"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Estimated Fair Value, Available-for-sale, noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r126",
      "r451"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets",
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r37",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r36",
      "r41"
     ],
     "calculation": {
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Total cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash as shown on the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r31",
      "r98"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements and Revenue Recognition"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "UCB Option and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r105",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r236",
      "r237",
      "r446",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r499",
      "r500",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r477"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 150,000,000 shares authorized; 49,382,453 shares issued and outstanding as of December\u00a031, 2022, and 45,300,514 shares issued and outstanding as of December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r138",
      "r140",
      "r145",
      "r434",
      "r438"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Significant Suppliers and License Agreements"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Upfront Payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Non-current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r470",
      "r472",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r218",
      "r504"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Available-for-sale, amortized cost, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r218",
      "r504"
     ],
     "calculation": {
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "totalLabel": "Available-for-sale, amortized cost, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r207",
      "r219",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Securities, unrealized loss position, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r208",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r102",
      "r111",
      "r338"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r90",
      "r549"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r90",
      "r549"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r90",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Operating loss carryforwards, domestic"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r90",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Operating loss carryforwards, state and local"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r88",
      "r90",
      "r549"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r90",
      "r549"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r90",
      "r549"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "terseLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r34",
      "r58"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r269",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r292",
      "r323",
      "r324",
      "r326",
      "r331",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsStock": {
     "auth_ref": [
      "r68",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Stock",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "DividendsStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r146",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r169",
      "r171",
      "r173",
      "r174",
      "r175",
      "r179",
      "r364",
      "r365",
      "r435",
      "r439",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r146",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r171",
      "r173",
      "r174",
      "r175",
      "r179",
      "r364",
      "r365",
      "r435",
      "r439",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r153",
      "r334",
      "r348"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r547",
      "r550"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r547",
      "r550"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r547",
      "r550"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r547",
      "r550"
     ],
     "calculation": {
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal and state research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested restricted stock units"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense expected to be recognised (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested stock based awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Potential shares issuable under the ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r67",
      "r122",
      "r142",
      "r143",
      "r144",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r181",
      "r211",
      "r265",
      "r327",
      "r328",
      "r329",
      "r345",
      "r346",
      "r363",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r392",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r366",
      "r367",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r94",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r248",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r367",
      "r404",
      "r405",
      "r406",
      "r461",
      "r462",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r248",
      "r273",
      "r278",
      "r367",
      "r404",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r248",
      "r273",
      "r278",
      "r367",
      "r405",
      "r461",
      "r462",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r248",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r367",
      "r406",
      "r461",
      "r462",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r248",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r404",
      "r405",
      "r406",
      "r461",
      "r462",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r221",
      "r222",
      "r223",
      "r249",
      "r263",
      "r361",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r460",
      "r506",
      "r507",
      "r508",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "terseLabel": "Foreign currency gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r34",
      "r57",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r224",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r335",
      "r336",
      "r343",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r141",
      "r332",
      "r333",
      "r336",
      "r337",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r431",
      "r495"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r55",
      "r99",
      "r108",
      "r120",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r390",
      "r476"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r152",
      "r210",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r358",
      "r359",
      "r360",
      "r373",
      "r458",
      "r514",
      "r558",
      "r559"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r103",
      "r115",
      "r477",
      "r498",
      "r509",
      "r553"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r125",
      "r152",
      "r210",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r358",
      "r359",
      "r360",
      "r373",
      "r477",
      "r514",
      "r558",
      "r559"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Other than Long-Term Debt, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License agreement"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities, Policy"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r182",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r31",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r35",
      "r106",
      "r119",
      "r123",
      "r137",
      "r139",
      "r144",
      "r152",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r172",
      "r189",
      "r196",
      "r198",
      "r200",
      "r210",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r365",
      "r373",
      "r459",
      "r514"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
      "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of restricted stock activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.",
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Off-Balance-Sheet Risk"
       }
      }
     },
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r189",
      "r196",
      "r198",
      "r200",
      "r459"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r385",
      "r476"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "verboseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://praxismedicines.com/role/CommitmentsandContingenciesFutureLeasePaymentsDetails",
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://praxismedicines.com/role/CommitmentsandContingenciesOperatingLeaseConsolidatedBalanceSheetDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r389",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r388",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesWeightedAverageRemainingLeaseTermandWeightedAverageIncrementalBorrowingRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Change in unrealized losses on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r134",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r505",
      "r510",
      "r518",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other debt securities"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance costs for at-the-market offerings and initial public offering",
        "terseLabel": "Payment of issuance costs for at-the-market offerings and initial public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of tax withholdings related to vesting of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r27",
      "r50",
      "r147"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r477"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from follow-on public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r80"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options and employee stock purchase plan contributions"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r59",
      "r128"
     ],
     "calculation": {
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r61",
      "r116",
      "r436",
      "r477"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets",
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetTables",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r84",
      "r121",
      "r560"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations",
      "http://praxismedicines.com/role/SignificantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r490",
      "r497",
      "r561",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r100",
      "r113",
      "r126"
     ],
     "calculation": {
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesSummaryofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as current.",
        "label": "Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Restricted Cash and Cash Equivalents, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestrictedCashDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage, classified as noncurrent.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestrictedCashDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r227",
      "r230",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r226",
      "r229",
      "r231",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.",
        "label": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r68",
      "r114",
      "r443",
      "r445",
      "r477"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets",
      "http://praxismedicines.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r122",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r211",
      "r327",
      "r328",
      "r329",
      "r345",
      "r346",
      "r363",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Line Items]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/UCBOptionandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r387",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, net of discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Sale of stock, gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold in follow-on public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/PropertyandEquipmentNetDetails",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r41",
      "r100",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/RestructuringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of stock option awards on the grant date using the Black-Scholes option valuation model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Shares ending balance",
        "periodStartLabel": "Shares beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value ending balance (in usd per share)",
        "periodStartLabel": "Weighted average grant date fair value beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant\u00a0Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares canceled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares outstanding ending balance",
        "periodStartLabel": "Number of shares outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price ending balance",
        "periodStartLabel": "Weighted average exercise price beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails",
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r296",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsontheGrantDateUsingtheBlackScholesOptionValuationModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares witheld for taxes for vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r67",
      "r122",
      "r142",
      "r143",
      "r144",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r181",
      "r211",
      "r265",
      "r327",
      "r328",
      "r329",
      "r345",
      "r346",
      "r363",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r392",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r181",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Future Share-based Awards"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r2",
      "r3",
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock from at-the-market public offerings (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r67",
      "r68",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares exercised",
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r2",
      "r3",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from at-the-market public offerings"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r49",
      "r477",
      "r498",
      "r509",
      "r553"
     ],
     "calculation": {
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheets",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r151",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails",
      "http://praxismedicines.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r249",
      "r263",
      "r361",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r506",
      "r507",
      "r508",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Available-for-sale securities:"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r16",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r456",
      "r470",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Debt securities issued by U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/FairValueofFinancialAssetsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://praxismedicines.com/role/MarketableSecuritiesInvestmentProfileDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r183",
      "r184",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, increase (decrease), amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r386",
      "r476"
     ],
     "calculation": {
      "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/CommitmentsandContingenciesTotalLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r170",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r169",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://praxismedicines.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://praxismedicines.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001689548-23-000044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001689548-23-000044-xbrl.zip
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M]%PB-<J[\'JQ_Q-; &0JR]E!UW -V'9;%;"03@BC+;>U"P**TKK2$GDQ>19
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M<*%$V$<\1Z8] 6'L4TUI5,OZ1@\CCZY3%%Q<8X\PK9BY&! J+V*TB$:$!FD
MJQNF-_"JM&#"WB9 7MU^-P9O^4R SA+=X7-C5JK7I1>@[6/2:5+LP8GL !Y*
M=-2D_B.-97'"KS%\"]Q!!;D(BWRZLG,8>#3;S122D24(NT$?+(5QQ=!9U(YB
MARG37A6S*>9K]!MGWI67@+CN>Y&TI[(4UVJ9+QVM$5N_->TA+\PWCH]XBDWE
M8-])K[$UX9T6Y>7%T2"/IMWO'KI9@FY^J)&S('(V_D]1II_;U'2\ B4?:(7]
M'XA>Y6$P"87'KR;T"O"6>![!JDC31-9 R&>5++W48"XJ_MS.N#2+^?X"\^V
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MC%&"N=4J9+*\M71;K6H<!7$S\8D$H8SF@CEDD7?A2CET(*YL0H>U]"1:>K
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M%16[)8GWXGJ2:H8J ,X 5SF;B% J1U0< "3!@!AC$G*^<7]>2B!3C$XQ>B=
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MW&IT[OLTWX:O?#[\!=#D:#]&:CZ+>O)?4$L#!!0    ( '%!1U:PI/5V9PD
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M2^4\9\657_>Q4OO9U*/_ E!+ P04    " !R04=6MDA]H1L&  #9.0  '@
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M#S'B.UV 70K>NJ8O/2:O7Q[_ U!+ P04    " !R04=6)81^54-8!  L<"0
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M!"@2PBH'06;J68H(N&7)I0WPC97:#J>VV9!L36&N=EF<P&W.Q1[/N<9GGW^
M<P&D3&,=TZTIX\"YA'<.PY\6&XB.]0S 78AQHZF);A4%)CR3+I7<.8HX$BZP
M6(.Y?$HQU=S!] &5'LF B0)%0(P(JE*#F$R]#<$BYI<0T+G('<P :!UDBB"(
M$3C&E=C0-&AO*=4*$R;H\@$]_=S!#.PQ<#2$$47>:%!?+!4@:*TEDE++%)U>
M'=DBF^%)%;C=S,IR8SFQ03OIXA2AP<(1B0*F(1!"E@>:&>4.)@03T8K:U*0$
M8E(&= 88OQ'P%><!84O%TL T[=S!A/#!2C@4*-?8IG'6'92)86Y308DV3(6E
MP6<.<@<3@HQ+2I 27D@(KK#VR@MK(7P&@^@LQ-,-U4B'5$,M/G:SBIS3QS,.
M-1G&00+P1<FPY,HP;+5Q'!DOL5)"!Q_P#,!=B'$33 CB2"J-\LP$&#$&K@?&
MCA&?&D.73RFF&CE/'U!F+$,Z4$659$ 9M B4*ILB$5(MK5T^0.<B<IX^T)(;
M%O-;J?6*$01>3!L18O$L!- >D^4#>OJ1\_11]<#Q/1=,"1JKQS0$TI)YI5T
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M4X:D40[^&U)EA-,N6+8TT,PH=S"I3D'8>,J=02$X%KM \U0Z)S6GSI#@[-+
M-.W<P83PT<;(E 0>*,<,<:(DH5)Y*N..(DHNCX6;@]S!A""S1!!I/;@F;Q@V
M6@%X3&*M;<H%TWQZD,UJ!! $EU(3''>/8HH9PSF-^[(1YU*BE6_(5CHD6TNP
M#'16N8/'-B_ $VM>@()SQ'-%):(,7(0*DB'*!14P]%+, MR%&#>C*4(LI30X
MSJS16GCM-;*Q]P-!%"V?4DPU=S!]0(,/-@U66V_C6D@"^#(CB8A;'6HCQ?(!
M.A>Y@^D##8S8QR;L7'G"*/ OIW4PC!#"N0]I6#Z@IY\[F#ZJ$@)4RN+R5\28
M%4H'Y*02B.F4&TF'D]N+#^84<P<3:L00HI(905*E"5 , @$/#T$#S:!& YE<
M&FAFE#N8$$P6>:.P<]S%S:.HT%)*)!WA&L@@LW)I8)IV[F!"^'C*L'1QOX1
MP*J!,G&(OZ(7LTJDBBT-/G.0.YA47RO-A:!!>,\8$TPKKJSU@FC!N<+I%)W2
MK$; 64&-8C8UV+$T5E[P%'G&!98T-<.Z@V'7@J78\GA&N8-'-R_ D^L]HI"P
MFI*@,6&I"-*@@ (52A))4J=G .Y"C!N,DB#,I$Y8RYBQAG P I8( ;1(&+E(
M2C$P9>8R75SMZX[?#14OK17BK-"7KS;BPN3=$&!PIA%XS #,-)"XUH0&1@!+
MI#0RF'@8:>0U(H$O$IAS$(','E#$K3<!44$48^"CI/<H98X%8QPB'"T?H/.0
M")H!T(+&+NHJKJJ,>[AY38.#Z%0@BA16E"T?T%-/!$T'U4$OJR%MGG2$4M?K
M<E#XVA4U/PZO,?QM^'>\R+UBHHE3'%FNI'6,<R^-2;U"F%D?)!'RUE;9\RPF
M[XL<1K)_];X#='ZCYZ*TG,5K_'9U<'7FQ_PVN.S,^K<#D),^C-+XL<_>ANL)
M&V=/RA3HE *F &G@GB'"E+;@ DS WI- \')B_(<V>:'[>7&UU-@Z'K320G$M
M/#AQ9+1(D90(2^,QMWK9L!VC:6>#OB^6&ER=>I$R+)1SL:F4-\AS(PWV@E&<
MI@O0_>MMUM,]F^G.=J_L%X-X]FT<B[.HIW[3F_Z^MX,BZV=^4=I_>:93;)7@
M!%&F-2B>#2;XE,56!Y0L T ?]M_EY[[H5;\<>SC6EPN)%;&Q/5O<)\%9%CQ7
M-B;J4DL0XH2RNBO.7//@N50F/#& #".,6TE3T"(6=.P;RHUPV!G&K IF*0#J
M=GT1CWBO8606!!C.%:'&"XVM8! >:&V9L@IPPK$+I5T"8&9LY2:'E2<LI%*#
M.W*24>:U1-P8G:8>2U DL@1855F<10%G%+V?%?EQH;OW1^_-CT^.WD/*C+$A
MQ:"(C"$G 6B2:F$<!UVE80'XA\Z*OW1GX'^[&GW\%UQ1%_;DZ@]_[CLWP1\=
MM-T#_E]61^!OP/\]#[-1EK[_IJ/+6TFF=M[S5VU=?/;]MX.>^Y;D?<^MVS7Z
M<2#?%OX_ [!&5P\,PMBAY5[4AC@1L2!\C&'.XS*.H)1BF&BI" ;.C QVVJ9&
M+I3LSE!<OEMMR$IVO[M9H: 0-1BJ>+7[3JJH=EQHS1473O)%B/LF($!T97<7
M4'8%(LYPA8'$>R8D5CCV_*<.&'T0;"&22BMQF9ZX8$.$4]X9#:$%QUP9+H*F
M&NQ?BC19@#T\%HUB?E\69R7"#^<OTL )0\*'V*\<I LAJIFDDJ7:"8472H1G
M+S4KPCE]$3;8<RV#317$^5XA2>!3_,QQ"-;\30+]:1+.E16>L A3DRI!31"I
M"$Q;J17C!F'E))$A=K59)!%>2<V4I,92HIA6.O76,YLRF2)//(4O+'72DJ60
MFA^>?5AX+OPWD6;-'-*6"DQ98%(RHTF<FJ%1GID-*VE>D=(%DF8D4@/DDQ%F
M8B@5E."(Q2\=IE[3Q<HD+00IG8EJ_4VD.;5QT:(CDDG/&$VUI-XJI .G6'*T
MLLTK ?I&IC3N;!0HQ.EQ"U#DI R2!QX+,(C!@BV4 *W8X0PL$#$ZE=H9G,9.
MUU2E*0*K%'N_>@*N]>\A0"M"]OV]2+AT::QFI<ZQU$GM/0M<&V&#20E"?P\!
M>@Y"]C<1())J9*E+-82G3%@OO=1""BVQT@CYQ9HI^9M@QCT1VDEC1$#,*:()
M<X:D <=6'-XO0L7GG-*.57'!<U<K!QOILK28"LVP,C'8<H0&@YG4X,@62G97
M-8!_*]F-G3,E]<)8Z9GVRH#QM<90D<:FREPME.S.%=E:V=WGEEWAN4+.:,>M
M8E88@SC2@GEKO>><+,):N)6X3$]<4JVD\90X(Q43(A@:($(0S'F#<"!XH<1E
M(2CFJHY@THM+8ZE)2@S1"$+;N/$VD$Q!+&)8&*+2A1+AV4O-BG#.P H;%YOT
MI#CVUT/"*2J!>P:J9"JYT2O"N;+"\R["CE$CF06I30FS.%6((J$0"LIKP^UB
M$8F5U$Q):DCL_V"D!G,'G!/%&54O0&3BYBY2*K104K,@]/,I?2I6HON5[>ZU
M$5R[H"UAE''#A2*IH@A\.?;(+93HSDY:5G1S^J*+E,.4"\F1#DR85$N"G#6>
MR)BR%XL5,2T(W5Q9W<FTEDB#IIXBB[AE<1=T15G*&1 ';05V<J%$=R4MSYT,
MAVA::8-!2B H\4**2"MY&J@CW"^)M"Q64?[?KHAP<M(<]X6WVCD+E).)-(!0
M&Z<H?$$YB-URA-B+)<TK$OK])!09PID&BXQ31JTW"*4^;E6LE$**+D)/R 4C
MH:L5 L_(-+P1+J32$&F9B[65A@H2M.9$<2X7*X._$J#I"Q#55#O$&;8",1:H
M#F 7B54(*T(#6JQZN;EBAP])\].;C:[$]^'ESU@)YH-5DGCF'#?!>XG@W\Y0
MX]%B)?)G*S$K,CJ#T,H:FQ)M).&.B6",THP*+VB@EJ?6+Y3X+@0975G?"8JO
M]%A)2FT*%V5"84,<2DF@B"H.XD872GQ7$C.-9O*>:XY4P"Y%3,0.9%@BRZDS
M04N;_DVB[U4R\OOK?82QP6JIO<4L]@MU'#[Q^+4DUBZ6R5E1KAE0+BH,#4)Y
MJS50+JV5MLR"_'!,*9$KRK42H&^$G(IJ)4(J@B @0$1KSV2*/:+&!+40^Z'\
M[3 #+LH0"4JG)&5!2$EHRE,ID#3><.+G?Q7ZO&UE^#S=)A@!G$PJG9:,:J<<
M,H9Z9"S1*;)B_E5KCF&:G#8I2CUE$.UA(IA(,6@0</G4,\-2E;(%Z-(VIQO[
M/L_N#,);8#8!<\P8#RFHEY%,<H52FN)%F+Z??[0FF%))&7&2$.:D9=QRXW2@
MJ0/&:C1&:@$Z-LW9ALK/TZ<RV,#B[E(I,4QKHSBB3CHFB0.E8GR9=&K:*$UP
M>1L6G@LB)0V4$<#)!RRT,H0$;J4?UAO#^#XW2D\> 32V,_1W;@_8&T0T[NP.
MV%P#/@XO\/B] :EP:6J5Y11<B4-*(*R$U$@*'DP]6P$.!3V_U#]I/+&,XSF9
MY$%*@9@*BSW3($_:>"P4D:D@1,*HZ/FUSF71![XY@'<ISC3H_8[NCBOYAS>_
M_6A&(-X!K(H;V/YNL>^+<_#$-_GN'_!-K_0+8N,5UAA#U"$="+L27BD<X+/7
M$$<:BMVGS:BJB(-X#3_,&^C#@=\?F#)SF2ZN]G7'[X;]?FX_CZ'_-N]T\HO=
MWON!@2L!B?*/B.T??_>^[E=I@^@_^E<QZLE[,8MPM_H\[U6/-GD) 2DH^IOP
M'+5]1;R%1R-\_=L(/?? H<-?OB=M)+5F2@I))&$@00;(G?>. KUC.G5-WG$E
M1?,L13=\] W!^)$I,<FQ%UH#G<0,I<% I,8P41S'U27(+)*=F31&DY#-T3SN
MN2\V0$+[\0%WS_IP_E+:&0CV4Q2\#!":D%0J;PCE!)BPMR9%M!8G8+VT-?PP
MM^+TMS<XM\0)@YC0QXG3C4-_0)S *H44@5U"*410SFKI$(ZI6:L9"ZF>@3@M
MQ+A988F$J @() :W'YMO<^-C9H<8D^)ZW" V0;@UKR'#8]7P=U]IGB]WSWRO
M[HZV<5QX_XA,P>(J(X$ ?2Q&_YI0W0I)?D"H)-&*.BL$QI*E/#4\52$FGGP@
MC"AQ4QE70K5H0O4$2S4YH5(^I9PB'PLC6*JL1 1):Q3AQFC79,G 4!$T!X9]
MC(&CF-4A: (,7",BG%5"Z#2N9R1:8.V014K(.&62SF]69Y3-[>C>K8S.P45^
M<)(/2MUS!Q=PM:NM[EDGO_*^$N3MGHUW/??QS 5)R!BN@^4N;O*HF=%!NV"0
MB]WEM4T97H!)_(T+7;B[\\ WD'FNR.29YA8#0\$%ZH'B*- A@"@HC%((:(DV
M=O[G0>8$D@FVI01C[KW@1"/+M% FAH.(*B53L&YF 39%O=>810OV@W;L1V6B
MNF$D"7"\CA*Q0+;36BD@6K-8$<0"\E(SI3RG@:7&X+  7:-64O$<97$01EAO
M@?^D+,7.*&&U\A)KRIBR"^!1GR(5[P>%/='E<@K%Y$R%"R 0BML0K&)2!644
M5R88)PFEGBR 3U\)Q>19A3;883 3/,36F5A2'<T$!H?B$#$+4);T "A[ONP7
MF>U[]_QS1A/<U\_IV/Q1<H<QLR9N_ R1D89!,]CZ16AB,@=P3+(5O*;!&8DM
M29EU6AD8K5@G0 R1G-2E @B#NVT-/\PK+G.7$ZO2/.A1DVBW#OV1230(7AFW
M#F'0L]1;,'<0Y$9_"/\): %V,YGCC- $BV6-@XA6BEB*R91$FFD>(DTAH'0<
M+<!:K@>IRKX_A_]XWUMXD(A2(@1&@#HZP">&G9Q3S01WSGNY #M SBU($R04
ME&'JE$]3;1EUR&BNA3=$4*4%;HI0%F.Z<MXLW^RG#1T.2"/BN:6!4<.!)<9E
M!C9E,K8?6<;YC2>$=?.B@DAY'Q"G0@D'G(-+ R0D4),JH0-WB^K,Y@*E":Y]
M0Q9A;RD$6< V2"0=VJ>.!PT&U!N\S(;R>>&:O9U4*@ADN5:",@9AM<;$6"$0
M"M9[[4E3B=E@NU+%[R^+?"RV>&+8IMR#B@J5FKAI1DR=<(P$!.Q,I I 7B"]
MG57J9 X4E&AL)/(B:,S \AJG+$TI3J4)F'@Q_T3F%G;UVIO>.4#GW2T /_2R
M_K<Z3<T+=Y&&6\53[%60<:6=829"991+!9<R+*YVS0"AV>N9=-+HU,!_/&*!
M8ZDDD%.46@H\1_(%AG.J]1VS!U)#S.>!OWBL&(-8WG A%)A*C!GWE*,%8C1S
M ^1,Z(NS@@6#%2'&,Z>#IJ!VS'@,UM98OTCEY-L]FW?]:)[AC]Q6DZ%WR(R/
M_:PV8,ABOZJ\6G>^=7GV/ M(9Z^I*'91P0993&G<G4 I$X*AP%JEQ*E8)$V=
M>X!GHL%6IE@SH*Y2:H8UUUX0*R5Q0CLBQ2)E6!\%\#O?\X7N +X;KIOU,F!.
M.B99EUF'I;#:62-C)R1JD,$V<*<\(E03Z=6RZ?!L(9Z)%G/EX@(N&;N108R3
M&L&-M$8K#]R8BJKP BND\+,OEG@JLM]H +&7']MO4J='BT_5,SG6"&35:MM;
MQ0-U'XBL=SQ:T?.L<2Y6+:1:>!(K11R23E$.J*/ I)&*V1! ZY625"$WQS,I
M<P!_W4WH+O;OBSQD_?T37?CW^NK9Q6&2:0\?>ZD11VD DY]ZC40(F'-NO'=&
M+4*<_ VYV,[!K"^CKPY4$>FHT#AUC*?$*!D,@R\LCSG_= %\]1Q -Q,?+)QA
MP6D5][MB*=&:IMP[!A89.X?L'->B3@"QQ73!DUS)8B3"&*?@;P6#_TJ>.AF"
MH!!%$>_3!;"YHY067,%EG4'DS->;2VQ=VL[ >?>VR+MUA]B*>N^&+5WT +'R
MO2\J9_G;U?T7F'6";#930Q9[A:@$@H883I$D)K4:,Y #(.END>9NEU0L9N(K
MJ/&&!ANWC+! V+'&L:K&&H:DE%JCE;7XVTTB$^NI9H2 X\",JZ" /:16*@(4
M0@AA5I9BEB(Q$RO!M)#.&PCF8UA/M?$2QPU!E%+ *E*[LA)?<1[+:".L01Y"
M"Q)GP9F1,BZJES:5%*)#XA%?V8C9"<1L9F^X  8AB*>QXP40"!YBW]\42X40
M\,SYC3EO9O0/].7&H'^2 XBW]GG9A%_+?F:K^+2X6I!HT,6$F[<D)MPJVB^(
MCDO:E9"4!;L ?0WF"9<)+OI)+6%>< C2'5,R-8$(08Q%Q@>I-%E\?:GFQC9Z
M+DZ-=7X'JU@Z($F+T[H'6X=CFU #T1$32&AMC"0HI3QEH%4+L(1X/A&:G YQ
MRRAVE!)D$1,FU=JCV'=38,DM474G5SHD(10!>/,*5>SV5^TNUM^**^;NZ8UP
M\X!GIA#T\10"#@4&FCZ50KS,+E\5OLP'A?5E_>>)UZYZ>)>=O_X5_M5D* 2B
M0BB&6/#@L:3ARE%L*/9$>";23U'_KL\I^U<=@*^;]5HG/CL^Z;]*U\E9_Y>+
MS/5/7F&$_O\7U8&O?RW/=._UKZ9X":?7G^NKW+E6?.*6[F3'O5=Q(5RU9T1?
MFXX?'F#R IZ\9?-.1Y^5_M7PPR\N*\\Z^@J$O)/U?*LZZ9>N+H[AZ4S>[^?=
M5QR>[=P7X,!TI[E)=;_ZY^:QE5I7*8E/WH<!ZKOAC9N76J]>ZF7?W?U-R76%
M'OX9K>/1;R^K:Q?# YK1HV?]%]5Y\%)QE/[Y@KZX]=[-F^"S?E+FG<PE_P E
M^:7YL9^?W?[E3#L'%/H52G!U\>N[OZQ&Z#XXZS&+%Q,P8/<A$A]N>#@\:UZ\
MBC>+]PL@=*V@NUGGZM7_;!29[OS/6JE[9:L$X0SUSV7VQ;_"\=K5GQ>-Z,#9
M%7+-8& 2A_+#SO;!UF:R?[!QL+5_4W:^(373>\;]K3<?]K8/MK?VDXV=S63K
M?]_\:V/GW5;R9K?=WM[?W][=>?#!;\KG<PXW>M2K?-S8_]?VSKN#W9VU9/--
M0A!GZ@<??KK:B\6ZH&JQM/?[=71LZ.=*:]_N[K637\'/]/+>SJ +%[%)XX[V
M?(C5:98A1S5A&#X%YZ525EJ,'$2RE)-["Q"3GHYDP?D,XA [Z#:^^T43?-&_
MKLQF?OX'V3L_I.V!.]TZ/WJG3G=/VZ2]V28[IY]1>W.O>W2PUSW\<I+M''0^
MM[^\S>"?3OOTJ+.S>4C_H#N=PR_YEYW3#?CGD.]L;J"C[@?XI\T.3S_PH\WV
MY>%I^_+H8)L<'?Q)=K"\_(,<71U^M&)W\Z2S\W&+M-]]8+L?C[H[<*]V_.[=
M7Y_;!\>H?;IUL;-IOQQVV^?NW5_,_>OWSA'IG)O3G.V^^X /#PXOC@Z.^5'W
M$.V\.[R []#1QS\O=S?_O&H?;*"=+SO9(99?VJ>'%Y]\2K CTK=\BE6+:29:
M&J>FY8VU<3XR!!I>O,:H]>_*VU^C\'JES/.CS-,T[#_%MM7);L__/)2 *;.J
M=)VA!UG5.!ZW?R/KC,I'(?DD 1'K1)"G",A#TC $G)Q=1LC'U:;CP]VAR<\>
M;XH/('HIDQU_D>SE7=U[K BPVR)0J\+SV^.-7F^@.WO^+"_Z+Y*0%UW=AZO#
M@$!<]\KD><?HN.N)R2\7TFR_S<R[#Z)]<(C;<(]V=XNUN]MDY]V'B\,OQ_CH
MXQ9N?_EP>?@%3#D\2WOS<W/.7W OWCLZR"]W3C]<M,&D'QX<7QV>'J*C@]].
M=S?_ZAP>?/BR<_#V=.?T-[A_^V+W+WGQQ\%&O[V/+O\X^,!WX%D^2<4XY3$&
ME%:T&%>H)346K9"ZH)VA'&/]XO5__T.E3/SRH.5OY/W'1;E6\&GQTTJ&-W9V
M/FS\D>QMO=_=.TC>?]C;_["Q<Y <["9 P@^ :2>8)KM[">8_N9^3W;?)P;^V
MDC%^/N+F&V\.XL]8479C8.:4=CW.R+_-BZ1_XI.0E8!2<N5UD?B>\VX:7.Q]
ME7W8JG,2-Y3_E8-O6EVXYTD\K>7T52L^6\OW%M(*?#=YNVR??O[DL4684=IB
MDM@6,U2WM#>BQ5&*$?,VB!0_J[%^,R@*P.MM)22'@,-C,?M;PH5X\,Q: $D)
MUV*.T99",:MJ2"S\-"I(_^+UIK=5.O"__X$%^B5F7&\:W[4D(O%4,CX?5F5W
M[Y'/.?U4W0^02IZFST$J0=GFG51^523(O%#)@P*>+XLS),M.)W=.M_C1P6?>
M/GU[ G00SOD=CCTY/3P])D?=K8O=@ZW+G2]_PKV/;]-)TC[H='8//E^U/\+S
MOSL$2@I6[-U.MKL)MNU@@[</MNC.YDFV^_8>.DG2$%+"2"O6IK888Z$E?6I;
M*=8F#:FEUJ4-G63+22</]C9V]K<KWC@?E++2O[FR_D-.V1_I8U+/,R6AR+N?
MFO\E_7SX\=/4L_2/>Y%J^4$9IP*3MQDXJ9UJ2_)7STF-MZHYP'BW^F8+::1^
M*%7YY9-*L2=<^U:*)/ G&]*6-@8"5XZ]91A+14F<Z<4MJD3<0>N[\I6W]:;Z
M>Y7 G-)LQ&PG&YY=@??\<;6<O->/:Z3^?DI,/\4MM5)D5,L'Q5L,$]%2#@-3
M(-(J$2Q$0?;%Z_=[&_^[O9^\W]MZLQUG/9/VUN;VF^V=K?VU9'OGS?JC=?N9
MY$D]+E.^=:EM/XE0)WE(KL%/=)GLGWD;RT]<DO62K%\F;TYT 0_X\\I.+8"=
MFL<Y+B[7*1+?,_2$KW/YN"F,IUR6HG5")G]9AM:E$M\?&XO'A!4UAC\:6'SG
MK,O](<:S>Z=8>5A A%S5S%=EADUU[IO<^;M1<QF/."OR\WB=!<WH#>/F;7SX
M99L>?CG*8MP;O1A<XZ*]N<UWR.^G1Z>?KW:Z._!\AW?CYM._3MNG[G2GNWUU
MM+F%CDXWP"-N7+1//]/#[DYW%Y[QD'RXVNG<$S<;Y!&SRK6"D;[%!"<MQ:AN
ML90R90+V--4Q)=C1%[KPDPV<_XX2?J OMYNZS[KSSP)'4],6W>V;HDNY%PHK
MW K80306I&R9U*8MPJWG2"'%!'[QFJ4MCA57[.&,]=+9Z9\JTYGD19+'9@7)
MZ5B-=N2!V;B9K0XKCG4O^U+]_?/2*?5/V^M[Z_OK2;.8JDAN:F"RDZ__?)\P
MW&)WF'^%WMW+X)[GT.\7U:]F*B<3LRR6-=YPKO!EV?SG#W@ O++$W[+$7VZ3
MB#_H7L?_:^_JZ*,[,X2)W8/CR\,O,#X'A^CP2Z>[\VXO.WJW?7GT<9ON;K:O
MVF3[R]&!I4<'OX6=C4_*"R&L=RU/N6DQ2VQ+I=:UJ$%*4>&M4/S%:Z62?X%H
M)/O]POO^W3G)&<@*6<G*5&5E=^,3D%1MM5$M2Q#X? 0^7XKH_84U,A#A?/3Y
M%/5/DK>=/"^^GJ996=Y96]XW\'&W.,@O5L';-W4)?5N7+#N$L3@\.#EM'WR@
M.^^VXG-\.?KX^\GNYN^=HX];5X>G&Q<[W:-H=[FC@>M4MG3J4(L94".-X9-4
MB#%)9!J4?_'ZM[SLY[W9V=N*RNX6[R'*!]JZF!GKQ143,+G*..*4""VC8HT7
M%J:EG18MX]/HM5/+'(A)>^.'3>UB!!/3DOOWH'>Z<Y2=U:FOE=1_4^IOI0=,
M"-I:"D8MI:+%F 6JX"1J<2^%96#ITB!?O(Y+L1^>J%V^S$ C73$+<%: 0<W.
M="?QE]Y6;4C@:XB*?;F$.0#0I"2JTCV1_K3G@A\W=W<]6???_Y $I[^42=]W
M_-E)WO-)K\H:KL5,3F<084ATX37 Y/RS5H%$OK8!=UI8H_0CD\<?R"=&*./"
MB!8*%&)5Z7W+@$%I.8VHPD9;@<*+UP*GMTU*ZQE!J?HPO(]RL<#)Y!\"AGY"
M"A-!.%C[P&F+.65;BG'=0K$](5'><\QB8 CTEHGOK<QYY"*)U7SWS.:[IV:=
MKQMV)45EJ'WA77(V*,I!+*_HYPD<4667,?G)_!S];:P\W+#]5X\7M@7J%T'I
MNF+?5X7^]=\H^[XSO_JP?!T1M2 /2T"_V7.O[IQ#QG:0]3M5U9+7]B2Q'5V6
M3V"E3YA<69#A*'3%\_:ONB;O_/0DBKYT@S$L:*M$PU_:$]T[AB]ZR<5)!M]<
M6^1O1W)W/-97&L\LQN \(]-LO-X5)J92SX5DFG5>XNC@K^[N9@>.LWCWX /;
MV?RM"\=>PK'H\/28'IYND)UNF[>[V[?R$F=PKT.XS^'%SI<ZU]!^=PBL= M8
MZ5ZVN^FR]N8A.?SR^>JP \]XN^+&.Y92;ER+0E37@FB"M61J6,LAI*@$8)Q2
M=84_R'/5]W,M.=-%<JX[ Y_\'[0.TH/CNH6D//FQDIQ'F(653GQ3)QK#7-OE
ME4(\0B%N)>JDIB(VA&[AH%6+>:5;)J5Q_E<;KK!/:5R5&@NR5[(^)_9_JW&Y
M]1J"VV69T2$O?$7F]-3ASYOJ$&RJ4A=$2Z=!QHEM\ \ 24OQ@)PQTFAD@0Y"
M,+FC2Z?_D[SKY$9W(-[L0,29Q-XX=^LC'DYZ3F6A;14RU^O)[_[[ZTLGLEXL
MUGJ%9:6^SQ#?W_^P3XKOCV_$]\E.WO-/?:G[&DK.R5!L]URLE/.)N4KLB;>?
MDV[LOY35;UQ<KRG)RD0G%[[3:7WNY1?P<%Z7,!0.?B@',5NMR\3YD/7J)2=[
M XCO&.+#L1L;<AC&]>00/B1)LV0W>?X)YX_PY/^.#[[?//=V]=@+:<.^.YM*
MVW#?W<UM'&W1[J:EGQQ&6M/ 6HQ:U&+.A);RC+3 :0>/K8O[P$!$EM\V.4/L
MQ"_)WU09>GD?OOG/((NF RQ&B$MUBZH#0'F_*:&Q&'?T5[5(^]JP-!HQ4H@I
MJ,1?>6?0Z^NB6O=;E'\O58@3"^R3U0 \#Z3EE.8MQH1K:<5MRUKNE=!(<,+O
M%_]1[ZIE%_Z+$U^5F=_2@)_PS\D)F/PH]B[1G<Y(]L>5POCF +CF33VX(?]C
MSF%(/J-.Q)]CDX+$P:^]X^K0L\);7^7*,$FJKC]E\A-<#VAJ4@[L"<3->5SG
M.%S[WS_1_=O/?J'+NZI;G=R\P\_@S7HN^8G4[VB [,+OYC12,#B^.A1.BD_1
M7*?:"[!ZB.HA==E/%$J<OBK7IZ#)3:.DNO](#%?[NC_X^RGTX>4GK+A6,(HM
M+(-M,1(;SP416C[(U B) V/@S\#4/JC1T?3NY"-+?$=5ETR/HWR#:'>S?A^4
MH8HRBKP7H]W.5>(A\KU*MF,0K&U50K*I^[KN2G%+S:^O,>[[QEG@GC\>=.HU
M&?NM@^2G&!^DOQ!*UD<T$=PJ:/]97*;\W#I?/^](E7WY\S04=6PHXT@V>OOW
M4]2K3X1YQ'Q<W^524%3M5$L;!#Y8I!ACA@25= J*^L#$\T*H;A61=> %?**M
M!=4M=-2_*,TQ'.O=^RWPUE[KWA_*+N@\W*48>A&0_RZ\^=5:]-=P.7!R<;".
MD^,BO^B?#']>!_?MJV>KPK^J\TY5@A8KFPB\Y@-/6/V,?QD>]LT#'GZ^X8'1
M9S<'/_"LPR.' 2HFID6&+&2<>JP_'-;<V$#B+*];#;TJ?+1MY_[.EA+7"<A*
MQ-#U*=J4P,#[=T_YUBX4];]/BNLTZ+%OF<+KSRT=P,"\TIT+8!XO7C[;YA=S
M4,SPU8YZ7YMRQX\OC'G*93E>%\_0J8^0=9I.OLD!61?\<=4,D^W_-\G6:=^T
MJ17*?]QO?N:[*]SC7NVVYUO@5]GXN^#S]%J[*2X^_M'5<@N$S52:Z15O0*"/
M\^+JGFFTZJ!*U&UST$+/J.V^V\O:U3W:7XZJW[<N#[O;Z/#C-M[9?)L=G7:R
M]L</N/UEX_9*$';T;OLBOL_AEYUN#!3:!V^SP].]$WA.U/[X>W?WXS8\YX<O
M[;?RZKKBPL(]/N-/ 7F5"N);.-6NQ8Q +4-P:''EJ0D,T.,^IO#N8;V+U2GT
M"39'+(5/V'^(\"_#RSV[_:E&[[=!"7<NRYL=TT-VZ5VK7PP6N<1K>@:G?:L9
M,1%6$Q]:!AO2 HS2EJ8!MR@VCAN*4XS\X_:V^)MQ@>=YDKG5\*W[4Q KX_4(
MXS4<NW?5T+VI1^X^(Q9TIUQ9L6]:,73'BDFFF=4I:]F4ZQ8C/HV[1<" ,N%P
M<#0$]LB6ZH]893FK=&KX2MHR+J]\Y&Q_G".I9D: .,9I_WZ>#,HZY0EO5^];
M<T_7\;RH[M6YBC>_R.#6<-NDYR]B/K7PYUE9$=&>[EEXTYBBB.T0X\%Q\V.G
M"U<FL?]AYAXJ3J(_Z9_OSUY>%]8LTOP5YM\U?]7,03=$,:X4B)E@W>_[V$,R
MCA0,6NR!V]4]?5S-U8Y6W>JR!'X4OQH.I _!5S,TO68I=3PSBQ,W/4 IVKHB
M[R0Y&.$Q\*XYZ@!&[;K,@R$VMD!L7Q=&PV5;NY<=?U5-<?^$>?)A?7_]S7J2
M$A%7D_T<7_SZ+9O2--,!0SLF(B$KNO5$UQG<6\>#0*JJ6BQ7/;$>N*S?/-=U
M-OMY2U;O!_09O<6V#<5&?-&\V+B&^VU''R^7L_B!G8$./J"=S6/:/MT P_^9
M[UQ\XIR*E 79(M[*%@L>M:3WM.6Y@1$WW)HX1_XMT[_0!2^UH0E)>5UX BKT
MU,6>#[J0<5MU;2.JAK9UH4A^MZ*L6NM?UT[6IS7E):$J_(U?V;PH_*C-8_1L
M11$+3O)H LZS?%!VKH86X+Z[/MD*/&DOB_O'>!&K*![CA:(GKT#,@0C4.%S#
M,Q2F,< K2SVJ/XBNRN95<05XI,Y5F95-Y\Z8%CSW+:,C-XCLP??*VH7%&@CX
MJ2JE&MU]7(1&+NUVPX^B'"^F*(#)G$>)&SU"PU?&);ZIS6!H':/-%@:QGR?A
M64B3\[T3_.6)[W2&I#7YZ9XJZP<GL7]NBDJ?/]<4GW$IH[0?JG(AGXCCU'"L
M6]Q1%AM7Z);ABK:,("G':6J9X ^ZVAL%+O>4FLZ]M,=E+/KX&"0ZBGRW6KO2
MK'0$:;7U(L@R+H),0( JRU95IX3H_."4>_SD6E*;QKSVDK:3E]&PG<%X51?5
M];K).]>'#[\/>CZAJ-[@,*G*P2(WKBUJ_^LK;N+Y5:E8W&RRJB739Q":768@
MZ!Z\[O]I5.QM5=P%!P]Z6:U@@]*]N*5Q.B422Q(0! ?44>58JH@W00?/A-"?
MMBN-$Q2] %6W<(M.^<\7+7Y7[=Y74<';3J[[+Y*X1Z:O>E?]G=3L<N?T3QYW
M?MG9_!/>:^/BD^"!.<=)"S/N6_%C2YDTM#C'3J16"$Y<W'&>KLNAP@U1>YV
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MIP7M>"/]^?3A^Z.7\2C>YH>IQC@Z.NK>*=87C*&)JDOLIWA<?3,K=C:Y0K:
M55JV"^\$\UL.OCU@A(N:U]=&0\B&6ZVM!/,D0A%IT&P)5[!*;0'/3I[]?/B=
MV0IM@689-/ Y#X1LL"<ZOX/O#J)&/#PXB%S$(?!<@D6__.<:."S+F!?35$?J
MA;7J4UEP82&YEF7AT#JOTI V_%AG]I;LZA_ZTN? $WSN5.*P]OCF :U]'X;R
M%T,E?(J;FAI61Y^]BNS' B8(5W&TZ\4""3ZKG;=87I_Q\P\O;;FX&+7-A.Y:
MDW_8(ZE,KO&3P__OXG#_M^7%_R(=L]KVIU1D'7UWM/SPO2ZE2B/<Q"O81]!Q
M\EX>@OQ9+^G7WSY=?L"-_K0]D;OW8GBM_V]10$<'HT=_/WG][O"QK'O !Z94
M@*Q6?SGY<?2CI>9';\]?_CD]G>\V_O_'5/?HD6C;QTZG/GK[?U[_='Q&D_K?
M^6+Y?="O](>3UT?'>R_K%X_5RA'\07^R<.Q?T/B+S>A4^?=8 +Q&KLVB6="V
MKR1V]'-!!^;R7OJ5B-"]12"A('M5%N18X^JP([C?[;-HW/PA+^SS"XM?"\M[
M2%,.-6PX?F9A>IC1J;7+9CQW5MV6?=H?G1<3<;#0%B#T,F*3=RZF%S/R3;7^
M.H9[X#1]1:<,0W&@8T0!M>\D()E&_XSAN*H03@.YL6=JKVL)/KF,Q7P:.KK6
MZU7+,)1>FCC,/2R(F5#LJ0D>63R5Z&L<SW^GQ5T43>#]UH]D@]'$<3YY?]'4
M].X]W>09_^_[/S?,F"\V-:><R'[EUK*(4Y''0Q>R;-E5^_RQD^.7;ZWMEM%5
MM1(6-$N[;LH+9+C$^VK1Z:AAIY87<'0I7G<^G3)]>R@U$DB-^91CS;%IDFY2
M<@O*15&LM$P89>3HXVNA0?AA7.[;KG'$.(#&&/EPO)AD&XZ4G(DMR!L// B
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M??'L6*:'M\7'\;G%KD/^%68H2_$^)/>>L!%.O7_+*#-I."7E%^2M%^_5MN8
M>M$JC*5AIU]S]3,,7'**(R38$U=DR^"L7)4WB\9"9U\785G4"!;,>1WE&$+(
M)Q2P>=P#/S-_@<U8.)<+=<SCY]OQ%A6VO'[OGK\[/WZ;C3 XD,=RZ6THW#3P
M@YU56L=%&S..\F5/ &]LB:+%WHYV7)2K!)RQ2KZC$/^L GND__N5BUK8<4)1
M5RE%-1\CIL.411"CA%ID<?$))/$2SQ.Y-2"9&4=:U16)OB7]IBIH.2?N"69
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MK!VA9\F>GR_X!C:]0-"CSPLD'-[N8O_BSP$TWL(KBN[8C&A&JDOBH7'=Q1Z
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MUG9Z$T@RF*<VE(K.I<T#?5;2PZ/&6ANE**N0G4J&2](Y9^,H@* Y[4#N> F
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M\'F_>R)BS'[WW=$WV>%3Q'%OB;;>*.UHP$#I\=PQ^E@V;&-.GV]*GPS%-^)
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M-YQ)4LY)JJ^8MHFEEP\  /6L'"^<95"]HD.].7C0,U!)XV*1:N6>7%=26EP
M1MOJOX(VN^)SQP1'&2K4$,%6%D&9ESD=*J=:LO7Y.I.: YR$$=' K'$G"<GX
MTX]_2@AA:Y1V:\CLJB0E\_G#&0'3T:XO+F!7D<E!GBZ[8$RWW+XW?JW@@I*G
MWQ2YA*XFP-$9Z9GM97_SP$3$5U7J;NU<Y*%[2HA$U4UR1D;CIIY<DN'_L7&F
MW8R=)M&E !XWLTM1)/E&5AA&E*/9[J7,DHP'K;WU$@\Q@9@(RNU"Q910/_2:
M<V]+;BSY0;(K8H$E(0FQ\_G@D%LH5V_.D0\.CTW8^!\:O)?8 Q.1*%<HH%$R
M0TQ)S2<<R4YZJ]SF[2+<(S.)^O,!5_'#X3</N(K[,)2_+J[BLQ.^;&&4(E$4
MDG-)D!/J9Q;0XI%L,6_;>B+DH_P0;ZJHU@/+B%#XBXF\,V[12>Q+)W#\U*C,
M'#W%NEUK_$B92YSO,%!6+!EYV(2!0CM^?M@#"MA-0>%SVA5^%JTNF1 T0?C4
MP<83&I8(Y 1Q@1)S6QF[]#KPP,FD0*'RR.1_@B,^T']T#TZO3$' @^G#[;5F
M"4_RI5U0;5@E)#HR 'S#J@[&^8HFWW;=; Y-#:4;XZXD*VQU$>R^JW''GMJ=
M"AXBR;+#6W:Q-ZRKETW)42>F%L)+@NU?S-7X0Y"!1J#_#-#;<$3"&@4EO/+9
M"5?X,<"@HR2!AB=.C! ./97638&;"DBHN;TLYK/1O)SM#(#CE7?D0Y6:JS+$
MTFY!XN\(VN.X)0]7?!#.HLW6\X$@?*"CZ,*LLZY3[''4O004>\,IK%K2^NS.
M=/(TFKAU)S!".B+&/&&VB:5(PD CAG+DL1FZR3"L;TNW:]FB(JE]8$=(%G%*
M>M%:YO]M+. 4JBE$;K5=T!Z>GZ+'\I3&R!W ->TU./$#ZCD?7>?EE613BP_%
M0KM>"OW7_G;K^I[IPG>Z\BJ2F.0_1,HW=LF4*8X6K/4H;Z$D_SH!BL=5S@)[
M"@LJE<L+WJB9PDJ2L'G 'EX6&STCB!R7HD!BU]I08Q,VZ\I**&6G?9"3??QA
M)4SB,K2>D#$& ODP1 [H2?>(*^%WZM3/!N@@+<NTR:\K92-*$[.*Y!H:A@S9
M?\$_W@C4W2$U(H4(=N"KPQ-HD4[WHW\CZ8?>,_G3VOHK;(8^BIMDC2YJ+6TJ
M&*^SNFP[-.;T-R[/HD/)#^ ?#K]/.@S#Q4"XLYGZHQ0768EU)#+2*M?<HB:%
MRA51IL%9G98?>N-0HG_#O[G7,IE=N=KTSL6T+L0?%B^.S(="G&V>KU+T&1I)
MQVPVCB9;Z<9*#'B\44W$QTQ,D"UGC=ECR7D/35^D!*4+G+,W2>>892UI"\8R
ME!7T 0N7=SB/3@>&;X5\YRI_3],\/!C>N956JPT?!(\A?22;U-G$QQ)FO'D_
M'EG[A60C'NN17*4"^;8C:?@=!./(AURN+@<O_\[$O.TTRL!;5Z0?Q.&PZG0R
M4JY.*14UCJ-=FGE,DX^ZNF6D^02,N!(@1%#F9'<;7^@T<&ARV.H2;7UP4]IP
M%-J(D_:%RP.&0RV<F=.0ONY;X?LCK;@3':]]H81>TFJEPMEF!+R"I+N3N^:P
M;>+PI%/LFO;CV]X+/6(O\^;%8,%N+FW!(X[,8IAQB08J>5,?:V?.\'!]@NC=
M62'P/:]V)'C:9S](XK+Q\R).*W)FE)VURR:J72I'TQ)6 BHL8A4'B/XTT=PX
MN-?QT/M%\="R%7-!'$7\GH+U_ AEWTNKQ=-,#!LI#+L*7Y%+IA<\"QGQ8"@K
M2H_Y'1> HZI>8.'O[V[B!UW6Z_F4*PPLRRJ)) !WKX5CU0H?HLZS"#!SN8<^
M./ZUK>KEH=T9H^=[;%'=BCKJ?G]"!AM:1FRDIF21OV=-4$RDM\#N6<2AND)O
M9X\6EU&(#B7#Z>;2L&HC<>DO-IQ..G_^ZFW&R-9L"^8QY\_P5EG!!Z,?JI01
M0B$/:4"H7J]X2D+] LA+CU!"L)-<4NZ_&0,>X?4!86H34%)[(%IR1:,"Q12;
MAFD\D->C&S?,26V0'P;S7H?$+=N*F%@'5@JM#:*>B-A2/FGV@):['F(@ZDJ4
M39B4-DO@RV' 7/Z>[,7%&I<MBU4-?+[7E?V=>RID6@3-.77ILJ#RO)A'9BI=
MT?AB YJB34Q3<E0GX:35^%3$.4;X9X2M\MH!ZK.(A6'D5#NSU1^7M'A ["PY
M82XTZ)!+$]G<V.DC8P@OXT+VQIL]_!?07F[W- NB'-5 6,G6#B<CL_F$%E.8
M"#Y+YT@0?-FWJ[+&(^*$6(NS'>Z@WZ^5T C!49M2.0NAD)V),*<]LT*QS!F=
MR!R'9'1NR<;G-#.Z:\<3#GH<'1P\87EQ=O[\F'>3"Q54RC>%8;JQ^(8R8:><
ML=#+I3^G5=P+7*T T19IT^&-T?)_DQ.1;,T58WBY85@I\FG*!4>2(G4%(LE<
MRC(GX8BK%&9-9R*"U8*,,F:!:1V8C#LU3['9W?"C%-T^0,;3-XTU%F2GMND'
M"] .NF@:\7[C&[O0$P9DU@*YT&XJ@N@9GJV+3/#U*-C_2XOL1N2\(H;RD)K]
MX?#;A]3L?1C*0VKVDQUI%LK.)80<1E.P-O1<6'G=/G7F2,;T[UXT60*3.<G2
M9W3H1Q*<291.CBAFAUQ.#C&;S:V)OM<*M5.EDZ_2S$9:_UT,T^]Y7T9H^"H-
M.SIV. /]H55B$YZWK>]6%DJX_IR*P3OBW3X_IBM)024(\R2F0G9T87W_)$ M
MYU1U(!NU(:"KC<9-0TH#L?.7XM%WOAF,I/9&$BZV8]A'"5:R]HX8=]B&C#$\
M?C#)+1UC)&+/3N7[A3<(Z,IR#F.BP3<]LER-@90#RX$8M^H9^^KX2>V?F$KA
M*+O(0,XI+V_3F5WET/2]]<=O9/1B=&N3V=AQ/ BC> ^"6R2Q#04!I'D_3IO@
M%394>DDW1J1W;I3K4\-4=5K<;!EUE0AF<]8'+" Q>.U('CI5 _'"_Y'0//M
M.2\+-XFD=9IFW8'1#":7=2U]T_446PXG;C&]$<AFZ\@X>"*T%WPDUG!'W))*
MW=U6-PVO3QXF?8H9OR-O3M*K(20;^ E9VMFN2%R5CT7_/NZ/GI,;H/<E"81P
M<FQX:>.SUW,4OZS0CPY+A[#0M.CM.&]'2-#(*'M=FT--N-_SW5%AO(QE=++5
M_6UC#46&\!!6B:NE;'TDV#=$$9CB9P*7]DA;+J%AEOM:-KK.N:I5:M'H&N9K
M8[ZQT$DXBN9)Q71^\O"TKTQ &\3KMZ6>(>N!8&:" S8_U#(%X6V!B ](^>:J
MH*/*#M,2M0/Y0AHONBINWQ5=&Q19WZ(A7I@D8,,!5<9P2T!'PJ-II(;#8=(/
MOD#+X[)=&-^&Q2W$'T7*T!K4HBI+NNCR$$, 3<$,&A>>E0$WE.YLFMM>-M)8
MF8GM<$YL"1-%Y]J?6^5V%SR"/8S?"34%S?!"D[J3BI\@;-D'7FV6@N22_L^A
MY#@<W+ A%BX3@DW.]R:G,S6G['$2% @R)I1H<?PA(DHL16YK8>>FQ[6[!4"T
M*R"I-\T2H 4V8:Q4WXXNF17S=5M>T0':$3S4+R% IO-"8Q]IY>,MAL!)8*B!
M@!CD_*EB$>JX- 9(D("[U.AJ\58M55[PE;@7V%"MZ:-83+DH\BH4"Y36S9Q$
M<'%M )*C@X.,%H</\U4Y76LC!$R@T^8H I2T3#MD9%=6=%+5"N]GAUJ0MQH6
M#@Q6=&^92RNT,=-ZM_=2WY"N4&#%'&Q9Q-$\7_7&5LK0FK"-,!:/Z8J+4CGW
M'SK&.W'U&):Q8#8WQO<A;FF]Y?1J+E:!,#$9&X+2]H 2-1UDAIE=%JR7I.[>
M *"AJMU5[*'5VRJPB4113')?S3];.K9X=,3<<$S)]4-?)[:8HR;/YR$X.KB"
M,5192F][%HA^&>#2"^J"@:5./(Y4XSL(UO;CF[SH.F\=IT=:<!R/N7++\>QL
MSO8I)U;V[9X._(VOBK/E[?+Z2#\3\8FZ[Z9[5U;'UJO!QB^WSK.%+A2" ]T^
M*WY+KH%C-1&9T9FCLU+#'O<+2Y6;QN_+N*GSJ4D"3L.F"XYKQTF[]'U)/TTU
M^J141Y!/\V(ZN.Y^O4,>99QW@CV5]KRWR;&4#7PB93-9+T)]:E)#E'<HD^(]
M"#NAG49=:]%DH]S2( A_B9RA4#B9)8A.Y&MFAFVVV0IFK'!B"C.Z@(@J&E>O
M'RD1Y#&AOIN6\C<Y)=&NBZ4*G*S.7.V#B2E_V?GD^)76++I1^S%P3$VW:8&B
M7A)XC-C!$V7M?;9VF]1CHHK\ _DU!9/!<T=9W:6DS61$G,94VQ!$M7<]W=NR
M$>T%798FBWX6+=(5 )> :TR1L4&FMV1A0SO7 /_'TFR=4J(XEVR(%%V11+MB
M49UC&V)TU"1-U[CJH-E&5S5)[Z+9%9[!4]@IAT<9 O12<QTSBA%I58]RYH':
M-ED.+AEG &Q^.ZW#:S@@[0S#J%X%KI9'DQ75I%ZC^ZEOK8HWQ4[$ +*4M%87
MQMLMZ.69^+3PC&S+$L/FYJ'V^)@L=1N'FD70)@GZ.NH)'S)QR%94].HX]==J
MIPZ/P$Q6: +K_*R5G[+XZM4+$)4D1E$L9,U,;?<0EUJJ'"7Z8K#"0L=<DF7;
M.+G?29?.S&(>N"I>T\IHQ!+=<HQXCBLRXUJ Q1Y%#33>L#WYF ]DF'8=%)H.
M1D;F'T8K$AP_?2ZG44BP5>O%6"4G1]<=>-J>4+;,$L%9]SG$>,!06!GR>PMF
MAE%?YB)"-X4!'E9ZD9)@G??;E6?LJGXOAM"VU5'-=--BIUEO^R(L#[Z_,#MD
M>#<W+%5K$N!&6%"Q4ZG%G0O/,+%=H/\;):>_>TA.WX>A_+63TU_:6'C!/( -
M@J=M"/0[-7@G1<: PD?YXX 2Y'CEK-@#"1N)EDK#KRS5?"#DQB_0B:)?M2OU
M'$F&+H2Q2..K/@C#&':.4HS+!CY,/3K\5GQ%;HTT>C1^G+C1;>)?)@5/%@=2
M$[@3KMJ/9A440UUA0*E]Q69FA($]TXF?F1(X%R7P#Y7E9A\)'>E;U$>P'GMR
MD)$A=_3TWX,DY 297[9=8)-YRW/0E'$,5$9V"$93Z+'@+)NUY!6G%O:%/71P
MN]8")MB-?X]%/YWY.9LED4(0RQ!IB?QMP2#><M2?]0-^;R:K&J?Z4 [U(*YT
MN]$J\3-)YB/'6G$WFU%!0KA45SW:QAWKJOLLR<Z&J(T5V(3SU.\,GX[]ZUUQ
M=U^ [XK,V,G[;,0FBO4AD"#I9M#9=<[PKCB\9GF7J:=;NV2"N82)#XF0^Y2-
MY,0#-<R#GI^-HBYB5D'3[L(2M$" B$'H<X9,F_F=>*3YG32CUTA&EA=RGP9X
MGX5-34,^@QM\6V3#_7UWDNOOZN3JBT^[;5E">%K8)*P*6:LQMI&\]A)(G>T;
MW;9]O-J.]*'M9(/=*>H?H1@E=\?AQ> $8XU1S3B@=24E<C/+/\T:#0A@5HVA
M<$*<UZ5(5T7.3"]V*Y)+(<ATBS3XQ$(DS.Q[P/D%.'AC-7-KV"(7W.QM7W]/
MN(P!9*4<..! L2>!#_7 :?5S<-5WJ&+T>+ #X:W'\59I$K>D>W-N$QO:A*$S
M)H2F3-_>*GC*6<(V$& BQ972[&DBP0/AAMA=YUJ9*>PV8R,LEW"^*]J4 !+4
M>NLC<THOZIE8/ ]$N6#U+Q(; ?CB0QEX9FA.C)>H!JM#D>9P](*T6T*D+S<B
M68I0:Q.!8NG19SML5G 'PS8I]=%T,NURBV67IL;A3O,-1044 SFXDII/ WU1
MF)[I'\IOK3TSK#F!\<4+4E8ZE3@I(-;21TF")-,D36Y,$;9T1H6ZB#RV9H?J
M8%^4 R6P#JP0V0ZZ.K;<VLL'=[9UMSG1'M8GG&W2;'3-56\Q]>4/G#^ZX(;W
M-;&>S]ODLT.>ZG5C,L5P^8;-<"]2MY:6I;7K_3DWA1;TMC?,@6M+ Z>FW&_)
M) >$0[B3H&,<?HKUS)K/UW+=8=D/U]L'2<25P<8#FJQ>-E()9BEZ+SMHF.O0
M6SR/IM\>@[98*,/),+Y0I.4F:WP ;ZDN<64[5,2^@ISWA:&"1<Y:H+O?I@S6
M*V[OR3E//Z6MQ5[<D0[IEJ2*243^5D.Q:R)-RX;+YI6S.U^M7%X&;?G6S21B
MQ5+"><&))5Z]EHNYG*0'M3)_!UM'"H'19:\X&SSH/3)M1:0WP<-O(;70U'^T
M3H;X2G;(JC T:K1WK5--VR-4"JTGS/%()=Z<<_-=9*\]MJHYJ8),#=-()":L
MO$O?'*$N0?Q(!UG^D+-*?7&+0T[H^8!QE[#+;G,#NN>94XNW&2Y*QB;P1(E7
M!%Z,I.K&.,B9NBW"2[;J4/_='4NA'T\FQ;P0<1KGD*\NK_-=02(>IUG,K:9Q
M/C35 #/TJ>P_;)9W6"(T\@RJ.(]CLPX(';/4M QTX%J:0G7I!#6%'$);ZR5+
M2C, .FC#OKJ^% 25: U(62OE 6Z8!(2TB!!S=V3\3@'4"'#[^T*HUI< ODQ<
M._$PJ8:E=R7&[()#B8YX)7VZSH?6"?7Y4S9M2X-DE0TP 8VT"R%Q,"ZGI=A!
M],,JE_[H]-/IJU?9W0:;3)V^%@'BW6EDII"X+0PX-M?52C,<-"9^=9,W-@2@
M%_*YZ>>M,$)CJ%*[1_'B=+@@WYBNC9:LXKQK<AR..YT$8F(W2O,("%3<=*"H
M2'  :KB$1/_@]9?^!K'6G(F)NEU&ZFI6HF2D;KH-WU@I8Y5F&XV;:(&5'$K>
MBV"/;=\*.RII(")4UZ0UDH;;<""V>$L$XC\T53FJ,7 HT8AREFE ,4<L(C/%
M%R<L%7*AB%,GF\ZO?S52S\&P=[H]X6'6@8^-J?Y;U<R#CN7"G*J2PKL!+EBU
MFW!_%/@E,)YG[$LK&G=X8:3%7J%TC8P/?, 0_'!T\( AN ]#^>MB"#YW3W=&
MQ[-P26WAK3XF ZR UC?Q0=9Y9-<VO-$H(5.!'TE_6-3Z,:NM,NB?YG Z ILU
MY:!^TK!:IWZ(?8) M!F2?G=W[+ZP*?[+_MO]KBEK'O#NU0<))72"Q8Y41FZ'
M7SP[.68[D+LABK9QI:J!32WH>DO]#<,(R'_L*FY^@[/*9W24]Q@TIRXJ,*IU
MM;>$:;^2FNT4K!^@)"D&3T,@4DP2RXQ#QZI>>R<7?F!F9K%R)/IP'!/70Q_P
MU:<&8(35"?]DOO'$<E:F$6"W2B1DV$!?"K"H2P;B:\F)>/@:&9'8/#,HL(D2
M_"BYEQY5SJ_1 -JD(/LB4M@G^\_+G08@&)PO-+ZS>'MIN8['8_S -Q_:1/ Z
MOO:"/G[,!=N\J%\=?/5H_/C1T6->Z(CKY/Z^5D8J!0.R"VPPDS=6&WAR#]UG
MX&\D#=M70A/O[V7&2R(R<<ZK9SP \1 $H+XRKW&1=SZ:%Q>(+W*%/+>#8>#N
M1.B<YG,#;^:QA#\IF![];(4 '79@#8XZ.F(&T<SJ=:,M1,71U;/ _@3=(Q>Y
MX5"E1"#I3<'5PL4HJQGVDP.4NQ/A?V=7GX,!X?Y+'U%9DP2,E%QY1*R-5%3*
MN@)15^CHJ'X[?R8D@OCJFN&?],%%''<5J*O'99UX@:$..U98UP$U'4$L3LH8
M(YBBR1W*1?NNMVU,3G>%: ='TW%W>O6]TOY2"HRU+X.13X9UP W1"@%>8Q&Q
M?E6Y^E A=IU0(CT+-7)=(D)\ZH85%>_2;AK-[K(<E[&$37JH!9+88R-=B]<]
M$1JM2^WHK0_OY3N)U18\E=Y:1"N#,A'G?G#B <&V3<>EOBQ;8GN2'TV%F:A-
M3;O;Z \?VX[BN _*B&J5%&CVWG!M!*5![#@_%)[YF%5N?H/D"A*SZ'8RT#KP
MFV()G?!!0J:9)'BW6*667%-O=V<H!R/2KE.S9BH+)?JRW*%N:]$WK(:LD_W1
MX,-YI4(=+IGHK4^?<**XM/+[\,J^$K=:(/KN'G\W+2<5;60>0L)B8*U*0V^
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M(Y8%9W'1.N'EGYZ=G<<O_;+_]WW]E=N3P:/T+]T0MN]UI29E,UDO%-R0"8U
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M PW^FMPMLN[^5L^K7N(.S6XU#LY86W,^Z7+QI1!FWM)04)+>>#0M[SY 7FG
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M_S0*2)33(_/5Z\D"2Z>TU@"9(%7!:ZQ/;A[:8H@(VZ]@_P@J;Q;9;Y1WO ^
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M9CK#>!: 8YHO$**+:%47+XE?[P>P%Q?,*DVUB5O$8_$Q@\;S&('6<3H7=.E
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M5-*IPJ#GK?=&31\?__GS.<+ER712HF[^D8'5)%TL?\]^+WIS9O:#P)R-;>4
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M(JY=2LO303O:?^5BV:E@C[\J :^ 2GC&<\:6,X!B>F\78B$P))!['Y9WREN
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MNG)8<V$*JNRDX90 ]>?E0^BCHP*3O D*A4F=(X//0.F#FTB!HCY>7-=ZGDV
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M_/12 0>)-$%.PJ)F '3H':&NV+BPB3VV4@GGJ2Q;6"D*\)DSO6\ROH);T6'
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M-W:7C&C (O6PO8I0!$3)MNZU+(9(69\;,SU BS/=</<,H/&OW\J3C\JJKAZ
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M)4:?D:U6&+C. ' Z O%&%8R;;O["H72$0>(3YN=B[D  ]6J%"Z-$<HWL2D[
M&YXST#QEU"FP,I:HF&&OK:3N<^TWE_UC??F_OOCTH\?Z\GT8RN^DOOPAC7#T
M'<GC+*++34\H1+J4OSUUMM,N=V*QX#Z.:( SS*^&OJ X<0"L>!NRE2+Z]S"
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M)MDR/OBPV,I6F+>W8L >VQLVZWHCQ"?)SN.,"/YH6[])6@#"[(88$)ENW"0
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M)A(*I%6DXA$7;@BTW#++ 2YTF9M*KA['91T\NU'[@<V7X5L)HBBDM\/GU5R
MZ\8/E%XW,C"L^V%Z?=JV3UX?# V>M"*&K+6Y;\B%Y9,Y_6*97D?='N_1V-Y_
MQ]YQZ>QNPI3UAR;74[K&IHN%G<H*]!U#FS;A\%.2P_2;!"OG>[$S)T&;4T W
M$6D."OLA]7'=@2BT@GOU[1WS*$AF+N\1M=#Q:4JJ^0<++IVS$P\3VK\!@QN4
M=(BJ+7AQ#3-=_Y=\X?1,X<;4[G=S@L9T]1XJP<YW'1H'$Y:I^9,DZ V[[XRK
MXM8^_(0"3*!?P)09=.P!>X^E KT&^LB**YU#PK!1F5V14*D2\PV2"248-O?Q
M'#I44<7:+U.(RX*]Q.G/ETP#OEBFHJ&ZY68@GQP.SEJP9(,9=G$96JUCQ#^N
MQ'?03_YK7Y<^Q#Z*+U1#5S'V](X9@?RT8>U;E >??_3L(_9]SEZ<+6Z"098L
MG&9#7&%SH^_._L]-?4@P!$0*@!"&(Z^PN2ZG[,]E88LTA\(E-'D*&*?FU29$
M81TBU 51:2,?4!TH+AH3->"8-B![ 9DP>DSG">8Q_*GDI:BJB/N6$SP&GK:L
M7A-<45!?*P[DXT\^^I(U%JB0!*"[4 -_;OP! 'U1CF3;["[[%8WS0$-0I:MS
M;/XP'DQKJB81T88F3?45/>U[_)6I3P%J4&^6>U:96(OP@\8NP,^%0)M6/3@7
MC/Y%X7C#/R/T+@IX$)WZ"=OZ<Y=Q 48H;,7M?AL'\NN,'/Q7.W!12FQ]+G@L
M_#ZK=#7=T*,IBC:X?B_SX:UXER;]3)\[M,]*N\K7C7*WUC\W\$,F*F.: SL?
MF'J"O(5PCS()$6:6-4),GQ+KJSIBBY<$J/Z*LWQ$SW)17TWV1Q6AQNGCT4&
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MPI5!.TC?B)7/F6R%-5V"Q7?-3V&VXKW'-I_F:E934MA)*)SWBD,. UK@37C
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M4TA><17\I .JBO$,N329,LE/<P^P3Q3P&S=)FO737*!XO%%:X@[[$JD+D V
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MC<5?F"R\\KOVBDAK*($EF\V3QT^-%>T$%):%XS("TW=16@<MYANACU?=+TW
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MU $^K!KAGJ-WV@T-77TZ&UH$]=!3OVW[H6L.UJ:U;AYYFM[77M6=YAGG]M(
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M9U"(!^NY5[:R6W*&O[5Q>^W[K'R$;>[M.FV]C7)9^ZZ^H9_ .NC^9PUS0A6
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M5W6Z[<D>[6*HV[?!M)34Z W/$L,J@_CV66);>Q%N>605GSEA 4ZG_PB; (,
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MRVLZ\0<]&L<E993>TYXV^V8J/H \GY2P (VL.X'@S9#?Y5<)Y\K7_&#=J7$
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M2ZJ16W,GPKRG]JA;S?PX81-_WP/N6F7Q.'\ W8AL_<H 8:X;!%VGE;R[Z.[
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MQDX(?0 /\S],4Q9(E#HS8N(U@XRK;7>I9-JD-9[[B(>2NN67,9/XB!I9%U)
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M=E0Z;&5AZOBC:;GN7/V,.3C 6A(F?E.B[$A%9K&J*7=L?QB7SETMG:D]2U;
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MH^"@J5@BA%WZ*,8E70F^T'R"1^&&0B[48'8_"".<<\'1\\"E0[,6P& @O;K
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MY)^613PV+.V+,J$H/U)<V.3<^T%)+Q^'7J'<'\U9DY?8L%X1L@C@,E1,R@6
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MYCTD\8"C>]6LX&.&<8PE_^S%#.O-FB1.Z)I'O)5?U7T*6G+&XF&;HXXC AS
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M\*$0!?O%,"^RK+CB6Z9%@H_$K FD?-O[4K'HL+D&+_]<($>75LB;"!_U#X8
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M[D[IWF^ 9WDP(\M;B_!32.3-5@66#+&%8/]:D4D+\@RJSM1.UZS(D^:O@)H
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M+$BB-*GOOM@R4*U%L<.6^'S7[\FAN7ZO+X$8SEP=BXOW%)E//23T&9,;RGO
M[]_$=F6]<BN.A 6\>MT$FIM!=/>D0MVZ:5JL0>@JGIF&Q'B%,1&;K<$QQ+U<
M$2D$KKR%L5&A#:W-VH:OZXJT@#CJ;M'$@A6,UREMU@F<?R7J[Y:715,Y'FG[
MIV=_O .$1P5*"="X;9\)A).)R=HNX]PT)4*BS*<9TU+;F7"L<.EJ&F?08'%J
MPVG[-MED6D+^<FYWO):!@ V?F(PZI?@K\)S^JIPR]U?._;V1OSNM!?<*_S'Y
M)-E4+%0JH@=.*7B:T\.XQX"+6V_:&L.8Y:V)Q[LT1'A+]\J*!4Z%&P],T\94
M9<@P1RISX&9&QA]0YI?09T*0G2VST7\K1Z4'/./ H%6FIH:BA[77-4I-1).F
M<A2_X+4Y0@F),1-85G)E^V5[&C)XB0=0C U.TNGD!?1_R?55.AIPXRL0WUHC
MDTFQ*&.X/?%=*!5MCT;")F*/G^/O\)PF,.TP"RY+_8^=HKLG=TJ)<_'5*7%N
ME&%ID>3<.\61>&;]A6G9K.Z:L@<'YO[CBY_H/$4Y3[O%;&3?P!+B)697<)UF
M]J+81K/NKN*6M>'6"&21D[_8[7=5E.Q7(*()C0L\M<NQK!NR*<S. U)&98I:
M<: (!\( R#>!>]0:03S;'<@3C *I%:A]>WC+]>LS.'W)<F5.IW?@FS?55UZM
M4 FK2.S*AHM%WLPR4]1I0AV,3]]!QMRM8)0O@[PPX9$CMK.@X^?6#<AES0 O
M.'PJF'Q!7.^S98'UPQSSZ,[L1ZUUO+*!39& <=]"QM#* ']UO^DUA1MT?,G>
M9T]@BFI%H,T4+R!:F5&#I_W)/NW)HL$V3RSNQW#B9P;5O*F)#"#;%&J)KX1C
MA%M;!Q"Y'7MFK['GMMR"L+@L0*N^'N<I^ RKPCX>MWU!9M+.R=+ZWS3T2&0#
M40JP\^0$&U>K 9Y_R0*<Q?S$_B]J-*VQKY#?#=N_^*@'3]&_XQ67EJ&[<YJE
MU1)&0."WH$$5T:ELGQ"(K?YX-P$?TP8.:4%G\QQ#WM#1[(H%V&BG+&R0MV*1
M1>6#X$N3=[DAM7C442BJ>L($H$GW@JHP(\</;R]M^+/T4VR?JK:K*S&3'^&W
MJ CX,2^NH*-] B"<DR?WL1#CE>D!QYT7#2*;BS7J(TCPY:*Q-Y!IGUQ,)R^J
MBOR1<S<*=HY)XW%BY(_V5\9Z?[BY7[R/7 "6VJ-(I IA<0'4A!Q :*^%L)D4
M\H2M*F^_%#]'S[UM<& #P*K(_XK!OT$* 'O[-\^WW]X=7S@4X>N[N!%:H7N?
MN_W(6\SL?+Z?+-C=6W98L+B4'CR\<#/RXO=?7O_VW#Y DVRV#C@[N5)5G15+
ME*BS7WGW[(^+IR?/7[S .;'_>HS_BL(IVK):02P((A!U3>K"ALS6!(@TNHO.
M,SC%_"[GDZ6Q"VZY >5K$,7%OG)X+2A]PWL_O'B\=6U<M)Z89:![EI==U"?T
M/#>W!'RR=PT!/N,%5SYOLLMIOA*2=5T6I9-#L9/[]NG_>^%G-WQNH0I( %F3
M55UY%F1JE#CN%TF!J112;VA_.OG,<_BK@$2N3 _)XL79^8.)J"@:G%*53*4/
M0($N)?U<.,>DL17/*>O/8%8$%(_K&&TK.-*9X_OS'2+>WY8(%KPEL9/47\/_
MZ!Y8@(Q+,R=O V"I#$[FACX-?80;!C=$_DB,?#H3#&&..N,V[JT(ZD1@+$\J
M(<%]R;^-DY5]( (2@ 1[L\9MPBP&X"OZIEG8K]0B;O<IIR4OTQ(>4#*2@)>*
MR]FRXPBBNP&+D/(+=G=?VGDG F2[;)PJ).P&8$Z)4)4LGL(T8KX42?J@K:>-
M"5O%>0/)4ZHP%^7".CC_"92:^(ONV8+/4'KH[6MR=E@&>_O4H2IT2CG>P55#
M>673$8^RGB\H<]IW1Q/<!3\ KHDR"A7 /3B!1,@"CV[:&1_QU;UC22T%$T=.
MF^0"D5O6.*8)7J D?DKBX'EC:(1DVR#ZBQO'".CGC:S]A3U4D,83W>EL DH<
M%1&HH#Z#@^CTZTSA U<U]$6B2LS .E OQ.0EG@A"7L%=7=XB[/&T#C&VA=I/
MS7TF #LR2>'9[10&;'OZA2XX$N@M&TJQ6J<3*D"\R/%-<],F:^TS0>G<*17@
M?L<YP=Y^"-]*6'^TSVA%VY]8.*QJ;P05GYA:/@5PJ0L;%I]1YZI=9)GD+?]R
M_O#1Z7GX>R%3P?D; HO@M^T/YY'4@$C K@5&"IIR/2()F0R\VNZ(;OCY\?V1
M ? 0'N4; RKL&;=W#>$?V%QTI?_RX-[9Z<,)6QCR:=S)020F.O?/^O#<@= V
M>F*?ND!Q"/7)\Q?2G4'72+L3 7DX?$MNA&H4WHN MN=YUH!S:,\8]<!2ON5@
MR [WB<1%<-\-,@<4*$T5\1&#YMQI@FM4;1#@>_H@'!/[D VS'E!CQD[O]\%H
M0+XC0W"C?$5G[JQ$9H7PO7HX>M"WRHEYRM\FHL&_5AZM-YM]_\$WG<W^;$4<
M7(Q0>.QX#>VL5T0 Y0Q7)OEY8:9(=DT-G492/'SQ_EKYD7&^;C!?K:0=E_0'
M<G>],_+F^3@CM[V#7,JNFU3B9!;G\,()&B=B+Q-Q<;%](C#?-L[$'<P$9','
M9T)2PN-,['<F=*)#)4,@+19Z@N/0W\;02\:>A<KYA%ZG:P/?'\=X?V,<IHQG
M\9H2;S9T&$?]-D;=AL(?)PQ:+,J-%Q$3!'8W\S@._&T,_ JPY_;_(DX\ .ZD
MJ"&Y04$Y\-+C!+QZXRM(X]#?RD%*NF"D]'62I3-$6MFQ7^:(J1E'^39&V6&&
M !Y%)2 2W2+&[X0)W*<-@ZOG96S_#7DR8D;6I1$C6AA@BBI%V<^,QJP!I:[/
M9FPG^<MQ.G>83@2X"T.I2_N!@5J:.)D5#57)I"J-W.4:73B?(\8D9MU33KUV
MZU_\P>,IFJK6(:Q4D0Z("5$(&HH.E"DL>J!'"XK?:=ZHBIU34P,V 1KK15E<
MH<0C]4D!E72=9D39B2(ME,N&U@-7UM0Y\FT%VG0^(;63  ;#Q?%V;=SU!D@9
MW%6^(5<]K7VS5N54#CSA#&$P=.'1 _<]F,!+6K88YOT5>2#2F58$U"2JDX8P
MD0 KBM-0HP FHF)A!G0\<49F<KMX41KNC8)>@K($6@7ZM]H,D%7W$@$HX4HR
M(UR]?C6'\9S':>:?0<:AY];JIC'-?K#QV-YAJ1>^$F3=43\QFE0SF(\IJH24
M!/C%E65Z>7H^OP*-5R?)1O@[BCE@-M+/I3]>:0SAX*7*ZA%M\%\\+2WR8#1V
MO*!G::"9L,.C+R.G1MYU8?G5J0EYI;8#&BMH6$G)"4UNXBLP> H::O.;.],#
M]-!\38$LP%2RNQG"%TXG+T ]@KZ-T _^9@<3P3:"UQ^ .(2@F*\'7-3A6N]\
M@+:1?NFJJ;H/1<AS90ZG<942JW N#Q!L;+>^6S;*;D'$6=DQ [ VE\6F6 .<
M&2:WLF^'#T:BRRAT$USE>-;I3A@*8-2*B%<+S#7UFHDH+'A/.*B*F@E9<\[.
M3A]('=:QTL!B8\1YX[G U.A!O[*NR8K9"XJ2KE^P#_UZ7U!;1%=VPT>/MPR(
M8^H.03[M5X!E-"=K#@SR-3/A?+(_7!GH*&9R% <)2T1X32'"4-[CVK9O;F9.
M;MAF3<2#R$COO8VD:.P1;$_1AGP+A79RFP6.EPG58[$EH,P)&<6>V64J7T*)
M(9@Q)BUJ7;!SK,HT#SH/K4K^-1Z&/TV$QPD.(Q %-(*U\[Y&Q_F(0G^B=:CW
MNB4T#/8*[7=T$,W.P<S]V<1N;G^W((BF9S??QAR@[J,\/0<5%1?'D$I/2=[=
M%&E][%'3E#&1K+-FDR@0^#V(H'MW--"1D)#,'#@I7<>THS+@Q>GC&8#&Q/ V
MH:LC&+0I'E.X3  140G;%3SM:JT4M5G9G'P9>\.KL@!(+&,,:4R;2G8_#;Y'
M\%:%=5.8_/)*<Q?2T@(>']>2CTP7%S_]EMH%DT@'WS.^Y%NYY"EC8T=DV<^/
M'XS(LD-XE!%9ME?F3<DX?2X!XU=P\P!X]L_&!FC.KYO:\P9<9A\,VQT)$[02
MKZ:80;SB+"<?2&TLD" >?$L,FLGAJJ_ MS(\$]MU26G3E^X^Y*EHM>-AYU)_
M8X[3%*/<"C6(Q.2QNSC57A)ZK]&AWYWP]:O/X0<%U/[+^>F9^-;4+0YB;$(
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MFYHF!G,M:RH,!M!V6UG@ZH?!O4DL].3MI.-2#92=_+*EW&HE\S;/VIA:MDK
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M@RW\J0/S=4U*Z$6[6@>AS_-.6D1U/8LF%@PL&2M.OP3D#.T[E7!.@VH,Q_5
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M)U=CU6K41LT_>&]A?VH*D):\EC8;UO32:_!BL49-&!NGAD\.+K'4>&:9 5Z
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MF.5Y=A#2.,7LN+'KOA@3"&5B,A_^L<!K-<"H>NB@'T/<(>?+NKFVR$30X>5
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M)YY2)&^3Y%L]!]I,S&:RY5?\CR==+\&0Z@L<#),)"&*ASQ!Q NQ0+N,P>D8
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MXH ->NJPLAH-]@T)K"NS.B4T/>L3!YYDC$?(!Z1B$D42:A\\1%S)8)!2)))
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MXYX\J;GGD23CYW&:=A57M.5MX[C?9;TY)Q--'$PXXV ,ORO5VA\P348ENW(
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M93)[T:S*U;#.:TZQ7'*%'[_$]%CYCFS +[5M(>2-[/2OP5U\2?'-1PKX?:#
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M+Y_IM*"27',\"GN[??3;[84^BM5JKZ[5)O&O_9!@&4C$*5'^2 39<^9C%,F
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MK6<5DZ\HMI.OWF$I=O*5G7RU^.2KO:.6VMR_#]HGAW\?-#X?G=@)6'8"EIV
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MW/;]Q0HPE_N;Z[EVK7:M/_I: V^9XN8)V],UX8G-+G@.%RI.W3-@'R> 0+E
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MH4!Q3!@*(M<-'9\G,B9K=NE]V *1O4O6NY"-%(2NF$2OYW WE!QVV>"['#)
M3LC*8?3-1D\.(3 R9'<_0GV(#:-;VEC:6-I8VEC:K%MJ,)).E&"7*FO8(6[@
MT3!V2!1*GB3<(7(1:WC.2(&CX:4<0.9O("]E+TMOI!G_^[6T$OYM4H5_L+0'
M,X&/>B>EB: .(5-_JMO3;3D\2D[9G;6>E[*>SZ8&$X0\B1S.'(3C)$*$1!+%
M@?20RZE+:4!\)PRW=L+ICE!;.K.Y<KX"K]?*^7K+^927'#(G#B6-41A!C1R/
M*6+_G[VW;VKK2-K&OXJ*YZ[Z[59IO//^DMQ%%<$DRSX!'!LGZ_R3FI<>(T=(
M/)*PC3_]K^=(8"R!C8R @YC:C2WK2$=SIJ>OOKJGI]LS3@*7N!Q<Y%&U2-'7
M-E$ %W3C#S^%G?\:(ZVRJ;*ILEDGV2SE3OEL#951:5:Z>+,@3/80A?".<:G%
M]],LM")37O7KC:M15.)T$^(4%SI-6A&28](2Z\&7!$M&@K*4.$Y3DM0:S6GI
MW-9E[C;<J6IO1=:G+9MV.+ 56>\,61=<TF08T. IX:5_KW0)01;%25)",VD<
M2Y!UNZ!U#?9MS97*]Y/O-^GK?M+YS^D .H)V.[QIY??].[*WZ.'9$DA:,G4]
M>$T9%12"EUPSZQ" 8HS<"A&E$[/FEM_.6-]N#A TV2+3+/6#T\EXX@=ESFIN
M^NH@Z>UBZ3%E@LV6$_#)$ DZ$A<I$!FED9;ETIJT%$CL*J.Z\HINO6WL=+FB
MH/D=JGL[0G.U9>^56>'?A6HW:]E;"=1R:#7GF@* IE8S8A(ZI%*!)@%%1)36
M,;BLG-!Y8W-5/2(J2%60:BM(:16BXC'[9).,2@:F$[<T,Y$SY_Q6(%5=P-4A
MV/QY%<HU=88#$=8ARV*4$\>$(4H)$X, KGUI=6-5EQI:<:SBV&/$L64"6]P[
M$4TP7#"05B678M#XEE*9LBCT]4!V33RK(MH=(]H<)S,A>LU](EIY0:16R,E,
M L*8,A&H4\(C)Y/%A>2+[N/2N185S"J8M1;,F-.)9J$\BT:"!N1FDJEHM"@!
M7Y=7 F85KY;"J_G\3P5<)2T4B1P4D99:8A4(PJ(/-@6ED_(;F]HNLJ^*516K
MVHU52T 5]89;9GFFDDJ1A$O2. XA^PQ2:U\=R'; U\(>HI!..",3D91E(E7V
MQ&E@1&LNJ+*"4FM+-1G;M=H]"@]R;5-?&]T@34?U4B/KH@A<!SZ6UW";E-@;
M]N=N\V;CK7)3[K@_^0.DK52)5HFV3J)+, JT/9RB*=)6&<D\.- Q6F JQ!0C
M5;,4)7.>HN26*+-Y.-S"^2HC\/U2Z']WL.U/>A/?;](%PGR5S9> 3&3<F\ K
M&+WO19@>K7D)<?AVT-REJ4Y1B<KJB,K?BY%N#TEIG8A'9DFD!DZ"\H$8\#$F
M$2)C35,S(VX=YZX TEX J2:A2K1*M-T276:[)CO&K42[Y((L(;.D: #+G-,^
M0V;5R*^UD5^(1G#O*% -A (O-;B3)5Z'0)+0TCD>-1CZJ*S\?2<\I][[-E3M
MSJ/A<<=/R.0(R+1J5><$)[87\9,9RO'TSW6K>N<WB</Q9%S>^9^'1) 7_JR!
MCX-\48JNC&Z[#*XJ^#(*_FYKLK?]!8M_GW[Y7:9__Z?_)^^_#^].^G_^LJ?>
MO'O#WQS^+0^>_TW??/KYZ.#Y#C_XX^?^_B>\YR_[[PZ>]__>[]N/^^]^4WOO
MWHC]Y[]]W/_TYNRO;#D-6J)+$#(C,GI%/*>6:)=38 JX,6ICD]'%L.4%2#3J
MLLY5+9;+P-=2:YZXL<&!#!G52"(BHT))#B8$\0UE6K9X_#Y\:"[5?N"K5;J%
M]GDVHH-L"!/@B$Q1$"^5(U%J%A*-/(O2W:G+J.K2E>7DMVA/<AT5NY8,:Z]L
M'C+*^;7ZN4OB;24Y-\/;^5"ESRRB#8TD2TV1EU!.@C62<-#*&:<,J%#:E3K-
M*]8^!GVN6%ME4V7SN *!U0[>O]^Q4%C>>VDM\X0+)XG,/A(?P1.;@L?GHH8[
M:)\A7-O\H=]A/,$!E@@;.M^342].(,T"=D4UGT1-O58'1%Y>B*7YV-8'/TJ_
MC&Y<2*4&2&X"5#N? R3O?CO;?[?[5S!&:)N!2)L]D29QXB$J8KG/65&MC=0;
MFZHKV*UQJI9":B\IK+*ILJFRJ;*ILJFR>62R68.Z:M><>6AX<>=#;W)T!/U4
M:'!I=(5OE5?O[\2C>611ENM/E-Z72]/\3$FQ^GDX.O0?_RC"FG8IP#>:JS_-
M9UM5AV9U#LWN@D,#$'P*.A-O/2<R\$0L>$$"AQRXA*@I*SN^6MAVM"NH0=0:
MX'Z$LEGF,/]=GF=Y"7V/EN]P>&/TK:'MI0!V?PY@J0+I;6 D:8, *Z,GWDE%
ME.&6)LMY3"5/M8)KRQ6X@FN5397-'9?DNL,S'M7PW;5G<;&G^X;NO7MS]I>(
MV5D6(M$N:70M@B169"":AN %%YEIU1K+M[9;N=<>O#@]:>I!P"CVQLW5Z=O#
MDR*$NL'[T!N\S<6#J3!V9E)*-19R)YN[LVS,I+)"$0,1CI7-7<4),G>._P0N
MI?<1@MO89)9VN61U>_<QJ/B#A]NK;!Y=[OLUR%OIX%+@.I_J+I.-2II(DHR!
M2,TR<8D!05$9D8623/N-37G%$;RJO"U4W@JL5395-NN3Z%Z-WDH\BOF\=DHM
M9.D-*=5-T>JA<^&RY(2F+-'ZA01.MLWJK6V&R/:1'[R%3J]HW0AP%)\@-1WB
M.ZB(T]H3OI3T&$-$]9CTX'/EB8G_^!021&H@O<JFRJ;*ILJFRJ9E;%B&**G/
MP@EG9=#.ZRR$BX;J;+R-<6DV?# Y@E'9\1O!$0S&O?<P[4;]^H(;_'NZ1?B+
M[PU*B^J#P:L+8H"//L9+EVGT/DP.\J'_6$GSDAN'\WTRA"J%$*(ED49*I&!
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MUC78KS57*M]/OM^4*?.3SG.(<!Q@U!&LVRG:<YO=V%E)_>D#+535OT4#T):
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M:1C%WKBY.GU[>%(D\7U]S-:EK>*5";PT1LX@>^US+/7!75:.9>-HQ/^D8-^
MN2LR>9L(1Y$/I,L=$J=9O<W%@ZDP=F922C6_=U7(M;^]D-\+/FBNE"7*1$\D
MRY*XE(%XRH1DWENF2WZOXEVULGHD+=K)6$<-KXVKVRN;AXS17(.\#3N\!G@K
M*UP&6^?C*L[[X**A1"MAB0R2$\M+$66.GH+7P8=$-S:M8A57'X/N5ERMLJFR
M>5Q1E6KS[MJ?F(^$6'".H7-(- ,T>J \.A0N$*8=NAF&@>:R;49O;=,)MH_\
MX"V40E>G@Q'@*#Y!:CJV=U /C_WH;YB5J8*(VC'IP;C;&<"TNJ'_6),-:CB^
MRJ;*ILJFRJ;*YOX//SDF>(@A.D]!:I&L8R&F3#,5+@1';\"&KSD%U91M^J)@
MT[1/].L+EO#O8;_,YR^^-RBEG X&KRXH D["&"]=YM/[,#G(A_YC9<_+L.=7
M"R<.C%?"R@@DLA"(Y)$2*Y!& \H>G XJL8CD>3$0_R -I*N:KT3-5^#T5C5O
MM9HOI@MP;=%1Y@2=V%R<9$F<-I)XFAAW7DIJ>'OT?&W3!' ]-][P4]CWKQ'2
M*ILJFRJ;=9+-,BR+61VH:;A6E,X))TP.2D5A!3?,BN]G66A%IK2J,*B:9KDR
MWK1832*#E>CY"F*5SZ5W$KYB6A(F5 "O8Z(\;6QRTQ6K:"Q7E;<"ZQ.533O<
MUPJL=P6L"PXI*,HDBXIDE0V1+"ABT0DE 0S-AG$9*+0+6==@S_:;M:?W_"@>
MG1>>9K?9CGUJA:>#XTYX9[U-27I\21T$YI'H222"9EK_\";IZK7P]+U TME"
M8KK2U'&?'.&! R)21*Z7@1+O<K96>RNH; I/:\ZZ5+H5':MI1_V=;T3,[U#;
MVQ&8NWG]G>6>^#'AVB+3^CY0JX6G5P]6\X6GC;)&^"0)%3P2:9-!^B2A[-M)
MH5%0 NP*"D]7C*H8U7*,DB"CXIY9'JB,TI<MZT0M@A2'LH=]&XRJ#N#* &S^
MJ(J"S!S2*N(,3T1*&DA@QA A \K1>$2W@  F>5?Q"F,5QAXEC"T3U>+64>:$
MB8QG:9RW3'%M1)),(]5B_GH<JX6G'P+0YK<*HJ1<H0=)0DS(R&@!M) TOE*^
M"#*SB(#&C.XZOECS<.DTBXIE%<M:BV7!!)! @2JE91;99Z]LU"R[P')B="58
M5N%J&;B:3_S,*EF5A";:2T6D D:LUPKIF \9$GB?V&H2PBI25:1JJ_/H PT&
M_4=!$Y5"\I!95M:5,H0(7^(KI*MRK?L,U<_O'FH02@M$+^YD)A+=?(+.).*8
M2" UU5DYL;')M>HJIAZ%][BV*:]W4F!ZL>:WP'E/P]-RMO11[3+>*BGEAL__
MB/)5JD2K1%LGT24(A3">HB4*5".AP&7@E*4V>J5!EC94>9:;),]SD[2@M4KG
M>O"4@\5Z3)HKF:5S)-I$D:983]#;\H1''B4D02U7&YNJB\MN]5TP*GZT!3^J
M1:@2K1)MMT27L?'!9!YXXEQEZ6FPB47A*&4>\9RJ5&W\.MOXA5@$-2QP9P3A
MW#,B=3'R@D/)9%81I.9@[*,R\O>=Z)QZ[]M0J3N/AL>H*/W^\ /!-T]P4GL1
M/Y6AG$>_*%-U_@9^>3P9EW?^YR&QXX4_:X#C(%]4GBM/MUT&5U5[&=5^13]\
M0=^W'?WSOT<T'O\^\'^XTX/CWS[^^7SG#)]/'?R"S_WNMP\'SR.._>]/;XY?
ML_WCG;/]\O[Q:_[?3SMXC[_/]M]%NO\<?_<P_J6LY%R"(HQY3V1@DGB@@0BC
M?4Z.N>#*43*^F%=\ 0^-HJQS$8OE4NX995SYR*2P04+(SIE(G79&)TL3]]_0
MI65+Q>_#A^;2#0\&U2S\&^G<?!:^I]Y+)B3)VI8T"A6(4T )RU:QF*SQO+&F
M1M$NO;U%K<5I6D:N;ZG4RQ5DO:32U5(NH[7SZ>@A T1(DD NYZ2I%20$80FC
MCD&PI7Z8W-B\=076JJTMT]:5A[MOJ*W5GUV9*L_'K$6*6B;@).?@2V]&3QRD
M3)QP5O/(P'"]L>EL5S)>]?DQZ'.MSEEE4V7SN$+"U0[>NR.ZT%= 21J"CB0+
M[8CDW).@DB+)6\><1SGG-#.$BQ4J:HO%VF*Q!4C5AKA9;;%XM\UA#[<F\] 5
M4,!*9T6HSYS(2"-Q*&FB@D%O#13C-&YL"LZ[[/;850MDM9<H5MFTC2C>9\"D
M]IM:!;CNS^_W"^Y=EH&8&(!((0SQ B+1D UEN53Y+">GZ*T+!%7EK<!:95-E
MTT[9M#4Z4HW>2CR*Z:8 &KXW=._3KOS+:"88!TJ$-Z4Z7DXDZ)"(TDY+F;EP
M0K7-ZJU!Q<[:9;'&U:MLJFRJ;*ILJFS:*YLEV'#FVBIC5-!@9 K2,63&.@4=
MO>,6Q-)LN#9=:P5IWID<S$6*?%!(CW,F+NB$G%DRXF@,)+JLM:8IVVPW-L5B
MC9VJXH];Q5?N\%85;XF*+_C%D3E(7BDBG*%$QI2(5]P2!N!%MCI["RW3\;7-
M$*C=%6MHM,JFRJ;*YG'*9JDF8#0"$T+89*34P884N5"NU!RU3LF;4*S:!.Q^
MV=/NY+SKSN>NU(!N,!,DH3M$)$^*."8XX=)*+95%6:I"GKHHQG8T :O:6Y'U
M$<IF&61=@?-:D?6^D77!+P7@05-NB$]*HE\J.0D\>^+!&9N9!UPH[8+6-=BM
M_69_Q?^<#J C:&VON'3.NO&! Y,%F&1. FD"=4EX",9K*<\[D7T[5;VV5[P?
M2-I;2$HW63*9J296.T&D]4"\R*J)E/$<HS+*E(X_7;S<97I5ATMK^?DVA.9J
M^?DKBUU\%ZK5_HIW@59SKBFW( 570) &LU)7/A)?.F48QM!C32@E0/[T.&K+
M5Y"J(/7](*5$1H\A>V#,2&J#2_AW-F5/VZ<<Y6U JKJ JT.P^7,J.2OC2B4>
MJ9,M#<D$L28'PI57-DD)T9?BT])TF:PX5G'L4>+8,H$MS0((E0+-.4DE(2AC
M4[)>B11X3O%Z(*L=%A\&T>8X65(Q9BH3R<$D(HUPQ%+T($WP006J#+*TC4W.
M1%=P6QN753!;8S#S(5C#L\I",4D5=Y8+ZT!8S7QP]BNN8VVQ>%=X-9__B?S+
MQ(PHE2 9(KG-!)'*$Z:40U8MJ"XGA=5B$=,*516JV@U52R!5Y)K;",8'")(%
M[Q"SI&7>1Z.T]*KZC^U KX4M1"5$UIIIDDQ$!U*7T#U3G+# T/47-%)M-C:%
M$%UC'D>T?FTS7VN3Q=JNITJT2O012W0)1D$S#]:C_%G,TLD0E!(R,L93,MP[
MF&4HF?,,)5<;,*T/4?EM(=#M9%1ERY1(+TIB063$@S0D2J<TBZ:0S(U-W57\
MU@7H*X"T%T"J2:@2K1)MMT27,O(I<5!.6"HDS\EE*ZE06F@EK=75R*^WD;\B
MH=DJ%:-' T\UD<";S9] E$JF=%G,BIM'9>77(-_YX0MUKTL-@2N3GH,7E$HC
M1$Y*QN"]!@^>1J^MY%30;T!@+=3=,E1[O9 3+5CR5&M!4BC=[E)I&QMM::/%
M- ,7O JEQP#MNML7UJM50MK+6:ML6L<^5QQBJB5+[QI;Y\-"S.?""A,Q8#,2
M1K#$LA1)S,I&GA%AN=C8%!58'X?R5F"MLJFR>5PAEVKT[MRAF ^3!,U!4/#$
M!YE*F"03R[DDUJKD V666MLVJ[>V:1FS.MWW5J3[D56EJ!5#JFRJ;*ILJFRJ
M;%I&A3/D:'+T$2*7,7(OJ R6:Q>%]\'JI:EPK>#;"L;\9O&0!D^2"4^)\2$0
M='L<<;*<]G<@$\^>A>0V-OFM3\A6%6^9BJ_<VZTJWA(57W2*1:DSR0/)B@.1
M$11Q7E*2LO-@7?3:F);I^-IF!]RJ2/<CB[W5N&B5395-E<TZR6:I(MTV@:'<
M*@=<"BYL\CX'R3E7"K+)-Z!8M93L_;*GN%!UHY1)<5P$XD(21 8MB4O@"5?@
MO!')FI2;NHV&+A*HI4^R5^VMR/I$9;,,LJ[ >:W(>M_(NN"7NB"M2L82G3-"
MJZ- K(5,$O7&"N]%4+9=T+H&6[7?+-+]"DXF<!Q@=+M*W8NG")Y$I6XKLA'2
M6Q&IE%$[GVFR3E/IC0I6N%FYCV_GJM=*W?>#2V\7LM*IH\[0H(B)41$)1A#/
M."-H<S+E5'F6Y126K.Q2<P?G;1ZPB-$W@N9WJ.[MB,_=O(C1<D_\F(!MD6]]
M'ZK52MUW@59S_BDD@0N1<P(H&B*E5L0GFTD&SY1EGG.O5U"INX)4!:F6@U0N
M(;:@N7&>HU/(K0.5LT?'4)0*J>HV(%7]P-4AV/Q)%1^#,L(G=/YX(#*C0^B8
M"X3%9)@'RD04B&!*=)VI.%9Q[%'BV#+1K4@A.):22A"D$]I;:ZE-7'DMM(SV
M>B"KE;H?!M'F&WO:J'SVGGC-;>D^A]BFG"0Z)YN"XSK+)N'"=M$VW;[]7 6S
M"F:M!3,0DME$L]29H[N(W$PEP\N6:'3:.+D2,*MXM11>S2>!1N=3$"P2"=DA
M XN2!"44 >Y,0&>?"0-7)HA5J*I0U6ZH6B9=PRNM1=8 4DHMO5,.'U]SKY5R
MS-PJR%79U@HC8 OYK2ZHD (0'Q(GTH,@Z$ER DHPB]@E>:G4S9WJ.G[K2MWW
M F1KF_YZ)Y6Z9P^_!@4";Y6?TI*2CRM,7:D2K1)MG4278!0I:A&<C":P)-$,
MA:P,!:DTL\($/4L Q=M.TY08%ZP6\5P7HO+W0J [9)>9HZ@3RFLB64+&0I,E
M6J@0A=%1*59J>#*J5]]/I )(6P"DFH0JT2K1=DMTF=T:1W7THIR5YM+H; /-
M- OM++?<)%^-_%H;^<6L9JERL,&30$4IU\TT"=)+8H/E$$0(4J1'9>7O.^DY
M]=ZWH5QW'@V/.WY")D= IO6J.B<XL;V(G\Q0SJE_KEAU_@[>83P9EW?^9ZG3
M#%1S&4S2,4H98N"*41>YUCE['>S2"/+"GS7P<9 O2M"51]PN@ZL*OHR"O]N:
M[&U_P>+?IU]^E^G?_^G_R?OOP[LAOO=3[\_#__3?_/'ZPY]__$;?_+$CWOSQ
M^_'!'V\XSEY_#\?SYG!''/QL/^(]U-Z[-^4W/^Y_>G/V5T89:^,5R38*(D7T
MQ-G "8]9.P6<J<PW-I5;[.=\ 1*-NCS)HA97)N";S&DT3F3)49>H\S0P#MHZ
M"I[RK+ZA3,M6C=^'#\VE&YX5JCGY-U2Z.=?9Y&"B4QEE%C*1- @2 I5$1ZV8
M%]2D<@I3.-9USK2HCD6M55-+A3U"V3QDC/-K57.71-M*<6Z&M@LM!76*S'M#
M-"X/(J.EQ&L#)"K'G4K 0T)68KI4W+J.;M7GBK55-E4V[93-0X8!JQV\?Z]C
M/I87M44/4GHBM9&DY!$1:R0Z($RA]X%R#CZWSQ"N;?90;:WW.(,DM;7>'4/7
MSD+ )&6PU@1*A#.&2*,DL=(I0@,5-JG 6'0;FVBJNE*N:A_BD6Y7/A85K\6K
MVBN;M@9,:INA58#K?'Q$JQPE8X)XSI ,>@HD9*^)8IY[R;T) <%5FL5=FZJ\
M+53>"JQ5-E4VZQ,=J49O)1[%?#!$@F(&:" V>%9<BE(35UKT,)#)6.N,EZVS
M>FM0L/&KO?5Z@]I>K\;5JVRJ;*ILJFRJ;!Y)412J(H1,A>9.2A.T!:!&)IE#
M2)0K>@,Z?$UUE-J%JQ7T>7>AQHI@H$THX2)M-)$I).*$5@2DM]PQB;*/&YM,
M+9837KK(2E7TUBCZ"OS>JNCM5O1%/YEE%G/4)%N(1'*1B6,6_XB6F:"X##JU
M2-/7-EN@MMJK8=(JFRJ;*IO'*9ME>)86/#6%OR&#E!Z\R"ESJZF@CCDAOY]G
MU890=\2<]A;*YB8+&0F2)MZ*0- CXL0S)@EX=(VM@6!D:65@N\HNEG&KK?;:
MI;T56=LKFW9XL!59[PQ9%WQ2I8W32DDB*$-H33(3'STC6GCG96 I\- N:%V#
MG=MOMMI[#G'6:8^MK-/>]($6"H$\M3Y\8"(3WOAD/9.1L6"4#\I)'IA/P&<]
M%&Z0V%[[\-T/:/VVD,(N=-(H-4N >L2L ($$ $,46J.@<](VJ8U-J;J"TJYB
M<K65?6^E1X^C@/GJH:(=@;_O+6]^N_EX3)!Y19N&[\++VN'O+G!PSBWFC@(U
M61.<?L1!UY0-+7EWAH-C(FN4W,H[_%7XJ_#WA."/"XE>D \N"B^ML5Y;JW7F
M#G5,Z\AO W_5L5T=-BZ45-8!F1^48XZ<(38Z0YS)0+AR%HQBRGN/V*A-]ZH:
M:A4A*T(^:81<)A H?7)6H$9ED23SW/($2!$Y9S$[ _)ZB*Q="1\&*^=XI,]9
M>^>!1+")R(P\TM(DB1!.:<N=0_J_L2F8[FJVNE9?%28K3#XEF!0!G%'46ZV"
M!(T>6J+*4RNCDCZ*U<!D1<*ED' ^%U>F:(0U2!,M,T1J3XE'-YHX&F3BTUZ[
M&YO,+!;&J"A84?"IHN RF\:^@)\W2!6]+'O'/DF#@&BX8Y"#JNYT.X!Q<9^8
M99E-9B0I)H@$R4JLT1#M;+8!GRP*43K!TJYE*VZE^" 0V>PR_ZLY*GM>2AW_
M.!_RL1^][0VFO\V_Q*8(N-Q'JU$_1K^E?[SHW^$1='PL71/]X*PT&Q@,)S#N
M^!&^/>CT<#QO1[[?.?&CZ3'?(QA#4<MFROP$4B?W!GX0<2 X8'RCZ1'P[,M"
M\I>>?O;C0N/H3H;CIH'(#R/H^TGO/?SXH9<F1^?(<.E;,S'2SU_Q 4=P.KG^
M*P\[K8R*N5KZE_XLHVR01&@JM':2R@PR1QN42X(%P8!KD-K\Y<S&^9>.1N<C
M/_%O@801^+^18."#_>#['_S9>.-?7RXS7&.S(4G^S"@<]OQ473LA.7\Y(8>]
M8UP3^_"A\W)X[ ?73(W]5J8"SLQTM2.R#D=-<YD?4'-A5#Z%0_)M&4KG:%0L
MSO_YMH!0/H?-D7C4C>UBK'#Q_^^__.:UZ_^Z9;GYOV'TK]5\[<9?7K4J7#7+
M&YLO7F[]=_=5Y\7+G>W=5[L'^YV]G>>[V[O[.Z^ZG=W][>NAXA)0ZGO$R:N?
M8OM@_]7!K[O/MPYWGG=>'>)?>SO[AZ\Z!S]WMK=>_;OS\Z\'?[QZ'(_RCZUC
M-)B3<:GS,#D:GN*]TOB?-QF[:BC\K ;$.3(WEA1'W/<G8_CA_,6/J3<^Z?NS
M'WJ#9@3-EWZ<W6L&YP63Y@QI,S/3RY_AZAF=0M8L<6OVR[/+SYI+<[1@>LVP
M9XSS:R_39^S::U^[+>//I-/?==NO7Q-6WLU@[8UN^XWDN&_FLKJ%CU[A?DW7
M^UWZ'>Y&"7-OP(\Z.XCXZ8N$N2]HYFTGY))[?%.^V<:I0J^*7YM#N,PS/H&)
M8LLLH#:FF][L2;?]^*B3^\,/XVE'L^$)%!*%[D-QVMXWQX%_N,F:^8;[=LO%
M]-T'RU<_PD=X('9^*2QW(/;6QQK:\7@W#]1=]5SW&G"[V0,M55$D2IJ$YY+A
MJYS .A=M9#1EQX7BH3FFP2F;'M/@:WY,X^P\_+:C]H]?\S=_[,F]=R^/]P]_
M8WO'OZF]7W;HGX<_'>U_>GOVYMV6.OCE]W>?PV\1__V&O3E\B__]S?8.?Y,'
MSU_V]O_X&<>QP]^\^_G=WF&4;_AO8C[\MO_I;_GGN]^/#I[C?X>O/^X_?ROW
M?]EE;_[X';_S9V_OC[V/^Y^.WOWY/.7S++^]5Y3A9^7^UE])<2X$$R3Y6+8E
MC")!,_PCA)PB_B_KB*:+R2[EB_T&'O,!N(I CQ^!=$S>.PTLLR %D]Y1*SUU
MGH<4E(K3@V+G"+3N!\4>!P)]FD,@X(YJ'S,)/B,")9:)M3P0G:TWD+0*46QL
M,FVZ5-^F?,G3/B=V,]V[U :\,QEV1H#:%GM]:,IX-I4^\=WR.A:&?SI&][@W
M6#V];PN)OTNJ/K4HHHVKX#F<H.1[3=B[ Q]+JW=XW 5M;O;<]TM]O[0WE^>\
M6I0E+,IY=O8EBR*Y\PR2($8:7FHZ!(*LP!-<AEDHR(YQOK$IV:W[9[6/U#YQ
MM5P!'ZQJN2JUG"=ZV8'@BC.234:U5!2]3,DM<2EF[IA1*EDD>E<4 WCTM=Q;
M;.R;="?DWH7+E3P/-/:W-_RMJ:[9?L/?'/#_J4S_]J79KQ[GRH"HM\ /N!8I
MH&-);'2:2&H8L8I1$J.*SFCKA60;F]QVE1,M:K'Y),OCMI\B5 6^<P6>9Q(&
M+&,1"7Z6R1#II"6>&4>\<R'$(),%0 7F7=TJ!5[_R,'^<$":T-#GD% ?4#5J
M%.%^R,3!^;3_6F;]91G507X]AJWQ&"9;QT.<FD\-/.U,Y5&!:!D@6MP]4YI1
MKY0B("0RB1@H"4(9I-/:\\PX]])O;!K5)I>F1AI:22.65]U*,%:FUPL$(P5N
M&97$BP1(,&(D%G0@/&BE%;(.S]!#8%UY^P,I-5BQS/[4)3TH.?4G(SCNG1Z/
M.WZ0.JDWCM/,Y:^VHZL!C7M*XMF*<03EYR]+[2 _/Q?3UB"]F,EO=_ >9ON.
M%==6A6L'VPM\Q4=O592)*)<%D48GXEQVQ+*H<@H 6I40;)?2-OE--?#1$L92
M%;VMBCY/8*Q-C$601"-C(5(F15#Q.<G)6@4I96Y*6E^76M,B15__ ,FTA>YX
M+FNF4/PIA^GW?.CU;Y%!<U.O[2'OL4J>RE4;Q8QP=^)[Z3SL-97ML'1/ZR 7
M'2'\S81>R>@]D='= =HH=*R?P_3OW<%,1L\A THDS=QJM%5-E[O&[1Y7,[1,
M;N?AUN=ZVO@[!\]_^\M!\LXJ2H(2D4B=/0E&,Y*! E,F,5/J:2O9)BM4Z69;
M<K-7H\*59JY0O\^^U&]A7;).98+"=42"B<3IA/XE<^!EL!(BH'YWC:5KU7FR
MQ=P#O;%I%.S$GY7X5]USN]L]MT58.I? BZD *@*M#H%V%AB&]]P::@+Q,4CT
M=)4H/:X]R<H[F74 7:I'B:YU;0K5UTVXEH2TJBX_I"[/LPF9;0I4$\ID0EV6
MC@1A*?(*+WVR7#J:-C9-E^M;^PLMW79K+:48G<+G<,93B%JTXR#\E8!49/'K
MYT!AQ:358=+N K^((8I@;2*"Y^+A,$,"HA1Z.-Z;F+W2,I>"?EVI5U# O,8O
MGA:WJ*I\EZH\1R\"H*L@$Q#F4PE&.DE"@D2"CH)&#SE0B:JLNE(M1BO68U>L
MG?SB8"Y;^-(NV%.(7CPLU3@9^8]7@-.7^8A?8%2%H25@:&^!4020V4@&Q"IM
MB32(14UOO<2UHU$! QTV-BUK2;&+&JIHRW9(5=Q[5MPY_L!2S-9E2:0PC$BK
M./$R:B* ^IP8TQ#9QJ;1B[ESC[E*38MYP_G&7V<$[V%P6L\JW_M61REJ7D;R
M1V]RM'TZQKF T3GD/):^&8\"C2ZW*H\?\)Y_)1^#8-F2+&D@LK@T@89,=% I
M!.?!B5"V7G$-MLB9J<&)1Q*<6$*S<^\C>M&?8#2L2KVL4I]]J=1<^X10K8C)
M*1&I>2ZY^8E0I_$-IX,&OH'J:Q&M?VR16C^!&$5)*7H*T8@'/;]<)OG"@=FZ
MJ"98"HK_W!]^>'7>0J@"S?>RAYDOPT&)8)DFS-%,I+*9!*Z "!ZC!PDQJZ:)
M=8OV66L@HJ6!B*J]]T839MIK'?>><4DTI9%(!@)I0N:$*@?6B!R=#:7"X?H%
M(H1I(SG8OTE)W-M$)V[1T?010M2=-A8H:/1B-'S?2Y!^.GN- KL4,_T,6C5X
ML3H >[V852$!N#2>L.@$D39+$G+(1"'[\(  %LNY$'S +I6W":<NI3Z/**;Q
MM/#@3LO\5SQX"#R8(S0^A:"" 0+0;*WH1&P.@BAT-DR@S$2O$0^X["HEVXX'
M:]#,Z69]O7K-:?Y5%/Y_0L>6V\=>7YR.XI$OQY2;DCJ%NT[.FB/+\/].>R?%
M8WL*.VOWS%"_-$0O_%E3%>-PN!5QTD?P8B:'%WT_F&P-TLZY**JM6<K6Q 7N
M:34#HU RVHI,I =&K(^<6)J2ES8PEPPZSW(%=N:1LLMUU-B5;YDMH[&5.JY0
MG>>S<H)#R09.?-:12!HBL<D"45Z:DIQ/7<Y-3:LKDGH?\Q'DEO.(*POP/87]
MLW;1B*WWOM<O4OAY.'J%.//J0A;/(51D6B$RO5T@&CB/B@IO"; HB.21$71E
M)0DL4:M"Y,*JC4TKNDT'[39$ZNL6VR/A&E6M[U&MYX\16<]4#HXD)@'56EOB
M>))$@.<&>%807&E8*;O,W(9RM&\'KGV48\]/9NM^M9SCD3E"#THY1D.<K#3^
M>30\+E"$GL],*F<'>>]"(I\1JJ+3ZM#I[P72H;T 9IP@(*@BDD4@P2 Z6<$$
MMTS*U*"3I5VA%@\LU\3@QZW=JV<>5;L?5+OGN(=*3 2>+;')HW8G;8ACE!.7
MI<_)1:Z-W=CDLFM:E?6_RO3@EF< G<RVDCOAK/./63K0/Z_<*;M-,.3Q[_\_
M)&6Y9M=_]UQ(==?_#M#LW6)U6!.!JV@B$:+T<0/%B+.&$PK)Z807P>:-3:>[
MUJZJ5W,[,H%6&#]Y_$C0ZDR@B@EWC0ES#"=FQ5&B@23)2Y=HXXA5-A(9G$W4
MYNBS0/]%TJ[B*XBNM"P3J'UQEYME N7>P _B*C*!;NK?/>0]UG<';^;M387J
M)V1R!&0:5>L,<\9[#MY.NVB5<%MO/#Y%J0/.P?@[6QD\LDV AR"M39F/RV[X
MUN3P"*:N]\&Y3/;+Z]V9/+:+.*J56IV56JP*&(0WB2J'CG?V1/I(B8_6$PLA
MT! =5^4 CNLJO7@&IYZ@>]R:O;(86]7L-FCV?(1-ZF!3MH2IXI,&I)[.\$P4
MQ&AM5$K*6&H0"]HFS5X#HGD31I*'?>2<!/7SY#3T>_&"E*R2DZSO[L"=[OV=
M8]1!WAX>'P\'KR;#^'<M%+(2F%HL(BAYLJ5<(/$Y( '1$@D(<$JT4%E([6(&
MW<9"(76;KU44Y#L5N9*.6VKS'.G(U&?'#",Z.B 27"Q]>051.2J7$XVVU/)R
MMBM9FQKSKF\<9)IOMT@HBA9<%Q=I3DSU4&GQU^?YR5,(CK0B\?D@-W UYS!5
M>%H"GEY_46H0G^\O"\%G $N4TP')AC8D> $$+%#-?*::FXU-KFL6\SKIZ)UE
M,5<=786.GLWIJ&;&QQA)]%$1&:4A#K(FR0KE$&)EHJ43H[E-DY(:L+@Q=6CR
MD2?^8^=#;W)T-.RGAB&,H.\GD#J38><\'P@_-L*7HUXL%\9%,1JE?!*QBU90
MAI=3H1P.#_W'/SY+JYRL./(C^,F/(:$G5%I?^3+("E5+0=6;RW3B8U/D5#)%
M$9"(%YD22<$1GW,DV3IEBZ4)*A<ZT9+SFC5DT<Z0Q7>K;PU)KD:MS[Y4:YJE
M-4XB V&E('E,F00PAF@%P*-(AGK1QI#D^D8QOM@[@8\PBKTQ%,8Q/"ES/HU8
MP/%)?W@&,.,>)[-#W)V3/@ZSJ/"H%TZ;CS^%($9;=E,:#^E@*J:=F>12#<+>
M"2V9!6&!*<]T%L2IR(A47!.;%$40"TIZ<-&I4I.P*WFMBKQNNGRWYZ:J+M\;
M%YGI,C59EJ ET3YJ(H5P))3.32D:[8V(3$F'+D97RG7M)/V(CDE=E3S\M(LE
MM_!PU,_G0JH'(>X"PA8/<BN=0N Y$:-"(FB,,K&2:A(4==2QJ!RGUS:>_CYO
MJAV'HVJ9Y)9PF(H$#X0$<V2&2QEXL(FPD"V1%'T2+[DD%%#<C*6@M2](8+K*
MWMHUJ162;]>1<MH_K?2 *#RG.V4[I8[N>]2!LB]48BZ7=GS*]:=]$KP=G2$*
MTI7_=CZ+ZN6%E,J%K4'Z\HU+GWR!#SY,BTWT8O^TB&#G8SSR@[?PTD]@)V>(
MM4+7Z@#ST^*Y<DN=3$9'PAVC1#(MB0O:$4A"&I,$&D.D3L9T]17GREMVA+0>
M*6]_FDN%E/6#E+/Y?'O+M093CJ5'(@VUQ#E*"9(E*ID/5GE #J9,5UK;=DQ9
MV^2;[1M3KFXGP-O>8#!+P3EIM.TII-PL@8S1JR#!FRR2EX)G[Y,T6@6#9A5R
M4'_MWLR/O!4.5EA;':SM+#"ES*,7M!Q<-MP3"5*28%@BW(:,\J:>\E(\7;BN
MN:+:1CU&],@5'-!54JC4*B?)3/+61)DLDX8KFZ)N%)Q6!7],"CZ_$194CCY%
MPH(R1%)#B?7<HI9K<(XYE'Q)W7>FR^DB;ZE).0]*40#?O):<W*$7UXZ9^I\[
M>N)'CME>!R,L"\"9%)0[*H-/5E@?I>3!-9A]@VV^BMDMP>S%XC(V)1,, %&L
M^)I2">)EB 0I&9<4L@]*;&QJWJ5B534H'D4,JR+>$T6\ZH:N&^+-L52CJ(>H
M+$D2!+)4QXAUTI,D*/,<7<_$S,K<T!IBNTWEQY> RAE[_5YSF*+0TYOO<]ZJ
M(N0E>0D42AJ>ECX?7PCLH8M%+CO$M79RF@4PORKJ$8([(_-HO>9LUM9DVX]&
M9SAGO_O^*503MCH3]ML"::>!(P1P3;QUADB7 O$Q>4)S )8,),T<DG;6U>S6
MZ7KU^$#K]'AU%+7J\?WJ\1P5=2'EJ*@C47I*I%'H=P>E2?+<2PX^@;2%BMJN
MH8L=HA_]V8'V<8F7*\B56^,MG!4QB 5/>,'_K;BR!*Z\7N '3($#CI"20ZDK
MBP(CGG&'+JYTH$P,&I ?2+:J!-ZZR]H>%5T-.?BVBE9>L$+]G>,%5D7)G>;$
M)%1=F6G90S6HSE;I9%06U)BFS7RK-'C]&Z\=#B>^?XM<^[JI\$0W%>HVZEHA
M]A7U''P&5U)?4,J"R* 1L2E8HFT(6K! C:[;J!7QG@[BU6W4=4.\.8ZJHY:&
MTDB 4D:DY:ST)S(DA0!@!/,IT[J-VHIMU%>G)R=]* 7LD+VFWCCVA^-3I*IE
M0Q6%0AHJNZ)>>G7G]/'LG!Z<P,@WA6'[S3GB1D?(,)-3_(<?CZ%4E@T3CU\L
MQ>8[,#L'UA2F'\Y]N=_SH=>_LI[*K3=IVC%=2YOZ-3+H*Z_\\K*,XR"_'L-6
M66@'LV6V.S@_;/CS<'2Q/G\M*^S7V0([JT4U5V+2WRXX,9H+$VCBQ.>2O^\X
M$.N,)1SM>:1,RNCERHIJMF]?N<+4HX>IE9>E61E,5??CEE@UYWX$!\$GIDEF
MS!,9>2*.J1)Z4<"<X,8ZO[$INU3?^J11W3B_ 96<]1Z:=2[J-:4#IJS1QS@Z
MQ9?PL93%7H(=WIRNKPTB+_G(CQNL5]NU^CG@"AQ!.E^)3:>7W=DZW!ULQ8@3
M/1F_\&<>)W-KD+:FZW)GMBPKJUP)4B_6%C2)19#<$ \0B<R<DL!CZ3=G96;9
M:>?=JDNUWU"!'CA7H2+?$T6^U7;UOCWR581;#N'FN&CD.LB4-0FVG"@"'XD/
M.1+%F0C22F7"-2WK6HEN:QOO?#%K-]$$OD]&)8(Y.9OVI?A_I[V3I@OG2ICK
ME]L5TP==$-530O>53LCCQOZ51U*W_4EOXOL-FJ?>I&SL(/B?%HOPT^ED?SAY
M Y,7OI<JP5T!_.-S+!ZA%T$CK06"1D 3Z14C%BDOT5HS+U1*M/3R6&W8="6:
MU/)X:X7/"I]W'^&].7Q6F%P.)N>K0W'#M/*,*)HED89;XE-F!,!2&3-/CC4L
M>55-4AX4(AL._:])<;CP[]1[O_F_^,?YF(_]Z&UO,,UCX5]"4T02"J/5*!^C
MW](^WF0U'T&ANL-C_,5R\*\S&$Z0(_L1OCU 'CR!MZ/29=Z/FB;UDR,8EP[U
M@R;]IFDQ.VNJ@A\:3_"-IE7BLPMYS3_][,<E?V84#O!D..X5,?_0-*SMO8<?
M/_32Y.@<&BY]<29*^ODK/N @3B?7?^5A9Y:54WN79^'RGV64#9 (38763E*9
M0>9H@W))L" 8< U2F[_PL3;.OW4T.A_ZB7^+E&,$_F_B,S[9#[[_P9^--_[U
MY5+#=38;DRU6<'ZBKIV.G+^<CL/>,2Z*??C0>3D\]H-K)L9^*R$)YV6ZW!&3
MAZ.FKL,/J+LP*I_"(?FV#*5S-"H&Y_]\6SR(6H=%T8MR;!=;U=0>\)O7*L!]
M+<JKGAB]X)=;_]U]U7GQ<F=[]]7NP7YG;^?Y[O;N_LZK;F=W?_MZO7THU+KZ
M,?8/#G=>=0X/.ML'^Z\.?MU]OG6X\[SS\^[^UO[V[M:OG5>'^,;>SO[AJZM4
M\ ;2V/S?,/K7%4*\J<Z*C6_,H6W8\/W-&'O6F1&M_=-CO$5<@6,ZU\3%%_YT
MD&<[XF@B'I8K?<1[O_]S\)^C/_%[;Y#7[+]#CG2X^^'@CUWZYR]O^,'A'O*E
MWY$[[;+]/WZ3>(\/;WJ._OG?(QJ/?Q_X/]SIP;O]PJ7X_O/7'_>03[UY]_+O
M/_'W]S[]_>'//]ZPO7>OV9_/CW"\/_7^^RG2_7=O_V(<J-4A$S"B[$XK3D),
MC$B6'&2&O%2(*;'M#4XA;16G7.>414J"BA2EE\DGQHS.5@"327F[T0%DH"=E
MQ8Y.$2JGDSVSR)V?3L<H\/'XG#S-1#RW?O':[$>G%74:X7S[A[\<J *?$X4
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M:^]N 1)+-ZIYQ[;4M>5V]G.>XZUW$ "E$SB/%E0QL<,+,^KMA[@%..Q[.T[
MASC]+R]\T R\+=6OSG ':>^&";>X?5LUB*&X\KY1">I!F;BPZ,<+*7\S#_,9
M1/K(;55O=FD&7TQOZ!;VK!8*\L*_[JR^?<50R/T,*S"]C<KRW[=55K9*7V;#
MB34RWB6<8YS6W7:P!.[YE701AF_:@;(B+%2E2Q:Q*/ $NV/CUL;X<$NQ ([A
M@4O7S:[^@SOI S?;/ PEBJV=PGO&_N 4;M?I>#Y1)D]C#337^U(@T!6YX37G
M>^$]GH'S&$9?6\"@*J[P[2Z=<&-]2@72W=I^:?$F$6C&9_?"ZD.?C/%\ -'M
M+\;K0J?>B]'KNU>J<I#5:2GUX!#5J[YS,9\X#=+?+?-4^)X/Y)G3?KX^H$8[
M;N+.^V@,_O_YQ$^ITE2#E[K&WR!#(AP5"25R9WVG=^N0"RYF2\Y+=6^960AA
M# -93T[V.NW/_Y9G$N?KYO/,X'6#P6;IOXV:P9NIVV^Q-&[G+R;F0I1Y;TVS
M0HIIOT@##YK'$-( S-0O67 [E]V <XQB. I3]^/4BC+V48,C+DRC\<3M$<1"
MW)&;3#UG*HY*.,@WST&//<O,04)Z/OM"G\^GLW Y..'<;/(==L8 A%;J2:UJ
MX ;M8P;%2.&FB4]R@]E4<83 _HN_+G^V/DM_)H>P1WD61,64'=\$=3[P@[J?
M?W:U?1O'XVU+GM)U*WDB#U[R]*$* 54^];_=*7+B='KDOO3'8*P^/[EN>ISK
MIA=GQT.G8P[?D9/SO:_[;]]%)T?'5\?_'O2/G=YY\J_33:]/X\/=U]?[5RW=
M=/BF?TQ>DY-=]Z7SUY<GN^\'!^=_GAV3/\\/=T\&[MON.47WC_:O_W.]%Q]<
M[UU],G$BXYC'B"70X%)@CB2+*3):)FY!8Z+M0GD1E]:M/W?F$S54VHACRW&"
MTY@D)L$R;==!?9@/AT#5[G#7-J,>X2BVXSMJHVX>3'/P6BN&=6JIE3$EB68$
M_M]8&Z=":BD>T_ETQT#8'\!Y?6X8:/&CD'R\*4&Q!Z9ROS:'MKXR.R/=T?Y*
MVM\GCO:%D<)FR#!F$"62(2E3QP"H$-I11\S2J$W+]Z-6.'GOG@.G 4C=D.+@
MC5=?].'U,!"W%8-PNKE[[\6@TA4^CGR^R(>95ST<4>SX@R7*\L"W.SM_%_5_
MV[T=R/."!#>?EQ'>,34YD +D*4+1BO+*'V2T!U5ZVAL:$4PN_VRA-8CY[&P\
M\55S;FKP(=";+4!<%,-;&KY]-=:5<E",<^?#J[),$72(G0\?IX5= +'@[1N9
MX@.2U:MR=]V0/>%<_>1D R(SXBF/,=(2*^@DE@*N5(P4)DQG-"4R2=IDL[[9
M%7]7E!7"@M5^;XIHN9UE4)@$LYR#%;E =?O;)_QX/\<8.-'X$OJJ@)^CK_L"
M:MFV>GE*[X?@2;IRCX:LWL+B75V^W-N![#>W+:+WMWOPKYEV;&DP\/@MDT;I
M<9Y76..<!O+C1D7NL*KOTA+[H,XL'I8_?)Q"?NITUA\"&_XY.4+\221NDX0U
MR!!%$<6$()D*Z-)!M"8X<;HFWQR.\#%8WN6N;A(;"!I&:7W?ABLL:")>GI=%
M\T,Q$J?!F^ND_U!\-E#M%58FN+BFT_GPHG O@IO(6I\]Z]T+D!0(JDPM][!R
MB=2< UMEZ7J50Q4,EU/X]/*'>KE?K'#IWC*:FWM:EPVN %+MZ;D/D5;W>2W,
M;<Q83[<;9MSJU7 Z$Y3EE:'O6[F8<S:]Y3.#(?#<S@XN,%_S"L$+T=??2#\-
M\]D*!0M(BJEW: [AU[(0WM>65JO2\ B-EV=N0D1 %_42,_&UOD'>Q^1^#LD"
M7BY X4. :'A=K=;$Y L*R:\#4$^_],UE6*V!]Q+!&? ]3,(Y!>2 (;C<%9P7
M<*5-:Z74QK__576_:7RJ=&+E"FKX=,]GDH(GS_UVY62-]T+YNCXGG-1L'G)[
M?<5.\ ,[#18T87@QD*P;=^[$@@*>\I,W"*6UY7T/[8LRIW LWQ<4%33J3J]V
M4I1^4II0FF*"8L)39XXR@ACE3J_F-#)N>ZR,3-N;0Z6R)J,R5B*A.A/"F:PI
MQ9BR.+6QM NNJ+ !-SB:NN1.2.Y,N^3.)Q]*E]S9)7=N5G+GC?[U%@<G4<JL
M%EQC2FC",AXE&(LL5G%*'"^/UAJK;/D2W"B4%I(35Z9W38.\NM_$PKV#-PL)
MA7-(0"EQ 4>GA:!LI':Y95*0WG7I-,FI&9697=%/I[*\)@='>Y^PD5F:91)A
M30$ZD">(T]0B$]-,)\IM3)J^>#D>F<6\KBJ%(=_BY9D:D-%@:S?K$L/&&:*3
M+>^L>N7O>?W5J+GW1Q]"JA!<#*;K=*D!4\N)\3'^AF'F0_QETMC%?.*4%E,:
MK]-I;@OZDP&.<F_X.1M'A4$Z@Z&>]#(4Y^/)-VRIP1@0B/I?B@![L%?.S$ O
M]?5O+U'/'M,C'GK:W]3SOG4]J/@_'9EXS?[Z$Z/0"I)E*$X@T!2)%/%(9$@3
MDZ0ZY0IKN3G^L5<^U1#^W7O=2C6LCH&_ODF>LT(<%04+4Z#HWIF[RYGX U^"
MZ<CQBRDR:2[R5CUY=;:C<#<C &4"T-/@G7+TSJ.>=N8 Y,H,(.$+W&/*O2O8
M0.!1DV8A:W,[+*Y/J&DG=!9>?'^AX!%2C KLN=R555SQOG4W9B2-\ ZMH>/&
M.3C4S">%%5]K9(WZ1+3)I \L:>:K^8N$)U^,_#7WJSC>U)_TK.A/BC>"S\=L
M3I)8[;SZ!07/V,0G=P[,;&9"O;L"&*Y9*0ZD&1G;+\ T>P.W[&Z(15QBE!>W
MEU6O"]S>HR=9H<H*Z?8@G.@I\JB\2.B9?LBH+++_)CW'WU'QU^#3"\" >29?
M/K1@1ODH=?BJVU+PCGEQ^Y11DP_JS.@Y0'O<)#=^;J?0WN6G%&(KF7%2P]D$
MB*8Q@_RD"#&+16JMLR_L0K[1H^T>;%9KPR#I!$",CMQ!W*O8I3?-?_K-M#&8
M>$F,,LPMHE0:Q"@5B!L<)2EADB;F#GK D[-/G]+M48U\K*0 *IUZ(:)6RK 0
M)&@R/3&MXC$Y+VNIY &P>7IF3%'W '@5@\#VQCYWNXCC+'F^%F$!E@Z?M&[<
MT]XO7L<>S]TZZ.FOO]U&=(5ESBLJ"O>F;];BT^(OIN:WX@^_Z_[T8B"N?NN/
M_/+YAW[/WY7[1,&1VFK5XC<V7*Y\A=M1\!?FC0_S+^>7M_VE5N>9<"W#VYB0
ME9>C;;SRVK=>B\DVY>EWO?;;UV)&'V:P[%:OO:&YY-KWD%S>BZB<";_-3((C
M[C'GLF!J^+D4E4&]&&\U9O3,-ZG6LZ[J @6=GCQ#ZQ6#VH =!"7BOJ;9;L_W
M/)<+W^6@W]C1^Y84X!;L,8__2OOV!QH-?WN_GT67Q3M/>K,[*7YG)?>2!HK+
M3,N=V2MG#X-U_ \X+6Y7P_W$K16_VW0Y_O?/Z<G1Q=G!D4H.CTZO#]^^&1Y<
M?XSVC_:NCL__.3_^]_WP\.@XV2<?DX/AF\%Q\<Q__CR30STX'+YV[_N<'.ZZ
ML?U['!\<O?NZ?_YG_^#?@[.3MV[LYY^O3XX^$VBUZ,R=A0ZTL::I8 PC+F-G
M^1A)$,N<08LYQXEVID^2QB]>IG@KQ<G]]R"_410\:)/9%D>^=9/9CL7]#"PN
MD=2(S,9:T)A8(33-TD1FA&-C9>)9W*UZQ'8L[K%97*M[K*6*8YYE*,TL<RR.
M9H@G*4>1R#+*E8@)(R]>XIAM9=!T<S-XW)W5SU9'[?54/UL>]Y7V";G;1)<R
MX$WD2?>C=MWDV^\XSITXSOZ"4B4P2QGE"8(,(D2IT$C8A".*LSAF7)L4FQ<O
M*5Z$U?F^?M6/J32U/KG2]/]92?1^U(:;2;33&.Z1?EL:@\%$I](Z4TA!OWE#
M"1)1HE$JL!*&4T)3T!BVHK6BX.?ID3KR$:1OH&@M"5A-SZ#]TUVB3=^IW^6!
MHOABYH&F!J;4\7YFX_ ^5F73Q<#].<AN2NAK_M#)B >1$>\6=+PHCD0290HE
M&A-$,\*03(Q$<28)-S2)TMC)B)1L13&^7Z/R'LAK,SQK'7?MN.M#^^8Z[KH>
MW+6E@6.N$L53B[BU$E$A".)QE"'&E<1,"J&L!I\=W\K(JKY9F\=>O0;_/SX5
M:57^Y^/F@^Z7"+4?2H#:G[EB(/HD(BJD4^>0E)%!U!IG)$JJD8F8%6GD>%&T
M4-N[OA4#U?[VJ@W>Q.* 4  P]65'YBOTILI3MD=+$NMS, 8):)S00*NT!WU)
MS_:'[=[1Q(CI'!K"55 0<&]_-L\;ZZD*72>\SS]7:X<F3LT(P-Q"PKG[S!@P
MR4+&>JB9R@L#1K7JA=[I1&B37X<,?\!WE>ZEO1V$X2]_N__(J][L<ER,=W8V
M,<:1;8"3]6@-:GPZ<NL8K-W^-+2!R]\YGIR*48Z#V@3A==S.C3; .@\ KK;
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M&L#WOK&K[02A(AL+?BV7K81A6LH=O#>Q:H'HOBZ#2!Z?AN'6#J#GFK71YSA
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MB.&8^!TH&R :[[E1)J]$&HXG^7BO@CX-ZF) ]P&']\2#/$U*I.@SLWHBH1X
M?+*^OFK+/9K7>X V"FBB =_:>R3<6/I.E=[0OI>-_*LR#]ZO2)&*L[1B_T;2
M@28,SB12D[X,(2'8'Q3V!\'^H+ _[AYGF>7U<(LO:@"BA\3""A$=CD-CJ!X"
MP@.!M3#MPN\>=<%3IW'G,G<UKZ:+"KW/GU1/R-.J9J4P]\(+(:4JQYB8CVH+
MYME'62Q9HDT5Q?+@!*R#Y-9*%&NU>&!SE(Y]7U3C>(W'27[20@ X1!-S9MQ4
MOI@@8(+NT&D03H/ GV@6N?\G*4H()XC2.$4RI00Q(5(>\Y2Q#&^.!M'8[1X8
M&9NB1S1'#IIX1=J%.1\JX0I<]4K<>G<Q<"@GB'-G$@0G(1I<$K/YFOL,O- K
M'01Y@L!ME?TMM3C,O,A[6G<\A)%6(P1V$P15861X;%-(PO5RTK?H[=^"6:SM
MR7M@-O9:3*!R<?JWF?C2IHY[.>X5?TJX%)'0SCXV"7/V<:(1-XE ,A/4G>0D
M3B/:=F+KF%(;<9$FS%">QE*JF"J,28ICG?(%)_:!.]/ 22!OHN<7O^LG>7/J
M,>E2CY]\*%WJ<9=ZO%FIQS>F$K?[/$:".%$:I3R)*.$9MTG"B+!:&B4S:M>Z
MS^/R);A1/+W\0TR=AE&J6B"60EIE/R1RSF<AC\KGC8#U5]Z:I[$M9#Z.YE[=
MJV74POL\^!:DEOJ7E W&&E5PN5HY+9]HY$8TTAE*512,:DAA@Y#8;G\P+ZS'
MIYR-%S\ LEA4MU<H<;D72,-(?6%\\);50>\]%D-^N?'-H%]?S"?0JC%W]L&\
MQ$#-!P446VU8M<Y+[B'ED3*JE:TOYY;3J<,BKEQP;X27N/SY:R"#V'/ZJO58
MF9V9)XH6'X9$I+8CX#93KOMNSDJ0 ;]#U>;UO9>JP% LVM9!/LVX](ZJO('=
MRB,"_Y1E9KD_PEM-TYH+;>F0*X.C=UDTNX <:E3<L21T^IB!#J<9U)K(3\:C
M,3B^O-NJ<U^462S)I]AB92.ID%"2(FHD0,L9@4R6$:N<#" L60 OR%(5"\5%
M%G'*(ND$1<2X4X=B3I5-Z.:X.]X;$/J]ZJ3TFD?EELZ/1YO%*@ Z%7(E=K3C
M?X[2?W0^3R[9]QI0F)B';$P/AY!7<.Q\^-@[&&_[JPB3]<!%J,??>K_DH TT
M^K7 2 @I\F6^:&V;0)PVGGY\Z(1?7L":YNL)  H@AN"G,K-_6N+8U$;=<*8[
MC<(,^B&3!O2 W-7FE!Q3">:B"*3H'^K+)VBTU5B K3;$J?>@0[)^CLT!W4/@
M&]7WRSIK:#,:O/'-D%Q51Q)4A:+8>LOW>"U87.-"2-UJ.NW"%T,&<G[="=/3
M'+O+"?E^0-4-D;D $!$:W'BAN]3/^+L?92@R")AUO@2D4',:\RS[__EH07^8
MZP"_EX42C?ZRMAD"JT<0X1,%N%N(?M;BE-N]PU'O3^%D]^2J%]R8N-7*2$R@
M.US!<ZK#$PHPW':5R W^[5NA,& TKE(IW,D"M.3QDL+XE;':XEQ4?7DW"+C/
M,;8_YR,#*Y4N96JA4L]QMO 'N _A>&L=N%L8T9MR7_:J6I"<P;WRA]\[^TH&
MF&,KD[3@@OO-X%[S&7<2EG[@81;@%M,-5EI9!=5(370*IW?W.ZZW=.<8 LFU
M]!)'$5U]*5EY"4>K+V%/'LNND@A%<>^7O%*KO",_7 5.32M4.@T]!-OWPE^&
M8UVTR00*[D\"CFK1$3*OG"H@24/](1@>=?X& +8#4=5 Y-4;@ZL HUIBKBT\
M&'B K]WU#; ;W=P@6"R=G #3;!* [FV][@H>GLXO($D@SU:H2B@]!+?OKQN8
M>/AT#7#0,<1#-1N#4G)[A@BK%DIEO50(O,N?G,#2BFI*OZ9];XW.:IRS$'O;
MO;>^@4%>@U(&PQ>*(?K>JO4; K.TCJ&._3 A:37 GRYAO^TJE.]EQ+=N9[8N
M*O->SGEOIS'?"25ES73J%1@"-]ERJSJ5W.@X/%A<G?'H9K< +*#_PHT^=QSQ
M%S<<-/9@:[S<GHRW>P^=CB&F@(L/_WGM>. 7,8!3NEN2X/HX-#[G#HUQ<G+T
M^?+X_!W9OQX,#H;OHL/=-X/C\_?G^T?'[MNO\?'1SM7Q]4=Z\*'ET#@?# Z/
M_NB[,5P?_ON1G.R^H_O__M,_>+O_]>#\W>7^T3]G^[M_GA\<G>+_N.?W+S]9
MRP3#.$(D,3&B7%K$<$00DW%&#,%*I5G;G2%C3C)+B,!"TE0ETG+(#A8:N]M9
M%+?=&>\K=R%LP_W6Y"PEMAM'N"ZM,\H\ASNJ:[>+YMVUI>;CK4FS9+7I479'
M!!;LO^Y02*!$*K.88>E.+(TCPB,JA68Q$XI2(OFGO64U(BA9TD@C'P8<U&:5
MP&@^1'KL Y_P_!J5"CPVXU#X$R?2QB91*$Z$112K% E.!3)0"2*B-,I8].)E
MM$V7E 7T!X,B;_%N>YQ(:D1F8RUH[+XB-,W21&:$8V-EXO=XH4;DYCW^:;=Q
M+S[8/8T/KC]?'ESO7!X>O?N4.GZ?<4*12*Q 5$N-G K!$-&:8DXY%A%[\1)O
M1RMW=:L&/SFXVNJ= 3Z!4Z('9C;+D2]S6Z%P-!6.IQQ%I-'U"IHK3'H#]^?!
MN VZXK3N/\;3&7QR7TRG3N-W9M#,O<%9G ,#T21G2GFXHG'IEFGPWG2KYO\)
MBGD896V0C\R&+B;BZV]_A:4ZM,'0?U]VFSH8C_+5Z1C3RA/][A.QA.J4*M!H
M,D1%;)%D*D/64I8XS9MQPN]4I?:CC*?;U7O8518+HYUY@VQJ):*QQHASHE&2
M159K9K2,5PB<U1((K/L:.GW>=JZA!3G]1J'^5W36UT[O_.UG6O4"I>3JX.CX
M>O_\^),[XPEG)'/2@3B9GQB*.*8:X11CK#&A49RT%.MN^:KEHPJS5&F*L#O'
MB!K*064RR,@HX59H+8FS2T)\!""L2DGH:W!*(\G_Y^96B"!T;[8ZVA+UE1C*
M25^?FAN$JB\I6_IN_!!2]2'Y[ZN"^?[,_+72 [^Z(_O)K:UE!C-DK$@0M4PB
MQC%&,I,6ZX0[8O?,-KTK;UWH+@1GI>,82SG&Z2<K(YXXQH#<28^=)F.=S'/V
M%6(XU=3:*(DD*SC&4F[Q8VRB5FB]Z(&\J^L1DW5S/=('=SWNE9&%Z=YHU\C9
MSDCOER4HKWT<^T.9%@9.RA#^/YH(R,W;\5NYAI[*H[V"--QW#OK[_[X?'@R/
MZ3YY'>V3=]'QT6OJ#O#UP?7!V?ZY>]^Y_GSRJDT:QY?[9._KR=MC<G)^>GU\
M].[Z9/?]V?[1&>"BQ>Y=5S#V _+^\W^NW3Q./QGFS"MM'#4X@8DH=9H'TRQ"
MAB08.VK0.%NHO'"*B4A-%,>*133A0IHT)7$6&X5CIN*%RHMJ=WK5QCPO#*&;
MEZ2YA,SPV)G_L0" #F,$UR1F">.)TLZ<<H?^P1LKJ3.CYP-S:'>**N<WX\D'
M)ZRK+7+BW)E1_4%HK^D+"WYJ:KG\%"7",=[8.+&!G;8)"8M,VA1%J8HEX^YB
ML@"VY30L$UNKH]1DP,IEE.',*5N$9X[2LK1-+1YL:@R5WS[?9@HM-N;#H9BT
M\:961%EOIZ/V?O'EU>.YHP4]_?6W6\045Q'H3U,+%7>U4$\^E*X6JJN%VJQ:
MJ-N)^B7M&VZ2&]_.!,\+L@MF.W$$A!3@"UY,S6_%'W[7_>G%0%S]UA_YE? /
M_9Z_*^?0P-:_.!4:@/7R;?$[%"Y7G&L["MQK-G'_Z.++^>5M?^E_9GKQ6D*V
MLPBOO!QM?^^UF-'O>O);@\5NL(QMR&#3;<<>N[$^R"'@R:U>^S^>&@)%.*(#
MEO'_OHA?5,J"]OT\HA[V1%N\[WMN)7CA7G+Q%>Y>% EM@@ZT?#]\EM_$9J/%
M](T2H:+DJH^\>-6M.:OTXO1BUO,>GAXLPN^/\Q)^AY>L\?Z^G4#6ZL<2+Z2Q
ML4^Z\FN\:*\+T/&G)X,-6"UH,'Z+8_6\)OT60#Y7SCK=I*F$6HN?;@??0 N!
M?Z"%P%VH7 KU&1H5C33*1Z>4,<X$_RZ&-S!V0:E_R)58,/*##E!X'I$=3]!4
M- "D?KN-Q%BU*'<1&-^_L#_R]FZ$&SG".U.I]?^W_K3X:CRY&/NV2=K(68T.
MOXL,6[-N;]!=5BOJK>V:_5=[;>XTK_I\)O#6IY_0'=)'1&;2C.*4:ZVI28V,
M3"*9Q":E,<XRN2(I,U[H:^5.6RU:VXI%[0P!1M>9#Z#KO;I+0E^\H0&JXW__
MG)X<C:.#MW\.3G;=';O'7]W[HV/BOG&DK@[_/?YZ</3YZ\D0$#ETOWSF/W^>
MR:$>')Z[=P__^7QPOG]Y</[&S>7]^?'UFS. &3\Y?XT/C]X,/2('^?/S?Z[W
M9_O]Z.M?1Z]G[IWX</?=)YE%G$=IA%A$!:)2*^2V6*"4,FXM3XG4\8N7<;(5
M4;*0IQ)B33]"%<"#[T@='6/J&-,],B:?UW8#5U)J/IS[-#SOYJB\'&"=Y6SJ
M]ETQ.E9U.U9U\*K)JC)+,Z8Q1C8U!%%!(L0QUBA.61H)EEF9":B?]^7^':_J
M>-7C3.B736%6X']99%8=4[H;4VKI3X9D&>8L1BS+%**Q3!!368QXFJ01(US@
M2+]XB=-X@2']VO&BIR;=9\>+GL"@6YU.V.13G37W -SHL*4B13:*56(Q F0-
M1)F63D5*!8H2GEJ<)$;&REES=(ME?(TTI._UA:^]EVVWZ5LK +?D5>C_>0H-
MC48^G5.<AD:7#^H%)W=;TJ6<>_,XG:$BP\H)9!+%5(B(,66E-1E-J!0QZ5Q7
M&\'L/BZXKN*($LH3@3*;,D25X8AQS9"U@HA84Y60[,5+NA5%R8_RNN7\YD$U
ML(ZF'Y*F.Z_/NE)YV^L3&YMBD25(1+&C<LX,%%#&*-&Q._")S2RH-/?D]>GH
M?-T\)D]*Z)W'Y#X(NB6VB8UU$@F,I*(*.M<!!H42R&8T<W3N+%#MQ#9>1,>Y
MO<.D(^-G)JX[9\,:$'+;V9 DPD0J-2C*#$4TBB425*=(N8U-LR2E-C8O7L9;
MG*^3_OUL,WJ.QC, RZTU2 '8<P&PN_"+KR8=CW),>N@:;Z9/DNQSNP3&Y^0U
MON6,-YO%?R=J6^=E62LNKQ:\+#KAS+*4(2TM013;!,E8IHA+);A,L-86N#S?
MBFAV3R[E6Z<XKW,(K&-S'9OK'$\;Q/@6THT4)Y01@6*",:()TXA;KA$5U))4
M6RV9O>]THX[S=9QO;5UQ3\KZ.E?<?;"XEFZ7D$P2(C726$.Z0)P@)F6"4DRL
MRBC-< Q(U=D])"]UG*WC;,]5I^N\DVO VQ:\DY$AJ9092MPN(FHSBJ3C:$C$
M<:)(9&EDA;-;V1;+%M&NUU%[RQV7Q2B*PQ[P$)^@DK*K%^U&V-7<WMU#+[Y5
M!?^$#OD<_BMV.Z3' %0>MNBGU7E^;#TZC6B91M2R_NK._#^@5V^G$MV?2O3:
MJ4-[L_T/H!9]3 Z.3J-/6*N8<!LAF4;.WDMCBUCLS+^$QR9+A5$RQ0_CR_\A
M8MH,J[#CGQW_?&3^^<U 01<AN']^^J[)3Y5.I#'.QI0$P/2EM4@F(D.*L811
MSG0&G=X>)$30,=2.H6XZ0WW,X,./<E2(/W2!A^_GG,=-SLF25,41$Y#Z&R'*
MN..A5 FD"(M(H@F36-UOY*%CF!W#W'2&N0;\<E5,H[/<[Y=?GC;YI:49C06&
M2"T6B.($RB<,1XDSW26G(L8\?IAHQI/P3>\"_A_?G>#E31VB7JSNTM#U2^CZ
M)3R3'@2;--:N7\)#]4O 3P\4W_5+Z/HE=/T2-H&%=/T2NGX)&[B#7;^$KE]"
M-\(-'>&SS=WJ^B5T\)IW\;\2I85,J)&15M2:A"N:I#A3)(H2$E/K_:^X*X?^
M3D_LUX.W?PX/KE_'AV_?GQ^\==\Z.KXZ'KZ[/B;OSTZ.7E_N7_]QOK^[=[WH
MB7T='0_=3(\4/7F[[YY[/S@X_[-_LGMP?O+6S>EHYWK_[?[E_OG!Y_]<OZO*
MH<_5U>'1WJ<LBYDD3*)8FAA1DC(D9,21U#KF:<:M3*(7+Q.R1?!].6(W*!#5
M,:9GSYBZ N9U955E 7/.JHB((HY-BK#4":),2BA@IHAK%5,2IXDB]YZ=U/&J
MCE?=8];/DS*KYUQR_'A,J:4_V50:8A*&=*(-HDE,D+0X1EIF:18+JJ-$OG@9
MXZY=0L>*GI/:U-4(KP$S.FQI2)&RW!*5HCC)@!FE&9(144BDU-EY[G^IE=Z8
MPVPQ$;%KE_  3K;AT$R4>TWO0ER82=<,X=[YF*2$)HK%&6..CPG-4YO(5&,M
M*57<RLXOM0FL[.."7XI0P1F-8D2-X(@JI9%4"4981X0E7,1I1'SG%\Y_F)5U
M\,K/C*@[G\ZZDGG;I\-EC+6.,I00;1'E:8Q8)"5*,BJQ(V)*^?WUP.SHO*/S
MF]PA'9W?#YVWQ#EG*L*9B!QABP11G,5("FJ08E&2\L1(361'YQV==\Z&M27I
MMK,A8YEDC%@4TR1%5-@(<<D<<:M86TP8M<:LH8;^;#-Z'JDWXPVNX5MQNMNZ
MB3>/TR4))[$TJ< JI3(S0BC*%7>,#R>69*IS1VP"LSM><$=P8TUB,H%4ICFB
M+$D0R[1$F>3<*"?:2 +(LF0+X\50S\:'GCNB_B&B[MP1ZTKF;7>$2%F44JY1
M2F.*:!8Q)+&-4:8CQ5)K8[?ASSC%Y#G2^5W2,YZ4T+OTC/L@Z);<CK6R$8X(
MXB;"B*:)04*2!&G&:,)QY*Q/)[?9L\K.>(Y4_ 0J>.=L>$(Z;CL;,.,L!GS/
MC&&"J%81XE1$2*0\3E(2$PMX(:!_1UUFPR/0X^'LS$SNI72H\YQ^L]$LH39C
M(HJI9DXE-8)%B90BRPQF6E+2^1,V@9^I!7]"1"2Q<:J0Y$2#/R%%C NGH3":
M4IRJ.,/RQ<MT*^:+NDD7#?FY:?H!W D=-=^)FMMN XRE,"E)D:+"("HT19PG
M BG+DH2F;L,3[K23CI([2N[R%S:#PEORFAHK,I:FR!UE@:@5#$E&&$HDB;")
MTP0;W.4O='3>N136EJ3;+@6BJ+(X98A14,&II8BI2""WHXH;0ZR.TZ""\S4B
MZ&>;OA":2=7R%R[[L[.>Z+GS#[]< 7S@>&1Z5T9,>N-);V"F3]E=ZN=#GW[N
M^-*)=(P]L[$6-"96."4^2Q.9$8Z-E4GG:-D$+G^ZZ&A)'.?E"4?,_0=1@A,D
M*%&($T)-9%)&M'2F691L93C=B+Z9'9_K^-S3\;G.^?34'*[M?-*$6Q)SA7 J
M,:*)="HL>)9-FF:<9"PCUMR#\ZGC;1UO6_?\G2=E;EW^SGTPMY;ZIB.*I3:)
M8VZ),](CJY"(,X,$-S'#6'-& 5YET4+_WK9*'6/K&-NS4]HZ_^,:L+:V_Y'Q
M.,'"J6PRYA)10U+$&<Z0BHQ,"3,ZMCQ8IFGVPTD C\+D<M]D,8KBM">A/]'C
M8SUWB-;="#M4\+5%!?_)\Y2? %'[8#Q2G6B_;]'^^O*OH[V\O:%[YOSSU2<I
M,B'CA"%,)'.R/4Z1$,H@:R+.$YPE2G) A=Q*TVR-TI4[PEX'POYA%VM%YEUB
MT/V3^KLFJ;,LEG&62,2)48BJ)$8\=:0>9RG1$B<<TZ@K&=PH6M\H1.>EQ-X1
M]1V)^KA)U-C**&4Z09G-K$_*1U([EFDYS1335$:2.ML\[@H'UYV6UQ@2N=/&
M'XJ:3UO4K&D<618CZ4@7T=0X$<UCB31V?^>,)LQD7AM/R ^G^G7%@_>7ZC<;
M]V:78Y_Q]R"UA3_N%7HVT92[S7BS^?P3I/IUK/Y!6/W7!<<+3Z62UAAD=$P0
MI;%"0C")F,JL87%FE0>ENQ?'RUT;LCYE 4?'ZCI6]Q39?ITKZB&97\L518R(
M$Q%Q1 R%(K6((@^AKR.1$1+I&*?DOHO4.N[7<;^U=<X]>3Y@YYR[#S;7<LYI
M2U-*,49*11I1*0GB*HN1P%DLB<XB3,V/.N<Z[M9QMV>NVW7NRG7A;RUWI<0D
M811:W&;.?*62&RA9TTAH1@6-*+-)<E_NRD?A<\\V72HX,D5!0,B1!9JZP__
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MS8@W2C/'MB4E5((OSO(TB2C\J'%L1'SKZ'5'O(]"O&V[/I)@R3F37L<D<[:
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M7\ 9&</9G6-=%9PM',ZFPEQ<1,HM"X@9G!!G42.K3$+687B;>:MUR'#&R<N
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M6Q5B6>,T+4 S-4X3XO,Q#^?J;F]8&G8V=_>YXMH(SE' B2".!47.<0G: N:
M@>U*8 8VA%ZCLU&O[$J5TC"9=7\WI(@:S$UIK:&$<*R22T1P0HT@0F.+7844
MSR(;!*Z]+[724BJ&A&$<<4$LTE%X1$ G-<8AVP0KZ[? B6L8,;VSG%S/D"X3
M_L[ZK9RW_=^7YR1%4#6=MMNK([^[U9\X-;E,R!^'77,VW=S;EV4<]@#<XYSW
M6#OH]P:#<170X)<HM=A];BKN/R&YUZ+ZGT<1HP]YK"\JQ/_T@DMWFKO[8'@Z
MP@5#TI"8DS1 <,%L11J@AAKLO,(Q.T9\S=QX+'D],#P.VM7L"<C*CU8.PK7/
MGT=6Y@#=7''9N3O2O4&!8?6+K_N.:DE5Y,B!EP,.&@:;B#F-/!6!&!:ML+XX
M^N$W'V.WRD.=2R@ITD=A ?-93MX7Q_S5@R),W $8O"PQNS25XH^3?/0[N,QB
M=M<*,>Z81?B\ODFC]WTRGCC//TFM=K$3U.SIL ?""5;CX#"V4TXX;PV&HU#F
M*)D]UKY$G[N+CX^8M\89)>\NIW/R!.CRFD5N"DAZVV9G.,)<^V&1,W##&/-*
MEOG3H^.[(L@[,:"9+>7DTM4>O1&B&]8&E\.%8=F<93?*CL\@,;@JB^FX<7U>
M3@J*O70=>D#[>[5!*Z?YVV[LG0[:4SE,Q=041XE70=]BSOZ,A5S!!W_]]:[V
MV\KEWRO_7"UVS<DBPGP6,1+#U6*/+H)RXPSY_,SE:7A>K<O=\ZJVY2Y(:#UC
M"J>H$W6<*FVBRY$F&47T3F%6(B$AF*'QBX4BX=L%.]K8/#YO''G<:((SN'F\
M;[4P*:2( .? &10>(ZLL_),$;$]"2U@7V"GI3Q-XIBV\F:+QXD!\B$#&$ #5
M<1Q>BMI$?<<\U2_K;Z]J60\S$WJG-1P7RH[UY4K26T5U3&O8+@]&<@0$$'5T
MM>R=7F'O)?WMW5@WP%-)"H.O@A7E-GBK R;,!N,MYTG97TCO#'%VX9P4Z2KO
M)@8[D97[Q_G55T9E,1N )V%<XUTXM#NI#&&5+N[2$74\MZ@WC_<-I=ADYCO.
M;?Z'> 1+R9 "?S=%IIE6L,>S&3'_Q_B@KW05RJ2-RYC&-<$O_)DK@9X"Y8><
M"SXL'.>EIUHDP%9/N-'<8B9<#)I2ZIPB=FZ(OW*RGU!$ZW#MXWUB$]4$&R2$
M 3-4:3!(&5?(>:P9$4YPC@LZ=R-6J9H5U;'/>Z,(3CF_U^S5.V[B#Y2IRIUY
M?)FZJ%\<["<6J(6E0O "?&'!!6SN6B-%$Q,I!<:ESC4GLWV*+_?W:4_FWN[+
M+3(-;@(\6V9E_G2[GHM]FEK#@I>2$,V54$XH U.A0TR44R.O;]<5]CV'G#:.
MMO8%=@8\[8A\SDO@T5MDO$\HPL8,EI6*=-0)32O OIO#C3_'OH<@W@,EJ7);
M%B4L!_O2)&F\ 3-.6Y=M.8:TT Q9(Z44 2ME#;@M\FE0[<5$97X&OQ-,6449
M_.GPL->':X>:MR?Y''UDXUYO%W*5[G-'B_1>%*=SP'C"ZRE!>.-RX!7VSE>G
M;0'O[SOL;;)*(.<R>W%N_F:"Y(@D+#FUR<O(?T)(><.JWH>0LEK5Q:VJ-TE@
M[!U,2)"(6]A 82DM\D([JX5D4N;CW/+(;NZQW6W/\5;O=9QOHF*"X4B8=%P9
MKS'%VCM#A0/]CZJ0$' :*+Z]A'RT_9W^E\R=$?[._?.JL_V+G&9ZL.^(8IC(
M;.MCD9O+PBXIHT*6A&  ;(GS;F6]:$U$YASNVW[9CW!UYHAVHU-&+O*6\3D6
MM"6A8*DK:8&*P,AVU_?Z)^-TY*NH>U$=.JH%R<E)$YG4VQ]WUFK_KTPCO*1K
MN>$4N6!?R3^ZJ@$LR:4RYUQO>!74CNT1-]7UC>N_![70ZL-'F?FM8/_JQVN1
MPUQF4ESH,LFA*$PL+OE]HGSE>Z]]VAUF^J^"8>OJSW;K?T]SBFMQ+!' LLCL
M*L5 2@*^48'9]6&5F^_AU1Q<3Z^9&J/-MNQ="@#>#%>,OIDKIN)ZJ;A>*JZ7
MM\[U,I\EX[X)S(_!:O=3A -ELWE3&?9;[G3^]I9#'78PB+D,>[.5#WJ[83#F
M?;L\#B\ITUK%=E+LMY=[3[=]7CL[C+!YV1'S9"M=_6[D __1L_U0'F5?<QFS
M+ST<QGAY1/=R?.1Y]28W,JL_[EAN'2W-96-W<]4LIC)X(R6X@%P3:B6Q 7ML
MI":<"W5K![P)^^?@M'\^X:Q==]%2ZT<,Z"+V>V_8(*^3G<V-?2<8\89*I(QA
MB!L+YH?#'%'*.)%"*N;TRGJW-V.,#TLBV((#=33?(\/XI9!NEI*1O878SWET
MV3Q_7U(V;(^2368J4AZA8JG,L_2',9RVKY^9CT?VOM<OQS4>5F&9O.D*IAQ7
MT-2QW-S*.>]1CG8C@R-'S%G"#2 AQW&Z(FF)2V>N$ZJ6#$>%6!;LX$6E3$$@
M/]_WS+([HAL9)TK]?ALU+)^R:CW\IEL/W[)?V],W7YG?6N9E=D9^:$_DE[I(
MKZ<3<=6R>9E;-C^]X(_LQ_ZD_3BN#<H;=.]T.!C:,JHZ.J@LJH,&-\K1S]K&
MW:GG[(ML*#?7*73")B^"X<)9[FRR(3D,7B$+UBM.XGU.9=^5I\?E^MUH9+_N
M4[VRW]Q)9V_S$V\<;5\TOGTZVVG"O8XV\&[GS\.=;W#-YK9H- ]HH[G+9_K-
M=?:.&YL'M'Y4)[F_70.>"YZOM=O9$KN=_$RYK]PN:1P=SFWZS)EE3DF+"/4&
M_$X<D+;2H.2M%HKF%!NZLJY7X?^KF.J'=IV[:\?FN_:C>Y06U!4<S,"!E.#6
MI9!8-)J;X W 0S($JR@MM<[?YSB_@H-G@(/IQM4T"0L+ASRG)+>I)<CFR@^M
M>*+1,@O"OK(N5[G4JV+.T? RPL$3M=%>#L-G%'RPN0ID,N,QYTZ,&& F6*VW
MN]E<S2?D']NV^Z;;;<^W>IA@,4I!,RD6;(LN5Z=A9HQ62G 7*JOG)<#<;#=N
MSAD.1@I$N4^("XR1890!Z@5K >N\D3E)=%4*O&K$3:2N3]QKM^J0O4C5]E[+
MI*PGAF*><-26&Q,%2UPY1U*H+)@7HMI3%@P.U%C08D2$YHA3QI'6*2"IDN%1
M:Y6X7UFGJU*J5:67I(WVVPO0_-1.V>J<M'OG,8X,ELN.Q?<V4N;,U.M!,HPU
M5SYZ3*7BB@1GI+<F:F(9Y\97H9D7@62?9HR4I,#T3$*AY WX8HPE,%( SG",
M&DS1B$,N>]+,K)H<$U^()_9"PR^O4[%# J4VPB<0 *Y-,LX(XY(+FC(6:15D
M>2F*/66B,*6(HM8CIQD#$\6:S$$54 1C-/'@@L=Z95T*O@JFZ1(I]IL*I'R/
M@Z+VKY=Y1W(RI1^.27Q*EIXJ6C(3+;&.! )6B$@<7&BBF<U6" &Q#I@Z7ADB
M+P&OOLX8(HI)1T.NN@X1(QZL0]IYA23E/*04-!@D*^N*LU4CELFAJF(E"U)L
M%2SEC&L1".'><:VY%\%J(QSQD;G*$'DABCT=*^$I&0:&B+#,(ZXQ1\81@H*@
M7F'P'94Q*^N<XU6L9NDPJTC)PM6R61"97.663M5-7*:9S@NEM*9SI>]_C#W*
M(F6P/*%WFG-2B\.XMW;(_1A,!!7L/37L[<[8,R$8\+>80$)E/ID0 S)*:F03
MQPZ3S'GN,[,AH!Y=U0\__EF@<KV@F$R%)8_-?U%AR3-@R73"C&%)<J&1-D$A
MSHB$5\:@E!0#//%:)9WYQ%<IPZM"+BJ<\YQ84EA?_RK*3B:9!28;""UMK=E,
MYZ.7T<_G#NQ,E\T/2Y[KL?F8^T=G#KKG(F.ZG/B*N><NM:&\OKFQKPC7RHJ$
ME H)<9X<TMPIY'TRWI'@A?'/MA]5"WO_A84-0FKL#&*@6HA+:9&1X(YSK[RT
M7#C)0K%YX'LP,N4S]0&@=\' ,T-#?Q^&ID<"@XJD:8YX-#;K^US'9"0'Q\13
MC#@1 5FN,8K1,^Z<328SL-^"I*G5+3B+>OU:I]>/N>%KT7F@(&Z8WB52ZT>Q
MCYSTSF)_D/L5E$*4"V;&[0QRG^Z2&FE,$)3O!A9#Z\26AR8G8SJC7F9Y*/F7
M+DG9)UM"A1']Q.@KN0%&%ZR/DH1]]-;W7G'1\9\@-[%3WF#\U@2ATLP0\\.4
M;.T%<52I'[G-Z+ U/!V6_7S/+^<D=T?HG0Z+]])IOQA]P?64B2Q*3;G.\?C?
M@_*:(W*,GQ/9WK!7YSKC)=J7=ZX*IJ[A-U@O/F/X&9B7@]A]<UKI?\!8>?WH
M*]EI;N.=YL$^@ZT9]DN./'4 X%2:S,KMD<"!Q'Q*[P5;JIVYY"&N5O47JRJ-
M4+ C1PGN' ^P(VMLP-Y20I& HR!4/%LLL5K5>ZZJ 6UB$0MDL+&(8PK&5@2%
M#=$:(G/CK4B72E<K&+[MT@8.7A"G M%$,^<S!H4U/"'B;6)*>>5$G$N><X\W
M;FEACUGJLPETM8Y3E#SS"1EOVTY<+ET[<?+H[<2O&H<7##V7/7$^9SLTM\D9
M# >%]OPQT1)GL#P4/;LC7>GA>O,KJQ]]RH''LP;\KO[A<WNW\_?Q3O-/^.\K
MK5_41>/;]OGNM*X<??K1:/IS&,,YZ%Z^]MG>A[];>]\^B7KGDV@T=R_J%\=D
M]^C/HTS1 W_O<V(P(=)G3IZ0<^(]F"F"(I J#I\(F'\SW;&;>!P,Q9%&KKD/
M08/L:>&T#R8H0L,TI4\!7*B8]MKDRMRCN?BO;SW=#]U)Z6DTW"ENO-2!<T&4
M<TP'PZUX(-_0,S&\92*BLK'%C/<R0_YZY<'E ^'+%FUW*_^K_9:_N5)\-?^]
M\L^:_94O,_<C4@0?GXET[DK[?]XSZX_IGEG7&W:\O!#64T/+9.N%C;/<HRC!
M:A&&'=C-'+PADR(R0EC$/ ]Y&6D0:65=K8*IM<KGE-Z,Q3L+UAVEAUK'A0^8
MP.ZBHM?,AL1RUC3\+^%T:SNLDIYGDI[M?2*TM02DA_+<B2W&!-)C!9(1?&Q%
MN;;!Y>;S1/-5/N=0?B0].3XT."D9Q=OG9;_,!<(H42,8W>Y^GX>=\/EML?.>
M2*D=F+M!2VYH[JZ%+>QP*<<:J  %P[&2]267]:.O^V  6RT$08X0 K*NP18+
M."*/*><$K#4:W5U]46J,3(G32'T D<C%K$(PRZ4((49-JAUT^>7"8K!D38@H
M.@(8:#5!6E.*1.0F$(RUX@4&&J96E9SM\G<3**[5-G*[X-&*7+8O+D^$N_%L
MS(@U#74%M&6(\AD(V[FWP&63ALN^#=TX&(PYIB^-QP+ANKW+&/JHT/.LU6YG
MDNF#W/(XAGGW6ZLMLFO2,QGO7R9YQL:Q@"ES_'*:KJ8Z_CAI]>-/G6C%.&'!
M1*6LYRQ@9X65T5')#-C,^#9.]+W;RF[EX15?_@@#Z\V).(;3_K*$I9Y:FP_X
MSL8^9R:Y(#C(4D&GI14RDH()' AQ21,G-%Y9'\9NT>5U,.T<C_HC@X2$4:^4
M0E'6:J,*I>&A'8Z$9+5H^3&,_4ZK"$"MU@:G_7YNOM(OPTZERMY*[,:'7H?V
M>SX/<Q'&ETYS;_0QCUZXU%S[W;;:!4_M3!EWT04E)QB5C4UNL+**9RC'/AKL
MJ'7,^#3,G>?N)>/SQ+*US"6?7QY[OEEQ!;C7U<]_;=[];.1?3RZ_-SJ\'-]R
M3O/)08&9$]Y*B.U6/K7,7^V,!S3Q""^%BOOVU?=+GC#5/%PBKOZQ S(6F-M%
M:WZV#).AFJTO'S_>QMV8-R&/^]SW=' "2=B"!2P\2YPY880#NX=ZQ7/5&:U"
M04NW]5TS9.&SK_LL&3!*6$+<X8!XR)E-1 68*TV$L.#2,[ZR;C1997A.(\Y[
M!X*PB3%AP:21@:LHM*/6)>:4D3:)4#G'RR<[O-[\M*^BD@$+C8+B("\$"V0#
M5LA3ID*@@K'XDY+X&T(_FZ=%D]8,E=G:JI6=Z>[08OINLF>PQR1Z%IFSW-(<
MFK%1!9$L6.S@T/VB[?D\(<S(7Q[NE\]2FMVE:(WWAS*';K0[Y,UA4(G:KV%J
M*W]_']:+:*4\BMB*S,0@D;8BUT,20:A6UG@PUPD'F-(WBMW,Q@T;<AEWO'\/
M'F.2Q%Y8(QGGW#M+J/-28IQ\C#;2LJ'T6)9N!6B+D*6E;-CSU&*T_6.G>7P&
M]P!1^BIV-OU^)C<(L.,@SPK.,8 PD)V$,//16G"S4DX8FMN\IPS!%!F(-PI3
M+=P>R,ATS^FJZ6-.3#!5T\=G'TK5]+%J^OBRFC[^,K%D*A$%O%;%O,;!> *.
MC[9,.2Y!R*547FGSI$TB[QCZ^7Q%<E0&'+Y>(SEZQ,9K8PNED3/_!S" JZ%,
MUA1EL[XU/%^RGFO/D-!5]%S#(A%)48K!(LXD0]9'!U-+$@M> YR^M)YK5ZW5
M1EW03CLP2KC(8-(S^[__I2E1_Q[,Y^0J*C2RD-RVY]I<Q'W:+FS&K&G![MF$
M#>O[=43[15\S01ZG"9MXG,$NI G;_6FA'L: MRS]HDJ4O4UKK3<^4=^*/V(H
M3(D-& YX#<7K#_FHKG3&-NVP?.^];?5K157C<_3B I1[2D:,KZ/]>^HLHC9V
M31^EW];KI0Q9&.O:O6/96_]["IOI=A>VVM,BD7XGYW(T#VVW3"(>7)IL9=3[
M=0<>1U0C[48'OK_Y!XSASZ.=YB[>:VZ)W>8VW&/W;*]Y3'>/-LX:S;VC2WJ2
M2ZJ1KW1O<_>L_N'K>;T#USWZW*XWVX?UH_?MQM$?[9WF7JN^N4$:G3K[S\76
M#&V1M8[YD 027F'$$V?(X!20559')H2A-"V,K>VN:O?,Q$2/"Q_+00[W?QYM
M\>ZP:,^/E3?S$]P/,.DSP.78AAB9#X7ED&V&;"X4UD(%EG<%RRE>)D^8"!AG
MYSAGDQ-*D!.1(6^24=(S'R7XQ)RLZ=GCYR6%R@71;Y< QY;.>BS/IBI6[1DS
M4,1DN33* ;:)#&^"8$D\Y5(9+^7MCY5/^O;'(Z);N8#;\W)#*UOP0? VV[95
MZN DIQSIH /B,E" -XF1(BKFW&!.<F\0J>2J?GC3UHJ2>UD-GH=! WT68*AL
MGX6#PS2M-R$69UKO%"C8/DXSY(@4*"0KF3/<JV1S5LN:># =Y?*1>B^K>?-W
M8?B_A>YEOSV7??/X#ERYB)6)LW@4F^W12@*WG(N(I(F 8HEZY+P!*%.*:<D]
MT2&S=&.^JO%L)=P_[^J^+5$PZS6"PC-:-T\-"Y6!LW!HF#)P>%!@QUB.$G8,
M<:(M,@F0@B5B6+1)%@3^G*_I1<7!J_C-+S7\?:^?8NN^-LX+<]9>L8USN8Z5
MF;-X+)OM\JJ$83((A80P:L1=%ZU&R4A+G _$Q;BR3J5>)7/<M=N;.540IS)S
M%H,,IX!OE8VS<%R8LG&"E3[R)!%3QHQJ2A*52&#A@Y X$*T!%^@:7J;X[IM,
M;*)5R[6E:R%;Y3R]0!2<;3V;2_ZQXQB1H&1&08:LTF L)>)!/!3#P2ZL]>P2
M]%:Z(VS>*N?@GKE2BT>DEYU&];#Y>$G(?+.M>C]XKC*L7@4T3QFHQC.O% G(
MQ@ &JHL).48<HO"O4=E6I0H,5+:&U2L Y@<UO7OV JN?]:19';$3G7;[T?<.
MNN-NPY=Z"7\,AF6GGY)MZW1L#L\MPAH4E#\_[2\U379 +7$:1YDLX1I;%T"V
M%"-*NT1HE/-1!8EI6+ED,8C][RT?YZ/,)4(4@#(H.BY/?IXIY!N]X6Z$P8VG
MXW8VGGRA0/( )@12W_3[-BB-O2!(&.YR7KI"QEB%4F1,)Z9EB"RWTUV;PZ !
M$MXNR.+.#EO^,'>CBC\R@TLI:"[6)F2R]SWS2-;.1LB.; GMM9,B2ID%_&<%
MJMH);X0BT20-=J1UW&6Q<P8,2Z%UND6!ZJ/)5QEG?=_KC][*WR-SR14S_<,;
M%+.=S8U]H[5E!+8:8C7L-Z'HW\(<DE+G+DS,) EB1M>DF&%5++@67PH'WR1+
M_Y/67W_QAS&<MN.(NVI&LHN!C<9556-?MM<XWG<T%_BS /9/SK<*C" KHT>)
M./B_#9$(][JKL:\19]Y<A/W4M=7@Y^3FB/<IKN84)MX\1KTR-X]37,VKP;ZD
MP0I\NP'](J)^AZ+K%U!;W1AS^!;%T[<N27]=DW!C@?G6B)&X]-\^@@U0O@\&
M<$D074W5>*H^QXYM=6'TQ5^9%RB['*>V7?S=C/W.FYNKC8.#?CP8$Q-LPXRT
MNH.6+X7ISA0%=SRP>_KHYOP0T[S@^AWJ]E[P8]Z%G:.:D07-R++H_F_;HX8#
M,_E";WY>2G')_0_@.F%J@EYG.L-$8]G'H&IYG9D)"VOU>^_#KU'H96+UWDX&
M0H_L?MLZ:WS8HO5OGW[4Z2?<^/;GT<XFW*OYZ;R^><SKS>.SQL4?AXTO4\=<
M1W\?[C8W\&YS]\?>YM;%WN8GL@OCA.>"9]D^VVD>_-AI;K#ZARTRK])6P6)S
MZB/"*N3HMJ;(61=R'A:/E#EB$UE9EZM<ZE7PZ98HW_R)J%5>Z['_*SR^7T8,
MFSJH'_NXA7=;@===P6OZC#ZR:!EF"$L1$#=*(Q/R:;VE,7#G;+1T99W(-4-?
M'W"]FFN\\L*A#V4OP+=0-G3'9C;W.=-[5-PNEFHP+@SZT.\-7GFSD:<%\-DB
M:)#XY*1-R#NE$-?.(FU=0IA3$I5.ADBP/MFJD6:5X0>#>%4DM*26VS- P>!.
M6%"9<8M$@2DSSB7MG.$"$1\$XLIB9&10B%@B!*&6&>]7ULT:G>5!>#T \-*O
M\<KY;<8:7U'</(DA][-N7I.)6I?+4MEIBT/H.57<UC,-QACBW(*C+3A'CA*-
M&!4V,>I3@"5=IU*L2CEKI55D-<NEWJ_#0!NK?F6C/0H"3-EH%I8UTD!0D %@
M (> C'$214,5)H1JEPF'V=J<]J55I*TZJGBS1Q6+Q5'$%AWRFD'1HJ+C,GWJ
M>BTAJ\#S5N#9F )/,)TX%9*AH&($&RI*9*+!* 4//J["4@>ZLJX75N)=T7G]
M4F??V:Z/[7:NN^K7*FZOEQ2EG^#I>4L<7D\%7[,L%2"$PFE!D2:F8&.WR'(;
MD6+."2&IL3E*3U89XZN$/(2L=(GC<Z\( 5Z'_S<'!BH/<)$H,,-*FIB0AB+J
MO$.<886TX0QIC@D76%I%29%L(9>)=GU9PN/+<HVWFO*["!*SM]2=T5OI%-/$
M14I UZG!W-F@F;:><^K,XS.55?G CX_RNW/R@8DUD7 4(T ]S[P7FAN)7$P\
M*.^B]1I<U560A%7\\-X[51_&EQ^>>VM]&)<1&BO+=Y&8.&7Y)N6T(A0C2?,1
MJ/ :.>4L\B$J9@21W&.P?-F:>7""R@O#PP59D,N%!8]&0)-UV?U:W=V=U?VR
M''RB$CP7@=/71K+TU$C0F+:.HE?"8XI4"AYQ(CTR^14+WH84& LN@G6T1N4,
M?=XM*K6K\\ W=QYX/UMB\<> $]A2G?T]##*FC >E''<<<\2E!8?*,(R<C03^
M@6U$6*:X(BOK@BQ3WL2"SOZ6+$@T,HH+BJY%!HE&#S]ALTUQMU91HD=WA2;6
MMHH2+1K4_$R42%M"-)4&61P3XDY:9*AU"!REF%N5Z91,KMMA1*Q2_N"TACMK
MV#.?%CPR5+PTL^WN3_V2@/$%!(HFT+$*%"T2%J=L/0'PQZ@/* 2F$1<N(,MH
M1%8S$X-4R810=*;6\JU!XH+,R.4"@V6-%-VL[S=%BEX='?=30\%TI,@E)730
M!A'%P/?CU"-+)4'8LF2BXP'G]A%J[2KG\T&1H@<:)*_5Y'C)1L5C1HH6@RW7
M(T6D"A7=%3.FS <O-*7,6$2UE(@'0Y&.DJ&(8>M01% :Y<JZ$4N47O4ZTXG^
M'K5#[(9K_3IRXXO'2"^J8D./ZOV4J[G1#5NCM6SV\EM58M$C@MO!3,@H8BPL
M=A2!\4,1&,<860S@1JU/4G#B/98YL4@RL5KHT])$PZO3NC=[6K?L@9U?0UL5
M[UDDIDW'>U0TU H)!ANS^8 O(&?@3RMY<HZDB'4J$X.6J;*OROUY>1&=.RMZ
M%>AY) R8#O0(; 5/1B-)"&  )01IRB1RB1HNN#0TX9P2Q!83Z*F,C%=G9"QI
M2M"O(>>RY4J5,O0P2)DR*W#BC#(6D6=6(NZT0=8D@9R6E@>)C5-J99V;134>
MKAH(YYZ =BS-M=98G&O?LSSG>,]D!\#<Q'7$.I;WTJ)C8-Y :Q$>(,QO0TSN
MW#58^F"MD9$DXC@CW!JLN<7&4A><$+XP.LC8Z)AA-9]M'_PT3"%5)^%YC32W
M0.>/2;T)6'(!NK]YL.\$BT*2S'>;70>J)3)*6)2BC$%8;[#*KH-9NTG)1ZV%
MUVIWE-W>%7ZOC@4Y:^UJ$>[\_I/(9VM0@_7SIV6C;%NVR@RME&(_=GVLN3@\
MB[%;O#W6D-I)=C3S*/*[ #VQWS[/59K7!Y7O5_QL, 1)R9=/MM6_>H1Y33E]
MK]/I=4<7*O6P-XA3%QX>VF'MT(:I 0UJ[=Y9S#^QW8?=&"X_O^_XG1?F"E26
M>:)[Y6U#?B3X_N7M'[H ]QO&Y47S>*8Z(&>UR8C:ZIX62'=M QJA/\]]5D]Z
M@Z(E]>]%#_C6]WC57C5;;A._&C5GQ5<_L6[0:Y\.;_[)3%>H)]W7X-^I29GX
M][ _'L0).(S(]:,]1C;!&'^W[3-[/ECYU_5-&W;LT=5U]AJF'_G&!TOI^H,U
M6QT0@$8\JWWN=6SWAD?4MWC"TG" _:77+];X]U+PX5LP)+LL0ZD=]O.6_E\M
M)C&3TG#,4^3):R=,8,0Q$JF,7*I],.N*EM-9![+CGFDP_N=?=OWZ(CZ#>,WO
MY?WQ\\9_MK_4/G[>>K?]97NG4:MO;6Z_VVYL?5FM;3?>W;HE^6SOM"=]C,9.
M<^M+K;E3>[?3^++SU_;F1G-KL_9^N['1>+>]\5?M2Q/>J&\UFE^6=!U^>U?B
M7 S_G!EA.8[UHBOF/"R80LG2,K.8*N8U#L83[C#8*,IQ"4(KI?)*FY6?-/A>
M]),7U[E]?_ELAY9/ CITK=E\[3;BN"P=RL]&X3QDRW@>F &#T\[DICJQ1]9.
M"[.AW!/_:(.?A[[XPUX;H&W4M#QONMD:Z/1";&>++D004D#T6/SF()/=HV)3
MO[X17]_,#\I6)OGWL7/2[IW'.%BM=0KK9S#>M__H@<]06I-@M:+++TZ;#L7%
MX#G[135&V9%]<.E033I6@RG/ZO+0O;A)]GYF>['/6=IR&1\YSNL/8SAMQYTT
MWY>:Y*Z^E-2-JZ4MT+\)(_JC#5]\<W[2ISR^?>.( V/7(<&$1#R"@P0XY)'!
M$3[27L BK8 )Z^U)AM[^:=[MB]##E:%6I,6"FK;MR2#^/G[Q[] :G+3M^>^M
M;J%VQ8_^/9*1D7673<+I]),,".7'5U;/&BXMGU'VR^C.OVZ.KL@:H?3--XCG
M1B^R0?S2AK)_T:_7O*0>V[LYRK4U@\558^UK' TOH3/P3U/6[O*,;Z"+\DS#
MX%?>ZN1S:W",4C\6,2LPSP;#&KBT\5$(U%Y^[F-WE#MXS9+403NK'/PO@J\O
MB#;:Q(B59R)9+=(OZ#+YPF+W[\&:+R+S$S9F7M_WL+S;H]7]#(M[&9M'](4:
MG>-#NYWF-F\<_=W9V_Q\O/>ACO<VM]CNT?'%'OP.[GU1!\.ST?G[<._=]*'=
M5U$_.J"-;WO'C0^?CW<O/A_7FZ&UTVQT]K[EYX1Q;A[3O6_OC^>ULN-!<A&M
M1M(Y@7A2"3EO!3(I!>XXN-.YB15=$XM*;;SU_G/7\[PGTZE_/$8&1 5+-\.2
MC<)'C%,DAG/)C!-2FD0H(2"Z3.!?G"E6L/0"8&DJEX YY60D&#G-# *G"UY1
MS9%0/L@$*$6"7%G'"ZA(?:6P],K[(&Q=GO+&?J?V6ZM;1MQF*-O?3OWNO6RW
M!65[SL/%R_2KUYR]^33P.-O8CF-&(P,\]$YA@$<1D.4",#)AKH-5("YA95VN
M8?449;IO1\GN98E42O9"E&R: LU*%5622./($(\X(1.D1M0H;$C&4,8*)=,_
M5;)7'G:YW(F_]W(:2KLU/'_31:4O+[ R7L&_+Q>P\F'NCA^S_8<B+#?GQ*,H
M<W]P(ATR)$9DF6<.) %V;+ZRKLT:79(RJ[<307F=*+/4<9(*91:$,M/]C8A.
MR@6+$F8)<9HX<I(%%%7TT@CLB0RY2>/B(K@O$V7>2D DM+ZW0NR&VGDKMM]$
M9\A7:(IMCA:QA,C)XI34^A$#NHC]7@6==X/.V:9!G&N%F=4 G=(CGHQ#UA..
M5'#"@\W&@\,YLT*#%/Q[.=B+EMQ$J[I2O@83K4*?1T&?*<--,N(39^ 4"D\0
MUP8C2P-&3@7IM6?,*E.ASQN(H(TI,&KCG/GY:>TGL5\K&,L>1#)0D2<\_\YP
M,T/3 XU3NNCBZ0]9$F_J4UQ\N E2>KF7O!IFIJ?9$V8;%$C&G L<(TT]0]Q3
M@[22#+%@I17)I62+(P?Y8#+-Y2-FJF#LU<#8 ZW<"L9>&HQ-F;:&:N&\"P@3
M#J8MTQ$9)C$",4A&QJB#XROK5*V)177B73P7S/2)[JUJ@9^Q^G+C&L'O=5*'
MU=HPDYZ ZO:C[QUTX;(9LZ]4"?[(Z?*QI&X8]N";(TJ-ZY64=V6#<<(F+X+A
MPEGN;+(A.1RPA_W,*T[B#:10,R0P6Z-JS"^Q_[WEXWP\:/1&@RY4?U#PO$Q^
M_@Z>L=$;[D88W'@6)@L;*Q:8^=6-=;[3/-Z//C#'P"KQ1#C$0R#(,NZ0("(*
M<&5#2'1EG8LU,Z/2M1'IRVKM[+#E#S-1R"1+BXNU";'L@8[6[&PA\4F!W5G&
M'SD+[M%DK=Q]WO?ZH[?R]UY=TLX#Q$PT+K;WI128, P2QI1'W#F#G*<",:$)
M2%E,1--<CT!F,MO*#-"U6Y7+9\1^YH+_ GE0(5BU2<FY/ORG*ON^E=!OM-L]
M7[S:2=-BG05^\*8KP)M^G\4$H*,3\M)BQ%7PR'JM4'!:8.42\US-5( O+Z%#
M*:)%(N)U:R&C=W<0"W/ ED)1,CZ-Z1!^*T@=>J=P]S#XYQUH#JIR^*H<?AF]
M^JH<_E6MUZNJ\GY01?SD8U9%\:^E$]#G.  E!U<K,PV%^#VV>R<Y*+:PJKCI
MY7Y- =G;/_0+B]9.!6>"S_T>B*'411YLL@R\!.XBX90['^TO#IMFJ;LWQJ;@
M?/=AJ[0:;Q=F>>$DW+C1J>/&T1_M^L46V?E6AVO\<;@#+D3C8DOL-;V T</U
M0KL^$WK]1'<OX%X?OE[ ?06\_E'_L)7'S.J9B/OB^&+W8O>\0;^>_>=B>S:G
MB860".-("@U.-&4*#'@JD4E16Q.D9%&LK)M5HQZ]H'_.EK#,YTL5UKUBK,/$
M"4H<]H0Q;F4PQJ7DF(A):Z+DKTZD*JQ;"JR;.F8""29!F(14= %Q$2)R0G-$
M /J\9? _SC/6,;&H IM'Q[H%9:DOF3GZ(79CW[8+:]2&3JO;&@S[!6?UF\Y/
MG]-$12MB>92 2I83*VR4U&M-@[2!:CD_IEO!U#+!U"S%D@U)&LX-,AFK."4)
M&>9R=VUK:)+8LQ16UHE>_?_9^]+FMG%E[;_"\CWWODF5J.$";LF]J7)L)^,Y
MD9S$RF3L+RX0!"W&E*A#2O'RZ]]N@)LHR99WR=9436Q+7(!&+T\W&MTV^J:K
MD.>YR?E^..#AVHP&S'<Y\8GI:[[.0BOPN&:8U'"YMP$>ZR#1#>"AAUP/J.VK
M.@^82G3"5,\F@>KZE+N<.CH+-&R@V#*)N4(2_:!YU-[*H0RQ"2\35J[9M+HC
MY,NWE4R8?I!,<).JF,5K]AL?@BIKKM_OL@N_T>^KI-]GRRO9/+2(Y5+5\VP=
M<)K)5&IS#[Q+0FW#XZY) +$9;LOR[JW?'UR@UB/,MM&G&WWZ&/T#-_IT%?1I
MLYJG9>NAJQMJ8/F:2FQ0JBYS-=757,?2?->#[T"?&BW[!>G3)5J+SN_U)ECL
MQIY;NHGMC*Y-<G0?+5]L?DJC;K2O3<Z]1\;B**47[PZ!R%$(!!^.MT]3+DY^
MK%#.X5DAF\;1KWV0/V9A_N#Q[IX&UX,<H+SNG7=ZGP:=W3[(W9EUL-/,.3R.
M.K^.KD">].[57V>=WG<8VP^"S^GTMB\Z/X_.#T#NX%[RS]7I9>?JVPEG/@M]
MIJFV#PB%:%17/2W0U(#Y!C--8@>^(76LZ+2UC2I.<RS=#PT&KBHAC@]2J-FZ
M26CH^:;+M9D<Q1KAE8KR"ZO>+6[0=?.+IP=J <<XMJ;;A#+B.,SW#(-RL!&.
MR9PPM%:XH=?W!'O8BY#W?C*,LBG"W9P.N0KYGP=#Y9"/QK4#);HX4*)[K:DV
M7B*W1W3RPFS^9-Q7*'R7C+AL*2AH\"5B(F6TI(+R!A^!Q]L-[?W,M^)S_?U;
MY3R"QTE:MI3](6LK;[;DGUMO9;<NJA39+BUX:QQ3/V]EV,H[J"WQ?KE"4W<O
M&HN\]"N B0%E?"+T?U8.37R[];;HHEJLN.P7-D4GH1D'(WC;D">3++X4[<F&
M(O\51S:B8%MXAI_2X#?%!JKP<90B2(\YP\T3!0Q=DL+3:P=W#G>ZQO8*)L'/
MY[!<2$I2KXMD_, FF6*99OBJE7-KO>M<75@H1J)8/,E@ 5O*>9+&P7D4<"7.
M'R3Z;^;/*)O(8D<3L>H3&BNC%$5K+!@F+5D_S_(2S(X]9['#+*S"%7:N38()
M&U=-ZL8IIV,A TF(^=L"^XKC8WP4Q7R4X2B#/^#J(9_ S57^&+P]B#*!G'!0
M"J>LKS# U/"/:.;GXZV7RF R+IL9XAL%5RJG?,C;RK6TJU/J/(*A@9C@X%O8
ML3B".23G^6&UHM<S/$#>EB[(>5,01_Z.A##1+ -3)A<E&N>TGKIY%--A&Z19
M000HM4A]3!$*6S9*AEF$@HH437DT\"=IAGT*\Z7'C_%J'*AX:0)K@;P@-,@R
M \T?!.LLUR9OG)CR_TRPL<UTK^&VLIT)?5%\3N<35'PLY@XL@25>E,E(#5/@
M=B1S!A^DY:K=YI0?0%/#\'TPYLPFON'XMN6[S*<>9Z9EVCZ>\M,]K)E[_2F_
M QAL"H,=1(([5^C(W5-#NWVSNWMJPK7@FC'CH'=ZHKF&;S.'J2XWP(6BMJ%2
M6_-52GT00C?03%.>BUIX^NZ6;6V?\]S)Q,^0T8$OT:(M T&$KB@DD=?E4"B-
MR5A-0G4$7@(?YU(9#=DD16LLA+62O%SDX(O)8D4E[7N)?Z0:$@W/417F4E^]
M@F8+A;ZM[!5W3X\(YB.//,*0\&9A2P2,N$T^ ;5]QW1UGQLZ,37#TXA/ ]=T
M 4X3P_?FG[_=[WZ:B:(P!IY \"6B/M;N!$+MX%C!$1L&W40.'"7VAF)1SW^@
M_JDE>>^BV_NF'>S*[[J[W\B)Y86:'MI,-8EOJL3R'-77/5OECDU<TW-#&X\X
M#I,921XK0%N.\K4\P'MV8=[.[2@P].6TS [H)5BMRT)8*2HJ,&[)$,'O98%/
M;F.( LT-/-,"^Z.%Q/5=C[ P=&WF>4!7+7"6/6Z^,41S#1'\?G02F)JFF]13
M+=?VP!!16W4#TU8I-ZCF6Z[!;;KUP6S/IMP5ADBH0$ @(2 P4="J6.Y,JM7-
MBJ_0BO?V'F+%9R5;&&R?@Z?"E6#"E?,^EWVVPR@%@#N//90^V-':+<+3 4>(
M1L,\;'2*5Q7,!)>#BYQ?#Q]*SSK)'?C*N%_K^Q<E"W 8V<3_!2Y8TZ'C%^AJ
M"?@OL(:,.<!%B2^&5CAV(F0L_?DIU,]@'A$6>VLA3C@'/P]_)LB0]6G!':6$
MS!6>@J2*S'T0&C5.SE49]U:#Z!1N 4B!1[&PH +HUB$O*)VA PDX!*/>>&M&
ML0O[[R2>#'C3V,R/6N?&)-?]!,_?CI),J/YW(CX!_FYU[/:_IR-W>9A>JVZA
M?@8O'R^^9>9PV9-:-;UVC$P2I?9O/ZW.29YRU0=W^TRE(8SQ'8W/Z66V]<>T
MR09[G3_=Q>W,YI073BP,IR?6BP:P:EU^#C9U0(<+IN@N,4,)&T!CYA+Q3L@+
M7@5#HJLR%*6?HA7XKYMW2YRM#Z)'/7+]#AH0$8:E'Q;"J*=BK_G!XZ_?M__9
M/U2^?M_;V3_</^@JG;W=_9W][MYA2]GO[MS2E7NV:70/>GN'2N] V3GH'AY\
MV=_=[NWM*I_VN]O=G?WM+\IA#S[H['5[ARNZ#F]VBNV(MS,CE./X\+]^^L>'
M>;I@[@;(G3<T5@++]^8'[29#,!:9 OYM'*%1Y2EH-(QWM<H8GB B7#B.8F$\
M,5XMXECOE#?16^G9@QL=50$HX0!3%-3"<F+P#.QI$1H3WX'=>A,5#Y@.LP;"
M'-,P!(<5WR:P0A1>XOLO)3B@/ER6B'A@+0;8F@[*->*IY0#SL*J,Z0T3$:,=
M%K8_Y2K,#S1.E/4!."""*$,,<ML"AEV,>XB (DH#$<,3,<8$;CPM0OKH(]6G
ME@<U:C,3$QXD$T0!XSX=B\3'-()50@L/N*7$((@B)F#1]R*!+^0+T1$K%VU^
MP$/$) KO4T&+!E/"@0S!3,,SV641>TRJ![>5ZYV_ZIWX=(8EE881QYT.05.8
M 7Q\GD9C("Q0>!PQ > D [25'R.D=?X,I+L/8*PVKY;@H9QYD.0Y%;(R-.^7
MSF<#T^7A)-S?5S#%H/;:-=E9N1;5KM\VRPT@76PZ%CMFXB>+1D)^0&%4H;<J
MRE?;,</'!\GY,.6GD[B4[FK'HMH_:0;R9_=2<L7SQ'LJK5SH0/3A6QAQAIP+
M8[L<\?H(VCD99=F>+)G9RL"J[Z@BT0E8X*3D^E!LRHC+A@!(=E6Q<8E_CY.+
M")GB]!)89!)<3D=*RPAML2F.;[TV.MM8J#EKV2J&';'*>#SDX,M!%\L\;\#G
M(L9;5K&[)N);5D^J18CGQI-Q:UO6;;QE&,SECNN[1F":@(9]AU/-#D/=LBR?
M\\#W;JHB/1L=*3;8MX?!;C616Z7.O;Y RI'1W=T[\4.7N@:EJN4ZADIT9JJ^
MQC15,PU-,SW-<4**C:R=Z\-EMUG^T/0,#-!0W0F(Y1B^YX8^@0^8Y3,;G*$;
M4B@WR_]0RW]Z8FI4"P@EJN?[5"4AQ<Q'PM0@] UNAKZC4W!-]6N+9BZC2Y8,
M9Y4I *)6HL)GBD")<K'B+<@:+6$A9+))?+E&FPXY%<H4C 7Y%[/!.F%C9A C
M7A!.4F%D%^=9+#(Z41'8Y''0! 37HH$IN[Z;@L<R5@XOAT&:#,#FRUI[PFQ)
MPSB)QUD!#B)1GA1]"(&^X37G2I!.P.2-1G%N*)<UVGF 4]!1E&YM4 _F]Q<%
M+S>]S(L-CVB$MNLV.LL.?!(&U",!=XD#^M)T+!X0+21Z$&B,;.+X]XWCGYUP
MZEJ&J7$U=#%3U- ME?*0J+:CF:'E4MNQ'$PAN":.7\A#R"66JB$>X=77OIX"
MWO.U5E:(!F:?8/XUE16GX4<)M8HDPDP))FG![*B]&LIKNN U>)X8;BTXM.#@
M&W-Y&(@#)O0M%P$0GL,\D5\C32D5)7KCODA0C,:Q1-NT=-VGYCBSDX/AC.K2
MN5\#_>1^0II<TECX7T#K6E@"^"5;G_24WHU6=E'4:UZ$*]_HE@$?P>C%'M4U
M@;4; SC7CV^"D9/;1W,J7JE>%DUEHF&_HECN<;%^Q#'$5B34B S6DCVF+<P]
M@D%B3/-C05/CFG[FG.0A&-8('.=8&$2Q-+G;WZIO_!7[C6!W Q6C!C*5+L.%
M:Y6^?QDQF!='DB->9DMMR8,@Q%BY@R#FHQT$*:NTTW0(*Y45'4A6Y1A(=W>_
M,/1@S+^9G=UM ]MN'.^>POO^B@]VOY%.KQMU>C_TKK%G'%UMZP>'34./F4+L
MO+-[C&TWSN">\\X #/WNZ47'V+_H]GZ81[WC7YW=']8_5]_T@^T3#]"Z0UQP
M,W6-J 0$6J66Y:K$T:AO4B_0S:!YN(*9)K,L[N,UA,!%U'5\.P@"V_>XP5GS
M%$@7X.>7)!,I<LJA[$1VZQ,@-[[TZ6J>;\/8@BB>H'=SR!G "S1->PAO 5E\
M I2-"B*/NAV$&XXK.<[H;)]HH6\&L *J[GD:>+:FJ5+;9JIC,H\'')8I#)>L
M=;XR5KURJ4:)V,RAL4!^F!"!2PXJOLK%K-(L\IV79#(&["I3*.A8QG'SKA6
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M:I#0"#U$66;+,^_3)7@3NEH]&7XD/+&1X<>6X<ZT#-O$='0;,(5A4DLE(0O
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MW%K*N,\5+.]&AY=*GP;*C_9A6PDY$)7&RO"&IK7*>3]B?65 +Q6?*T@C99S
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M(/UKKL:79!@DP]PS 3PA.15>(_A>WI+@5E):OVUF!Z9\Z3TW86JQXME]EX;
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M.^AE+Q4A;]4Z$LH(F&Q!:$H<NQV&P!EJ;^X9'5H&X%BQB7+8Y[6C')D4TJG
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M];+G .!P&R<3UE5:%1$O?;?,=$BS$#>QGKT0M[!H]OOG+<:MD[80TCS+ =,
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M6,1WRM)KN ']UX#^>E.LUO+MII;SK3?4OX'Z4ZUL6M?UDED<=]K0>WEZ3Q4
M;UU;@5L$%C9$?P"B?\2P#_B5W^EOX.J\1I"@_=3QN$;AM+6PT#]E0BLM=GBS
M <740D"F>#2D\/K 2-9V=J>VOD59UVJ/5V[L@ID?3.)3 <RK[PZK]@7;LD>
M[IFF@-8BF8<'90:^R/ 1&2/B^;+>33 !?[GA?<D$(<P+2KFHI"Z3E&I;S;@M
MOF!2D4B6!I<[PYTT":MQNUY,XK99(YM]Y7)?6=_L*Z_"4)YR7_G)TZ=N0/AK
MH7Q[XH U^A8B#BE6(..RO-@8SSV+S0HQJ051.(J[#\*=:N'9Z*%,HL*T<!HM
MYV25[GN*&CB5KME$')03D<ZJ/G8@8P4-'T?63A"YW^WE/)H27#0T5#[_0NMA
M,2(5Z!_34<;?%;^\!XT_BNGENV@HZ"EN>C^=N(DO^,U3<80J?XEXG_PZUQ^>
MUW8M$U7(.(7_@^+%N79I"^WRQSB8\YW3UBQKX==:6[_C=Z9[MZ=>-UC2U@SR
M"&.U3./!QVJW3=M9D[&ZP#WVFHS5:;OF7<?S4L;Z&+*E&VW#,#>#??C!NFUB
M+,=;?PCM+34XV BT/O^W96XU4EK>&:,+19]G=YJ&0MJ(AT$!WG(=?.A QB._
ME@>_ON9(O[2F.16NF:"&T]M:ZM(5IL41 (I7-^E#&B.&??.OMZ]NZA^3X203
M?O-KG+TXN2-FORV2B I"O-%?'RT.1*?,#3&JIFXBPTA08;_(,L*Z2I)&4TG,
M!:6,UT>I;7!1#W O=S%5S-='E9Y(:FRJU!N@4E660LT'QQCG8?@^=\5%E&<T
M5K(DC@(%1_[^&E)@_'PA(:X+VMV'&O.C+/4-P@4'B1YJ'.(Q\VIHS1_94AN5
MC1C<8L9<N("W8.Z'98*GEX?Y=,98X1)*8$/ 102T#:L%C]W0\!XT%&E)QOL-
M#>]!0[UE$JVEDPTGWH>*9LLF7HL8&RK>BXK.1B?>FX9NR]+=#0GO8YI;FN&V
M-,>]']8/Q7_W(^<C/&.%"8\5(^_$N:^+3):CM5R3;"CUJ #Q=5'*:#F.V;+<
M#5<M8Q]<UVRY=P0JKXQ6!*CE6!M*W0S<M)9C.!M"W>RQ:BU/LUINP]FZ:RQV
M/2*N4X<"5BODNN!PPFH$6=> GU<AE+H&9"+V2@0'UH!2*Q(670-*$9.T[.</
M?:X!I?2688+\N7=#<J^,5L2]LW?PRBCEM6SWV8.5:T HHV5J9LO0S0<-2:XV
MY)TZE[F*D'?V?.@],.^K\>&T>V'>UT4F8FEWQKROAE*;2.^38=[71:G[8=Y7
M1BM"-IIJR7!/2S,WVYS+8%[#-5N.93]HF/<A'(67ZVQH]]J&?UUD,CVS9=YQ
M&_[54&H3D+P53[FNT;*T#4\MH:1:.LB?X6[";$O0BMS=C7Q=E-+=EF-N I)+
M&#],5FBY]P5G:Q60G%>S;+7BDI^NJ9WVAKS=A"<WX<D')9/KM SB;2AU<R!7
MMUNV[;RQECDY^^J)9>HMT[8WE+H9KK0,PV[IUMT0RZNAU6:'X';RIQDM4]]D
M@B_CA#HVABC))D2Y"5&N()F(+6#'AE*;$.5#8@Z _;9^-WSVNFAEM(BEMS1K
M$WI;QIG<Y'<O':1T-T'*9<Q?R]*\EN[HL_#L#U'E^*'C=DL6J3Y9]-]R?62Q
MJ/8S]Y*HE9![JI=.]Y&PVHZ8,];[I@-@SW&6]R+@V -LE/(,BT")'J*GIUCJ
M>XRM([&76("_8K/?O%5D$LJF6U@Z4$E&58,Z[ J51@R?*+^<#+&K5%4@7-RW
ML!1XK;BWZ%Q4%O5N*2 4;"*;K&%1<,:2-, .JK)?0G64:AN^@:GA8P[',"31
M%U4T9)2=U+8//[;F7[23!%&(KQ.]M;8/=UI*+QE%3'%TMZT<8B^(N=2 82>B
M7=:8GHD^GXD8WD04U+K$GG+10(P[3-*01]BC,>\/1[-L,LBI)SI,8(.U?)X%
M'6ZQ .5BBO93HJ]E/!D,16N-C(_+>NY*-X&GZ7I1F1V;3V"U"3G(DI+9&#Z0
MC2R*!V[++FC?Q8OR.30YJ?'RE(>Q:,HH6M.69&=)-BZ:565<,HADH9R8HHDI
M-LLLN8:R,;Z<PW"3 2R+I(1H S*@EXHO>C1RX"=1??Y:/IN,DF'>3!>SD;/Y
M!&TIOW'QL*DG5J@?C^.RJ^X"/D]2L>09C<LGRD8(HKM7UJ>I[%V(_?9$STZX
MM:U\@MMVTW:Y25*V#I.TK4A+XRS!;J_Q)(#G_,LT6AZQBV9CHHZG(LM6EBL/
MU/L7@ 1BFL5ELL3E]'6M2OP+MH.WR"XF0/$:WV'_:>P;7?0T&=1D!CM:!N)3
M7/Z\-VV^L/!RT>IO?;2UL1[:.A<*'TO8 D_DW1=0L&I=INMZM=:31JA8;-1P
M77<&V:"Z%)@YW:5!4D?8]H/7VTN+I@ZH,O$EHKE.U7I1]N+)6_UTJR9WR76]
M\G)OLU!!HF9ONV@']"EO)2EE9[;]KL)1!^4-_\(P[P2T<,YBHJ)%[Z5L0"K4
M"A !_T*<E MWE.9R*L=4+$(N:4A]O#"<Q/&E4"78Q7%4MH\=35+6!^K6]((D
M9Z4;E @L1$DQ_!;>I^6BGDLRROAT;=:VT@%M(BI-UB=>3*.8 $KIS/";@Z\;
M]W/L/BH'!!(AOYF:B*&;+<^QR@D-E;\H/!H65#=$ST%3#DV<R)XW-.NQ1D;0
MK;QA8&"4Y<&9ZT;&YRSY_4:F8[KTM2-;'Z5IKHC2W&XJS*+7;&$]%08LJ(SZ
MV$0XY=' GZ294&J@0>@%-DS/$"6(!8$/&OW2@R@KU(-HGEJ[0[SI'!X^Q!:W
M/A]RT6\8N  _%'HP CW(D0]PE0$9@D:M&IPA&),F5J+"4O")IK\Y>ZN,A'RC
MOBME7"J]&1M1!PO3<Y3F <Q[-,G;%]/I.:!6 >T-EJ*   OG'D<A@H5LD@I#
M(_H?@T4YSWL ]:/!G?%-T=T6J2(:"8FV:;+_.&J(<@8X'21;-$0Q&U%TH:.1
M-!ZY:.;/^7\93A)FV.<T!BR,U,QJS8_ZLKD[N-Y5[W,*D#SK8_]C03O -4 /
MD. A]O %33WN"]7M"TTNB^C/<5#PR6.@D6RI  Y6RN5:3'51IMA-<8ZMW%K6
M2JK*WF 4)W*HVW#/\#2'\.(]R$A=8?5F"OQF[:WUT3-D1?1,Q=4YVW#1-[#J
MA]E(*%(X@ _9B7M[<CH!%RCOQ5OWI1JN5,E5.::O5)EL/IV*'LW @?_*<TOP
MMCHW5AVY:L.%V]#Y2IHLOQBAOZ;6@48C[6O3.O!EM@Y<.<5FK:)BRX,J^"L2
M%JV-Q+T 8K,)AJ<PY%7[-BK=$>'^*S$?@WQ41F\)&[=$^_3VUE*-_IZ\)^1M
MY[%DD\B'GL/"/-D%37+0HH@F01'/UJ*OY1YE_44^OH@F..^S:=@&8%@)HXN\
MO2_X!C+(D?MZ4RTO:Q$6$=H;<8:!,"68B"Z5"!S#_]_>FW:WC1R-PG^ESV22
M*^>%* +<[<3GR+(\4<:+7LN9N?F4 X%-$3$(<+!(9G[]K:KN!AHD0$(4Q45$
MSO-X1!+HI;KVKB7Q'>E'Q(]@[8$]P'UT",.QN]%8MLD$9:' 8P'CYU %*R>X
M0$8<W<PX9<[1S'&OZ"V_=X>PUG1[8>!Q].ZA(S5R26^'Y1DL^NYZGE@F_S'%
M2Z>(-]B[%!BT!VIG?._R!S)>$0;87#V>35&E\4C-!;7;Y[3+3,&4X-+]3V(8
M;,CL@%EDH!,J#.ZS_9?L- C+H$.*^?"_"?E41F$P83$()"(X^5^0RZ@_9-NA
M]0%^?N<Q,*1[CMM'L5T(SPR4!<#3=Y9"T.7PL<$N4P4OM>,-S36EW 8Y0(_R
MUESJ(3%TGP1.I''E!PZG\[/LB,!.R%U+GCH"QL\=41;\E<%^ED7 %I]I6]DS
MHFA"P3/-IGR&7,GM_L"P.D7/I?,AN 0$O-G*YM52-416L5?,3G<RKKV'W7*_
M#^)N16^2RZB[.7L/ GUR"XC?2E&3V(?T/Y9Z1=&5Q8&F7.G[1[L"G5HY5YAP
M%Q<[BV&4V :F 88[Z'OH37!]XK7*?ZP3EN9+1M33"%)[2O@6,G^"OA+@,'>A
M/3%6CW_'?1X21R-;1CC^AK#5>TYN<V3WZ:T8+@8E@><*AX<V))P=\'80&\ C
M4B:/ ]C <.PA>7D %# 5@PGO UAD- ,.-B'/QBCPW,"0BXG%:SY/@(,'=S,V
M=:<<#QGF=\9!*& \3F!B>B-VG4@NC?P@M&PX3'(Y9/V;L<<]"*$(T?+4\6QT
M4;E!S)VQ+Z9Q-">$<E@!K4L("C:9'H1^1%$4 '@0=L1G85DI!J7"" 2*C7@
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MQ%!&+F*;S49\2"(( \(PR-;^ >)PF#@Y;JCR&/7<@!LYI]5O_J(6=A$,!;?
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M*)-N,N>*2MUL=F%Z;NZ8W*A0AT:-NV*2\-PUDB%#D4A-076/7@/M!%#?DRQ
MZ4,XTBF-)*4LRF@4>Y]LE6/0>B,T/LUMNR@ET[(TLB"%U+-H>=E>4] &6M!/
M/HI*BPB3"X(="'=M+L^4Y%*D4&!&?F3 JFCN,-]H2D.V@06%3:F,["3E7WA[
M@$N@,#/%:#5]U;,?!*+FO:J+:+0P&6I%KS:]4:51$X%3&22,L=8T_%L^PABL
MRHFY^Z2@?/$5BV@U"2=-TNWI4I"LYD=F"LZSS1S]+IS!/!_-K-RYS,6<@5Z
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MUB!>&C9AM-I-PWQ:6%<-XN57XDV \)J1%C6$J]RC&]WVP&@_K0]S#>+E5_#
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MSFMY96KJFO?O:GWOGC/'=<O[KGB)];)V;.[T\G*KV%YLD/P6H-;DN?'L9=6
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M<0C_/U0SRY\;]--9/"SXK=_H]5NE/S<;9OFK];"K?FOUV\^SV&K#GA$V"(P
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M<<M3!ZCUV 9_IZ(/]FZ^N#J3PG$2)5^!R+3<,3,%C5=0G;*1;$)K;>?%<PG
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MI2!KX7A>%C H,CO3R;8*(:E+15+8^_Q6M]N9OPH_=2]F]9?AT";]IO,+7TJ
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M#+Z& BX(RV:1*L30>H]:1;;=H1K"8SG?8W)['I5W781W>&HE=JD"JL3HM.(
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M*;(MCQ"<?M[^2.S;_>-O_Q]02P,$%     @ <D%'5KJ? ]H8.P  )YT" !4
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M]+,+2WO*<U.2]]5$K+>QT< CIQD8#&8MM94BF'V->8;HB+KN;<>,M;NL;JZ
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MTN2?_<F7E]/Q9'B*HXN\I.\]5[P(R4CP(JEZ]X\!%V0$R[V5:%$7WSH7]$Y
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MQ0SYO_.\PA$A_(SS,JVKC[P/WV=-*/X(HWSIK=0U]89X:8%-]3J*G!W/QAE
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M*\\\1%H[#$0ID8,40I^W?58NUALMF8G22A-:&S"KT3PYPFRMBB41R-U3=)9
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M&;F"Q:B"S$O9.F%HCU2X)TMVWTS81-C=W/)XL2Z>9V\ZI8/PCMR[(FG]*]%
MU$E JIW4LT;K;>M65+= [#]9MH%R5D?^MY!L%YE=TSCNYWX8?;]VUC]C=6W^
M6H(B9]YD5^]5J;V(I83"C;39>L-$Z[X:*\$\#3NAB2JZ3=NIJ>/ORK6DC_,Y
ML0["C@R&^]$=R'IHH\X[LD8;ZJ*#360-I%@89X(A6);(+_>:TQ;J$3RM@+1Q
M6N:P>>^$ ['E/@/C4&391 4=D.3=5QR].#D93JIQ-;\\\WQ?1*55"BB 8?)U
M\!IB)!O+*W+TG?!,E-;)+"O![-_R:*VY81=B;WVEXZLA0?KCW>#]-)[TT[M2
M\%HO12T$\PP+Y%*O#&,T\)B#JH?@ECNFC=?K7==XUUL>C:+;RK-UROA_X@P+
MCM^=X>#O8?0[3B[O?KFXXUH+IW6)4**-\Z;D+A(CI9#*DY4=T=NUU'W_NQZ7
MTAO+M@-S\D;)J4W69<\=I*+K51"F0$0C(6DO,-@H)6_M6!ZRFOX@CL76 N^^
MPGX=-$^EPGXCS=Q=?;V-6+NOL"\L"Z\+!XL80 4DVR(8 4+KZ+$XE+EY*YDC
MJ[!OJ.--I+G?"OO7@YHIW_]ZO?R;:YL<#1I2T+'FAP2(Q4<0#LD 071JL5?B
M5B7V2UY]\!K[C12U?HW]KE(^BB+[C]/34W)ZAVOMA!T5WV^%H?NB_-U%LU"L
M[Z.QPN;H7>3*:!]$(OY%QKW,7#-V9['^5F@.4,1/<TRS4%,]8L@UG*[!BRQ
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MN/%",ZO7[&"VR5L/?BR\D7J&^Y!MZT.&E4"77 ]?$](241P"BEI4DS09,:6
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M4UI11K#NJP]>4: D*TR1XX'!UTH79R#0+ &MO18N22U+Z_+!!UQ1,&]N]'I
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M%7F[]J^I%CHPZO^& QR%$T+X(I^2J,>34:@]I&^"#,I&7HH$&VG\*@8+!#F
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MWB-AB,'0Q ":;?CYY'J<>DTHO<JY=M5X8,%/FBL3IF:)"ETHO>0["[XD*5,
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MC"CW>ZG03VT%MB*'ZM*RNV-*NJ26^\W/,#0'\.@E1&ET*<P:'OP<+8&H#JK
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M6#AXE^H2>F\AV=JO@CMV)MP6N_2E21'5@6BE;,@07"$,>F%-<ZU,Q<KIB9-
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M$?3K>MOCL /POUKAY"(0_)M'&&F+Q9,:?SV\@S<(<<=(IF'J0$N\6I_0$EB
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MU4WLV(<KYOX+&K(2B=O[0L";/V[Z_J4)-/SK@RFF2-K?#NAH#4*7KE.@2;'
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MQ]P B!R],V[Y)".9+8YUO%JA:<*B:5+#EBPW226N] .YT;<.ZGX\P,F.057
M8"MWI+!E\[@52P[KL07.)?!R1@'%JQ C_<([L.Q,9)K+?<$SB+;6'S'8B&U?
MCX:6391Y9M*ARII7'M> 'RU@.J6TQWZ8Y^J_*["2E:%SDI)JWV+X6F(.T4R
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MX5SW5V*U7T7#PNNTG$C0=W30/[6%K'<%HW>UAZ2'V%<$-^*'&<^B6_3.Y2[
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M7T7H 50J-V#4JS$(0N-TKI;(O4_)?"#Y_9BD-*TJIKT)V_I-J IY=!<CT!?
MWC#-TPPK6) L#G^F_.V!3/'].[S[:DA34<'R);VXL_SW*(TM;1;U_,3:UP4]
M@M)EF@2&^-03&0H:B^,Z3JI)8]QDIP7M5W B;W:U)PHW $+VK)H*N68!8Z,^
MZD06S3! W0OEV@>KR#)EA(0: ,K9VCJ3U7-^V;,_]BM@UV;=_BGQ[-N!]2]B
M.Z8";G)O?N%\%!OARS7GTWWRC-%)3T,>:J&<6QBL[R^VS'!XY9W]O=X:-WT
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MV1H&]=B C)863IU+4,H]W>=CC>B3C"YPOG0U9>[2ER[Z9BZ:I>DU]8D_Y@S
MGT=_Q]BS^1/H.ZOQ8[U>"3/B6BAI?%5 UYG:O%EGQ,)UHYY"AL/U5=*&H>K+
M8KHLQX*/%L)WI$=+-EF/N& K.I+^"G;NXH%0MM&K-^ #_XV+^_&<.;P-R@8#
MUQL;P$D/QC)I94L/X@XS\W$Y<".LK_(&(*G)83R:,!O3W;E0O_CHC&72%SZ=
M<PLP]D!T5\>%*:X2YWYJ3N3S.%2&5/8P;%)KE\CH#M-=,[X%7Z6"^@N<.W["
M; 2;8>$?5_P3S!S(ZYSC<LK'G&^@LH')[6#??X<]O(M%?DEKK?0UQ[SNH'^K
MYU+AP2C\]=&V#8<_PX9!YN[!$?6/C)3\=L"J^=W<>/;P3[,#!YD*E1?YFNP'
M-F*C?=%?7._\5;5M=M%XGDKRZU,_[3-3.D8#*]U!/$=:L)]4RTN9,*??Q7RT
M6EM,;G_'-@Y/B'UL9M+3\>!Y)&2+"&!JR8 E =59OHL,/K>4L84%.2KRY5?U
M=)B!4]*R:0H6<#"L\,_6S/BD0-+%5GV-8$^W-@ZP$IM,K*YK/>XX/5BE@#6&
M8;7@3NB#LR?$>/CR&L7=IXY[ISEOR+[@E:SC)19PF<G'F!&/B^"_/3I0I(MY
M3-Y,_O!+%\L3P&_.*XI$8?)QAH?(@GPIVZ__\-T'__\K,"8CJU*0UVB13K^5
M^[LTW3041QF;?5)S=X5II_I8 R?)HJ]FHM6-S@J+QY3.;9=\<^=_5XE9>A2H
MRZH*1&<_;]JC=BPOG2F6&NDU81ZMSB+!@#IK#7I:2WBR"E^[2&TT =FTE?&2
M!AA[_4Y-( W5Z*RPF;7E;&^/)4$#X;@GRLY.+,>#$7J)).G6=&NMFCGU;,FO
MU#=<_6&4;GN%+K4L0,/YWFC[=*[RT_=1D<:&8[MS1ROWH6K96'&4G9&=>$O3
MDEU=89MYI(=GG6DC_23CUP_DB@?5'@68@)E.7Z<HK!F/QQ#[Y=K%Q3DEY06(
M.QO8',=."^$S#R(<%O<0.CFC<&TO4G+;\DJZ 62/*$05R(?2DJ+&OMI 19R*
M[53^UAXV"9;Z<Z]5,-J(OY&^WZBB_*Y%1?K(X8^!(<_LU^Y^?3."9W<D769]
M(Q'-_DX(94,X%2:'-SQ!,K7ZP_R.+SY*(?&<@E \IKM<S9F/2#=.EU:)&FH[
M/PX++;X0['%)-#)(MT.L353%_KJPR-X_RM6]\)4NF,>1S313_C/H).61;W=Y
M[RG(NC(3W;=01T$U6/F;5&PD )0,[S9X)TV,R7*<+X-G^10M#3I0-497;\^^
MZ+_S-_"\(HNK#3D,O-QL^UU0%&O\Y&AX>26XH<9$N$SC(5E7+R<G-Z^3+QU<
M-6/LB&9H)!2J@E +\Q(1/_B5'_M%UN,C7? !2=. 3F=P/?YS12;W'>-3FAM
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MX8J!FM5%*C268\+*G1G4+<<R]+*5M+>?*;W$W/:"$.N/.EJ=V;]  ]OG*7M
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MSZ%Z]1-"MS3/A*\1A17VO%39K/.^],C/(/]!B*>*TW@3+ASR4 N02]4+.JJ
MWP!(<<^PM),>SR6IK\2P$E/2C-[6\G6VT-<E&+O>74@@28[4GV,)_J9':S**
M]S)^K&^V:D](DJ!@B!5X,UZ9/M;V)SHDFH&ETE]G3E*@</XZLX?UA/U;"HL$
MZA%/#WZ$RRS--MBF#(C@[8;30F4PP=;H\Q'M*0_EDA:EP3>F#W?5FS\G\1G\
MK:#YWOD9[O?!)4%F2.T)Q(!R'XFZ 70TIF+P.DTX,3'(*P6TSO?+PR]UO@&)
M'P7+N1W*N-^2L:^6=Z\FXMD@'84"*$V@+S'9:(YNG-1$ ..\OB'&#9&'JRJ[
M986=;..&^K'@YU+5]L=W'E._+_X55)KWB56'O7*-\1:X&*&<J 5UM%-W$8YA
MKY42M5$1*D3"5@U*0WI0%'VD.S_N%+Z[O5CZK8L4F<#;!8X%/SB0U$3[=9Z?
M4\)(H7>0QO3N&2+:'Z5SI2(^A^KS/'9[VVE&U=C[5D-;AF7SCHZ.:,5<5E<J
M(Q;$"#?A0^.'9.9!<KS?Z>GW^=E5A3M5.)+3^DPP[<<IU=)]*%]S?:EV727Y
M[(<WL#?S 2HIN<"VT3,OQYM7,5A?19H*:7M&$#[$]2L1T!S-IFK(6FBPX]AL
MB<I"C'3I2U-B(+UNWHT+/9=G(3.14.WK1!=;)TC!@ACG/>>!JQGGX>.G1!,;
M@'2RFBM-0RP-9@!-V0<FJX;'U%**S(RE10&!O*%"3^)U(I?,0Q>5QHJ+G+AU
M7=JIMP)E] Y;'T'9T9DI5QQ8T>D !B@9JJ+;P:^;<CYOLZ00DRQ7TQ(_3[6I
MQXW4?*GS<-DH&B!*Q<$H#5EGC,&Q3T$5T<#W*FZ=RXPHQ[(\ 5LO [70T_Y2
M[IPD:GI3=Y<-Y<-%(HLMFRV [GC;XX\8 32\ _:PE*=55-_;'$?F]-!@QVVG
M#!&CY%R7);!8'_?QSJ]]RE9/ZQ9H<H5MHVIRJ9W.I<?E'HU#RY\O"W:$M+T\
M9CK/V(X7B-,^D=0T4'?\D);_".)W+=6ZHLD4VW3KI 86WF/\HUW_S_8=W4?F
MUYNJ+Q1YXEI-JTL5<"G'X$1*0?4Z#:%8Q(S$\LOK.>?.'WHY6NPNQ,%M26V(
M]X+. P.)>>"#^KYMVZ=B+)O<$8>/$MZ6Q/>Q18G-$3V.OAZ7L\1\^1&WP%B5
M\L3Q4,_SP."^_MTU?>^S][]AB6XXUD K&V'CPZM%85=?SX(/F\=<&(^/D-Z>
MMN2KJ@M-^K["\HS@XIC(/L8E%G"BBS3#5P4?9LG#V6AL&8,?7-.8?/!>M##K
M0MM.FOGI9G[7EEQ1ON11% $NE06XH2[K_,R^, R\WZ^%JWDQR"5ZO,CK4$?J
M]E=S'J-0-VP":XXXQKGWG3P%+UMF\E!=HTJR_L!"'NN/G/AX\3SQ9+RV"S4,
M7R$= ]VY 7!+8["^9M_&4^I?Z7GJ62Q<DLF4UUJ[H>"O'9SZ+N4RIO>BO-=%
M@/71'Y_\O.?!](5 ND9A32UBN 7I8/[>OZIKJ_HYA6*WC6>%9A^>E'CJ\G76
MF:!:A*?S'POR(>+^M#Z-1W7@H%2D4.'RB%YKK'4,>Z@/,RR9B<_L@:2%VY'1
MRQD*T&DDUK!MW=]2T=7YFDW-=BI+I-2<5/L&D"!R K)]RKM&\FI^N%>LH#E3
MED;>4)3UDMCE:+YE3^4ZY2"@*T-!+UYYD]%W&5]O$B=F?M8_4N,#ZUA2[5+
M1.29&/<]<;GO_6>[/8=2_KVJVF]^>;6/J9?'S:43E :?D0\=?_=M&^%U-5A!
M0DHB>GM4[8QJFW1T5,]UEH\.1_\J=&<1+'0:?"XPG<G].4[1YN'\H[D.;XR9
M@.ER*W 7(@95=#$G,L PRJ?.L].::FB)4,;? -H__24P>>*U9U)W)>L]?-6E
M\D.A8("^Y&=<YB9$\!NP*43CMXPDN<N!B8 ;6KE;!!6^B:9'G0?)US'&NQA[
MV^ITC\<H18 SLSS:-+?<YO6MY. EP1W#[UUV<])K%.=4AG= "TN1_@M2>&O
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MN"B?^MO3*>U>)ZV\#5NB*'UN/:Z2F*X7LO?(=A]\3V8HC,RH]['T))D;QMT
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M!PC73@OR]\FA*7K#V+/=J&LF>52SB6O1?2= T=:AWX6N[>12D)\H6$0 _5S
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M#X,;W6M!C\BMV%5O!@6$?#%3<67TI3CI!Z.B7$U;]#3!8N]/MC@!J3WTV+6
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MK:O\94P<KTQL0 2XL\GV!!=BJYI8$Y^"$GT:,A</F?3ON^I;7%BNXY/SJ%&
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M.6/'P($IZB5_5[%74^@RYDV=.1:4]RQO D[&4*(&P.F-N*BN7JAPH]\ 6]J
MAJH<BYVJEO.Y&[3":MXCD #ILA;IS[!6-JRLW#9[#"W1%$Q'&#Q=<#GNT#?7
M:Q39#4S>6<$O-S\%0ZHN-=A6YJ2TNWLUF<(,9)Q6CK(CZ$BJG$[%A=Z"J#L=
M5@=1PD?OXZEU" "FTM^V@[F5ZCWV[L776^#KL. C3ZY(O?.]64&OE(3G";IV
M<N)#_IM<LU5M#HX,!LH$#")B#K=[1>KQ6V=4)A%Y"9]*P@M(!BZO%#D=)ELJ
M.+8;8>Y(T\C5M2BT8WU&B:HH0+\H7?,CP"9Y=)]/)Z,[=4*>T&IZP)* WGR0
MXF81U_,1<!II=V??>5JV,DPR^C/QN68 2!Q\51(X7X(34OLQ!N:9L"S+%P#J
M=3MFF]^6WPKL=%M:F-1*^595!=S&>C?;9%B#+HM:G/077&G*JK..W<U)H*Y[
MC@ULZ;@8_76_[W>0I3N=+ERUV=#*A/4LIU'[[G7LRG=J0W@ XXY:L%Z3=;"!
M_)WLXJ^$7Q=;13<_;^ABYP_4;E[K8):Z' MPM0@]<[O%<O,_X3MI3!#38A,Y
MB.DB!=QYBD_.=LR0N>??X+01D9K5B;$U'L3\ K1_+W=PB*Q;<#WM/*,/N7$+
M#AQW.^X.Z+ZF]/68*=>W;:.=SD<Y!)0NOUJ]M2S[_%5;)>[7D;+I%M.+R[#Y
M@NMAPS79MC0;FX(Y.LM^9TU=4]&=Q.:Q)^FYUY3R1ND*#"B=[*PW%YR<SEW$
MKL#OM5-WS*N!T%_ISNW>KL^WEX J$,OHPE@U3%*QVA21??#==)F;B^O@6T6.
M\-0"&^Y'0'Z=N\AQEQU&CE*V SFKL^_ (R#UGE=8U<-0N2>V=QBW/NW)PR+3
MB0@:=5?]P/+U$?!J49VDH7FXH%"*(=S*__)EEJ)$6=NDI6Z"OM/GAD:-BX"F
M<X5MA4< 8-'/([V@8LG^K2"[[E)]RE J$=I@)Z0N&4Y7,BK9F0/\:'G:CSKW
M/J^.*+-/=T[_3>[ D+[/4\^0%5+PYT;C/%7B[N)6#Z?RH;T[O28C.C5>DV:4
M?TBIMU&B70K3\))-XL6F<ZKV9'EY12+#O-.@(*8_V^= R1;KQB7EGO>>YE86
M-@Z%=N=REGH)@KR"0AX__FYND%!!]0YMF!OY]\68)GHHR16SUZ_%WO'L>:D
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M9?,X:I(=C8]DG*0/W12WKV6CV&%_C?5@+\+O$4"GZ%1LL-2<U:-\RY6('@0
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MYRN050OAB@6SR&6>ZC//T>B*%JMUF?6T\'YHL:=!(&+#EB3!::$:JNT.#\.
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M.:<";IVHG%^4><9(F%R4(MX4V29+ATQEJJI2FQ;84#3G%G-F@L3%Q\.3NN8
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M[J?![6A<!<AK&5-$NY5&YJ<_7-[F)]K&. NQD'2\)"YR;I50M5-M^4BX?1D
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MYLXCS)?$N]SCP"QV,R;>,3 -"^\Z#4G6$262R[P-8F@B_UO/XG*B(PN.K!,
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M/@1^#],)V]XA,*J[)>BNQ?$$R 8M=TLHE%JUHY:+D%S-@WQ9A4FQ-!2L]P+
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MW*)*LNB7DW\!O%)1VAYG#Y9HG.71%=+]CG]IH5XOB6'&0?$"R BV S@?6M7
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M^PSC7YQ=E]")?!Z?-U4R7 2G9(74>5NI4D=#_MP2+]0KGG!W3AI7Y'Z2K5F
MKS#[K5]JF51<EH6F_6;SXI='(Z-)RTE_T-&[Y9>CZ6LBO'?N6: B&[P:$(#U
M=G!4^[<)OI$7;-.3%Z&,WG+/C,!=.&VJ?L!..$7/;I.<BD@.KC7,?)'TN(Y!
MSDH\,ZVK:6,?T>>#YF:E>?D'-P<?7.X]1_1S\9B$"UEKLF3/3ANJ],_5<VDW
MYA^?( %@&Z>D518+S23ZZ'7J\^C+JW)AW[(54PDCC0^Z( I2Z0%IOW57=)V6
MFG"=ED9>-:&F-"HF:WI<AP)H3@-Z<=A[4$J&P;<71QDKGB0OD+T4W6/B%AU
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MTO:]Q<5[P4PL"@RT+K?@V"]E@GS[M2\,:'^OTG4(1@<_S^'/S]J;>P$#9;*
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MY!KY=B[CNB-K;$Y8[R;0 B-I#-V)F7R_!M_G"6 ;?*R>[I#2/\2UPQ+=9M#
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MY2BNE1B9?8]KGR&B)53A0C;"UI_B@L%:6J[GRWQ]%6BI-T)_*O@]EN\?TW'
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M?1$Z-UZ:2TO*$_E+ P;(-'SU&E:O9WYG/A5+J2,+KDY1@:!^VOM\:@YH@=/
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M1$;-$P#K6>L3(#XTN^/&=ZCI=]IA!P361QDXNJ2E:R\I*([W?O-E5FM,Q:R
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MH/IWU!,=X/WZ@H<*VQSJKN^CMOS)_:2_"ZFDT'HAZ-M LD9+4Q1#C2J4[@$
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MQU,A1HZ+S$^!9]-'(S9W3A37T^Q%-HOR6\&I<)/4!6B?B=!?82N\7MO>]2?
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M'E^^SW#!Y!]9ZR:[,_!_5G?-KV<;XU>TUL936M_^MWI)3F+R\B'??9A<*$R
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MMOW[&+Q/(Z<BV:CT?0FL+V]J&UJX!0T1)X<C/]!0W0H-'[:-G;6T*-_4^5V
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M-QJK2M?RN!3K7OV7I'5 8$NKB;WS@;NGW)/@*_CO97L$Y'HBF_REY^ GDY;
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M_#H:4"RTN3&BGWU76S^]T]F9M?71#(>N]1*@Y?O#P>L]7L.8,@%5ZQ[?Y7&
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MMQF*(H8DW]I^,OE8:P8-Q;RGETVU@TEP#OH;P]UC!,([U IL4K2)O7G6C?J
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M41-B?W::!+PAUE@T?HR5:OA<_!%F;@D9&?O!,U0-[ EHX CRU8230*B%_\G
M.26S 2.:*;H9.OA:JJWZ&L2W"(\QO0>_[KG[ B+:61E8>CO^H.QIO D!H=AU
M;BDVHZR-^&=/FXQQ5FY3]HQ3X%[J!O4KBD3-25$4K1J-IR(\@S*2NP$6^F;
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M5U9AJY\(7"3B^@,W\OJU9_I\@ ?F\$ BM!S*:4W97N5I'>\]&Q=PX-LZ(]N
M(>YF>4&K0BV>32_2/_K%ZJI\.$K=D)L\B$H1V NNFNJ!G;*__)BWO/*L7'7G
MO7T!F-4V5_^/<\3W!60M D %4'\QF/ @A/?^'9,&"X]=398Z8(G<MY6*/L9X
M8)DJ+6QH7Q5MG10MR2<=O1"9W Q>I%B/6+-I#!,"_<Z+'_Y^3F9V:;MY+2>-
ML;[2L8';!FRO>#@&!0BQ??MR"RB]6;L%^)T"96YL[O<;1DS6&%:=:BJR'>^\
MM>7Y TL05)RS?&M1_)6K*U%14M5FP5]M2S;4==+6M8:EG"R17*PS),2 @=V^
MT$95%]MBF?U=;IU)WZ&*!?A+8&\#< F3K,_#  S%WDOC(<OFNEFHVN7\:<;(
M=P___<V.$=9IA7UGPAWR[]#_?6(TP/A1PIKYI.);B1P@[:(:P:SU^RH;\0.G
M;.)M602%T @7E"/X2*-VX)&4P0G+$6>@S(UMXO!X$!$YSAM30%$1?I2K(LMZ
MUF8VW7AQASC6['/!;LU! #7;CU(0<N^X<,@9S!*(\^NB@+D P1N]A0!&U69Z
ML"KRE#E2:%&;=!6)OA\&12H:;\7,%&(F3 FJ?B&Y"^,$[66*P+Y=*\;='O@D
MGSR-JQ-F&WA'_-> SRL)C,QJOEA;T88_NLC.=NS=,QU !*[)I:UF,JS]Q@C4
M.<BW>\TW!*=^[9[/W(MSR5(PU48/#+_VZ[%^U4IS>L+%XKWQ8(V]? .G(GLI
M>HJGN:*P+J14-?^Y.6>;#IO[M?)(7SG0@7HCT<2HHW-31EAJ[_ZK:]*1'9.X
M-&0+G"$\EU!JI*O!WJZXFIW9RI)F+88$GQWKQP.+YA'R@/ZK,N%"8P3WNI0P
M OU#LJDAP>\,)T/@U$+T&K)5$G5L?Q2.X:IJ!A^BQ<IDG(D'JV?[RZ_*'=0H
M4SZ,ZB6S.28J[5SV&!8>O\BD<WQHI"2R6Q\HE"LLP8G4TA[-@]1.)T!D?]H1
M-U^K3NI#OW7= LIT)?)"BLQ1,]+0!\1QO&5.4D#C3#/YUDR+1&J,42S_MV,V
ML\/XHSC<BP(4Y[D7*G[MT1BI;.,$U[&(\1[^^L]X]0H1( I7:'O&5!R1NC^6
M9[S#0)@%)$'!][F\8-5%?$9!WF^H&3-N ;@C$E4KW&#4OH.H[GI?7G[$5V3<
MKX8359C<(L.1[(>X?2D&S<*A>!5-(Y&\5N:EF_J]G ',I"G3K]HVQ"T@R-W@
M<[->:/D#$O+M&1; >M8ZX,6V06F/P\$T]LF'E3AI9G%_$% &-5-N#'9Z@^KF
MNDH-Z]B1$F <\,IY.Y_;:.$Z;M1P,0(>"<BT#YI$X\#%?8D;1G+-C';L64?J
MAAQW'G]<.?P </S#C.CV29,H,G?^U2%FZ()*KG54TT5?9L+L=M!Q$NYVNN4<
M.Z:\]@Y6/TUU=9N"!B\F2%3_S"0JKLH7GX&&TP3;D^49=)]<5IT)"0T*E$0D
M4C_@<&NQO8PO+GE/OA+C;[_S9)VOL!/?6+$.?*A_BC4Y+DNKPBA+S5KI:*0O
M';WYX;J0K@IS,>J)WOY(0G)HU1"^/XJ\.5G>N8,/9SY3>+_J*8E/J/J)CQ0\
MXP<G(PGS)$:<Q[,/I4'GELIO:*I_EBJTZRCS;P/Z2EUF#SXJ4:\?$$@TP'T#
M7R;4*< UOTX7XUUP*?-?3=GR6J=XIN&:'1;V0[_DZM(P=8W]&:C6BQI_^B>"
M#O/N?=)9D9=AYQA+HY.>N-XQ':9.W^/WGM[3\0V/$]9N"#-MEBHN0V=QKF-.
M(\HQ[Q@F/T_?G(&;2_NZX9V__V[VD6.!J.Y7.;&.F"1#MOT+PHA<6Z:8=X+A
M[VTDU5Q5A!T,<F*Z[?Q^R=&\,<G^@BE,E\39Y1)VUB]*/)1]$4B ?T)^83Z!
M$**?SN&H_=)[_<MHRV'.6NK@!EO3Y+N9)WRY,R[K,L^T]F!!;_R/!YG&VR]_
M[]/(L7$QMWH\/FP-7A(2"%O;/"U)+J45J.%(+!'H<B<+$V[+O?G$4WOPHFN9
MXLC#GOB@G <8EK[?D&ZAZ@#;)-=7[MX,4J(TKEAY1#U,Z-?!<JPOR-7ON1K9
MX^JS!JO8SF*90@LXQ<67+.W(8<:5\:&_%B1 -O5?[K$(.##[?03TTX7$R?))
M'AG<%$&$B#^['V&#25>W4;ZKBG77#FY&BZ52I1Y^H]67-O1K*A&-B[5$"G1Q
M;LL!8\LU./%2_ %S <SAG8;&-=M9[(TFNIU=,T\4;U+.#1@-_#:;WGC@\@UD
MJ4I3K>OUI,S.HTV14X4A\YWJJ*TN=91+\F]WT3/EX ^6S)M:N/[?59WUZ$ZD
MX_TG(/CEX._G]U,5$8?9'G#?%J>H$^1/V(#;YH]QN!K_JXJ#SPF?I'?%,_1&
ML_"SU(@P,\O5MX#@HY4X2=^.K/M9A(8S@X3G]FF"\S/"AV2(_IQ'6ZC>:2@(
MPHW\WHO!GG 4O,. J+6N -J)0U;[R+)3?UU?!5,Y'<T-9@_-;ATYEPQV^E)>
M)61AA""(5"3B0&C1L+.+;3#!P]ZHCZF%ERG%\\5#XA-./C:),,8SP7OG(K^!
M<7Q^2@AH+S=_ !6*N#W+K%/28N\ 0S&^6=>4_##8K]XKK3WFJ(]J-WJ$2H)X
MW[4+_?PF+Y@E>$71Y>"ZW4QX&\,^[?>RH5-IJK*V/?##E?]L31.X;>SC.N4G
ME3RGV*@*]74Z@KCG,)&H.B@1;%>W6;4JL,#(SIG6:/OC8199R^>,;QMXTNZW
M *MJ=JQET(=L.E-42+O7,AY/P&,3OW?C/'5%'J6<XK1S^UD]J-YU[T1E&K[C
MM/MA1!K2FLI$/PL/SN#;$N;7.N!^9?'O]J7<$H8[+O[Q#&\=L&LU^B/DU5E)
MXEQ]/2NI$-!XB-H*^"BI,XMY"B*5NLW48L)S963N'")J(,RW]% -1U+EW>B_
MHK#_NMY8UC_JC?G\7]<;^ZN]_,5YAU,UJK+#\*,EQ=?F!PQZA;Q,IP<=W&!R
M?WSD%1"E)D6"%D=N_#B!M*CMM\K.H)ZI QYXTDZ;7>_XR_J=F?%VJLY9O52#
MAR1;89ZQ!9Y<9@T[0N>?"=66S>0J]>[@[%^N^HMTW)E^M&BS'>^50YY7S>!#
M&H/WTH-&"]9.O]0Y<U#QA;/+*&8#AU?CX\><1K8\8T[O#'(5F36W-Z@>.TL+
M(;=^WP)@)4>K7Z,9@LMVCDJW$8D.>:$=(P"V9]ZKJ2Q?'CVPKN![Z-7+.Z^Y
M!N<-/82(K[9R.%#T("5:6EHB9;(41O0G>?%P5S(R/LG3WWVQ+N<X-SW19!C$
M^&C$H^[(_\C7O6&U^"*Y9J&-"IML?])AP+'^NLTZ&1S2 SN**XQ6GZD3.Z/]
M*A/RM(.1^2=CQX]S=6R?K7TG[V?0'IN?K]YX"5,^4<C-4<=R0Q55XMSI3[PH
M:"_]%L!QQ7:N5V_V: <CA(H$X\%L8&XR#P\I#+():X%F*908&-Z-5P2S:IR*
M80Q3HOW7Y[9EF8G*4]F/4OH]^$]W%?</EQ.G,#B?[2EV[$N791@(7$:8>):^
M$4B73$Y;[!O$*8JQ9IJID:V1I:U)FHSJ5GY&R[!]1FOEVG_II!]LMMH7*2:8
MFV.66^VH%R=I%$HQS*) LN:L+)/:,C".%UQ+%><MO0ZT%1Z=9XWLS'UWULDN
M]$IJ9'J]%M4-)XX$44IA@8_A(]U76=%>+G"G>ZBP]F<080'>*\-YA5WD" .Y
M<Q06^^\'),6FEM=ZIB8[(,);@+4*PS"I9:X1BHE>%8M(0V7]@J2N,\8%DAP;
MN?>U%!9^D+JZ9Q1/B8KO@#XJ\^-' KMU12A>QD<D&6;!YP+&Y6'OPX:^<+SX
MHC#P2]-MA/$D@.PF'\+KAMCJE")!?4?T@R*JP";Y)A17DJX. C:,"2%UD/PG
MZ$D"T6UI4;)[IY3[V=>*]@&LR(;>Y>BKGM2"3+OY#L\++]VO[,AVKW//6-RG
M<P@3YGL1:RP9VB"2 -J=;*);P/OLV FP0TP;'I*A\@<JI+/FL=Q'1Z"KG,RZ
MX$<&)F*Q^*RZU1FS>KGB,G#\&D-=*<H'_WMVA"'[& FG42Z!H3%'2<)'S=A-
M[#<:,16JJG+VE&HWQ4+B@7-J.BAFWWS_MAY_)?$]>O6%?6&-2%V]\/Y9KU(%
M^IK&=W\6P63W=H'8?M[P:%I@9&"M5Q>]3J%])HT3_HZ*H$;W34W1@..O7KRN
MJ!*+,/9.*0"0??>UWL^ WPR$2&A(P&-3\$F'%"UDQLE/!GX@HM2D\.D>1?Q'
MC,-ZK@MM2.IQ?=S>\@.]9##TO HEOU9)A#)Z-87!,A5.6"WEK;*M%VX32<<U
MUW1C/C R2Y=W2LNL'O1),A5#BJ^1@&\!OT&$$&:KGSR1^6 1U?0Y>9C?>4MS
MEIDP?#TSNL87N\-OWO-F;19PD]=&E1T2R"#ALH*DZ78HV-7$?Z/+'6W SPUE
MR[A48_ _F2GWU>OA!BI-!9!@!K(8IL]FT;2KBK6$KW9-3/8WF^.H\YH\$P8U
MK#)JN"PWJ&F/P3MP*%W;"V!L>GQHG7(FR\Y56\KJM20%!K$0&9?_K#F%\JTP
MS[05!^Z _]B0;T/G+8 :3'&RRAON]P3),"*-//B:P#*S1.-6NK#S8LZP__5B
MKT15SPW+ )>1LD@JZ_0M0)LE4I4/E1E70F6(*IC"%3-J.+N1)$KJ 3ZDU+S)
MD7A=C#9&/D?E6*[> L+-$-\NZRDZE1QTJ3ID'9R>RA) _1\E':U*"X6O5F*C
MB+MY$?+PY2"TD$CP5!NS <I29Y00W3!*/:W@R)3UW.I9C^5'/C'J'OZ0%E6G
M.(JKWIYRK1XMNR7R5L1FW0^1L!Q$?J>:$RG*G2,\RJ#G(FP5+PSHG_8SR8E!
M/;&^"<G<(6",?CGAA\,:NLK[ &QI&M_M:4@_A9X8*7ZI$"MXX:5"S==?])WB
MF?P?16>CBZ<GYZ?0;WN8_M[ D33_Y9G3&8\ X'D[RO\.-RNCOB-%C,<QG(9[
MIL]3NRZ.55;?CU::)^+X-DG,8D;W-OAC$A_A$#;$_2S!=$.1)T@HID\O(O#4
MV",6">J  ;N)(TVYD0Z%L8*^Q"C%,]]6UY[AO<## ZNTC:1A9RA+PA&C'!;E
M<1YSV2OC^" SZM/X8"E^I-7047@>LCZDPD9OB2YKXJ!7U9O[D!I+$<(2JOB&
M&:O@J+57A.9+=L>AFUX[G*_XY:A+VPP&FC>Q&R^#4*"909-NP;5?AJ3]'(,8
M%2S:1C.[$(SGQ)FDG;URQ9ENYD6QIW8&AM.$]SK1@T/445#K?'"[^SRU5OO1
MZO7.>V]2U2!92EB*WY?W>'G\HB;H4Z'U97*H#?>+[FRB.]\>OH2+> LD1I,[
M%=&;PH<\J(7PO\]WA/&SU#07/]4*RG%^>669@UJ\UO)C0$'7")6[EEA1C_P]
MX/ZOIJG6H>&]I&^"<T/-8S\KVS>$QH*/HD;7Q)7C[X,I>\RJH/LPC  JTQYQ
MKNSK1(*O?RAHU"J]&#:E>DR ]^HC#.I;@7E)<ZEZD/IZAF=&:3)VDN\MLCT0
M3_ 5N/-Q!7G3O3"B:>JMAZTA=SZO=J2SY180LG0/%;A6^5G$E#>UO<H.W[K$
M"%6A(B':W")"1*#H.-NCX6UY\:+'Q509OOA:80JB6+1D\_)-.E&\X.!Y\_N&
M#SOEN9*/^W64UR:#I2EK?0^(==LT*HV^R\*Z*\K:5(;B1!@?6$O.,)P-U0MX
M'C>M"2;7X0G[D&VXO>K5?3Q_$W?,6S=+FL#@C$Q":S0@LAW#&_,A8V\]-P_[
MS>IGXZK9.[L/[I#'HXMM7YKAXK*C"L'YT*QIW3"-G@U)^9PSAIYL7FW*[3_/
M[2V')SSBS_J;=>Y4ZVO5<^'#0)A&O[\>\ZSV"Y2;1FB20\U"S^4<=]&)!G*$
MH"DWS6-4S.RU\%]Y#>Q_2ZSXN^@450:N#0=>;2[WYQM&76 DMFX!%0[H(JRD
M?PY&*%#!%*A=J!T73K#> K38K@LOU1_JD&E(,_R+\WK[_]J\ ( _G:EB6KO[
M;[-N0\1O 0QJMP 3XF/R8H. .R 1SW8W<?@EWN1_=$Z-<G>I.:7S.2_$'$H5
M#CHY8F-1TSD\7?%7,U>[60@\G8(BES&M0GG65&SX<_)*'VSNC3 K3FZ-?_[2
MXUKX\+OL?88)\9LMRS/!?O8?V(N*_ZG504L<?U*4TE\SI)C3RM@^P9EA.R;+
MR8D_+/YR!<4Z)B/XZ%);B)<W^=TR_$CDV_*B5N\6AJPG<]V8-'0_-_AMWH/$
MM^/O&,C<-7X7;1=G_K@6P-8]:5J8@W]SE%6N/>">I?,H[-EK)%%RH".C&[^L
M>MXOVW@+\'F=/1Y$(CH ^E/P#D>,ZGZUA$(QS?PC*]X!(,^+'O"1X;CJL?/0
M\2W W1G$T8YD^UMW+$92F>8/+0F/<9,&0!P7ZQZ2>XY-1W>NMG?O%C#S MWM
M+MBE=DY=7TH&*Q.@CKB?20]Q8,KY[L;?PVR,J1T:7R1[I7Q I:X&T$J7C7SK
M0E>UFG=VSC 9-=JP:3#[%:]2HA7_X6_@:PW_IO(!+HU738>Y+NC=XDLO1M@<
M"$R\H7DWT8^^S8#.Z^R;P VESJ87)D*5"/GSD!%<*35,*],"U=J)51SKR((9
ME]O1:9%%K([?CK?9JA;:&LWQG,56OX8N^Z2; C\3)PS#:(\AAOB64VIFO\U$
M>=8EY!+O_Z;C.V=JI9@YAZ!2G(B_7G5I.0,\:\.=T9YNJ)GH2>2\WT]%HX'X
M*DFC;?&9S,@!/M$^-[B-G%-+E-.1S6YN3->H<6V):"7KV"(X=PT4$\ H-]W<
M$%$GMN)WV! Y+OHML#:"[,E9Q2LJ\]@H(U4:M^PE@83@@_@MG73=!+\B9H[P
MDDJN9<-?T_%.P*\&S%Y L0];-Z,X(,.=W/#<T/":'&SL.9;4%6O-<J7QS6(V
MML5=*:'&,(6V3MX16AP#\R3BQD!*XQC/RDHI1LPD S$2V-ZJI0H^?#_CM$\S
MN7-L),6<DNIX"^"+S==I>R<S@A5DO_[P6C(1XIMEJT;0%PH(] (-YZJ\4I!Y
MS-'QTN4KJ-R;.DLY=*A$HS2B=4>\5-QS[-*F!?2BY=&WZ=\]><\-)W2]9JX6
MXG /:;_IOO6ID$;O+H!L;>\+'5+=,0*'+33(,$I\X'L!;O<'+(P/.R.QIC^'
M_F9P=->7DMZ8/H$J4QPS4\F6&<@(/\77&\98Q(C T_8OJU[9AT$X2OG"#5["
MTDG]# DQ6A^^3K\KD=A.D"-WID4>#+$(/W?+YK"0+Y63!FJ]4K1KKS\7@F 1
M^(3'0T2P8=R3+^P\Q_KH.GV:T[3)&1$R]+'^27!"4&?]+8"JS(\D^Y&[43G%
M,;FMAZ\__^,.I2J00&_PI]Q&B9D_4H"X$57D5G@%SQDGV#Q$LSYAH9Y<6RDO
ML3?HH9C0$;26\H <3BC24ZT/%NG197YCKS^29O&T\69U>%^!_)>/NX3>5H;,
MYV[+$QIMO@$?MZE^#<5%@R5)O3<74H6<E?*$GS.5EH<8(NOKFF=R=X=N :%0
M//2+U6P:/_-?#GB=7;KI?'6I:BJJ<SR>CE&V!'8FBBL'6G&J8QG3>E&0%ZN5
M#'X/9B!:@2M&H >[,./L[0,KG+G/L\^#'G8O4%6IRJP[VU.>FZ&"K59;F>$Z
MF%)XM)&_Z>X2M</&)(^.5;J544C*B=H1K1LOW1GUGIZ$+9)6%35W+2$CG%NI
M/X]J4,AVKZ=,39BGA3=B=TD7?2Q]2$6UD(=WN3OKY\$UU=2O(N=NL6MJ]J?R
M$,TC8#?N]&%$E]QYHMWP.>N:1M%<X(OZED7N5,V+_>(5[H<@W"544C>-9&R7
M80KZI6,F_4:S2M]3+\+?:VY2XOXC 7YM-K65GY;I'05OO%3KIVJ5Q>NCE#E+
M=3*EAECQ_KP)VN@0J)>7L!05VFL30/6M0#]C\!%FH?NG0[R]D;8D"_W3+].Y
M="_899:OZUP:6Q06UNB]AS10Q?E@SC61+K5[X& )M9\&L\M&O.>0%W;J>;]*
M[C'E/G_WNOX\_@<S5AQG+GYTUP"U&6GLYVG@XX+4Q/#.]YEPF)I[!:QNL%0C
M[]?I]NH&I6Y2["W@X.#PW.Y\=[_AY6+@:O@G##DTIHUQ]V5 :JD-J=$;F%S2
MLS)7&;HX,;S/#I?9CKATSQVGD%TT%)5PKQ9HS?A6EG!"6ENWS9)FE1A[#B5^
M;.<&U>]N_]@R/WT$J-N^D@8M,25$^$)A].!''#>O9M8J<^2ZS*?^P5?HR@9'
MXL$?YY7?T/S(U!XHWFK;F(1XA8SE!YXL10H8OF_$DC0Y?FFUL QN(^/*V9$)
M6O"$?:S\@-E/OLG)!A;/QK%1H[@'%4YMN\IHZNAXF7Q)7^R[C*=R8F8"FVCX
MVJMQ+;&==7\&K>*4C^KH5)_TV/O>75]3HZFY2*Z=.+Y2O%),U7=!KV*[!R0X
M=7H2,'T,EN%:JQJ%[7@9PNZ17-K:/;.BVFFQ[:,[5C.UCT QPW'-48NK-Y;Z
M;9^FA=ML#QT/32QBE3E)!E7)Y=1^;;9D>L%5XU?C8;N!%.7K>E=<7DHTNWW3
M[_E;BR+3E!)I:>/57B^U().1R2=<KW.>BW!)I.LY/%\:2/WIXY/1Z&V^$9)_
M0**HH[A=L>;@=*-_.G_T""4"M_131J04AKBWWM_J0,('M*MB-?6<*S^ML[-8
MO21QI;K8;*K$W\XB1VDAK-O;&"?]GA6""[60SXY?2Z1'<498^J]_)*"Z3R[_
M]GVB&ZS9?H0"++*:ZZ>,=*B,.6T-V.I^LCGPMCK!5-N_,FA5D=$Q((\ X(LT
M'@FM&\'WTT.]6#DBWI7BFH!P%J,<+UDSA9Z3/Q@K0 A36#U(,4=]XE]J>Y4]
M+1G6-K&[<'K9)KX\UQ9X9)0U4Y\J.7?-:UO(6[^1TD;K%W"4<NGD6,^"I/P=
M^$ ?,S:=3C\%F[7U^<RW-+_=9CS(HYRF S=X',^.17&HAGSGW@TF[AK"DD.,
MQ/"6"7(;>/BR+QX/.+%(O<9Y9WZSQ5U[[\1=K&+D_"<J,A^M@/HQDRZX;#>Q
M[\!<I1SZ@"O?8#'-;?+#JQ?+U#M#WN0!H5]674I"Z51Y:K^[PS/H:_V74EL;
MVAH6]U,'/GC\.LQ7$GS>TZ]RPK/88H0X6$Q.SE&V!F2]Z);4?S76+'R!Q2*
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MYZS&MX (T!H2M/<-\Z$9;PLM<PL 1MX"C'M/! '@0 P(B&G*WN3\41'8>0M
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M"W K:0;<*Y'A+]#XU?H,8#RW1GX]K/[O3M<)&,-X\$/9?S-[58#)65#F[,8
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MQY(C,)< G7'+,R,=WJ^6TUG[1V_&9%X<WJXR_[(<_3&&^QD^?G[&NOQCF@C
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MAOHGM^^PA.>92R6O?_7S/$IJP/BS1[C(,6<A9AU3Y0LE8>(!!V9.=?1UU%7
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MX96YQ_Y5D?37\]B7L_\74$L#!!0    ( ')!1U;IKP1^.^X! .^N @ 4
M<')A>"TR,#(R,3(S,5]G,BYJ<&?LO'D\E&'?-WQ:)^L@:V3(6DA9DG5(ME2H
M$&+*DB1-E'W,6++OA%*6BA1E*EO6L0O)3I:8,93=C-!@EO?L>I_W?9[GNJ[[
M\[[W?K_W>YV?^?WAG-]YSOD[?MOW>Q['@?&-@0?XSIE:F ),X'&.Z1P ,*8
M8X"%F?G/!SQ8P0_; 38V5E8V3@B$_0 W)S<W%R<7%P^O !\/+S\O%Q>?,!__
M04$A(2%NJ(BHL*"H@*"0X)^;,+& U["R<;"Q<0CR</$(_K,/1C/ ?X#U"SN9
MA>D(P,S/Q,+/Q&@'8 # Q,;TEP/X'P<3,_B,[) #')Q<H$(5'\#,Q,+"S,KR
MYZG!;\/ [P%6?C8!Z9-&[ =M;D".^ JJ1:0_/R!SYD.+T*5!DJRZJU\D!Z>P
MB*C8(3EY!<6CQS0T3VF=UM8Q/FMB:F9N<>[R%5L[^ZL.CF[N'C<];WG=OO_
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M_!0&7SI;W51&HILW<5&@UO3^<7]=CTR749E'ICOO+5N=9#+TJOUWG\2+V^1
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MAY"0HICN60J,WKR)613)VM#$SX!#GXDCP6D1\PQ@0%619>;6OR(\_UJ4OC
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M56/=Y@G]=M<'/9"2Y/!!6Q8??GH;^UQ/@0$<*4]F "[6(*ZJ>G?[GP(XL#\
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M P*OCEY8RBP;59K8RY,H675#XI>)V.<8/"H3;.) EC,&#WH29,QL8*'-W*.
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MV:QU__ND87A!'.S/.;BGNNS?W4:7(NL6@=DV;F0XB+ &-]JEKT,T40_R%=2
M/!W42_O,>*$*?[/<\3MQ: H9_A+5+M^*^GFK:<$?_K<W:?0B-0%EV'@>Y _:
MQ2%OE* _ZO[P4[)DLKWMEVL*@RX-X1G/I!/=LY.>_^2!.S$0^U\_ /#I6F6
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M#2KUO-+%0,H[: *OG_.J&L<1H_KVJ;;*Y$(D:/_7*R<R&W(04]45KV!]EY1
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M$Q*G=$[2.+?#H<7VN;@Y,)0COX[8]6K;C4.C-3545&=-/.6^Z$W=]]\TFK_
M.5 .#+9(!PFBSU40C.*V85QSU]DUWK^?S C)+0S0Y3#-:CRJL;)E3Q*AOG+!
MN#PELG3!XM+C/N#OC50)/JH:&O6KX7=^"Y9N?"+77K#K*&*GN=G_\ B<V@![
M*"I,LB.\QW1BGN^FIX9?4E?TX:@)#+31O_+<0C/*XW!)I^;]F?O),8>*C(3U
M'H)']J4[,4\@\1?(^LA^) ^Q/?3JCL%;SNK/'/Z'U+JC]-W5CHH'QO6NV/3]
M!_?AA/"@?E6 _*6B25TQI_)!.7#W&M<?B]$OW_RTO,XG6P\O,IU69A,Y<=L6
MX<U+DEWS(>X/D1P!%KR;\,V!ZGP.F-V@R\*"4? I:;;Y6I9+;>2R*J26OR3)
MK $()RL D1U".?H!\W,G;OGT24?1'--,O:02 \X]W%1N GK(51W1'8,MG7)?
M=AV#&9SI5EYN';GNW:;*R:I-60J/).DU# *S5Q-5NU>WU6B.I:9#<R14$LU"
MZ:#<VT&4@9)!H[-XK]FF^I+!4(P4'>2&GIC'2S:C)N&&U'PDSY+7<C4=Y!"W
M:Q(QRO=V8D:*=4&NL\ CU']3 'U]\)"IY^*.232(8C^&P7X\^'#-@,?]>.K&
M"\6,LX2YR WO*>JY6;U\60^YWI,=I^V^!7@D]K(NAEG#6K(8")8+@\VE@ZI\
MXXD%G4V0C#88AX+@HR"!MUF7]+!>$DJE%2"[F=,R$ME'?C5/^GXB9W7.E?<0
M==>"L48Q=W0_='WX$WA_YCWU!6."2_RFW%&';H(,BVL"-[O4/>#:?SGO9OD%
MIG")ZV(&*7>(3V;-K2Q8*H9"T_!/9B)K?\BIH$>6SV>#>S"3PKBY]GA <F[-
M[@O"!_#+[L,S(-CI1/,J [.$]/,/[,%>+DHM;]]T'T[HB<U>L_%]'0B+@A#,
M_C2Z8$<9'* 5#O(/06B.Y))E*E,_B_2Y2'O4"^"?.DZ#ZUGO-!P./0I>YK1?
MFH4,;@=\3&\SK"A/<7V2.'LX-BL$^IA%_?S*G_/,\_' .=AJ>!'R!QT$WD'Q
M^D].M\S/\<GI:S1^;W*2OM\G80+9^[/Z;:-_E^F7H1ECBV;0NNMKULX2,#?'
M$!!75X073D4B<W!4B6VW>O"(7&L!+?#0RZ6DB9!?A:O[YYDW5W!N%#[!1F8L
M$8=Y97.(R QLZ<6O5AC9"=UP?>_.;"3R+98]8;=4@%L.](-%A:"%HX/:8<#Y
ML37S?(H#D0Z*S/^)Y ."YY,,*VIU3DSK\J2&3G(W!TR\WDC15'HG1TR^LU^&
MPE%E[]=&X'<-*QIK(]_FUSX730J%FNCH<LQH&!4[_.N+IOY/'__YHBX12!LL
M%,H-Z!;Y=]TE?']1[9<I,Y(_6F6?B->_,68B+U_+H:=IH-Q;RSO[SU04 <_)
MUU$M5U$.62*(8" 5;\B#6YSRMK9MG\S\8.M%K2G07;PF,YRH0[;!ROTR$[E\
MV/XU)W)N+!*()$T#O#C8B6>!Y]!$9:W2D<JIS\YHF7,);6T*KB8WW%*_E+]&
MOF$"YO]R)E> ^K<S.8.#,SEB?Q2D M,.#H-*#2E 7HJ)U1+L?F3C3M6/7)81
M<&7[<<ZPN[=..#HI1"<PFLHPRP@*-1/UI\@?1:-AZ" >./B@# +C+!N&$8(>
M_T/C(#RH <<T:O&5\=)!DVLN"R<F;I3U%I-'C07?U<<6)H3H=_*?@O@BV^@@
MCIWX,$QY5TBC.%KQ77I^^-<V_7-9[C4G5/M\% ;*]1HO7SCS+MYB]^:>&NV8
M&S[6L@-6YA::]2!1/[W3X"MTTO&X@66'6I$M-!IZ;37$%UWD\%?9<%CX5!"-
M+>8160-(>@"@L"Y@LEO7 S7;AJ;A@<3.CO?,(2=/#$%'[X;<U]']-BX-/P+W
M5R8U4NLO82K1WG.\_JD&&8LO9WF'%)+A9BE:)R5%/.MLG[]+I[ZMH";3^"PH
M=T>AXM^Q:S 38LEGU6G#PF<W76V4[MV[RUTGS<46]@:TTX.^ >?YL_D,,^%4
M:%:='XKLO&3\/<3]]K=%M.AY9J(1@S.%*E&"1G)TZQL(R.AO#:_\)O.*[M%!
MWGN7]>2WK\X7&Q2A6@1IZHZEJ37#%/Y"I4%$@\9MG\?!L"#7,%B<-&DYX:U4
MXFW00I(F)"P=UC(W)4E2K@W: /^9E1VX^-A6(N9#=WUQ6(A7D]ECN:XXU?H%
MYJET,@^)8<NAI:C6'T2;<,(N/B[$FT'>EOT\ED8M1I,$R1H=;:4W]'&2WK?,
MGM<97#*:T91>-0+1AN>.-UU 6(\B1?VU+.!<3JJ*8?"YF?''!E<]I'1_'?.*
M1-22TY@/<X-Y/\S#)RIP!>U@80?DE5'$Z8(>_ S?/J=.OV5-?'>#^0?WI:8;
M+0G7X/7D2,EHT';O 6 DNAB08( E&N&) 2I*@ "$%IX<_OQQ\)W&%2<C*<58
MH?-Z4PVLQW]S7/MU<ZQR0!/R!E+M1\G/PJ92?1D1@);: R_<V;M&MD?UFM..
MH<;<&%:YA$C>QVA"$C&0*&(JA>]NBY#=@'Q;OLW2(0G;5E8L_T,.TFP'1N@O
MNA7Q QA&0,:6-[&.7(I//HX.RJV\.-YV[!1?&(2@<.8@4W@SB<8>E5]<4DQP
MLWAQLLY_Q\ W[38K5U5NU\;(]!@#ZK>8(2P]E%>5\WZ(=/K,6-[23_;GX# Q
M"M50OE% X)V'$RQ7MCZM9!U5D';N"ZBX][:U,65+:$!\?CHWFH0"I&$O[.'C
MD;>B)<XJB-H:)KH4A-\YF;*W[YJL.Z\I=G"(MS60^Q/UF('2'@Q(II0[NGCK
M%AHJ))91#)*LX6O/<[O0R%X,?]$O(WG:!<.;3VQ@H[K.FY)P4H+3&\;K#ECA
M6LDJ0[46OIQ6[<JO^BPNHB"OSP5Y?EWZ"[54\>4V9,((OS,=_XL.ZKCP^7IL
MUGSBQ+P1)6 T!'J;\6O)%1XK6C]2<<@J)7JH_;M"P-IOBV;6_:?JM'.8&]);
M0S36@AP#>[*J/^9NHEQ4,#Z 6PG6639UK9O4=YG"B0S_M^_@]WTX3?KUJI7Y
M=]W-+4-/]GF<Z4S3.*K?88'.HH-<^Z-L(( A VSEMJMN&_A=?%:Z],#EM!&4
MNGG*AE7B0E\I;5D1A#A+]D5H,WQ0$[6X49& TOS*CV0E/%=6K?I>E)&3XLGT
MOD:6Y?%JN)%]@)K0;H.E0U%Q3DU-[*/0DUQ=0AQ2GP1 QYO9]FI(PH"I<C@2
M8@5T/7@0'-0A2\J2L[%V*;_Y9+].YK1&FV1^L P\9;&VO_AQP!GJN./6"@TN
M'EI4E^_:U4<[PC"F*^"U@8\KZPS6!GC-KTX]T\@)^^;QM?_1KULFM^9?+MB)
M.I&4518\I3>'2!^!&]#+%/'A(ID/6XJ%X&VJPO,M06.13MB<=5]<FE20Z0"&
M< L]^4PV'EZQGI6S7)-C) AHF]X<%D_&!*FS77'SZ)<\KW1EI4E)\A.ZO,>C
MD#?\IM%L7/RVJJ-!NN38]AWM8*;2?WD=Z/^EP_1OE=<.BN4)J(-B^3C8*AA"
M>V[__Z-6'IZ $L9@$V "R+,(!^)N3&4_M[\8IW*[V*EA14NSDHT-OB?106EG
MM=VK7S$?\7A]3/#'L15X23(Q-1Z%+8(<@8H B^TV/",NB'N3'\,^6RWYN;A]
M;!](RT[."7[Q[9AUM[O[U35-"!<=U)8,5::#?@[]I5CUJ/(<)1(.13A0XQK=
MR+) 35LIQ6SH8RDA,]\W 5J776XCKB,@>"- .NKZDQ=)KA[3S/!/<,*>;$C6
MUN(\F,+;P5B&E5\,S.E'.7FW&5ZYV.JBUMQT;$#Q>>QMF9N+)J.GHGE?Z21*
MY3TK62C;.FZVUBRPZ >"?*&#0!08%L..X">XIA'6]7X3[EDX&^8;"6]L??#
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MTOV] C(4'>.->4$3#.L@:$1&.7_8E!!S<#S4V?'X<:_>M/%I28V %?ACBB2
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M@'LY,[S21I1X/ ,_PW)[=-MIW$=4\DY-W/+@YM$9D0'5"-V[?ZX=#5$XT*
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M@[6#,58U\4BQI4SH$"*F?;,DEZ6[\=I6.^K+?OQ" #KUNZ?9O*Q%7!(%0H'
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M;,N4(KN"U*FHPJ0KLGFO6LUAZ5 MTF4,(FJ6H18?'-VB53P%"142$*@76.G
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M,T&KZ&OE35HL@Z2UZRJ2[B!^U]:0;IILUG9G+IG@/GC8T9G>4PT^[M5EUSQ
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MU@NQ$N7[[Q+K3_RTY+QSI,])^UJ/KI'(EDV$NA"\@'Q!=V-S[LT^#GW@^]U
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M;9"?6E.JX:E2-YF:;T@/_2\&)=(>B?%41C?V(NZ7$,D?S,N^%&ZM;DLPE)&
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MM*.2X_9EKL 3=64^^G)N=NJ [JWQ:'(G48.:L8N> F$&,UXH5+B.UX4L>N'
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M?FO%V>QU#X^,=1JT%K#Q'PQ63(Y\=T!<(;41",) (%4>C:G%TJH,D=FH(:+
MOF4W?A&C=OV^,:VLL<(U*H/K./64]WMX>0L3V%N1><I9G8MZ7"?<32^8DUYB
MKA 0?_#(()\QUN_4-;;5UQ Y>! 9H*Q-=4<3X4S@+)%G<#CVEWKB$NOR8?6!
M(6H0A^WX2[/&I(N[.[F%0?#$_@N%PMZ8? "3*-D_I&^#A^Z#IRU<L[>TM3CV
MI2_/$#9Y2#R=_5&I,)JP,M*-]VM\-D,RR<3#]E(N4(]8MGBGBSQ^/7K@*VQ9
MX*[8; D!]@Q+M(2,E8WAK6/K_ FPATZMB00>W7.ICGURR=5?JE7F$CU\.9A
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M2>DP5FB;=62#'C&@J'#WQ,<<-Z^AU>/-;\J:/T771_&C;_[R?,6+ QD3=CD
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MZN..'L<%O[/0QMI^?@BU_EK?3P:[)K(!SC6%>U@4=GPZD],OMC9WNNCP39[
M0Q6SCXFL'9424BF 6JYIH! +&1>!$ ?QL%M,AFX4[7@>W/N<"_*U5UH!9REC
MS0>BA:P841ZJO?F[<6EPHK_'^OGM8^ :5(B!R464.]16U1)C@[9.K[4<"P].
MS7=EKQ^9.:1+!FE\7X39#O^$TD1030R. 6T4JW=([$-DJ;X_MZZ-%_G.:)?:
MB<QWVCX*H;T.IONUXR]6L?I=-FN495V7!#E7FZOD=%!+."].!A*_+2WI\*#K
M5NTCF3-CIX6W4I6E"IK8(@\;R4:Y/D6<9>"P1#L_SK #E-.$;I:PT\2&]\Y&
M5<Z2KLZG'/(<LR\\I'W*[,F^A'^J_M*#56>=_??N%H#Z+GZKG^Q%_]@@B1C,
M4AW4-\#7Z'S"K"]J5'\)L-".UL<>N1!9=M3*Q1_EM'WH'Q=B3U']F_C1+11L
M0!;XT/.]T"4?$%'U.=>NJT,91N3)C0[DXU=<?]K_3(!4Z](R,"CHXE,,(\W(
M;<6-GWH7V?&.LL;X -+V^6N@L(@N!>U4A1C*:%/7 !&O>PEZRK[Y(R]D5-S>
M)P\C,:7ZWG S!_N6;CH7C/JV H)C_"8]W@G&2,&Y-3G895OS6_:_*WF686OG
MT8J0)9*S">&VKE#;:N_09U291WJ:6?CMH6YP2!Z.HEOHIEV5?H:?3^E3=:$*
M40,ANM@U8=#R).FSY\'7+(Y6DY:?LQQVE:7/6"XO&)B>WI+8<FYOV#- XWHG
M:7E*[?6UEMM_R3UGV/#Z+:;+?R0@+.\=QKC!#56=RBCZ*F[4'V0ZY,9/BGDQ
M;:FH43%2C3'?[RNCQ%C<AULW*/0%Q1J3H*.Q9Z$#F6?]X^RQ>[ZVQN"]:5K\
M-IJPTIJI.[4'W? ](92"6UD:;[BV"9F (;N%-T;<_+GOD .T"[:VD<G]5CEI
MJ+LE(-2:ZXK\KU_#:L5Z=X]&6=%3$$)MTZZFIVM(G-T%I_-.N_N<:#Z7HH"J
M^< .J%E^6[N_<E)FS!@1A*$)I[:JO4*-E+=?DS$2-&<"GRJP1+(&/[*W"M[/
M $=WYPK+-L08 4>V?*LS9@(F(]/65+HR$]C?RP1XKY)$Z9(>B="5=30MX20D
M>]U^-I9FD- *6_?)TF8"V#[DJCKD?Q[X7_7 .PN31/OB"T;]/[$#.]'W(EY#
MA_$==X,">\\\E^7Y,M3(G<)NT!4^2\3BTM!"#9(4YW8[D=511^_MZU7Y/'64
MM?V..8Z[JHY]&H]"G07FY_X3N:+^Q&[PWRY<#>_L!O]MXO/_U&;P?TTAT@B5
M\FR0H]="\:^<NF.90(5AQ]%*S/=O1OZ'#U4YA6.>/SJP8+?7',?R\F5R30:=
MAFG2&%7I;T>^GUQ>+H)CSU:;S5K>G&Z54!OF*ZWZ6%ZK*9I0==+QVGVB$=O1
M(TVO>'MA(%-MDD-ZC(N:)XW9O!\.,PKD4YV8N%EV9NG[C\B64E.W9_HLOZS;
MH$2;;HHR)A9YG0EP>S+TB$JOD1JQ&G[#Y^KZ-@ZRE3E][OW83OHD)/# !!\S
M(U"C(*6QX+?T@K3M-WH7CT@@<?KQ0KAWHO[T+:Z3,151/\[V:A4NN7')WS85
M6X$]@Q#M>$<3VB8,*05(HGF%Y[UZ]I83CW15Y (SIFV?+P]F)]=(VE^;W<OR
MH\Q\&H"\PA(MF4"\!*H-^0V$B]M)I5HN"R$AEF\L;R^G)?O,>$Y=#4G]L;=)
M.<7(8'&^=HM*YJ) "\+VT9_4<1 R;^ZI&N:IRXBF[<MU$_=5#*[+8W^]OS9[
M\S3L9,]OLULH,[YCWZ-H1Z.'HVZ ='R:P;=",;5=/LH$KM$_+LL$/YBEASD'
M;AENC8])T:^XZ5$O(OH1DO0G#.'OE)96_HYP_90$2UV+^Y$=H7<^?RF-^CK(
M8J'U^#;[*3-;%J(?[1B.4>C!<$+3QTS_ZF^89M@Y$,_D(WI@?)4'9]Z3SAGR
M]#N6RZ!?C;3?WP/_4E)\T$!K#0AG/[O]TV],=4JC99*B)!IIJ,@$FLTVF0"?
MCA^?X<N,O-<"5GWO)EQ*[6P/&\5\SS\7 9?%][!7(5JQ1*M)BCL:XMV@Q 2B
M[S,!CB!RWG-Z)AFV!"L-AM6;Z_ZBGGE.?=;.[E9)OA360MW+& V$5+&W4$=*
ME@B]-._L9].#ZQ2.51AB.;4EQ;G3I^AHRMG'1@J7T?EO_X$YS7DCL?CRR=6;
M$LKTQ"KDMD606W0^J"P,QQ@?-%:%9[%$QY4M'1Y!1OL8E*[X$7,*I-<S$!\F
MX)*^Q0F4_MFC!GX/"H1_;?P..)R$7$'@D*LW(>S8)=L^$*&GG2!S@C3F]W#@
MY.X;\(26$&1\Q8=[]+/CONHSLUGBDN4'ETR+O7HO'&CW]T^IO1R&(LD3?+.)
MC+7@\:!<LV\Q)/M\JL;<9/;RW'%+9;NZGHV]?D6'9(861+ZGF-PVI:#<AQK&
ML.^K!M5^5GR,/J2>YYIB+/OY/28#H1(F_H$8:E[@=>57A>V=SL'E^A>#R%$:
MW7K6,<]27WZ[793@M(6A0)+_Y9@A=X)?&Q4J=2K-_J/:1J7;U:\"80'7-C?<
ML&X3B3#.%NVT?H7W'XW5;HE+<W"_N2=+UEG7;48FDA;=K)*G..RD3S^((;T7
M0)Z<2%SIH8=L?[""%SK%'!QUA2!AT"]]F<[S\B.@HJ3*O_E[J=Q_4PWC,12U
M35I&3!P3</=!,U+&AR<J_^BUG&/MJ6 "6^QCR&%%QJFB2^'_#WHL_$\$&/U6
M"&!_D '*YN]=;4L:OQ6)DS)-_]F#+_YV6/OO<L[NA+7_CD[^+JY=V-1J6'OY
MJG--D0Z7\\BM'X==<NLZY6*,FDP!6M%AN#[)_C^>T"7LT\J-2!9$CXRD)1=N
M0J*")(*6?"ZW5JU0]<N$RUB%;\YLL>+1],OA<%AW_K(-:6PJ?5F:>A:>;]R_
M8<VW,-2[F&XG(1ISK_KY4_EXDZ0CTK4!CW.N/^-.?4GJ8=WT)O V9[+BD2V9
MDDTRHO&>]Z05%2RNU:1^><R>/./3=3_UPU@&2&,*AQB[&)\1AOV(8Y2U1I!P
MU<&*QDVO^+R=)YH&*):W\'Y:E.HWE>!+2%S@FI6:PBI@"4^17LAM91@?E+CO
M9PTZ'L:.4*7I]"VM&,I28*VU/-&M[:I> 9\4DW13O10O8L4;E9,&6.C\-"Y*
M1PZC!\I9 8%0 H<8W29#=O;541<2Y6MLI+H%_2X&V:R9M%Y!L86KUF%F>0G(
M)@AJM"HU!XYI!,%WYL2SLH1,7=L^]7S/(-S!K6G555J9',T(,XD> :%"EAPE
MF8AJR9A-"--%$C2$.GWE![4S3XW@X247?@1>NL(H?CA1#[^L]=B3M>>OX8OJ
M*LB9PHMA'2160LSCK],6L18?:Q.U5I]G7;(WG%'SVJ(.+Q:'I8+$29R>] M[
M$U3[@0*4NY]ATO";YH>T*YXW*WZ_LUO0641AMWK943O]/>>D]J@!^M73N!8(
M:Y@N:(VLO3GPX8;M>GK+[*8?TVVK$O7'MA1J*SPRS-G5ON ^3 /< #"/O0QA
MA>M-B=($8YNW35'WNO0N$%MX[)PK!P;#WMKX^099U#&!0A7-,Q&1]4;"6_)3
M2$F:.\648.D!"N[##5Y^>-#)S(B/Q)*W1>])*I_$!8Q6"^[9?7_&\VAF]AE-
MB^0\M?FHCC>/)D6<*)_BN="28K;H0W"5%J];7=5.RMWOVA>YU!7SB?:6=:&;
M(O\4-X+T[A9R]D(IC+IDB==+OL$_2_LUT#X30@=QZ"X=JLU?L,]A[-5,;[(7
ML:1\:E)RK!B=&&8J=9OGV(D/_4L#O_8NU04G?;L!/-XENUAC_WW@-PH Y+,5
MN.6#!.B(-R$3]TC_XNK9/",?][PQ]^Z&&MFGB5J-> $'(F!@Q4*Y<))>";VU
M@I((:U"C7"$B+:J)ON2C73H?'G^-;S-SO)$!A;)'7C7ZG/5,)YIZ>PR[?'HG
M.Q;%G^CTRY$W5CNZ*O[7Q'$S!0O(V*%OR(",<7<7<#[S(!+@J&F_9NO(Q>N$
M<>]VA@#1OS+^F'K%BV*KB<'LASQO100:WP&'CS6V 6'5U)UE*',_A%K8.60T
M3%1?532B06X+)?PA3C%R(C@=7:ZM)4#LK%:\\P4B)J9X.KP[/-POS]'%S;5;
MNC*WSD>M_TN3K;9-V@WE"( M=1FF%F9)?]0@A>A'B]$.DK FI,RVJM>Y"8[J
MF#H-@[JAS13G<]?B[5*YQ9($9>F#-EF[=W:Q%X2=K:7<I4K#4U3%)X966NT#
MMP4ZQ9OX/Y]+U>C-CKEH^-63M7EGI\CN0Y1R$G;*)!_LW%1"G8S2^_X. 6^G
MIW4I%1T?;WX1#?/R?62$RS"_\E5H9N].R,GNPY1JHNZ422;!>M2#T.HF4XJ5
MOU&<-Z:O>>I%U?.JE12]AP/T%;7(/?XU!.L>*-$"&UT%VP=U![&/F[%O\D*6
MHN:B;G]TBYGKR!6VC<9H^<;Y%-R'?&33>4/A>:P ]!I$U.V[$TZID)"+<NC_
M=?8'X>#^N B#V[W:$4G/1ZW'A5@VK%Z\'5V4""^F)[;:I]G;J!%=3A&FTXZR
M/!V,9>,S8@L9S*!L,C@L2)JS4\I+H=G.;E:^A^JTPOVS1:]:!/LOIPD;=@KU
MOB7;P*[\G3<J078CFSRP,P/:UE3)6SN6Z5<]ES43>!Q>3;\#FU'M1O[[($J(
MY>J?=ES^86%I?+$9ZNNWI0.300ZKPNAJD1&&S?0D$(,-&/(BO^7F@F!*+6!)
M>!HTRY.TC-BF%:I0!9:NF%0?^2^^).^<3X^2LI_&<+[_)-^7:0S V=M0]XN]
M9[UE)!]42-5MAW _V?#$^3.Z?2>B6E5_+:SRQC,!MAP2>V:AYY$B";2&^MOF
M7%R!#&H;XMX5=M0G><VM@3\$1\-V_CI^TW91,(-B36I;7U$V)4EU*>9S[%Y;
M[0U1S5I<&0B:SN^Q^91J4F;RF?2>NRA?-JHG"L;UW;G3PU]!L)W8)2D,G[$M
M>A/ )A-3+T_P:+? [.Z0R7R;_K%7#+\/XY>UN&!@O[HY^[F\VN1;F'/_Z^7%
M'UN"5L45R1O"PLZ6 \4!"6)^:OD6+QS3[UB(?[IBY[W.-O!T"'<95"J-_X.*
M_LFH".%.<Z(W&&K2$)3%MV$'Z,_NC?F+9"HD=T\=E(WW>.XNIX#68A4ZO.<8
M]VFML#=\#NJ(5$K*T (3:*G-K7R2=6EIJ S']KQ]A),OGZA@/S-,XT_'94D1
M15M1<8;L)*GW<XS#@VTY#J;P,WY:SA6+!K6@559G29:\_".RE,$)K((TL[9Z
M&48,7)GV>Q3&6]A4B&P^/A6:2VKE;]O=4_LQR9Q[T]"Y7?SUISM.ZD7LQP I
MQ M&"[9*)),*HQVI&73Z:B#?EJ$?YU/L]3CMB,DO,9S:F9FM.[MO[;K#>?AX
MH_O/G3-7'J;X@;)0^>3._@Y)FL7 I>28TZSZ6VPA]I4[D0>EPRW0D< 5AX]$
MF<QPKZ!"DV37KB"D&N.JO(C-^\RHW2BYN]UNEH 7HQ]=D1^-O8Z.WD0<(6GI
M-$V2PZ'G[D=D,&8B[12ZC2(LCA!.*J=&( 1ZH3[68];3)BD,34HP,=0"U13]
M?!G9DV67=?@L7C_UM971]#TS%M7^G6SGG/;!&CB_L4*":%-[%FS)P3*Q\HN9
MV8CB\J>U&8B9B&#6-YWMC[GS@1E*S[WR'9QQ'NX>G,YC8\T?;0_TGGIW8 D
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MTNZW)<\XL1-%M,E(K0\5I0E@P.YKA&Z,V>YT7SS%2IZA"#5!GJ1X,!9!A"I
M0Q6#6IRR1K[]-X:'-;Z?(>8$FE9A'0TI]:7N@'!/=8F!M]]>[6TW6D2/H[Y^
M=/K[[@+A_3?$H1OV.S<G#(3539;0&9RA,A,8EH30-:HP65B/R2TY)"\36&*]
M#F(BVX:/L=#$"_T;4$F2%KV3EZ&\)4T7LH&%( VB_TPJ%/])<>P,BK+(:-2=
MW+;:^#8L37K!,&,"2=@E5E#FWJPX##&DZL5W$H^%Y#(4M[+:0"!4R 12I8B\
M], !['K#5$,E)@6+?XI<=<]B80(EH^F,]._V0Y647GK5WS.AYD\<CI>B9)JD
M+T>*G)Y*7YJ<HB(Y%LJ^;)J:U#PM9G3+,X$B!P7.S[VERINVP"L!31. K@S2
M5'[&GC!1>@'C^$VD1)TR845D?D(B9K%UTP;^TZO$O5KT1%QRZX+$WN=D 84M
M]S%QGB1CQ L&#E(Z&8.]QLOR??Z$:_^BF^R@M-+@QH?7_)4M;^5LA#RN6:0U
MIU@YQNF3YM&\AMP4/8)5X5271?,HE.RZ$E]Y7"?Q*JS24G>T9.:&1ZJ 'EO'
MC:WS*FN-)4,1^A[D(GIZG0[5(4SC1;,3#9,_?EICM*++;6]+I_MM%I;(%%TY
MMIASB2TULOS$R0?8Z]"QUWA$4A@O'AKGI-W ASHRVDE^EGDY\1DZ=5ED6<VA
M0_$\_MJT@?>&2CQ 224K[20VP39"Q5QIYR@HC.DT-&XXR_W-G)O9+3>7K3X.
MR,\,>VZCQ]&--P"IGPUC?RO\9FV-_&7GI*D11C<3X,.$L>/]]CG#\V%]8YT#
M*QL<GT?&/E^$* KOFY>^&_/CU&/[U)>(^\.$ZJ4MJOX<4AJ+SV'H$9%M0D]?
M50\&9)JL6 GJ\[P]EZX65K]P>K?>E^>V'!?Q:QD U9HL![XEVXG1YW8"U>BF
M3:3G1],NP%%*SP/ROW1YA5RRT-:#J4N],)+_>?F;_(]C/ O0"F6:D& 3I!R*
M2V0GS#[27FPK'=3^YO=C^-8WLRHE\]R''%?;IUX9UY2E-$)JO?$:8XMD)'%V
MR8!Z)NP@Y3YQJMU'TJBVUM7HWD:6>1I7X?&IX%U:I9>34I0_F4L9'L.'ZM)$
M)/&\T3K6L;7V[?2C4W#:F4V[C&M?E#RJZRKA,YZ?+FR*W]ZK&F%T*S(8@.2%
M^.9Z%7M59<2@ WB6H[^;&]0/?HQ-\APYK5JX3]Q,-O*8[&#&EA:#PWMJL5N$
MT=; 1;VWZM*=9Q&45Y02L/HZDY:[K:)Y@'Q>SW[HMXO56R DV2U _]"@&\9%
MSP] << A[9/?LB#5I>49>M"E%Y*)):0]=QL<I).L"S @%YZ;K%BA"W737GDA
M:8FP6L/]%&,\3.PFJL![@I/XJ_IM[;O*GZ]SC?RU#H@!'[,56/HSP &.":4X
M,H$S_3LYB.4J091XCX42Q01X3>CYR+D\Y ]6BQTWY^\?GH<680*>O-_Z\0VE
M=U][CP;=_U59>./@4?1KRDW)>?DK+U]7G']BPG:Y\+#LAO3-_.:5T0MD=4IE
MH5&N5P8R\EZ]72"7<,D'PK-;0:5S.>;[^5-" (C"=#RP"J,HXI:C24'D1Y3Z
MJ2[!*4@"DB#7KW9//MB/G>R36=71T"O@.\Y] /?CAIA"4HC]?/A=0Q&*.WZ%
M=<(BB(#EF$- :C.@*N;K]4<E/>Y]TK/8'VER\IAA9.W-?]+YF/]-P<%?/J_A
MU/B4^*VE1?EFCV=(]X=.F!@+.';U5RU#&9LZZU"4AJUJJ9<AA>HPPM&GZLU2
M K4Q,L'2-U48H4^T?#F^'*I"4KB'-]9@Z)7D-/MV.)?!,&,W.SWL^=7X.(6Q
MIGG;X94M&>2#[K>A9_?UPX3<%FG#'EL&O$UK=0G"R</D@,$IAK@Z>LMP<7T
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M1+4]G.8PG#K$-MMG,WUL=:42 ]U*>(F$"X)Y24>?!K>"D=17>Z#':9A A!2
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M$"<AQ=*O>)<Z\T)-P0I:8>#.*(<.YQF9WHL'Q);'3/\=F8U,?XT'V _>_G.
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MZ?K:X725THDZG^_<K&<ZD!?C/Q=?3Y$KXHMF,E>H\;9I@,5S?E#Y44K?:IG
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M2A<>]MY#F58->KE>.E1=]Z4V,*%9*#I):M=;ZD4O,@ HI'. E&9X;1;AAQO
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M,/ACX!GES.BUX8R*I,%UE^L>DF;JQ]T.S#TYL'TP[!YXN&]L%)>&62&2PG0
MU/TBN,N(D$F*>-WP 3:?3@D#V$^0*R<Q3OM%NO1/2,@_Y2H+R!/K".XQ$'YW
M#2A!\[1?L9+HR9%O?HX/W02_NR9=33IU//3(%5REH)U$'N0A0A%(P.^#HJ8/
M#&C8X5U^,A#?=M+:ZL8A[@LZTF"\][VN+C_.;)_B].<*- _\'G.K+?=(>1S?
M^/@T\'1]T*#BL'O)7/G!&^MSFR#/NF@[M>.8;A/@9'$&"MR"C?)W3)7< /17
MDC;<XQ&9]Q4_L>PJZCGL$M=B(=0[M M[=5JG?=U;LFXYN]&X)$=YP%P <JE7
MCBMWHU+MV!'):N'SZVZ(V=7Y+W%T-G5R,/Y0%LY&![\63(/ZX>5%+.4GM@("
MS3P\/0J(XS&J;T\ZW/P,EW^T,O55S?$#-YS.<8JL?S?1$/ CH2Z_,E%O%7!<
MITPK-Z:978T=EU@JDE:T&Y'4+"3VC0WAI,*@#)D6<DD^B*;NPLYQ]]:,[:?[
M]MC:<QJ=<YJ&=D-0K_OZ(-C/WVF2, (S *&0  _"Z7)Z?U3SI1MO\F43&UK1
M7=CJM\4K(FY?K6=)JACM?L8<16,%H:Z:[#,$2-M:Y'8ZI'J$S]:9+AC:62Q1
M^N+KP_;7#E>#@^F?I)4/RTQ4L8-VF2FSC,".R".:$C <OIAFH:FX()IYWK'(
M?9"YBZ-3;3B_0E6'MKP@5WGB0$GZ(:VO _CZJD&9!\-N$G7#$B^.S1,D?[RZ
MQL?J8/W^P-/+?8*8=HZ:AO.HQM/(B[Y/!ZDMR6(*@.FG:R;QJ:U%D^Q=ISF8
MRS@"7G-^4BYA_=E]8969(MW<(/Z9[!2V^<7=Z+V-<\J;3[#*LGQQ0\YP46'6
MA#?W_+8^< G]>4^WD\SZ<C..WVKG4C&:BS#+_@U[:1]4VYP "(UD9MZ,,5CO
MM3FT$.);2'&Y,Z,25L&5AQES]P]D?D%KG[6%$N19E[5XT5W?O7:*U)HZFL_,
MZ(E OHZ.5_#W?E*)UU YJJ\AIS#0D?$F+(.U"/%-.HST_<N2UBQU=(JNKY'?
M2LP@U9;<X<P.XM;FGP',9Y]%U"N6GI5#5;@*Q)W>EOD: )V&Q.I7^&]'_JYN
M %Y.G1^*^E6ECYZ,(26NOB3O@Y@D%FV5&!K8]C2I>$>HCWIEP(^JFV0/"BA6
M 7>+;:U77*"URR27YP4\BUO"]AY7O9&>3\&R(_Q)"^$^NK[$+)LJ8;=8.ZEQ
M[?:]K<A-7T>C\!&#-/N8T-O]<T>7N!#25@V"Y&\U>$%F9__HD<7W;PVG> -O
MDH$MC E'2V)<740,;60?Y#.3X/&)/D )X2=H\>UE$W/'P.$R7&6;*G?\['=?
M:\1]1>?XSX<1C.5;DK /!]<ROD1A7X])KS3G0RVIG')0KFAX3=J,&]9C2+#-
M2NB6J:[_P;^IG.[?J_WU5,#OK)$_GJ_S^F/>B">*IUY:)98N N0U^VS'Y5F[
M"-T>0?///>[JU_A<*O,<(UYP[ZD: 7L&BTO=!Y43,2ME9/7V&3;ZA>E>?(TW
MUU75827826DKH#%6-^T'J?1,' \D>4Y0]9X+Y5"](F,6K<!(492D6@8N"?G>
MMQ^5B+Z:,H)6M)Q^+,J?=D.2^0.WL. L'],Z;"6+>A-Q'H 0P..%+=-GR<AW
M[@[>9-:;7X9P536&Q4IG>H;XE <*>C)*JQUV_%CBU8KEZ6PN>$W4K G1D*Q#
M"1HNWP>5/$PVFY$\^#:!,E$S8L?G!%&(E E"+6;ZO[?:>P7%I6#!&A:,9XKJ
MIVF3^L+G!Q&*A+HT^<M1-]-=##"?S/2/=EGP<];<AJ<=/]OW!9D&P)K\55[4
M:]IE^ 88E0]XN1QON3.B?%[&]&K69]-V;(UD/VL?DD$'@USHW[3.C6YINM\"
MO"E%)F:U2>M+*&*OH49G]M/5B3NX,]WG54%,Z0>?TB\P[K:C]UXR>:G4/0$/
MG;[]O2)Z0U>*LIKK4]O6>H/K&UC<&_/Y8V5.7F/A8I6/RC7;\26IH-LL0::O
M"P1%54\_APHRXMGK?5 IMFEMW(@!W5(M[IRHIJN[&K5/?Z")'(5PR6MRU]%+
MIXS'UH?6G([/"BKMNE--:0>C9@56Z@A]H;47S_(-+CJ+)?*]$I&A_)2LO++R
ME.EA@A%O__OO,V-4RFW DZK07*Q+HAI4#R9:/K3<- F0_;9QY,G;C>,,);AW
M:?Z+SW.H/!27C*V$AV@) ^P;.&S+E"7DX-(N_UZS\ZC09-#(9%:'I=6S9^+Z
MYZX/BBA?$&9^HS3,P/+K4#=Y%F/2,S/ @K0/@I>2PR)H-\P&EVRX\6X9I54\
M9[V=)4Y=+W5=;[&3//3 8SUX,ZR][P<8UTX4+#8L!E*;GUKX1MX\YFJG6ZU<
MUOOBN3WS60D[9L^SCT&*+R(S2#ITMB$2%"<?3J3I9/JZN<)M*^Y1:D._/'6;
M'FOL\!TZH/3DB4[(Y/E&/B84Y0  #J!JT'NT!$CS)> QFK8?]L[W$](5&>D(
ME=<SQ).'^ZD91+CN7_@77 M(I>P!3+@9GD?CA\K()]O:[PX6SY=\J0@PRE7H
MXWV=P';TB(&#1) ^'],F/_\&C*81]KM45V8.@_OB^&?V08)9=#&=WZ6Z!LR&
M&,2%G<&*HOM9!\MA:J0U@E084L97Y089_G)+=0L-7CHQ/K(KZ65Q15WO!S<S
MYP6%.9_BV#^>N98/QXHUB-!.8LM+R9@8+SB'S52+8U78[7H#H5NL!Y,]YIC;
M^4E.-#X..KMFON^AC:_+) A!^<7'5F_1Q1&N2*LE8<'K8C>(C97V%QO>-6YB
M<K'N)F.GH>.CN%^#7O,5Y>3T!.CXIM%RZ6W^6);/=2 #0SY.7."<SK?S\*B9
M\NV5@%GLF!R*NW76KSP";FL55D[OK/5[?N1M\]ID5-Q68>R77\P4."Z.^)U4
M: FHXV)TVE#\M+.NA.4BH4%76T$,_L4@,=/\0OF]YR_5W).91:4#VB!5K%^I
M4+9E\Q^(^Z1/SP;&KH^LN0?RMT2)ZWS^I*/>H=J$6\A!WJ1I,&:3&<T92,5!
MP;YU^K6DTD5+XDNA-Q\GERYD9YZ]><G-E(WI<[/$Z5H(X.G>CMVA_;:O.+4/
M8H2<M1G2=<R$)Z&=(>VU71H$@3""-F9Q\*&B[7A+I3*EVU7&L^60QMM1\4_%
M6H_3!5+VM#'A4%PZBF02HT\Q^NZ-/0:469=\K[?X>#?FDKJKC+K5N%6RA8A?
M[,=O/0/M-'$N=&NZULP_3J/^%SN-2H)/2% ^AE%T .<\H&FA:5OK;.B&F?%Y
M5^)JTJ2^A+YDY+=6*_:KUU59W_N/?H&]I_=CF3=-QA7QX' -9HRBMO/'JQJ%
MU<,7D\JR6",=1+MJ@_3T\#6>00^9NY"G$58E &,VLZR1,7'EOXX-SMB03F=X
MC40II*X,[B7I)HGBN%HE8==Q3N[:@_7I&TUT$;(^C8=G &'HSM)_%^ E4I[V
M/"]72;C:Z];A7RBH7*Q_L\5+$M9)/PFX4^_06Z&'Z1(T3=<#D..(4R,7ESN*
MO85ON]0%G+&/2+)Z6UG:Z>:3UB-I\\[LB9^=U',Z!/D=6@GYNA:&Y7R\J>[.
M2A,M+7]QJ$2!J@'K;^\REEMPEFH4O!5SY=BXR>6OS$M@X.34:HX'50%($H[O
MS9L <O&/Q^(T)JP4\R%3G)Y;CIA'>ZDH=_F#R"$X+\T8YPK6&?7BLM.I='GW
M8-0N5"5>LI#O@\Q3+7;U,QK;&).]](:#OZ!E<4TV'%_3Q<0<BM%B3O5>'*=^
M-GO*K![R<R0F/N?7_LI/AA"-J0=IAB18>QA IJK:-+L3SLH)4;:U>22?"D>H
ML,U%]>Q-)G0=3X[H^)GJ]O3 <V3"Z&S>BY&9&XS)WV_3BOM^N\35G^QF5_$U
M[G1C+^Y>_3VC^40T0:QB$7ER+VL?Y.X>+N0)&!D!2JPA2E:O%3J++19+KYBK
M[F2E$'R"%(.W8P.US:3'40R5\)D36R99&Q:KX8'BKB)+W0G)L.,H_[Q(5C_D
M#7.S?],AG-U^?+SFX+OG6A:,?][MJ_$06R[5#!6"6QDJ1Z!R9%]^Y2Q4JACJ
M/+EWS1HC-F.YYSFX963L:50V_%A.HJZD/D1.=O6DFJ&=-^<G\!-M5C(&LE>$
M==ACI7P&#)_AN2S=5XA7! _.ORD\>2A /8?ED 20\.)<]Z28PI4$4EXST8Z"
MWXO>5,09P<-&L+SUY^W>EA=61&RQA)YO"D\1Y#&%9%[[\.+K^/G+8B$,T5[Z
M_6)' PB W'B71?^!;NG6+'5CHKTE.ED8B+8MGNBKL=P=HD"'O+FD*## R.DC
MJ]4/Q/F\PNQ@SN .XWS]!X7E2'Y2V(O?;F>QV$JGMEX5 H0H+8(4(U6^79X#
MGO#KI2@%SCA&\CDJM+2(KA+G%=H4X[MWD_D,.9U%'I:T/3^7&7V0^0/SX'/(
M_VQO5HJ "9D6(8=N?_E\=S65;EN$?287:"BB0CLL1,;RT[_YM[UK<#V&5[K+
MJF5$4 M;6*^:UWJS&<(_]Z#TTVE%B[:^V@%&U-IYU_7>H88TG95KZRQ@XAKH
MHI33M!5I?Z:9='&"Z\JR4:U1JOH[5SF!U6Z.U_>!2*J5)8F>2I V=RWXT1P
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M<5QUS:"DBYH5:X!5 V[:_)(T\7[]$W\1YBTL#2JLPX@3AODHW#J4?AZN2I^
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M7.&R'4#H%@!/EXE"#ILCYL\4:IB^A/_2+RGND3\ZDK=*L.NI6]D'=:_+*:4
M<54/,6C$6:JAS<1*6,LQ:9\TKN\?V*2&,W!T%EB)KU-[BD#4+*O1\(-T:_N)
MDK%S>S<W@$U,2=.\K[7CZSR,4Q;]"W?X<'3E)4:/?-&Y_'\&LC:( R$,$(D
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MJ!8W27.N"BE,2@_#4PNRUK/11D/W*Y]=#RXO/2-ISQS\2SKW3X*I;Y2FG0O
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M!!>@1S)9&7"UT7KGC\>=O,J9_G:56'QBPN%#Q$B6&F?(FVJ'G 9A$ Q)A-@
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MM.3..;U>L[5YY(A910Y$(T1FE5 [RLU3J"I;KPD127PY$I]TY6U6JFQT:;P
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M(>(A#72NK\+GRV%F.P.6<]H"I^#!E,(F<7M$BP[$W51^&OJ\LF"HB1>PGYL
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M9%GJX'O%E],&CL?712/TX<V6/4B"6=+/M^ Q>3QE9*&*,$76(1XRV,__D3.
M-:@]ZR$4P&8LV[:I^N&V\G8.2-S%K<M^#!7['_X'0MG(",HS+UD7.N6]@1EE
M-@_0R>](?-3=EDK&;EZ$FX7 -1]QQ2-/DG3?-GKL_*;_5>A=#]4A\C& =R@P
MKF._/<IDV-_SC #L[=Z=RDJ9W0*-R&2?<#&1L;,;B'_T'U!BV,[Y[VPZ\,\.
M)X\IOD'8#>\Y]ZKC4X7:CM!7B,G[W61V]P&+,YT>&>Y+G,>(T#6,</8"87LO
M?INWN@'UXY( .!IB0P_H3P3*VQ)>_%%@YGXQXD7"0/5 %\LO5,6*>EQ@Z9M
MYP2IF$Y!M9.*GW^+;:->=OA0!=&-AA.(J$FJP8EW?%51K<WI8N'A=K@(+:7
M[%:2. FZD_Z6N!,\T<12'H+?F\4VIG4@0#!UE'>F&?O;25&$C^H5LSI1).&$
M3"?9D@!MG^+%R8]!*DKXD%I?Y<,VT(%PJUU4^L=,9P''Q@+U\0;$;:I[E_KS
MY94D1P*J:Y-C=?PT6H[^( 6?@"MFY8E(@IC,8,G&Z;H(J<@K6=("UN+W>MN&
MN4:;>)=;ID<QD62W$N"J]\6KP\Z5 E^O<!P4<X3O619$S%Q-V?556+ ;3=H8
MWSJOC,1J#;UMN-B*K,A_]#"J747TQO).D9;EBOGK/UI6[(3/Y$AW\%+AZ0CV
M%?_3*GN9E'F-I';+G_?]CJDHP!<"0NHH7==<!!ZZ#^CS+&7\KW1H\(O-_;&"
M\FL(NM5*$/LPB5DAZKIVEE9#Y^5S6=+QL=991M+8O'H9YNAY'77'?DV978XF
M>4HU9#K[*>>Z-4I_AL)M(WJ"V)P@5E>7RJU<23:J,5-@8+8S /F8]5[0:19C
MW!K?60+&W$@WX2.7O]?B59&W!R1(YY/>4)<'%A-.GCD7S\C^2R.> 83O-/!8
M/2AM\NXPE9D.6,--FXVE=EVK2;MC![Y66S=\Y':5;>!1J5N+<N)]C-S-()=4
M,]$PDC@-U"(Q UPDREPE=K7+<X\!&;L&K[PJUJ5-(CH^U]R\:B+3S:C2%GF;
M3>L>J\0Q\#N$Z^9/EV9T)5_[)@M0WAF@VN>))[E4AYS[%CU(N19WNOA+R'3H
M)K,ETR8^4@VT")G.U.)J("2MV4Z'(1C'S3YJ3KTOZQGND&M[F;TT\/S^6FO3
MYT]8KVRWM\M567"D!WMZ1+XQ<V-E'5,B_XCNIW.)/-H@T"70[:Q_ZK!"YF\3
MZ"T/ZA?_IA[M/U' ^ \Y7ZD:P3004ST@0!3OW-^-W2YB]]T.\=KWU%U_,R)P
MO$\F\U%1XF$K(M1V0!M,YROZ)OH()@2P$V4,B9@(V<IH?XK,=]+%27=368>^
M"#SLHS Y574V=LO48F>?>%#F/_V&"R9 ]'\?]19@146\X/OJ>>YNW^*X=T5
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M?1SAXNQNV(%^([/A3-*AU:.?EDGDCS-."OT>YQD43 3FK0YI1L^=H$<F_0A
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M_XP$R/2B33'-9DR 4""*% J@XJ)G>0*Y%4E,((NCG&@9=$C]K,YIT>_^"W>
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M:6S)BC)=6TH ),P ;NU*Y#,$Z0I<S LCB7=/B494QD2CQX(DGU+&[[\XW?9
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MZO(>.,?_Y9S?9Z2*R2=6%<T.SQ2:D.J5:CP]<?.9VL2Y&H=V>D/3Y31%#6[
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M]Y7[^YU[SCCCO3/.&^^//49&QMIES;W6G-^WUYS?,IUBX $1Q4,A1I*H7RC
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M]$/I'48J,QV17!:EO$6L[6O10$.M.6>53.J&$9AT1.VKH,A*JS[\W6Z9Z,0
MN?:SY$JPN;OY=K.^)O#+"K>U-<5N7#,*L?>,RR1R7[=Y,A-HO!EX5=B+T,=W
MV]SZB9?&\7,Z1FZ&Q%+*QUW/R7C,KPI,V:.^NF9O8I;T0\<?E4VW8=_4_+=-
M0E?+V\M/D0<!69*.F_IYRCNX"OPG#<1^_STB#J8R3S%68]_PS'!(DI";"(<3
MO[.FI+RVETE.-Q,6LJ6!6D7I(*L/!J&!;-7NTD Z[PD#W/ A)-VWN4,F6:"
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M_8HTM_M%-%E4KO.(9N\R2)#5(HATD)B+-J+[!;$Y&H@/E7.%*N]L<PD0\B9
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M;7@(5D;@6A=%(MMT]Y7\\*<I&GR&1J)2VMZ_Y. $E,@8Q $:#A<;G3(;IG(
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M.7#L+CB!I.3[O)/7AZGH<S7):[4F#2;96P^^G9QH'2F-[('M&EC)%FBO-E%
MG]TEKUS]<5(4@=]Y1T6?GR::,L2@\=:C=3HO?_)([K.M4T Y!#6P-6KH6EV#
MZ7?G4CXO /6HYKJ1B>8];A-KS;_+6#QMQ"? !A7U+R#2J3PPAFB1#]@P[2W+
M["_H*ZH<N44U+C4/NL5KB(SQ[/*U0(#+M6V&46G)M9^W5,93%_Q._&TLV*[>
MTCLB.+_.=8Q8UQ67R[.R%O?]2Y_58]1DPG'K0K'4:6,!UH)SL>8@+^XG(JY/
M1YH4\JR<&YIS8/E.K]UN'"I-C$A?TQ2,JFPL9RYB,+I/#[+Z5$Z47)*A[6X0
M5AD(\>I7ZC!7^]''FY,WV^WU<D77F$7<[LNYH#/L=,:=_Z,DR)@ADDKWH2WZ
MS^8NXB_&8SK1'\VG%4O]>0KK/NS'0.1"#B&S @KH_SS9\O^.Q_]+H94_A]'P
MOB7D3HAIU0R+I?IE.Z>\F'&><*L[4?7,ITT7[ X6RX;^;15'Q"MDZR.T'3(2
M7.4=V\3^!:Z**R"**YJ_3%7X-HJ>5DQN?AI]=4%.K=!0I.5",PO>A,@520C!
M04(.1)!0G$AS8J[3H$+G+'8BK*HJAG_4KASB1%));%E%YZ@0J68;-.:#,AY&
MT !W[E8FZ'A^@UKVGVCI<#+F.,0H'AAU(V[9/)H.@%QNYD ,4$ <ZFJ;)KQ6
M-+B8_$4SEQ"'A/%K7]LS U?<.9A:6Y[3+2PIK#>K4\_I3QY$LC;=\BBC1AW6
M \;]/KOK!HI97BX(&\VQ5)F5^*# 7O%G($-GD@7URX; V];CV.U S*Q2>Z5Y
M6:6UAZ?"ENGWR. &IU\E"3%Y-ZR,QS>J;Z]=T3C>,1^_00&Q.RF]R2SV<RUP
MJBFOJN4S<9=VNQM@5RDO#+IE $)<_=M.*CM,D +",ECC3W<=ZJ?K#-HTU(Z^
M((_3;Y^&^7)*[NKT:ME&MXN]_66#AFWAY@E7J$#0Y<_S\Q.3@%H+0+_#_'>Y
M*WT)RTKWQ?1SF:8IST^/6<;??.KV]<S82?S?F0;XQT0;.BI3'*#%N[,+^^A9
M^'AA5?23 G_G<&G1A>'5'Q\<61;/(,2I([NOKD0TQHG68]@0%-"]1*UQ%ZN?
MV&?#XTIRM98E[ QS:*L\4B %Y%"?YX ,%J15Y>SX,)^ 7'@\#SR#3*V1PR&A
M%-#." 6$?TQ#13HWR>.9$%+2;Z^M6)J!@IF^4O'+KR?&86Y)8?4:]1#9XZX!
ME&@2EHHS#V.GA<A!5G^4<%60T8A/6]!R\'8?IE'.NYBHC/N<XFSQ+/. ^/[7
M&[8?"PYOCQY;@4F12/L=/K/T;^P8"NB=0O'#V/F-W:.-GIZC^)YE#PT6:M([
M ;"+J&E9@E<E/C;J<W66>8I10XU#9< =T9Y)^B-M!&Q#984L#+^&0[7)LA:$
M-@GE3 -^]W2M["LJZ;1$8LSJ)1,M_W=43/G:H4>Z)IW($UYK"FCHC;V_'_3\
M'W60]TEP$PJH_#F8Q/?9).<= $,&DQT7.W8,B?J[#A-5#^_YKCG^(VF8!+@)
M(,D>KH:UN'.W=@RQ7T.\\M0O5OMPW>]XHG3HZ8<2&6E[);V*!N(WIO>/DU)Q
MU6,EXTJ<FFY<K6I_/5R*UZOXNLFX#9M&<!'=81!);;QX)Q;046!0ECN6#JVC
M@&"U"&710#P$(Y,2*S.].6^?62V(N2JWVQ<30<Z=+SS<@,INF<L<AGI=+E%@
M\:YN",/DNAV__05^",TPSHWL*3[1>XGW?P.1)+T1-M!+;%"?TS;CL.2_?NUO
MSQ-&BE?!P5"!,KCHT$9#CE\I]\?+FX2YK<WFXJ,WX/PJTNV9QY4AOW]ZUM>D
M>FM+.UQI:]Z1_>&XRGV4DY>\54ND+>-Z9,Y+!;@'!O\0&3#*HL1&2EY>71U(
MHG.1P@JH/N9T YB)2%(T@G,:V:J#=G0-HX"XFV5U%;_D;<B^/#]H7>?SR?5F
MW[)FO8Y]B'@8L4CS^3-=R$W725U;LUR?Y0<]"\67US4WI?#]GI#(+)PN!11-
MOC11Y<ILL 1^]V8DV"]X[ESRK&4:?8(]&\$O[+!B932$%6!0!@DAJ4@60HL8
MS#H-<10O'Z* *HE.5-L3WN*U$FJNBI_XKF.D&#*4J&JN*(XZ]W4VSA]128T>
MME2DP@>7PBENM4%XB+>^K'??J[\[F#^F&"[:.T*Z3\M[ZJ)QU\*UBBLQ?+2K
ML8#D/!:/R\+\0G+L4T_MG*+.W8@WB4+![SA)=!;WNPB;L/";SNFT7FDI/J47
MO.ZQ<1R?#;S]"V\<Z5"\WA!<5IIOI76QIKDB]7F(W2T!$5W66ZW9;,S$-.I
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M#:,^X]38"M!CP&>FO^.FM])63[ZEBKYX=?='>>T+5\\7HO@O6&C.V*X)D7N
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M"B^_N[?#*;36/\W0/_"*]> 0N%(QC+-KY%[!M/YK? Y-ANWM9=;#F]GL;5G
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MZ1UJX#B%#/90"<FXFJ'8>_HQ:4*$#6(P)C%B_YTXE-44FD,!;4W\7)DJ?=J
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MZ_W(O,EYO9*2BJ<SXE'\GN?B?$6*L*5YO(I;]%5R,VWU,\(Z/%KW[X,.;]
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M+M N=SKH:YV:@8^?0)7 6W_ E\3'*WH2P5ZJ'2N#]5%_-TYD0I!B6J4">;!
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MDY8;>XIL7)2V23#Y5 WRTA"->(#<:<XL98]Y"_UK'N)[&E/:Y"BG @5&I##
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M]T!+)(Q&T3JT)BE5\IL\]W*7_BI<8?&GP^$<OVX2D>7W7[\=]3=1 ^CO2NX
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M"IH3[.XN. <OFNT6)#.95)8E:2AJO9G,-/([%R4A9X:":_3>#II;ZAN_".F
MTD2(FZLYH[@WUA-#9LLGZ>"4EN6W@\XI+99BFW^D+@BKA121?\Y]>#M,AT.3
MN*_O=Q_DLKTDR9=C7=OEH]VO1[)ARH&*R?J)OB./U"HCWZE*KK\2SL4?1JF
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MM3U"43-9&3SPHZ1K0Z231&.8>G2SN>^DS_)^4$FSQ!EKCS<06*3&W=#*%AU
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MMC&Y&/R0 ^07I.&%081:04EBG/(9[IQ+CSMVCZ6;)5G-&)\1#5H<IG_SM*,
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MC\-H%@8VA< M ^17'VKI\2#R!T7D1/B,)C+.FZS4?'7X-*JJ5&G?&7%&Y@$
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M'0RGB5XE[G8UW4<[@DZ![NX+[KUT/#>AV"7>1+Z(:D\*:H#L6HLU-R7=?<9
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M]J A5'O>_\1C?FZ<%3E@4A7:'X[VERTP@CUD@1K*=@#F._DUCB2.[39==O1
MC:(FE&,_GGZ_'88*95C2, E#@4?5$@IS%3:^8K0:7."^,%[EJ_W*10R9KW0%
MC<]D6W74C4A'=(8C[/TH,!^.Y(EM ";EW^*U*<O4VMY-W& FU 2)T@6Q@'3J
MH.O#%MO2B2(3_M:C492I!V'TES,AJ/G2+!8H:T.$]-J(?AX9PWQ(ZF3@A9@'
M-R%V , CSRQ,_"NRAOX/ OCO+YNTFLWD=LIS+\7M0("=[GY+/D>(X'84.<E[
MP+[MIM6Z5)OW7!I%C+$7&X\:S]8]2/7*0':HS.*$[I14K'5X7([KO%CU72D]
ME=A"-5(L-"^UO6F19CAGN/!TROMU"!B]70> >A#\I%8#(41:1E?[$FO\6AQ\
M9:8)9M_I$=4Y[)_2W>3BS+[6&Y RV KQR1LHJD]V/7A+ KD/-;X]T4_GIS"#
M$"97>AX2$#2?)YT="S=G"IF#9S],GJ^*(]F.VC=]LVD9SXR:3Y3SX9H1OQ$3
M+,H"@:M)1@PA<W[4^!W(A)[,#]IIP(2KZHHR.U#"Q009JHLCV9=2>$.XZ]SN
M@@"/@Q6"+5VE/^(&)4\ZQ1R?Z:\MQT:A;L.H1SF>; >]8R2L0]0Z=\YM*?V@
MJWXM2_*_K.-Z(#)SWY.9I^5TCT7W7V1*-P)TX5$+(J"LMCQ2D;[_TRGQW0\J
M[H<8LT"IZQQT7=-) GV3"@7\G@\+1-YB6"50%*F\<C'+I.@&G@4?F]D3MS!?
M< I(70249+W(1D.Z07;J<$S4"$ULA*DMGBN.3NF F$>)?S@8RY/D<Z)NQ+H=
MWF4N?HT%$D@#?/TO%:6Z 'G$4S=8(%TDH"[UUW!T).Y"M2P+M)/,2*V&O&W,
M-B"UF_12SCIYU%Q3'UEQB?^Z=%'R="_/ S$IZQ8,R0(S8#0!?! 35DB_1O6X
M52M<T^VU&+]Q/O9K8H)"^=EXM:=O/F"+CNI:[8P_*1<2_(K&3D>2-1>/T$X/
MP?'-A0-&^:8YHW:?9C\67[X3&P)[\2HN8!V;H3"-ILJC6LR@D_X+K6\]_"J/
MO4J;T_ 7G*TL>??,3;J@RM%0N#A/ROW]N[/PJ7T\.Z;X=@4K_X\K^D>N:/NQ
MM-4,=NNUQL35W5@]*MAX,[U#E.'@AW1!<DA'M.>U"H0E*2:MNXP&\/,;[7X=
M[SF^EBMN<$4QRUR=O@H0U*3=3@!!/32[]A\$5;ZR:'ACI$J]O;R1DP0OS[+,
M1U%^0N>&M0MFWJ9;#Z_E/FQKPPZ6!T7>JUA7]A]]7WN8F5=)K\0\=:&?BFR;
MHXVMRQ?CC :9P8 %Q7[4-?ZWD=8_^]']=39AOTQF,/?OQ"\"?W/,9VM)BJEN
M;MY+]VKJW%"$4C%3_MO7!&?IE#^D:ZV(OQ68T[7?.'XG>ZK/FLM=;L9<$C5I
M^E<8L-5?>_[W_-2D$67@O[^BE*,F[3*R74:84: C] YNW[P55O1N=@OYMO*U
MA6O".>%WYZ*,ZYSD+'C+7Y2#I!YV!!W<OIBZ2X^1I:-/TZ:#2F4$*SVUFVH/
MXB1N2<281=Z9X.PV540M3EQE6YS>NY/_,'L(P&T4Z;S;0=!$..TKN[?YHH+4
M)![B--L,94KED@R889@("/4$L&RGM.CONYD2"*>4AA7ZK9XU+Q'I _VW7U7?
M +^ID+;W.'^( \E^[YK4#D[Y4%@^=.<VB1%G?L>0S%@@J?G29S /J)#:&PV:
MWHOB\FB'D6N;YP^4G]5_P[S6UNKZHZN-/0VTQ *YX*B'7!I8H$$L,3%EDL S
M/W:LME_Q0/+AM#ZLTJVR S9#&B.%P[(N/-YA4EMXO,BF-V"YRQB5=+=)0H09
M*9QHB-6,.%11DAPL>K57K.1GH@CA8'%<P-, #]FP.Q\/U\5S#F^A?[632'[D
MF.-N<O9"'NW.'%*G6PYC+E'Z?NS0=]_'US+:%F1<-\4.RMVV,GB==\Q0!N<_
M_Y(:36IMP(CJ*'M/$,1=]^K*=F73*&5='&R%(3\#,V)(7PSXFBYQ3)L_08V7
M)]US+3Q'-'_\?<R]JYG6_D;9_KB^6NI;^2=#)WJH8[6NC$+<>#KS! /[H!W"
M&RM(:- 5+"L7A0YJE.V>LW\5TJ!6).)0[W/O_7N5P5/[G-:@33"2$33$[D?K
M*V?E:!W=E*(?;D/Y=\MGT(3&(ZVZ%>-!,WVU@/3K=9%<R,[ !@]'"*G=/9GN
M<GRN<HUP)YG]=2C_/CE/9G>.5R"H#E#UVX@]_4BV[;L-&**"FZ)Z1R#3,W"N
MY;J5*4Q=-N[D@(Q!P*66\ZGZ-\$':C_\$13U:VQTB_([B:8,]I  V\U-[VJ.
M',-0DZ8ZL0!>6_WV_4^[^OIK8-2Z]_><$6ASGA(,6(WM).#,.@W8UD$%W ?V
M7YJP \ _]>%OZ6@BHI5!*:-F;7Y\&Z60MOI?PN6P2XV[HQ0D>MV(1[Z\<,TU
MM%.CW.[UN-+8&VMGX1W?IUZYWUEA+=VFP*S_[8/AGBR4+IF#FUB.+*,D7I5?
M("YG-X-7T1A/B#^MWZ!IX,X6FN)W.ZDXT*.8!?KBZ+#N\#RJ/NR<TE\"KI+S
ML#12JVC7MYL?!_(,*VE9T]4T;%4[H'V/YW[P$N_A7T!:=&L=,(29UG_L4J1_
M ^2QOR)WA[]P(=HR#PLTZ@TEPIZM%PA?ALD@O_TKKW/_]OG=B/@O'D64R>7&
M ATZ188RRP=8H-G@$L0Z31<8#C<5M<U>E!F"+]9'3M'=4S&Y5$(D9LD&18:V
M+?]\&T7KV5SX0\3AM]3G0\MOZ5%+&>G'SV\CHK0^9;+RUU_)Y7H!X@5@R_*V
M!T,",_QZ<6NUQ-H2; MZ\>.??,'[C]R>.P+,>"&"HX]Y@ME1.#<&*0T:M6\0
MQ0UU>H@IK@R)#<IS:G]Z%(^JDG22WU';#U"$\3P8+]V?[#3N]41'<UQ:U J_
MKH 1;+I[9ZWD)L^._DFE$SN/MD!<CIV9PB(N[8(,5%%>4S7)1A0#8%&%Z!@0
MW[ W)C^)"V6!.*<+WL[A"^UT(@K%[*X(\LO9"O&=G]G5IH/OP)!,8#%,2>K!
M2?/HVEWDI*BUX+UU ?Z)6T\8:Y?L=!)73'B:#][F,MUS0';GU'[9AXXB8+H@
MFI*0+.Q'<HA1;#RDB5>,5BYLRD0:9H<R]VC2C,U49*G6%Q[:C'\^5.9^-?B;
M%*;M$L<YVBEJR@7R#%TDF0 CA2K\'$J**@FJLGUKEJ?(NZM=+<2/KRJ%N:NG
M!#F!G]F@"W4R]^#RF!V.QRJI#\GLEWJ6$9:4V\4]#Q95#!,5#CYEDT/OOSJZ
M7UQ/6 14V+Y7$J7G^LL5[DU"+^XZ:DC0TW"V9\(H0ES"ZOI9DS8Y%JCD*FX"
M\-&N7EMRS.V,'"8L4+/UFJ7C5=HY9#=S-R.)+L "[5&.+=G[Y*"32.(;][>F
M5;.@G9F'C;^QB=\\\\'0N*V-8P)&/PY9Y 4P&*8)LC$+I;Z'_OJE>.9VHL)Q
MCT_N\:@&**G,/-1,2IZ2F"M7I F%+YSCQBRMHBT=>VB:J'J8#C<9UF2%E"(O
MA1' ZMJE OJYZ@/E/9E/UP1/777UN;?;0#F/"[1N3CWDU0@101Q@)"X@3D\J
M\<TW#G6[ER6HOR ^W&=X_6HY@!2LNEUTXLXI_0$6(=H(VS2Q;D;1]MY@@;H"
MG8.#8/L1ZBS0\Q<(:Q:H\#:$(?K..OTQU0/UA.E*;%HVIYNNN."++Y\+F'']
MTY*+_U[T98YK$_6+B0']:F,(>+9?FQ;@J/'&+J016=>)2;.G6] !E"GR/> ?
MA)0LW-1OJPWYG_62.25]Y,7I$Y.=!W!\1"3W"W&=QL-6I1^X?6? *[0J2,D]
MO%C+>QN>P;&M(S68Y[C.Y24 ,8G+C9*"6AUQ W\Y88SY)0+S.%EL:3\\ZUR\
MO,6'.)5\\$[^P*AU[*!7DZ,XU6%"VQQD;V?T=O;>B+EZI)6N17%W,5:\<U1R
MM)12SQ[#0[71/9S[\B@<44\C=YGBL!@,S($%LOCL\_J8N1;!JEM=PN\G)BEI
M*ECIG+!U-\3JW^XPK*A"9.4&"4"O=PR-PO/.EE:$GRV*L[G=>\/(D#_GZ!?[
M?:$#^%GY)G2XK@RU8CP8UB"CT)-TE43)XP];ZLJ$;^1<;^1YK/+T2R:__DZN
MS02F-)2FP0)]3\]!C2\M Z;9.B]I\D?(ZVRQL9G/WJ)@2Z*$VL_>G(DORV]Q
MIC( <^)VJH>LG=S6BMU/4>0'J(8!DA&#3Q=@3O69$+I#8#A="T7Q9('2#2X!
M3:,$P+1G_/HC9<S"7A8(X[&L"V;N3X0P'SD#EA6[JH-C[FU]!/WIO0UE>('E
M3MR^^5$XCMZ20@ ^,M082JU<!U,?L$ +PRS0F;!TH*T*QSQE]#L_RG#*98%T
M\6,0,L]'%FA-2)F^"_7J![ D2G4 ,V2 WLXKX<;! HD:T970.U'?)[?32DCH
M ^8%GX-JS&:!;A.VA-7!=.E1%HC\!;I=3+7(B\$E$<[D \ _]0=D7MI\DU*[
M?5#(&?BNM%>H<05ZI_(O_85.W('+,L,A8 #A=8.9QVH,?A''Y5\R@!]F@6SF
M4)TE&^%T T4H8R>PE-E@TP&HWW:UZ[<3XCOW'U5>!\N83W@-6" .?Q3=!_T[
M MMJM60&8ZNA1'' 0/T\!*-RL4"JP*_\IK-HJKT,)R#7UNUJ(VJ QXO& A(.
M-V=VX-8.NT.HVE4LT.3SWQ%7OQ9F=3$8Z"=_._!=^BHL4)WU9NJ?I3^7_U-]
MP-0P&]36GB3F#MQ7 "W_TMN,W^K3?._OS.2O$EN/RZ;38'!4DPKP5=\OX$@B
M3!< HO^FLY!?=,DQ_?>F\A=YY?M"9X9HC?]VU;^&:29$CO'54,TG[8-0>UWO
MCYB]=6R5NNQ^J:A*3&H72,-$/H9KH_,/_6HNAK_W^;7@9/S7(708-5!=]O)-
MYZ5BIDC/M/WOQ2B.D,HFO,*0W%3P>9)7Z%I7)C7H@K6]QV6%+]9!Q7&F%8K-
M;P8CY6M\?5?D%V[\V5E,!^6,G=SDG,]>LGT5!V+//81300 ,:I<8M9Y,(S8#
M\P%U7N9LS!FV+<KSV+B4WZF2.SR#/I$H=D!^Z96*_8^?%X= C)-O<6"<"PN$
MQA7C%]I),\TR*EUJIA!!A&8IV6$(_MC<4SAR;P8M75OUK)5-W\,8CM9$OMTJ
M]U V.&?,D&4CH<2ZP1XBX7JBY/EPQX>LK#;:U,?*2]Q-]NSW&A440)H*["$^
M:>SXG]B=C +<'?1N9!M2J*@782"U55J6*^J@:E#H;/OA_,.*P92(R9TYRH^0
M-T):HS;9 7CTZ#&S7U>M>X(,#8.ZJ%614K)?Q_.J, ..R<KN3W^JM2P%>>5T
M'4[7@U[,P<;AG&#4P\MA+)#;,K_FHY+1O;"==(-8.>]W[<JOO ( G<GGKV![
M',7F),D3LF?71V_*[Z,?D0E8R?*B0R:S#05>PXBX;XG,1"BM\UY^T%Q6^$+V
MP>TH6\WX$2<! 6K4AAT9-Q1-L2%E+[J-OU%M&%/N57^C:=ZS+M)+3#B;?#A+
M1='"D%W\P%//IH(ZT!2?*_LDYK>5)J 3&ZG;F^-N1#"=-Y2N !"1\*,(?D =
MLXD<3)X[J$T^]&_W(WZR/_]-]O&"SAV [MZB2TYB)>%!C?<0VGA/EWYUR6"M
M4U/5C_,]%?/$;H*F=@S2 <I)/V4Y'L[@A?)#24Y.+%";;^$X@2H[4X]EI^(,
MR-+HR&I?)0HZ>'?Z3G]1BIFDB7#T@? =WP4S<[YQGEPZS+X4^$NQ+UE&N>^R
M$+*/4-:?/NZIX=F"MT(WV)VN_GI6@R8E]V'@&]OS+PL#W[YSD*(8(]@&\/"!
MGB;4)Q1=6.$*N:3@?=MB02NQXT26Q<?15H7-^/VZ*?2!%"F2>18H>',<2I4%
M["V6C^HWA&^Z[*&KU/<(7.PNY"YHEP?U>=:D=W5M9^%D+C86,/)O8:2+L:(4
M%U)!$IK.G@.[1G6T+_Z$Z_&5%VQWD0W]T1:_2S+CX/FG(X^LX\'M&R[;EO5H
MV<+J))AWF#!7JX!IT$HQJIPTZ7LPGQ2_5UHO_O"8IOALR2>CJ](*1 +UB!%=
M6+4!5BP:ZJDKA="D6:6G1??6]OJVY_F7V8>*Z5Z[U$(-KDJYK_K^]=N0$PEZ
M$$]4_3%=Y3F8*.[6&X&2H/#J7L2I ,WPJ8IGGU;D3"4;$U*-HUSQ\@EENNOK
M-=N+=F<VU3X'<8+QM-C-]Z3=T'P3?G6>N$<X3]%"T?NL.:VK+N[T:^N!?U\!
MBG_J^9V+J=@<!6 54H]D PR\B07:F@34+XO2R[:*7Z !-%X9<+&,D#NXM?/6
MJ&L<OS3!"H%_0L'G-B%-FVC:HA?9=!4PIM;Z,W_DH)\X<U]?@8YV^IQ6S>K+
MA7RES,HW?:8"$D=N[^,SJ=.Y8B=3D4U-,BGN4\MK\UJ;SVGZ>&VX_-8S\WOG
M;OPF;&,+3-,ZU?X&F9T")G&_*4TNMG _(_E1"[W(C7[!L%Z7K@JEADN0UB5>
M),KOD;']K($W"=B$=F+O;\DVTJUDQ4/R+N9OOM!X[M6E7K8I4T_"3#Y(5D[(
MA#^R2C&?V%]])RGTN^9[9L9LS\^(VW%$X41YVYO/#&33OWP\S7FZ&6%.5.:;
MDQ'I.]BSKN!75H[&9_!]S2[7+1E"*%%Q >,!\2UK-=,1'5^#'7G6;U'683\(
MXY^JI^%NP?;BG[J7?:?H.-GU\[Y2P8,0RZZK:@5VG==Z)FH_EIOFV2;YF(@#
MSN<AY?314>1#\2,*V0_\ ,%=^)<D"?I7/[\XS: .1.$'^/0\H$&+!I/2ACWZ
MU62>>!N#NYYWBFKTHP;+7BO<TWC80WT""C8_!]>DJ[64 *R]T9$.L)58ZT*X
MZ;6DIC')GG63A4/=/RK17SVT8Y8C9I9>/^R<T)-8VW8<5N91"-MT*D2_LI]N
MDC_+A'1Y^FUNQ>4^2.PG+5V/KC7:;ZWX)4,^OLY7O0[5:$,'+/S;SP ^ EQ
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M GG<&#6?=F/1D7P.A)"FG4;5'S_ >(5S"^8FBH95NV]UAN5/5$69:5J5[@F
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M?+]$M>]; &=#;3BU@WR_D;"C5GR^5I-\NG-P[<TA=H6CSVH#P *-8DM+S5?
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M$=1C6W.CS^FGR2BTK^9YXE#UA&9"0.$UX39:LLZ -O.W[*8*EH]2"J$\:M$
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M[HV[9_SP=+\I_[/.FZ-E\@GR3GM<]&.H21 ]',4.GRT\ .R)?#T C+M,MIO
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MF^R[OP5U&[LFD"]6-_F[S?MO;_#?69$O.Y\&N!C,I * .:#4#@!.<F,IDZ0
M6D$]%Z'5C.B=&L@6U=C2BG9]+.9DXMQ]_')$M]B\O4S< < [>AW^)(%\;KV2
M<HFJ 1=>SI06D2?@B_O;"CO.18R[7QP>.]O96EO+)Y5+S>6S8>\$@(KAY0B\
MH#/E/E02(FSFE.QTZAEDRKS-U?-*^O6R2TQC+P$G$+4*"?=MVB J#)JD47$
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M.Y0W-OQ))_,?+5 E5,L!0-'SL5\!_=R>PNK$A0_U6Q7_LH=_@3W\-20EG;*
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M7I"*OJ8QL#,H5%.<[.55U)E]HR0XPS?[Y"&'F,Z::,\7%VLZ8SSNQBXV'F6
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M@HRN;/R]/ 4<BA\UGT!>I3?]MZ+#?VS[A+F20'Y-XZ<Q8Q"44@GJK4W-2H;
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M'-A-.]7?]*W(*.N-F(T+W\@Y(O_YF]B/'VRM( (9^1Q.> %WC:R_0:M;.'$
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MUO>E(\&OQ8:)[VD/]A;>6<G6J9@?4QG.GR-_::4NTYX+T5!)W#4 !/E1CQ\
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M"JTM3GM]\#]/E]>Y9ZVZP,Z_=-A=%VQ%N\!,ZHVF=I(-&0_\0EC/4ZHL0$,
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ML0/ (2%@=C.R_&-QT=GR\G"3TU(ZUT3>;/G7AW%%[GZD)'1YU%&+'TE=3ID
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M<&("M0W0K=YC2Z;65JUN(C<Z_=[LK4<__UV\POJP%@U(@=>JB$](T&'*TP]
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MMD^?(VC5X 1OK63X#B^_E6WR>MD8?X5R==@\/MOOT]39WG=ME54LW3TG7C\
MHLGQK@[5<3DI?/JC#Q([KHN]@+X-Q,Q*16I<;[21].1;KIERO\RE1<R";+Z%
M=CVL]OFDVA?^CI*5L$FGM6J?= H?/L6$0US?P0W&.$K8@AJJY[X?HJSG84 L
MVIIDS(J $F9B2'H>B,K#^H\7JP+C;^]S]!ZF3=<SM*..(8QP<5N?JDB?,K87
MK9RBQ)9W(V>/[Q8QOL[GO7^=^9C07&[&@J!O0]9I._]4.E0Y ''<RKOBVE?G
MBDFLER:&M4USCXFH?B;UH^;'MQ4O:AXA]P BP=#2P+ND%S_]"E^M1.TK?YM[
M<HA!"8+@J,Z&$ MNC9:'OLF_T]![ZWNB7/F"8ODZVFY/&:FUQIX: 9>NT&<E
MPF*?JSDO?XG;R$Z8[G%N_[='P;;[XM!E!Z!G6%<,^]@2^&0Y&-!7RE0O"6'$
M3ER4J[S-]5-KR5$7(AM_Z8[:\D #1R-]GD(Q@0%XSI>-QP#[&=R/-+P=U-+X
ME(XD ;"?QGN$AZU5B9=%';F?&<V6I0@=?W9U$_#K7&NGPY6^ Y#,?NX!2))N
MM3BJJ6^P2^D'H'G4/?I=9%">'8#"C<EW43\SB?3;8@S"'("X]"@74..9M!<S
ML6! YA<*B 91Z1@LTA;Y';9SFSX=V*^H+2/7P& :"X9\!8#"!I4;Y'$C8WZ:
M*BLR/59TOJ<LM;40UYKCZ1&:R_9^-I1#C1? T8$$FO3Y )2M.L=,8_T#HYVI
M,PX]S&)V"X;$3A]%6Q 2VEV5JBO(S'5)VT9#P\=>V.K:=EGYOSCQ-KGC<@:(
M^N>OCX\)-C26</H.(LYNDNG =)F]';DSPHA#/0.?H'!A6HN )SCL"U]V+U&:
MQ:=/2Q:5(PH;9IC*F[&7NLL8PKHD XI(_XYB27\3LIQ_:6QQ1J+*>K%T2)HP
MPZ-U7J^P)Q@2;]8L.6@]>68\) ,L^V#W%+EVBTES=63IOZ!TP?^.L:!QES#3
M.GW)PE//.'82O!<4^?<YG[5!,A=>9UMKI)S)V.8VV$"LTIEIJUG)C$JX?^UK
M39UZ(-YTC7,*3O&O1YOW;Y:K?ZX<DCM7^A;5H_8J;S_VC]B?75ZS7^4V[$%#
M$^XJCZ>;4/-ONP0XO;,B)Z$]#ZO]PXV#.?9@GB-[;VY%!X.% E'M&=AP+XUU
M&9.,WK+4>_!$[/3=9HI.$/V9@;CIVKT"(EH?+Y/R+W(.94.^0,+= _-)\$%,
M5>_[:95WTK]M)IWU&Y\W;M&]XJ\YY'G@"9Z3N4Q4[TZB9Z?AF\/J><=]*8\]
M%M]I#$H%0.?)<P<@!H)"Q2V783%18D0<ODMC2L8D8C.VW-W[#/7>%N3"&":\
M<.-S6?JYJI39= X+_=%\Z3_'?#&&A-QU!KPHIZ-UE)'[D#=YKO(ONGJ/R1;B
M635R]9NMQE7S7?A>1D<I66]P",J.,XZ=%B1:= UOD[76J\F:&R>3EX0WT'U:
MOR:APZ880RZQ(#.CIZ(L>8_D>$QM8O]ZPUV(KRNR#'31'E*.,UM1E[ML7)6T
ML;("JV%3R MXLL;##4 5B#GXK'2"'LXX6L.O0,;P0;;E-_^?>>.#5_!7GJ_9
M=;_7*I#9\IHQHG[ PL'A6"[:Q<!D_-F1L$9A5Y+0"](^1]96IV<P*5#,HDJ?
M*\6.247PDZR/_I'B:R#J<P(J5@D.#G2Y0^2,K!#P\^0WB?E1T5 EV:EX2A>7
M-2DTBFF#G!A%_@27]#7!(\$B%&'BT44K E-!HC"6?;(>X^'LZ-SF8U.F^-2S
MRC5%Y9(L:%Q?ZL\!:!;2OJX^-T*W]JP ^59XX:,_/0K>))?'"RP,/*EG6HN^
M\8YHN,"O#SQ3'S^/Z88#TE *CW8;4AB(X6]->)$EF:D;PF1Q=:'D/A119=DY
M9AH%D;W_#EA9%'FD!J):?:CIB]@/[R@D;+:,C"15M$_]2/%0&H1 _<,-%78E
MD^U$0;Q_7>!C==KCK[G\3^;Z?]SC&$J_V'(ZUG)I17,BQ?MFY2.R.!J!3_B8
MI^,#+N5O.A^=@S6(V)S2>_<Z@MG]RUR$\A]TY[K#7<)F4T+4?E&4G5\FF'T%
M:B$'GN;^5! GIKE[!(:&$&XFL :Z+[;.<%'N$*][SPE@[I=>UF<P@COWIPD;
MS-^,!VLUFNR\Y]2DHNF3]E5+"]#^M**-AX?Z;?*[0J?%:WY4:?[.4\EJ.T<^
M3QDZOR"N>.;B"_CO:*HY8$!T:(4(T\#+8I<)\>]KXR/S]!JE%2KF[C\F=F%;
M5IKRQ'*JFS&QD(><X4&0CKXQO;F$4+^>P-R288TG1381*:I/%=^L4VK2^A-)
MQ5I?948/-<ACS#;4!(0@7H[Y+O&CV(7*7QOXQOCAZ>;"@1_W,\^>'M?=5GU^
MDIR?(-\8"")MQD#XZT\35)L#D#+$RBIXMFOJ[]-9CU*3;K!8SNDPONMB9GV?
MQ;+$CM ,H;O"$L"<H_AT!4$OILCW.ZYHRM,A32P?G'&=8@E]36<!MLHQ: 'D
M$)J9)NH^,F@9>,/&T";]K=80M*8AB<6I4T):Q#!43U"KGO8NT!@G%:;!.6M9
M+_@!<#$L)=0_#GF[[.$>QY87"U;0UWJ@:? H53(YR97A%?4=RCTA$E4!CIC_
M5<^>7]%&RD9.?9P6CR!U5?J_=/@F<.6*DVSN,29)D:!UI%8@]'H)-1TUB_&G
M\0%!O6ZXJ5M;ZC;OSHT=@ )$5/T]E%Y=HOWV4>S*IYSF'L#>_U<*H<A2L^E.
MV)B1UD/C&J08S*5OB@_*8]*,PPL\8S><%>J?\3(_KU197+;/A6DB)\"E,(J*
M5*NG< N*D()JD:"^RS^71^I;VZS<RWR0*B_ODBD&&5[T-Y[J4.L"T4T?$-RW
MMGT N@X^B9I]=P#J2/CK-^H9:"(.!R!S.AJ2,Z:MY_R35^\YBVC'#]7_-$[:
M3QB7K 8W3KC7WM.?I.84?G%G(4*QI,.NM(VXE?>U-I?"$S;;D4 ,0D54\=<V
M$36NCI 8.FH]!!I_+3Z],H.NPP(-:A@Y:C)]VZ:B"#T'(&'?A"@8H0R+.TOK
MB\"#UV;6.$N?9CV2$T/TE3<JU$%\%P7P98>U](^]HTU2/Q71Y Y +8-;6OUX
M-&" +3D X<2FJJ@RZV)Z[TC9Z(W-L<VJ"A R]#_2AASZS\,>?];_.CIB'\&-
M*Z3Q[^7$<#= B/+?T/;].KR+[[+_*ZOC_:T/_6[16\5L'^^'7E$J-V%&T^E/
M9 3"J-%R/3[%?W)O.-!<:DIKF7(I9+6#8D[@;\L2FY'[Z%$P+J^^KK<)VHVE
M;U#$0N.G#_4:%D8OVMWG>BZN&K<Z2-^-30@_^W(V,2=12(T'EQ)Q7.L%]"X.
M%GU8^;>M=$C(T/P E&:#GM9)N,;YE\KU.435Y[[R_!W0>X,?JI,%N)]7FN]?
M620L_T7KNO!W6E=^@R'K*1QL2>0QZJ36_U.X_L0_%*XWBR^Y"F&E]6?H?BH5
M=9_:R>L3\W'6-Y[?EO^-K%C)\,]SR1\O[(T;4O5?'["TO8IN@[;7+D;Z'6I@
MT?=*,KKM6^XUP?T."]=/\;<)I45ZA?](#U%^/37._S^EL47@*&\><%F[+FD/
MLD6)%.IUDUA?D5GL8Z4-0%,G#M6NTWH_IZP?2.Z_ADA#;E2L(06)I# \T#SP
M1^!SFJ#*FO\MR"PSNLT;!@O_3JCNE3:V[].C!HERY0D^\N4QU0F*>/[W@<\(
MY"2831D>BRY-:X.S+"EH=I0$W$\>G^C<74QBR:GFDB<;SWLRU#R 94%*I=83
M9^&<R#8(5^.)P"H3&'O@YSZ=D3,#C:/A9[#\)[^WB ,MW\_ZVQ7&AF8:J#&0
MF!JUJ)4'H(>P%_1OB  '(#S[9@2W$3$^/7MF)>;KLJ*P2W6&3$#B[26L9(VC
MH+-=FW?MLZNP472KO3 01V9#7.Y77I<W)*K$G$LY9><V_H)KRJ:N4^%QJ6Y3
MWH7NW&./KV$^4""X7JF6H-M7[2,_C;F..ZIM%923?4,%M@S434$,DLE-*T9(
MB254*;8=]@Q;A@E'N<'"M=1KP\5:Y SO#7JF9&?\.I'B+)-J^.;Z?,K0 X.N
M^RR8@81GL,J.N#G,Z!1-":B E/V(A,M>_6V1]VKD\;K9&=L#4(\9,<4L4!%T
MA\GU:!J%AYM4ED;R ^#P0U:56@]DX_&/E&34_;;/AGD?'U%GE@QM-D'QO'A\
MHQCSHV]"AF0<0[*GOD8*7BS@V\0S1_G58"C:R-X&RB"3Q21$S7+WY!VDBXO7
MBR,KJ%+^=GD0Q8&:3=$CZU+\B0>@"%\C=\%>3(3&Y3QWT[QB'0&KHPHX!XOQ
M=/#E\J23PFXJD-FB Y"8EBC"'G@R>P+"&#ARDVCT*RM?H^KD,C1/_6;$289+
M=YNDZ"12'3"BLU!,,Y;$>)@DSF)G%]BY-D><PXVTH5@ >&L6'['H)69U^"I[
M>96U/SHHJ8]5TEMWK9OC&L=*[E1XL":(=]L6J=2/8"=# P<.0'98(ZT!(\7S
MIZ 6]VT[W9N1)L8Z\.[&UYBW.P<@MF6M"]2">@^W K?A_7>E;MZWBJ=T1;6C
MUD'W.1$*X)?O.77H-_<2\#L :6MBJ7MI!Z"HHD6=X8)ZG4\V[M:^JWX./IGX
M].M'TD:..==@@+M:C'3R:JA_ &JZ29_U%=\IQ4'=XM#NCFEU0WVHHTE+MBGS
M>X9/(.N_<ZSUR:0B0/4K[2<85']W5I3;*J%U/ZN0!),R?:UFB<C_XOQH;:_&
M,II(7:$<-L!1I=#9^(=O=)(^PP^CF(.09;8VG7['7AD)];!%F\YYISA)'..:
MY(*EH+CH[@N-$D$YH5Z.)R0<@)R-_ T;+LR/84LD,I1K0\^TUT?&PZ=LV["M
MR=C<;OU)Y ?J.YHPW8XT:Z"<9H3M +)]9H?_L-#K\9W!Y9-EW<5**C_7S%,Z
M]!4NA\Q>\AC".F'&8UK!%6G/_#CY JU_'(#NE)8-?1QTK/AUS..QH)DJ6W=L
MT]%2M@<)VGT\1_;,R>?H_UJ'OEO.NUE/A^$3(GL+ES(P49O*)WI&G3QLHHHF
M=:NX/L^[SCBWJVN9J?I,1E,# 6'B7#.V'/K,LQXV&V),UKN5^%WQ8Y1#QO#]
M(ZY.VKNV3&+O0X]+GC3N1A.,$R+IC_(GLCK%AC 2O1-L%'"S$8@L^#@<D!AY
M=\L&EU9;O")P/ZQ+?.09JED,+J]QF:Q#@1&<PK^/((6BV^>W ^:%].6/F31>
M]7),TD:[@TCR@$P2A:N><#&2.4%9G2P?]:I3-@MLQ,&3M=8VJ8H6+L6,]7SY
M7>S9[>_"P1E&401*R*@Q!+@T3)M0F9OGFN>>[_35/<B6\TN!^N/PFR\TWI[4
M5E00Y]#/726E8OFPLV6);EK*$]Z?1MT?JANJM[XA>N8*%K[BR+0VAT[TQR3^
MV$#!OC!LZ=%8G+P)/W;G/I=]!7:A(U+4;*^SM6.<+Q]RZ8K&L%!29:TV;FU,
M2K+>2&/-9?/X4XL5IZ]\4:H_EI6.UC8C["&$]W;J'9?'"W>V;-@QDL.#F+'Y
M1WX/M6[O<CT?Q]HGQEQ(JC,0O! <;,+PY5\Z*$P &HAWKP%G"3,P(O9E$;(W
MQY74\=1_#A'7I/\J(,#G2\ZO<'_>O1$Z$BXB&M'2"3+-UJ+U":*I>1A!K\H=
M;S994^$)W\R2E;"!9UH7@67ZYPR!":*-?1V<<W4+H47 O<KT5+TY7G;!?_NB
M_U[L=-TM#,2_G@ZA8%7P=4["G'7\AOS+1LG:U^!+XZN[["CN_">A:<+%QY=C
M'2IE=@9I+,ID34"^%566%4Z4=$L-2HNMUY8;2G)/UBTU=!,).'6C^&:;LT)4
ME8J:[&32T;DUV,L95H04,;DE "E,3 UWP;CQG^]^4!>E%IL81RP1U!--?WQ]
MR95A$34J1=H8Q'I@.>R7,RH^-;XD,NN]=&H<7!]]XY4M*3_^@/E5793%#0,S
M:'(U=#@%,"6S6_<0X#16\US@KGY#$JEEQ.8715/RZW6R>>W9%AF5JW']>E*_
M=)"K_VJAF'_3@)T^%"Z_3D% #T ESF J_V?H2,46?RMLSP#:CB+S/:";S""G
M( 'CB"H MA O>X=NY-JPYT*"=7B@6?[A_TV2S[_UP5O!KC)H4>'A,>'JM3ZQ
MJ:/(?!<0VNKCI?VH5<EK]!0*&'#1V#-*/RVU= =ZV-NA6R:!ZZ]Z.Z#PV'"D
M) &Y6U_L5LA/LR]$/173O*,& T[R?NN4:#U3_ZAKQ:<@]QC8Q&.C&Z\!)02T
M:LG.2*;"[M?!]YZ6M3TRSK/UA$3U-2 B9"+&=XO+]B#;M(8[;B8TBT 4'1P$
M)K?6G:E-\8O1F>NID_K.,'X'F^4QIB%-[&FUEQSC&6'6K_/2R&_A92&AZO9F
MR=!D $-"C.P8;;O%9O1^6>2*2SY"PVG0CJ'=MX7SK=:\Q$Z\<:PZ;.UP[R^M
M'50.6SOT))5ZHH)A-71K+9'EN^,RN;)Z)E^:K4!10"14T^T7,3><=MJ#QGE?
M:4I7?_:'43E:0X]V-!!L&F;_#6<\?J-EV_$J-=/2\.?DA!-^/X7<2IB"&;_H
M(U0G^.=64TCD ]"/#F*A(#Q[;<=<%&P[2+GN?M%WH@M^'])Y(J*S9$>K P,=
MT+UEF'%Q:7)OE03\I#PIH/4@Y=-PPX7Y;F+2@TF:-Z3ZO1Q#%UP='KO$62L*
M+,@MNJ[<8]U3)\&H)1J:1'42,Q V"^,)_* $Q'P 8-:5"BN[J&6AM_)P]7;9
M1XN*Q9PES\Z6IDNPR>R,-XI0BR"S&5AF"AP'$0E<O/E368ZY@V_?;N,3.S9B
M?H+WS_B-K3,5-7JP=T-'2X[))4\N?.$4)>JMZ\QBPK$$0PA[H-J?&$WM#OJZ
ME[GQC9^M[Y$DRK:G&GPR31;ZJB#AKRIR9#+A+O49Q"E0&3UZ:JX9?5*VJ'!G
M1G3&H-#(0Z1#.KQN[R@W&C=9V8_M[_3Q )-.'X!"/1$RY0!\%AYE?YDP7?@5
MZ,"/P;V4T%R5<H4NWP14ZOC%[XN6;M#,]T]&EWS]^L7<]-G72Z"=]YPQ$-S/
MF;(^*D,]G8V&11[&J'IHK$YD7HH2-97"/MM[MZFR-J5A.O]+KZ</'&/]V/3A
MY*7CLPM8U_PNK"MVS*,)77$NYJ,;\FI58W7Y0)'8PJCEE,!Q?[M<20[=\PP_
M4 XSHQA<;M-Y7PPX\,Z(663;U9'(AY5UP?G#&6>2GU[6&I((:SS;^;X+\V4E
M/C)G @C6&=S)O]3CY@ 7+3_]0_^F27[RY"QKP_]2_PP'H+4E QY/D2H X%95
M_-9W,"[*<9-2 #Z1]0KE):;K ,0.<)*B#JN#(>X1&3O#$5(!1 G<YR^SW<.I
M \;LWPVJVR4CSLI[7CUZ7?*1&B304X)T)AI$N0XPD(T1 ?!PI H00'B"2\WS
MS@M,:TL;C^N+>C2;@=N9*2]P_YE_S!+OQT*KU)WS]\\#C2Q)4;BK2!<R248$
MCD_!> .YC?H0/)_ND-"PMJ3%J\^W_5=&]Z)DOW^_(OE,D8=[%56FNK8-)ZL&
M&K=EG*VLNEB;,1+E]8>48>/-\C*7*^SDD<S3"&Q#QY.!!N0SB-8!"#XS"NU
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MGN'7,=,^<V/+Y354C4%0^)X+B)4\0F,I(T#;T1PH1W LA'OG5YHN$1ZUDY\
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M W5 )">IFK&_CA"8Z;)_+#*$7$#D3Z\DN[P)>)+=-/8CVO&(<HVL>MYM%;$
MZSW*]$_9;:<7N1$RD5?H\<A;$#Z: !F;'JB')'WMYQ/TF6I/RW\R4YW=)_0B
MZ$/\I4II_3D3_Z4]=UPKV_,KJT#;\VT83%OK*"K#8%^^7\IC]\3/PD[Y\DO*
MSR&&>Q'VX1X.':Q)F/C7-E:4JSB(F+0BX? =<X.BY9I&HI8<=2KF<;3@*Z;6
M.@8.GM%GA=EV4@B;8JM%;*0%)I"L9_IR9O7>T7B$UQ!]^[VP^G%#<8\!^6C.
MJR;LN5 RRV:X15CSBZN#7JJG^P*$XA/JMF@G6XKD)R//36Y"*.D):>?%Y'Y;
M"HF[21Y8/@-40";AZ:Y<-%WR'/YS]5*6Z'G]X:061?3]Y_XK)SICQ8F%MN%?
M]GPZIM/=K2/STU6 !6V%$0>M\&KKYZO"[W?/[DU*TO31,[]A,]HC()&_%7#R
MP[V.PT$?3/6'@*A2JCX3&-P#LHH(]X^/F4!%XU2);3%C&+EEB)% 3C=7(;^I
MA*S^M[Z:Q/:'DQH [J,2C6G"[\^#H47R&-)&59N'%[NS0SY2\;>@ 5YZF8.&
M*:^[5T [_911TY ,(SDR@041EK-N'>C+T%URI8FPC%-OHO9'P_:&8/\[@I^?
M*N9NJEO.B8YD\?<'JMZ@&1!?4C,CWO40<O$4EG8O^LQP-(QDQG+VELA#>MK$
M!M#QWG RLK$JUW7]_5/(\=._+Y"7T,^F^VG;^E <[!:<)QQ-V4]_L0W)9'#=
M?]_ YC>5WEZ4]U4=G>F]0AB/ZZEX*6$R3&I_!@B<I6I3C.BO(Y6H[D[A51 ^
MGS,?4S]#S+R??>]1,?TJ?FY]:Z$]POP9\7F#(SA(*C $ETG#+B182AWF4\5-
MRHJ8%WNDVN1IBZ+,3)&87Y:ST9H(*9KA"$,Y7/(".2QQ4Y0)G)]4O?IC,F3I
MX?7?=D@>I7=-16<YI(TB][,FG0+XAP!+,3A#^KV.(U79']>SK'?JF9V?S'V@
MKH0;"/AH\#U!^FYUDS)%!8HSX&*,%RFQS,!OGF8/:A$[Q%LB[G[)_=TS;7/"
M-!3DPA6I+MO87^%_YW'G]_34.*M4O,P$9@*M2*%)+R+]P>2FS[1+Y'XJ*I>$
MV!D=M?G)(T [>?GVQFJ'6-8C"T[4:KM:$M8-.R-G\4BOO== =$P>V_GZR;FC
M$VK)XD<S0__D"ANMM81FAD[U89L7U\?($ :W>(D9.9C !/I@ K[24N/U54DF
M(ZC]%Y2^#!RQ\>14[X^9R(Y,_V#1+!W/*%N[)_J4X'^<>'E2D^IL:_Z:[48S
M)N9&HB&7S,D3,EML7T*K?*2E1CL5*[HK?9YX%655G>T8;!K;&.7RF.][>E.&
M^^2'WJ4@4_U5]BT<X7>2@2++JE0B_? PL?# @9WA3(;0FMA[+V3IVM5-+R_G
M?A7!:[H7ZP=5KINH;[@9?Z;O YD ]9POA /F_2:8D*:\.#OWC3SO2Q**"=.<
MLUDX>6:?]^6<3V'2$R3^C36R0>!<&A$=!_-&)EQ5:/2M_*X:4NMW,);RR4GY
MT<+O [RW+XX&!!*\9]MT%KZYDFS7[I)@ZX%+6;S?<B_E"X").#A;IEDWW\./
M$Q[SRW(PZY(#DDOP=6_BXARR&TKV(QKW!0K9H9-Y"R1.995?$=3UT3YA/-U5
M=N0T5.+8G]MF7IFG&'M!(D%[79?JZ+.XQT VO(?8#SL0:7^("<0'VXP[/]ZH
M"/5*N-9V5$/VC[DHH:3])%$1%D9C^T0@;78U)#DX<<DE#N.>A+0_7Q>=5:=#
MEV"@RNA@*9BVI)A22Q8M]7KNRO$@Y-V;9RE_1 (_C'!^@I$L-V>;K>CYC/V.
MP_A\$YH7 5I>_:U 4/DURMIY=/Z6V_F'DM?VJ+<;*<JX@=4QR*5\A\VL3@T_
M CP-*:[GIYVEQ36YY;.NMN^]>#&OQXV\B* W!Q;BY#*!X44,E,2?J!<AU8E0
M('W.(QS;>'_(RJ8Q=?6"HV1JBC!11WS B;N1T"#BP]A'^ES>L+:3@<DI^S;2
MTK>P,1:?>6@\R)11:"ISP(?]9S7%'RPEPRBF]%=U,&_^%&GEU^3A!*W7'$_V
MU=WKJTP*ZCCWSOEQCWJF2;I1L@W0(+[ 2DJOPF>3^HMY5TC:/5D)S2W%O?Q2
M3K5*40*6JBA599R$\6NI!I7,:S!2\MSA;.,$&N=3:SH&ME0Z2O-"-;UN OV7
MS+.GYS\F2 0>@\V4,8'Z#/DL7352P[L(K^%OF.8E"&]XFN.KR9! OF]GBAJK
M'_CIG]OJ5ZI736W]I?[VG3U7X".W=.E[(YS=% C)A-))8@)S(8N9!IIM9.)
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M"84[BJ17*17*QD<:4P%PBE)";Z(%L](D@OD *ULNE/YM%33BASC1DG<K=/7
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MT;])HZW-#1:R:=0EDL4]' _(@M"2?0\/$7+3+"Z4')&7S](SK\6'M<E[ ?E
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MS"U1 %=%%=DO21-HAA!5^Q!N(\9"2T4O_Y5.\M]8V'JAG\HI3X:GGU"[;]*
MT2J#EF9D%BK0:E\54:-Z^&B0!KQVCHZ.=,N0.9Q+*J'W>-9C2OH>[; 0EZJ
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M()-LO]4S=[_\GBR@I!Q^1OG8':; _7ADJ+Q%5U8T/K^,AXZ<>+9GY7W\<L>
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MHDCE04(8BO 7M"C>_%6TCSF/1*JH(]QKAF"T9BA%Y^:@;KIK+N?< I/T,FG
M(P<GK!5)V:%#.=0F;J9+BH<(2L ]WO ?B$@]4/B\B@V(;EA:M-=_?W\2DP.#
M&.5KF8YH+)D<]?8WZY7Y1G1C($-C^N \!HI1'$2O" .148TBE\MC*D';LV[=
M0[KWJFYFR(?MCW-W7XKMA\E\BS5D:X:=Z!$#=69RKK3($;HK JN6G1^YA57M
ME/S*,!X"-4C'<3ZG&\[(CGP$]Z,!I%.WGY UHFY-QDA=I^@U39:-CLZBJ<IV
MTDYZ4S)/_]A][^D:NJF>RIXP7^5@34!VT@#V'Q:R:),GH9YOG"KX[455A+T>
M@PSG+OI(O<P,=0LE]L\I(DE*NRG<(Z4C!A]>)688<U<:=+ Q2]4R+,,)E$ 0
M-47^)0V(IY,T4A?X/_X1\Y@&M)^@__PF_F?WGR/]5R;IXC;D@.F/MEQ@TE6V
M#&HW#:BS0VY$$WILB>F(I)N$K_8ZG5^,:HO7KXN<9.;?_,$7#"IF5:/HWT-Z
M$'W2-((824'61+;D,,5 L/$83GT6ZF;&KY 5(4L%CI1FL<DC'5=VOP28*.KZ
M!AY7;BCE>\B\/02LM5(JMARHG)I$[4Y,G<B&*PXQW=$NDBZ<[1T9%'3W!5C%
M95\DZG]P]]Y1343ONG 0%!$0J=*# J(4D:ZT@$@3$:QTHJ+2I"E("PD=J1$0
M4)2B2)$6Z5)#1T2DMU"24 2!2$() RG<<,ZYZUO?^9U[[[IWG7//^;X_YI]9
M,[-F]KSE>?;>[_.FFD9L&;,HC%3P9 >TLA93&2\=/AR@:#A>,*(K'L![E]0]
MH62,\']!R^$H%%7UV7MNTJ'SSI(FETT<H ITSTW<#Q]A?,UQ-4[AJ5_+WT9J
M].6+(Q?D6+[V-#+&(#V\99;V@4%F(3$Y5> HCVK4\97TA5O<44T3GF>M6IIA
ML)^;3A*\'\[BC0+XL< 6'AM%/Q\0%,+>A3F6,Z]S]H&_K=O]-67F!$][9%IT
MP,-P+6X]T8E6-$:D%5'M'XG GR6*UXN7N21(UM<]49K!F"+KY<VWSJQ%#"Y(
M)/<'Z<!EJ?;$)$:88D'1*E7!/,!5]Q)4S/[PN[RJS-O=\WW/R\8^Q "9RO>2
MDWS>QO9RYF X%6_7C%=/FU_M]FVH;(R2"0_X==]DRD".>46?E93+?@]W *HU
M)MQSITA0E4:TG0+Q4TWF_.0*@=<*$HT"2^QMVHV[?,_"%KD3$*<=Y>;D<%R
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M(>*[#N/_.@/Q9 QP91XRO8R?Z'+1MI8@/D&&_97?\"R7+[3Q*+^1(?/=)5Q
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M(][^B^"[.IZM1+KV)[C(.H5K<EZOCT4JJ9Q92T-;B/$S3EJTHFMW7VG?PUL
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M -O?/^0:QRR1*@Z8RWKZVFF) U26B=5^/B92(97/C,SWGEP^Z(OF#K@]C[4
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MZ2,>S/69Z#*NZ9%7MD/ *1U_Y&K&#]IXWE\7VG3$^S/S=G8<M8J$)"A08#:
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MN]M'=O"VVSJG<256KY Z9["_'E:EC]CS5)Q!S7K#$K'0=\&43>/'6\>7'%1
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ML%VY/;UR8%6Y,1]9J^WS5LRM -GO380%D*U I 8JX"@>94DRS)\A%K4??DR
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M$3B($9*6:MDBIX%<Q44)ED1=%PQ9RZ?X\:WOWGZ>M[W& OQ["UYS?B^X^IG
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MC3XJP$D5_LL&07,SA;%40$#!VO$EJL\(11UL?2#YEP.T_^R@B+7A8Q;DBT=
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MZ^JF!PZRJ!E%.1UHC_VA5-4SNL4]0\G^Y,/'KG-3;RPW75HEC^@T/+EU-BW
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MD"Q1VE_(VS]8T5^]^;/G>^K*)@BY:(CL4AHD"E+%IN?!^R=:Z02Y[1F"JFI
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ME*$9VB!VVN#;/(@LM^F-Y#[8P!0,W9F"CD.\\8%PYC7\_#\!#0$[GM4ZAHV
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MC^^.S._^\_GO(VB"Q71RR'0'-BPDCP[$(Z_*Q"(1+B66_+]K?I:W\$JYPE(
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M-KX$&<KD-!T0S:6)P<D:=*#W32%Z9GV##B39_N2[Q (I70+$M4>K:9%<QG2
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M_)<-^!@RYA48[4(N#69+,*9%^L; P%,0.YSO@B 63PU'SR8\P+).T8'F #K
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M$PCAZ_XX2$O9@5^+@PIFEQ)I,,\,%2<'T!,_MFOA\4ZAK^6>U!&CG.US0<:
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M])5-33T^T4,76=3W^,GVZ*:+ZMCX:6_"1HO>(6X /'^A?:29M;TX*'M3]CB
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MQ\+RGZWJ7S,R>M)?1[O=;_^K"G:0U[,2> R9)[1>[Y-*FO(!0'Q0^WIR_N9
MR%9U%O+YGUVO\0RBQ\\6/4K9&ESQ/%KD5YT'/<+IQM&,/]=2X<.OMZ@VC@J(
MP*FQQC\TAC3?C*YP:H%%(XXKRS'XN[:KNU?.9:D(2M4-/YG)RK6:L4_QMG>_
M/7/KRU.6Y694,O5TD"(>U88"S^G1J(M]CA68J(?$Y?B5HZ/5H_BO,EN,WG/
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ME4]:72?ARB#] <#.3-)%#$H1F"G[IM1SZ/<9>YQ$&@,)>QND0,FH-$8?LS&
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M6/%KRP?Y$_KC*V@YV[FI:^/*1AYNN8V-=4:# G@1V6)IJ+[X; A4BVPQWR]
M'<1PVX\$N<[M-([)_>*J^HBRC79SL^\+5ND0VO+51V]\E&+>-B :@VXDD2 Z
M$B1:TY8 :]&&$EH#':PW6BAA7?O4.3Y8.BW/>9/L@&?])#+^AI:.I6K3 L#
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M@+<GQ,JIQHR7;ONR7;H>+SGSSN?B6ZE&&SO0 N&Z.FTSRH?YT4: [(A7[3@
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M7<J]/V)%;I[\5:YX'!#[$")[$Z8*0S3KHQTIJE;4'VESV6]W-6(VP\96'BM
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M R;0R-WLA>U99R)BUL=\_<S?5G5))VA$&\L_SK<6DM]*RA<).;K7N$2)@:O
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M4TA5U$H=+EH/NE"YV?%,HY-"-.20F>==2]T!9XV4]S$C?BZ7X,D6 GR!98&
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MVH;&:FM!8K5E\^=5KPP2%I-5?]7T!-L*V0QS $^"AS%=$^!#2 AT/@<,I0/
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M;WI]D X=O78 MLQ+1GE@Q2G.GP./@WDY;5F4RWV7ZJY\'7F]?^I9HK;%)=3
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MJBH'MQEP<19TGZJY=^[56Z'4&U-ELUGI3T)E#\L673+OF*].TVS(X/GU%Z?
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MUG#0V!(20 LZ<*@;!1K),I#N#L:*\38"*8K5=8R_ ?-U(H,#&6;\[KOILB]
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MW<&/7P.Z#A\7=RE[W?B\^6T(]]5'3KYD+52#"I([D*FJ>/!HWP<B-MHSTF=
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M L7N-9Q'![Y.!/LJ1T((5^RA;!,0=+.81OFMNW+?7L8'K":IF W$,,_K \A
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M?CJ._O)/=1\O7GB'3OPK_%_*RFN\;E#XYZ9[0^T+0H"\5TEDGLSX\*O#Q^/
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MAD'I=\EMH#$M=PDAOX11>=_HP1PPVB6__T3.5;M])+FKD7O@'W9.96:=$9S
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M) 6%YZG2JD>KISPXIZ%SF^P48^*?0Y7?$: *@I6AJX2=^(S]G2L$?.("B?M
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M(Z1>PODBW:@L2D-DSSDFNVJH>D0HWY!W6?OP*V;SF<FG3I.?'OQ\E=BV4_C
MRJ+)\C:C)^*T>\O03NB>8VM*0VVFOD].*D3#%TH/^^+>:%!9>Z&\J!R+9:F
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MY=PQQ<8.W7B.#&A"^@AOQXA])0W]%A90$;;;!<O.O79M?V&26NX5^XWJ(FP
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MB@"5L=KA(XP 5K8AP*G$DJ 4(93:F(E'1QD;U[="1FLI+]<*M$#4S#Z\&J?
M5&X/D;5I>!8"3X;A\3$&-0O/JKEO%)Z_V-L.L7M542RDA#D$L4@+@(HD :3
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M;#U\;*2C98NT<$YG6SNPF3&**QB!2<,8!_M"!4<4]E6#8/O1PY87.*+40>6
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M<>N:9[F>YCT^SKK2H*](_>WM;/''N[E:.Q^:((%U02V:I4+F1  F=+%P*3-
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M6C"^_LK,G7?SQ]6R?B^>Q QV)>TI94HS3@#,LD+W"X_;\-I20D$9@HA2JY8
M9\8:&S$TLOV/?X9Y_#^A8T[.$4#-C =/, 5F@DW>S4W4"GH3-:)&,$"[  -,
M?.?6'!GI9;)I3JM\,G_FS"V.94 >'F>+9R&:.*7N;4YD3ED*$Y!G,0&H2 N
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MSE9+M1?:G)V\^<YF*R[X6Z6,3E1<M6_=1[EO>O[R?/P!C3TC<BC+1.9 4;T
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M8 V&]T"^S!0==5"^D"AN*VY;5%M4.F.P.0-KF]A/."5Q&B<E2+#N8"-I#HC
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MOE"OL=.(#MA2[(@0H^L<=AHHEP9A9Y[FG$#4G/#\QW3Y[=6J7JJ!J_=30M6
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MM8IZ2Z*5;!SF6Y/7ZKDUA]&/C4N]U37JBTVTVOZT4]\SR+%<Z%GQMB<*).;
M6ZFP8!_NP */Y^P::@/^CI%)GA$HRB0#)*4%0$24@+!4 H)$6C""I2RM.IR<
M&VQL)+\):[7G]C.0&ON O  5WOW3A_X.0(Z7(?'G]#D]U-#^GHM*'W'U7+['
M,>V 5'/%175?6ESW9F(3FN>"4Y@"6.H^2(S%@"9, !)3&0N*&,^LLI>.CC(V
M>M#-?YN6O^LF Q%9+JLI7;6VQ7(1L:WV!-\6,P6S=D9H99H.!:N:.W<H.#X1
M9MQR-;R!2:67;]-LX"9J9/2807 . E_) D?'&#8OX)R:!RD 9R]VXXNM$ZR/
MRV^B^O*-S-\OYO=?1/6@3:!--OS:'T-36>8Z/@H7M 0(0@&PI!#DL$R+G$B)
M<JO^XO8BC(UIM+1 #?2P'7U@&3+E,!%F9!(6WL!,LR7\3=2('RV5_%&#N-:@
MV35NU]L(XE-SQ] 353D(,"B/N0.T3W)7/,F1 87:MXGCY_K/7?QY_7HE_E,0
M)4PEQ*000G"9QJ"D!00HY1R44DB0YYB*!).RP%8G9-82C(W_U.N:6;*=->B&
M9!<2RM!<U\A^LQ_]LU-72-FL5$1W9,IO(JU#U"CAD>A<\?/%<];C#TMSKO <
ML)SS@QP/U]@WP5<S\5%>2GO?^$%@P>)<9A+@3.=GIBD&E!4"9%2F69YEL,RM
M*A0YR# VHNM5T DA5Y5X\#9)AH>C8:$/3(R]S#K[*U+;]9-P=QV.PV3D7(&A
MKR-7!PF&/8UUA^C@H/:*1]E19%TM)Y_$HWI9ORD2OKU79*O9]Y4.O1+5(ZF6
MS[KC4=NT?))D.21267Q"ZJIB6'*@]L/JIQSEC#-49MB(%*U&'1L-;DO9],Z*
MOK:"&O86MX/\/,4% S(PJ3E@:$Q93IB<(RGUP"V"4G_;D)/=6(/0D9/Z/0&Y
MW>QHE6WYG=OCQ0GC<4QSQ2]%23A 2*8 YT4"""P92Q&,$Y+:U (Z',**3 :H
M^?-%C['C@O\?_UPFL/B?3?[ATK"#^!E(:9S%A"44I!E- *() 33.4\7;"5,[
M^$PD&9PH2WRZX)^7:GZ' '9_N'#P_B+NIW/M-HXH4?_ +$/FC^")24Y8C#C(
M,=0UZ2$#A,$,)%0BAB1&E+,.SS=S/AR:_6 !SSV:\@+>@#2TW:^")O JMBW<
MO_31.K=[IVQWQ&\AY-.(^#*T#P<8UHX^J>"!F7SZRH&K/[6COYLK8[W)G-MX
M;[NZ'6\7E133I6XO]1]B>O]-%_%X$A6Y%W]3#U^^)DNQ3JF=,,)Y690<X(PP
M96:G&!"I.%O*E%%&$DCH,+6AO*HU-CN^DUWPJT^[QX%OZ#I2+_8RA&;QZZM,
M==2_A<WV<=VZ!M460#=1#U'4810U($4:I:T2"2,H0Q5DWE^Z2)5?I?X<):R"
M3*2W E=AI'.H1=%&LMXJ>WIS&-N>6#3^U8WWF0O!L>Y:0$F9 Y1 78@"Y8!C
M 25E&4O,C@BL1AW;*GIP7O=*3=5B-N5$<]LO[69!<:<P[@]K-PGG%[U@T 9>
MDUJ1(R5SM!,$THIMX^F_YOTV+T01 N*!JE"<A]I3P0E;?,Y6FS!^V'"E)FSU
MVZDS87VS:V?0=]J)29HZPFJU(*^Z3DVZMH1$20E(5B8 R8;1J0 LIFKO15-1
M<,LNH<<'&AMUM[)&6\)JZY-TJ<J&U7(OHGN>H'UB%IB37>%RZ#%Z'HLK^HV>
M>/# O4?/JW?8A_3"]8Z^'J+/5QL74ELR5?VEJ2#]KJY7@K^;;V5Z3[)8L*0L
M,X Y5:9>GB> Y"0&.<X0%$7)2V@7#6(Q^-AHHQ4T4D8>UXF+<C&;+?X :K_\
MN**S*8L64HI*&X3:K=(6Y;;UI]A,C:'7(Q#@H7T3I VW:03O2U,WOV@GH94^
M:I-!>_D]^@P<4/.UL[<9>MC]MP,H![MDEV=<&_QV5RW49FWY?*=>,9W=J7?<
M31>IQLR:E$E,L@27($,\ PBS'!#-=@5,<Y9E)2I1XA;Q=G[@L?%;+^U-U,C;
MEHSO)>ZV7H;[+>LY,"2S ,@&)K+K0+TB7,T,(>\Q:A>&?:' -#,P3D>C&=[O
MX'3[[=4OOXJF&T:)4$'BE"E32Q]^Y2C7^S(!>)Y(G& *2UX8>]76CQT;R2C!
M+%PV&W0,W%U..@?^_)5,T==6*AM7U49O"U^4D_X#.9O.3;N=1^E R[,NH\W5
MP_F$#B3<<?H<_JNOTJ%KC_0K\CA=DMDZ8S#E!:.$<R"%H ")(@5E'#, J51H
M4<&A3*^M(7IJ<)MW<9ABHJ^^Z1.9IO;,8NW#)ZTS5*_.[LF<%E-B9N^$@3DP
MY5VL;MR)'B1ETQZQ8/5(3P[\PH5)+P%RN4+IQ2>X,=JOB[EX;BOOO%W->=VM
M@(7DB/!,:+I* 4K2#) <JI\H)CACDE*[H*#CPXS-3FJDC!X:,2.IY;3CHA-@
MFO'.]1 %YI@6G5;"J!'QLI5ES27G4?#$&R<&&90CSBNZSP<7KG;MQ*U+:@G>
M%[OH7E<:RUQ_XD!*J7.N80YHQA-0((@3*BA#)+?KOWULF+%]^[=,V>2K61-(
M\%K(*9M:=G \@:;9QW\]1H$__E[ :%V0QO^W?QX$;QVUCPXR<!_M<XH>=L\^
M>[5C\:J'Q]GB68C/HGJ:,G$\D.K#8MXV.&UBINHF?63[WU\MZN6'Q?(_Q5*W
M.;Z?3_\A>.-F[H*H)D24D$.( &9%HC9!. 94H Q(").$,4&172N_0:0>&S/]
M-J_6<NHR6IN84=UR=JZ,_DJTO+5<1*M.]S;+1Q?8TGU(&R LBVH-\H*8L>/H
MICWT0=RQX-]-4&-3@Z>;YIW.LSH>KEZJ?UU&S\I&V^AY$]T^Z*PZCT7#AIP2
M7T7(!I%YV*)F0T[#09&T00=W+3FD!-)C3-(T+>.<() D1)FUL8  EPD%+([+
MC'%24!S;I'NNGVRU7@R6Y=FV:&-*/DOBWR!F1LY.. 0FT'5T\)DV[ X%>_84
M]5:(IW_NP 5V]M0Y+)RS?X%C3]BF\F?S37=[HBR7:D.),1")5&8A9^I3I%D&
MN."DE )AFMCU?MT?86PF7"M@&UACV=[U #RSK_(J2 )_G=MH!-A&GE3=5^_5
M@^</VV/UE'H'O51/7GAM;(_1PG\[:Z9*_:0+R_1+^UV3/ZY99:NR4B)%EN 8
M Y+R%*"<EH!PD0-:(,P1C:5,K,J<!I-T;+SR>?7P0*IG':/7[/= N]\[MDET
MC2'R/==F]#6*&7SI7=Z;=N9X5X"K.?;9WLT-5(,KT QXCX+R+><+A4T%@OMT
MG%6H :_<L.WEAY44Q05.$("E+I&8E 4@)!. XY00PE(B2RN;\<0X8V/X]^MM
MG.,NSBJ#T2,XP^WP@M+@!21\;P%?(J?.4-63VT,O>7-;@0]MOXZ[Q6S*GK>Z
M[_ BYEB?1;)<JCVC;L=,2 IDCC$6F?H/=^N^LS?0V A@TU7&L>_./I!F#. #
MGL 4L$'F)FJEC+YV_PW;<^<$)+[[[>P/\S*]=DXH>[+/SJGK'<*TO_RAS.#G
MST*WCQ1BOK93]$Y'C:=^.WT2.CJ\\XS ,B\91#& :89U,+< ..,(*-; *<=E
MCIE1ZQV7P<=&&TD,B\[#LI:VR8:P"(BVQ?\\LX1&-3#;M))':]&C7O:C*+O$
MG]O";1&E'A#V@6+9[>#W%/;N"-O9X'C;9PX70N^H[4Z@O>LSW(S%35'_15V_
M(E7U+!=5<\SX?CH7[Y;BH9Y(@E-:"@AD4NA]8ZSL1IEPP)*8(I9ES#($Q6#,
ML:T%6U5S=(^V':&CKUKLJ)';,L_0!'TS8],SIH%7@NOAM#8]+0#R9(6:C#BH
M06H!P;YM:G.K8Q3]NG7MIFEM:PA/\A3G,$$<4(D@0+#(0!DGA3)*44X$990F
M5L4<3@\U-MHYVAB\WZI9!M:?QM>,8?R@%IA8S@(6=F][&1]?H?>G!QHV_/ZB
MP@<A^)?O<"U-3Y9BDY4?"U(@JGW< E/MZ(X!Q7H_*R2!*,,"F>UBCS]^;"2Q
MELZQUL$N=H:'B\Z(A#X1- ;#H9#W,9V]%?'>>?C !;R/*798O/OH56,KW/WW
M)E+RW;P]5[M<A#DK$QSG1)D4:AL#$$H8("C%:H:H5+\J20K3<=3NMM1L;#35
MBC_BVMVV;XXA4XY%WC&1]& 5O+N73KUS+4K_G<IX.\[_Z"MYV^KUWZ28M^-T
M#E?/VU5 -PNA+3+[:J^)>"R8H 1"(--2 L1TZ5<1"X!YD<:8P P55F&.1T<9
MV\K9B=<5^[ L[G$<1[.UZVIT J\CK7PW?477()4YSF+@B4N/CS$HKYU5<Y]C
MSE]\[4'$3G?A30/U29(1F,.D ()C E#&<K6KYP7($:<9I@+G=N$K%T<<&P\H
MR4 G6O2XJ!J+:2&WJ@&U"4M;A8!<3R-.38'M680'8(<[B3AH7[X1.,0QQ 5L
MO!]"G!KOA8X@+JA_^@#BTHUN]/-:2*&>P[^0[RV[J1]>J;]/ESNG'9]$+=2S
MOTTD+!->B 3DLJ0 $:AKDR40E))+499%@K&5B]%R_+%14R]7$V?/Q9.8+=I*
MH:S1P9*(;"?#C)8"0AR8I'K)=:!>U!L]^N=6_-WSTYNHU\ ?:SE"YXG#;$<?
ME-$<H=GG-]?'.,0$OI\RM2U45+IN%US?50LY73;[PFY+V-?>*?,T+Q')%;N5
MNGTJ8P"3N "EP)AD909SLPV7]<AC8[A6=A&17O2;Z+&1O?5B1H^=]!;1:E83
M<9[C@L(;F-W68D<;N6^B5O+6!=@[_PPJ)EV)LD5 8"BT!XH&M$#=4RB@"V!G
MXP"M'CA<$*"+GCL1@$X/\%._;JN$6U?!;9) Q@7))2!9G@,$A7:YE0F("U)B
MC-."VFV[+P\Y-NK?KFO'?=2U.X)RD4),=<?W(N5"H8S5BBND6G'3#&8B3EB*
MBLE<W.M[O@P.-F[!/AC_SXVYV;;![_L:>"T]K#'XXY&JC*>/7*\N.'@:G4#%
M!X\,^**%"$\#<*DHX9D['5VJ^@!G[3BYU?VX&J_@*U)_>SM;_+&.Z)B4'&&1
M" 0*J"L4LX0"4I0"Y#E)&:<2(B2L7*NF(X^-ZAO!+;VFQB@;>D]#8!?:B]H<
MO6]\J1NI;R(M=Z0%C]:2>W2GVH+ERZUJ/.ZP[E5;. [<K-8/N#)@LSUUUD?5
MB[FV:F^_3^L)3##,\S0!0F8$()%(4&8\!31.8(:(9&5J53[Y[&ACHZ NLF4C
M9/15B^D:U7D48#,F\@9;8/:Q1LP]]/,<$KXC08^.]3*!H>?4/ADG>O8F-]I8
M!Y?\*DB]JMJ]\2<=2ZX;6/:E\:C@298R0'E*E3$CF&*/@@(NB@(6$"-$K-)%
M3 8=&XEL(MGT<4 GJAV#&&%M1B2^$0S,)T?!"U!ESP863^1B-.2@'&,#PC[5
M6-T[<*!Z%S3WYKNHV+36(?-[$7/=OXB[:LK$I(A3*F*6 YC$!4!QRM4.+"&
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M+ L=A5:"$BN+B,)"T$2R%&5&E?[.C#$V7NG%C%HY(RUHU$AJQC3GX#S/*YY
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MW+1X\UU7;E W_"+F0DZ7=\H<T-5*A,AS5J8,Q+EN6DVI6K9Q0D L(:2YX*C
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M0@ARK-U>)&,!"L41H%+ C#.):>Y$)VLQYMB^_19YZ5?]^YFI!"DW++U:P]F
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M+U_4<R?R_8G.5L8,/"A3\UF6?%8I,?]'SH7>'_VVEM,"2IAE&01$9BE *D6
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M"9XGR^0Z^J!VJR<TQU:M[V-\D@"4T8V9R0(^_^^?EO,9?YD625X@C"60+,,
M)9FI^,49()1I /,T%0([11UN$&9LUM (.3DE&Z@"A(U"Y;\[!B=NF3#+Z,5
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MWPKP?L'U$K.6;V3UW_>+^^6B3&3XQVSS[7Z[WBR_R]6'&64E:\=42I'1HI!
M2E,X@4D,"D0D((G(,$\8U#^XK 6.XX]M57@CE=0KLHA6\EDN.CX@+^#;&:B
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M?9ED0& L!2E@(NW2CJX--+IE:"=G5 H:_6Y$C4I975>+2]A:VG@/B(6VS+W
M<C>@5Y#P9?8N#3.LL;JB[(F)N7;]@*UO?Z6SQ?UQITR&&$]9@D"!L*G73BF@
M*M4_,22S DL:Y\@A@=&?9&,S/<X-;Q^U4I.FJ\G W6[/3K7%><%K36!@2WA[
M!]1?R\F\?Y4FMV<G<X .M[=.ZI^FO:W[Y [3V[9K H(TMCT[X/B[VG;AY*6E
M;>< /MAV]XWS4B($$D4"&,F-9X]2O3*S#,0B3[(<H12G-Y'J]FJF-PQW[C[C
M>EYE7,^O=LUS@E:CEW"$)8"IJ3=#! *2$ Q0'LM<<2YY)EQZJGD =KCN:A4+
M<8.H,P?#)4SM-DL>D KL(9QD^P?HV'@%A2#\P*_4@?&*JMULO[XZ*O[VY=>E
MMER+,FSS*!>\YH39KP!UBD<>Q]JJQB:7B>8 I:P A2H44#1#1)"",N7$#VH[
M\-BV.*4GM>>BBF;K]5:[1^PE^NTO7_X2/>Z4BFBME9L1L9X0.ZL2 N; 9N:W
M+]%>YJ@1^IBCZGI.D[/M<<7*DS&R'G90Z^0*QK&Y<K[?9^U1%7N^6XB#U)]U
M22KS,HTAR@J4%(!R@K2/0SE@*50 )VE,"!;8D;&EAPQCLVIEGM29 RH?)4+=
MD^%P6A@.X@&/_\[0H42_5Q*'X3.^ ;J@M3?=$HR@JL8*(KMZ&;M']>R)S?E*
MEH]O=7QX4*;DWS#GF&243ROY?;;]OGY?'L65U(!3C'%.8*$WS31+ 5*)WNCE
MA &1R2*/4Y(HB'IPD/:3QNI;'9Z*]*!'RE)%3[7D9;Z5:%0R!.5G>4HGT<*5
MHZ3G9-H9T8!S,U#7[T:!Z*>V"C^;N=EIT?1&*_4PE8\[33QV";\)25_MQ/L)
M,6S?\9N .FE0?MO3^MG7UI.,_UJ7%&U>6C%2M]Q2^P>.Z--K"3VIMF(-:9#I
MZ=W:E05(/G4'S-,7YC#PH%^5.R#'7U*/)_3[>C[L@ZEZD-,V?;MOAZ1)2E*&
M %89!BC#*2 R%B##3%"14<I2I_13VX''MA-KR5U^8NN6Y/_Y'T4"\[]&LM3
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MYB]7M3K,ERK$%&$2D)2: UY4 (() ASFL&!I3G+L%!8].\HH%X%2R"L%*PY
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M=LB25<HH-XGNOB^W-[7.\#WU=A;N%2<T]%ZN^T36UUPZF]- B'NRP[ZE&]2
M!X+VV/*'&L8?'U!2AZJUL\AIF@@@8\,'Q#@"+,X4@+E4$*:((;<4[8ZQQF;*
M6WQ R>U\0,G-?$ ]8 IL("_S 24#\0$E@_$!)6/A TK<^8".;^G!3ED5WK^;
MK3F=_[>DJ[<+\:8LX2"P2)6D@!29Z4&1,U!D:0IB&,N80YS3PJJO>M<@8S,,
MM9Q1)6AD)(W>FE;GUJ47G9!V6PA?0 4V#;TP<J,$O0)"/W;02P\=CBCTBEH'
MG*'7KNW)&,2Y\5[7VN<UX6G3W8;SU5:V ]?[BMG]&0\O&(9Y)D&.<J5M09P!
MEL<"I$5.58QI0K!3?6I/.<9F+FJAF]V"8_2I[V38^1D#0!S8T#0:1+4*51.M
M&O+V2=M>C4!E_3=BZ8LWJ*<4PY('W0;5"8/0C8^[A67YX:ELRK%X+)E:FP%?
M?EL(/:"12HJW/[B^M H)3"&#1<*5MHHT3P#"* =42@+RG),"%XH3+GO4+_02
MQNHS'KYXP>CR7[N*UCY\S:Z38F<LPV$\+,?S3H.*[7FR,Y,ODZBM1E3I40>S
M?/,_]\31*S.TJPROP!G=$Z;S;-)]'];S*(*N%J;@Z).LBAK>S.9;/<*4Q47!
M!4U 3'-B$G]S4)1<L@7&6%$>H\S)3[PPSMC\P(]R$\W-B:2>A*H=2T0WF]6,
M;3>EX[)91KS5TJ7.S)Y$HE*G[.*R78O][8[-7"Y-AV68_W:0 YNW1L)(BUA5
M4TVB6DJ/L?=N&'S%T"^,,FPLO%O5DYCVE<M[YH92DT55)IY^U'/_H+ZNZ&)-
MN0F+OUE^I[/%5'&:*93$  M!JA2'@E(*6%I Q;!D,LF=TD"O#CDVRV(D-DE)
M52[U[Y60CH>'%D#;&0J_\(4^XG-#SCT%TQH,7]F6UP<<-K'2&H"3'$K[.WN:
MEI/ZIX_+397C_N5)NT7WR\6S_B=# V=.X>!4(!@72MN8!$L.D&GY3EG*0)86
MF<IR0@ET,S2. HS.[)0?S=J(.M&N2R-L5#:I=+0^KG-A:8L"(AS:,K5$_]]U
M^61DI*]I+:(O%>Y[%:+/G;B[VZZ>X/FR9*[##VO7>H)S8N7Z/J=OEFB;4?N8
M>5OO^E8;DV1@T@O:_0!REL>0Q8 G")J8E0",Y@B(N""<Y5"FLG!+(NTAA9/U
M&R#']!SY/VU$+VDI^S<#Z#=-=C8Q./B!#:-52X"=&C6E98@6 3<!Z2WIM8\,
M ^?$W@#3:<KL+0^[C:JH=D:;7I]E"M8T%@*RG"B04X(!(@@!PJ $<<Q4D9K=
MIW+JE]8UV-C\OR8G4N^?=JV&2SK>LOLMW8#--PF^T]4_I;E&R549G3'G<[.%
MGC\ZCYZV;#[CNW_L1S9T=EZT=QY36A3:5Z?:5R\0!RS.(5 J*3#B2NB)N8$F
MJO?TO!H5U"AGR6[%\O5-!%Z8VIQ;=55[@_=])TEU;P:G+D \LS2='>I5F)BZ
ME+[$MM1Y3\\D&?$_V_6FXH%?W@DQ,W$).O]$9^+]HMTMFAWG]7XV#$+KV:;)
M_JTR>NL,7W-!F;XW132A+$\+H)"BAK\R 2S/$.!QK@05BE,JG;)I @L\MM6I
MZJA156+P-L6NK/)P'--P0D^WG2D<TR0&-J=WG][?7V7%*\GJ5^8PLUS-S(<=
MM73RF-PS$/"^LH!"BSMLNM! X)_D%0TU;@^^+6T]EROSTKZ8L-&3$;*N,(!<
M^[U)D0&"%#*L^A(P)3B@B$&%$I$FF=7"T3W,V,S]7M"2H>^IDS/3!<YNP^P/
MI,#FM(7/3L@^;%>7@7)@M?("V$#L5>> \T10=16&3B*JRW</1SAU58,#8JGK
M5]_,;EJGQ$]Q3$6", 5):MK-*8$!X9(!DB4HDY0B*;*>?*;WXXQ'5YP'=<BK
MS63:FZKTWBFN?!M"H:W?7KA)=.\[$GQ9=?_TH_>O$<.]K& 'Q>CQE0&RK)O]
M_9NM-.4O7_]83C%+96&*4&B2&E(X 0&+&0<"09S&"<D40R[;9L?QQ^86Z5<)
M><R@/@.XI74(!V-HTV&1-;U91DQ&9E\PJ4K=M H#Y4M?QFZ(3.DSHX\G1_HR
M-$[9T1V/\435]%%NIB+)%.><@$P1[;!(C@'-&06I)%DF<LB12&XB:M*#C,UE
M,1G1_NF9#)IV1NE6C );GK/43!_+8YJRZK[N&#:?+_\P4>V ?$TM7$*Q-9DA
M7I>KJ:7D5::F]K4>FKZ:N&79QW$M5\_:\C0,/%PD4"F) <YSDWA3Q(!"B(%4
M,%<Q1#&63N1+-H..S8,Y[%9:1GBKEJ6EV#?0)5G-@)TA\8UK8,/B ]+;VK]>
MP2A$[]=+0[Y>X]<K('1V?;UVKR?/9.\2+=?K>[I:O:CERO3T6W_9LO^1?/-U
M^?;'TVQ5Q?SB)).X*!C(4*)]&)Y@0'*!@4@%32&","^<CBQO$V=LAFR_@2BK
MP'A;_$FTKA0P6PFY4^%&3\AM]GKZ3,'FY#6\J]8FS\S1_>$<?=G/T=OK<W2[
MV]4+VE .FILPK^O*]0+NJM/7[ZE]W<-GN=C*S](4NN@A/\F5'NR[\?,?V'SV
M6'VR::XH)EB!3,8<H%Q)P I$0:$0(P6%0B*G8)?5J&.SJ[\]Z3=BL8F>JGVZ
MJQ-H@[.M%^@9O>!N8"GO)-I)'+5$CO8R3[Q3 #A!Y<T;M!ES8'?0 893?]#E
MYIXU<F>S&TY[/K/CGL][0UBE/DPY5!DI! <)4]I488I!03@! L)4,!HG^AE.
MQ7.^)!N;.2N%;/F IMY?B^E83^=MWNQ,WZO,1F#SV$X]:VO5SC^+V,OY%#6C
MVZ3E)4:?NF?1O3K/-^*^RO:\R35L/9]O.$\*_;P/T,^BWR]73R8)0QZ6TM0Y
M/#SG.<3$E#BG.4 BD8!2F8$XXP+')(T54RY6NG.TL5G>G;"1,#5FZYVX;K:W
M&V$[>^H-M\ V<@_945E> /Y?*TP\6;'NL0:U3%9J'UL;NYOZ69"/R\6RV0F_
M7_#E=UDS6^Y:2*6HP%!!!'*H/3P4)P6@ A8 )5BEF*$\$4[;TJLCCLV2/&R^
MR54T*T7]+S?K<1U=.POB%;/ 5J0M:U0)&_U4B_MSD*Y:UNAXLB?7QQO4IEBK
M?VQ7[&\,D.WU-VK./C8O1ZTE"8&93" #%%%I&M830R<' 5)<24QP3I45!?D-
M,HS-_MCD+#6:>,P.NS!!=@8K,.R!39@+XD&;?MX XQ )8Q<D&$_26#=$3HEC
M5Q[EWH7A[6*C'W<GQ,I0=%;_,4>_R12F5 B5Y:9-2PJ0U.:OP&D&)(\3&B.%
M9&S=AN'B*&.S<I6@42WBI/DA,L)V9F Z -MMN[S!%=@Z]4;*J2/#521ZM62X
M_-3!>C)<5:S=E.'ZQ?X^?#BE6)"\;.W)<OWAYT1_^"(O $SC-*6)C$ENM=7J
M'.5/]>$_+!R:L%P&MO^'/R86N=Y(>?GPNRCA^G_X S&]62EF\^'?RME6[;-,
M%L)V\VUI'(J:CU5O=W(IRV:^,08H5MAL?! @25[$*$L%= NS7!IH;)]_'2$H
M\W8:27NRWE[$UF[/X@.QP!:@'UC.VXYK2'C:6UP<9M -Q#5ECW<)5Z_O>Y2S
M*&,N_YAMOMUOUQL]QFJW^9A*C"4M#,%^P7+M'H@<D%0P4"B)<XX2I!*GW/'.
MT<9F(IJ<H$]]<H*Z<;4]P/&$5O #G$K.Z \M:-1(V@I;^#R_L8#$V_E-UU@#
MG]]8J'UZ?F-S4P_:D*]_Z,_AI?ISUX76,"5]TF_4-[J6G_3KT1")Y"I!R!!<
MQVEL./0@((746PU.\MS4T,?*ZC#8=>"Q&1/]=L51(W--[=9('1FQ'>@S7/#O
MMC0A40UL="IYH_H_7<CV82AQ@=B!LR00U .QF-A#[HG;I =<G6PG+L\;CO^D
MAY8'C"A][N_G+#X\RY4I%2WIK!Z>S-M6?P-)D=*<D!2HHL@ 4G$*""X(*%+)
MN8CUWT7JXBA>'&EL=MT("G:21I6H;J[B953MW$0O6 6VUF=A"I#?<Q4+3[[A
MY7$&]0NOJGOL$UZ_P<TRK%>;Z:?54FSYYF%5\]3=_9BMIPAJUX[0!$@J"H"R
ME(*"\A@HGJ:TR$BB?VUC$"X-,#8[4,M8UL#68D:_&T$MO8Z+0';; !_P!/[T
M>R!C_=E?4[_K:]?WMKYT_;?]5W[QL8-\W->4:K[IJ]?U6^1WK! [4HCC(K;[
M;R;?^/VB;GPJ)(D58ESC1_**+8F2W+3W8(QD,N/([MRXKP!C,P5[6@W:*# Q
M>7P5Q>Q/0E8__5RV^NBJB/(S/79.1$C0 QN8,S0FD^BT,K=%\_O3F_T<^*Y*
MZPND)\?$>?A!_96^X!R[,;V?T\\DOJ.S54FVNV\ OG9,I>UZQ(B^)2-FR0LD
M6[WNUT'29VT0\?11= XUZ =@H_3QRVYU3\\-O<DQ-[5$*_E-+M:S9UD=,_VV
MT.9Q;KK@_)_E7,P6C[_2V<)4K#\L6IUS5K.U_J<W)9=(55?T46X>E/X$IY"E
M4M(D!7&:) "15 $6<P%$@E#,).6<.E5JAA)T;+Y#9;8BTZ5YIUE%]:&7MZK!
M2IGVN6[UKEI4;%X;^L,Q[A!J\BW#%B.8TM!1C_OWD^.BIO.]QO9*1[76D5$[
M^LDHKKT4)O6U,MJ3R6OG4>D7TK@W'J,G@:?$5_ EE)C#QFX"@WT2^@D]7D]V
M /Y-BJUITWO'^6HK18O]]Z@&0&F4">/F\# A>E'A*6!*0L!)P9,<$YX))VHH
M^Z''MDPTDAN[7\L>U44TCH6F#O#;F?4PH 8VU.?P;,D=M-C"'3!?5?;V P];
M1N\,R$F=O/L3>F9/T?4W\W_3BN!9+^2+S;IDV)OQC13F'RIZO=8O6E?N=I )
M1$(E"04%@0H@5)@N720&19'G19K&(HN3Z;-<L:5UGI4/N5R^S[9TX3Y3T_MF
MP?5$5N$>_;%R+?JD_+/LV%)K4,::5SO]RG]W+*'U,[-V)G/PV0IL3>_+23%_
M1BU!#474;D:J2VK"T/8OVW<$"3MX!=M7IID7F8;-2/,)XTGFFM>']Z8QG2T,
MT<I"#\.V)7>*?LOK!(N5B<6L9-G+:_72OJB.NA>*L 1!!$C!3-X;E8"(/ :2
M(1R+ F'(7&E,;Q!G;/YKK4W$6Y)&3_J2221KC2+15NGPRC[G)C?.IYTE'VZ6
M IOP9H+:0I:979,F[VL5'6AS>*7O0Q4_N/IC-;U%F*%933T =X;5U,=3>Z0>
MMXYY6C[]8>WTY]GCM\V#^FTMRY.@J90H(S&%(">%-L4Q3 %+DQ2H7"&E,"2"
M9PYMO/O*8?5U#]_:N\4H79Z-KHS48*G 5O^E[*7AD#;;9WJZ+6M0M%^!)/J@
MB=@)T4.I!'A00*M1G5H'!M\A=SGP) R4PQQF,MS2FF] LC.]N<]SATMSOD'K
M@W3G6Y[3,T2]96OYKZU^.=\^ZS_*"-(T$3A-.,L QP4&R%3/,IYD )IFD3F,
M,7)KK7YND+&Y[7L9HU+(.B[J6"][%D[+X/*-((4.([OBXQXL[@# 5UCXW!##
M!H [E#P)]79=>P-?]2_7659_.6%9_==VMGEYOS M5LIN;^61V]=O=%%E6J__
M+M?:JWO?T"+'N2!$%0P0G"< <90"4MH1A"02+(.2)8UC:FE$!A*]AR\;V#15
M\E4\RJY'8$/-MZ6-&],<_GE8LDOEHY;V446@N='ZU_4FVLFK7Y-9("[M :?-
M)]7V$&(/S\0]X&2<)>H><OR^=%#:B7XO]#@S->.EC!^W9>699+C@<<Z!(#P#
M*%,4$(CU7W&288)AFJG8C1+JPDAC<W%KLB.S.SP4-ZKD=:6%N@1P]UK@%;;
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M!#A!)8 HQP4268XD]3M"<+ ZO?.$HRX0<N]VQ!X:#>!(9HS8+L^9E@P0E!6
M8U8 1,LBAQ+G+/=J]1P9[JNV+>DZ@ @&W6UQB SEP*M"%XH#E UX #1&EY)K
ME!)X0.#5I21*><&;V9H]/*Q473ARIS\9,XM']7Z7!I])0^F28D )S4RXFI>
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M)%PK1]%AR"G7*EEFHA4BY-;5>_<2,FTBTQA@.5[>'1Q.MYDX?W>9A<(C&B:
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MX +](Z''6'CFEK4^=@^A<S\D_F@/!:-KK -4OD;B H>AMG=8L<E'$[.$E.L
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M0/$5_7(]X\QYEU%3K$KAAPJUP5K@!6) GZ)'RW3K][Z[5$Q[FS#&>728@#N
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M/J> Z#*+K9_1'DGB?J\6[)\/MBU5UV&,MXN]:U?=+G$T=.J#2$6!XLE!Y-J
M+8D<*!:YDZU[9S^>ROWP^4_PK#:R G\@B,ZL\9Y;'^E$J(X/'0[@BD4P/O$8
MO$NZ^4O:OK3M!\=_@M>S4935<2/MQ]2/S6Z]LK0OBZ,5IBB,N\W896G<SXTE
MVWH(^Z/7&%.Z3SY@_1&E8]%GC<@3L) B'1DRU>:IA4Q"4$C;M?#4.KCJI?3P
M9B1RT47@8JKBQ>_7LU2B,-EH*";61@+,U)F>#GC2)H7 DGKBXL0]"?]ARA<?
M@\'')76,H>(.'*=#F)X9]$8I[B#%.NL'*<#VBB*9FB904UYYB3W >-ILI(Y1
M^R@%=MQMX&68KX;I4\NK%.WM@+_+L1RW?OXW#.M38B!LKO[;17A?Y;>:+SX-
MN3!'^ KC$M3*L7A"L37R0BY7?3%?IY-EI>5J]V!"[GAFH'VH]6I,@<NB@(A6
M8A:J*-,Z[>PA>HXN.;_X]E;T9#=>ST.<GYS7!VP5\79Q*7SZ"Q2WKV[H8ILF
M;C#I$*P!YFO7KHP./-)1I*5*HBC.[CP[MA/,L<1/7"7<"F]WZMDG46X'?L8E
MX[^<#:P_/PGK]5!Y7:(OQDM&IUTTH+RS$%QRX%C.DB5=C&Y]([.3F$Y0][3@
MV 71HS35$^1NGF'7!#A([+?%,JYQ-31D>K7X>EK[,RWI[#N9#XJ_+H7SFB_!
M63$V)]"H/"AK&$2320Y<*_*@7 JB>?./D7CI!/#'0>UA&SN-WCO _]^6"SS;
M7B*]/%WDRXI6R84360+/MB88<@9!>@\R2\^)$RM5Z\KX^RGI!'N3HF397&4=
M ._A]A),6<L#284B7@U*8@#OK0!;F,A1V:A,ZU;YQ_<$&>V6H$L8ME-@%VB\
MK_5$T0ZU9:F6T)(37Q(Y\;2/(*'C07+#A6\]'N3P_B"C%21UBKYC%=8!ZO9N
M,%'K4X(V%JQT!901&0*9=4B*H>?*(.K6W;R:]@H9K0JI2VR.HM8.X+J[%47D
M(7*9.#@3*)14E@2EZV@@IRC(5,(DV;J%UW%]0T8K*.H2D&T4UP$"K\6"E[_\
MCSFNB*C/9Z_Q&YX,@6'*UOMA-%4J$I1(%!CZ& !5Y@E]]K:T?GK:C[*NW,CI
MKXY:Z; G9)[+<7C2N\O?^6;67K$4H@(9$LDOUA[>R4;(1AHFT'#;W+%\%(&=
M1-T-$;(+A,W5U1,6AY-E/4B,7_1MU-YQ'CU8I&A,*2VW:>\4I3F5),_1MK[8
M>8"<3G#6'@2[X':D1CH%ESAG11@*]!D%759E\F<5"2L$)T%(%;SV)J;8NJ7A
M ^1T<MA. JY#--(IN.3%_69 (9)14((<FLX7B$*0%RR89L%YM&ZT,_,N.9U<
MR4P"KD,TTA.X?CF[)K:7*_RO4XK1SP:?0B=MBB%W(LJ80"5&/D44&J3S4G$*
MB@J.!K+=9'4"ME["AB;:ZPF0]S%TOG<=L<,X6>S(K:(]EA)$Y1B8P J76+)V
M[ DBA5MD=>*WM8+"'L'!,7KI%&KKRQU[<1F43"W4*: Y&745F(=0I*FS7:QB
MUA.[HR79/$!7)V!K!89](M%C--,3VHXX,5Y?5I&E7(A!<BYTC#5 $I8V->WL
MK$.QW%K%5>O'CZ8,=/5",O7I_>2(Z& [W#\R\)[TT1G%^\SSPH'7"D95O(88
MH@5CH\U2E9A8ZRSEO8GKQ P_/8!NOSR/HLT.8'JM%N4^;DR6&2UQ8[QSQ(W!
M.N1 @K><1^XQ%-T:FP]3U,G]SN2 ;*BW#E"X%>>]C!CKK*LS8%3M/FN,!Q\%
M@N'D8\GB76Z>4;N3F!\_(F^#O3;:ZK@L_]UJ^157F[.PK<S[6K?9&]P<4?[U
MG2^VJM]Z#.&-"K NEGQW$A87I8S#NM>J8I(:'C=BHL-0J>(HCB&H2>EC1./K
MFT?C+?Q=HMK--=FYU-9_+I+35N,>-#.TSWSDX+T3@$$'&8QGY"4T9GY?VJ;U
M[=KB9O<LDX;ZZ>"@W,G-+V=U(M%P"Y9S=,9Y#RS5,?.&S''D+)('ZIQ-,?%@
M6[?,W8.L7@:5M,3#<ESE](RWRM#Y19AG,I&W($%@#K5D/$/,UD,)05F>427;
MVD7;@ZQ.K=NA4-@7:@?JI0.H/5]^^7I*G[MDY:*H(.=<@K8@L?:&KD_:(=D$
M)FC.1 Q&V/95(?>2TBFD#E7YW>3ZH^4_]?R$MZ7,$[X\72WF&XI'KDOI(C>B
MSJJGW07<44RLM*0(Q>8(3M,NU$I;O-WE;4>OXN\N->U-Q5AH&4',4X.&OE!+
MFI:KL]M<R,QK7QX/3A6RT)9+<#9Z4)+')%VTA:F]P+)SB6FO%$8%21NQ=G P
M[932U6U*$4YFZSS%)KJ.FD,'T:@,VKH2%0O2-1^A^GVJ>AFY-H7'?9AJ>@;;
MT-=ZICPW)56?T8O:]Y)8BCPE" :SEMI*$<Q3 6V@J%.?Z$#][PNOQRNC VA=
M:Y+^ HF(-#_O$?GU! >%+?+Y^+?AYSN9GPD2)[/D!T8N"UEM.A*\<XDVL/84
MMYCL;?,6SHUH[]0I:P/7211\=)O\\4WG&]S,(B:7+84M6@4%*M>,545>*<FS
MI*@PVM#Z(?,A>CKU^T8VFX]51 >C3J]OI)FKZ86V.&"LAL)))HB%!>#!6^D<
M+[YY1?;U]:?-*1H9- <+NN,NE&205Z>8?_WC*R[6>-5#\=;/CWA7?.0*K=X9
MCV&LU;MC.*OA0WT''U8-)]?Z\$G)5*  DY<*G]HP-1H7H9!Y$2F8$%SK>K<'
MR#GJ<N)2HH3613AY3TJK51ZTS(M:E;$<=N"%O"^FB$1IBN-*@9>BU*Y %D(.
M2"=Y,,)DH>_TO=QQ;W'(ZA-'!(U@<>,J8W0E3'T%=L[@._K:<K% XG#P(F^S
M%)#;G$T"+*P6EKG:WT=F8-8D(:VW+NO'X.H[ZTWLK(^(I):"[B"R'%I-G+-V
M+2GI@AOC9 HB(IA(_U"*8HH0N(: *OE,OW6R=;?9ARF:V/MN#*P1M- !IG8S
M0KM!9:L,<*YK4Y0Z6Z8D#IEYEJ1F1J81KA^.0-)X+OE(2&HC^XX3_&HCL?DV
M>S8L\O/E8C-?G/=L:CTDYM"E6KGJ35AMY+-?H^79+5JNDD@O$2R2*4F8 !@M
M!Q6U@.BB _HYC[643XG6>8./(O HCXL\@%1U^@E?+=(*PYK^_6RQH"W\"_WZ
M?=UKUL@Z^]I SC%"?6<C@RT1DE'"1DX"N5W[OL/;^OY:T_KLX\'BAN_56.0=
MG)%OO^(J5&&]KMR\GW_ZO'E;?EMO,\1G3D0G>;:0Z.0'Q4($%YRG\Q^]B)X%
MW[QWPH,$3>O.CP^R]EKI#F(7'L'9+"EKI5.:HEM68UKB(-1^AB&($EE*'FWK
M^_0=I$SKS$\%J\,T<3"@ON$J+D>^+7W 4[G)._W1>GDRSS5R_B6<A$7"#Y_Q
MJ/J,9FL_@=MVA# F\>.2BED78:'4X6=*"@4^&SI9G9!2*J3 =(0$SO']N/WL
M/5J;'%E\B+)RKPO6<:AD 8K%;%)&V3QCX_A3N!-7[S'(>=PI_!BM]'L*7T3E
M3"DG!87A0=N:22X#A.)EG1(7R=O0F)KW\'B8HA_)U6L'LJ/TTB_*KLW^#AA3
MM(R!QEJ2I44!IR@^LEK+R+21=*0^#= >.:N]$_]O!*P=J)U^X38KW$;R44RM
M]LN@O%<0F!)@DLY*RE X:^TO'!-:C':[.SFT'J6)'_.V]^.P^-:/7F^.R<1X
M_")/$"KLP]XD,4%0!"L6&""KM6^B:' F(V"PY'O1;S&WGATP84Q0A3]+.@7.
M+07FQ<HZ]X&<3U^= =2!HO^2BV\^+N$.%3^2]_\8C#QLT1XM_PY.Q_\,JWE]
MW+MB("BA5,X"O.(,E%4*HD !T5B>A31<_Y_VOJS'K217\WW^"S&Q+R\#9&V-
MNJ@N&RYW7]PG(1:&K>FTY)&4KO;]]<.0E/NF)8Y.*.LVT(:7+(G+1P;)8)"Q
M];GXB(AS"NR/P<]QTN\ /K>$VQ"3<LJ#=5A 91[!>R; 6LYTBMJITOIMTGYP
MZ20V/P8NATG[/$.F7Z[JF\\UQ^_#]^T6^R'"IA>^Z 2ATZYLCE-2]5Z'HAG(
M('D=PAW %1W(-TECA?,JQM:[;DX:/OV&RR7B,VG)C3JN\'>2_L<_\?(;_IT(
M^KR<^&"=M)3[6*\I"R*;AEBT 6%*BMDEFW/K2MBAM)Y3*+8/WA[[QA/HLHL3
M=S<^_PO#XN.?\XE)+/+,$@B.%%!XFR'4I]!1:0S1QHBL]=B4/4D\IV#O% @]
M1'/G!DQ"&DXD,PH91I#1*:BB Y<B@LS*)A>C,K%UP^[>1)Y3:'DR<.ZMO3.#
MYR_SJT5]G>J$80Z\8)Y"[*P@2,D@L1*C\,$PU;HO<%\:SZIP?")P[JV[,\+F
M1%HF*0G@X.L  ,5C'=-O'0AAE Y:)Q-:%_=VI6W<U:C]87$O777P OE%OOXQ
MRR3%^=5L_8@HT8]>?*E_JH8F37 6K)5U>&;6%*,@61N%T-QGM );KY YB-"=
MT&G>.#J;:+&?00S/72=JYIT/,H+0@>)F1K\+LG@0E,\EQXO2IG4E\IB+77O^
MJ&NAB;=6I9P\Z($8L$Y)7S5JI?(AJS>URO\]C-#_$VN;'>:+;P2[3_2Q=8+<
M-?K(OWRA_^#!SZR?8M0/"Y<_S!>+^9_TXQ_('0U34AZ P!,H>&BQCO.Z"ZVW
M,430.110J;XDM,P"YT%Y5[@W^0UU!;^J0CZ)(C/&\]H)DY\7(I- %$)F2L>D
M'7>\=4U_7QK/J62]#[Y>/C8;ZZZ#M/9%_G[:AJ+576R?S$U4XL4I7R!%$X@_
M^IT7@K+X4+++F8N"P_9]OD[C.16K!\/FL;KK>);2/W[\X=W7]6OENO@FU7$9
M%Y\6N#[DC@@6=OG85D?\WBPT.I@_X#><7>$OA-J*S K!_YRN/O]XM5S-O^#B
M!I8,)0^),@V''$'5K9.N% .!6VU<LD&XUHLC=B3MZ"ENTV7X1*+^M%;<N[+]
MVLT 6H4B8:@C5G2B)-NCAZ"* AZTT<X&E5CKVMU+](Q[R Z!E4>CWEII8\2C
M=+E8D=.O%9L%"7;U_??P9;/505OGUB\]1-'UB6=&2JU3!)65]$PJS]-.1D1?
M< =)]*=;%#WWW>,BIYU6YPU%/#)$/N#7JT7Z'.YX^H<L7:\3)IMQMEB(SBM0
M10KPQ9%IA<2CY$ZRO--K_5=PLS-!XX"IC<[G0RM@['EM%$E<+XD6PCJ4"2AD
M=*!<(:J%-^"3T4+$B"C-:S'0_8\<3_$#Z6I^M.!&=B+O%_-\E5;O%G_@XAO%
MC6N#B,CJ&%T' I%$D**C SAE4)BR<U[(DG<J%[SB+Y[Z[G%3K4'.F:-%W =$
M:O*YY6!YLZ:>YZRY@BQ0UEG>'IRT 5!K[G2.]/N=WI_OAI/'!(SG3H[7Z6.
M'"G@#FH_V\1SZP5-TCHY84'[^BBF8""76HL#B8DL5!W]WKS3ZRX!HZ/C6(4^
MO.8]6+H=0*-.]KX)N(A.[TS)D'F@@ MKET1]UU#GD$J1BF&J]?2HN]\_;GM?
M\S/F:!%W!(^MF20N/5E$;:/)50S20<BB@%>6\1"%*[GU,/S[%(P\:/I@33X#
MB0/$.G8:\O'/^<?/\ZMZ8?GQ3Y+9]Y^_?+V<?T?\8S5/_WJ_#>8K@UN'2,=M
M824DL"'R^@:S@$MT#@LM%.=!A&0?!*W/9"O[?G,?6#E$Q?-3R;L##_.,V_WM
M9L&$I=3.2G*]2=9[ME@'JO@ZTECI7+(7A?O6=Z2OT31NJ^]@!U53570 K:>*
MV;?]4*YXL@4CP8M$68$2!EQMC[*< C>TJ(MO/VKV!8*ZK.0>J/M':V9;*6+L
MTV\KEIM^@/>X6$]1GB5\%R^G&^E=/R2O8_JF>7UU2TK<='?JHJ)'K*L.D<28
MO:*H(2%@T5[E[&5Z.,C\F=/P6$JZ+.@<![?3:Z@#)[<3OY-<R/>'DD#JG.K
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MGDUZ>!RF!M5%7^[K2=;>W?/-*()4F3/0*0KRS99DB>MWB9QCU(B"M^[[W(O
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M/M(/KUMVLV8L<,[K)EU#Q.=,9PRQP:53I@2?0VK=OGR/@+-IS#I U_-6@N\
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M&_?H'Q4\#Y\SM==DSY76*8FQ3%.8K2X^+7#3#'Y,"?6ESVM6&]V9Z$9%3P+
ME^EJ4_V9Y3K;;CK[A+,TQ>5M#>EV"($+(AH9H 1)F1"W'#QR#K)@YO4.K(C6
M-<Z]"#S6U[U;?<;%G6_<'!Y8M S1$:^\[CY1=0@#1@LJERR1)[2B=7O@DX2,
MZ\F&0\I#/W6\%CHX-A\RL:XD^."Y(X<"!4.]+^82*"YA8 0:=-)SK5I/U7^*
MCG&!U$"]KP!F;UEWB)=MQL:9ECP'#LPP36*AY-TK1ERX&*)R)*O2>I#FTY3T
MA9G]-?P*9 X0=P>@^8U"RMER/7_G.EC8YN%:%>[)[8*BE)Z,B MP%+J!%3KG
MD"5'W;HZ\BPQ?4'G$$W/AQ#[B/BI\>=37+Q?S,MTM4X/KN\$K^LZ4H:B&1(G
M(H)"Z<!)S!"L"]K$R%,RKT70>W_KN,!II.7Y*40^(I:6BQ7%AE?U11[)=?6]
MOA!?NV?A(XLL28B9.4I5HP&G38!4":]M1V6WR7/T!7?<#_WIUO4\]]WCEK#:
M!3A-9#LR-C[@UZM%^AR6> /ZARQM73)ZI:QC F2L"[A2KALQ;82L.==D6=[N
MEEV^ IB="1K'_;31^7QH!8Q]>GV8?TJW0R,T,\D4!%.?,RKG-;CB)$B6;,1B
MBS=VI]/I[J>.I_Z!-#9O(;ZQ]?[K?#:]/B&9SSS$B. KXXI+!C&Q CHSR@"L
M+('O%I3<^=!QCHX3:?U0X760ZCP\5&]+XD%)*:,VP BNH*(C1K1%P,B<#:J@
MMZVG_#U+S+AO;H>OK!PF]?[@,T%.P;I+1+Y1=>,G4>Y8"4"ANS J.6%+ZS:5
M!R3TE14?J-B7X;*7E#L R45*BROZUFF(]97W%)<_7BVJ-"]F^??Y+&W^,/$H
MLQ0N@8A,TG$I9#TN*?TCKVDL=\;QUK<@NU'65]K3!E(#Z*0#I+W8MS4I%,T7
M'1E@8J$.T2>S0;(B9%P605&9>1C.#MM#U]>IU@97[330L(VI_2WX[[CZ;;Y<
M?L7%NL1T\\HFS%;3/+V\JAU<2R0K6IL6_CM=7F7,50GT$5^O-C3,"XFJ[CZK
MG[.LGW/$/?K %+6ZB3^EX!K=Y?^\_:[W6YIO+F-=D"*54$ %KT 5:< S^J.(
M)8J4529\M^Y)>X:6=H^.+NXHXH\;1?R\5<0OI(@?;Q7QKCPD:!,;:W(<@:)A
M8"%E4(8["!(-!2A&!:MTYJ;YFO.F'(S<W=0"<<\_(#JYBCN(#([D^8?O3W_
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M\&17U?'ZZ!=:V[Z/HHRWUGE(6&?*UTVF45#F;<@HF3>L"#5,:]XS!/70:-5
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M+65Y8V]N<V5N=#(P,C(N:'1M4$L! A0#%     @ <4%'5I*@;1Y["0  <54
M !X              ( !]30  &5X:&EB:70S,3$M<&5O,S R8V5R=&EF:6-A
M+FAT;5!+ 0(4 Q0    ( '%!1U:PI/5V9PD  )%5   >              "
M :P^  !E>&AI8FET,S$R+7!F;S,P,F-E<G1I9FEC82YH=&U02P$"% ,4
M" !R04=6MDA]H1L&  #9.0  '@              @ %/2   97AH:6)I=#,R
M,2UP96]A;F1P9F\Y,#9C97(N:'1M4$L! A0#%     @ <D%'5B6$?E5#6 0
M+' D !$              ( !IDX  '!R87@M,C R,C$R,S$N:'1M4$L! A0#
M%     @ <D%'5L! 44[3#P  <+(  !$              ( !&*<$ '!R87@M
M,C R,C$R,S$N>'-D4$L! A0#%     @ <D%'5EF6O907'@  BS ! !4
M         ( !&K<$ '!R87@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M ')!1U:ZGP/:&#L  ">= @ 5              "  635! !P<F%X+3(P,C(Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " !R04=6@GI$G18\ @"W: ( %
M        @ &O$ 4 <')A>"TR,#(R,3(S,5]G,2YJ<&=02P$"% ,4    " !R
M04=6Z:\$?CON 0#OK@( %               @ 'W3 < <')A>"TR,#(R,3(S
M,5]G,BYJ<&=02P$"% ,4    " !R04=6\ M%SQ'U 0 ?MP( %
M    @ %D.PD <')A>"TR,#(R,3(S,5]G,RYJ<&=02P$"% ,4    " !R04=6
M0YD6JV@" @!OS ( %               @ &G, L <')A>"TR,#(R,3(S,5]G
M-"YJ<&=02P$"% ,4    " !R04=6N=*L+7S,  ##MP@ %0
M@ %!,PT <')A>"TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ <D%'5AY[
M?JXE?P  8-8% !4              ( !\/\- '!R87@M,C R,C$R,S%?<')E
:+GAM;%!+!08     #P /  P$  !(?PX    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
